keywords,len
Patents Act 1977,3
European Patent Convention,3
legislative drafting,2
implementing treaties,2
harmonization,1
,1
right of priority,3
patents,1
Paris convention,2
European Patent Convention,3
TRIPS,1
applicable law,2
,1
intellectual property,2
patent,1
trademark,1
copyright,1
trade secret,2
BayhDole Act,2
America Invents Act,3
patent law,2
United States Patent and Trademark Office,6
US Patent Law,3
innovation,1
nanotechnology,1
nanomedicine,1
patent thickets,2
utility,1
novelty,1
nonobviousness,1
subject matter,2
statutory requirements,2
prior art,2
,1
,1
,1
competition law,2
Indian patents act,3
patent thicket,2
TRIPS flexibilities,2
,1
compensation,1
competition,1
compulsory licensing,2
patents,1
South Africa,2
,1
patent law,2
Letters Patent for Invention Act 1835,6
patent history,2
,1
Commercial law,2
sale of goods,3
marketled growth,2
structural adjustment programs SAPs Sale of Goods Act,8
Trademarks and Patents Act,4
warranties,1
,1
European Patent Convention,3
Unified Patent Court,3
patent claim scope,3
law of precedent,3
patent law international cooperation,4
,1
,1
,1
biotechnology,1
patentability requirements,2
European patent,2
unitary patent,2
Directive 9844,2
Regulation 12572012,2
harmonization,1
,1
Australia,1
intellectual property,2
patents,1
unjustified threats,2
,1
,1
,1
licensing,1
licensor,1
licensee,1
intellectual property,2
patents,1
invention,1
inventors,1
nanotechnology,1
patent law,2
ownership interest,2
United States Patent and Trademark Office USPTO,7
nondisclosure agreements,2
due diligence,2
trade secret,2
material transfer agreement,3
confidentiality,1
noncompete provisions,2
BayhDole Act,2
Government marchin rights,3
crosslicensing,1
export control laws,3
severability clause,2
,1
,1
HATCHWAXMAN ACT,2
DRUG PRICECOMPETITION,2
SETTLEMENTS,1
INNOVATION,1
LAW,1
Human Genome,2
Moratorium,1
Moral Clause in Patent Law,5
Mexico,1
,1
,1
,1
copyright,1
copyright reform,2
United Kingdom,2
Copyright,1
Designs and Patents Act 1988,5
,1
,1
TISSUE CONSTRUCTS,2
MYRIADGENETICS,1
3D,1
ETHICS,1
POLICY,1
CELLS,1
Patent Medicines,2
History of Patent Law,4
History of Medicines,3
History of Drug Regulation,4
Colonialism,1
History of South Asia,4
History of law,3
Cultural nationalism,2
Business History,2
,1
access to medicines,3
COVID19,1
international patent law history,4
lowandmiddleincomecountries,1
Paris Convention,2
TRIPS Agreement,2
TRIPS flexibilities,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENTS,1
POLICIES,1
TRADE,1
,1
,1
local working requirement,3
TRIPS Agreement,2
Indian Patent Act,3
human rights,2
patent working disclosures,3
RIGHTS,1
TRIPS,1
,1
PRIVATE ENFORCEMENT,2
LITIGATION,1
STANDARDS,1
AGENCIES,1
LEGITIMACY,1
QUALITY,1
RIGHTS,1
STATE,1
,1
LAW,1
innovation,1
patents,1
employment nondiscrimination acts,3
ENDAs,1
sexual orientation,2
WRONGFULDISCHARGE LAWS,2
MARKET VALUE,2
GAY,1
MIGRATION,1
COSTS,1
STATE,1
,1
INDEPENDENT INVENTION,2
PROPERTY,1
RETHINKING,1
DEFENSE,1
RULES,1
America Invents Act,3
first inventor to file,4
prior art,2
postgrant procedures,2
,1
,1
,1
Article 31bis,2
compulsory licence CL,3
Patents Act 1983 PA,4
public health flexibilities,3
TRIPS Agreement,2
ACCESS,1
patent law,2
invention,1
patentability,1
human inventor,2
artificial intelligence AI inventor,4
,1
Compulsory Licenses,2
Patent Rights,2
Public interests,2
Balance of Interests,3
Iranian Law,2
,1
,1
,1
Intellectual property,2
Patents,1
Traditional knowledge,2
Disclosure requirements,2
Convention on Biological Diversity CBD Nagoya Protocol,7
Genetic resources,2
,1
,1
HATCHWAXMAN ACT,2
CORPORATECONTROL,1
SHAREHOLDERS,1
MARKET,1
GOVERNANCE,1
GREENMAIL,1
PAYMENT,1
DELAY,1
NO,1
,1
GENERIC ENTRY,2
SETTLEMENT,1
INNOVATION,1
HOLDUP,1
PORTFOLIOS,1
LITIGATION,1
ACCURACY,1
PAYMENT,1
ACTAVIS,1
TROLLS,1
,1
PATENT HOLDUP,2
Colonialism,1
India,1
innovation,1
patent,1
science,1
technology,1
LAW,1
COPYRIGHT,1
MEDICINE,1
DESIGNS,1
direct infringement,2
indirect infringement,2
joint torts,2
multiparty infringement,2
patent,1
,1
,1
,1
,1
,1
,1
,1
nanomedicine,1
nanosimilars,1
nanopharmaceuticals,1
regulation,1
patents,1
US Patent  Trademark Office PTO,6
patent laws,2
patent classification,2
Commercialization,1
FDA regulation,2
invention,1
patent thickets,2
BayhDole Act,2
European Medicines Agency EMA,4
Food and Drug Administration FDA,5
Doxil R,2
Nanotechnology Characterization Laboratory NCL,4
postblockbuster world,2
Abraxane R,2
monoclonal antibodies mABs,3
nanotechnology,1
nonbiologic complex drug NBCD,4
followon biologics,2
biosimilars,1
immunogenicity,1
pharmacokinetics,1
pharmacodynamics,1
Abbreviated New Drug Application ANDA,5
New Drug Application NDA,4
bioequivalence,1
PEGYLATED LIPOSOMAL DOXORUBICIN,3
TUMORNECROSISFACTOR,1
COMPLEXDRUGS NBCD,2
COLLOIDAL GOLD,2
PRODUCTS,1
NANOPARTICLES,1
DELIVERY,1
PHARMACOKINETICS,1
ACTIVATION,1
STRATEGIES,1
,1
,1
traditional knowledge,2
intellectual property rights,3
patent,1
copyright,1
TRIPS,1
,1
,1
VORNADO,1
Patent Litigation,2
PCT,1
National Treatment,2
Mexico,1
USMCA,1
NAFTA,1
,1
European Patent,2
Accession,1
Patents,1
Middle income countries,3
Regional patent system,3
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PROTECTION,1
TECHNOLOGY,1
,1
LAW,1
Indigenous knowledge,2
Aboriginal and Torres Strait Islander peoples,6
biological resources,2
patent trends,2
legal geography,2
biopiracy,1
access and benefitsharing,3
Nagoya Protocol,2
NORTHERN AUSTRALIA,2
MYOPORACEAE,1
KNOWLEDGE,1
ECOLOGY,1
LAND,1
,1
,1
patent,1
asset class,2
market intermediary,2
convention,1
regulation,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGY,1
TROLLS,1
BROKERS,1
FIRMS,1
gene patent,2
compulsory license,2
Myriad,1
research exemption,2
Taiwan Patent Act,3
patient access,2
patent eligibility,2
,1
,1
ADMINISTRATIVELAW,1
America Invents Act AIA,4
patents,1
product portfolio,2
systems,1
systems thinking,2
unintended consequences,2
intellectual property,2
,1
,1
COPYRIGHT PROTECTION,2
COMPUTERPROGRAMS,1
FAIRUSE,1
ART,1
LAW,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
INNOVATION,1
INDICATORS,1
CITATIONS,1
ECONOMICS,1
RENEWAL,1
RIGHTS,1
FORUM,1
,1
JURISDICTION,1
RETHINKING,1
COURTS,1
Biotechnology Inventions,2
Patents,1
Ethics,1
Morality,1
ICMR,1
Bioethics Principle,2
Patent Protection,2
Public Order,2
,1
,1
ACT,1
Biologics,1
biosimilars,1
FDA,1
law,1
patent,1
pharmaceuticals,1
,1
,1
FEDERAL CIRCUIT,2
PATENT,1
QUESTIONS,1
SEARCH,1
COURT,1
LAW,1
,1
FEDERAL CIRCUIT,2
SYSTEM,1
TAX,1
DEFERENCE,1
ACCURACY,1
CHEVRON,1
MEAD,1
LAW,1
,1
,1
,1
TORT LAW,2
PROPERTY,1
Patents,1
Paris convention,2
E Merck,2
regulation,1
,1
patent law,2
China,1
law reform,2
,1
,1
ANTITRUST,1
LAW,1
RULE,1
HOLDUP,1
REASON,1
FRAND,1
GOALS,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT,1
CREATIVITY,1
LAW,1
HISTORY,1
FEIST,1
Inflation Reduction Act,3
Medicare,1
Patents,1
Price Negotiation,2
Takings Clause,2
,1
,1
FEDERAL CIRCUIT,2
TROLLS,1
SYSTEM,1
COURT,1
,1
,1
Balance,1
innovation,1
patent law,2
patent policy,2
social costs and benefits of intellectual property,7
INNOVATION,1
ECONOMICS,1
LAW,1
,1
,1
,1
MARKET,1
Antisuit injunctions,2
Standard essential patents,3
Litigation,1
China,1
Act preservation,2
International norms,2
,1
Drugs,1
Patent protection,2
Generics,1
Drug labels,2
,1
Patent,1
China,1
SEP,1
Antitrust,1
Patent law,2
COUNTERFEITING TRADE AGREEMENT,3
TEXT,1
,1
,1
,1
,1
,1
HATCHWAXMAN ACT,2
MEDICAREPART D,2
GENERIC ENTRY,2
PATENT EXPIRY,2
COMPETITION,1
INNOVATION,1
DRUGS,1
BRAND,1
LAW,1
ACTAVIS,1
,1
LAW,1
CIRCUIT,1
CHOICE,1
COMPETITION,1
SELECTION,1
,1
INTELLECTUAL PROPERTY,2
FAIRUSE,1
1ST AMENDMENT,2
1STAMENDMENT,1
COPYRIGHT,1
DOCTRINE,1
LAW,1
STANDARDS,1
MATTER,1
MISUSE,1
AI,1
copyright,1
IoT,1
patent,1
,1
Dissemination,1
gender,1
incentive,1
innovation,1
invention,1
patent law,2
reward,1
sex,1
INTELLECTUAL PROPERTY,2
COMPUTERSCIENCE,1
WOMEN,1
LAW,1
ECONOMICS,1
INVENTION,1
GAP,1
SEX,1
INNOVATION,1
FEMINISM,1
genome editing,2
genetic interventions,2
Oviedo Convention,2
human gametes,2
human embryos,2
research,1
reproductive applications,2
precautionary principle,2
safety,1
morality clauses,2
CRISPR,1
BIOTECHNOLOGY,1
,1
,1
RD competition,2
Patent laws and legislation,4
Intellectual property rights,3
Patent priority rules,3
Sequential innovation,2
Management of technological innovation and RD,6
INNOVATION,1
exhaustion doctrine,2
parallel importation,2
Thai patent law,3
parallel patents,2
exhaustion of patent rights,4
ASEAN Economic Community,3
free movement of goods,4
LAW,1
,1
POLICY,1
SCOPE,1
EU,1
Competition law,2
Antitrust,1
Patents,1
Divisional patents,2
Pharmaceuticals,1
Monopoly,1
Judicial review,2
EU COMPETITION LAW,3
Discretion criteria,2
Administrative enforcement,2
Innovation,1
INTELLECTUAL PROPERTYRIGHTS,2
REFORM,1
,1
,1
,1
FEDERALCOURTS,1
SEPARATION,1
CIRCUIT,1
POWERS,1
QUESTIONS,1
VALIDITY,1
SYSTEM,1
POLICY,1
Adverse selection,2
Appropriability problem,2
Blackmail,1
Patents,1
ECONOMICANALYSIS,1
PROPERTYRIGHTS,1
,1
INTELLECTUAL PROPERTY,2
TRADE SECRETS,2
HUMANGENOME,1
LAW,1
ECONOMICS,1
PROTECTION,1
SEARCH,1
SCOPE,1
ASSOCIATION,1
COMPETITION,1
,1
,1
Technology transfer,2
BayhDole,1
Law,1
Patents,1
Legal research,2
PATENTS,1
KNOWLEDGE,1
,1
,1
Patent Law,2
Whacker oxidation,2
double patenting,2
electrochemically mediated,2
terminal disclaimer,2
,1
,1
,1
,1
MIXED QUESTIONS,2
,1
INNOVATION,1
,1
,1
Patent strategy,2
Patent law expertise,3
Patenting performance,2
Intellectual property,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
TEAM DIVERSITY,2
INNOVATION,1
FIRM,1
STRATEGIES,1
MANAGEMENT,1
ADVANTAGE,1
SUPPLIER,1
ENTREPRENEURSHIP,1
Universityowned patents,2
academicinvented patents,2
patent quality,2
patent management,2
patent value,2
technology transfer,2
TECHNOLOGYTRANSFER,1
INNOVATION,1
ENTREPRENEURSHIP,1
INVENTION,1
QUALITY,1
OPPOSITION,1
OWNERSHIP,1
ACT,1
,1
,1
online patent infringement,3
China new patent law,4
notice and takedown rule,4
liability of ecommerce platform,4
liability of application distribution platform,5
,1
Patents,1
Inventions,1
Realism,1
Antirealism,1
Nature,1
Causation,1
ANTICOMMONS,1
Indonesian Patent Law,3
innovation,1
International Patent Law,3
technology transfer,2
TRIPs Agreement,2
,1
,1
,1
Unified patent court,3
European unitary patent,3
European patent convention,3
patent itigation,2
European patent system,3
,1
HatchWaxman Act,2
Infringement,1
Patent dance,2
Patents,1
Litigation,1
Inter Partes Review,3
BPCIA,1
,1
,1
,1
,1
C VIRUSINFECTION,2
NATIONALHEALTH,1
SOFOSBUVIR,1
PROGRAMS,1
ACCESS,1
food and drug law,4
intellectual property,2
,1
,1
,1
,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGY VENTURES,2
EMPIRICALEVIDENCE,1
PRODUCT,1
PERFORMANCE,1
CHINA,1
INDICATORS,1
BUSINESS,1
STRATEGY,1
ORGANIZATIONS,1
,1
STANDARDS,1
debtor protection,2
credit markets,2
innovation,1
patents,1
personal bankruptcy law,3
small businesses,2
RESEARCHANDDEVELOPMENT,1
BANKRUPTCY REFORM ACT,3
PERSONAL BANKRUPTCY,2
SMALL FIRMS,2
ENTREPRENEURSHIP,1
CONSTRAINTS,1
FINANCE,1
GROWTH,1
genetic resources,2
TRIPs Agreement,2
Convention on Biological Diversity,4
patent,1
disclosure of origin,3
,1
Democratic Peoples Republic of Korea,5
Invention,1
Patent,1
Utility model,2
,1
Patent litigation,2
Patent quality,2
University patents,2
BAYHDOLE ACT,2
QUALITY,1
INNOVATION,1
DETERMINANTS,1
TECHNOLOGY,1
OPPOSITION,1
OWNERSHIP,1
ENTITIES,1
TROLLS,1
,1
HOLDUP,1
Bayhdole act,2
Patents,1
University innovation,2
TECHNOLOGYTRANSFER,1
INCENTIVES,1
,1
,1
,1
SOCIAL CONSTRUCTION,2
COMPUTERSCIENCE,1
WOMEN INVENTORS,2
PROPERTY,1
BIOPIRACY,1
MOTHERS,1
WORK,1
GAP,1
CAFC,1
entry,1
patent law,2
patent strategy,2
strategic patents,2
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
IMPACT,1
TECHNOLOGY,1
STRATEGIES,1
THICKETS,1
COURTS,1
ENTRY,1
FIRMS,1
,1
,1
,1
FEDERAL CIRCUIT,2
SUBJECTMATTER,1
COURT,1
RULES,1
LITIGATION,1
SETTLEMENT,1
SELECTION,1
DOCTRINE,1
DISPUTES,1
TROLLS,1
,1
DISCOVERY,1
PATENTS,1
SCIENCE,1
DRUGS,1
,1
,1
Intellectual Property,2
Patent,1
Innovation,1
Radiopharmaceuticals,1
Nuclear medicine,2
DRUG DEVELOPMENT,2
REGULATIONS,1
PROTECTION,1
GUIDELINE,1
,1
,1
,1
US PATENT,2
LAW,1
,1
MERGERS,1
FIRMS,1
TAKEOVER,1
RETURNS,1
,1
INTELLECTUAL PROPERTY,2
CIRCUIT,1
JUDICIARY,1
ECONOMICS,1
LAW,1
,1
PATENTS,1
,1
,1
,1
,1
,1
HISTORY,1
PATENTS,1
,1
FEDERAL CIRCUIT,2
EXCEPTIONALISM,1
SYSTEM,1
Copyrights,1
Technology transfer,2
BayhDole Act,2
Intellectual property,2
Knowledge exchange,2
Law,1
Patents,1
Legal research,2
INNOVATION,1
ENTREPRENEURSHIP,1
PROPERTY,1
Copyright,1
Copyright Act of 1976,4
Federal agencies,2
Federal laboratories,2
Federal Technology Transfer Act of 1986,6
Governmentowned contractoroperated GOCO laboratories,4
Governmentowned governmentoperated GOGO laboratories,4
Government Works software,3
Invention licenses,2
Patents,1
Software,1
Software copyrights,2
Software licenses,2
Software patents,2
Technology transfer,2
,1
Main path analysis,3
Clustering,1
Research theme,2
Development trajectory,2
Citation network,2
Patenting,1
BAYHDOLE ACT,2
INTELLECTUAL PROPERTYRIGHTS,2
KNOWLEDGE FLOWS,2
EMERGING TECHNOLOGIES,2
COMMUNITY STRUCTURE,2
SCIENTIFICRESEARCH,1
NETWORKS,1
QUALITY,1
POLICY,1
UNIVERSITIES,1
,1
,1
,1
LAW,1
CENSUS,1
RACE,1
FREEDOM,1
PATENTS,1
ACCESS,1
SYSTEM,1
RIGHTS,1
Patent disclosure,2
Innovation,1
Spillovers,1
Proprietary costs,2
Corporate disclosure,2
PUBLICATION,1
PROPRIETARY,1
INFORMATION,1
DIFFUSION,1
ECONOMICS,1
SHOULDERS,1
GIANTS,1
MARKET,1
,1
FEDERAL CIRCUIT,2
INTELLECTUAL PROPERTY,2
PHOTOCOPIES,1
LITIGATION,1
CERTIORARI,1
SYSTEM,1
POLICY,1
RETURN,1
LIFE,1
BAR,1
,1
ADMINISTRATIVEPROCEDURE ACT,2
PATENT,1
COURTS,1
RULEMAKING,1
HEARINGS,1
CHOICE,1
POLICY,1
LAW,1
,1
,1
National scientific research institutions,4
technology transfer efficiency,3
patent,1
technology transfer law,3
comparative study,2
US,1
GROWTH,1
POLICY,1
patent litigation,2
nanotechnology,1
patent thickets,2
United States Patent and Trademark Office,6
American Intellectual Property Law Association,5
reexamination proceedings,2
,1
patent law,2
intellectual property,2
Konami,1
slot device patents,3
,1
patent law,2
Edmund Burke,2
James Watt,2
Richard Champion,2
patent history,2
steam engine,2
porcelain,1
,1
,1
INTELLECTUAL PROPERTY,2
PUNITIVE DAMAGES,2
ANTICOMMONS,1
REQUIREMENT,1
RETHINKING,1
UTILITY,1
TROLLS,1
HOLDUP,1
LEVERS,1
RULES,1
FRAND,1
Standardessential patents,2
Data sharing,2
Data Act,2
Digital Markets Act,3
LIABILITY RULES,2
PROPERTY,1
employee patent rights,3
intellectual property,2
service patents,2
case law,2
employee inventions,2
France,1
innovation,1
ownership,1
,1
,1
PATENTS,1
INNOVATION,1
,1
,1
,1
LIABILITY RULES,2
PROPERTY,1
SHADOW,1
HOLDUP,1
LAW,1
Patent antitrust,2
Patent monopoly,2
False positives,2
False convictions,2
False negatives,2
False acquittals,2
Error costs,2
Ratio tests,2
ELASTICITY,1
DEMAND,1
,1
,1
patents,1
history,1
Switzerland,1
chemical industry,2
product patents,2
process patents,2
patent scope,2
,1
,1
,1
Counterfeit products,2
Indonesian trademark law,3
Intellectual property law,3
,1
aesthetic creations,2
art,1
patents,1
,1
intellectual property IP,3
strategic intellectual property management,4
intellectual property portfolio,3
patent,1
trade secret,2
copyright,1
trademark,1
patent thicket,2
patent clearance,2
Patent Cooperation Treaty PCT,4
America Invents Act AIA,4
IP acquisition,2
IP portfolio strategies,3
,1
Germany,1
patent law,2
compulsory license,2
,1
Patent,1
blockchain,1
smart contract,2
Hyperledger fabric,2
,1
geneedited crop,2
GMO,1
patent,1
EU,1
INTELLECTUAL PROPERTY,2
GENOME,1
CRISPR,1
LEGISLATION,1
TECHNOLOGY,1
PRODUCTS,1
POLICY,1
Discrete pareto analysis,3
Patent landscape,2
Zipfs law,2
Benchmark,1
Consolidation,1
Fragmentation,1
,1
,1
TECHNOLOGYTRANSFER,1
PATENTS,1
Patent law,2
Multilevel model,2
Patentability,1
Inventorship,1
Industry 40,2
4th industrial revolution,3
,1
,1
,1
Agreement on a Unified Patent Court,6
European patent litigation,3
European Patent Law Agreement,4
European patent jurisdiction,3
Rules of procedure,3
Brexit,1
Constitutional law issues,3
,1
Distribution of corporate innovative output,5
Powerlaw distribution,2
Simple patent count,3
Qualityadjusted patent count,3
RESEARCHANDDEVELOPMENT,1
SIZE DISTRIBUTION,2
CITATION NETWORK,2
MARKET VALUE,2
FIRM LEVEL,2
ZIPFS LAW,2
FLUCTUATIONS,1
STATISTICS,1
PARETO,1
CITIES,1
,1
,1
data,1
gene patents,2
genetic resources,2
genomics,1
patents,1
TCF7L2,1
LANDSCAPE,1
VARIANT,1
INFORMATION,1
PROGRESS,1
HISTORY,1
UNESCO,1
nationalism,1
multinational intangible heritage,3
Greece,1
Turkey,1
CULTURALHERITAGE,1
POLITICS,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
,1
PUNITIVE DAMAGES,2
LIABILITY,1
Patents,1
intellectual property,2
technology,1
innovation,1
methodology,1
INTELLECTUAL PROPERTY,2
PATENTLAW,1
INNOVATION EVIDENCE,2
EARLY HISTORY,2
INVENTIONS,1
INVENTORS,1
SOFTWARE,1
EXCHANGE,1
SCIENCE,1
MODELS,1
Patents,1
Patent ethics,2
biotechnology,1
novel beings,2
morality provisions,2
European patent law,3
,1
synthetic biology,2
patent,1
gene patent,2
biotechnology,1
Myriad,1
Venter,1
,1
,1
FEDERAL CIRCUIT,2
LAW,1
RETURN,1
intellectual property protection,3
patent litigation,2
Beijing courts,2
inadequate enforcement,2
trade war,2
discrimination,1
damage,1
LAW,1
Patents,1
Innovation,1
Uncertainty,1
Regulation,1
Utility patents,2
Patent applications,2
Patent grants,2
Pendency,1
United States,2
POLITICAL UNCERTAINTY,2
INVESTMENT,1
US,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
ECONOMICS,1
LITIGATION,1
RENEWAL,1
IMPACT,1
LAW,1
,1
,1
patents,1
intellectual property law,3
access to medicine,3
prenatal testing,2
genetic testing,2
special issue,2
,1
computational media,2
digital mediation,2
intangibles,1
intellectual property,2
inventions,1
materiality,1
patent law,2
,1
,1
PROPERTY,1
ANTICOMMONS,1
LAW,1
Biotechnology directive,2
Bioeconomy,1
Patent laws,2
Stem cells,2
Plant varieties,2
Animal varieties,2
European Union,2
,1
,1
,1
pharmaceutical patent,2
patent term compensation system,4
China s path,3
,1
patents,1
technology transfer,2
biotechnology,1
innovation,1
drug development,2
GOVERNMENT,1
UNIVERSITIES,1
INNOVATION,1
PATENTS,1
GROWTH,1
Convention on biological diversity,4
Biopiracy,1
Legal geography,2
Text mining,2
Endemic species,2
Patent analysis,2
INTELLECTUAL PROPERTYRIGHTS,2
TRADITIONAL KNOWLEDGE,2
GENUS,1
CLASSIFICATION,1
CONSERVATION,1
BIODIVERSITY,1
INNOVATION,1
PLANTS,1
competition law,2
standard essential patents,3
,1
,1
,1
shareholder litigation,2
innovation,1
patents,1
derivative lawsuit,2
DERIVATIVE LITIGATION,2
AGENCY COSTS,2
CASH FLOW,2
LAW,1
GOVERNANCE,1
FINANCE,1
MERITS,1
EQUITY,1
IMPACT,1
MATTER,1
,1
,1
,1
FEDERAL CIRCUIT,2
LAW,1
CERTIORARI,1
JUSTICES,1
,1
,1
,1
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
REPRODUCIBILITY,1
QUALITY,1
REPLICATION,1
LITIGATION,1
STANDARDS,1
DISEASE,1
COULD,1
DRUGS,1
MADEY,1
Standardessential patents,2
Competition law,2
Innovation,1
Internet of Things,3
Huawei,1
Interim measures,2
COMPETITION LAW,2
TECHNOLOGIES,1
,1
STATUTORY INTERPRETATION,2
COMMONLAW,1
PATENT,1
RULEMAKING,1
CHEVRON,1
DEFERENCE,1
POWER,1
ACT,1
OSSIFICATION,1
DELEGATION,1
,1
ACT,1
LAW,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
UTILITY REQUIREMENT,2
ECONOMICS,1
RETHINKING,1
SCIENCE,1
NORMS,1
LAW,1
INFRINGEMENT,1
DISCLOSURE,1
INNOVATION,1
,1
PATENT,1
PROPERTY,1
Human embryonic stem cell,4
14day limit,2
patent law,2
China,1
TRIPS,1
,1
,1
,1
EUROPEANPATENT,1
TRADITIONAL KNOWLEDGE,2
STEMCELLS,1
PATENTABILITY,1
COURT,1
LAW,1
INVENTIONS,1
DECISION,1
JUSTICE,1
TRIPS,1
,1
FEDERAL CIRCUIT,2
SUPREMECOURT,1
PATENTLAW,1
ATTORNEYS FEES,2
APPEALS,1
RECOVERY,1
ACT,1
Globalization,1
Transnational Law,2
Equality Law,2
Arbitration,1
JudgeMade Law,2
,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
PHILOSOPHY,1
COPYRIGHT,1
LAW,1
,1
,1
,1
PROTECTION,1
PROPERTY,1
REACH,1
collusion,1
auction,1
bidding,1
competition law,2
rule of reason,3
social welfare,2
BIDDER COLLUSION,2
PATENT HOLDUP,2
Patents,1
trade secrets,2
single innovation,2
innovation output,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
OPENNESS,1
PERFORMANCE,1
SPILLOVERS,1
DISCLOSURE,1
STRATEGY,1
THICKET,1
SHADOW,1
LAW,1
,1
FECAL MICROBIOTA TRANSPLANTATION,3
CLOSTRIDIUMDIFFICILE INFECTION,2
INTELLECTUAL PROPERTY NORMS,3
INNOVATION,1
BURDEN,1
INCREASE,1
IMPACT,1
DRUGS,1
FIRMS,1
,1
PATENTS,1
standard essential patents,3
competition law,2
patent infringement,2
FRAND,1
willing licensee,2
injunctive relief,2
,1
patent law,2
knowledge governance,2
gender,1
women,1
STEM,1
INTELLECTUAL PROPERTY,2
SEXDIFFERENCES,1
SCIENCE,1
WOMEN,1
FEMINISM,1
LAW,1
TECHNOLOGY,1
ECONOMICS,1
INVENTION,1
EQUALITY,1
Artificial intelligence,2
Intellectual property law,3
AI,1
DABUS,1
Machine learning,2
Deep learning,2
America Invents Act,3
Text and data mining,4
Neural networks,2
Patents,1
Copyright,1
Trade secrets,2
Software protection,2
,1
Ecommerce platform,2
Patent,1
Liability,1
Ecommerce law,2
China,1
Notice and takedown,3
,1
Patent citations,2
Power law,2
Pareto regression,2
Fixedeffects quantiles regression,3
QUANTILE REGRESSION,2
Gene patents,2
genetic engineering,2
biotechnology,1
patents,1
CoViD19,1
EUROPEANUNION,1
UNITEDSTATES,1
DNASEQUENCES,1
MYRIAD,1
DIAGNOSTICS,1
IMPACT,1
ELIGIBILITY,1
FUTURE,1
LAW,1
US,1
,1
INTELLECTUAL PROPERTY,2
LEGAL CHANGE,2
RETROACTIVITY,1
RULES,1
LAW,1
COMPENSATION,1
TRANSITIONS,1
DEFERENCE,1
BENEFITS,1
TAKINGS,1
,1
,1
National Law,2
Transnational Law,2
Patent Disputes,2
Equitable Arbitration,2
JudgeMade Law,2
,1
Drugs,1
Pricing,1
Patents,1
Evergreening,1
Pharmaceuticals,1
ANTITRUST ANALYSIS,2
ORPHAN,1
PATENTS,1
POLICY,1
LAW,1
INCENTIVES,1
PROPERTY,1
LIFE,1
ACT,1
US,1
,1
UNITARY PATENT,2
TRANSITION,1
PROPERTY,1
SYSTEM,1
Antitrust regulation,2
Innovation,1
Intellectual property,2
Opensource software,2
Patent market,2
Patent transfer,2
INTELLECTUAL PROPERTY,2
MARKET,1
POLICY,1
POOLS,1
COMPETITION,1
TECHNOLOGY,1
TRADEMARKS,1
INDICATOR,1
LESSONS,1
FIRMS,1
patent revocation,2
intellectual property rights,3
NAFTA,1
PCT,1
investment law,2
expropriation,1
FET,1
utility,1
ARBITRATION,1
AGREEMENTS,1
MEDICINES,1
ACCESS,1
RIGHTS,1
,1
NEED,1
LAW,1
patent history,2
pharmaceutical patents,2
compulsory licensing,2
Patents and Designs Bill 1917,5
,1
,1
,1
patent,1
property rights,2
antitrust law,2
anticompetitive practice,2
FTC,1
PROPERTY,1
ANTICOMMONS,1
intellectual property,2
patents,1
BayhDole,1
grants,1
international,1
innovation,1
INTELLECTUAL PROPERTY,2
PUBLIC RESEARCH,2
PHARMACEUTICAL INNOVATION,2
DEVELOPINGCOUNTRIES,1
PATENTS,1
MUTATIONS,1
ACCOUNTABILITY,1
UNIVERSITY,1
RIGHTS,1
DRUGS,1
patent law,2
gene patents,2
purposebound,1
functionbound,1
Biotech Directive,2
EPO,1
Germany,1
Switzerland,1
,1
,1
PATENT,1
ECONOMICS,1
INNOVATION,1
COPYRIGHT,1
MISUSE,1
INCOME,1
Pharmaceutical patents,2
Patent policy,2
Competition law policy,3
,1
Brain patents,2
Neurolaw,1
Neuroethics,1
Human rights,2
Ordre public,2
Misuse,1
,1
,1
COLORECTALCANCER,1
FAIRUSE,1
RISK,1
SUPPLEMENTS,1
INVENTIONS,1
VEGETABLES,1
PARADIGMS,1
BRASSICA,1
SYSTEM,1
Copyright law,2
Patent law,2
Confidential commercial information law,4
Energy efficient innovation,3
And protection of innovation,4
ECONOMICGROWTH,1
COPYRIGHT PROTECTION,2
EMISSIONS,1
CONSUMPTION,1
COUNTRIES,1
PATENTS,1
SECTOR,1
GREEN,1
LINKS,1
FDI,1
,1
INTELLECTUAL PROPERTY,2
EQUITABLE SERVITUDES,2
ANTITRUST,1
MARKET,1
LAW,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FEDERAL CIRCUIT,2
US PATENT,2
INNOVATION,1
MARKET,1
RETHINKING,1
LITIGATION,1
QUALITY,1
HOLDUP,1
LAW,1
,1
,1
Request for Continued Examination,4
After Final Rejection,3
Carbon Dioxide ElectroReduction,3
Hydrocarbon Electrooxidation,2
Obviousness,1
,1
health,1
industry,1
Intellectual Property Law,3
patents,1
,1
,1
LAW,1
,1
COMPULSORY LICENSES,2
INVENTIONS,1
SYSTEM,1
MODEL,1
Patents,1
Technological innovation,2
Industries,1
Intellectual property,2
Patent law,2
Artificial intelligent inventions,3
computer related inventions,3
entrepreneurial trend,2
management of technology,3
patent law awareness,3
smart technology,2
survey on technology institutes,4
,1
,1
,1
FDI,1
Economic growth,2
TRIPS,1
Intellectual property,2
Patent enforcement,2
Patent systems,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
INSTRUMENTALVARIABLE ESTIMATION,2
RESEARCHANDDEVELOPMENT,1
PANELDATA,1
PROTECTION,1
US,1
PRODUCTIVITY,1
COUNTRIES,1
IMPACT,1
American Inventors Protection Act,4
Earnings,1
Innovation,1
Patent disclosure,2
RESEARCHANDDEVELOPMENT,1
INVENTORS PROTECTION ACT,3
VOLUNTARY DISCLOSURE,2
MARKET,1
INFORMATION,1
COST,1
PERFORMANCE,1
SPILLOVERS,1
INVESTMENT,1
CITATIONS,1
patent law,2
oil industry,2
materiality,1
competition,1
technology,1
innovation,1
,1
,1
INTELLECTUAL PROPERTY,2
TRADE DRESS,2
COPYRIGHT,1
PATENT,1
PROTECTION,1
CREATIVITY,1
COSTS,1
INNOVATION,1
SYSTEMS,1
NORMS,1
TRIPS Agreement,2
Indian Patents Act of 1970,5
Generic pharmaceutical manufacturers,3
Patents,1
RD,1
,1
,1
DECLARATORY JUDGMENT,2
INJURY,1
COSTS,1
LAW,1
,1
PROTECTION,1
LAW,1
,1
INDEPENDENT INVENTION,2
PATENT HOLDUP,2
PROPERTY,1
DEFENSE,1
VIEW,1
,1
PATENTS,1
INFORMATION,1
,1
RESEARCHANDDEVELOPMENT,1
PHARMACEUTICALINDUSTRY,1
RETHINKING,1
HISTAMINE,1
ECONOMICS,1
LAW,1
PRESUMPTION,1
DISCOVERY,1
BURDENS,1
RIGHTS,1
deextinction,1
ethics,1
morality exclusions,2
OncoMouse,1
patents,1
transgenic animals,2
ETHICS,1
CONSERVATION,1
PROTECTION,1
BACK,1
synthetic biology,2
patent,1
gene patent,2
biotechnology,1
Myriad,1
Venter,1
PARTS,1
STANDARDIZATION,1
PROPERTY,1
European,1
patents,1
plants,1
,1
,1
SURVIVING FICTIONS,2
COMMONLAW,1
PRESUMPTIONS,1
,1
CANCER,1
LIFE,1
,1
,1
,1
POLITICALECONOMY,1
INFORMATION,1
LAW,1
CONSTRUCTION,1
INVENTION,1
DOCTRINE,1
REALITY,1
SCOPE,1
ACT,1
,1
,1
,1
RECOGNITION,1
,1
INTELLECTUAL PROPERTY,2
COMPETITION,1
INCENTIVES,1
ACT,1
Patent trolls,2
NPEs,1
Capital structure,2
Innovation,1
Patents,1
Law and finance,3
FREE CASH FLOW,3
FINANCIAL DISTRESS,2
CORPORATE,1
COSTS,1
DEBT,1
TAXES,1
LITIGATION,1
INNOVATION,1
DETERMINANTS,1
PREDICTION,1
Patents,1
Pharmaceuticals,1
Drug Pricing,2
BayhDole,1
Government Patent Use,3
,1
Right to fair trial,4
Compulsory licence,2
COVID19,1
Pandemic,1
Status as a party,4
Right to inspect documents,4
Right to make a statement,5
Right to defence,3
Public health,2
Public authority,2
State of danger,3
Sufficient quantities of essential supplies,5
Exploitation right,2
Fundamental rights,2
,1
,1
SOCIALIZATION TACTICS,2
EXPERIENCE,1
COMMITMENT,1
CAREER,1
access to medicines,3
flexibilities,1
Nigeria,1
Pharmaceutical patents,2
public health,2
TRIPS,1
womens right to health,4
INTIMATE PARTNER VIOLENCE,3
REPRODUCTIVE HEALTH,2
CARE,1
TRIPS,1
DISEASES,1
OPTIONS,1
patent rights,2
TRIPS Agreement,2
comparative analysis,2
Iranian laws,2
European Union,2
,1
disclosure,1
analyst forecast,2
patent,1
information asymmetry,2
American Inventors Protection Act,4
RESEARCHANDDEVELOPMENT,1
CORPORATE DISCLOSURE,2
INFORMATION ASYMMETRY,2
PROPERTYRIGHTS,1
MARKET,1
INNOVATION,1
IDEAS,1
PROFITABILITY,1
COVERAGE,1
RENT,1
dynamic panel data,3
local linear estimator,3
patents,1
transition probability,2
Zipfs Law,2
ZIPFS LAW,2
CROSSSECTION,1
PANELDATA,1
EVOLUTION,1
GROWTH,1
CITY,1
GMM,1
,1
TRADE SECRETS,2
PATENT,1
COPYRIGHT,1
IGNORANCE,1
ECONOMICS,1
COSTS,1
LAW,1
,1
,1
,1
EVOLVING STANDARDS,2
PRIOR ART,2
,1
,1
Patent law,2
optimal patent design,3
patent monopoly,2
deadweight loss,2
INNOVATION,1
IMPACT,1
IMITATION,1
LENGTH,1
POLICY,1
,1
POLICY,1
STRATEGIES,1
LAW,1
Inherited risk of cancer,4
patents,1
molecular diagnostics,2
genetic testing,2
coverage and reimbursement,3
CLINICAL LABORATORIES,2
GENE PATENTS,2
INNOVATION,1
CLAIMS,1
Disclosure,1
Followon invention,2
Knowledge diffusion,2
Patent,1
CUMULATIVE INNOVATION,2
KNOWLEDGE SPILLOVERS,2
CITATIONS,1
FLOWS,1
,1
PATENTS,1
WORKER,1
OUTPUT,1
LAWS,1
ATTENDANCE,1
,1
HISTORY,1
CHANCERY,1
biotechnology patents,2
genetic tests,2
method claims,2
access to healthcare,3
DEPENDENT DNAPOLYMERASE,2
INTELLECTUAL PROPERTY,2
PERSPECTIVES,1
STANDARDS,1
VIRIONS,1
,1
INTELLECTUAL PROPERTY,2
DISCLOSURE,1
MARKET,1
RIGHTS,1
DELAY,1
LAW,1
,1
TOOLS,1
Democratic governance,2
EPO,1
UPC,1
unified patent court,3
unitary patent,2
IP,1
separation of powers,3
economic law,2
,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
ASSIGNMENT,1
Information dissemination,2
American Inventors Protection Act AIPA,5
Stock price crash risk,4
Unethical behavior,2
PRODUCT MARKET COMPETITION,3
VOLUNTARY DISCLOSURE,2
EARNINGS FORECASTS,2
BADNEWS,1
CORPORATE DISCLOSURE,2
INNOVATION EVIDENCE,2
AGENCY PROBLEMS,2
SPILLOVERS,1
COMPENSATION,1
TRANSPARENCY,1
,1
,1
Intellectual property rights,3
Patent law,2
Gravity model,2
Bilateral trade,2
F14,1
F15,1
O34,1
TECHNOLOGY,1
PROTECTION,1
VARIETY,1
GRAVITY,1
RIGHTS,1
IMPACT,1
Legal breadth,2
Patent scope,2
IP culture,2
Forward citations,2
Fourth industrial revolution,3
K11,1
O23,1
MARKET VALUE,2
KNOWLEDGE DIFFUSION,2
INNOVATION EVIDENCE,2
CITATIONS,1
US,1
INCENTIVES,1
QUALITY,1
LAW,1
BREAKTHROUGH,1
DETERMINANTS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ARTIFICIALINTELLIGENCE,1
RATIONAL IGNORANCE,2
DECISIONMAKING,1
INNOVATION,1
SCIENCE,1
LAW,1
INFRINGEMENT,1
INFORMATION,1
TECHNOLOGY,1
Computers,1
intellectual property,2
patents,1
software,1
USA,1
LAW,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
SCIENTIFICRESEARCH,1
SCIENCE,1
NORMS,1
RETHINKING,1
COPYRIGHT,1
LIFE,1
LAW,1
abuse of market power,4
Huawei  ZTE,3
standardization,1
FRAND,1
Orange Book Standard,3
essential facilities doctrine,3
IMS Health,2
PATENT INFRINGEMENT,2
HOLDUP,1
LAW,1
employee inventions,2
awards to inventors,3
Patents Act 1977,3
patent history,2
,1
Environmental regulation,2
Green innovation,2
Chinas new environmental protection law,5
Patents application,2
IMPACT,1
COMPETITIVENESS,1
PERFORMANCE,1
DECENTRALIZATION,1
DETERMINANTS,1
PRODUCTIVITY,1
ISOMORPHISM,1
FEDERALISM,1
HYPOTHESIS,1
DYNAMICS,1
subsoil use rights,3
subsoil resources,2
patented mining claim,3
mineral extraction,2
miners license,2
,1
Election,1
Restriction,1
Divisional Patent Application,3
Solid State LithiumMetal Battery,4
,1
,1
INTELLECTUAL PROPERTY,2
NATURAL LAW,2
DEFENSE,1
WEALTH,1
Pharmaceutical patents,2
Brazilian industrial property law,4
LPI 927996,2
INPI backlog,2
Patent term extension,3
RStudio,1
BACKLOG,1
,1
FILEDRAWER PROBLEM,2
DARK DATA,2
SCIENCE,1
SYSTEM,1
CLAIMS,1
LAW,1
PUBLICATION,1
DISCLOSURE,1
DOCTRINE,1
PROPOSAL,1
protection of patent rights,4
nonjurisdictional forms,2
selfdefense,1
claim,1
warning,1
mediation,1
,1
,1
,1
,1
OWNERSHIP,1
CONTRACTS,1
ECONOMICS,1
PATENTS,1
GROWTH,1
COSTS,1
,1
PROPERTYRIGHTS,1
INTELLECTUAL PROPERTY,2
INNOVATION,1
PLANTS,1
,1
INTELLECTUAL PROPERTY,2
UNIVERSITY TECHNOLOGY,2
COMMERCIALIZATION,1
INNOVATION,1
PROTECTION,1
SOFTWARE,1
TROLLS,1
RIGHTS,1
NORMS,1
FAITH,1
,1
,1
Patent law,2
Optimal patent design,3
Patent monopoly,2
Deadweight loss,2
INNOVATION,1
LENGTH,1
POLICY,1
,1
COMPETITION,1
COURT,1
,1
POLICY,1
SYSTEM,1
,1
PATENTS,1
SCIENCE,1
GENES,1
DNA,1
ACT,1
,1
RESEARCHANDDEVELOPMENT,1
INTERNAL CONTROL DEFICIENCIES,3
SARBANESOXLEY ACT,2
ECONOMIC CONSEQUENCES,2
FINANCIAL DEVELOPMENT,2
INFORMATION,1
COMPETITION,1
PATENTS,1
COSTS,1
DARK,1
,1
PATENT,1
STANDARDS,1
PROPERTY,1
LAW,1
,1
,1
Patent analytics,2
Patent landscaping,2
IP analysis,2
Power law distributions,3
DPA,1
Ranked pareto,2
Technology trajectory,2
Landscape consolidation index,3
Metalandscape fragmentation,2
,1
intellectual property,2
university,1
commercialization,1
INTELLECTUAL PROPERTY,2
Alzheimers disease genetics,3
research tool,2
nonpracticing entity,2
patent litigation,2
patent troll reform,3
enablement,1
Authorization and Consent,3
PROPERTYRIGHTS,1
AMYLOID PLAQUES,2
TRANSGENIC MICE,2
DISEASE,1
PRECURSOR,1
NORMS,1
INDUSTRY,1
SCIENCE,1
,1
TRIPS IMPLEMENTATION,2
DEVELOPINGCOUNTRIES,1
generic drugs,2
Food and Drug Administration,4
drug access,2
regulation,1
bioequivalence,1
INVITRO,1
,1
,1
,1
,1
,1
,1
,1
BAYHDOLE ACT,2
UNIVERSITIES,1
PATENT,1
,1
,1
Trade secrets,2
Patents,1
Remedies,1
Proportionality,1
Fundamental rights,2
Public interest,2
INTELLECTUAL PROPERTY,2
COMPETITION,1
Innovation,1
Intellectual property rights,3
Patent strength,2
Patent enforcement,2
TECHNOLOGICALCHANGE,1
PATENT RIGHTS,2
PROTECTION,1
,1
PATENTLAW,1
COPYRIGHT,1
HISTORY,1
INCENTIVES,1
LITIGATION,1
QUESTIONS,1
STANDARDS,1
POLITICS,1
MYRIAD,1
LEGAL,1
Patent strategy,2
pregrant publication,2
patent secrecy,2
INVENTORS PROTECTION ACT,3
TECHNOLOGICALINNOVATION,1
MARKET,1
KNOWLEDGE,1
ACQUISITION,1
OPPOSITION,1
DISCLOSURE,1
FRAMEWORK,1
,1
BAD,1
US,1
Japan,1
patent law,2
secret prior art,3
CRISPR,1
COVID19,1
university patenting,2
startups,1
innovation,1
STEM policy,2
,1
competition law,2
human genome editing technology,4
patent pool,2
ethical license,2
exclusive license,2
technology transfer,2
,1
Violation of patent rights,4
Legal liability,2
Civil law,2
Utility models,2
,1
Assessment,1
Inventive Step,2
Determination,1
Invention,1
Patent Offices,2
,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
KNOWLEDGE SPILLOVERS,2
MARKET,1
ALLOCATION,1
DISCLOSURE,1
INVENTORS,1
SECRETS,1
pandemic,1
innovation,1
incentives,1
patent waivers,2
intellectual property,2
TREATY,1
Gibrats law,2
knowledge size,2
hightech,1
patent,1
INNOVATION,1
right to healthcare,3
decisionmaking,1
distributive justice,2
law,1
,1
,1
,1
international economic law,3
moral rights,2
patents,1
traditional knowledge,2
TRIPS,1
INTELLECTUAL PROPERTY,2
RIGHTS,1
Knowledge diffusion,2
Patent citations,2
Information disclosure,2
Patent policy,2
Technology spillovers,2
AIPA,1
REGRESSION DISCONTINUITY DESIGNS,3
INVENTORS PROTECTION ACT,3
TECHNOLOGICAL OPPORTUNITIES,2
CUMULATIVE INNOVATION,2
ABSORPTIVECAPACITY,1
LOCAL SEARCH,2
SPILLOVERS,1
LOCALIZATION,1
CITATIONS,1
GEOGRAPHY,1
Public health,2
Law,1
Human rights,2
Vaccine,1
COVID19,1
Intellectual property law,3
Pharmaceutical patent rights,3
Right to health,3
INTELLECTUAL PROPERTY,2
LAW,1
,1
OPENSOURCE SOFTWARE,2
LONGTERM,1
PATENTLAW,1
SOCIALRESPONSIBILITY,1
ANTITRUST POLICY,2
PATH DEPENDENCE,2
CHICAGO SCHOOL,2
MARKET POWER,2
SHERMAN ACT,2
INNOVATION,1
Japanese biotechnology regulation,3
Japanese gene patenting system,4
life science and law,4
ANTICOMMONS,1
,1
,1
,1
,1
,1
TECHNOLOGY,1
PROPERTY,1
,1
SUPREMECOURT,1
FEDERAL CIRCUIT,2
JURIES,1
Employment,1
Startups,1
Patent trolls,2
NPEs,1
Venture capital,2
VENTURE,1
MARKET,1
ENTREPRENEURSHIP,1
NETWORKS,1
pharmaceutical policy,2
intellectual property rights,3
trade policy,2
NAFTA,1
free trade,2
UNIVERSAL PUBLIC COVERAGE,3
PATENTS,1
ACCESS,1
DRUGS,1
COST,1
BAD,1
PHARMACEUTICALS,1
NEOLIBERALISM,1
MEDICINES,1
BENEFITS,1
,1
PATENT,1
INNOVATION,1
LAW,1
RIGHTS,1
,1
RESEARCHANDDEVELOPMENT,1
WORLDSFAIRS,1
SPILLOVERS,1
PATENTS,1
FIRMS,1
,1
,1
drug discovery,2
grace period,2
invention disclosure,2
novelty,1
open innovation,2
patent law harmonization,3
,1
TRIPS,1
Patents,1
Length,1
Breadth,1
Disclosure,1
Continuations,1
BAYHDOLE ACT,2
CONTINUATIONS,1
POLICY,1
outer space,2
patents,1
space commercialization,2
extra terrestrial jurisdiction,3
,1
Differenceindifference,1
patent commercialization,2
patent ownership,2
technology transfer,2
university,1
BAYHDOLE ACT,2
ENTREPRENEURSHIP,1
POLICIES,1
,1
REVENUES,1
TAXATION,1
LAW,1
,1
LAW,1
PROPERTY,1
MODELS,1
REDUCTION,1
ENTITIES,1
TROLLS,1
RIGHTS,1
,1
FEDERAL CIRCUIT,2
,1
RULES,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
DYNAMICANALYSIS,1
INNOVATION,1
POLICY,1
indigenous knowledge,2
Southern Africa,2
patent law,2
benefit sharing,2
feminist studies,2
SAN LAND CLAIM,3
COMMUNITY,1
,1
,1
Patent law,2
COVID 19,2
Research Use,2
Compulsory License,2
Vaccine Nationalism,2
,1
Patent,1
Policy change,2
Litigation,1
US,1
LITIGATION,1
EBAY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
EXPERIMENTAL TESTS,2
CONTROLLEDTRIALS,1
EX ANTE,2
INNOVATION,1
PROTECTION,1
POLICY,1
LAW,1
,1
,1
,1
,1
Intellectual property,2
patent,1
cybercrimes,1
business performance,2
economic growth,2
OPEN INNOVATION,2
PERFORMANCE,1
IMPACT,1
,1
,1
compulsory licensing,2
patent,1
COVID19,1
,1
,1
,1
,1
ANTITRUST IMMUNITY,2
LAW,1
FEDERALISM,1
ENTITIES,1
,1
,1
humans,1
incidence,1
logistic models,2
odds ratio,2
radial artery,2
TRANSRADIAL CATHETERIZATION,2
PATENT HEMOSTASIS,2
INTERVENTION,1
ANGIOGRAPHY,1
PREVENTION,1
HEPARIN,1
PROPHET,1
Intellectual property rights,3
Patent assertion entities,3
Patent licensing,2
RD,1
Innovation,1
Sequential entry,2
ASSERTION ENTITIES,2
Intellectual property,2
standardessential patents,2
injunctive relief,2
FRAND,1
RULES,1
LAW,1
patent,1
artificial intelligence,2
inventorship,1
invention,1
inventive step,2
,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
PATENT,1
LAW,1
,1
INCENTIVES,1
PSYCHOLOGY,1
PATENTS,1
LAW,1
,1
INTELLECTUAL PROPERTY,2
GENDERDIFFERENCES,1
EX ANTE,2
COPYRIGHT,1
INFORMATION,1
MARKET,1
POST,1
ANTICOMMONS,1
INNOVATION,1
SCIENCE,1
innovation risk,2
patent infringement litigation risk,4
innovation risk evaluation,3
patent risk factors,3
logistic regression,2
INDICATORS,1
LITIGATION,1
COSTS,1
,1
INTELLECTUAL PROPERTY,2
LAW,1
ECONOMICS,1
INFORMATION,1
IGNORANCE,1
HEALTH,1
,1
,1
,1
PATENT,1
COPYRIGHT,1
LAW,1
INFORMATION,1
HOLDUP,1
,1
PATENT OFFICE RECORDS,3
UNITEDSTATES,1
LAW,1
,1
RETHINKING,1
LAW,1
EQUIVALENTS,1
INVENTION,1
DOCTRINE,1
ART,1
,1
LAW,1
WHITENESS,1
CULTURE,1
PATENTS,1
Limited tax liability,3
withholding tax,2
Germany transfer pricing,3
taxation at source sale,4
transfer of intellectual property IP,5
licensing of IP,3
intellectual property,2
cost plus method,3
routine patenttrademark registration services,4
,1
,1
INTELLECTUAL PROPERTY,2
PATENT,1
CONSTRUCTION,1
,1
BAYHDOLE ACT,2
,1
MARKETSTRUCTURE,1
DISCLOSURE,1
BayhDole Act,2
Technology transfer,2
Patenting,1
Structural change,2
CHANGEPOINT,1
STRUCTURALCHANGE,1
TESTS,1
SEQUENCE,1
PARAMETER,1
BREAKS,1
,1
,1
Technological evolution,2
patent citation network,3
knowledge adaptation factor,3
knowledge genetic decomposition,3
TRAJECTORIES,1
GROWTH,1
SYSTEM,1
DESIGN,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
SCIENCE,1
WOMEN,1
LAW,1
TECHNOLOGY,1
,1
INTELLECTUAL PROPERTY,2
SCIENCE,1
WOMEN,1
LAW,1
DISPARITIES,1
TECHNOLOGY,1
,1
,1
,1
STRICT LIABILITY,2
LIMITEDLIABILITY,1
FEDERAL CIRCUIT,2
SUPREMECOURT,1
COMMONLAW,1
RETHINKING,1
CERCLA,1
VEIL,1
SPECIALIZATION,1
INFRINGEMENT,1
,1
,1
,1
,1
Pharmaceutical patent,2
public health,2
COVID19 vaccines,2
compulsory licence,2
government use,2
Patents and Designs Act,4
,1
,1
,1
,1
LITIGATION,1
Patent,1
Litigation,1
Infringement,1
Prior art,2
Fee shifting,2
America Invents Act,3
ECONOMICANALYSIS,1
PRIOR ART,2
LITIGATION,1
DISPUTES,1
INFORMATION,1
SEARCH,1
Patents,1
Innovation,1
Corporate investment,2
Law and finance,3
BANKRUPTCY REFORM,2
ENFORCEMENT,1
FIRMS,1
,1
FEDERAL CIRCUIT,2
US PATENT,2
EMPIRICALASSESSMENT,1
SYSTEM,1
INFRINGEMENT,1
HOLDUP,1
POLICY,1
JURIES,1
LAW,1
,1
DISCLOSURE,1
Patents,1
Medicines,1
Vaccines,1
Right to Health,3
Human Rights,2
Social Policies,2
COVID19,1
TRIPS,1
,1
,1
WALL VIBRATIONS,2
SOUND,1
CLASSIFICATION,1
ACOUSTICS,1
PATENT,1
LAW,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ORGANIZATIONS,1
LAW,1
MYTH,1
EVOLUTION,1
,1
,1
Patents,1
Patent enforcement,2
National patent systems index,4
Intellectual property,2
Patent system development,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
SYSTEMS,1
CHINA,1
,1
DESIGN,1
LAW,1
,1
,1
,1
PATENT,1
TEXT,1
COMPREHENSIBILITY,1
CONCRETENESS,1
NOTICE,1
CHOICE,1
RECALL,1
BIAS,1
LAW,1
crop mix,2
farm capital use,3
farm innovation,2
farm labor,2
legal Arizona workers act,4
LABOR,1
IMPACT,1
STATE,1
MECHANIZATION,1
INDUSTRIES,1
REDUCE,1
,1
JUSTICE,1
PRINGLE,1
COURT,1
,1
,1
,1
FEDERAL CIRCUIT,2
PATENT SYSTEM,2
,1
TECHNOLOGY,1
,1
LEGAL PROTECTION,2
INNOVATION,1
DESIGNS,1
TROLLS,1
START,1
,1
INTELLECTUAL PROPERTY,2
PATENT HOLDUP,2
INCENTIVES,1
FRAND,1
COMPETITION,1
LAW,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
PERMANENT INJUNCTIONS,2
PATENT HOLDUP,2
CONFUSION,1
American Inventors Protection Act AIPA,5
corporate venture capital CVC,4
disclosure,1
patent,1
startup,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PERFORMANCE,1
IDEAS,1
BIOTECHNOLOGY,1
INVESTORS,1
ALLIANCE,1
NETWORKS,1
SHARKS,1
MARKET,1
,1
,1
chemical industry,2
technological information,2
clean air act,3
change detection,2
outlier test,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALCHANGE,1
PREDICTION METHODS,2
NETWORK ANALYSIS,2
ENERGY,1
INNOVATION,1
SUSTAINABILITY,1
PERFORMANCE,1
INDICATORS,1
RESOURCES,1
,1
DIFFERENCE,1
Trade secrets,2
Defend Trade Secrets Act,4
Economic Espionage Act,3
Uniform Trade Secrets Act,4
TRIPS Agreement,2
Knowhow,1
PROTECTION,1
,1
FEDERAL CIRCUIT,2
POLICY,1
COURT,1
LAW,1
SYSTEM,1
Antitrust,1
Collusion,1
Patent challenges,2
Patent settlements,2
Pharma,1
SETTLEMENT,1
Patent strategy,2
foreign patent litigation,3
patent trajectory,2
intellectual property regime,3
O31,1
O32,1
O34,1
K42,1
INNOVATION,1
KNOWLEDGE,1
SPECIALIZATION,1
TECHNOLOGY,1
MANAGEMENT,1
RESOLUTION,1
DIVERSITY,1
BEHAVIOR,1
IMPACT,1
DEPTH,1
,1
FEDERAL CIRCUIT,2
LAW,1
JURISDICTION,1
UNIFORMITY,1
JUDICIARY,1
DELAWARE,1
REFORM,1
,1
TRACEABILITY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PROTECTION,1
KNOWLEDGE,1
Patent,1
Computer Program,2
Indonesia,1
Comparison and Several Countries,4
,1
event study,2
welfare effects,2
reverse payment patent,3
settlement,1
payfordelay,1
patent litigation,2
EU competition law,3
antitrust enforcement,2
evaluation,1
COMPETITION LAW,2
,1
INTELLECTUAL PROPERTY,2
KNOWLEDGE SPILLOVER,2
GERMANY,1
RIGHTS,1
INNOVATION,1
GROWTH,1
MARKET,1
TRADE,1
,1
,1
Spray booth with hybrid electrical heating,6
Car body shops,3
Infringement,1
Injunction,1
Counterfeit products,2
Unfair competition,2
Invalidity,1
Lack of novelty,3
Predisclosure,1
Passing off,2
Disgorgement of profits,3
Cumulative protection,2
,1
China,1
university,1
employee inventions,2
Mixed Ownership,2
patent transformation,2
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
PROFESSORS,1
KNOWLEDGE,1
PROPERTY,1
,1
PATENT,1
COPYRIGHT,1
LAW,1
University patents,2
Renewal fees,2
Licensing,1
Technology transfer,2
Large entity status,3
Federal sponsorship,2
UNIVERSITY INVENTIONS,2
MARKET,1
INCENTIVES,1
INVENTORS,1
KNOWLEDGE,1
OPTIONS,1
SCIENCE,1
ACT,1
Water resources,2
waterrelated patents,2
scarcity,1
industrialization,1
,1
,1
,1
,1
EQUITY,1
RISK,1
LAW,1
SUPPLEMENTS,1
INVENTIONS,1
VEGETABLES,1
BRASSICA,1
STANDARD,1
CANCER,1
MISUSE,1
,1
INNOVATION,1
PATENTS,1
,1
,1
Patent classification,2
Inconsistencies,1
Classifiers,1
Deep learning,2
Large language models,3
IPC,1
,1
Intellectual property,2
patents on agrobiotechnology,3
plant variety protection,3
seed laws,2
subSaharan Africa,2
accumulation by dispossession,3
PLANT VARIETY PROTECTION,3
INTELLECTUAL PROPERTY,2
POLITICALECONOMY,1
SECTOR DEVELOPMENT,2
FARMERS RIGHTS,2
COTTON,1
FOOD,1
BREEDERS,1
KNOWLEDGE,1
SYSTEMS,1
,1
PRESUMPTION,1
VALIDITY,1
LAW,1
,1
,1
genetic resources,2
source disclosure,2
patent law,2
game theory,2
mandatory model,2
volun,1
tary model,2
patent applications,2
regulatory bodies,2
cost benefit perspective,3
INFORMATION,1
Strategic patenting,2
legitimacy,1
liabilities,1
patent publication,2
China,1
RESEARCHANDDEVELOPMENT,1
ORGANIZATIONAL LEGITIMACY,2
EMPIRICALEVIDENCE,1
FINANCIAL PERFORMANCE,2
FIRMS PUBLISH,2
RECENT SURGE,2
INNOVATION,1
TECHNOLOGY,1
MARKET,1
INDUSTRY,1
Australian Register of Therapeutic Goods,5
Federal Court of Australia,4
Patent Term Extension,3
Pharmaceutical Substance,2
Therapeutic Goods Administration,3
,1
Patents,1
Technological innovation,2
Entrepreneurship,1
Intellectual property,2
Technology transfer,2
Commercialization,1
Education,1
Academic promotion AP,3
intellectual property rights,3
entrepreneurial universities,2
patents,1
technology transfer,2
technology transfer offices TTOs,4
university industry links,3
TECHNOLOGYTRANSFER OFFICES,2
INTELLECTUAL PROPERTYRIGHTS,2
RESOURCEBASED VIEW,2
BAYHDOLE ACT,2
ACADEMIC ENTREPRENEURSHIP,2
INDUSTRY COLLABORATION,2
ECONOMICDEVELOPMENT,1
QUADRUPLE HELIX,2
INNOVATION,1
KNOWLEDGE,1
,1
SUPREMECOURT,1
DEFERENCE,1
PATENTS,1
MYRIAD,1
RULES,1
,1
UNITEDSTATES,1
PRICECOMPETITION,1
INNOVATION ACT,2
BIOSIMILARS,1
INCENTIVES,1
CHALLENGE,1
KNOWLEDGE,1
Right to repair,3
Patent infringement,2
Exhaustion,1
Unified Patent Court,3
Physical and intellectual property,4
Implied licence,2
,1
Bundesverfassungsgericht,1
German Federal Constitutional Court,4
European integration,2
EU law,2
international law,2
satellite treaties,2
Unitary Patent,2
Unified Patent Court,3
Treaties Supplementing or Being Otherwise Closely Tied to the EU,10
enhanced cooperation,2
,1
,1
BIOTECHNOLOGY,1
UTILITY,1
MARKET,1
,1
,1
,1
ANTICOMPETITIVESETTLEMENT,1
PATENT SETTLEMENTS,2
GENERIC ENTRY,2
DRUGS,1
PRESCRIPTION,1
EXCLUSIVITY,1
INCENTIVES,1
STANDARDS,1
ACT,1
Prizes,1
Patents,1
Innovation,1
INDUSTRIALREVOLUTION,1
INNOVATION,1
INCENTIVES,1
BRITAIN,1
,1
LOGIT,1
OFFICE,1
,1
ECONOMICS,1
LAW,1
Global energy interconnection,3
Collaborative innovation,2
Standard essential patent,3
Ownership,1
INDUSTRY COLLABORATION,2
,1
DNA PATENTS,2
PROVISION,1
MYRIAD,1
,1
SUBJECTMATTER,1
PATENTLAW,1
European patent law,3
Patent claim construction,3
Doctrine of equivalents,3
Actavis v,2
Eli Lilly,2
Harmonisation,1
Judicial cooperation and dialogue,4
COURT,1
DOCTRINE,1
LAW,1
,1
PATENT,1
,1
NOTICE FAILURE,2
FAIRUSE,1
COPYRIGHT,1
SERVITUDES,1
LAW,1
POSSESSION,1
RESTRICTIONS,1
INFORMATION,1
CUSTOM,1
PATENT,1
Scalefree,1
Patent litigation,2
Complex network,2
Shannon entropy,2
EMPIRICALANALYSIS,1
STATISTICS,1
TROLLS,1
patents,1
innovation,1
research,1
INTELLECTUAL PROPERTYRIGHTS,2
SEQUENTIAL INNOVATION,2
BIOMEDICALRESEARCH,1
MARKET,1
LAW,1
SPILLOVERS,1
COUNTRIES,1
IMPACT,1
agriculture,1
biotechnology patents,2
food security,2
Iraqi Patent Law 65l1970,4
Order 812004,2
TRIPs Agreement,2
,1
Africa,1
patent landscape,2
pharmaceuticals,1
access to medicines,3
TRIPS Agreement,2
PUBLICHEALTH,1
ACCESS,1
FLEXIBILITIES,1
AGREEMENT,1
TRADE,1
,1
,1
Alienation,1
Patent,1
Justification,1
Biotechnology,1
DISCOVERY,1
RIGHTS,1
LAW,1
,1
RETHINKING,1
LITIGATION,1
INNOVATION,1
CITATIONS,1
Patent,1
Valuation,1
Anchoring,1
Value,1
Novelty,1
TECHNOLOGICALINNOVATION,1
CITATIONS,1
UNCERTAINTY,1
MECHANISMS,1
JUDGMENT,1
BEHAVIOR,1
QUALITY,1
DESIGN,1
BIAS,1
,1
FEDERAL CIRCUIT,2
EMPIRICALASSESSMENT,1
COMMERCIAL SUCCESS,2
OBJECTIVE EVIDENCE,2
STANDARDS,1
INVENTION,1
LAW,1
PERSPECTIVES,1
PSYCHOLOGY,1
PATENTS,1
Artificial intelligence,2
Patent law,2
Pharmaceutical patents,2
Nonobviousness,1
Inventive step,2
Big data,2
INVENTIVE STEP,2
PRIOR ART,2
STANDARDS,1
NONOBVIOUSNESS,1
COMPUTER,1
LEGAL,1
,1
ACUTE MYOCARDIALINFARCTION,2
COGNITIVE PERFORMANCE,2
FINANCIAL DEVELOPMENT,2
CIGARETTESMOKING,1
COSTS,1
ADMISSIONS,1
ECONOMICS,1
NICOTINE,1
STATE,1
LIFE,1
,1
,1
,1
REVERSEPAYMENT SETTLEMENTS,2
INTELLECTUAL PROPERTY,2
UNCERTAINTY,1
AGREEMENTS,1
POLICY,1
LAW,1
Patent scope,2
causal inference,2
innovation,1
measurement,1
patent examiners,2
examiner toughness,2
,1
,1
BAYHDOLE ACT,2
QUALITY,1
CITATIONS,1
INNOVATION,1
UNIVERSITIES,1
INDICATORS,1
legal protection of computer programs,5
copyright,1
patent law,2
,1
ESG,1
patent utilisation,2
responsible investment,2
startups,1
sustainable innovation,2
,1
,1
OFFICE,1
DISCLOSURE,1
,1
MOUSE EMBRYOS,2
SELFRENEWAL,1
DIFFERENTIATION,1
,1
SUPREMECOURT,1
EMPIRICALANALYSIS,1
FEDERAL CIRCUIT,2
PATENT,1
NONOBVIOUSNESS,1
STANDARDS,1
DOCTRINE,1
LAW,1
Technology performance improvement,3
Technology improvement rates,3
Moores law,2
Differences in improvement rates among technologies,6
Decomposed technological change,3
Patent citation network,3
RESEARCHANDDEVELOPMENT,1
SCHUMPETERIAN PATTERNS,2
INNOVATION SYSTEMS,2
FUNCTIONALAPPROACH,1
PROGRESS,1
INDUSTRY,1
COMPLEXITY,1
EXPERIENCE,1
HISTORY,1
GROWTH,1
drug registration,2
patent linkage system,3
pharmaceutical patent protection,3
,1
,1
STATUS UPDATE IMPLEMENTATION,3
BIOLOGICS PRICECOMPETITION,2
INNOVATION ACT,2
Janssen Pharmaceutica,2
Longacting Risperidone,2
Public Health Program of India,5
MENTALHEALTH,1
CARE,1
,1
IRREPARABLE INJURY,2
CIVIL PROCEDURE,2
PATENT HOLDUP,2
JURY TRIAL,2
LAW,1
INJUNCTIONS,1
PROPERTY,1
HISTORY,1
FOUNDATIONS,1
PRINCIPLES,1
,1
INTELLECTUAL PROPERTY,2
BIG DATA,2
RACE,1
COPYRIGHT,1
GENDER,1
PATENTS,1
COMMERCIALIZATION,1
LAW,1
AGE,1
AI,1
,1
,1
,1
PRIVATE PROPERTY,2
NATURAL LAW,2
COPYRIGHT,1
PATENTS,1
ECONOMICS,1
RIGHTS,1
PHILOSOPHY,1
RACE,1
,1
ECONOMICANALYSIS,1
FAIRUSE,1
EQUITABLE SERVITUDES,2
INJUNCTIVE RELIEF,2
PATENT,1
LAW,1
RIGHTS,1
COMMONS,1
RULES,1
ANTICOMMONS,1
Eventstudy,1
Stock price effects,3
Patent oppositions,2
IPR,1
AIA,1
PTAB,1
,1
,1
LEGAL PROTECTION,2
ORIGINALITY,1
LAW,1
,1
RESEARCHANDDEVELOPMENT,1
GENERIC DRUG COMPETITION,3
BRANDNAME,1
INNOVATION,1
ACT,1
PRODUCTIVITY,1
LEGISLATION,1
CHALLENGES,1
PATENTS,1
MERGERS,1
Indian patent law,3
Patent infringement,2
TRIPS compliance,2
Evergreening,1
the Novartis case,3
,1
Information technology,2
Information technologyenabled services,3
Electronics,1
Software,1
Outsourcing,1
Patents,1
RD,1
ELECTRONICS,1
Regulation EC 469,3
2009,1
Supplementary protection certificate,3
CJEU Santen judgment,3
Product patent,2
Medicinal patent,2
Application patent,2
PHARMACEUTICALS,1
PATENTABILITY,1
CONVENTION,1
copyright,1
moral rights,2
integrity right,2
destruction,1
MORAL RIGHT,2
REPUTATION,1
ARTISTS,1
AUTHORS,1
Patenting,1
Commercialization of research,3
Intellectual property rights IPR,4
Science policy,2
Goal displacement,2
Isomorphism,1
University performance contracts,3
OECD,1
Denmark,1
INDICATORS,1
KNOWLEDGE,1
INDUSTRY,1
UNIVERSITIES,1
PERFORMANCE,1
SCIENCE,1
EUROPE,1
IMPACT,1
,1
RESEARCHANDDEVELOPMENT,1
BAYHDOLE ACT,2
PUBLIC RESEARCH,2
TECHNOLOGICALINNOVATION,1
TRANSFER AGREEMENTS,2
KNOWLEDGE,1
RETURNS,1
SCIENCE,1
COMPLEMENT,1
STRATEGIES,1
patent flexibility clauses,3
patent suspension,2
trips agreement,2
COVID19 vaccine,2
WTO,1
Pharmaceuticals,1
Secondary patents,2
Section 3d,2
Prior Consent,2
TRIPS,1
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPINGCOUNTRIES,1
DRUG PATENTS,2
INNOVATION,1
PROTECTION,1
LAW,1
biopatent directive,2
Brstle,1
embryo,1
EPO,1
nondestructive parthenotes,2
patent,1
stem cells,2
,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
US PATENT,2
PRIVATE,1
TROLLS,1
RULES,1
COSTS,1
LAW,1
INNOVATION,1
INDUSTRY,1
PARADOX,1
Myriad,1
Mayo,1
35 USC 101,3
natural,1
law of nature,3
,1
Patents,1
History,1
Behavioral sciences,2
Histograms,1
Computer architecture,2
Business,1
Law,1
Technological innovation,2
,1
,1
TRIPS,1
LAW,1
stem cell patent elibility,4
stem cell patent ethics,4
human embryo,2
stem cell commericalization,3
legal interpretation,2
,1
,1
US PATENT,2
CITATIONS,1
FREQUENCY,1
NETWORKS,1
SYSTEM,1
,1
INTELLECTUAL PROPERTY,2
SIMPLE ECONOMICS,2
COLLABORATION,1
INFORMATION,1
RIGHTS,1
LAW,1
INTEGRATION,1
PATENTS,1
LOCUS,1
FIRMS,1
,1
,1
,1
BAYHDOLE ACT,2
PROFESSORS PRIVILEGE,2
PROPENSITY SCORE,2
INTELLECTUAL PROPERTY,2
IMPACT,1
TECHNOLOGY,1
FACULTY,1
COMMERCIALIZATION,1
INNOVATION,1
KNOWLEDGE,1
,1
COPYRIGHT INFRINGEMENT,2
ECONOMICANALYSIS,1
SOCIALINFLUENCE,1
PATENT SYSTEM,2
EARLY HISTORY,2
MARKET VALUE,2
TRADE DRESS,2
LAW,1
PROTECTION,1
INNOVATION,1
antiantisuit injunctions,2
antisuit injunctions,2
FRAND,1
litigation,1
SEP,1
standards,1
telecommunications,1
COMITY,1
University patenting,2
China,1
Patent quantity,2
Patent quality,2
Subsidy programs,2
Project 985,2
BAYHDOLE ACT,2
PUBLIC RESEARCH ORGANIZATIONS,3
ACADEMIC RESEARCH,2
IMPACT,1
US,1
COMMERCIALIZATION,1
TECHNOLOGY,1
CITATIONS,1
KNOWLEDGE,1
EXAMINER,1
acquisitions,1
innovation,1
sleeping patents,2
IP law,2
ownership,1
PATENT,1
TECHNOLOGY,1
STRATEGIES,1
AUCTIONS,1
MARKET,1
IDEAS,1
patenting,1
universities,1
technology transfer,2
technology transfer office,3
COMMERCIALIZATION,1
FACULTY,1
ENTREPRENEURSHIP,1
MOTIVATIONS,1
ENGAGEMENT,1
KNOWLEDGE,1
ACADEMICS,1
INDUSTRY,1
SUCCESS,1
IMPACT,1
,1
INTELLECTUAL PROPERTY,2
ECOINNOVATION,1
PATENT,1
INFRASTRUCTURE,1
TECHNOLOGIES,1
Strategic patenting,2
Evergreening,1
Pharmaceutical patents,2
Anticompetitive effect,2
Generic competition,2
Access to medicines,3
Access to COVID19 treatment,4
INNOVATION,1
THICKETS,1
DRUGS,1
Iron Redox Battery,3
Slurry Electrode,2
Indefiniteness,1
Novelty,1
Obviousness,1
,1
patents,1
leniency,1
collusion,1
prisoners dilemma,2
RESEARCHANDDEVELOPMENT,1
RESEARCH JOINT VENTURES,3
EMPIRICALEVIDENCE,1
PRISONERSDILEMMA,1
TECHNOLOGY,1
DURATION,1
MOTIVES,1
COSTS,1
International law,2
access to medicines,3
right to health,3
legal hierarchy,2
treaty law,2
IP,1
patent rights,2
TRIPS,1
RIGHTS,1
DIGNITY,1
ACCESS,1
,1
SCIENCE,1
INNOVATION,1
DISCOVERY,1
KNOWLEDGE,1
US,1
,1
INTELLECTUAL PROPERTY,2
PRIVATE PROPERTY,2
LAW,1
REMEDIES,1
HOLDUP,1
Patent policies,2
Commercialization of academic patents,4
Spatial regression model,3
Innovation distance,2
China,1
BAYHDOLE ACT,2
SPATIAL AUTOCORRELATION,2
VACANT LAND,2
COMMERCIALIZATION,1
INNOVATION,1
DIFFERENCE,1
QUALITY,1
HEALTH,1
INVENTIONS,1
OUTPUTS,1
,1
FAIRUSE,1
NORMS,1
COMMONS,1
PATENT,1
RIGHTS,1
Disruptive innovation,2
Truncation bias,2
Exclusion bias,2
US patent law change,4
,1
innovation,1
intellectual property,2
natural products,2
patents,1
,1
Patents,1
Licensing,1
wtp,1
npe,1
Welfare,1
DEVELOPMENT SPILLOVERS,2
EMPIRICALANALYSIS,1
TECHNOLOGY,1
PERSISTENCE,1
INCENTIVES,1
MARKETS,1
TROLLS,1
Patents,1
RD,1
economic growth,2
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT COMPETITION,2
SEQUENTIAL INNOVATION,2
PREEMPTION GAMES,2
PROTECTION,1
MODEL,1
LAW,1
INFORMATION,1
BUYOUTS,1
RACES,1
standard,1
standard essential patent SEP,4
injunctive relief,2
injunction,1
competition,1
antitrust,1
Antimonopoly law,2
competition law,2
fair,1
reasonable and non discriminatory FRAND,5
reasonable and nondiscriminatory RAND,4
,1
Genetic Resources,2
Traditional Medicinal Knowledge,3
National Medicine Patent Development,4
Collective Action,2
,1
Drug detection,2
patent statistics,2
patent analysis,2
development trend,2
,1
,1
,1
,1
,1
,1
,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
LEGAL PROTECTION,2
TRADE SECRETS,2
SOFTWARE,1
COPYRIGHT,1
PRIVATIZATION,1
TRANSPARENCY,1
INNOVATION,1
PATENT,1
LAW,1
innovation,1
intellectual property,2
natural products,2
patents,1
,1
,1
CLINICALTRIAL AGREEMENTS,2
CONFLICTOFINTEREST,1
NATIONAL SURVEY,2
SUPREMECOURT,1
ORGANIZATIONS,1
ROFECOXIB,1
INDUSTRY,1
PATENTS,1
LITIGATION,1
OUTCOMES,1
,1
FAIRUSE,1
LIABILITY RULES,2
COPYRIGHT,1
RIGHTS,1
PROTECTION,1
LAW,1
ANTICOMMONS,1
INNOVATION,1
FAILURE,1
PATENTS,1
,1
ECONOMICS,1
PATENTS,1
NORMS,1
,1
,1
Bibliometrics,1
Patent quality,2
Invention,1
University patents,2
Higher education,2
University,1
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE TRANSFER,2
TECHNOLOGY,1
SCIENCE,1
PORTFOLIO,1
SCOPE,1
ACT,1
,1
MARINE GENETICRESOURCES,2
PATENTLAW,1
BIOTECHNOLOGY,1
LYSOZYME,1
PROMOTER,1
RIGHTS,1
AREAS,1
AIPA,1
duplicative research,2
knowledge disclosure,2
patents,1
PRODUCT MARKET,2
PATENTS,1
SPILLOVERS,1
IDEAS,1
Patents,1
Designs,1
Trade marks,2
Literature listing,2
Patent analysis,2
Current awareness,2
INTELLECTUAL PROPERTY,2
TRADEMARK INFRINGEMENT,2
PATENTS,1
INNOVATION,1
TECHNOLOGY,1
KNOWLEDGE,1
LAW,1
IMPACT,1
RULES,1
MODEL,1
genome editing,2
CRISPRCas9 technology,2
legal regulation,2
EU legislation,2
US legislation,2
international law,2
patents,1
FUTURE,1
CROPS,1
BIOTECHNOLOGY,1
,1
INTELLECTUAL PROPERTY,2
VERTICAL INTEGRATION,2
INNOVATION,1
INDUSTRY,1
RIGHTS,1
PRODUCT,1
LAW,1
COMPETITION,1
POSSESSION,1
EVOLUTION,1
licensing,1
patent publication,2
invention disclosure,2
PROPERTYRIGHTS,1
INNOVATION,1
DISCLOSURE,1
IMPACT,1
SALE,1
US,1
,1
DECISIONMAKING,1
PROPERTY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
TRADE,1
ACCESS,1
WTO,1
,1
,1
,1
,1
,1
,1
,1
RESEARCHANDDEVELOPMENT,1
NAGOYAPROTOCOL,1
EXPRESSION,1
LAW,1
FOOD,1
,1
PATENT SETTLEMENT,2
,1
DEVELOPINGCOUNTRIES,1
THERAPY,1
TRIPS,1
CHALLENGE,1
ISSUES,1
HEALTH,1
WORLD,1
,1
PATENT HOLDUP,2
COPYRIGHT PROTECTION,2
ROYALTY STACKING,2
LEGAL PROTECTION,2
COMPETITION,1
TECHNOLOGY,1
ANTITRUST,1
RIGHTS,1
SCOPE,1
LAW,1
Patent paradox,2
complex industries,2
licensing,1
SCOPE,1
ECONOMICS,1
INDUSTRY,1
BREADTH,1
POLICY,1
LAW,1
appropriation,1
innovation,1
patent law firm,3
patent system,2
INNOVATION,1
MODELS,1
INDICATORS,1
EXPERTISE,1
MERGER,1
IMPACT,1
,1
,1
Covenant not to sue,4
Covenant to sue last,4
Infringement,1
Litigation exhaustion,2
Consent to placing on the market,6
,1
nanotechnology,1
nanomaterials,1
nanoparticles,1
patents,1
regulatory,1
legal,1
legislation,1
congress,1
USPTO,1
NNI,1
EPA,1
FDA,1
America Invents Act,3
AIA,1
,1
,1
POSTTRIPS ERA,2
INTELLECTUAL PROPERTY,2
PUBLICHEALTH,1
ECONOMICDEVELOPMENT,1
ACCESS,1
MEDICINES,1
AGREEMENT,1
PLUS,1
WTO,1
,1
COPYRIGHT PROTECTION,2
COMPUTERPROGRAMS,1
PATENT,1
SOFTWARE,1
DOCTRINE,1
DESIGN,1
ICT,1
Communication,1
Knowledge diffusion,2
Sciencebased innovation,2
Universitypatenting,1
BAYHDOLE ACT,2
INFORMATIONTECHNOLOGY,1
DIFFUSION,1
INTERNET,1
PRODUCTIVITY,1
UNIVERSITIES,1
GROWTH,1
COSTS,1
,1
INTERNATIONALLAW,1
CRITICAL LEGAL,2
HUMANRIGHTS,1
DEVELOPINGCOUNTRIES,1
BRAZILIAN POLICY,2
TRIPS AGREEMENT,2
AIDS TREATMENT,2
PATENT SYSTEM,2
CIVILSOCIETY,1
ACCESS,1
patent policy,2
commercializing academic patent,3
spatial differenceindifferences,2
spatial spillover,2
quasinatural experiment,2
BAYHDOLE ACT,2
SUSTAINABLE DEVELOPMENT,2
TECHNOLOGYTRANSFER,1
VACANT LAND,2
INNOVATION,1
UNIVERSITY,1
IMPACT,1
AUTOCORRELATION,1
EMBEDDEDNESS,1
DIFFUSION,1
Business method patents,3
Relative centrality,2
Structural equivalence,2
Brokerage roles,2
Joint patent application,3
Patent citations,2
Knowledge flows,2
Social networks,2
INTELLECTUAL PROPERTY,2
INNOVATION,1
PERFORMANCE,1
SPILLOVERS,1
EUROPE,1
POLICY,1
Remdesivir,1
Taiwan,1
patent,1
COVID19,1
compulsory licensing,2
,1
Product innovation,2
Process innovation,2
Patents,1
Trade secrets,2
Product announcements,2
Insider trading,2
Disclosure choice,2
Financing innovation,2
RESEARCHANDDEVELOPMENT,1
TRADE,1
VALUATION,1
SECRETS,1
IMPACT,1
Bradfords law,2
citation immediacy,2
citing determinants,2
Cox regression,2
life tables method,3
patents,1
receiving first citation,3
survival analysis,2
USPTO,1
KNOWLEDGE FLOW,2
LAW,1
Patents,1
Software,1
Innovation,1
India,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PROTECTION,1
COUNTRIES,1
Dominance,1
Fairness,1
Article 102 TFEU,3
Standards,1
IoT,1
FRAND,1
STANDARDESSENTIAL PATENTS,2
COMPETITION LAW,2
FRAND,1
HUAWEI,1
DISCRIMINATION,1
INJUNCTIONS,1
INNOVATION,1
SEPS,1
,1
INNOVATION,1
ANTITRUST,1
drug patent linkage,3
drug competition,2
evergreen patent,2
approval waiting period,3
reverse payment settlement agreements,4
,1
law,1
litigation,1
natural language processing,3
explainable artificial intelligence,3
interpretable machine learning,3
patents,1
postgrant reviews,2
ARTIFICIALINTELLIGENCE,1
LEGAL,1
LAW,1
COMPUTERS,1
,1
SUPREMECOURT,1
FEDERAL CIRCUIT,2
LAW,1
AGENDA,1
EXCEPTIONALISM,1
PRECEDENT,1
technological evolution law,3
TRIZ,1
BP neural network,3
international patent classification,3
companys technological distance,3
INTERNATIONAL PATENT CLASSIFICATION,3
ABSORPTIVECAPACITY,1
TECHNICAL SYSTEMS,2
TRIZ,1
KNOWLEDGE,1
IDENTIFICATION,1
DISTANCE,1
SERVICE,1
TRENDS,1
,1
LONGTERMCONTRACTS,1
PATENT HOLDUP,2
ADJUSTMENT,1
PRICES,1
LIMITS,1
LAW,1
Patent Protection,2
Intellectual Property Investments,3
World Court,2
Assets,1
Interpretation,1
CONTINUITY,1
LAW,1
,1
,1
,1
SUPPLY CHAIN,2
,1
COPYRIGHT CLAUSE,2
ACCESS,1
DRUGS,1
LAW,1
Nagoya Protocol,2
Pacific islands,2
Vanuatu,1
Patent landscaping,2
Custom,1
Community protocols,2
Access and benefitsharing,3
PACIFIC,1
BIODIVERSITY,1
INNOVATION,1
PROPERTY,1
PLANTS,1
PLACE,1
Law and innovation,3
Citation networks,2
Patent analysis,2
Technology transfer,2
Nanotechnology,1
Thickets,1
,1
,1
INTELLECTUAL PROPERTY,2
DESIGN PROTECTION,2
COPYRIGHT,1
ECONOMICS,1
INNOVATION,1
PATENTS,1
SELF,1
,1
FEDERAL CIRCUIT,2
LAW,1
INNOVATION,1
JURIES,1
Quack medicine,2
Patent medicine,2
Proprietary medicine,2
Regulation,1
Pharmacy Act,2
Poison,1
Rentseeking,1
,1
India,1
Patentbased indicators,2
Patent commercialization,2
Strategic management,2
Technological innovation,2
O30,1
EMPIRICALEVIDENCE,1
SURVIVAL ANALYSIS,2
MARKET,1
BIOTECHNOLOGY,1
DETERMINANTS,1
US,1
INFORMATION,1
PERSPECTIVE,1
STATISTICS,1
OPPOSITION,1
,1
LAW,1
,1
OPTIMAL PATENT BREADTH,3
SCIENTIFICRESEARCH,1
ECONOMICANALYSIS,1
LEGAL PROTECTION,2
FAIRUSE,1
COPYRIGHT,1
INNOVATION,1
RULES,1
LAW,1
TECHNOLOGY,1
University patenting,2
Patents,1
Ranking,1
Publishing and patenting,3
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
KNOWLEDGE TRANSFER,2
ACADEMIC RESEARCH,2
US UNIVERSITIES,2
QUALITY,1
IMPACT,1
PRODUCTIVITY,1
SCIENTISTS,1
INNOVATION,1
,1
HATCHWAXMAN,1
ANTITRUST IMPLICATIONS,2
INTELLECTUAL PROPERTY,2
LAW,1
SETTLEMENTS,1
POLICY,1
STANDARDS,1
AGENCIES,1
HOLDUP,1
,1
PRESCRIPTION DRUGS,2
,1
RESEARCHANDDEVELOPMENT,1
FINANCING CONSTRAINTS,2
RESEARCH PRODUCTIVITY,2
DIVERSIFICATION,1
DEREGULATION,1
INCENTIVES,1
INVESTMENT,1
MATTER,1
RISK,1
Human embryonic stem cell hESC,5
open license for patent,4
open access,2
patent,1
China,1
PATENTABILITY,1
,1
INTELLECTUAL PROPERTY,2
PATENTS,1
LAW,1
HISTORY,1
PROTECTION,1
DECISIONS,1
STATUTES,1
CITIZEN,1
CUSTOM,1
copyright,1
moral rights,2
art,1
honour,1
anthropology,1
iniuria,1
,1
,1
PUBLICHEALTH,1
TRIPS,1
LAW,1
COVID19 vaccine,2
patent waiver,2
Jewish ethics,2
duty theory,2
,1
Moores Law,2
Power laws and experience curves,5
Forecasting,1
Performance trends,2
Quantitative,1
Empirical trends,2
PROGRESS,1
PATTERNS,1
CURVES,1
Ambiguity,1
Dynamic contract,2
Patent law,2
Innovation,1
RD,1
ROBUSTNESS,1
Intellectual property,2
protection mechanism,2
patent,1
data exclusivity,2
TRIPS agreement,2
INFORMATION,1
ACCESS,1
Patent pools,2
Procompetitive patents,2
Knowledge creation,2
Urn processes,2
Patent dynamics,2
SEQUENTIAL INNOVATION,2
ECONOMICS,1
ANTICOMMONS,1
PROPERTY,1
LAW,1
Optimal patent portfolio,3
technology standards alliances,3
innovation competition,2
patent pools,2
MODEL,1
Human capital,2
Selfefficacy,1
Organizational support,2
Resource availability,2
ACADEMIC ENTREPRENEURS,2
SELFEFFICACY,1
INNOVATION,1
DETERMINANTS,1
METAANALYSIS,1
PERFORMANCE,1
EXPERIENCE,1
MANAGEMENT,1
KNOWLEDGE,1
university patenting,2
internationalisation,1
patent families,2
licensing,1
Spain,1
INNOVATION,1
INVENTION,1
QUALITY,1
ACT,1
Innovation,1
Patents,1
Compulsory licensing,2
TRIPS,1
Intellectual property,2
Economic history,2
COMPETITION,1
COUNTRIES,1
INDIA,1
Academic patenting,2
Finland,1
Professors privilege,2
University ownership,2
ACADEMIC SCIENTISTS,2
EUROPE,1
ACT,1
,1
DILUTION ACT,2
SHAREHOLDER VALUE,2
ENTRY DETERRENCE,2
MARKET VALUE,2
INNOVATION,1
QUALITY,1
BEHAVIOR,1
RETURNS,1
PATENTS,1
LESSONS,1
Employee invention,2
Patent,1
Reward,1
Additional remuneration,2
M52,1
O31,1
O34,1
RANDD,1
UNIVERSITIES EVIDENCE,2
MARKET VALUE,2
INCENTIVES,1
INNOVATION,1
INVENTORS,1
COMPENSATION,1
CITATIONS,1
PRODUCTIVITY,1
MANAGEMENT,1
,1
PATENT,1
SYSTEM,1
Artistic design,2
Individuality,1
Copyright protection,2
Infringement,1
Works of applied art,4
Intellectual creations,2
Individual character,2
Unfair competition,2
Priority of use,3
,1
hESC inventions,2
ordre public and morality,4
patent law,2
,1
Team size,2
Time pressure,2
Competition,1
Innovation,1
Patent,1
PRODUCT DEVELOPMENT SPEED,3
PATENTS,1
TEAMS,1
COLLABORATIONS,1
MOBILITY,1
LABOR,1
FIRMS,1
Intellectual property,2
Jurisdiction,1
Competition law,2
SEP policy,2
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT HOLDUP,2
INJUNCTIVE RELIEF,2
ROYALTY STACKING,2
ANTITRUSTLAW,1
STANDARDS,1
REMEDIES,1
,1
POLITICAL PRESSURE,2
INNOVATION,1
PRICES,1
ENTRY,1
LAWS,1
PROTECTION,1
INDUSTRY,1
THREAT,1
FIRM,1
,1
FOREIGN DIRECTINVESTMENT,2
GLOBAL PATENT PROTECTION,3
DEVELOPINGCOUNTRIES,1
INNOVATION,1
TECHNOLOGY,1
TRADE,1
LAWS,1
PHARMACEUTICALS,1
PRODUCTIVITY,1
DIFFUSION,1
Brazil,1
China,1
India,1
South Africa,2
patent opposition,2
public health,2
TRIPS,1
WTO,1
MEDICINES,1
ACCESS,1
software innovations,2
software patents,2
patent scope,2
opensource software,2
intellectual property,2
public policy,2
Alice v CLS Bank,4
INNOVATION,1
ECONOMICS,1
FIRMS,1
APPROPRIABILITY,1
COLLABORATION,1
SURVIVAL,1
INDUSTRY,1
IMPACT,1
LAW,1
,1
INVESTMENTS,1
PROPERTY,1
research evaluation,2
academic patenting,2
patent survival analysis,3
legal status data,3
patent lifespan,2
patent information,2
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
INTELLECTUAL PROPERTY,2
LIFE SCIENCES,2
IVORY TOWER,2
UNIVERSITY,1
QUALITY,1
INDICATORS,1
ENTREPRENEURS,1
IMPACT,1
annualmaintenance fee,2
economic stimulus growth theory,4
elimination,1
legal politics,2
patent,1
,1
,1
PATENTABLE SUBJECTMATTER,2
INTELLECTUAL PROPERTY,2
RETHINKING,1
RULES,1
PRESUMPTION,1
STANDARDS,1
JUSTICE,1
MYRIAD,1
RETURN,1
COURT,1
experimental use,2
patented research tools,3
Chinese universities,2
legitimacy,1
SAFE,1
Patent eligibility,2
nucleotide sequences,2
BRCA,1
Myriad,1
Mayo,1
USA,1
Australia,1
GENE PATENTS,2
LAW,1
INNOVATION,1
,1
COMPETITION,1
ENFORCEMENT,1
DECISIONS,1
PATENTS,1
LIMITS,1
COURT,1
SENSE,1
Pharmaceutical Patents,2
Product Patents,2
Grassroots Innovations,2
Indigenous medicine,2
Herb,1
Social Innovation,2
INTELLECTUAL PROPERTYRIGHTS,2
MANAGEMENT,1
SCIENCE,1
SECTOR,1
Commercialization of university patents,4
University innovation ecosystem,3
Basic research,2
Spatial spillover,2
China,1
TECHNOLOGYTRANSFER,1
INNOVATION,1
KNOWLEDGE,1
ECONOMICS,1
OUTPUTS,1
GROWTH,1
ACT,1
inventor performance,2
marijuana legalization,2
patents,1
public health,2
regional innovation,2
MEDICAL MARIJUANA,2
CREATIVITY,1
KNOWLEDGE,1
HEALTH,1
LAWS,1
MANAGEMENT,1
MARKET,1
ENVIRONMENT,1
ADOLESCENT,1
STRATEGIES,1
access to medicines,3
Agreement on Trade Related Aspects of Intellectual Property Rights,9
intellectual property,2
least developed country,3
TRIPS flexibilities,2
TRIPSplus,1
,1
,1
,1
France,1
Industrial property,2
PACTE law,2
More efficient procedures,3
More progressive offer,3
,1
Disclosure,1
Discovery,1
Invention,1
Intellectual property,2
Licensing,1
Nondisclosure agreement,2
Patent,1
Technology transfer,2
BIOSIMILARS,1
Access and benefit sharing,4
Rooibos,1
Research and development,3
Convention on Biological Diversity,4
Nagoya Protocol,2
Biodiversity Act,2
Social justice,2
San,1
Khoi,1
TEA ASPALATHUSLINEARIS,2
AFRICAN HERBAL TEAS,3
SOUTHAFRICA,1
BIODIVERSITY CONSERVATION,2
ANTIOXIDANT ACTIVITY,2
CONSUMPTION,1
HEALTHY,1
TRADE,1
PLANT,1
,1
,1
Building information modeling BIM,4
Cooperative patent classification CPC,4
Patent analysis,2
Social network analysis SNA,4
BIM,1
TECHNOLOGY,1
INDUSTRY,1
KEYWORD,1
SECTOR,1
TOOL,1
,1
RESEARCHANDDEVELOPMENT,1
RED TAPE,2
VENTURE,1
GROWTH,1
FIRMS,1
FINANCE,1
PATENT,1
HETEROSCEDASTICITY,1
IDENTIFICATION,1
INSTRUMENTS,1
,1
,1
Britain,1
forensics,1
inventorship,1
law courts,2
materiality,1
patents,1
telecommunications,1
WIRELESS,1
,1
OFFICE RECORDS,2
HISTORY,1
FIELD,1
courts,1
patents,1
litigation process,2
decision reversals,2
Unified Patent Court,3
LAW,1
HARMONIZATION,1
ENFORCEMENT,1
APPEALS,1
JUDGES,1
RIGHTS,1
,1
,1
,1
,1
Trade,1
Innovation,1
Intellectual property rights,3
Patents,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
TRADE,1
INNOVATION,1
DETERMINANTS,1
INPUTS,1
LAWS,1
Patent transaction networks,3
TFTLCD,1
Social network analysis,3
Intellectual property strategy,3
Technology diffusion,2
POWERLAW DISTRIBUTIONS,2
SMALLWORLD,1
TECHNOLOGICALINNOVATION,1
KNOWLEDGEDIFFUSION,1
EMPIRICALANALYSIS,1
MARKET,1
CENTRALITY,1
EVOLUTION,1
FLOWS,1
Investors,1
patents,1
signaling,1
financial constraints,2
RESEARCHANDDEVELOPMENT,1
CASH FLOW,2
DEVELOPMENT INVESTMENT,2
PATENT CITATIONS,2
INNOVATION,1
INFORMATION,1
PERFORMANCE,1
FIRMS,1
COLLABORATION,1
IMPACT,1
generics,1
Hatch Waxman act,3
innovators,1
secondary patents,2
US FDA,2
USPTO,1
,1
Invention,1
Patents,1
Patent law,2
Licensing,1
Entrepreneurship,1
Samuel Hopkins,2
,1
obesity,1
plussized,1
patents,1
stout,1
historic clothing,2
support garments,2
,1
Academic entrepreneurs,2
Patent propensity,2
Technology spinoffs,2
BAYHDOLE ACT,2
UNIVERSITY INVENTIONS,2
PLANNED BEHAVIOR,2
TECHNOLOGYTRANSFER,1
EMPIRICALEVIDENCE,1
PUBLIC RESEARCH,2
UNITEDSTATES,1
LIFE SCIENCES,2
SOCIAL NORMS,2
SMALL FIRMS,2
COVID19 pandemic,2
incentives,1
intellectual property rights,3
law and economics,3
patent protection,2
INNOVATION,1
ANTICOMMONS,1
PROPERTY,1
TRAGEDY,1
DISEASES,1
COMMONS,1
,1
PATENT HOLDUP,2
LAW,1
Patent policy,2
Universities,1
Outputs,1
Commercialization,1
BAYHDOLE ACT,2
US UNIVERSITIES,2
PUBLICPOLICY,1
IMPACT,1
Biopharmaceuticals,1
Biologic Medicinal Product,3
IP Exclusive Rights,3
Innovation,1
Intellectual Property,2
FUTURE,1
,1
,1
,1
DOUBLE JEOPARDY,2
RACIAL BIAS,2
BLACK,1
DIVERSITY,1
ETHNICITY,1
WOMEN,1
JOB,1
INTERSECTIONALITY,1
ASSOCIATION,1
STEREOTYPES,1
,1
PROPERTY,1
RIGHTS,1
Trade secrets,2
Espionage and Foreign Interference Act,5
Economic Espionage Act,3
DTSA,1
TRIPS Agreement,2
Patents,1
ACT,1
Pharmaceutical drugs,2
Patent protection,2
Paragraph IV settlement,3
INNOVATION,1
Media,1
NPE litigation,2
Patent trolls,2
Antitroll law,2
LITIGATION,1
MANAGEMENT,1
INNOVATION,1
RESPONSES,1
EQUITY,1
PRESS,1
innovation disclosure,2
credit markets,2
patenting,1
private information,2
FINANCIAL INTERMEDIATION,2
PROPRIETARY INFORMATION,2
INTELLECTUAL PROPERTY,2
PATENT PUBLICATION,2
CREDIT,1
PROTECTION,1
CHOICE,1
IMPACT,1
TRADE,1
PRODUCTIVITY,1
Component architectures,2
intellectual property,2
patent law,2
patents,1
product development,2
research and development management,4
technology management,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
PRODUCT ARCHITECTURE,2
MARKETSTRUCTURE,1
EMPIRICALTEST,1
INNOVATION,1
MODULARITY,1
PERFORMANCE,1
PERSISTENCE,1
IMITATION,1
Patent infringement litigation,3
corporate innovation,2
executive risk preferences,3
dynamic competition,2
innovation investment,2
INTELLECTUAL PROPERTY PROTECTION,3
FIRM PERFORMANCE,2
UPPER ECHELONS,2
CONSEQUENCES,1
ORGANIZATION,1
INDUSTRY,1
RIVALRY,1
RIGHTS,1
TRADE,1
FirstYear UndergraduateGeneral,2
SecondYear Undergraduate,2
UpperDivision Undergraduate,2
Curriculum,1
InterdisciplinaryMultidisciplinary,1
CollaborativeCooperative Learning,2
CommunicationsWriting,1
Applications of Chemistry,3
Consumer Chemistry,2
Biotechnology,1
DrugsPharmaceuticals,1
StudentCareer Counseling,2
Systems Thinking,2
,1
,1
FEDERAL CIRCUIT,2
POLICY,1
PROPERTY,1
LAW,1
ANTICOMMONS,1
INNOVATION,1
ANTITRUST,1
DESIGN,1
adherence,1
compliance,1
digital pill,2
FDA,1
ingestible event marker,3
patents,1
FACTORS INFLUENCING ADHERENCE,3
MENTALHEALTH,1
ANTIPSYCHOTIC MEDICATION,2
UN CONVENTION,2
SCHIZOPHRENIA,1
MEDICINE,1
NONADHERENCE,1
RIGHTS,1
SURVEILLANCE,1
DISABILITIES,1
Divisional patent applications,3
Procedural rights,2
Pharmaceutical patents,2
Double patenting,2
PATENTS,1
Breakthrough,1
Innovation,1
Radicalness,1
Technology,1
Patents,1
RESEARCHANDDEVELOPMENT,1
BAYHDOLE ACT,2
INTERACTION TERMS,2
VALUECREATION,1
QUALITY,1
IMPACT,1
INVENTIONS,1
OWNERSHIP,1
INVENTORS,1
PATTERNS,1
Intellectual property,2
Patents,1
Technology transfer,2
Policy evaluation,2
TECHNOLOGYTRANSFER OFFICES,2
RESEARCH PRODUCTIVITY,2
UNIVERSITY ENTREPRENEURSHIP,2
LIFECYCLE,1
ILLUSTRATION,1
RESOURCES,1
SCIENCE,1
UK,1
joint patent application,3
the structure of collaboration,4
open innovation,2
long tail,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGEBASED ECONOMY,2
POWERLAW DISTRIBUTION,2
BETWEENNESS CENTRALITY,2
PRODUCT DEVELOPMENT,2
FIRM PERFORMANCE,2
PATENT,1
ORGANIZATION,1
TECHNOLOGY,1
POLICY,1
Commercialisation of academic patents,4
spatial spillover,2
research funding,2
universityindustry interactions,2
China,1
BAYHDOLE ACT,2
UNIVERSITYRESEARCH,1
RESEARCHERS,1
SCIENCE,1
PUBLICATION,1
COMPETITION,1
REFORM,1
IMPACT,1
LINKS,1
,1
ELDRIDGE,1
,1
,1
Pharmaceutical,1
Patent Law,2
IPR,1
Healthcare Industry,2
Legal Scenario and Policies,4
,1
mutagenesis,1
CRISPRCas9,1
common catalogue of varieties of agricultural plant species,8
herbicideresistant varieties,2
GMOs,1
essentially biological process,3
plant varieties,2
exception to patentability,3
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
MARKET,1
INNOVATION,1
OFFICE,1
IMPACT,1
Freedom of Information Act,4
information acquisition,2
information search,2
disclosure,1
agency costs,2
propri,1
etary costs,2
competition,1
lawsuits,1
DISCLOSURE,1
MARKET,1
DETERMINANTS,1
SEARCH,1
VOLUME,1
,1
PRICECOMPETITION,1
INNOVATION ACT,2
EXCLUSIONARY CONDUCT,2
TRADE SECRETS,2
Social networks,2
Patents,1
Technological trajectories,2
Semiconductor manufacturing industry,3
Moores law,2
CITATION NETWORK,2
,1
,1
arbitration,1
patent,1
public order,2
,1
intellectual property law,3
legislature process,2
competent administrative agencies,3
State Council,2
Standing Committee of the National Peoples Congress,7
,1
,1
PROPERTY RULES,2
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
ROYALTY STACKING,2
FEDERAL CIRCUIT,2
INFRINGEMENT,1
TROLLS,1
HOLDUP,1
RELIEF,1
LAW,1
,1
STATE COMPETITION,2
PATENT,1
EFFICIENCY,1
JUDGMENT,1
JUDGES,1
COURT,1
SHOP,1
LAW,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
DNA PATENTS,2
HUMAN GENES,2
SCIENCE,1
DIAGNOSTICS,1
MYRIAD,1
ANTICOMMONS,1
INNOVATION,1
ACCESS,1
COURT,1
entrepreneurship,1
examination,1
innovation,1
patents,1
strategy,1
timing,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGICALINNOVATION,1
DECISION SPEED,2
US PATENT,2
FIRM AGE,2
MARKET,1
USPTO,1
TIME,1
DETERMINANTS,1
COMPETITION,1
Dormant companies,2
Patent litigation,2
Nonpracticing entities,2
Patent assertion entities,3
Patent trolls,2
Patent transparency,2
ASSERTION ENTITIES,2
EMPIRICALANALYSIS,1
TROLLS,1
TECHNOLOGY,1
LITIGATION,1
MARKETS,1
Collaborative innovation,2
dynamic governance,2
European Union,2
governance,1
patent law,2
patent reforms,2
unitary patent,2
SYSTEM,1
government intervention,2
intellectual property,2
public health,2
social function,2
DOHA DECLARATION,2
PUBLICHEALTH,1
Reverse payment patent settlement agreements RPPSAs,6
patented drugs,2
generic drugs,2
competition law,2
,1
,1
,1
access to essential medicines,4
developing countries,2
pharmaceutical patents,2
rights to health,3
women,1
INTIMATE PARTNER VIOLENCE,3
CARE,1
PREVALENCE,1
COUNTRIES,1
India,1
Patent classification,2
Patent law,2
Traditional knowledge,2
Traditional knowledge digital library,4
REFORMULATION REGIME,2
HERITAGE,1
,1
,1
Law,1
Intellectual property,2
Patents,1
Social media,2
Inadvertent disclosures,2
,1
,1
GLOBAL PRODUCTION,2
TRADE AGREEMENTS,2
PROPERTY RULES,2
ACCESS,1
PREPAREDNESS,1
VACCINATION,1
BIOSIMILARS,1
COMPETITION,1
MEDICINES,1
HEALTH,1
,1
INTERNATIONAL INVESTMENT,2
POLITICALECONOMY,1
TREATY,1
PROPORTIONALITY,1
RIGHTS,1
LAW,1
,1
,1
,1
PATENTS,1
green principles,2
intellectual property,2
sustainable development,2
green patent,2
TRAGEDY,1
Patent novelty,2
Patentability,1
Patent rejection,2
Examination prosecution,2
Deep learning,2
Datadriven theorizing,2
TECHNOLOGICAL NOVELTY,2
INNOVATION,1
PRIMER,1
scientific and technological innovation and cooperation,6
GuangdongHong KongMacao Greater Bay Area,5
university patents,2
patent application,2
spatial econometrics,2
fuzzyset qualitative comparative analysis,4
patent transformation path,3
QUALITATIVE COMPARATIVEANALYSIS,2
INDUSTRIALINNOVATION,1
NETWORK ANALYSIS,2
DOLE ACT,2
KNOWLEDGE,1
DETERMINANTS,1
REGIONS,1
IMPACT,1
FSQCA,1
,1
BAYHDOLE ACT,2
LIFE SCIENCES,2
INDUSTRY,1
TECHNOLOGY,1
US,1
CITATIONS,1
GROWTH,1
EXPERIENCE,1
INNOVATION,1
GEOGRAPHY,1
pharmaceuticals,1
HatchWaxman Act,2
patent challenges,2
market exclusivity,2
generic competition,2
RESEARCHANDDEVELOPMENT,1
EXCLUSIVITY,1
COMPETITION,1
INNOVATION,1
RETURNS,1
,1
CHICAGO SCHOOL,2
ANTITRUST,1
ARRANGEMENTS,1
MONOPOLY,1
POLICY,1
aesthetics,1
copyright,1
Denmark,1
functionalism,1
patent law,2
PH lamp,2
,1
Intellectual property,2
developing countries,2
international trade,2
protection,1
patents,1
internal laws of states,4
,1
International patenting,2
Social network analysis,3
Quadratic assignment procedure QAP,4
Country differences,2
Proximity,1
F14,1
F22,1
O33,1
O34,1
O38,1
R11,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGY DIFFUSION,2
INNOVATION,1
TRADE,1
CHINA,1
DETERMINANTS,1
COMPETITION,1
KNOWLEDGE,1
NETWORKS,1
Patent Licensing,2
Patent Financing,2
Trust of Patent,3
Invention Patent,2
,1
Technological knowledge diffusion,3
Patent protection,2
Patent lifetime,2
Patent claim,2
INNOVATION,1
CITATION,1
INFORMATION,1
FLOWS,1
LIFE,1
Patent,1
Intellectual property of pharmaceutical,4
products and processes,3
Pharmaceutical drugs,2
Unified health system,3
,1
writer engagement,2
patent disclosure,2
genre analysis,2
Corpus Linguistics,2
vagueness,1
,1
epitope mapping,2
intellectual property,2
monoclonal antibody,2
novelty nonobviousness,2
patent,1
written description,2
,1
technology and innovation management,4
patents and intellectual property rights,5
transaction cost,2
EMPIRICALANALYSIS,1
TECHNOLOGY,1
INNOVATION,1
POOLS,1
DETERMINANTS,1
GOVERNANCE,1
ALLIANCES,1
ECONOMICS,1
INDUSTRY,1
TROLLS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENTABILITY REQUIREMENT,2
INCREASING RETURNS,2
ENDOGENOUS GROWTH,2
POWER LAWS,2
PRODUCTIVITY,1
PROTECTION,1
INDUSTRY,1
IMITATION,1
Proportionality,1
Injunctive relief,2
Permanent injunctions,2
Abuse of rights,3
Equity,1
Patent assertion entities,3
Complex products,2
HOLDUP,1
Performance curves,2
Moores law,2
Improvement rates,2
Technological change,2
Technology dynamics,2
Patent centrality,2
,1
Intellectual property rights,3
Debt financing,2
Legal enforcement,2
Financing constraints,2
PATENT PROTECTION,2
CAPITAL STRUCTURE,2
MARKET,1
RIGHTS,1
INNOVATION,1
CONSTRAINTS,1
COMPETITION,1
QUALITY,1
GROWTH,1
CRISES,1
,1
,1
Human gene patents,3
Chinese scholars,2
Patentability,1
CONTROVERSY,1
PROTECTION,1
MYRIAD,1
,1
GEOGRAPHY,1
Academic patenting,2
Patent transactions,2
Patent licensing,2
Markets for technology,3
BAYHDOLE ACT,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENT QUALITY,2
EMPIRICALANALYSIS,1
ACADEMIC RESEARCH,2
TECHNOLOGY,1
MARKET,1
INNOVATION,1
COMMERCIALIZATION,1
SCIENCE,1
Pay for delay,3
Japan,1
pharmaceutical,1
US antitrust,2
competition,1
comparative analysis,2
theory of harm,3
Japanese Antimonopoly Act,3
Europe,1
patent settlement,2
SETTLEMENTS,1
ACTAVIS,1
Innovations,1
National Innovation System,3
National Innovation Capability,3
Patents,1
Public funded research organizations,4
Intellectual property rights,3
Emerging economies,2
Patent filing behavior,3
RD,1
BAYHDOLE ACT,2
EMPIRICALEVIDENCE,1
ACADEMIC RESEARCH,2
TECHNOLOGY,1
SCIENCE,1
CITATIONS,1
CHINA,1
DETERMINANTS,1
INSTITUTIONS,1
INDICATORS,1
Copyrights,1
trademarks,1
trade secrets,2
patents,1
entrepreneurship,1
PATENTS,1
INNOVATION,1
PROTECTION,1
COPYRIGHT,1
,1
DEVELOPMENT COMPETITION,2
STRATEGIC EXPERIMENTATION,2
INNOVATION,1
PERSISTENCE,1
DYNAMICS,1
ENTRY,1
,1
,1
,1
SUPREMECOURT,1
REPEAT PLAYERS,2
US COURTS,2
LAW,1
EXPERTISE,1
LAWYERS,1
QUALITY,1
REPRESENTATION,1
SETTLEMENT,1
patents,1
rewards,1
patent specification,2
patent extensions,2
heroic inventor,2
RIGHTS,1
,1
US PATENT,2
INFRINGEMENT,1
DISCLOSURE,1
ECONOMICS,1
PROPERTY,1
TOO,1
Patentable,1
Invention Disclose,2
Patent Scope,2
EnergySaving,1
Information Entropy,2
INDICATORS,1
INNOVATION,1
DETERMINANTS,1
tort law,2
liability,1
litigation,1
patents,1
propensity to patent,3
transaction costs,2
MATRIX ESTIMATOR,2
ROBUST,1
INNOVATION,1
PANEL,1
,1
,1
,1
CITATION ANALYSIS,2
SCIENCE,1
LINKAGE,1
market agencement,2
performativity,1
promissory,1
market representations,2
narrative,1
Sector Inquiry,2
pharmaceutical industry,2
market studies,2
EXPECTATIONS,1
CONSTRUCTION,1
SENSEMAKING,1
TECHNOLOGY,1
DISCOURSE,1
Firm innovation,2
Debt covenants,2
Covenant strictness,2
Patent filings,2
Patents,1
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
PROJECT SELECTION,2
AGENCY COSTS,2
DEBT,1
CONTRACTS,1
MARKET,1
DETERMINANTS,1
PRIVATE,1
QUALITY,1
Financing constraints,2
Firm innovation,2
Patents,1
RD,1
PANELDATA,1
DEVELOPMENT INVESTMENTS,2
CASH FLOW,2
EQUITY,1
SENSITIVITY,1
PROTECTION,1
SIGNALS,1
IMPACT,1
,1
,1
copyright exceptions,2
contract,1
copyright,1
Copyright,1
Designs and Patents Act 1988,5
,1
Academia,1
Knowledge production functions,3
Patenting,1
Professors privilege,2
Research and development,3
Sweden,1
INTELLECTUAL PROPERTYRIGHTS,2
BAYHDOLE ACT,2
UNIVERSITY ENTREPRENEURSHIP,2
EMPIRICALEVIDENCE,1
PANELDATA,1
PRODUCTIVITY,1
KNOWLEDGE,1
GENDER,1
TECHNOLOGY,1
SPILLOVERS,1
Patent mining,2
topic modeling,2
network analysis,2
opportunity analysis,2
augmented reality technology,3
NETWORK ANALYSIS,2
TRENDS,1
FREQUENCY,1
MAP,1
Cyber risk,2
Hacking,1
Corporate innovation,2
Patents,1
Trade secrets,2
TRADE SECRETS,2
FINANCIAL CONSTRAINTS,2
INFORMATION,1
DISCLOSURES,1
PROTECTION,1
PATENTS,1
FIRMS,1
PRIVATIZATION,1
IMPACT,1
Patent Medicine Vendors,3
ACTs,1
policy change,2
malaria,1
artemisinin monotherapies,2
nonartemisinin therapies,2
MALARIA TREATMENT,2
CHILDHOOD FEVERS,2
PROVIDERS,1
SERVICES,1
SELLERS,1
,1
,1
patent medicines,2
consumption,1
sensory history,2
marketing,1
packaging,1
,1
Patent transfer,2
spatial diffusion,2
firstmove advantage,2
resonance effect,2
TECHNOLOGYTRANSFER,1
NETWORK ANALYSIS,2
CITYREGION,1
INNOVATION,1
COLLABORATION,1
TRANSACTIONS,1
DYNAMICS,1
FLOWS,1
academic inventors,2
academic patenting,2
inventive productivity,2
inventor behavior,2
patent process,2
TECHNOLOGYTRANSFER,1
TRIPLEHELIX,1
SCIENTIFICKNOWLEDGE,1
INNOVATION,1
COMMERCIALIZATION,1
UNIVERSITIES,1
EUROPE,1
ENTREPRENEURS,1
MANAGEMENT,1
PUBLICATION,1
Lenalidomide,1
Thalidomide,1
FDA,1
Generic drugs,2
REMS,1
HatchWaxman Act,2
POTENT INHIBITORS,2
THALIDOMIDE,1
DRUG,1
CC5013,1
ANALOGS,1
MYELOMA,1
ACCESS,1
DEXAMETHASONE,1
BORTEZOMIB,1
STRATEGIES,1
,1
INTELLECTUAL PROPERTY,2
PATENT ENFORCEMENT,2
ANTITRUSTLAW,1
HARMONIZATION,1
COMPETITION,1
SHADOW,1
CHOICE,1
University,1
Technology transfer,2
Academic patenting,2
Disambiguation,1
Peer effects,2
BAYHDOLE ACT,2
RESEARCH ORGANIZATION,2
PROPERTYRIGHTS,1
ENTREPRENEURSHIP,1
PROFESSORS,1
PATENT,1
EUROPE,1
UNIVERSITIES,1
EXPLORATION,1
INNOVATION,1
Chorzow Factory,2
investorstate dispute settlement ISDS,4
patent expropriation,2
reparation standard,2
international law,2
,1
,1
,1
patent alliance,2
innovation,1
network effects,2
,1
The drug price competition and patent term restoration act,9
market exclusivity,2
patent,1
patent term extension,3
patent term restoration,3
PTE,1
PMA,1
LONGER PATENTS,2
antitrust law,2
asthma,1
COPD,1
Food and Drug Administration,4
inhalers,1
patents,1
,1
,1
,1
Technological impact,2
Indicators,1
Journal technological factor,3
Journals,1
Scholarly journals,2
Patents,1
Patstat,1
Citations,1
Research performance,2
Bibliometrics,1
Nonpatent references,2
NPR,1
Nonpatent literature,2
NPL,1
IMPACT FACTOR,2
CITATION,1
SCIENCE,1
LINKAGE,1
SCOPUS,1
PUBLICATIONS,1
REFERENCES,1
Intellectual property strategies,3
patents,1
biopharmaceutical market,2
monoclonal antibodies,2
biosimilars,1
,1
Bundled rebate program,3
Patent licensing,2
Modem chip industry,3
Law and business,3
LICENSING STRATEGY,2
,1
KNOWLEDGE SPILLOVERS,2
SOCIAL NETWORKS,2
GRAPH,1
INNOVATION,1
MODELS,1
GEOGRAPHY,1
MOBILITY,1
COUNTS,1
SPREAD,1
GROWTH,1
,1
PATENT,1
Radial artery occlusion,3
Transradial coronary catheterization,3
Acute coronary syndrome,3
RANDOMIZED CONTROLLEDTRIALS,2
ACUTE MYOCARDIALINFARCTION,2
TRANSRADIAL CATHETERIZATION,2
FEMORAL APPROACH,2
DOSE HEPARIN,2
ANGIOGRAPHY,1
INTERVENTION,1
METAANALYSIS,1
ACCESS,1
COMPLICATIONS,1
Lei do Bem,3
innovation,1
patent data,2
PrincipalAgent model,2
COSTS,1
,1
,1
,1
,1
,1
BOUNDARY OBJECTS,2
DISCLOSURE,1
KNOWLEDGE,1
LAW,1
MARKETPLACE,1
AUDIENCE,1
TIME,1
Institutional investor,2
Firm innovation,2
Patenting,1
Mutual funds,2
China,1
CORPORATE GOVERNANCE,2
PATENT STATISTICS,2
PANELDATA,1
PERFORMANCE,1
INCENTIVES,1
INVESTORS,1
QUALITY,1
INDICATORS,1
TURNOVER,1
PROPERTY,1
,1
PROPERTY,1
SYSTEM,1
Competition,1
Intellectual property,2
Randomcoefficient logit demand,3
Patent,1
Smartphones,1
MONOPOLY,1
EQUILIBRIUM,1
PERSISTENCE,1
INNOVATION,1
DEMAND,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INCOMPLETE CONTRACTS,2
PROTECTION,1
INNOVATION,1
TRADE,1
QUALITY,1
LEVEL,1
WEAK,1
Patent markets,2
patent assertion entities,3
unitary patent,2
forum shopping,2
LITIGATION,1
patents,1
concerns,1
feminine hygiene products,3
health,1
environment,1
,1
Innovation,1
Institutions,1
Patent enforcement,2
Unconditional quantile regression,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
ABSORPTIVECAPACITY,1
TECHNOLOGICALCHANGE,1
DOMESTIC INNOVATION,2
NATIONAL SYSTEMS,2
COUNTRIES,1
IMPACT,1
Intellectual property rights,3
Patents,1
Trade secrets,2
Foreign direct investment,3
Technology transfer,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
PROTECTION,1
Emerging countries,2
patent,1
regime complex,2
transnational network,2
policy diffusion,2
intellectual property,2
INTELLECTUAL PROPERTYRIGHTS,2
CHINA,1
INDIA,1
DIFFUSION,1
POLITICS,1
patents,1
computation of lost profits,4
legal remedies,2
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
PRODUCTS,1
,1
,1
,1
,1
patents,1
claim construction,2
ranges,1
relevance of ranges,3
Illumina,1
Regeneron,1
biotechnological inventions,2
validity,1
sufficiency,1
,1
patent office,2
technology transfer,2
ActorNetwork Theory,2
Patent Management Systems,3
developing countries,2
EGOVERNMENT,1
TECHNOLOGYTRANSFER,1
INFORMATIONTECHNOLOGY,1
COMMUNICATION,1
CHALLENGES,1
KNOWLEDGE,1
LESSONS,1
INDIA,1
Patent eligible,2
biotech,1
immunotherapy,1
CAFC,1
PATENTS,1
protection of nonpatrimonial personal rights,5
patent infringement,2
judicial and extrajudicialproceedings,3
legislation of the Russian federation,5
administrative procedures,2
,1
,1
,1
essential patents,2
healthcare,1
incentive theory,2
IP  jurisprudence,3
IP system rationale,3
patent pools,2
pharmaceutical industry,2
,1
,1
INTELLECTUAL PROPERTY,2
PATENTS,1
COMMERCIALIZATION,1
RIGHTS,1
Legal system,2
Digitalization of law,3
Intellectual property,2
Electronic services,2
Scientific and technological progress,4
Patent service,2
,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
METOO DRUGS,2
PATENTS,1
INNOVATION,1
ATORVASTATIN,1
COMPETITION,1
RETHINKING,1
PROTECTION,1
STANDARDS,1
Coronary heart disease angina pectoris,5
Chinese patent medicine,3
compatibility law,2
association rules,2
complex network,2
GLOBAL BURDEN,2
Patents,1
Inventions,1
Sufficient disclosure,2
Knowhow,1
Transparency,1
,1
European Union,2
European Patent Convention,3
European Patent Court,3
Russia,1
,1
COVID19 medical innovations,3
intellectual property rights,3
ISS National Lab,3
pharmaceutical companies,2
space law,2
space pharmaceuticals,2
,1
External knowledge acquisition,3
Open innovation,2
Innovation performance,2
Internal RD,2
Patent backward citations,3
Patent collaboration,2
Patent purchase,2
RESEARCHANDDEVELOPMENT,1
OPEN INNOVATION,2
ABSORPTIVECAPACITY,1
FIRM PERFORMANCE,2
PATENT CITATIONS,2
MODERATING ROLE,2
DYNAMIC CAPABILITIES,2
RADICAL INNOVATION,2
TECHNOLOGY,1
DIVERSITY,1
,1
LITIGATION,1
JUDGMENTS,1
PROPERTY,1
,1
CLINICALTRIALS,1
PATENTS,1
ACCESS,1
BayhDole,1
Economic incentives,2
Employee inventions,2
Patent,1
Replication,1
Universities,1
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
INTELLECTUAL PROPERTY,2
PUBLIC RESEARCH,2
FACULTY,1
COMMERCIALIZATION,1
INNOVATION,1
INVENTION,1
SCIENCE,1
RIGHTS,1
artificial intelligence,2
machine learning,2
algorithms,1
automation,1
inventorship,1
AIassisted inventions,2
prior art searching,3
essentiality checks,2
standard essential patents,3
standards,1
,1
Thailand,1
Intellectual property regime,3
Knowledge transfer,2
Automotive industry,2
Coevolution,1
,1
patentapproval linkage,2
biosimilar,1
Korean Pharmaceutical Affairs Act,4
Green List,2
Purple Book,2
patent dance,2
,1
,1
HISTORY,1
Inhouse RD,2
high and medium technology,4
patent,1
technology purchase,2
nonlinear,1
FOREIGN DIRECTINVESTMENT,2
EXTERNAL KNOWLEDGE ACQUISITION,3
DEVELOPINGCOUNTRIES,1
ABSORPTIVECAPACITY,1
DEVELOPMENT SPILLOVERS,2
OPEN INNOVATION,2
2 FACES,2
IMPORTS,1
CAPABILITIES,1
PERFORMANCE,1
,1
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
PATENT HOLDUP,2
COVENANTS,1
KNOWLEDGE,1
DOCTRINE,1
LAW,1
,1
LEFTVENTRICULAR OUTPUT,2
BLOODFLOW,1
DOPPLER,1
ECHOCARDIOGRAPHY,1
HEMODYNAMICS,1
NETWORK,1
DISEASE,1
NEWBORN,1
Ground for refusal,3
Time of the decision,4
Time of filing,3
European Patent Office,3
Patent maintained with amended version,5
Action for revocation,3
Binding EPO decision,3
Revocation proceedings,2
Inadmissibility,1
,1
,1
INFORMATION,1
EXTRACTION,1
cost effectiveness threshold,3
external price referencing,3
market power,2
,1
,1
WRONGFULDISCHARGE LAWS,2
PROPERTYRIGHTS,1
SILICON VALLEY,2
JOB SECURITY,2
EMPLOYMENT,1
INNOVATION,1
MOBILITY,1
COSTS,1
WILL,1
INFORMATION,1
,1
INTELLECTUAL PROPERTY,2
SETTLEMENT,1
QUALITY,1
LAW,1
,1
FEDERAL CIRCUIT,2
PATENT,1
AGREEMENT,1
COURT,1
LAW,1
EXPERTISE,1
APPEALS,1
,1
,1
,1
LOCAL SEARCH,2
PATENT,1
LAW,1
TECHNOLOGIES,1
EXPLORATION,1
CREATIVITY,1
PSYCHOLOGY,1
KNOWLEDGE,1
TESTS,1
TOO,1
Patents,1
Task analysis,2
Technological innovation,2
Training,1
Noise measurement,2
Deep learning,2
Law,1
Deep learning,2
keysentence extraction,2
keyword extraction,2
patent,1
patent analysis,2
post training,2
RETRIEVAL,1
ART,1
Mineral extraction industry,3
Green growth,2
Green tech imports,3
Rule of law,3
Transparency,1
China,1
,1
social network analysis,3
patent knowledge development,3
knowledge exchange,2
innovation system,2
NETWORKS,1
PRODUCTIVITY,1
SYSTEMS,1
,1
DIRECTINVESTMENT,1
PATENT CITATIONS,2
DOMESTIC FIRMS,2
GEOGRAPHIC LOCALIZATION,2
SPILLOVERS,1
PRODUCTIVITY,1
MOBILITY,1
INNOVATION,1
COUNTRIES,1
BENEFIT,1
hydrogen,1
hydrogen fuel cells,3
technology evaluation,2
patent analysis,2
energy,1
AUTOMOTIVE INDUSTRY,2
ENERGY,1
STORAGE,1
FUNDAMENTALS,1
INDICATORS,1
SYSTEMS,1
,1
,1
EU trade mark law,4
EU design law,3
International jurisdiction,2
Applicable law,2
Sanctions for infringement,3
EUROPEAN PATENT,2
JURISDICTION,1
AGREEMENT,1
COURT,1
,1
PATENTS,1
PATENTABILITY,1
IMPROVEMENT,1
RETHINKING,1
STANDARDS,1
INVENTION,1
PROPERTY,1
,1
,1
,1
RESEARCHANDDEVELOPMENT,1
MARKET REACTION,2
IMPACT,1
INFORMATION,1
PERFORMANCE,1
GOVERNANCE,1
INVESTMENT,1
MANAGEMENT,1
EARNINGS,1
TERM,1
Patenting,1
Open science,2
Academic research,2
UNIVERSITY,1
SECRECY,1
ENTREPRENEURSHIP,1
TECHNOLOGY,1
SCIENTISTS,1
DISCLOSURE,1
PROPERTY,1
DYNAMICS,1
GENETICS,1
PROGRESS,1
FRAND,1
patents,1
standard essential patents antisuit injunction,5
TRIPS,1
WTO,1
SUIT INJUNCTIONS,2
TRIPS,1
Article 30,2
3step test,2
,1
,1
INTELLECTUAL PROPERTY,2
SECURITY INTERESTS,2
ARTICLE 9,2
GOVERNANCE,1
CONTRACTS,1
COPYRIGHT,1
PRIORITY,1
ACT,1
FRAGMENTATION,1
COMPETITION,1
Competition law,2
Intellectual property rights,3
Article 101 TFEU,3
Article 102 TFEU,3
Refusal to supply,3
Reverse payment agreements,3
FRAND terms,2
,1
Crossborder acquisitions,2
Equity ownership,2
Preemptive power,2
International patenting,2
Signaling theory,2
INTELLECTUAL PROPERTYRIGHTS,2
JOINT VENTURES,2
REAL OPTIONS,2
OWNERSHIP STRATEGIES,2
GEOGRAPHIC DISTANCE,2
DETERMINANTS,1
KNOWLEDGE,1
MARKET,1
PERFORMANCE,1
GOVERNANCE,1
Electrolyzer,1
Seawater,1
Patent analysis,2
Green hydrogen,2
HYDROGENPRODUCTION,1
ENERGY,1
EVOLUTION,1
STRATEGY,1
CATALYST,1
STORAGE,1
DESIGN,1
ARRA,1
construction grants,2
impact,1
research facilities,2
,1
Right to Health,3
Pharmaceutical Patents,2
Covid19,1
Pandemic,1
TRIPS,1
,1
Glaucoma,1
ocular hypertension,2
IOP,1
rho kinase inhibitors,3
netarsudil,1
ripasudil,1
INTRAOCULARPRESSURE,1
RIPASUDIL,1
EFFICACY,1
,1
,1
,1
,1
abortion,1
intellectual property,2
drugs,1
patents,1
right to life,3
,1
compulsory licensing,2
Nexavar,1
TRIPS,1
,1
SEP,1
SSO,1
FRAND,1
competition law,2
new economy,2
IP,1
comparative law,2
COMPETITION LAW,2
HUAWEI,1
FRAND,1
AGREEMENTS,1
patent application,2
divisional patent application,3
division of patent application,4
Indian patent law,3
,1
,1
INTELLECTUAL PROPERTY,2
PRICECOMPETITION,1
TRADE SECRETS,2
DRUGS,1
LIFE,1
BIOSIMILARS,1
PATENTS,1
HOLD,1
ACT,1
,1
,1
TCM patent,2
community detection,2
evolution analysis,2
weighted complex network,3
node correlation degree,3
node importance,2
node similarity,2
node direct influence,3
node common neighbour influence,4
global modularity,2
RULES,1
Green innovation,2
Environmental penalties,2
Environmental regulatory risk,3
CLEANAIR ACT,2
INNOVATION,1
REGULATIONS,1
POLLUTION,1
Artificial intelligence,2
Industrial property indicators,3
Patents,1
Intellectual property,2
,1
,1
US,1
AMERICA,1
IMPACTS,1
CITIES,1
genetics,1
innovation,1
intellectual property,2
patents,1
qualitative research,2
trade secrets,2
LAW,1
Cotton industry,2
spinning,1
hand mules,2
selfacting mules,2
patents,1
20THCENTURY REVOLUTION,2
TEXTILE MACHINES,2
LOOM,1
Social sciences,2
Humanities,1
Patent citations,2
Technological impact,2
Science base of technology,4
LINKAGE,1
Patents,1
Intellectual property rights,3
Patent stock,2
Diversification of procedural and administrative cost,6
PATENT PROTECTION,2
MATRIX ESTIMATOR,2
GROWTH,1
PANEL,1
ENTREPRENEURSHIP,1
DETERMINANTS,1
QUALITY,1
MODELS,1
RIGHTS,1
RULES,1
,1
,1
Academic publishing,2
patenting,1
project management,2
research grant,2
Japan,1
BAYHDOLE ACT,2
UNIVERSITY ENTREPRENEURSHIP,2
SCIENCE,1
JAPANESE,1
COLLABORATION,1
RESEARCHERS,1
CREATIVITY,1
KNOWLEDGE,1
BEHAVIOR,1
DATABASE,1
possibility degree relation model,4
TFNTOPSIS model,2
patent value estimating,3
multiattribute decisionmaking,2
DECISIONMAKING,1
developing countries,2
Global South,2
patents,1
plants,1
seed,1
PATENTABILITY,1
TECHNOLOGY,1
PROTECTION,1
GENE,1
text mining,2
NLP,1
technological information,2
patent analysis,2
text structure,2
TRENDS,1
Environmental protection tax,3
Green innovation,2
Patent quantity,2
Patent quality,2
,1
,1
BAYHDOLE ACT,2
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
KNOWLEDGE,1
QUALITY,1
ECONOMICS,1
MOBILITY,1
FACULTY,1
PARTICIPATION,1
INVENTION,1
,1
WOMEN INVENTORS,2
PRIVACY,1
TIES,1
PROPERTY,1
STRENGTH,1
Life Cycle Management LCM,4
Patents,1
Exclusivity,1
Abbreviated New Drug Approval ANDA,5
New Drug Application NDA,4
,1
Academic inventor,2
Nonuniversity academic patents,3
PCT,1
Technological domain,2
University academic patents,3
INNOVATION SYSTEMS,2
TRIPLEHELIX,1
UNIVERSITY,1
EVOLUTION,1
EUROPE,1
INDICATORS,1
COUNTRIES,1
INDUSTRY,1
ACT,1
linkages between science base and commercialisation,6
public research organisations,3
patents,1
publications,1
university,1
quantitative,1
KNOWLEDGE TRANSFER,2
TECHNOLOGYTRANSFER,1
EFFICIENCY ANALYSIS,2
ACADEMIC RESEARCH,2
UNIVERSITIES,1
PRODUCTIVITY,1
DETERMINANTS,1
PUBLICATION,1
SCIENTISTS,1
PROFESSORS,1
access to medicines,3
Article 30 TRIPS,3
patent exceptions,2
public health,2
Sustainable Development Goal 3,4
TRIPS flexibilities,2
DECLARATION,1
BTK,1
covalent modulator,2
EGFR,1
FGFR,1
KRAS G12C,2
SARSCoV2 Mpro,2
targeted covalent inhibition,3
patent landscape analysis,3
INHIBITORS,1
POTENT,1
KRAS,1
communitybased conservation,2
ecosystem management,2
ethics,1
human rights,2
politics and policy,3
DISCOVERY,1
PLANTS,1
automation,1
Amazon,1
robots,1
future of work,3
digital technology,2
Taylorism,1
TECHNOLOGY,1
COVID19,1
pandemic,1
patent waiver on COVID19 vaccine,5
vaccine,1
,1
Patents,1
Government funding,2
Research  development,3
Measurement,1
Breakthrough innovations,2
Funding mechanisms,2
RESEARCHANDDEVELOPMENT,1
BAYHDOLE ACT,2
PATENT CITATIONS,2
ACADEMIC RESEARCH,2
KNOWLEDGE FLOWS,2
TECHNOLOGY,1
BOOTSTRAP,1
,1
,1
Dislosure of origin,3
Benefit sharing,2
Plant genetic resources,3
Agriculture,1
Biopiracy,1
Food security,2
,1
patent law,2
corporate decisionmaking,2
engaged shareholders,2
licensing of health technologies,4
access to medicines,3
Covid19,1
INTELLECTUAL PROPERTY,2
CORPORATE,1
ACCESS,1
COMPETITION,1
VACCINES,1
CONTEXT,1
TRADE,1
compulsory licensing,2
Indian Patents Act 1970,4
patents,1
public interest litigation,3
,1
DNA,1
genetics,1
patents,1
Myriad,1
innovation,1
ethics,1
LAW,1
New Environmental Protection Law,4
Ecoinnovation,1
Differenceindifference,1
Policy evaluation,2
,1
,1
INTERNATIONAL COLLABORATION,2
SOCIAL NETWORK,2
SMALL WORLDS,2
PATENT,1
INNOVATION,1
CYTOSCAPE,1
EVOLUTION,1
SOFTWARE,1
PATTERNS,1
Patent infringement litigation,3
Performance,1
Profitability,1
Internationalization,1
Intangible assets,2
Product diversification,2
International diversification,2
RESEARCHANDDEVELOPMENT,1
VALUE CREATION,2
CORPORATE DIVERSIFICATION,2
PRODUCT DIVERSIFICATION,2
TRANSACTION COSTS,2
GEOGRAPHIC SCOPE,2
PERFORMANCE,1
INNOVATION,1
RESOURCES,1
RIGHTS,1
Patent troll,2
Litigation,1
Empirical study,2
Chinese law,2
ENTITIES,1
QUALITY,1
,1
COMPUTER,1
REPRODUCIBILITY,1
Innovation,1
clean technology,2
directed technical change,3
legal origin,2
energy policy,2
O31,1
K49,1
Q58,1
Q48,1
INNOVATION,1
DIFFUSION,1
,1
,1
Machine learning,2
Smart grid,2
Patent law,2
Copyright law,2
AI,1
Compulsory licensing,2
,1
anticoagulation,1
indexing words,2
patent hemostasis,2
radial occlusion,2
RADIAL ARTERYOCCLUSION,2
CARDIOVASCULAR ANGIOGRAPHY,2
CATHETERIZATION,1
INTERVENTION,1
PREVENTION,1
PROPHET,1
SOCIETY,1
FLOW,1
copyright,1
intellectual property,2
BRICS,1
Russia,1
China,1
India,1
Brazil,1
South Africa,2
,1
,1
RULES,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ANTITRUST,1
,1
SOCIOEMOTIONAL WEALTH,2
CORPORATE DISCLOSURE,2
PERFORMANCE,1
OWNERSHIP,1
PROPRIETARY,1
AGENCY,1
PUBLICATION,1
INFORMATION,1
INNOVATION,1
SUBSIDIES,1
Innovation,1
Patent,1
Voluntary disclosure,2
SOX,1
RESEARCHANDDEVELOPMENT,1
SARBANESOXLEY ACT,2
INSTITUTIONAL INVESTORS,2
INFORMATION ASYMMETRY,2
INTERNAL CONTROL,2
STOCK RETURNS,2
CASH FLOW,2
EARNINGS,1
MANAGEMENT,1
COSTS,1
Georgias and Estonias legislative frameworks in IP commercialisation,8
intellectual property,2
IP commercialisation,2
INNOVATION,1
Innovation,1
Debt financing source,3
Tech bubble burst,3
American Inventors Protection Act AIPA,5
G21,1
G23,1
G28,1
G32,1
INFORMATION,1
INVESTMENT,1
PRIVATE,1
Compulsory License Covid19,3
Patent Bargain with the Government,5
TRIPS Waiver,2
Vaccine Equity,2
INTELLECTUAL PROPERTY,2
DECISIONMAKING,1
CONSENSUS,1
ACCESS,1
HEALTH,1
IMPACT,1
Employment protection,2
Inventor mobility,2
Labor Contract Law,3
China,1
EMPLOYMENT PROTECTION,2
DEVELOPMENT INTENSITY,2
CAPITAL STRUCTURE,2
PRODUCTIVITY,1
PERFORMANCE,1
INVESTMENT,1
FIRMS,1
NETWORKS,1
DATABASE,1
TAXATION,1
drug discovery,2
research and development RD,4
target discovery,2
academia,1
pharma,1
translation,1
translational,1
nanoscale,1
nanomedicine,1
lead discovery programs,3
hit discovery,2
lead optimization,2
US Food and Drug Administration FDA,6
World Health Organization WHO,4
nanoparticles,1
nanoscale titanium dioxide,3
silver nanoparticles,2
nanotechnology,1
nanomaterial,1
nanodrug,1
nanotherapeutic,1
nanopharmaceutical,1
nanogovernance,1
regulation,1
US Patent  Trademark Office PTO,6
patent,1
nanoproducts,1
toxicity,1
new chemical entity NCE,4
investigational new drug application INDA,5
new drug application NDA,4
new molecular entity NME,4
abbreviated new drug application ANDA,5
Academic Drug Discovery Consortium ADDC,5
intellectual property strategy,3
patent protection,2
license agreements,2
litigation,1
commercialization,1
valley of death,3
lead optimization,2
quality control,2
scaleup,1
preclinical testing,2
safety and efficacy,3
clinical trials,2
phase IV postmarket surveillance,4
basic science,2
benchtobedside,1
translational medicine,2
translational science,2
preclinical research,2
the BayhDole Act,3
the HatchWaxman Act,3
current Good Manufacturing Production cGMP,5
irreproducible preclinical research,3
scientific integrity,2
scientific misconduct,2
crowdsourced analysis,2
National Institutes of Health NIH,5
Good Institutional Practice GIP,4
Technology Transfer Offices TTOs,4
publishorperish,1
trade secrets,2
physiologicallybased pharmacokinetic PBPK modelling,4
panassay interference compounds PAINS,4
antibodies,1
FDAs Center for Drug Evaluation and Research CDER,8
Biologics License Applications BLAs,4
Center for Biologics Evaluation and Research CBER,7
Tufts Center for the Study of Drug Development of Clinical Trial,11
freedomtooperate,1
nanopatent land grabs,3
nomenclature,1
terminology,1
nanocharacter,1
emerging technologies,2
regulatory guidance,2
National Center for Advancing Translational Sciences NCATS,7
DRUG,1
PATENTS,1
FDA,1
,1
RESEARCHANDDEVELOPMENT,1
EARNINGS MANAGEMENT,2
MARKET VALUE,2
DEVELOPMENT INVESTMENT,2
PERFORMANCE,1
INCENTIVES,1
PATENTS,1
EQUITY,1
FIRMS,1
CASH,1
,1
PATENTLAW,1
ENBANC,1
CERTIORARI,1
UNIFORMITY,1
DOCKET,1
TRIPS,1
intellectual property,2
hepatitis C,2
antiretroviral,1
direct acting antiviral,3
patent,1
generic,1
HIV,1
Cambodia,1
,1
,1
,1
,1
RNA,1
INTERVIEW,1
,1
,1
Intellectual property IP,3
Patents,1
Indices,1
TRIPS,1
Law on the books,4
Law in practice,3
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
RIGHTS,1
KNOWLEDGE,1
PERFORMANCE,1
STRENGTH,1
COUNTRY,1
INDEX,1
GOVERNANCE,1
innovation,1
patents,1
COVID19,1
plantbased vaccines,2
biopharma,1
,1
,1
CORPORATELAW,1
STATE COMPETITION,2
NEWYORK,1
BANKRUPTCY,1
FEDERALISM,1
LITIGATION,1
FAILURE,1
ISSUES,1
RACE,1
Patents,1
Neurosurgical inventions,2
Neurosurgical innovation,2
Intellectual property protection,3
Copyrights,1
Trademarks,1
Trade secrets,2
,1
Patent oppositions,2
Adversarial relationships,2
Negative relationships,2
Interorganisational networks,2
Network analysis,2
Motif analysis,2
INNOVATION,1
,1
SETTLEMENT,1
PRICE,1
,1
,1
Patents,1
Value Pluralism,2
Evergreening,1
Ordre Public,2
Open Source,2
INTELLECTUAL PROPERTY,2
ANTICOMMONS,1
TRAGEDY,1
SYSTEM,1
,1
DATA EXCLUSIVITY,2
BIOLOGICS,1
Business method patent,3
Innovation,1
Policy,1
Intellectual property,2
Empirical study,2
Court case,2
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
LESSONS,1
COSTS,1
SCOPE,1
,1
PATENTLAW,1
INCENTIVES,1
CHALLENGES,1
ANTITRUST,1
TAXATION,1
,1
SUPREMECOURT,1
CHEVRON,1
OFFICE,1
FOUNDATIONS,1
QUESTIONS,1
STANDARDS,1
SHADOW,1
RULES,1
PTO,1
Antitrust policy,2
Intellectual property,2
Patents,1
,1
,1
PATENT SETTLEMENT,2
Research and development,3
Investment,1
Costs,1
Patents,1
Government,1
Uncertainty,1
Technological innovation,2
China,1
debt financing,2
patents,1
R and D,3
state ownership,2
CASH FLOW,2
INNOVATION PERFORMANCE,2
DEVELOPMENT SUBSIDIES,2
CORPORATEFINANCE,1
FRUGAL INNOVATION,2
SIGNALING THEORY,2
BUSINESS,1
MARKET,1
CHINA,1
APPROPRIATION,1
,1
INTELLECTUAL PROPERTY,2
PUBLIC RESEARCH,2
INCENTIVES,1
UNIVERSITIES,1
RIGHTS,1
ACT,1
INVENTIONS,1
DISCOVERY,1
GROWTH,1
NORMS,1
University technology transfer,3
Invention disclosure,2
Academic patenting,2
Incentive system,2
Conjoint analysis,2
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
ACADEMIC RESEARCH,2
SCIENTIFICKNOWLEDGE,1
IVORY TOWER,2
PATENT,1
ENTREPRENEURSHIP,1
IMPACT,1
PRODUCTIVITY,1
EXPERIENCE,1
Patent,1
Industrial dynamics,2
Agentbased modeling,2
QUALITY LADDERS,2
INNOVATION,1
ECONOMICS,1
POLICY,1
SCOPE,1
APPROPRIABILITY,1
PATENTABILITY,1
LESSONS,1
RATES,1
SIZE,1
,1
PERSONALIZED MEDICINE,2
DRUGS,1
Drug repositioning,2
Patent law,2
Regulatory protection,2
Clinical trials,2
Empirical study,2
Generic drugs,2
MEDICAL USES,2
PATENTS,1
intellectual property rights,3
patents,1
utility models,2
trademarks,1
Korea,1
economic development,2
TECHNOLOGICAL CATCHUP,2
KNOWLEDGE BASES,2
INNOVATION,1
FIRMS,1
LAW,1
Multidetector computed tomography angiography,4
acute multiple brain infarctions,4
patent foramen ovale,3
left atrial appendage thrombus,4
complicated aortic plaque,3
PATENT FORAMEN OVALE,3
ATRIAL APPENDAGE THROMBUS,3
CRYPTOGENIC STROKE,2
TRANSESOPHAGEAL ECHOCARDIOGRAPHY,2
CT ANGIOGRAPHY,2
AORTA,1
METAANALYSIS,1
DIAGNOSIS,1
DISEASE,1
ADULTS,1
,1
INTELLECTUAL PROPERTY,2
SILICON VALLEY,2
FAIRUSE,1
LAW,1
PREEMPTION,1
COPYRIGHT,1
PATENT,1
AGREEMENTS,1
INNOVATION,1
FREEDOM,1
Deposit Microorganism,2
Genetic Resources,2
Budapest Treaty,2
Patent Biotechnology Protection,3
Urgency,1
,1
patents,1
pharmaceuticals,1
TRIPS agreement,2
new use of known medical substances,6
novelty,1
inventive step,2
Asian patent law,3
EUROPE,1
staggered board,2
life cycle,2
Tobins Q,2
investments,1
innovation,1
investor composition,2
POWERFUL ANTITAKEOVER FORCE,3
CORPORATE GOVERNANCE,2
INSTITUTIONAL INVESTORS,2
FIRM VALUE,2
TAKEOVER LAWS,2
INNOVATION,1
The America Invents Act,4
Patents,1
Intellectual property,2
Narrative RD disclosure,3
Analysts forecast,2
Information asymmetry,2
CORPORATE DISCLOSURE,2
INFORMATION ASYMMETRY,2
NONFINANCIAL DISCLOSURE,2
INTELLECTUAL PROPERTY,2
ANALYST COVERAGE,2
AUDITQUALITY,1
BIG 4,2
EARNINGS,1
EQUITY,1
INNOVATION,1
University invention,2
Research commercialization,2
Licensing,1
Patent,1
BAYHDOLE ACT,2
PUBLIC RESEARCH ORGANIZATIONS,3
TECHNOLOGYTRANSFER,1
UNITEDSTATES,1
INTELLECTUAL PROPERTY,2
LIFE SCIENCES,2
ACADEMIC RESEARCH,2
INDUSTRY,1
KNOWLEDGE,1
GROWTH,1
,1
PURE THEORY,2
PATENTS,1
INNOVATION,1
Technological change,2
labor laws,2
worker power,2
inequality,1
PRODUCTIVITY GROWTH,2
MECHANIZATION,1
LABOR,1
foreign direct investment,3
innovation,1
patent,1
regional innovation,2
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
PRODUCTIVITY GROWTH,2
DOMESTIC FIRMS,2
FDI,1
SPILLOVERS,1
COMPETITION,1
,1
INTELLECTUAL PROPERTY,2
FEDERAL CIRCUIT,2
PATENT SYSTEM,2
LAW,1
MYTH,1
APPROPRIABILITY,1
PROTECTION,1
INNOVATION,1
,1
BIG SECRETS,2
PATENTS,1
PROTECTION,1
MECHANISMS,1
INNOVATION,1
APPROPRIATION,1
STRATEGIES,1
KNOWLEDGE,1
ECONOMICS,1
VENTURES,1
,1
INTELLECTUAL PROPERTY,2
INDEPENDENT INVENTION,2
RIGHTS,1
ECONOMICS,1
SYSTEM,1
SETTLEMENTS,1
RETHINKING,1
ANTITRUST,1
DEFENSE,1
LEVERS,1
proprietary costs,2
RDactive firms,2
singlelender financing,2
American Inventors Protection Act,4
financing innovation,2
PRODUCTMARKET COMPETITION,2
CORPORATE DISCLOSURE,2
ACCOUNTING INFORMATION,2
PATENT PUBLICATION,2
EARNINGS QUALITY,2
CREDITOR RIGHTS,2
PRIVATE,1
INCENTIVES,1
INVESTMENT,1
INNOVATION,1
technology trends,2
digital health,2
patent,1
bibliometric analysis,2
,1
Inventorship,1
Ownership,1
Biotechnology,1
U,1
S,1
Patent Act,2
Japanese Patent Act,3
Firsttoinvent,1
Firsttofile,1
Conception,1
Reduction to practice,3
,1
Bangladesh,1
mailbox patent application,3
TRIPS,1
graduating LDC,2
pharmaceuticals,1
access to medicine,3
HUMANRIGHTS,1
HEALTH,1
PROTECTION,1
FRAMEWORK,1
AGREEMENT,1
TREATIES,1
,1
INFORMATION,1
Corporate lobbying,2
Firm innovation,2
Information transmission,2
Information value,2
INTELLECTUAL PROPERTYRIGHTS,2
CONGRESSIONAL VOTES,2
CORPORATE,1
POLICY,1
MARKET,1
LAWS,1
COMPETITION,1
GOVERNANCE,1
POLITICS,1
FINANCE,1
Internet of Things,3
Standard essential patents,3
Abuse of market dominance,4
Lockin,1
Patent holdup,2
Prohibitory injunctions,2
COMPETITION,1
trade secret,2
misappropriation,1
spinal implant,2
Defend Trade Secrets Act,4
confidentiality,1
,1
Graphics recognition,2
Text detection,2
Optical character recognition OCR,4
Competitions,1
Crowdsourcing,1
ROBUST READING COMPETITION,3
GRAMMATICAL INFERENCE,2
ENGINEERING DRAWINGS,2
INNOVATION CONTESTS,2
SCENE IMAGES,2
TEXT,1
SEPARATION,1
UNCERTAINTY,1
PERFORMANCE,1
SYSTEM,1
Barriers to entry,3
Biologics,1
Biosimilars,1
Competition,1
Exclusivity,1
Innovation,1
Patents,1
Research and development,3
HURDLES,1
Radical invention,2
Novelty,1
Patent,1
Recombination,1
Public research,2
BAYHDOLE ACT,2
TECHNOLOGICAL NOVELTY,2
PATENT QUALITY,2
SCIENCE,1
KNOWLEDGE,1
INNOVATION,1
UNIVERSITIES,1
ENTREPRENEURSHIP,1
REFERENCES,1
DIFFUSION,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ACADEMIC RESEARCH,2
DISCLOSURE,1
INNOVATION,1
MARKET,1
TECHNOLOGY,1
INCENTIVES,1
RULES,1
,1
,1
Examination of inventions,3
France,1
intellectual property,2
patents,1
science and industry,3
specifications,1
,1
Utility model patents,3
Utility model patent regime strength,5
Utility model patent regime strictness and appropriabilitystrength,7
China,1
East Asian latecomers,3
Catchup strategy,2
INTELLECTUAL PROPERTYRIGHTS,2
PROTECTION,1
INNOVATION,1
IMPACTS,1
INDEX,1
Patent,1
Synthetic biology,2
Iraqi law,2
Malaysian law,2
,1
Law,1
conservation,1
wellbeing,1
oceans,1
human,1
health,1
biopiracy,1
bioprospecting,1
patent,1
litter,1
COASTAL PROXIMITY,2
BIODIVERSITY,1
ENVIRONMENT,1
INGESTION,1
DEBRIS,1
BEACH,1
SEA,1
Open Payments,2
orthopedic spine surgery,3
Physician Payments Sunshine Act,4
royalties and licensing,3
DATABASE,1
,1
COVID19,1
LAW,1
VACCINES,1
STATUTES,1
invention,1
patent licensing,2
star scientists,2
LIFESCIENCE PROGRAMS,2
AGRICULTURAL BIOTECHNOLOGY,2
INSTITUTIONAL TRANSFORMATION,2
ASYMMETRIC INFORMATION,2
KNOWLEDGE SPILLOVERS,2
TECHNOLOGYTRANSFER,1
INNOVATION,1
SCIENTISTS,1
PATENTS,1
PERSPECTIVE,1
,1
INTELLECTUAL PROPERTY,2
KNOWLEDGE,1
LOCALIZATION,1
EVOLUTION,1
SEARCH,1
Personal income tax,3
Corporate innovation,2
Inventors  financial incentives,4
Revised PIT law of 2011,5
China,1
FIRM INNOVATION,2
MARRIEDCOUPLES,1
MOBILITY,1
CHINA,1
TAXATION,1
PROPERTY,1
INVESTMENT,1
RESPONSES,1
ADOPTION,1
NETWORK,1
,1
COMPETITION LAW,2
POLICY,1
DISCRIMINATION,1
JUSTIFICATIONS,1
EFFICIENCIES,1
CONTEXT,1
LIMITS,1
ABUSE,1
Patent infringement,2
Litigation,1
Reform,1
,1
,1
DRUG DEVELOPMENT,2
LIFE,1
COMPETITION,1
HEALTH,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FRAND,1
,1
FEDERAL CIRCUIT,2
TROLLS,1
INSURANCE,1
MARKET,1
SYSTEM,1
PTO,1
,1
BAYHDOLE ACT,2
ACADEMIC RESEARCH,2
TRANSFER OFFICES,2
IVORY TOWER,2
INDUSTRY,1
IMPACT,1
ENTREPRENEURIAL,1
PERFORMANCE,1
CREATION,1
EUROPE,1
Dutch Republic,2
early modern,2
invention privileges,2
inventive step,2
inventorship,1
Jacob Floris van Langren,4
Jodocus Hondius,2
legal technology,2
nonobviousness,1
patents,1
PATENT,1
,1
,1
,1
FEDERAL CIRCUIT,2
RETHINKING,1
COURT,1
SITUATION,1
SYSTEM,1
POLICY,1
FACTS,1
LAW,1
Shareholder litigation,2
Green innovation,2
Climate risk,2
managerial entrenchment,2
CORPORATE GOVERNANCE,2
AGENCY COSTS,2
occupations and professions,3
patents and intellectual property rights,5
archival research,2
extant data,2
STRATEGIC MANAGEMENT,2
EMPLOYEE MOBILITY,2
REVOLVINGDOORS,1
AGENCY THEORY,2
FIRM,1
ECONOMICS,1
CITATIONS,1
INDUSTRY,1
MODELS,1
COSTS,1
3D printing,2
3D printers,2
additive manufacturing,2
additive manufacturing processes,3
STUDYING TECHNOLOGICALPROGRESS,2
FUNCTIONALAPPROACH,1
ENERGY TECHNOLOGY,2
PATENT CITATIONS,2
EXTENSION,1
Seed activism,2
legal activism,2
intellectual property,2
GM crops,2
Brazil,1
India,1
PLURALITY,1
FARMERS,1
RIGHTS,1
intellectual property law,3
patents,1
claims construction,2
Coase theorem,2
,1
,1
INFORMATION ASYMMETRY,2
ECOLABELS,1
,1
COPYRIGHT,1
LAW,1
PERSPECTIVES,1
Compulsory license,2
intellectual property rights,3
TRIPS agreement,2
DOHA declaration,2
TRIPS flexibility,2
MEDICINES,1
ACCESS,1
BRAZIL,1
DRUGS,1
Universityindustry linkages,2
General purpose technologies,3
Nanotechnology,1
Technology transfer,2
Markets for technology,3
Complementary assets,2
BAYHDOLE ACT,2
TECHNOLOGICALINNOVATION,1
COMPLEMENTARY ASSETS,2
CITATIONS,1
KNOWLEDGE,1
ECONOMICS,1
INDUSTRY,1
MARKET,1
EXAMINER,1
RENEWAL,1
,1
INTELLECTUAL PROPERTY,2
RIGHTS,1
RETHINKING,1
ECONOMICS,1
HINDSIGHT,1
SCIENCE,1
INNOVATION,1
NORMS,1
Pharmaceutical policy,2
Intellectual property,2
Access to medicines,3
Essential medicines,2
Global governance,2
International trade,2
AIDS TREATMENT,2
ACCESS,1
abacavir base,2
abacavir sulfate,2
neutral and acid salts,4
sulfate,1
hemisulfate,1
protonation,1
pKa,1
patenting,1
xray diffraction analysis,3
atomic formula,2
molecular weight,2
active pharmaceutical substance APS,4
patent claim,2
Ziagen,1
registration,1
FDA USP,2
,1
artificial intelligence,2
copyright,1
expression,1
freedom to pursue economic interests,5
idea,1
new knowledge,2
ownership of knowledge,3
patent,1
true scholarship,2
,1
,1
FEDERAL CIRCUIT,2
PATENT,1
Main path analysis,3
Subjectactionobject SAO,2
Causality,1
Link weight,2
DEMATEL,1
MORPHOLOGY ANALYSIS,2
NETWORK,1
EVOLUTION,1
Patent ownership,2
Scientific founders,2
Knowledge technology transfer,3
European biotechnology,2
BAYHDOLE ACT,2
INTELLECTUAL PROPERTYRIGHTS,2
SCIENCE,1
SCIENTISTS,1
FIRMS,1
TECHNOLOGY,1
INNOVATION,1
PERFORMANCE,1
FACULTY,1
EXPERIENCE,1
entrepreneurial universities,2
university patenting,2
university publications,2
East Asian universities,3
national innovation systems,3
BAYHDOLE ACT,2
TECHNOLOGY COMMERCIALIZATION,2
ACADEMIC ENTREPRENEURSHIP,2
UNITEDSTATES,1
TRIPLEHELIX,1
QUALITY,1
INDICATORS,1
KOREA,1
CITATIONS,1
QUANTITY,1
Transportation innovation,2
Patents,1
Executive orders,2
Policy impacts,2
Abatement costs,2
CLEANAIR ACT,2
ENVIRONMENTALREGULATION,1
PORTER HYPOTHESIS,2
TECHNOLOGY,1
ENERGY,1
TRANSPORTATION,1
INCENTIVES,1
EFFICIENCY,1
DIFFUSION,1
,1
,1
,1
RIGHTS,1
INVENTION,1
carbon emission intensity,3
green patents,2
ARDL model,2
technology innovation,2
empirical analysis,2
CO2 EMISSIONS,2
DECOMPOSITION,1
CONSUMPTION,1
human coronavirus OC43,3
stability,1
leather,1
antiviral,1
infectivity,1
TCID50,1
229E,1
Intellectual Property Court,3
Patent Infringement,2
Prevention type,2
Confirmation type,2
Perpetuation of Evidence,3
,1
intellectual property,2
international property law,3
international regulations,2
trade flows,2
multiple regression analysis,3
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONALTRADE,1
TECHNOLOGY,1
INNOVATION,1
Licensing,1
Innovation,1
Grantback,1
Patent,1
TECHNOLOGYTRANSFER,1
PATENT,1
MARKET,1
CLAUSES,1
Patent linkage,2
Linkage,1
Access to medicines,3
TRIPSplus,1
Constructive ambiguity,2
Free trade agreements,3
INTELLECTUAL PROPERTY,2
TRADE AGREEMENTS,2
TRIPS AGREEMENT,2
PUBLICHEALTH,1
LEGISLATION,1
AMBIGUITY,1
AMERICA,1
balancing competition law,3
EU,1
exploitative abuse,2
pharmaceuticals,1
patents,1
,1
intellectual property,2
patent,1
public health,2
,1
intellectual property and patents,4
compulsory licensing,2
marchin rights,2
geoengineering,1
negativeemission technologies NETS,3
carbondioxide removal,2
biomass energy with carbon capture and sequestration BECCS,8
direct air capture DAC,4
INNOVATION,1
ANTITRUST,1
ACCESS,1
PRICE,1
CO2,1
Knowledge transfer,2
Network dynamics,2
University,1
China,1
TECHNOLOGYTRANSFER,1
RESEARCH COLLABORATION,2
SCIENTIFIC COLLABORATION,2
ABSORPTIVECAPACITY,1
INNOVATION NETWORKS,2
PATENT CITATIONS,2
INDUSTRY,1
IMPACT,1
EVOLUTION,1
SCIENCE,1
,1
LONGQT SYNDROME,2
SETTLEMENT,1
IMPACT,1
Disclosure,1
Knowledge flow,2
Patent,1
Pregrant publication,2
Applicant citation,2
Examiner citation,2
CITATIONS,1
IMPACT,1
eBook readers,2
Location surveillance,2
Privacy,1
Law,1
,1
Intellectual property,2
Low earth orbit,3
Patent,1
Satellite debris,2
Trade secret,2
O34 Intellectual property and intellectual capital,6
Q53 Waste management,3
L51 Regulation and industrial policy,5
K11 Property law,3
TECHNOLOGY,1
PATENTS,1
MARKET,1
,1
PATENTS,1
BIOLOGICS,1
DISCOVERY,1
DEFENSE,1
DRUGS,1
BayhDole effect,2
universityindustrygovernment structure,2
indigenous technology,2
university patents,2
developing economy,2
Malaysia,1
INNOVATION POLICY,2
ENTREPRENEURSHIP,1
SCIENCE,1
ACT,1
SINGAPORE,1
SYSTEM,1
corporate governance,2
innovation,1
patent race,2
shorttermism,1
simultaneous invention,2
CORPORATE GOVERNANCE,2
AGENCY COSTS,2
CEO DUALITY,2
FIRM,1
PERFORMANCE,1
COMPETITION,1
INVESTMENT,1
PERSISTENCE,1
INVESTORS,1
MARKET,1
Second Law of Thermodynamics,4
Entropy,1
Heat Recovery,2
Thermonuclear Fusion,2
Climate Change,2
Climate Change Mitigation,3
,1
BayhDole Act,2
Intellectual property rights,3
Technology transfer,2
Publicly funded research,3
Gene patents,2
ACADEMIC RESEARCH,2
GENE PATENTS,2
OPEN SCIENCE,2
UNIVERSITIES,1
KNOWLEDGE,1
INDUSTRY,1
LIFE,1
ANTICOMMONS,1
INNOVATION,1
SECRECY,1
Agricultural science and technology,4
Breeding patents,2
PEST analysis,2
Neutral cognitive map,3
Breeding technology,2
,1
Energy conservation and conversion,4
First principle of thermodynamics,4
James Watt,2
Mechanical equivalent of heat,4
,1
Development bank,2
Development financial institution,3
State investment bank,3
Equity deal,2
Financing innovation,2
Patents,1
RESEARCHANDDEVELOPMENT,1
COUNT DATA,2
GOVERNANCE INDICATORS,2
DEVELOPMENT BANKS,2
INVESTMENT BANK,2
PRIVATE EQUITY,2
MARKET,1
PATENTS,1
MODELS,1
IMPACT,1
,1
NATIONALHEALTH INSURANCE,2
Green innovation,2
Shapley decomposition,2
Coast area,2
Inland area,2
DECOMPOSITION,1
rDNA technology,2
Genetically modified plants,3
Transformation,1
Plant variety,2
Patents,1
,1
Competition policy,2
European Commission,2
Commitments,1
Law enforcement,2
PRETRIAL NEGOTIATION,2
PATENT SETTLEMENTS,2
LITIGATION,1
INFORMATION,1
ILLEGALITY,1
COSTS,1
LAW,1
,1
CONSTITUTIONAL CRIMINALPROCEDURE,2
STATES SUPREMECOURT,2
QUALIFIED IMMUNITY,2
JUDICIAL DEFERENCE,2
RETHINKING,1
APPEALS,1
MYTH,1
PEARSON,1
WARREN,1
STANDARDS,1
Knowledge spillovers,2
sophistication of export,3
patent applications,2
FDI,1
FOREIGN DIRECTINVESTMENT,2
RESEARCHANDDEVELOPMENT,1
FINANCIAL DEVELOPMENT,2
ABSORPTIVECAPACITY,1
PRODUCTIVITY,1
TECHNOLOGY,1
SPILLOVERS,1
QUALITY,1
TRADE,1
GLOBALIZATION,1
Research collaboration,2
Academic patents,2
Technological impact,2
Germany,1
Inventor team,2
BAYHDOLE ACT,2
PATENT CITATIONS,2
KNOWLEDGE FLOWS,2
QUALITY,1
UNIVERSITIES,1
SEARCH,1
SPILLOVERS,1
INNOVATION,1
PROXIMITY,1
DISTANCE,1
Innovation,1
Patents,1
RD,1
CSR,1
RESEARCHANDDEVELOPMENT,1
EARNINGS MANAGEMENT,2
TECHNICAL CHANGE,2
COMPANIES ACT,2
RESPONSIBILITY,1
IMPACT,1
FIRMS,1
university commercialisation,2
technology transfer offices,3
triple helix,2
university industry technology transfer,4
BAYHDOLE ACT,2
ENTREPRENEURIAL UNIVERSITY,2
INTELLECTUAL PROPERTY,2
PUBLIC RESEARCH,2
COMMERCIALIZATION,1
INNOVATION,1
INDUSTRY,1
PERFORMANCE,1
PATENTS,1
ORIENTATION,1
Biological weapons,2
Antiterrorism,1
Viral agents,2
Patents,1
HISTORY,1
,1
INNOVATION,1
AMPLIFICATION,1
BIOLOGICS,1
ECONOMICS,1
INDUSTRY,1
THERAPY,1
HISTORY,1
GENOME,1
IMPACT,1
PRICE,1
Interest in bringing legal proceedings,5
Action for revocation,3
Filing after patent expiry,4
Infringement action,2
Main claim,2
Independent claims with same content,5
,1
Board Independence,2
CEO Power,2
Corporate Governance,2
Innovation,1
Powerful CEOs,2
SOX,1
SarbanesOxley Act,2
RESEARCHANDDEVELOPMENT,1
AGENCY COSTS,2
DIRECTORS,1
MANAGEMENT,1
OVERCONFIDENCE,1
DETERMINANTS,1
PERFORMANCE,1
INCENTIVES,1
INNOVATION,1
OWNERSHIP,1
,1
HUMAN NPH INSULIN,3
DIABETESMELLITUS,1
COSTS,1
GLARGINE,1
THERAPY,1
ADHERENCE,1
ACCESS,1
Gender Identity Law in Argentina,5
trans interpretation,2
posthumanism,1
queer critique,2
,1
trade secret,2
public policy,2
myriad genetics,2
marchin rights,2
genetic test,2
genetic variant,2
SEQUENCE VARIANTS,2
ASSOCIATION,1
GENOMICS,1
,1
RESEARCHANDDEVELOPMENT,1
STOCK MARKETS,2
FINANCIAL DEVELOPMENT,2
CORPORATE INNOVATION,2
POLITICALECONOMY,1
FIRM INNOVATION,2
GROWTH,1
LAW,1
INSTITUTIONS,1
ENFORCEMENT,1
,1
,1
,1
IRRATIONAL IGNORANCE,2
FEDERAL CIRCUIT,2
PATENT,1
ACCURACY,1
LAW,1
Financial bottleneck,2
Reserves and distribution of university patents,6
Highvalue patent,2
Patent transfer,2
Patent evaluation indicator model,4
TECHNOLOGYTRANSFER OFFICES,2
BAYHDOLE ACT,2
PUBLIC RESEARCH,2
PATENT QUALITY,2
PERFORMANCE,1
INDICATORS,1
INNOVATION,1
IMPACT,1
,1
,1
Algerian law,2
American legislation,2
innovation,1
legal protectionproperty right,3
new plant variety,3
patent,1
plant,1
,1
invention,1
patent claims,2
HalfCausation,1
HalfCausation Branching,2
HalfCausation Encapsulation,2
philosophy of technological discovery,4
philosophy of inventions and patents,5
philosophy of technology,3
,1
Sustainable agriculture,2
Bioinoculants,1
Biopriming,1
Patent landscape,2
Plant biotechnology,2
SEEDS,1
,1
,1
Prior art search,3
graph traversal,2
citation network,2
document similarity,2
patent analysis,2
PATENT LITIGATION,2
COCITATION,1
RETRIEVAL,1
INFORMATION,1
SIMILARITY,1
MANAGEMENT,1
INNOVATION,1
Classification,1
Patents,1
Patent offices,2
Technoscience,1
Paul Otlet,2
SCIENCE,1
Globalization Trends,2
Knowledge based Economy,3
National Law and Transnational Law,5
,1
,1
,1
Artificial intelligence,2
Law,1
Patents,1
Task analysis,2
Robots,1
,1
,1
JURY,1
,1
PERCUTANEOUS CORONARY PROCEDURES,3
VASCULAR COMPLICATIONS,2
ANGIOGRAPHY,1
ANGIOPLASTY,1
PREVENTION,1
WEIGHT,1
ACCESS,1
ANTICOAGULATION,1
INTERVENTIONS,1
COMPRESSION,1
,1
,1
,1
LEGAL,1
Babesiosis,1
Buffalo,1
Cattle,1
Clinicohaematobiochemical,1
Prevalence,1
Lowlying areas,2
PCR,1
Punjab,1
India,1
,1
,1
,1
corporate finance,2
corporate innovation,2
government policy and regulation,4
labour economics,2
LONGTERM ORIENTATION,2
MENTALHEALTH,1
WORK,1
CEOS,1
DISEASE,1
STRESS,1
LAWS,1
Efficiency of the common law,5
Civil law,2
Contracts,1
Rewards,1
Unilateral contracts,2
Property,1
Innovation,1
Finders keepers,2
Salvage,1
Maritime law,2
ECONOMICS,1
PRIZES,1
PROCUREMENT,1
INFORMATION,1
INNOVATION,1
CONTRACTS,1
PATENTS,1
,1
HEALTH DIPLOMACY,2
ADHERENCE,1
FRAMEWORK,1
THERAPY,1
DRUGS,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
SERVICE MARKS,2
INNOVATION,1
FIRMS,1
PERFORMANCE,1
SURVIVAL,1
PATENTS,1
LAW,1
DISAMBIGUATION,1
,1
BOUNDED RATIONALITY,2
Competition,1
Regulation,1
Innovation,1
OECD countries,2
RESEARCHANDDEVELOPMENT,1
INDUSTRIALSTRUCTURE,1
DOMESTIC INNOVATION,2
PRODUCTIVITY GROWTH,2
TIMEINVARIANT,1
COMPETITION,1
TRADE,1
VARIABLES,1
PANEL,1
LAWS,1
Design right,2
Design patent,2
Repair clause,2
Law of one price,4
Price dispersion,2
European car market,3
Automotive aftermarket,2
Spare parts,2
PRODUCT DESIGN,2
INDUSTRIALDESIGN,1
EUROPEAN DESIGN,2
LAW,1
INNOVATIONS,1
PATENTS,1
CONVERGENCE,1
COPYRIGHT,1
LESSONS,1
MARKET,1
Civil procedure,2
litigation,1
intellectual property,2
LITIGATION,1
FEES,1
Patent text mining,3
Technical phrase extraction,3
Graph construction,2
Structure and position information,4
,1
,1
INNOVATION,1
PATENTS,1
ANTITRUST,1
COPYRIGHT,1
BIOTECHNOLOGY,1
COMPETITION,1
IMPACT,1
MUSIC,1
ENTRY,1
LAW,1
Vaccines,1
Intellectual property rights,3
Gavi the Vaccine Alliance,4
Human papillomavirus vaccines,3
Rotavirus vaccines,2
Pneumococcal conjugate vaccines,3
Trade,1
Patents,1
Vaccine manufacturers,2
Developing country manufacturers,3
,1
,1
,1
,1
INDUSTRY COLLABORATION,2
KNOWLEDGE SPILLOVERS,2
EMPIRICALANALYSIS,1
NETWORK ANALYSIS,2
OPEN INNOVATION,2
COMMERCIALIZATION,1
LOCALIZATION,1
ENGAGEMENT,1
INDICATORS,1
PROXIMITY,1
Nitric oxide,2
Nasal airway,2
Nasal cycle,2
Unilateral nostril breathing,3
Congested airway,2
Patent airway,2
AIRWAYS,1
HEALTH,1
Breeders rights,2
Plant Patents,2
Biotechnological inventions,2
plant varieties,2
agricultural innovation,2
,1
Intellectual property regimes,3
Wage inequality,2
Hightech and lowtech firms,4
Managerial compensation,2
 Snailshape Patent race,4
PRODUCT MARKET COMPETITION,3
RESEARCHANDDEVELOPMENT,1
TRADE LIBERALIZATION,2
MANAGEMENTPRACTICES,1
TECHNOLOGYTRANSFER,1
INFORMATIONTECHNOLOGY,1
ECONOMICPERFORMANCE,1
INDUSTRIALSTRUCTURE,1
PATENT PROTECTION,2
SKILL PREMIUM,2
Biotechnological inventions,2
Embryos,1
EU law,2
European Court of Justice,4
Excluded subject matter,3
Jurisdiction,1
Patentability,1
Stem cell research,3
PATENTS,1
Cancer drug targets,3
cancer therapy,2
novel compounds,2
pancreatic cancer,2
patent,1
personalized medicine,2
PHASEIII TRIAL,2
EPITHELIALMESENCHYMAL TRANSITION,2
NABPACLITAXEL,1
TUMORGROWTH,1
GEMCITABINE,1
EXPRESSION,1
THERAPY,1
ADENOCARCINOMA,1
SURVIVAL,1
CARCINOMA,1
Aneurysm,1
Aorta,1
Dissection,1
PATENT FALSE LUMEN,3
ARCH REPLACEMENT,2
RISK ANALYSIS,2
REPAIR,1
SURGERY,1
GRAFT,1
HEMIARCH,1
International innovation partnerships,3
Central and Eastern Europe,4
International copatents,2
VAR,1
Impulse response function,3
Vector autoregression VAR,3
F29,1
F50,1
O30,1
O57,1
P52,1
FOREIGN DIRECTINVESTMENT,2
ECONOMICGROWTH,1
ABSORPTIVECAPACITY,1
IMPACT,1
CAPABILITIES,1
COOPERATION,1
SPILLOVERS,1
ALLIANCES,1
FRAMEWORK,1
PATENTS,1
,1
HEALTHINSURANCE,1
INTELLECTUAL PROPERTY,2
INCOMETAX,1
POLITICAL ACCOUNTABILITY,2
ADVERSE SELECTION,2
MANDATED BENEFITS,2
PUBLIC PROVISION,2
SELFSELECTION,1
PRIVATE GOODS,2
INKIND,1
,1
LANHAM ACT,2
,1
TRIALS,1
RISK,1
China,1
Intellectual property,2
Legal transplanting,2
Local communities,2
Patent law,2
Traditional medical knowledge,3
INTERNATIONALLAW,1
TRIPS AGREEMENT,2
LEGAL,1
RIGHTS,1
TRADE,1
HEALTH,1
PRESERVATION,1
CONFUCIANISM,1
RENAISSANCE,1
INNOVATIONS,1
University research,2
Industry research,2
Patents,1
Division of labour,3
Useinspired basic research,3
BAYHDOLE ACT,2
PASTEURS QUADRANT,2
ACADEMIC PATENTS,2
IVORY TOWER,2
SCIENCE,1
TECHNOLOGY,1
KNOWLEDGE,1
IMPACT,1
QUALITY,1
UK,1
Trade secrets,2
Noncompetition,1
Economic espionage,2
Mobility,1
Breach of confidence,3
PRINCIPLE,1
EQUALITY,1
ARMS,1
,1
GOVERNANCE,1
GERMANY,1
GRAVITY,1
IMPACT,1
,1
PATENT,1
INFRINGEMENT,1
PUNISHMENT,1
ECONOMICS,1
CRIME,1
Market knowledge,2
Scientific knowledge,2
Patents,1
Inventors,1
RESEARCHANDDEVELOPMENT,1
PATENT CITATIONS,2
INNOVATION PERFORMANCE,2
ABSORPTIVECAPACITY,1
UNIVERSITY,1
PRODUCTIVITY,1
SCIENCE,1
IMPACT,1
TECHNOLOGY,1
COMMERCIALIZATION,1
transposition of great arteries,4
bridge to surgery,3
ductal stenting,2
atrial septal stenting,3
,1
,1
FUNDAMENTAL LEGAL CONCEPTIONS,3
FAIRUSE,1
PATENT SCOPE,2
NATURAL LAW,2
COPYRIGHT,1
PREEMPTION,1
POLICY,1
INNOVATION,1
ANTITRUST,1
PROGRESS,1
G32,1
G34,1
G38,1
K22,1
M48,1
O31,1
SOX SECTION 404,3
COSTS,1
CONSEQUENCES,1
INFORMATION,1
DISCLOSURE,1
DECISION,1
IPOS,1
,1
,1
algorithm,1
computer program,2
patentability,1
software patent,2
intellectual property,2
G20,1
BRICS,1
,1
Trade secrets law,3
Unfair competition,2
Parasitic competition,2
Slavish imitation,2
Passing off,2
INTELLECTUAL PROPERTY,2
PATENTS,1
SPILLOVERS,1
marchin rights,2
BayhDole Act,2
governmentfunded research,2
National Institutes of Health,4
BAYHDOLE,1
DRUGS,1
INNOVATION,1
PATENTS,1
ROLES,1
,1
PATENT HOLDUP,2
LAW,1
LIABILITY,1
INFRINGEMENT,1
RIGHTS,1
ABUSE,1
UNCONSCIONABILITY,1
INJUNCTIONS,1
CUSTOM,1
RULES,1
Boundary spanning,2
Externally acquired technologies,3
Pioneering technologies,2
Star scientists,2
Upstream alliances,2
KNOWLEDGEBASED THEORY,2
LOCAL SEARCH,2
PATENT CITATIONS,2
INNOVATION PERFORMANCE,2
ABSORPTIVECAPACITY,1
EMPIRICALANALYSIS,1
ESTABLISHED FIRMS,2
BIOTECHNOLOGY,1
CAPABILITIES,1
SCIENCE,1
,1
INTELLECTUAL PROPERTY CLAUSE,3
JUDICIAL CAPACITY,2
SUPREMECOURT,1
TRADE SECRETS,2
LAW,1
PROTECTION,1
LIMITATION,1
HISTORY,1
LIMITS,1
SCOPE,1
technology evolution path analysis,4
agricultural machinery,2
patent mining,2
technology roadmap,2
LDA clustering,2
METHODOLOGY,1
SCIENCE,1
VISUALIZATION,1
INFORMATION,1
ROADMAP,1
BERT,1
Foreign Office,2
Diplomatic Recognition,2
North Korea,2
International Maritime Organization,3
Zimbabwe,1
,1
Biosensors,1
Technological innovation,2
Biosensor research,2
Biosensor market,2
Biosensor development,2
TRANSFORMATION,1
CARE,1
intellectual property rights,3
innovation strategy,2
institutional change,2
emerging economy,2
China,1
SOCIALSTRUCTURE,1
FINANCIAL PERFORMANCE,2
CULTURAL DISTANCE,2
PATENT RIGHTS,2
TRANSITION,1
KNOWLEDGE,1
NETWORKS,1
SURVIVAL,1
EMBEDDEDNESS,1
LIABILITY,1
Wireless telegraphy,2
Intellectual property,2
Law courts,2
Experts,1
Innovation,1
,1
,1
PATENT,1
INNOVATION,1
jurisdiction,1
infringement,1
validity,1
bifurcation,1
territoriality,1
private international law,3
LITIGATION,1
antitrust law,2
standardessential patents,2
patent licensing,2
licensing negotiation groups,3
monopsony,1
patent pools,2
PATENT HOLDUP,2
INNOVATION,1
Gene editing,2
Patent analysis,2
Technology trend,2
Topic word network,3
CYTIDINE DEAMINASE AID,3
EVOLUTION,1
ACTIVATION,1
INTELLIGENCE,1
LANDSCAPE,1
COMPLEX,1
National culture,2
Corporate innovation,2
Individualism,1
Uncertaintyavoidance,1
Innovation efficiency,2
OWNERSHIP,1
BUSINESS,1
QUALITY,1
VALUES,1
LAW,1
Fast fission,2
Fusion,1
LANR,1
NASA,1
Space power,2
,1
Technology transfer,2
Battery electric vehicles,3
Citation organization networks,3
Patent analysis,2
KNOWLEDGE TRANSFER,2
POLICY,1
INNOVATION,1
EMERGENCE,1
EVOLUTION,1
INDUSTRY,1
COUNTRY,1
FLOWS,1
,1
DRUG,1
,1
INTELLECTUAL PROPERTY,2
SOUTHAFRICA,1
ACCESS,1
MEDICINES,1
HEALTH,1
POLICY,1
INNOVATION,1
PRICE,1
LAW,1
Research productivity,2
RD resources,2
Panel data analysis,3
Korean universities,2
RESEARCHANDDEVELOPMENT,1
IMPACT,1
ECONOMICS,1
DEPARTMENTS,1
PERFORMANCE,1
TECHNOLOGY,1
INCENTIVES,1
INNOVATION,1
RESOURCES,1
QUALITY,1
Patent,1
Pharmaceutical industry,2
Generic drug,2
Compulsory license,2
Bolar exception,2
Evergreening,1
,1
UNDP,1
patentability guidelines,2
patent examination,2
pharmaceutical patents,2
TRIPS Agreement,2
DRUGS,1
TRIZ,1
40 inventive principles,3
recycling machine,2
innovation design process,3
brainstorming,1
CREATIVITY ENHANCEMENT APPROACH,3
DESIGN,1
entrepreneurs,1
protection of rights,3
Intellectual Property Law,3
crimes,1
legal assets,2
,1
D23,1
G32,1
O32,1
O34,1
RESEARCHANDDEVELOPMENT,1
CREDITOR RIGHTS,2
INNOVATION,1
OWNERSHIP,1
INVESTMENT,1
AGREEMENTS,1
ENFORCEMENT,1
INVENTIONS,1
EMPLOYERS,1
LAWS,1
private prosecution,2
Singapore,1
intellectual property,2
copyright,1
patents,1
locus standi,2
abuse,1
,1
,1
MEDICAL MALPRACTICE LITIGATION,3
IMPACT,1
,1
UNCONSTITUTIONAL CONDITIONS,2
PUBLIC RIGHTS,2
CONTRACT CLAUSE,2
JUDICIAL POWER,2
PATENT SYSTEM,2
PROPERTY,1
HISTORY,1
LAW,1
ORIGINS,1
OFFICE,1
,1
INNOVATION,1
PATENTS,1
SYSTEM,1
COVID19,1
Vaccine,1
Patent waiver,2
TRIPS,1
Compulsory licensing,2
Intellectual property rights,3
EXTERNALITIES,1
JUSTIFICATION,1
verticalaxis wind turbine,3
hemispherical cover,2
power generation,2
extreme wind conditions,3
computational fluid dynamics,3
SAVONIUS ROTOR,2
DESIGN,1
OPTIMIZATION,1
PERFORMANCE,1
IMPROVEMENT,1
Environmental Law,2
International Economic Law,3
Other Areas of International Law,5
Law of Development,3
DEVELOPINGCOUNTRIES,1
PUBLICHEALTH,1
TRIPS,1
GOVERNANCE,1
ACCESS,1
POLICY,1
DECLARATION,1
KNOWLEDGE,1
FRAMEWORK,1
RIGHTS,1
evolution of ST,3
applicationsoriented,1
DAT path,2
phase transition,2
environment of knowledge utilization,4
mediator set,2
JOURNAL DIFFUSION,2
HISTORICAL ROOTS,2
RESEARCH FIELDS,2
PATENTS,1
DNA,1
Technological innovation,2
Patent,1
Trademark,1
GDP,1
Environment quality,2
ECONOMICGROWTH,1
ENERGYCONSUMPTION,1
RENEWABLE ENERGY,2
EMISSIONS,1
,1
PATENT,1
ENTITIES,1
,1
,1
,1
RESEARCHANDDEVELOPMENT,1
EMERGING TECHNOLOGIES,2
IMPACT STATEMENTS,2
BROADER IMPACTS,2
PUBLIC RESEARCH,2
PATENTLAW,1
SCIENCE,1
GOVERNANCE,1
CHALLENGES,1
LESSONS,1
DYRK1A,1
DYRK kinases,2
heterocyclic compounds,2
patents,1
microwave chemistry,2
kinase inhibitor,2
down syndrome,2
Alzheimers disease,2
BETACELL PROLIFERATION,2
DOWNSYNDROME KINASE,2
PROTEINKINASE,1
BIOLOGICAL EVALUATION,2
COGNITIVE DEFICITS,2
ALZHEIMERSDISEASE,1
LEUCETTAMINE B,2
DRUG TARGET,2
DESIGN,1
DERIVATIVES,1
O340,1
BAYHDOLE ACT,2
PATENT CITATIONS,2
CONVERGING TECHNOLOGIES,2
ACADEMIC PATENTS,2
KNOWLEDGE FLOWS,2
NANOSCIENCE,1
NANOSCIENCE,1
UNIVERSITY,1
TIME,1
TERMS,1
,1
EMPLOYMENT PROTECTION LEGISLATION,3
WRONGFULDISCHARGE LAWS,2
MARKET,1
FLEXIBILITY,1
PROPERTY,1
COSTS,1
CO2 emissions,2
Renewable energy,2
Foreign direct investment,3
Tunisian Patents,2
ARDL model,2
CO2 EMISSIONS,2
CARBON EMISSIONS,2
EMPIRICALEVIDENCE,1
ECONOMICGROWTH,1
ABSORPTIVECAPACITY,1
TIMESERIES,1
TRADE GOOD,2
CONSUMPTION,1
NEXUS,1
TECHNOLOGY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PARAGRAPH 6 SYSTEM,3
PUBLICHEALTH,1
TRADE,1
WTO,1
BIOSIMILARS,1
PROTECTION,1
POLITICS,1
CANADA,1
DRUGS,1
,1
,1
time pressure,2
innovation,1
productivity,1
deadlines,1
incentives,1
INCENTIVE CONTRACTS,2
DECISIONMAKING,1
TIMEPRESSURE,1
PATENT,1
PERFORMANCE,1
CHOICE,1
Technology transfer,2
intercity network,2
patent transactions,2
proximity and dynamics,3
the Greater Bay Area,4
RESEARCHANDDEVELOPMENT,1
RIVER DELTA,2
ABSORPTIVECAPACITY,1
ECONOMICGEOGRAPHY,1
INCREASING RETURNS,2
KNOWLEDGE NETWORKS,2
INNOVATION,1
MARKET,1
SPILLOVERS,1
CHINA,1
,1
STATUTORY INTERPRETATION,2
HABEASCORPUS,1
CANONS,1
COURTS,1
RULES,1
ENFORCEMENT,1
STANDARDS,1
INVENTION,1
DOCTRINE,1
CONTRACT,1
,1
VISUALARTISTS RIGHTS,2
SUFFERING DAMAGES,2
PUNITIVE DAMAGES,2
FAIRUSE,1
PAIN,1
DEFAMATION,1
REPUTATION,1
CAUSATION,1
LIABILITY,1
GOODWILL,1
Exploitation of Patents,3
Protection and Enforcement of Intellectual Property Rights,7
Viet Nam,2
,1
,1
INTERNATIONAL ECONOMICLAW,2
INTELLECTUAL PROPERTY,2
PUBLICHEALTH,1
GLOBAL GOVERNANCE,2
DOHA DECLARATION,2
FREETRADE,1
WTO,1
WORLD,1
AGREEMENT,1
DISPUTES,1
Proprietary patent medicine vendors,4
Recommended antimalarial,2
Artemisininbased combination therapy ACT,4
Stocking,1
Knowledge,1
Perception,1
DRUG STORES,2
MALARIA,1
KNOWLEDGE,1
Small business policies,3
Enterprise development,2
Innovative startups,2
Innovative SMEs,2
Italy,1
Stochastic frontier analysis,3
RESEARCHANDDEVELOPMENT,1
FIRM SIZE,2
DEVELOPMENT PRODUCTIVITY,2
MODERATING ROLE,2
STARTUPS,1
PERFORMANCE,1
SMES,1
TECHNOLOGY,1
MANAGEMENT,1
GROWTH,1
Corporate social responsibility CSR,4
Innovation,1
Patents citations,2
Emerging countries,2
PERFORMANCE,1
CSR,1
LAW,1
COMPETITION,1
STRATEGY,1
ENHANCE,1
IMPACT,1
RIGHTS,1
CEOS,1
,1
COPYRIGHT,1
PATENT,1
Copyright,1
digital rights management,3
fair use,2
innovation,1
intellectual property,2
open source,2
participatory culture,2
patent,1
peer production,2
threedimensional printing,2
,1
Righttowork laws,2
Corporate innovations,2
Financial distress risk,3
FINANCIAL CONSTRAINTS,2
CAPITAL STRUCTURE,2
LABOR,1
COMPETITION,1
RISK,1
DETERMINANTS,1
UNIONIZATION,1
BEHAVIOR,1
FIRMS,1
HETEROGENEITY,1
Stateowned enterprises,2
Innovation,1
Patents,1
Hightech industries,2
Knowledge intensive services,3
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT SUBSIDIES,2
EMPIRICALEVIDENCE,1
COUNT DATA,2
FIRM,1
TECHNOLOGY,1
KNOWLEDGE,1
IMPACT,1
GROWTH,1
INSTITUTIONS,1
,1
AGREEMENT,1
Medial AI,2
Patentsharing mechanisms,2
Innovation,1
Twopronged solution,2
Knowledge sharing,2
ARTIFICIALINTELLIGENCE,1
PATENT,1
INNOVATION,1
FAIRNESS,1
LAW,1
iPSC,1
potentiality,1
pluripotency,1
multipotency,1
derivation strategies,2
bypassing pluripotency,2
direct reprogramming,2
tetraploid complementation,2
patenting,1
ethics,1
EPITHELIALMESENCHYMAL TRANSITION,2
DIRECT CONVERSION,2
HUMAN FIBROBLASTS,2
IPS CELLS,2
EPIGENETIC MEMORY,2
SELFORGANIZATION,1
AXIS FORMATION,2
MOUSE,1
MICE,1
PLURIPOTENCY,1
Scifi,1
Liquified law,2
Robot law,2
Artificial intelligence,2
Intellectual property,2
,1
Exclusivity,1
IP,1
right to health,3
affordable Medicare,2
South Africa,2
,1
electronic equipment,2
circular economy,2
patents,1
environment,1
sustainability,1
WASTE,1
TECHNOLOGIES,1
STRATEGIES,1
METALS,1
Relational infrastructures,2
Institutional entrepreneurs,2
Collegial oligarchy,2
Normative alignments,2
European Unified Patent Court,4
SOCIETY,1
PATENTS,1
LAW,1
new energy vehicle,3
higherorder interaction network,3
generalized degree,2
simplicial complex,2
TECHNOLOGY,1
PATENTS,1
INFORMATION,1
MANAGEMENT,1
intellectual property,2
constitutions,1
constitutional protection,2
human rights,2
patents,1
access to medicines,3
Islamic law,2
Egypt,1
Tunisia,1
Arab Spring,2
globalization,1
postcolonialism,1
PATENTS,1
ACCESS,1
EGYPT,1
LAW,1
corporate governance,2
law and economics,3
innovation,1
patents,1
shareholder litigation,2
SHAREHOLDER LITIGATION,2
MERITS MATTER,2
FRAUD,1
FIRMS,1
patent protection,2
rewardpenalty policy,2
remanufacturing,1
closedloop supply chain CLSC,4
waste collection,2
LOOP SUPPLY CHAIN,3
STRATEGY,1
,1
SUBSTITUTION LAWS,2
FIN 48,2
incremental innovation,2
IRS scrutiny,2
patents,1
radical innovation,2
unrecognized tax benefits,3
RESEARCHANDDEVELOPMENT,1
EARNINGS MANAGEMENT,2
FIN 48,2
TAX,1
DISCLOSURE,1
FIRMS,1
INCOME,1
CONSEQUENCES,1
OWNERSHIP,1
ECONOMICS,1
anxiety,1
addiction,1
Orexin1selective antagonists 1SORAs,3
Gprotein coupled receptors GPCR,4
Takeda Pharmaceutical Co,3
schizophrenia,1
OREXIN RECEPTOR ANTAGONISTS,3
CLINICAL CANDIDATE,2
SLEEP,1
DISCOVERY,1
RAT,1
ACT335827,1
PROMOTION,1
INSOMNIA,1
BEHAVIOR,1
POTENT,1
Acinar cystic transformation,3
pancreas,1
jejunal atresia,2
subglottic stenosis,2
hemochromatosis,1
liver,1
,1
Pharmacy administration,2
intellectual property protection,3
drug industry,2
SQUAMOUSCELL CARCINOMA,2
,1
COMPETITION,1
LITIGATION,1
GERMANY,1
HCV,1
longacting,1
glecaprevir,1
pibrentasvir,1
sofosbuvir,1
VIRUSINFECTION,1
GENOTYPE 1,2
SINGLE,1
PHARMACOKINETICS,1
PIBRENTASVIR,1
TOLERABILITY,1
ABT493,1
SAFETY,1
academic stars,2
administrative data,2
licensing experience,2
patents,1
university technology commercialization,3
BAYHDOLE ACT,2
SCIENCE,1
INVENTION,1
PATENT,1
DETERMINANTS,1
INCENTIVES,1
SCIENTISTS,1
INNOVATION,1
,1
CONFLICTSOFINTEREST,1
PAYMENTS,1
PATTERNS,1
GIFTS,1
US,1
Standard Essential Patent,3
royalty rate,2
Fair Reasonable and NonDiscriminatory terms,5
unfair pricing,2
Article 102a TFEU,3
EU Court of Justice,4
United Brands test,3
benchmarking methods,2
efficiency defence,2
competition law remedies,3
COMPETITION,1
JUSTIFICATIONS,1
citizenship,1
clothing,1
gender,1
invention,1
patents,1
participation,1
,1
Technology transfer,2
Policy evaluation,2
Spinoff,1
Academic entrepreneurship,2
Propensity score matching,3
BAYHDOLE ACT,2
KNOWLEDGE TRANSFER,2
SPINOFFS,1
UNIVERSITY ENTREPRENEURSHIP,2
DEVELOPMENT COLLABORATION,2
START,1
PERFORMANCE,1
INNOVATION,1
PROPENSITY,1
VENTURES,1
,1
EMERGING RESEARCH FRONTS,3
,1
NATIONALHEALTHSERVICE,1
PROTON PUMP INHIBITORS,3
GLARGINE 100 UML,3
PRESCRIBING EFFICIENCY,2
UTILIZATION PATTERNS,2
COSTEFFECTIVENESS,1
GLYCEMIC CONTROL,2
CROHNSDISEASE,1
NPH INSULIN,2
LOW PRICES,2
expressions of Folklore,3
Intellectual Property,2
Naga,1
sui generis,2
GEOGRAPHICAL INDICATIONS,2
,1
BRUSTLEVGREENPEACE,1
STEMCELL RESEARCH,2
HUMANRIGHTS,1
LAW,1
PATENTABILITY,1
Hoodia,1
Patenting,1
San,1
Indigenous peoples,2
ASB,1
PIC,1
GIs,1
,1
Law,1
credibility thesis,2
endogenous economic growth,3
China,1
institutions,1
FINANCIAL DEVELOPMENT,2
PROPERTYRIGHTS,1
INSTITUTIONS,1
CREDIBILITY,1
OWNERSHIP,1
DETERMINANTS,1
GOVERNANCE,1
REFORM,1
,1
COMMONLAW,1
PROPERTY,1
ENFORCEMENT,1
POSSESSION,1
RULES,1
Artificial intelligence,2
law,1
ownership,1
patentability,1
liability,1
copyright,1
creativity,1
,1
BayhDole,1
Express License,2
running royalties,2
sublicense rights,2
,1
,1
,1
German Empire,2
monarchy,1
consumerism,1
royal brand names,3
legal history,2
trademark law,2
cobranding,1
Manoli,1
Wilhelm II,2
,1
,1
,1
complex systems,2
energy infrastructures,2
scaling laws,2
obsolescence,1
forecasting,1
INNOVATION,1
GROWTH,1
ORIGIN,1
market device,2
market failure,2
market innovation,2
patent pool,2
patents,1
pharmaceutical industry,2
PUBLICHEALTH,1
DEVICES,1
PATENTS,1
PHARMACEUTICALS,1
INNOVATION,1
POLITICS,1
PERFORMATIVITY,1
CONSTRUCTION,1
DERIVATIVES,1
TECHNOLOGY,1
Intellectual property IP,3
Intellectual property right IPR,4
Traditional knowledgeTK,2
,1
Patents,1
inventor,1
inventorship,1
artificial intelligence,2
software,1
Patents Act 1977,3
,1
Cereblon,1
immunomodulatory drugs,2
glutarimide,1
protacs,1
nonthalidomidelike compounds,2
IDENTIFICATION,1
,1
LIABILITY RULES,2
PROPERTY RULES,2
RIGHTS,1
VIEW,1
LAW,1
climate change,2
technology,1
environmental agreements,2
gravity model,2
Poisson pseudomaximum likelihood,3
CURRENCY UNIONS,2
KYOTO,1
REGULATIONS,1
GRAVITY,1
Property rights protection,3
Intellectual property tribunal,3
Firm innovation,2
Institutional change,2
China economy,2
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
INNOVATION EVIDENCE,2
PROTECTION,1
LAWS,1
INVESTMENT,1
OWNERSHIP,1
,1
,1
legal profession,2
lawrelated practitioners,2
symbiotic relation,2
competition,1
corporate consulting,2
dispute resolution,2
,1
,1
,1
Pharmaceutical industry,2
Revealed comparative advantage,3
MNCs,1
Trade,1
Merger and acquisition,3
RD,1
Patent,1
PERFORMANCE,1
,1
,1
Argentina,1
Biotechnology,1
Brazil,1
Chile,1
Commercialization,1
Cuba,1
Development,1
Latin America,2
Mexico,1
Patent cooperation treaty,3
Patents,1
PCT,1
Technology,1
INNOVATION,1
RIGHTS,1
Country image,2
Trust,1
Consumer protection,2
Product quality,2
Financial brand equity,3
International marketing,2
Country of origin effect,4
CORPORATE SOCIALRESPONSIBILITY,2
BRAND TRUST,2
PURCHASE INTENTION,2
MODERATING ROLE,2
CONSUMERS,1
PERCEPTIONS,1
PERSONALITY,1
PERFORMANCE,1
IMPACT,1
CONSEQUENCES,1
RD,1
RD strategies,2
Technological structure,2
Technical field,2
Patent applications,2
Technological development capabilities,3
Technological proximity,2
Technological fusion,2
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT SPILLOVERS,2
DEVELOPMENT INVESTMENT,2
VERTICAL KEIRETSU,2
KNOWLEDGE,1
RETURN,1
corporate social responsibility CSR,4
employee treatment,2
human capital,2
patents and citations,3
technological innovation,2
G3,1
J24,1
M14,1
O31,1
CORPORATE SOCIALRESPONSIBILITY,2
PERFORMANCE,1
INVESTMENT,1
BANKRUPTCY,1
WORKPLACE,1
COSTS,1
LABOR,1
FOCUS,1
LAWS,1
PAY,1
proprietary knowledge,2
common knowledge,2
patenting,1
knowledge monopolies,2
social inequality,2
,1
,1
SOUND,1
,1
EMERGING SCIENCE,2
PROPERTYRIGHTS,1
PARTS,1
STANDARDIZATION,1
PRINCIPLE,1
CRISPR,1
LAW,1
,1
HEALTH,1
THICKETS,1
Catholic social teaching,3
Common good,2
COVID19 pandemic,2
COVID19 vaccines,2
Intellectual Property Rights,3
Patent waiver,2
Universal destination of earths goods,5
Preferential option for the poor,5
World Trade Organization,3
INTELLECTUAL PROPERTY,2
innovative development,2
technological cluster,2
national project,2
digitalization,1
vector of technological development,4
patent activity,2
neoindustrialization,1
,1
,1
REALITIES,1
SELECTION,1
India,1
Pharmaceutical industry,2
Efficiency,1
Productivity,1
Data envelopment analysis,3
RD,1
Size,1
Ownership,1
TRIPS,1
Product patent,2
RESEARCHANDDEVELOPMENT,1
PRODUCTIVITY GROWTH,2
TECHNICAL PROGRESS,2
EFFICIENCY CHANGE,2
FIRMS,1
DECOMPOSITION,1
BENCHMARKING,1
PERFORMANCE,1
SPILLOVERS,1
INVESTMENT,1
Data quality improvement,3
record completion,2
gender name mapping,3
patenting,1
,1
intellectual property,2
multinational corporations,2
nationalism,1
nonmarket strategy,2
patent disputes,2
INGROUP BIAS,2
INTELLECTUAL PROPERTY,2
FOREIGNNESS,1
LIABILITY,1
AMERICAN,1
MANAGEMENT,1
ALLOCATION,1
IDEOLOGY,1
DYNAMICS,1
IDENTITY,1
,1
,1
nuclear war,2
nuclear weapons,2
nuclear winter,2
nuclear proliferation,2
national survival,2
nuclear safety,2
global catastrophic risk,3
existential risk,2
intellectual property,2
patents,1
OPEN SOURCE SOFTWARE,3
OPEN SOURCE HARDWARE,3
ENVIRONMENTAL CONSEQUENCES,2
PATENTS,1
INNOVATION,1
WEAPONS,1
WINTER,1
KNOWLEDGE,1
ECONOMICS,1
STATES,1
,1
,1
directacting antiviral,2
generic,1
hepatitis C,2
REDEMPTION1,1
,1
P2 adoption,2
Corporate environmentalism,2
Environmental innovation,2
Instrumental variable Poisson,3
VOLUNTARY 3350 PROGRAM,3
TOXIC RELEASES,2
POLLUTION,1
ENFORCEMENT,1
PERFORMANCE,1
TECHNOLOGY,1
ADOPTION,1
INDUSTRY,1
IMPACT,1
POLICY,1
machine learning,2
clinical decision software,3
accountability,1
secrecy,1
innovation,1
intellectual property,2
PATENT,1
ECONOMICS,1
Artificial intelligence,2
Technological forecasting,2
Moores law,2
Technology improvement rate,3
Complex networks,2
Centrality,1
Deep learning,2
E27 D85,2
,1
evolutionary game theory,3
genetically modified organisms,3
intellectual property rights,3
INTELLECTUAL PROPERTYRIGHTS,2
BT COTTON,2
MODIFIED CROPS,2
MODIFIED FOOD,2
COMPARATIVE ADVANTAGE,2
DEVELOPINGCOUNTRIES,1
FARMLEVEL,1
ADOPTION,1
GM,1
BIOTECHNOLOGY,1
University patents,2
collaboration,1
knowledge generation,2
technology transfer,2
BAYHDOLE ACT,2
TRIPLEHELIX,1
INNOVATION SYSTEMS,2
KNOWLEDGE,1
NETWORKS,1
INTERNATIONALIZATION,1
ORGANIZATIONS,1
DETERMINANTS,1
INDICATORS,1
FIRMS,1
compulsory license,2
pharmaceutical patents,2
TRIPS flexibility,2
the balance of interests,4
China,1
INTELLECTUAL PROPERTY,2
PUBLICHEALTH,1
SYSTEM,1
Economics of outer space,4
Orbital debris,2
Outer space pollution,3
Space law,2
WASTE,1
SPACE,1
DESIGN,1
,1
ETHICS,1
EXTINCTION,1
,1
COMPETITIVE ADVANTAGE,2
LAW,1
STRATEGY,1
Research collaboration,2
Technology transfer,2
Outcome quality,2
Patent reassignment,2
University patents,2
RESEARCHANDDEVELOPMENT,1
BAYHDOLE ACT,2
NATIONAL INNOVATION,2
KNOWLEDGE TRANSFER,2
PATENT QUALITY,2
UNITEDSTATES,1
INDUSTRY,1
US,1
COMMERCIALIZATION,1
ENTERPRISES,1
,1
ACTIVATED CARBON,2
ELECTROCATALYTIC PROPERTIES,2
CATALYTICOXIDATION,1
NANOTUBES,1
NANOPARTICLES,1
NANOFIBERS,1
H2S,1
DESULFURIZATION,1
BIOGAS,1
Anticoagulant,1
antiplatelet,1
cardioaortic embolism,2
cardioembolic,1
embolic stroke of unknown source,5
patent foramen ovale,3
percutaneous closure,2
stroke subtypes,2
APIXABAN,1
ASPIRIN,1
,1
BRAND,1
GOODS,1
CONSUMERS,1
MEDICATION,1
PREFERENCE,1
ANTITRUST,1
TASTE,1
Research funding,2
Academic patents,2
Collaboration,1
Nanotechnology,1
BAYHDOLE ACT,2
RESEARCHANDDEVELOPMENT,1
NETWORK STRUCTURE,2
IMPACT,1
TECHNOLOGY,1
INNOVATION,1
UNIVERSITY,1
ENTREPRENEURIAL,1
PERFORMANCE,1
QUALITY,1
Eurasian otter,2
Lutra lutra,2
Parasite,1
Dirofilaria immitis,2
Heartworm,1
Natural infection,2
SERBIA,1
Cloud computing,2
Property,1
Intellectual property,2
Copyright,1
Trade secret,2
Patents,1
Contractual terms,2
Dispute resolution,2
Data protection,2
COPYRIGHT PROTECTION,2
SOFTWARE PATENTS,2
BIG DATA,2
LEGAL,1
FUTURE,1
ISSUES,1
FIRM,1
WIPO World Intellectual Property Organization,5
Intellectual Property,2
Trademark,1
Design,1
Image Rights,2
,1
Carbon intensity,2
Innovations,1
Renewable energy,2
Urbanization,1
OPEC,1
RENEWABLE ENERGYCONSUMPTION,2
ECONOMICGROWTH,1
CO2 EMISSIONS,2
PANELDATA,1
TECHNOLOGICALINNOVATION,1
ELECTRICITY CONSUMPTION,2
GRANGER CAUSALITY,2
GREEN ECONOMY,2
BLUE ECONOMY,2
URBANIZATION,1
medical countermeasures against COVID19,4
immunization as a global public good,6
community interests under international law,5
international intellectual property rights,4
TRIPS Agreement,2
TRADE,1
Return migration,2
knowledge production,2
multinational enterprise,2
internal labor markets,3
BRAINDRAIN,1
ECONOMICS,1
SPILLOVERS,1
DIFFUSION,1
PROXIMITY,1
MOBILITY,1
FLOWS,1
FIRM,1
patent system,2
patent markets,2
fieldofuse licensing,2
price differentiation,2
SEP,1
FRAND,1
digital economy,2
economic development,2
DISCRIMINATION,1
AUCTION,1
SYSTEMS,1
D23,1
G34,1
G38,1
K22,1
CORPORATE GOVERNANCE,2
INCENTIVE CONTRACTS,2
AGREEMENTS,1
OWNERSHIP,1
MATTER,1
STOCK,1
INVESTMENT,1
INNOVATION,1
SALIENCE,1
MOBILITY,1
Healthcare,1
antitrust,1
patents,1
market power,2
PHYSICIAN PRACTICE COMPETITION,3
MARKET CONCENTRATION,2
HOSPITAL MERGERS,2
UNITEDSTATES,1
PRICES PAID,2
CONSOLIDATION,1
NONPROFIT,1
POLICY,1
indigenous knowledge,2
New Zealand,2
patent law,2
,1
Additive manufacturing,2
Strategic management,2
Service operations,2
Spare parts,2
Patent law,2
Digital businesses,2
INTELLECTUAL PROPERTY,2
OPERATIONS MANAGEMENT,2
CRITICALITY,1
trademark law,2
trademarks,1
social movements,2
hashtags,1
Black Lives Matter,3
,1
Intellectual property,2
compulsory licences,2
health crises,2
health,1
innovation,1
,1
,1
CONFUSION,1
Video games,2
mechanics,1
patents,1
copyright,1
technical problem,2
ideaexpression,1
computerimplemented inventions,2
,1
human immunodeficiency virus,3
hepatitis C virus,3
coinfection,1
access,1
patent,1
low and middleincome countries,4
directacting antivirals,2
people who inject drugs,4
INJECTING DRUGUSERS,2
ANTIRETROVIRAL TREATMENT,2
INFECTED INDIVIDUALS,2
VIRUSINFECTION,1
BARRIERS,1
PEOPLE,1
IMPACT,1
PATENT,1
China,1
intellectual property protection,3
legal enforcement,2
INSTITUTIONBASED VIEW,2
PROTECTION,1
REFORM,1
,1
STATUTORY INTERPRETATION,2
ADMINISTRATIVELAW,1
AGENCY INACTION,2
POLICY,1
RULEMAKING,1
RULES,1
CAPTURE,1
DOCTRINE,1
CHEVRON,1
REALITY,1
Open access repositories,3
Web 20 tools,3
OAIPMH,1
OpenDOAR,1
Open access policies,3
Patents,1
INSTITUTIONAL REPOSITORIES,2
BANGLADESH,1
Digital transformation,2
Copyright,1
Patents,1
Intellectual property rights,3
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PATENTS,1
MARKS,1
LAW,1
,1
,1
China,1
rule of law,3
governance,1
rationalized enforcement,2
accountability,1
intellectual property rights,3
environmental protection,2
DEMOCRACY,1
standard essential patents,3
licensing levels,2
FRAND,1
supply chain,2
automotive industry,2
antitrust,1
FRAND COMMITMENTS,2
PATENTS,1
3D printing,2
Pharmaceuticals,1
Intellectual property,2
Additive manufacturing,2
Patent law,2
Innovation,1
Regulatory development,2
TABLETS,1
PHARMACEUTICALS,1
FORMULATION,1
FABRICATION,1
Genetic information,2
Patent law,2
Property,1
Property rights,2
Donors,1
CONSENT,1
ISSUES,1
Qualitative,1
startup,1
venture capital,2
patents,1
intellectual property,2
technology commercialization,2
INVESTMENT FUNDS,2
PRIOR KNOWLEDGE,2
INNOVATION,1
INVENTION,1
DISCOVERY,1
MARKETS,1
FINANCE,1
MODEL,1
FIRMS,1
,1
ECONOMICS,1
innovation,1
networks,1
peer production,2
free and open source software,5
commons,1
motivational diversity,2
OPENSOURCE SOFTWARE,2
INTELLECTUAL PROPERTYRIGHTS,2
INDUSTRIALREVOLUTION,1
NORMS,1
INFRASTRUCTURE,1
ORGANIZATION,1
SPILLOVERS,1
EMERGENCE,1
INVENTION,1
OPENNESS,1
biotherapeutics,1
biologics,1
biologicals,1
biological products,2
biopharmaceuticals,1
biomolecular drugs,2
protein products,2
nanomedicine,1
nanodrugs,1
nanoparticulate drug formulations,3
nanopharmaceuticals,1
nanotechnology,1
nanomaterial,1
nanoscale,1
patents,1
commercialization,1
research and development RD,4
US Food and Drug Administration FDA,6
European Medicines Agency EMA,4
drug delivery systems DDS,4
sitespecific delivery,2
nanoparticles NPs,2
protein aggregation,2
smallmolecule drug,2
New Chemical Entities NCEs,4
New Biological Entities NBEs,4
New Drug Application NDA,4
Biologic License Application BLA,4
BayhDole Act,2
HatchWaxman Act,2
Biologics Price Competition and Innovation Act BPCI Act,8
immunotoxic effects,2
complement activation,2
immunogenicity,1
antidrug antibodies ADAs,3
antibodydrug conjugates ADCs,3
adverse drug reaction ADR,4
conjugated proteins,2
functionalized antibodies,2
Federal Food,2
Drug,1
and Cosmetic Act FDC Act,5
target mediated drug disposition TMDD,5
pharmacodynamic PD,2
Public Health Service PHS Act,5
pharmacokinetics PK,2
Humira R,2
protein aggregates,2
active pharmaceutical ingredient API,4
hypersensitivity reactions HSR,3
anaphylactoid reactions,2
complement activationrelated pseudoallergy CARPA,4
Doxil R,2
Ambisome R,2
DaunoXome R,2
Abelcet R,2
Visudyne R,2
Cremophor EL,2
PEGylated proteins,2
monoclonal antibodies mABs,3
Humulin R,2
PEGylated liposomes,2
accelerated blood clearance ABC,4
reticuloendothelial system RES,3
immune complexes ICs,3
biosimilar,1
generic drugs,2
bioequivalent,1
interchangeable product,2
nanosimilars,1
nonbiologic complex drug NBCD,4
NBCD similar,2
glatiramer acetate,2
Copaxone R,2
immunomodulator,1
clinical trials,2
immunopharmacology,1
immunomodulatory effects,2
iTope TM,2
TCED TM,2
Epibase R,2
EpiMatrix TM,2
EpiScreen TM,2
immunogenic epitopes,2
artificial intelligence AI,3
singlecell genomics,2
user fees,2
druggable genome,2
cryoelectron microscopy cryoEM,3
epitope mapping analysis,3
benchtobedside,1
translation,1
druglike molecule,2
CRISPRCas9,1
IMMUNOGENICITY,1
COMPLEMENT,1
MEDICINES,1
MODEL,1
PIGS,1
,1
RESEARCHANDDEVELOPMENT,1
MEDICAL MALPRACTICE INSURANCE,3
DIRECTED TECHNICAL CHANGE,3
MARKETSIZE,1
INDUSTRY,1
HEALTH,1
LIABILITY,1
IMPACT,1
LAW,1
SYSTEM,1
business enterprise,2
intangible assets,2
financialization,1
Thorstein Veblen,2
John Commons,2
DIFFERENTIAL ACCUMULATION,2
PATENTS,1
INNOVATION,1
DICHOTOMY,1
ECONOMY,1
COSTS,1
AYRES,1
data exclusivities,2
drug pricing,2
healthcare reform,2
health law,2
health spending,2
health technology assessment,3
patents,1
pharmaceutical policy,2
PATENTS,1
DRUGS,1
Law and technology,3
cultural study of pharmaceuticals,4
patents,1
legal things,2
DRUGS,1
Africa,1
biosimilars,1
crossnational study,2
drug utilisation,2
Europe,1
health policy,2
insulin glargine,2
prices,1
NATIONALHEALTHSERVICE,1
PROTON PUMP INHIBITORS,3
OFPOCKET PAYMENTS,2
PRESCRIBING EFFICIENCY,2
GLYCEMIC CONTROL,2
NPH INSULIN,2
MEDICINES,1
GLARGINE,1
HYPOGLYCEMIA,1
METAANALYSIS,1
Foreign Patenting,2
Innovation Enterprises,2
Economy,1
Economic System,2
Cluster,1
ACADEMIC ENTREPRENEURSHIP,2
COMMERCIALIZATION,1
UNIVERSITIES,1
PERFORMANCE,1
OPENNESS,1
Complementarities,1
matching with contracts,3
stability,1
contract design,2
COMPETITIVEEQUILIBRIUM,1
STABILITY,1
NETWORKS,1
DESIGN,1
Engine,1
Variable compression ratio,3
Mechanism,1
Kinematic chain,2
Reconfigurability,1
,1
biotechnology,1
intellectual property rights,3
EU acquis,2
Albanian legislation,2
legal approximation,2
,1
,1
MONOCLONALANTIBODIES,1
DOCTRINE,1
TOLERANCE,1
THERAPIES,1
HISTORY,1
POLICY,1
VIRUS,1
Innovation and Invention Processes and Incentives,6
Intellectual Property and Intellectual Capital,5
Resource Booms,2
Comparative Studies of Countries,4
Exhaustible Resources and Economic Development,5
Institutions and Growth,3
NATURALRESOURCE BOOMS,2
CURSE,1
INVESTMENT,1
,1
,1
Yoga,1
rhetoric,1
intellectual property,2
vernacular,1
decoloniality,1
dewesternization,1
LAW,1
Requirements,1
market potential,2
natural language process,3
decision making,2
patents,1
,1
hemodialysis,1
cvc,1
central venous catheter,3
ijv catheter,2
internal jugular vein catheter,4
pfo,1
patent foramen ovale,3
brain,1
septic emboli,2
ABSCESS,1
efuel,1
synthetic fuel,2
patent analysis,2
technology management,2
clean energy,2
network analysis,2
ELECTRIC VEHICLES,2
NETWORK ANALYSIS,2
SOCIAL NETWORKS,2
KNOWLEDGE,1
CENTRALITY,1
COLLABORATION,1
INNOVATION,1
ECOSYSTEM,1
SYSTEMS,1
FLOW,1
citizen science,2
participatory research,2
intellectual property,2
patent,1
commons,1
ETHICALISSUES,1
LAW,1
employee mobility,2
innovation,1
IPR protection,2
multinational,1
R D,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
RENTSEEKING,1
HOME BIAS,2
INTEGRATION,1
COUNTRIES,1
POLICY,1
RACE,1
LAWS,1
Trademarks,1
Innovation,1
Patents,1
Brand creation,2
Brand scope,2
RESEARCHANDDEVELOPMENT,1
PATENTS,1
MARKS,1
MANAGEMENT,1
INDICATOR,1
FIRMS,1
LAW,1
Development stages of nations,4
Innovation and stages of development,5
Development of nations,3
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
EDUCATION,1
COMPETITIVENESS,1
PRODUCTIVITY,1
TECHNOLOGY,1
INVESTMENT,1
SPILLOVERS,1
SYSTEMS,1
DEMAND,1
Incentives,1
pharmaceutical innovation,2
Epogen,1
empirical research,2
pharmaceutical industry,2
POLICY,1
insolvency,1
key topics,2
patent,1
security,1
,1
Bitopic ligands,2
muscarinic receptor subtypes,3
orthosteric,1
allosteric,1
PROTEINCOUPLED RECEPTORS,2
ACETYLCHOLINERECEPTOR,1
ALLOSTERIC MODULATORS,2
LIGANDS,1
SELECTIVITY,1
DESIGN,1
,1
LEGAL DOCTRINE,2
reasonable capitalism,2
rationing transaction,2
managerial school,2
bargaining school,2
B25,1
E32,1
P16,1
,1
,1
CANNABIMIMETIC INDOLES,2
HUMAN HEPATOCYTES,2
RECEPTOR,1
CB1,1
DERIVATIVES,1
PHARMACOLOGY,1
METABOLITES,1
AGONISTS,1
TOXICITY,1
AFFINITY,1
,1
INTELLECTUAL PROPERTY,2
COMMONLAW,1
COVENANTS,1
FOUNDATIONS,1
RULES,1
Licences,1
Injunctions,1
FRAND,1
Jurisdiction,1
SEPs,1
Competition law,2
PATENT HOLDUP,2
Breast genetic testing,3
BRCA,1
genetic risk,2
hereditary risk,2
multigene panels,2
,1
,1
,1
,1
EMPLOYMENT PROTECTION,2
PRODUCTIVITY,1
LAWS,1
,1
DATA PROTECTION,2
,1
GENETICRESOURCES,1
PROPERTY,1
AUSTRALIA,1
BIOPIRACY,1
HERITAGE,1
CULTURE,1
PLANTS,1
Invalidity,1
Lack of inventive step,4
Pharmaceuticals,1
Generics,1
Unjust enrichment,2
Culpability of conduct,3
Strict liability,2
Cancelled patent,2
Judgment on validity,3
,1
postmarketing evaluation,2
Chinese medicine,2
pharmacoeconomics,1
guideline,1
,1
Intellectual property rights,3
Agamben,1
Biopolitics,1
First nations peoples,3
Wadawurrung,1
Australia,1
,1
,1
,1
AIPA,1
coordination,1
patent prosecution,2
plural sourcing,2
vertical integration,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGEBASED THEORY,2
VERTICAL INTEGRATION,2
ASSET OWNERSHIP,2
FIRM,1
BOUNDARIES,1
BUY,1
CAPABILITIES,1
ADAPTATION,1
GOVERNANCE,1
Nonsmoking laws,2
Employee health,2
Innovation,1
Patents,1
Research and development,3
RESEARCHANDDEVELOPMENT,1
DIFFERENCEINDIFFERENCES,1
DEVELOPMENT TAX CREDITS,3
SMOKING STATUS,2
CASH HOLDINGS,2
TOBACCOSMOKE,1
IMPACT,1
WORKPLACE,1
CANCER,1
MARKET,1
crystal engineering,2
crystal growth,2
monolayers,1
polymorphism,1
selfassembly,1
SELFASSEMBLED MONOLAYERS,2
CRYSTALSTRUCTURES,1
NUCLEATION,1
SULFATHIAZOLE,1
SPECTROSCOPY,1
GROWTH,1
ACID,1
Watersaving innovation performance,3
Groundwater overexploitation,2
Green authorized patent,3
Annual reports,2
Patent data,2
High water consumption companies,4
Water resources tax,3
GREEN INNOVATION,2
MODEL,1
GOVERNMENTS,1
POLICIES,1
GROWTH,1
LAW,1
Sectoral green growth,3
Energy transition progress,3
Nonrenewables consumption,2
Green technological accessibility,3
ASEAN,1
Q56,1
O10,1
Q41,1
F55,1
,1
venture capital,2
entrepreneurship,1
RD tax credits,3
payroll tax credits,3
skilled labor,2
startup scaling,2
INNOVATION EVIDENCE,2
INVESTMENT,1
SCIENTISTS,1
RIGHTS,1
POLICY,1
STATE,1
Transparency,1
Accountability,1
Research projects,2
Spanish public universities,3
ACCOUNTABILITY,1
Abdominal angiostrongyliasis,2
Angiostrongylidae,1
Pet,1
Zoonotic helminth,2
Reservoir,1
Molecular analyses,2
REDESCRIPTION,1
CESPEDES,1
MORERA,1
LARVAE,1
Academic enterprise,2
Markets for technology,3
Search heuristics,2
Capabilities,1
Knowledge diffusion,2
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER ORGANIZATIONS,2
COGNITIVE DISTANCE,2
UNIVERSITY,1
KNOWLEDGE,1
INDUSTRY,1
INNOVATION,1
SCIENCE,1
FIRMS,1
EXPLORATION,1
clandestine laboratory,2
fentanyl,1
gas chromatography,2
mass spectrometry,2
GC,1
MS,1
illicit drugs,2
impurity profiling,2
synthesis,1
ALKYLATION,1
Biosimilars,1
offpatent biologicals,2
competition,1
sustainability,1
Belgium,1
IBD,1
technology emergence,2
blockchain,1
complexity theory,2
structuring,1
innovation,1
patents,1
LOCAL SEARCH,2
INNOVATION,1
DYNAMICS,1
COLLABORATION,1
SCIENCE,1
DISCONTINUITIES,1
PERFORMANCE,1
HIERARCHIES,1
ADAPTATION,1
SPECIATION,1
The fuzzy domain,3
Science technology interaction,3
Machine learning algorithms,3
Network analysis,2
PATENT CITATIONS,2
BIBLIOMETRICS,1
PUBLICATIONS,1
DECADES,1
LINKAGE,1
Pyrolysis,1
Bibliometric analysis,2
Technological evolution trend,3
TRIZ,1
Laser pyrolysis,2
Patents,1
WASTE TIRES,2
MICROWAVE PYROLYSIS,2
PLASMA PYROLYSIS,2
AUGER REACTORS,2
BIOOIL,1
BIOCHAR,1
BIOMASS,1
ENERGY,1
TEMPERATURE,1
INNOVATION,1
Borneol,1
Internal prescriptions,2
External prescriptions,2
Primary diseases,2
Proprietary Chinese medicines,3
Medication rules,2
,1
tender,1
procurement,1
offpatent,1
biological,1
biosimilar,1
award criteria,2
switching,1
interchangeability,1
sustainability,1
competition,1
,1
,1
INTELLECTUAL PROPERTY,2
COMPUTERPROGRAMS,1
LAW,1
PROTECTION,1
SCOPE,1
FASHION,1
PATENTS,1
,1
PROPERTY RULES,2
LIABILITY RULES,2
LAW,1
COPYRIGHT,1
PSYCHOLOGY,1
INNOVATION,1
,1
MONEY,1
data breach,2
earnings management,2
mandatory disclosure,2
real activities manipulation,3
EARNINGS MANAGEMENT,2
INSTITUTIONAL INVESTORS,2
CORPORATE GOVERNANCE,2
STOCK LIQUIDITY,2
FINANCIAL FRAUD,2
CONSEQUENCES,1
EXPECTATIONS,1
INCENTIVES,1
LITIGATION,1
PRESSURE,1
Human capital theory,3
Attention based view,3
Corporate venture capital,3
CVC unit heads,3
Patenting,1
Breakthrough innovation,2
RESEARCHANDDEVELOPMENT,1
UPPER ECHELONS,2
SELECTIVE PERCEPTION,2
KNOWLEDGE CREATION,2
MEDIA COVERAGE,2
MANAGEMENT,1
INVESTMENT,1
ATTENTION,1
INDUSTRY,1
EXPLOITATION,1
,1
G2M ARREST,2
STEMCELLS,1
APOPTOSIS,1
EXPRESSION,1
INHIBITION,1
MICELLES,1
ANALOG,1
PROLIFERATION,1
COMBINATION,1
MODULATION,1
Innovation,1
New products,2
Commercialization,1
Employment protection laws,3
Institutions,1
Small firms,2
INSTITUTIONBASED VIEW,2
INNOVATION PERFORMANCE,2
CORPORATE GOVERNANCE,2
KNOWLEDGE SOURCES,2
FIRM PERFORMANCE,2
LABORMARKETS,1
IMPACT,1
CAPABILITIES,1
ENGAGEMENT,1
MANAGEMENT,1
Prior art search,3
Patent analysis,2
Deep learning,2
Bertforpatents,1
PQAI,1
,1
European Union,2
internal market,2
European Competition Law,3
antitrust,1
restrictions of competition by object,5
ancillary restraints,2
case law,2
Generics judgment,2
Lundbeck judgment,2
Budapest Bank judgment,3
,1
Polymeric nanoparticles,2
Patent search,2
Targeted medication delivery,3
Generation of nanotechnology,3
Safebydesign,1
DELIVERY,1
CHALLENGES,1
RELEASE,1
DESIGN,1
Technology transfer,2
Technology transfer regulation,3
Regional development,2
Brazil,1
BAYHDOLE ACT,2
INTELLECTUAL PROPERTY,2
TRANSFER OFFICES,2
ACADEMIC ENTREPRENEURSHIP,2
COMMERCIALIZATION,1
PERFORMANCE,1
KNOWLEDGE,1
IMPACT,1
INNOVATION,1
CREATION,1
,1
,1
Copyright,1
Abusive litigation,2
Creative Commons,2
Open licenses,2
US copyright law,3
Statutory damages,2
Troll,1
,1
market integration,2
intellectual property,2
brexit,1
European economic area,3
international trade,2
EUROPEANIZATION,1
Pharmaceutical innovation,2
Entry,1
Regulation,1
Advertising,1
DRUG DEVELOPMENT,2
PRICES,1
Migration,1
Inventors,1
Multinational enterprises,2
Knowledge integration,2
Knowledge exploitation,2
Ethnic ties,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT CITATIONS,2
BRAINDRAIN,1
ABSORPTIVECAPACITY,1
EMPIRICALEVIDENCE,1
INNOVATION,1
FIRM,1
US,1
SPILLOVERS,1
Business,1
Runtime,1
Regulation,1
Monitoring,1
Computational modeling,2
Computational complexity,2
Patents,1
Business process,2
event log,2
compliance,1
regulations,1
crossinstance,1
instancespanning,1
runtime verification,2
EFFICIENT,1
VERIFICATION,1
Validity of a patent,4
Inventive step,2
Obviousness test,2
State of the art,4
Dosage of a patented compound,5
Balance or symmetry in patent law,6
,1
CNSrelated disease,2
epilepsy,1
neuropathic pain,2
selective Ttype calcium channel blocker,5
BIOLOGICAL EVALUATION,2
CA2 CHANNELS,2
DERIVATIVES,1
LOCALIZATION,1
SULFONAMIDES,1
DISCOVERY,1
POTENT,1
Innovation,1
Culture,1
Gravity model,2
Trust,1
Acceptance and tolerance,3
L26,1
O30,1
Z10,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INNOVATION PERFORMANCE,2
GRAVITY MODEL,2
DIVERSITY,1
RELIGION,1
TECHNOLOGY,1
LANGUAGE,1
CULTURE,1
TRUST,1
heart rate variability,3
fractal,1
residual power spectrum,3
powerlaw function,2
acute myocardial infarction,3
POWERLAW BEHAVIOR,2
BEATRATE VARIABILITY,2
MIDDLEAGED PERSONS,2
PROGNOSTIC VALUE,2
ACUTEPHASE,1
MORTALITY,1
PREDICTOR,1
SPECTRUM,1
HEALTHY,1
TERM,1
firm growth,2
RD,1
quantile regression,2
pharmaceutical industry,2
GIBRATSLAW,1
INVERTEDU,1
EMPIRICALANALYSIS,1
INNOVATION,1
SIZE,1
COMPETITION,1
SMES,1
AGE,1
DISTRIBUTIONS,1
SCHUMPETER,1
RD and growth,3
Sequential innovation,2
Public RD,2
Patent laws,2
RESEARCHANDDEVELOPMENT,1
GROWTH,1
ECONOMICS,1
Schumpeterian Growth Theory,3
Inventions,1
Cumulative Innovations,2
Fundamental and Applied RD,4
RD Incentives,2
Intellectual Property Law,3
Public Sponsorship of RD,4
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
MARKETSTRUCTURE,1
ECONOMICS,1
TOO,1
PATENTABILITY,1
UNIVERSITIES,1
EQUILIBRIUM,1
KNOWLEDGE,1
IMPACT,1
,1
ORGANIZATIONAL INNOVATION,2
PRODUCT INNOVATION,2
CHANGING WORLDS,2
VALUE CHAIN,2
MANAGEMENT,1
ADOPTION,1
CONVENTIONS,1
MARKET,1
COMPETITION,1
GOVERNANCE,1
,1
,1
,1
ANTITRUST,1
PROTECTION,1
EFFICIENCY,1
ECONOMICS,1
CONSUMER,1
COSTS,1
Corporate innovation,2
Director liability reduction,3
Korean market,2
INCENTIVES,1
OWNERSHIP,1
,1
,1
,1
INVENTORS,1
GROWTH,1
,1
,1
TRIPS Agreement,2
Access to medicines,3
East African Community,3
EAC and TRIPS flexibilities,4
Patent laws Kenya,3
Uganda,1
Tanzania,1
Rwanda,1
Burundi,1
ESSENTIAL MEDICINES,2
ACCESS,1
PATENTS,1
patent medicines,2
opioids,1
drug regulation,2
colonialism,1
South Africa,2
CAPE COLONY,2
OPIUM,1
RACISM,1
TRADE,1
,1
,1
Ownership,1
Corporate innovation,2
Antitrust law,2
COMPETITION,1
GROWTH,1
MERGER,1
FIRMS,1
Intellectual property rights,3
Bank loans,2
PATENT PROTECTION,2
CREDITOR RIGHTS,2
LAWS,1
INNOVATION,1
DETERMINANTS,1
MARKET,1
LIFE,1
Irish migration in the Middle Ages,6
interaction between the Irish and English,6
Irish colony,2
Anglicization,1
IRELAND,1
IPRs,1
antitrust,1
power of disposal of IPRs,5
essential facilities doctrine,3
IPR entitlement and misuse thereof,5
strategic patenting,2
,1
gene editing,2
CRISPRCas9,1
patents,1
regulation,1
interdisciplinary perspectives,2
ELSI,1
SYNTHETIC BIOLOGY,2
PROPERTYRIGHTS,1
PATENTS,1
SCIENCE,1
ENDONUCLEASE,1
CRISPRCAS9,1
CRISPRCAS9,1
Composite manufacturing technologies,3
Technological change,2
Technology trajectories,2
Performance improvement rates,3
FUNCTIONALAPPROACH,1
MOORES LAW,2
SCIENCE,1
EXTENSION,1
PROGRESS,1
TRENDS,1
Immunity,1
International organizations,2
The Netherlands,2
Right to a remedy,4
Collective labour law,3
,1
,1
ONACHIP,1
RECENT PROGRESS,2
,1
DUAL SGLT1SGLT2 INHIBITOR,3
IMPROVED GLYCEMIC CONTROL,3
GLUCAGONLIKE PEPTIDE1,2
GALACTOSE MALABSORPTION,2
POSTPRANDIAL GLUCOSE,2
RENAL IMPAIRMENT,2
CGLUCOSIDE,1
LX4211,1
POTENT,1
KIDNEY,1
Environmental protection regulation,3
Green innovation,2
Information disclosure,2
EMPIRICALEVIDENCE,1
PORTER HYPOTHESIS,2
INVESTMENT EVIDENCE,2
RISK EVIDENCE,2
FIRM,1
PERFORMANCE,1
COMPETITIVENESS,1
DISCLOSURE,1
INCENTIVES,1
EMISSIONS,1
Arbitral tribunal,2
Constitutionality,1
Generic drugs,2
Marketing authorisation,2
Patent nullity exception,3
Incidental competence,2
,1
,1
INTELLECTUAL PROPERTY,2
GENETICRESOURCES,1
NAGOYA PROTOCOL,2
OPPORTUNITIES,1
DISCOVERY,1
PATHWAY,1
ACID,1
LAW,1
Intraosseous myoepithelial carcinoma,3
MRI,1
Diffusionweighted imaging,2
PRIMARY INTRAOSSEOUS MYOEPITHELIOMA,3
DIFFUSIONWEIGHTED MRI,2
BONE,1
Metaverse,1
Intellectual property,2
Copyrights,1
Patents,1
Trademarks,1
Business,1
EXPERIENCE,1
,1
FORCED TECHNOLOGYTRANSFER,2
WTO LAW,2
US,1
CHINA,1
ECONOMICS,1
AUTONOMY,1
POLICY,1
,1
RIGHTS,1
Discrimination,1
Fake news,2
Religion,1
Covid,1
India,1
KNOWLEDGE SPILLOVERS,2
PATENT CITATIONS,2
GEOGRAPHY,1
LOCALIZATION,1
INSTITUTIONS,1
INFORMATION,1
VIOLENCE,1
TWITTER,1
LEGACY,1
RADIO,1
3D printing,2
Art 30 exceptions,3
COVID19,1
medical equipment,2
patent rights,2
right to repair,3
,1
Big data analytics,3
Hadoop MapReduce,2
legal decision making,3
machine learning,2
pharma patent validity,3
LAW,1
AI,1
Infringement of intellectual property right,5
Joint and several liability,4
Liability rule,2
Property rule,2
Platform liability,2
Seller liability,2
Trademark,1
K13,1
PRIVATE,1
DAMAGES,1
bioprospecting,1
Convention on Biological Diversity,4
Indigenous,1
intellectual property,2
Maori,1
Nagoya Protocol,2
PROPERTY,1
CULTURE,1
,1
,1
C14101BHGD01,1
chronic obstructive pulmonary disease,4
longacting muscarinic antagonist,3
pharmacokinetics,1
mass balance,2
tissue distribution,2
metabolism,1
LONGACTING BRONCHODILATORS,2
TIOTROPIUM,1
RISK,1
affordability,1
generic competition,2
global health,2
longacting medicines,2
low and middleincome countries,4
voluntary licensing,2
OPPORTUNITIES,1
FORMULATIONS,1
CHALLENGES,1
THERAPIES,1
PRODUCTS,1
Nuclear Receptors,2
ROR gamma t,3
Allosteric Modulators,2
Structure Elucidation,2
Drug Discovery,2
MODULATORS,1
REFINEMENT,1
TARGETS,1
networks,1
graphs,1
research and development,3
innovation,1
technological change,2
organizational studies,2
strategy,1
universities,1
BAYHDOLE ACT,2
AMERICAN UNIVERSITIES,2
RESEARCH PRODUCTIVITY,2
PATENT QUALITY,2
INNOVATION,1
DETERMINANTS,1
DISCONTINUITIES,1
BIOTECHNOLOGY,1
EXPERIENCE,1
SCIENCE,1
Data envelopment analysis,3
Indian pharmaceutical industry,3
Malmquist index,2
Productivity,1
Efficiency,1
Indian patent act,3
RD,1
C02,1
C61,1
D24,1
L65,1
RESEARCHANDDEVELOPMENT,1
DATA ENVELOPMENT ANALYSIS,3
TECHNICAL PROGRESS,2
EFFICIENCY CHANGE,2
GROWTH,1
TRADE,1
DECOMPOSITION,1
SPILLOVERS,1
INVESTMENT,1
RESOURCE,1
Regional technology innovation,3
intercity technology innovation network,4
Yangtze River Delta,3
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE SPILLOVERS,2
EXTERNALITIES,1
CONVERGENCE,1
PATENTS,1
GROWTH,1
CITY,1
BUZZ,1
carcinoid heart disease,3
contrast echocardiography,2
neuroendocrine tumour,2
patent foramen ovale,3
percutaneous closure,2
DEVICE,1
Antimicrobial peptide AMP,3
Antiviral peptide AVP,3
Peptidomimetics,1
Patents,1
ANTIMICROBIAL PEPTIDES,2
ENVELOPED VIRUSES,2
ENTRY INHIBITORS,2
GROWTHHORMONE,1
HIV1,1
PHARMACOKINETICS,1
ENFUVIRTIDE,1
TELAPREVIR,1
LOPINAVIRRITONAVIR,1
PEPTIDOMIMETICS,1
Asthma,1
COPD,1
inhalers,1
Scottish NHS,2
expenditure,1
reforms,1
drug utilisation,2
PROTON PUMP INHIBITORS,3
FLUTICASONE PROPIONATE,2
COPD,1
INITIATIVES,1
SALMETEROL,1
MANAGEMENT,1
DEVICES,1
IMPACT,1
MEDICATIONS,1
EFFICIENCY,1
Malaria treatment,2
Patent and proprietary medicine vendors,5
Diagnosis,1
Rapid diagnostic tests,3
,1
,1
,1
Knowledgebased entrepreneurship,2
Patents,1
Spinoffs,1
University,1
TECHNOLOGYTRANSFER OFFICES,2
UNIVERSITY TECHNOLOGY,2
PUBLIC RESEARCH,2
ACADEMIC ENTREPRENEURSHIP,2
PERFORMANCE,1
POLICY,1
SCIENTISTS,1
SPILLOVERS,1
COMPANIES,1
IMPACT,1
counterfeiting,1
criminal liability,2
drugs,1
superpotent,1
toxic,1
,1
3D printing,2
Additive manufacturing AM,3
Ethics of technology,3
Intellectual property,2
Safety,1
,1
,1
CORPORATE GOVERNANCE,2
KNOWLEDGE SPILLOVERS,2
LARGE SHAREHOLDERS,2
STOCK LIQUIDITY,2
PATENT RIGHTS,2
MARKET,1
INVESTMENT,1
PERFORMANCE,1
COMPETITION,1
OWNERSHIP,1
,1
AMERICAN ENGLISH,2
BRAND NAMES,2
WORDLENGTH,1
LAW,1
LANGUAGE,1
PATENTS,1
private property protection,3
quantile regression,2
economic growth,2
Intellectual property rights,3
QUANTILE REGRESSION,2
PATENT PROTECTION,2
INTERNATIONALTRADE,1
INNOVATION,1
COUNTRIES,1
FLOWS,1
LAWS,1
FDI,1
,1
,1
Intellectual property,2
Pandemic,1
Patents,1
Regulatory Framework,2
,1
,1
ERADICATION,1
,1
DETERMINANTS,1
LANDSCAPE,1
ORIGINS,1
IMPACT,1
GROWTH,1
SHOCKS,1
WEST,1
,1
STATUTORY INTERPRETATION,2
INTELLECTUAL PROPERTY,2
LEGAL DOCTRINE,2
DECISIONS,1
HISTORY,1
trade policy,2
health policy,2
progressive neoliberalism,2
investment law,2
drug policy,2
,1
,1
INFORMATION,1
COMPETITION,1
BIAS,1
International law,2
political economy,2
international transitional administration ITA,4
agriculture,1
Kosovo,1
Iraq,1
LAW,1
,1
,1
AI personhood,2
artificial intelligence,2
DABUS,1
inventorship,1
patent,1
,1
,1
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT INVESTMENT,2
FINANCIAL CONSTRAINTS,2
ECONOMIC CONSEQUENCES,2
ENTREPRENEURIAL STATE,2
MARKET VALUATION,2
AGENCY COSTS,2
OWNERSHIP,1
LAW,1
COMPETITION,1
Appropriation strategy,2
counterfeit,1
intellectual property rights,3
litigation,1
value capturing,2
RESEARCHANDDEVELOPMENT,1
STRATEGIES,1
PATENTS,1
compulsory licensing,2
competition in pharmaceutical industry,4
drugs,1
PESTanalysis,1
COMPETITION,1
Renewable energy promotion,3
Feedin tariffs,2
Innovation,1
ENVIRONMENTALPOLICY INSTRUMENTS,2
TECHNICAL CHANGE,2
COUNT DATA,2
DIFFUSION,1
US,1
SUPPORT,1
MODELS,1
Professors privilege,2
Sweden,1
Science policy history,3
University patents,2
Academic entrepreneurship,2
MORAL ECONOMY,2
BASIC RESEARCH,2
SCIENCE,1
WAR,1
CONSTRUCTION,1
ROAD,1
Remanufacturing,1
Patented product,2
Fixedfee licensing,2
Royalty licensing,2
Game theory,2
RESEARCHANDDEVELOPMENT,1
TAKEBACK,1
COMPETITION,1
STRATEGY,1
CONTRACTS,1
CHANNEL,1
MARKET,1
PRODUCTS,1
,1
,1
innovation,1
patents,1
institutions,1
economic growth,2
Germany,1
BERLIN STOCKEXCHANGE,2
SLAVETRADE,1
GROWTH,1
TECHNOLOGY,1
COUNTRIES,1
GEOGRAPHY,1
ORIGINS,1
CULTURE,1
FINANCE,1
MARKET,1
Urban Cooperative Innovation Network,4
Dynamic Evolution,2
Invention Patents,2
GuangdongHong KongMacao Greater Bay Area,5
IMPACT,1
,1
SUIT INJUNCTIONS,2
alternative dispute resolution,3
cyberspace,1
intellectual property,2
arbitration,1
,1
,1
HEDONIC ADAPTATION,2
ECONOMICANALYSIS,1
LAW,1
WHEELCHAIRS,1
INNOVATION,1
HISTORY,1
POLICY,1
RIGHTS,1
WORLD,1
REHABILITATION,1
Human right,2
Intellectual Property,2
Health Right,2
Right to Life,3
Patents,1
,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT INFRINGEMENT,2
PROTECTION,1
PATENT,1
RULES,1
Copyright,1
Design right,2
EU law,2
Patents,1
Small and mediumsized enterprises,4
Trade marks,2
Unfair competition,2
,1
ayahuasca,1
DMT,1
epistemic injustice,2
indigenous rights,2
psychedelics,1
BETACARBOLINE ALKALOIDS,2
POSTTRAUMATICSTRESSDISORDER,1
INVITRO,1
RECURRENT DEPRESSION,2
PSYCHOTHERAPY,1
PSILOCYBIN,1
RESISTANT,1
EFFICACY,1
PLANTS,1
PHARMACOLOGY,1
,1
BAYHDOLE ACT,2
PHARMACEUTICALINDUSTRY,1
INNOVATION,1
GOVERNMENT,1
PATENTS,1
ORIGINS,1
PRICES,1
ROLES,1
Pharmaceutical market,2
COVID19,1
medications,1
patent protection,2
parallel imports,2
medical law,2
,1
Amarked,1
enamel,1
English porcelain,2
hybrid,1
hard paste,2
ONSITE RAMAN,2
VISCOUS BEHAVIOR,2
CERAMIC PATENT,2
YELLOW PIGMENT,2
LEADTIN,1
IDENTIFICATION,1
SILICATE,1
TEMPERATURE,1
DISORDER,1
GLASS,1
spacecraft,1
vacuum chamber,2
thermal vacuum tests,3
capacitive aspiration system,3
dust control of the spacecraft s own external atmosphere,9
,1
Knee osteoartrhitis,2
Patented crystalline glucosamine sulfate,4
Symptomatic slowacting drugs for osteoarthritis,5
Algorithm,1
NONSTEROIDAL ANTIINFLAMMATORY DRUGS,3
QUALITYOFLIFE,1
CRYSTALLINE GLUCOSAMINE SULFATE,3
CHONDROITIN SULFATE,2
DOUBLEBLIND,1
EUROPEANSOCIETY,1
ECONOMICASPECTS,1
INSULINRESISTANCE,1
ORAL GLUCOSAMINE,2
SETTING TRIALS,2
crime against humanity,3
deportation,1
genocide,1
migration,1
,1
,1
MG SUBCUTANEOUS INJECTIONS,3
GLATIRAMER ACETATE,2
PILOT,1
COMPARE,1
EVERY,1
,1
,1
Q55,1
Q58,1
O34,1
O38,1
Innovation,1
regional analysis,2
renewable energy technologies RET,4
energy security,2
governmental policy,2
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTAL INNOVATION,2
SOCIAL ACCEPTANCE,2
WIND POWER,2
SPILLOVERS,1
PATENTS,1
FIRMS,1
PRODUCTIVITY,1
EXPLORATION,1
PERFORMANCE,1
Innovation,1
Research productivity,2
Open science,2
Intellectual property,2
Patents,1
Research incentives,2
Publicprivate partnerships,2
Networks,1
BAYHDOLE ACT,2
CUMULATIVE INNOVATION,2
ECONOMICGROWTH,1
PATENTS,1
CREATIVITY,1
UNIVERSITIES,1
KNOWLEDGE,1
INDUSTRY,1
IMPACT,1
COLLABORATION,1
Farmers rights,2
Right to traditional agricultural knowledge,5
FAO Treaty 2004,3
Plant variety law,3
Malaysia,1
,1
,1
CONGENITAL HEARTDISEASE,2
SMOOTHMUSCLECELLS,1
GENES,1
EXPRESSION,1
ENDOTHELIN,1
FORM,1
Proprietary Information,2
Bank loan fee structure,4
Competitive bid option CBO,4
G21,1
G28,1
G32,1
INNOVATION,1
CREDIT,1
INVESTMENT,1
INCENTIVES,1
MARKET,1
LINES,1
,1
HEALTHCARE ACCESS,2
CLINICALTRIALS,1
MINORITY PARTICIPATION,2
SERVICES,1
FILIPINO,1
CHINESE,1
BURDEN,1
Compulsory license,2
Copyright,1
Patent,1
Right to health,3
Right to information,3
,1
infringement disputes,2
innovation investment persistence,3
intellectual property protection,3
PATENT PROTECTION,2
RIGHTS,1
J24,1
J63,1
G33,1
O31,1
O32,1
PRODUCTIVITY,1
ALLOCATION,1
AGREEMENTS,1
INNOVATION,1
ECONOMICS,1
MOBILITY,1
LAWS,1
Microneedles,1
Photolithography,1
Polymer,1
Enzymes,1
Electrochemistrya,1
ARRAY FABRICATION,2
DRUGDELIVERY,1
FLUID,1
Material transfer agreement,3
MTA,1
Open science,2
Scientific material sharing,3
Repository,1
Academic competition,2
TECHNOLOGYTRANSFER OFFICES,2
INTELLECTUAL PROPERTYRIGHTS,2
BAYHDOLE ACT,2
SCIENTIFICKNOWLEDGE,1
UNIVERSITY,1
COMMERCIALIZATION,1
INNOVATION,1
PATENTS,1
ECONOMICS,1
POLICY,1
,1
LIFECYCLE,1
MATRIX COMPOSITES,2
PATENT DATA,2
STEREOLITHOGRAPHY,1
FABRICATION,1
PARAMETERS,1
,1
RESEARCHANDDEVELOPMENT,1
TORT REFORM,2
IMPACT,1
STANDARDS,1
Trademarks,1
trademarking motives,2
industrial organisation,2
innovation,1
entrepreneurship,1
MARKS,1
LAW,1
PERFORMANCE,1
INDICATOR,1
NECESSITY,1
INSIGHTS,1
PATENTS,1
PRODUCT,1
Antitrust,1
Competition policy,2
Innovation,1
Mergers,1
Most favoured nation clause,4
State aid,2
PATENT CITATIONS,2
INNOVATION,1
SPILLOVERS,1
SCHUMPETER,1
universality,1
power laws,2
urban indicators,2
scaling laws,2
urban scaling,2
POWER LAWS,2
CITY SIZE,2
CITIES,1
DIVERSITY,1
GROWTH,1
INNOVATION,1
LIFE,1
Pollution emission,2
Cleaner production,2
Sulfur dioxide,2
Firm heterogeneity,2
Porter effect,2
ENVIRONMENTALREGULATION,1
INTERMEDIATE INPUTS,2
KUZNETS CURVE,2
GROWTH,1
CONSEQUENCES,1
ENFORCEMENT,1
ABATEMENT,1
INDUSTRY,1
,1
INNOVATION,1
,1
,1
Arbitration,1
ADR,1
theatre,1
business,1
politics,1
culture,1
Georgian,1
Sheridan,1
THEATER,1
TRIPS Agreement,2
patents,1
regulatory approval,2
innovation incentives,2
COVID19 vaccines,2
compulsory licensing,2
national security,2
LESSONS,1
TRIPS,1
,1
US PATENT,2
TAKEUP,1
COST,1
TOO,1
Patent intelligence,2
Circular economy,2
Green transition,2
,1
Innovation cooperation,2
Copatent applications,2
Structural heterogeneity,2
Ruralurban dichotomy,2
International borders,2
Knowledge networks,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE TRANSFER,2
NETWORKS,1
PROXIMITY,1
GEOGRAPHY,1
PATTERNS,1
GRAVITY,1
COUNTRIES,1
SCIENCE,1
GERMAN,1
vaccine injury,2
vaccine liability,2
vaccine hesitancy,2
autism,1
causation,1
zombie idea,2
public health,2
LAW,1
IMPLEMENTATION,1
HESITANCY,1
ANT,1
,1
INTELLECTUAL PROPERTY,2
HISTORY,1
TECHNOLOGY,1
PATENT,1
BIOTECHNOLOGY,1
INVENTIONS,1
RETHINKING,1
access to medicine,3
ChinaUS trade disputes,3
regulatory exclusivities,2
undisclosed test data,3
TRIPS Agreement,2
,1
,1
BAYHDOLE ACT,2
UNITEDSTATES,1
PATENT POLICY,2
DEVELOPMENT LABORATORIES,2
DEVELOPMENT AGREEMENTS,2
INTELLECTUAL PROPERTY,2
RESEARCH INSTITUTES,2
TRANSFER OFFICES,2
GOVERNANCE MODE,2
UNIVERSITY,1
incubators,1
patents,1
innovation,1
forward citations,2
licensing,1
BAYHDOLE ACT,2
PATENT QUALITY,2
LIFE SCIENCES,2
IVORY TOWER,2
TECHNOLOGY,1
DIVERSIFICATION,1
RESOURCES,1
IMPACT,1
COMMERCIALIZATION,1
CAPABILITIES,1
Judges opinions,2
lawyers opinions,2
genomic era laws,3
genetic data misuse,3
genetic discrimination,2
gene editing,2
genebase crime prevention,3
PUBLIC VIEWS,2
ATTITUDES,1
KNOWLEDGE,1
DISORDERS,1
COURTROOM,1
LITERACY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FREETRADE AGREEMENTS,2
PATENT PROTECTION,2
PLUS AGREEMENTS,2
ACCESS,1
DECLARATION,1
GOVERNANCE,1
POLICY,1
Institutional investors communication,3
green innovation,2
investors green activism,3
green governance,2
JEL,1
C78,1
G23,1
G34,1
O31,1
O33,1
RESEARCHANDDEVELOPMENT,1
GOVERNANCE,1
PERFORMANCE,1
ENVIRONMENT,1
OWNERSHIP,1
Science Parks,2
Innovation,1
Growth,1
RD investments,2
TECHNOLOGYBASED FIRMS,2
INCUBATORS,1
PATENTS,1
PATTERNS,1
PROFITS,1
IMPACT,1
LEVEL,1
MODEL,1
Patent rights,2
Indian pharmaceutical industry,3
RD intensity,2
TRIPS,1
Innovation and invention,3
Processes and incentives,3
Management of technological innovation and RD,6
Chemicals,1
Drugs,1
Biotechnology,1
DEVELOPMENT INVESTMENT,2
CAPITAL STRUCTURE,2
CASH FLOW,2
DEVELOPINGCOUNTRIES,1
PRICE REGULATION,2
MARKETSTRUCTURE,1
DETERMINANTS,1
TECHNOLOGY,1
INNOVATION,1
PERFORMANCE,1
Informal intellectual property,3
Information asymmetries,2
Unpublished technical information,3
Innovation,1
Intellectual property strategy,3
TRADE SECRETS,2
EXECUTIVE MIGRATION,2
INNOVATION EVIDENCE,2
PATENTS,1
LAW,1
KNOWLEDGE,1
RENEGOTIATION,1
PROPERTY,1
MOBILITY,1
LOCALIZATION,1
,1
INTELLECTUAL PROPERTY,2
TRADE SECRETS,2
LAW,1
INFORMATION,1
PROTECTION,1
KNOWLEDGE,1
ECONOMICS,1
COPYRIGHT,1
CONTRACT,1
Intellectual property rights protection,4
Panel data,2
Asian developing countries,3
Patent law,2
F42,1
K42,1
O34,1
O38,1
O57,1
INTERNATIONALTRADE,1
STRATEGIC MANAGEMENT,2
PATENT MANAGEMENT,2
ECONOMICGROWTH,1
IMPACT,1
INNOVATION,1
INVESTMENT,1
ENFORCEMENT,1
TECHNOLOGY,1
STRENGTH,1
Advertising,1
biosimilars,1
competition,1
Italy,1
public tenders,2
scientific information,2
,1
,1
COMPARATIVE EFFICACY,2
UNITEDSTATES,1
VENOUS THROMBOEMBOLISM,2
PRICECOMPETITION,1
BRAND LOYALTY,2
HEALTH,1
INNOVATION,1
INFORMATION,1
COST,1
PROMOTION,1
zeropoint energy,2
quantum vacuum,2
vacuum energy,2
detailed balance,2
casimir cavity,2
stochastic electrodynamics,2
GROUNDSTATE,1
2ND LAW,2
QUANTUM,1
NOISE,1
EMISSION,1
HEAT,1
Coinvention,1
Collaboration,1
Network analysis,2
Preferential attachment,2
Small world,2
Community structure,2
INTERNATIONAL COLLABORATION,2
SPATIAL ASSOCIATION,2
PATTERNS,1
INDICATORS,1
INNOVATORS,1
EVOLUTION,1
DYNAMICS,1
GROWTH,1
JAPAN,1
abnormal returns,2
market value spillovers,3
mergers and acquisitions,3
resourcebased view,2
technological signaling,2
RESEARCHANDDEVELOPMENT,1
RESOURCEBASED VIEW,2
HORIZONTAL MERGERS,2
INDUSTRY SHOCKS,2
ACQUIRING FIRMS,2
IMPACT,1
RIVALS,1
RETURNS,1
STOCK,1
COMPETITION,1
intellectual property,2
copyright,1
patent law,2
invention in medicine,3
largescale invasion,2
,1
technology transfer,2
institutional policies,2
university bylaws,2
TECHNOLOGYTRANSFER OFFICES,2
INDUSTRY,1
IMPACT,1
COMMERCIALIZATION,1
PERFORMANCE,1
INCENTIVES,1
TYPOLOGY,1
Europe,1
ICT firms,2
Mergers and acquisitions,3
Patents,1
Organizational learning,2
ABSORPTIVECAPACITY,1
TECHNOLOGICAL CAPABILITY,2
FIRM PERFORMANCE,2
MODERATING ROLE,2
ACQUISITIONS,1
INNOVATION,1
EXPLORATION,1
ADVANTAGE,1
PORTFOLIO,1
CREATION,1
Environmental regulation,2
Green technological innovation,3
Moderating effect,2
Transformation rate of innovation,4
achievements,1
Heterogeneity,1
RESEARCHANDDEVELOPMENT,1
PORTER HYPOTHESIS,2
NATURAL EXPERIMENT,2
EMPIRICALANALYSIS,1
ECOINNOVATION,1
CHINA,1
PROTECTION,1
VOLUNTARY,1
COMPETITIVENESS,1
PERFORMANCE,1
acquisitions,1
contracts,1
technology ventures,2
innovation disclosure,2
adverse selection,2
RESEARCHANDDEVELOPMENT,1
ADVERSE CHANGE CLAUSES,3
JOINTVENTURES,1
MERGERS,1
MARKET,1
FIRMS,1
PERFORMANCE,1
SELECTION,1
EARNOUTS,1
INFORMATION,1
Path dependence,2
Intellectual property rights,3
Kenya,1
Counterfeit,1
ANTIMALARIALDRUG QUALITY,2
PUBLICHEALTH,1
PATH DEPENDENCE,2
AFRICA,1
MEDICINES,1
POLITICS,1
PATENTS,1
ACCESS,1
Energy use intensity,3
Pollution emission intensity,3
Differenceindifference,1
Vertical monitoring,2
Commandandcontrol environmental regulation,3
AIR ACT AMENDMENTS,3
POLLUTION,1
ENFORCEMENT,1
QUALITY,1
INNOVATION,1
DYNAMICS,1
INDUSTRY,1
POLICIES,1
IMPACTS,1
LAW,1
,1
,1
Artemisininbased combination therapy,3
Preference for ACT,3
Healthcare providers,2
VENDORS,1
MALARIA,1
Foreign suppliers,2
Corporate innovation,2
International knowledge transfer,3
Uncertain risk,2
CORPORATE,1
PERFORMANCE,1
INVESTMENT,1
KNOWLEDGE,1
knowledge production,2
useful knowledge,2
research usefulness,2
research valorization,2
knowledge cognitive proximity,3
PRODUCTIVE INTERACTIONS,2
TRIPLEHELIX,1
SCIENCE,1
IMPACT,1
INNOVATION,1
TECHNOLOGY,1
SCIENTISTS,1
FRAMEWORK,1
PAYBACK,1
REGIONS,1
longacting cabotegravir injection,3
preexposure prophylaxis,2
HIV1,1
Africa,1
CHALLENGES,1
ADOPTION,1
KENYA,1
,1
ADMINISTRATIVELAW,1
FREEDOM,1
SPEECH,1
LABOR,1
,1
COPYRIGHT,1
LAW,1
INNOVATION,1
ECONOMICS,1
PATENT,1
PROTECTION,1
CONTRACT,1
STANDARD,1
HISTORY,1
FUTURE,1
Market manipulation,2
Endofday dislocation,2
Patents,1
Innovation,1
Intellectual property rights,3
Shareholder protection,2
RESEARCHANDDEVELOPMENT,1
STOCKPRICE MANIPULATION,2
INSTITUTIONAL INVESTORS,2
CORPORATE SCANDALS,2
PROPERTYRIGHTS,1
LAW,1
DETERMINANTS,1
INCENTIVES,1
EARNINGS,1
EQUITY,1
,1
CAPITAL STRUCTURE,2
AGENCY COSTS,2
CASH FLOW,2
INNOVATION,1
PATENTS,1
FIRM,1
BEHAVIOR,1
GROWTH,1
MARKET,1
ENTRY,1
international trade,2
intellectual property rights,3
TECHNOLOGYTRANSFER,1
PATENT PROTECTION,2
RIGHTS,1
INNOVATION,1
ENTRY,1
INVESTMENT,1
TRADE,1
LAWS,1
cardiovascular medicine,2
neurology,1
stroke,1
medical management,2
,1
conjoint analysis,2
market research,2
choice models,2
scale,1
MINIMUM DIFFERENTIATION,2
PRICECOMPETITION,1
PRODUCT,1
EXISTENCE,1
PRINCIPLE,1
digital innovation,2
clinical decisionmaking,2
chronic patients,2
,1
,1
INDUCED INNOVATION,2
ECONOMICS,1
GROWTH,1
European Union,2
Integration,1
Intellectual property,2
Parallel trade,2
Pharmaceuticals,1
Regulation,1
PRICE,1
LAW,1
Antioxidant,1
apoptosis,1
cell cycle,2
cytochrome P450,2
glutation,1
hormetic dose response,3
leukemia,1
lipoperoxidation,1
lymphoma,1
minimal residual disease,3
mitochondrial superoxide,2
multidrug resistance,2
multiple myeloma,2
nuclear factor kB,3
proliferation,1
reactive oxygen species,3
resveratrol,1
sirtuin,1
stem cell,2
tyrosine kinase,2
CHRONIC MYELOGENOUS LEUKEMIA,3
CHRONIC LYMPHOCYTICLEUKEMIA,2
MULTIPLE MOLECULAR TARGETS,3
CANCERCELL LINES,2
TRANSRESVERATROL,1
INDUCED APOPTOSIS,2
HEMATOLOGIC MALIGNANCIES,2
DIETARY RESVERATROL,2
HISTONE DEACETYLASE,2
SIGNALING PATHWAYS,2
Digital economy,2
Financing constraints,2
Corporate innovation,2
Transmission mechanism,2
CASH FLOW,2
INFORMATION,1
GROWTH,1
antithrombosis,1
Chinese medicine,2
extrinsic and endogenous coagulation system,5
medicinal food,2
pharmacology,1
ARTERIAL THROMBOSIS,2
MODEL,1
ANTIPLATELET,1
SAPONINS,1
latrogenic injury,2
Innovation,1
Resident education,2
Spinal cord injury,3
PEDICLE SCREW FIXATION,3
COMPLICATIONS,1
foreign direct investment FDI,4
innovation,1
panel data analysis,3
panel OLS,2
Azerbaijan,1
Turkey,1
Georgia,1
INNOVATION SYSTEMS,2
KNOWLEDGE,1
FDI,1
TESTS,1
Institutional investor networks Innovation Mutual funds China,7
PROPERTYRIGHTS PROTECTION,2
CORPORATE GOVERNANCE,2
BOARD INTERLOCKS,2
OWNERSHIP,1
CEO,1
PERFORMANCE,1
GUANXI,1
CERTIFICATION,1
CONNECTIONS,1
EXPERIENCE,1
migrations,1
communities on the move,4
international innovation networks,3
social capital,2
KNOWLEDGE FLOWS,2
CULTURALDIVERSITY,1
PATENT CITATIONS,2
GRAVITY MODEL,2
IMMIGRATION,1
PROXIMITY,1
TRADE,1
DETERMINANTS,1
SPILLOVERS,1
MOBILITY,1
Technology transfer,2
university RD,2
technological innovation,2
patents,1
innovation management,2
regional RD,2
TRANSFER OFFICES,2
INTELLECTUAL PROPERTY,2
RELATIVE PERFORMANCE,2
INDUSTRY LINKAGES,2
PATENT CITATIONS,2
UNITEDSTATES,1
IVORY TOWER,2
EBUSINESS,1
ADOPTION,1
KNOWLEDGE,1
,1
,1
Technology transfer,2
University license,2
Exclusivity,1
University prestige,2
BAYHDOLE ACT,2
COMMERCIALIZATION,1
GOVERNANCE,1
INVENTIONS,1
INNOVATION,1
MARKET,1
CHINA,1
APPROPRIABILITY,1
INSTITUTIONS,1
PATENTS,1
Standards,1
Companies,1
Standards organizations,2
Patents,1
Licenses,1
Moon,1
ISO Standards,2
Technology standards,2
standardization,1
technology management,2
concept map,2
competitive strategy,2
INTELLECTUAL PROPERTYRIGHTS,2
DEFACTO STANDARDIZATION,2
INTERNATIONAL STANDARDS,2
STRATEGIC STANDARDIZATION,2
SYSTEMATIC REVIEWS,2
ESSENTIAL PATENTS,2
DOMINANT DESIGN,2
INNOVATION,1
MARKET,1
TRADE,1
Sustainability,1
Social utility,2
GMO,1
Ethical impacts,2
CRISPR,1
Norwegian Gene Technology Act,4
FOOD,1
FRAMEWORK,1
POLICY,1
CRISPRCAS9,1
SCIENCE,1
FUTURE,1
CROPS,1
German Employees Inventions Act,4
BayhDole Act,2
Professors privilege,2
Innovation,1
Entrepreneurship,1
Technology transfer,2
BAYHDOLE ACT,2
PRINCIPAL INVESTIGATORS,2
TRANSFER OFFICES,2
ECONOMICGROWTH,1
PERFORMANCE,1
COMMERCIALIZATION,1
US,1
EDUCATION,1
LEVEL,1
INCENTIVES,1
technology commercialization,2
motivation and incentives,3
academiaindustry interface,2
academic entrepreneurship,2
economics of science,3
research,1
innovation,1
BAYHDOLE ACT,2
EMPLOYEE MOTIVES,2
PUBLIC RESEARCH,2
SCIENCE,1
INCENTIVES,1
MOTIVATION,1
INDUSTRIAL,1
INNOVATION,1
KNOWLEDGE,1
QUALITY,1
,1
ACCOUNTABILITY,1
CRISIS,1
,1
HATCHWAXMAN ACT,2
EXCLUSIONARY CONDUCT,2
COMPETITION,1
DEFINITION,1
ANTITRUST,1
CONSUMERS,1
ENTRY,1
DRUGS,1
,1
,1
,1
RATIONAL DECISIONMAKING,2
SOCIAL NORMS,2
BIOMEDICALRESEARCH,1
CONFIRMATION BIAS,2
LAW,1
ECONOMICS,1
PATENTS,1
TECHNOLOGY,1
BUSINESS,1
CULTURE,1
,1
PATENTS,1
LAW,1
innovative development,2
food security,2
intellectual property,2
patent law,2
agriculture,1
developing countries,2
,1
,1
LAW,1
,1
,1
,1
MARKET EXCLUSIVITY,2
LIFE,1
,1
GENETICRESOURCES,1
Private sector healthcare,3
Case management,2
Health economics,2
Malaria control,2
Informal health workers,3
Private sector engagement,3
Targeted subsidy,2
Artemisininbased combination therapy,3
Private sector copayment mechanism,4
MALARIA,1
PREQUALIFICATION,1
GHANA,1
bleeding,1
chronic coronary syndromes,3
percutaneous coronary intervention,3
QuikClot,1
radial access,2
COAGULATION TIME,2
CLINICALTRIALS,1
THROMBOSIS TEST,2
ANTICOAGULATION,1
THROMBOLYSIS,1
ANGIOPLASTY,1
CONSENSUS,1
THERAPY,1
IMPACT,1
ARTERY,1
Acces to medicines,3
Hepatitis C virus,3
HIV,1
Antiretrovirals,1
Directacting antivirals,2
HIV RESPONSE,2
Sciencetechnology linkages,2
Deep learning,2
Network analysis,2
Node2Vec,1
BERT,1
COMBINATORIAL OPTIMIZATION,2
INTENSIVE APPLICATIONS,2
PATENT CITATIONS,2
KNOWLEDGE,1
NETWORKS,1
REPRESENTATION,1
INNOVATION,1
CONVERGENCE,1
ALGORITHMS,1
EXTRACTION,1
Simulation experiment,2
Historical development,2
Dye industry,2
Industrial development,2
University education,2
Patent law,2
COEVOLUTION,1
PATH,1
,1
STANDARDESSENTIAL PATENTS,2
GOOD FAITH,2
CONTRACT,1
LAW,1
INFRINGEMENT,1
HOLDUP,1
POLICY,1
Innovation,1
Internal governance,2
SME and GME listed firms in China,7
PAY,1
FINANCE,1
LAW,1
poor relief in early modern England,6
briefs and letters patent,4
British charitable traditions,3
licensing for solicitation,3
concepts of Christian charity,4
POORLAW,1
SDGs,1
United Nations,2
Sustainability,1
Efficiency of SDG policies,4
Energy Policy Act,3
America Invents Act,3
RENEWABLE ENERGYCONSUMPTION,2
IMPACT,1
Breadth of diffusion,3
Innovation diffusion,2
Patent citations,2
Longitudinal analysis,2
RESEARCHANDDEVELOPMENT,1
BIOTECHNOLOGY FIRMS,2
ORGANIZATIONAL INNOVATION,2
ALLIANCE FORMATION,2
KNOWLEDGEBASE,1
PATENTLAW,1
INDUSTRY,1
INVENTIONS,1
PERFORMANCE,1
DEPTH,1
,1
INDUSTRY,1
DRUGS,1
Proprietary costs,2
Trade secrets,2
Disclosure,1
Information asymmetry,2
Innovation,1
Patents,1
RESEARCHANDDEVELOPMENT,1
VOLUNTARY DISCLOSURE,2
DISCRETIONARY DISCLOSURE,2
INSTRUMENTAL VARIABLES,2
INTELLECTUAL PROPERTY,2
MANAGEMENT FORECASTS,2
SEGMENT DISCLOSURES,2
AFFECT INNOVATION,2
AGENCY COSTS,2
COMPETITION,1
intellectual property,2
global law,2
global health,2
methodological nationalism,2
international agreements,2
FREETRADE AGREEMENTS,2
PUBLICHEALTH,1
DEVELOPINGCOUNTRIES,1
TRIPS AGREEMENT,2
PATENTLAW,1
PHARMACEUTICALINDUSTRY,1
ESSENTIAL MEDICINES,2
POLITICALECONOMY,1
AIDS TREATMENT,2
ACCESS,1
Drug repositioning,2
Regulatory exclusivities,2
Patents,1
Empirical study,2
Intellectual property,2
INNOVATION,1
PRICE,1
Stress tests,2
Small business lending,3
Home equity,2
Entrepreneurship,1
Innovation,1
CREDIT,1
PRODUCTIVITY,1
COSTS,1
STATE,1
public international law,3
artificial intelligence,2
legal personality,2
natural person,2
juridical person,2
corporation,1
corporate veil,2
copyright,1
patent,1
CORPORATIONS,1
OWNERSHIP,1
LIABILITY,1
Transistors,1
Manufacturing,1
Patents,1
Electric breakdown,2
Electronics industry,2
Silicon,1
Dennard s Scaling Law,4
ITRS International Technology Roadmap for Semiconductors,6
Moore s Law,3
planar technology,2
semiconductor,1
SiCMOS,1
technology roadmap,2
,1
,1
PUBLICINTEREST,1
INTELLECTUAL PROPERTY,2
PATENT OFFICE,2
MARKS,1
INCONTESTABILITY,1
INFRINGEMENT,1
COMPETITION,1
CONFUSION,1
DEATH,1
NAMES,1
4,1
0 technologies,2
regions,1
innovation,1
ENTREPRENEURSHIP,1
PATTERNS,1
CITIES,1
skilled worker migration,3
human capital,2
innovation,1
total factor productivity,3
RESEARCHANDDEVELOPMENT,1
HUMANCAPITAL EXTERNALITIES,2
REGIONAL CONVERGENCE,2
INCREASING RETURNS,2
DEVELOPMENT SPILLOVERS,2
KNOWLEDGE SPILLOVERS,2
INTERNAL MIGRATION,2
GROWTH,1
DISTANCE,1
PATENTS,1
Scale Inflexibility,2
Scale Adjustment Costs,3
Corporate Innovation,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
FLEXIBILITY,1
FIRM,1
DETERMINANTS,1
COMPETITION,1
INVESTMENT,1
LAWS,1
OWNERSHIP,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PUBLIC CORRUPTION,2
CONNECTED BOARDS,2
CORPORATE,1
ALLOCATION,1
GOVERNANCE,1
LAWS,1
MARKETS,1
FINANCE,1
IMPACT,1
PayforDelay Agreements,2
Generic Drugs,2
Competition Law,2
California,1
Health Insurance,2
Legislation,1
,1
Activin A receptor type IIlike kinase 5,7
ALK5,1
antisense oligonucleotides,2
antiTGFbeta antibodies,2
cancer,1
clinical trials,2
ECM,1
endoglin,1
extracellular matrix,2
fusion protein,2
microRNA,1
oligodeoxynucleotide,1
PAI,1
patents,1
plasminogen activator inhibitor,3
plasminogenplasmin,1
solubleuPAR,1
suPAR,1
TGFbeta,1
therapy,1
transforming growth factorbeta,3
transforming growth Factorbeta receptor,4
Type I T beta RI,5
Type II Transforming growth Factorbeta receptor,6
T beta RII,3
type III nonkinase TGFbeta receptor,5
uPA,1
uPAR,1
urokinase type plasminogen activator,4
urokinase type plasminogen activator receptor,5
EPITHELIALMESENCHYMAL TRANSDIFFERENTIATION,2
RECEPTORRELATED PROTEIN,2
LATENT TGFBETA,2
CELLADHESION,1
INVIVO,1
BREASTCANCER,1
POSTTRANSCRIPTIONAL REGULATION,2
MONOCLONALANTIBODY,1
SIGNALING PATHWAY,2
COMPLEXFORMATION,1
AIDS treatment,2
compulsory licensing,2
Doha Declaration,2
healthcare rights,2
intellectual property,2
key topics,2
TRIPS Agreement,2
,1
Corporate innovation,2
Air pollution,2
Haze,1
Patents,1
OWNERSHIP STRUCTURE,2
MARKET COMPETITION,2
PRODUCTIVITY,1
GOVERNANCE,1
PERFORMANCE,1
POLLUTION,1
REFORM,1
IMPACT,1
CHINA,1
LAWS,1
Regional Comprehensive Economic Partnership RCEP,5
intellectual property,2
trade,1
sustainable development,2
innovation,1
PROTECTION,1
Trademarks,1
brands,1
gun making industry,3
Basque Country,2
Spain,1
handguns,1
arms,1
,1
institutions,1
innovation,1
culture and demographics,3
market development,2
laws and policies,3
government regulations,2
INTELLECTUAL PROPERTYRIGHTS,2
CORPORATE,1
PATENTS,1
FIRMS,1
TRANSPARENCY,1
COMPETITION,1
RELIGION,1
FINANCE,1
STIFLE,1
MARKET,1
Innovation,1
Firmperformance,1
Negative binomial,2
GMM,1
C13,1
C35,1
L25,1
O03,1
RESEARCHANDDEVELOPMENT,1
EMBODIED TECHNOLOGICALCHANGE,2
FOREIGN DIRECTINVESTMENT,2
PANELDATA,1
ECONOMICGROWTH,1
BUSINESS GROUPS,2
PRODUCTIVITY,1
PATENTS,1
IMPACT,1
CLUSTERS,1
3D printing,2
Intellectual property,2
Patents,1
Trade marks,2
Designs,1
Infringement,1
,1
,1
TRADE SECRETS,2
PROTECTION,1
PATENT,1
MANAGEMENT,1
QUESTIONS,1
LAW,1
IP,1
,1
INTELLECTUAL PROPERTY,2
FIRMS,1
INNOVATION,1
PATENTS,1
PROTECTION,1
SURVIVAL,1
INSIGHTS,1
ADOPTION,1
MODELS,1
LAW,1
Board independence,2
Corruption,1
Affiliates,1
Innovation,1
FOREIGN DIRECTINVESTMENT,2
CORPORATE GOVERNANCE,2
SHAREHOLDERS,1
DETERMINANTS,1
PERFORMANCE,1
OWNERSHIP,1
PATTERNS,1
RIGHTS,1
LAW,1
firm lifecycle,2
innovation,1
explorative innovation,2
RD,1
financial regulation,2
corporate governance,2
financial reporting quality,3
SARBANESOXLEYACT,1
SOX SECTION 404,3
CORPORATE GOVERNANCE,2
AUDIT COMMITTEE,2
CAPITAL STRUCTURE,2
INTERNAL CONTROL,2
EARNINGS QUALITY,2
AGENCY COSTS,2
CASH FLOW,2
ECONOMIC CONSEQUENCES,2
social movements,2
intellectual property rights,3
resistance,1
seeds,1
sensorial engagement,2
reflexivity,1
political action,2
legal anthropology,2
multilateral governance,2
farmers,1
,1
Institutional ownerships,2
Board diversity,2
Innovation,1
ESG,1
SarbanesOxley Act,2
FIRM PERFORMANCE,2
DEVELOPMENT INVESTMENTS,2
UPPER ECHELONS,2
INVESTORS,1
GOVERNANCE,1
DIRECTORS,1
GENDER,1
AGENCY,1
WOMEN,1
US,1
regional happiness,2
financing constraints,2
informal institutions,2
green innovation,2
PROENVIRONMENTAL BEHAVIOR,2
POSITIVE FEEDBACK LOOP,3
EMPIRICALANALYSIS,1
LIFE SATISFACTION,2
DRIVING FORCES,2
ECOINNOVATION,1
SELFIMAGE,1
PERFORMANCE,1
IMPACT,1
VALUES,1
COVID19,1
information ecology,2
innovation,1
intellectual property,2
knowledge commons,2
patents,1
ANTICOMMONS,1
INNOVATION,1
PROPERTY,1
Incentive system,2
Innovation intermediaries,2
Intellectual property,2
Japan,1
Patent licensing,2
Regional innovation systems,3
Unintended consequence,2
BAYHDOLE ACT,2
UNIVERSITIES,1
SYSTEM,1
INCENTIVES,1
GROWTH,1
IMPACT,1
POLICY,1
Intellectual property rights,3
China,1
Reform,1
Innovation,1
Technology transfer,2
,1
,1
PROPERTYRIGHTS,1
LAW,1
LAND,1
PATENT,1
STANDARDIZATION,1
STRATEGIES,1
DEMARCATION,1
INFORMATION,1
EVOLUTION,1
ECONOMICS,1
Antimalarial dyes,2
Transmission blocking,2
Triarylmethanes,1
Drug uptake,2
Brilliant green,2
Food dyes,2
REDBLOODCELLS,1
INVITRO,1
MALARIA PARASITE,2
NUTRIENTUPTAKE,1
METHYLENEBLUE,1
QUANTITATIVE ASSESSMENT,2
ANTIMALARIAL AGENT,2
TRANSMISSION,1
TARGETS,1
DRUGS,1
Anesthesiology complication,2
Central nervous system,3
Court witness,2
Credibility system,2
Medical law,2
Oxygen depletion,2
CENTRALNERVOUSSYSTEM,1
RECURRENT HALLUCINATIONS,2
MECHANISMS,1
KETAMINE,1
EXPERIENCES,1
PROPOFOL,1
,1
PIRACY PARADOX,2
TRADE SECRETS,2
LAW,1
INNOVATION,1
ECONOMICS,1
SEARCH,1
NORMS,1
social capital,2
interorganizational relations,2
social networks,2
beyond the organization,3
law,1
embeddedness,1
interpersonal influence,2
TOWORK LAWS,2
SOCIALSTRUCTURE,1
REGULATORY FIT,2
MEDIATING ROLE,2
BRIDGING TIES,2
SUPREMECOURT,1
WEAK TIES,2
NETWORKS,1
KNOWLEDGE,1
FIRMS,1
,1
BAYHDOLE ACT,2
INNOVATION SPEED,2
KNOWLEDGE,1
UNIVERSITY,1
PERFORMANCE,1
DIFFUSION,1
IMPACT,1
GROWTH,1
DETERMINANTS,1
DYNAMICS,1
Constitutional design,2
Coase theorem,2
Framing,1
Preferences,1
Rights,1
Battle of the sexes,4
PROPERTYRIGHTS,1
COASE,1
COMMUNICATION,1
COORDINATION,1
INNOVATION,1
FAIRNESS,1
PATENTS,1
BATTLE,1
family firms,2
intellectual property protection,3
trade secret protection,3
UTSA,1
RD investments,2
socioemotional wealth,2
SOCIOEMOTIONAL WEALTH,2
CORPORATEOWNERSHIP,1
INNOVATION EVIDENCE,2
EMPIRICALANALYSIS,1
MARKETSTRUCTURE,1
NONFAMILY FIRMS,2
FOUNDER FIRMS,2
PATENT,1
PERFORMANCE,1
AGENCY,1
protein engineering,2
carbon sequestration,2
thermostability,1
conformational energetics,2
AMINOACIDS,1
STABILITY,1
PROTEINS,1
Bad faith,2
Registration,1
Statute of limitations,3
Confusion or association,3
Distinctive character,2
Cancellation,1
Reputation,1
Customer diversion,2
Unfair competition,2
Change of business name,4
Cancellation of domain name,4
,1
TRIPS,1
vaccine inequity,2
waiver,1
intellectual property,2
PATENT,1
RIGHTS,1
TRADE,1
HEALTH,1
D85,1
O31,1
R12,1
Z13,1
STRUCTURAL HOLES,2
KNOWLEDGE,1
INNOVATION,1
GEOGRAPHY,1
EVOLUTION,1
PERFORMANCE,1
CLUSTERS,1
DISTANCE,1
Universityindustry collaboration,2
strategic human resource management,4
incentives,1
industry liaison office,3
intellectual property,2
TECHNOLOGYTRANSFER OFFICES,2
PERFORMANCE,1
BOUNDARY,1
ORGANIZATIONS,1
PRODUCTIVITY,1
GROWTH,1
ACT,1
,1
,1
,1
INNOVATION,1
GMM,1
QUALITY,1
IMPACT,1
,1
APPROVAL,1
COMPETITION,1
PROTECTION,1
ECONOMICS,1
PATENTS,1
GUIDE,1
LAW,1
,1
MG SUBCUTANEOUS INJECTIONS,3
GLATIRAMER ACETATE,2
DOUBLEBLIND,1
PILOT,1
COMPARE,1
EVERY,1
Intellectual Property,2
Customs Law,2
Copyright,1
Transboundary Movement,2
Digital Environment,2
,1
Consumer choices,2
Cult of domesticity,3
Illinois,1
Patent medicines,2
Advertising,1
Health,1
,1
A,1
A,1
Albert,1
AFCRC,1
ATM,1
banking,1
block ciphers,2
Claude Shannon,2
communication,1
cryptanalysis,1
cryptography,1
ecommerce,1
Horst Feistel,2
IBM,1
NSA,1
SIGNATURES,1
CODES,1
copyright,1
intellectual property,2
patents,1
sports,1
trademark,1
,1
sustainable development,2
technological innovation,2
intellectual property rights,3
research and development,3
patents and trademarks,3
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTAL INNOVATION,2
GENUINE SAVINGS,2
DETERMINANTS,1
INDICATORS,1
EMISSIONS,1
GROWTH,1
ENERGY,1
Regional innovation,2
Triple helix,2
Yangtze river delta,3
Subjects collaboration,2
Spatial correlation,2
TRIPLEHELIX,1
MUTUAL INFORMATION,2
PERSPECTIVE,1
INDICATOR,1
NETWORKS,1
SYNERGY,1
SYSTEMS,1
,1
,1
,1
EXECUTIVECOMPENSATION,1
PRODUCTSLIABILITY,1
HEALTHINSURANCE,1
RULES RATHER,2
ECONOMICS,1
TAX,1
POLICY,1
LAW,1
PERFORMANCE,1
INNOVATION,1
Intellectual property rights,3
patent law,2
traditional knowledge,2
WIPO,1
India,1
Traditional Knowledge Digital Library,4
REFORMULATION REGIME,2
PROPERTYRIGHTS,1
GOVERNMENT,1
PATENTS,1
IGC,1
IP,1
medical device industry,3
innovation,1
patent analysis,2
regulatory,1
market potential,2
INDUSTRY,1
RISK,1
Nanoscience,1
Bibliometrics,1
Lexical analysis,2
Power laws,2
Terminology,1
Subject categories,2
Search strategy,2
Compound words,2
RESEARCH FIELDS,2
NANOTECHNOLOGY,1
NANOSCIENCE,1
SCIENCE,1
INTERDISCIPLINARITY,1
PUBLICATIONS,1
PATENTS,1
WEB,1
,1
,1
,1
PATENT,1
PERSPECTIVE,1
RIGHTS,1
LAW,1
capital,1
political epistemology,2
democratic professionalism,2
,1
,1
,1
,1
ACTION FAIRNESS ACT,3
MULTIDISTRICT LITIGATION,2
NATIONAL COURT,2
DISPUTE RESOLUTION,2
BANKRUPTCY COURT,2
DISTRICT COURTS,2
SUPREMECOURT,1
LEGAL,1
LAW,1
APPEALS,1
Breeders rights,2
Exhaustion,1
Commercial exploitation,2
Right of ownership,3
Acts of production or reproduction,5
Variety constituents,2
Planting and harvesting,3
,1
Seed laws,2
statesociety relations,2
Venezuela,1
food sovereignty,2
bottomup policymaking,2
PERSPECTIVES,1
HISTORY,1
BRAZIL,1
Corporate governance,2
Innovation,1
litigation risk,2
Generalized method of moments,4
Propensity sample matching,3
FINANCIAL CONSTRAINTS,2
AGENCY COSTS,2
SHAREHOLDER LITIGATION,2
POLICY UNCERTAINTY,2
INVESTMENT,1
PERFORMANCE,1
CHINA,1
FIRM,1
MANAGEMENT,1
AVOIDANCE,1
,1
TEXT,1
MODEL,1
CHINA,1
Complex product design,3
Technological evolution law,3
Neural network,2
TRIZ,1
Cutting machine,2
TRIZ EVOLUTION,2
AXIOMATIC DESIGN,2
TRENDS,1
IDENTIFICATION,1
INNOVATION,1
SELECTION,1
MACHINE,1
SERVICE,1
IDEAS,1
CRISPR,1
Human embryo gene editing,4
Legal status of human embryo,5
Research regulation,2
Morality,1
China,1
CRISPR,1
judicial studies,2
judicial specialisation,2
specialist courts,2
access to justice,3
adjudication,1
COURTS,1
DISPUTES,1
JUSTICE,1
PATENT,1
Exclusive rights,2
trademark registration,2
nontraditional means of individualization,4
olfactory trademark,2
patent law,2
,1
breast,1
breastfeeding,1
breast milk,2
expression,1
difficulties,1
pumping,1
,1
Carbonic anhydrase,2
Cytosolic isoforms I and II,5
Tumorassociated isoforms IX,3
XII,1
Benzothiazole6sulfonamides,1
Docking,1
CRYSTALSTRUCTURE,1
ZINCCOMPLEXES,1
ISOZYMES I,2
PATENT,1
BENZENESULFONAMIDES,1
ANTIBACTERIAL,1
SULFONAMIDES,1
DERIVATIVES,1
BINDING,1
PYLORI,1
Researchfunding,1
Public knowledge,2
Early firm engagement,3
Sciencebased innovation,2
INTELLECTUAL PROPERTY,2
LIFESCIENCE,1
IMPACT,1
COLLABORATION,1
ECONOMICS,1
OUTPUTS,1
COSTS,1
Technological innovation,2
Urban development,2
Ecoefficiency,1
Spatial autoregressive model,3
ENERGY EFFICIENCY,2
ECOEFFICIENCY,1
LIFECYCLE,1
ENVELOPMENT,1
PRODUCTIVITY,1
CONSUMPTION,1
SPILLOVERS,1
EMISSIONS,1
GROWTH,1
Certificate of Supplementary Protection,4
Shingrix,1
Belsomra,1
CSP Register,2
Minister of Health Canada,4
,1
bronchopulmonary dysplasia,2
IL17,1
necrotizing enterocolitis,2
patent ductus arteriosus,3
retinopathy of prematurity,3
sepsis,1
DELTATCELLS,1
COLONYSTIMULATING FACTOR,2
HELPER 17 CELLS,3
RORGAMMAT,1
TH17 CELLS,2
TH17 CELLS,2
NECROTIZING ENTEROCOLITIS,2
INFLAMMATORY RESPONSE,2
DUCTUSARTERIOSUS,1
PRETERM INFANTS,2
Pyrrolopyridine,1
azaindole,1
anticancer,1
kinase inhibitors,2
vemurafenib,1
HETEROAROMATIC ACETICACIDS,2
ACTIVITYRELATIONSHIPS SAR,2
KINETIC RELATIONSHIPS SKR,3
HUMAN PANCREATICCANCER,2
BIOLOGICAL EVALUATION,2
ANTIPROLIFERATIVE ACTIVITY,2
METASTATIC MELANOMA,2
KINASE INHIBITORS,2
CSF1 RECEPTOR,2
PROTEINKINASE,1
Intellectual property rights policies,4
Academic entrepreneurship,2
Multilevel models,2
KNOWLEDGE TRANSFER,2
NATURALSCIENCES,1
UNIVERSITY INVENTIONS,2
PATENT QUALITY,2
COMMERCIALIZATION,1
OWNERSHIP,1
RESEARCHERS,1
IMPACT,1
WEAK,1
ACT,1
Selfacting,1
air foil thrust bearing,4
cascaded foils,2
square foils,2
wedge film,2
pressure profile,2
and stiffness,2
FINITEELEMENT,1
Zea mays L,3
ExPVP inbred lines,3
Quality traits,2
NCII design,2
Combining ability analysis,3
GCA,1
SCA,1
VARIETY,1
Innovation,1
Grand Challenges,2
Intergovernmental Organisations,2
Global health,2
Patent pools,2
INTERNATIONALORGANIZATIONS,1
INTELLECTUAL PROPERTY,2
INNOVATION,1
POLICY,1
DYNAMICS,1
TECHNOLOGY,1
NETWORKS,1
INSIGHTS,1
POLITICS,1
SYSTEMS,1
democratization of science and technology,5
genetic diversity,2
intellectual property,2
maize germplasm,2
onfarm genetic diversity,3
Zea mays,2
HYBRID MAIZE,2
GERMPLASM,1
CORN,1
Enterprise investment preferences,3
Environmental legislation,2
New environmental protection law,4
RISKTAKING,1
CORPORATE,1
Free flap,2
Submillimeterdiameter vascular graft,3
Acellular,1
Tissue engineering,2
EXPANDED POLYTETRAFLUOROETHYLENE,2
VEIN GRAFTS,2
MICROVASCULAR GRAFTS,2
HEMODIALYSIS ACCESS,2
LIMB SALVAGE,2
RECONSTRUCTION,1
SCAFFOLDS,1
PATENCY,1
PEDICLE,1
FIBERS,1
,1
INTELLECTUAL PROPERTY,2
ECONOMICANALYSIS,1
CONTEXT,1
PATENT,1
RULES,1
COSTS,1
LAW,1
,1
BEHAVIORAL ECONOMICS,2
RATIONAL CHOICE,2
EX ANTE,2
PATENT,1
LAW,1
COPYRIGHT,1
MARKETS,1
IRRATIONALITY,1
INFORMATION,1
PSYCHOLOGY,1
Adam Smith,2
Reputation,1
Commutative justice,2
Defamation,1
Libel,1
Slander,1
Perfect rights,2
Natural jurisprudence,2
Esotericism,1
,1
AGS 6,2
DSH,1
ADAR1 homozygous mutations,3
PDA,1
VSD,1
mitral valve calcification,3
ADAR1 GENE,2
dataset,1
location,1
organization,1
personnel,1
RD,1
ORGANIZATION STRUCTURE,2
INNOVATION,1
KNOWLEDGE,1
PATENTS,1
Child Health,2
PPMV,1
Common Childhood Illnesses Management,4
Under Five,2
Malaria,1
MALARIA,1
HIV1 NNRTI,2
RDEA427,1
Carbonate prodrug,2
AntiHIV activity,2
Metabolic stability,2
REVERSETRANSCRIPTASE INHIBITORS,2
BEARING BRIDGEHEAD NITROGEN,3
BIOLOGICAL EVALUATION,2
PATENT EVALUATION,2
DESIGN,1
DERIVATIVES,1
STRATEGIES,1
DIARYLTRIAZINES,1
OPTIMIZATION,1
MOLECULE,1
adolescent girls and young women,5
Africa,1
men who have sex with men,6
PrEP,1
prevention,1
stigma,1
longacting,1
CABOTEGRAVIR,1
Private sector healthcare,3
Case management,2
Diagnostics,1
Health economics,2
Malaria control,2
Informal health workers,3
Private sector engagement,3
Targeted subsidy,2
Private sector copayment mechanism,4
IMPACT,1
ACT,1
Social venture scaling,3
Scaling,1
Social entrepreneurship,2
Technological environment,2
Technological endowment,2
Arbitrage opportunity,2
ARBITRAGE OPPORTUNITIES,2
ENTREPRENEURSHIP,1
IMPACT,1
REGRESSIONS,1
ENTERPRISES,1
GROWTH,1
Government funding,2
industry funding,2
academic engagement,2
STEM faculty,2
BAYHDOLE ACT,2
UNIVERSITYRESEARCH,1
INDUSTRY,1
PERFORMANCE,1
ENTREPRENEURIAL,1
PUBLICATION,1
INNOVATION,1
KNOWLEDGE,1
INVENTION,1
SCIENCE,1
Organometallicacylhydrazones,1
sulfonamides,1
carbonic anhydrase,2
inhibitors,1
CRYSTALSTRUCTURES,1
ISOFORMS I,2
ISOZYMEI,1
COORDINATIONCOMPOUNDS,1
COMPLEXES,1
PATENT,1
DERIVATIVES,1
5NITROTHIOPHENE,1
ANTIBACTERIAL,1
CYRHETRENYL,1
Trade secrets,2
Intellectual property,2
Competitive threats,2
Predation risk,2
Market dynamics,2
Product market concentration,3
RESEARCHANDDEVELOPMENT,1
PROPERTYRIGHTS,1
CORPORATE DISCLOSURE,2
ANALYST COVERAGE,2
COMPETITION,1
INNOVATION,1
INDUSTRY,1
INVESTMENTS,1
INFORMATION,1
OWNERSHIP,1
Leisure externalities,2
Multisector growth models,3
RD and innovation,3
Patents,1
Endogenous labor supply,3
Spillovers,1
TFP,1
Panel data,2
ECONOMICDEVELOPMENT EVIDENCE,2
HUMANCAPITAL ACCUMULATION,2
ENDOGENOUS GROWTH,2
DEVELOPMENT SPILLOVERS,2
INCREASING RETURNS,2
2SECTOR MODEL,2
TWIN ENGINES,2
LONGRUN,1
TIME,1
INSTITUTIONS,1
,1
,1
Principal investigators,2
Technology transfer,2
Market impact,2
Universityindustry collaboration,2
Commercial experience,2
UNIVERSITYINDUSTRY COLLABORATION,2
INNOVATION,1
Financial institutions and services,4
Innovation and invention,3
Criminal law,2
Litigation process,2
IMPACT,1
LITIGATION,1
ORGANIZATIONS,1
aorta,1
delayed embolization,2
ductal occluder device,3
surgical removal,2
,1
Innovation,1
Quality certificates,2
Patents,1
Corruption,1
Government governance,2
DETERMINANTS,1
INSTITUTIONS,1
NETWORK,1
Innovation,1
Institutional ownership,2
Investment,1
Monitoring,1
Patents,1
CORPORATE GOVERNANCE,2
PRIVATE EQUITY,2
MARKET VALUE,2
DEVELOPMENT INVESTMENT,2
INNOVATION,1
FIRMS,1
FINANCE,1
MERGERS,1
PANEL,1
LAW,1
,1
COMMERCIAL SPEECH,2
JURY,1
MARKETPLACE,1
NEUTRALITY,1
AMENDMENT,1
FREEDOM,1
COURTS,1
RIGHTS,1
LAW,1
Case Study,2
Innovation,1
Intellectual Property Rights,3
Manufacturing,1
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALEVIDENCE,1
PATENT PROTECTION,2
TECHNOLOGY,1
STRATEGIES,1
INDUSTRY,1
public health,2
foreign investment,2
access to medicine,3
right to regulate,3
intellectual property,2
general exceptions,2
police powers,2
margin of appreciation,3
necessity,1
ESSENTIAL MEDICINES,2
ACCESS,1
GATT,1
LAW,1
CHAPEAU,1
PATENTS,1
URUGUAY,1
TRADE,1
,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
Malaria,1
Inequity,1
Socioeconomic status,2
SES,1
Artemisinin combination therapy,3
Nigeria,1
HEALTH FACILITIES,2
PERCEPTIONS,1
INEQUITIES,1
SERVICES,1
PATIENT,1
PERFORMANCE,1
PROVIDERS,1
MEDICINES,1
KNOWLEDGE,1
BEHAVIOR,1
Certificate of supplementary protection,4
Manufacturing waiver,2
Patent term extension,3
Supplementary protection certificate,3
USFDA,1
,1
Australian colonization,2
Agamben Giorgio,2
postcolonial law,2
social transformation,2
discontinuity,1
postcolonial temporality,2
Indigenous sovereignty,2
,1
WTO,1
TRIPS Agreement,2
TRIPS Waiver Proposal,3
TRIPS Waiver,2
compulsory license,2
patent,1
COVID19 vaccine inequity,3
COVID19 diagnostics and therapeutics,4
intellectual property rights,3
pandemic,1
international law,2
,1
,1
SERVICE MARKS,2
WAGE PENALTY,2
INNOVATION,1
DISCRIMINATION,1
PERFORMANCE,1
DIVERSITY,1
INDICATOR,1
WOMENS,1
BIAS,1
urinary bladder neoplasms,3
immune evation,2
immunotherapy,1
LAG3,1
CHEMOTHERAPY,1
environmental risk,2
informational cascade,2
solar eclipse,2
ECLIPSE,1
hypozincemia,1
hepatitis C,2
directacting antiviral agents,3
AMINOACIDS,1
ZINC,1
VIRUS,1
METABOLISM,1
THERAPY,1
BINDING,1
Land Law 201301,3
Land use and management,4
Benin Republic,2
,1
implementation,1
localization,1
intellectual property,2
traditional knowledge,2
India,1
Brazil,1
PHARMACEUTICAL PATENTS,2
DOMESTIC POLITICS,2
PROPERTYRIGHTS,1
CIVILSOCIETY,1
IDEAS,1
IMPLEMENTATION,1
GLOBALIZATION,1
INTERESTS,1
POLICY,1
STATE,1
Congress,1
intellectual property,2
trade,1
United States,2
FASTTRACK,1
POLICY,1
CANADA,1
TRIPS,1
Conceptual design,2
Computational design synthesis,3
Functional modelling,2
Indirectsensing,1
Closed loop,2
FUNCTIONAL SYNTHESIS,2
SYSTEMS,1
Chinese herbal medicine,3
Chronic atrophic gastritis,3
Efficacy,1
Metaanalysis,1
Shugan Hewei therapy,3
,1
Zea mays L,3
ExPVP inbreds,2
Hybrids,1
Combining ability analysis,3
Gen action,2
INBRED LINES,2
HYBRIDS,1
GERMPLASM,1
NIH funding,2
FDA approval,2
Marchin Rights,2
BayhDole Act,2
,1
medicine,1
pain,1
TOLEFT SHUNT,2
TRANSCATHETER CLOSURE,2
PERCUTANEOUS CLOSURE,2
AURA,1
ASSOCIATION,1
PREVALENCE,1
ULTRASOUND,1
THERAPY,1
Body Donation Program,3
Cadaver lab,2
Foramina transversaria,2
Transversoclasiotome,1
Vertebral artery,2
Patent,1
SCHOOLOFMEDICINE,1
FORAMEN ARCUALE,2
BODY DONATION,2
SPINALCORD,1
DISSECTION,1
ANATOMY,1
HEMORRHAGE,1
GUIDELINES,1
UNIVERSITY,1
CADAVERS,1
,1
INTELLECTUAL PROPERTY LAW,3
COPYRIGHT,1
ECONOMICS,1
FASHION,1
DESIGN,1
,1
,1
permeable pavement,2
monitoring instruments and management systems,5
flow law formula,3
lowimpact development,2
,1
Operating risk,2
Environmental regulation,2
Innovation incentive,2
Environmental management,2
GREEN INNOVATION,2
PERFORMANCE EVIDENCE,2
POLLUTION REGULATION,2
MANAGEMENT,1
IMPACT,1
POLICY,1
FIRMS,1
MIX,1
,1
,1
the rule of the copyright holder,6
copyright monopoly,2
the Venetian Patent Law,4
the Statute of Queen Anne,5
exclusive right,2
related rights,2
open licenses,2
copyright,1
copyleft,1
,1
Trademarks,1
Technical conditions for use or infringement,6
Stocking,1
Intermediary,1
Personal pursuit of aims,4
,1
China,1
intellectual property,2
legal orientalism,2
patent,1
Qing dynasty,2
TRIPS,1
US,1
,1
Documentary film,2
geneticallymodified organisms,2
agriculture,1
seed saving,2
science and technology studies,4
controversial issues,2
worlding,1
PATENT,1
HISTORY,1
,1
,1
Lifeworld,1
property,1
commodity,1
assets,1
monopoly capital,2
INTANGIBLE ASSETS,2
DATA JUSTICE,2
LABOR,1
WORK,1
RD subsidy,2
Regulatory environment,2
WTO subsidy rules,3
Innovations,1
Patent,1
Utility model,2
DEVELOPMENT INVESTMENT,2
INNOVATION EVIDENCE,2
DEVELOPMENT POLICY,2
PROTECTION,1
LAWS,1
GOVERNMENT,1
TRADE,1
LESSONS,1
SYSTEM,1
IMPACT,1
Healthcare financing,2
Hepatitis C,2
Treatment,1
DIRECTACTING ANTIVIRALS,2
VIRUSINFECTION,1
INJECT DRUGS,2
UNITEDSTATES,1
PEOPLE,1
ELIMINATION,1
SOFOSBUVIR,1
THERAPY,1
CARE,1
HCV,1
,1
PGLYCOPROTEIN,1
CANCER,1
RESISTANCE,1
PLANTS,1
PHARMACOGENOMICS,1
PERSPECTIVES,1
INHIBITION,1
THERAPY,1
TUMORS,1
Knowledge transfer in universityindustry collaboration KTUIC,6
knowledge transfer,2
universityindustry collaboration,2
bibliometric analysis,2
visual analysis,2
TECHNOLOGYTRANSFER OFFICES,2
BAYHDOLE ACT,2
TRIPLEHELIX,1
INNOVATION,1
UK,1
PERSPECTIVE,1
PERFORMANCE,1
COMMERCIALIZATION,1
ENTREPRENEURSHIP,1
ORGANIZATIONS,1
Domestic production of medicines,4
technology transfer,2
hepatitis C,2
Brazil,1
sofosbuvir,1
directacting antivirals,2
HEALTH,1
INNOVATION,1
EVOLUTION,1
VACCINE,1
SCIENCE,1
AFRICA,1
ACCESS,1
POLICY,1
Employment protection,2
Firing costs,2
Innovations,1
Patents,1
Productivity,1
Market imperfections,2
EQUILIBRIUM UNEMPLOYMENT,2
PRODUCTIVITY GROWTH,2
CYCLICAL BEHAVIOR,2
SEARCH,1
TURNOVER,1
DYNAMICS,1
accidents at work,3
allometric scaling,2
statistical data,2
size of an enterprise,4
ORIGIN,1
LAWS,1
Aid for Trade,3
trademarks applications,2
developing countries,2
least developed countries,3
F14,1
O31,1
RESEARCHANDDEVELOPMENT,1
MARKET VALUE,2
INNOVATION,1
PATENTS,1
DETERMINANTS,1
REGRESSION,1
MODELS,1
LAW,1
,1
,1
,1
LIABILITY RULES,2
SECURED CLAIMS,2
ONEVIEW,1
POSSESSION,1
PRIORITY,1
BUNDLE,1
INFORMATION,1
CONTRACT,1
EXCLUDE,1
NOTICE,1
Triaxial compression test,3
Seepage pressure,2
Digital image correlation,3
Progressive failure,2
Space time evolution law,4
PERMEABILITY EVOLUTION,2
STRESS,1
DAMAGE,1
FRACTURE,1
DEFORMATION,1
COMPRESSION,1
SANDSTONE,1
PRESSURE,1
Firearms,1
gunshot wounds,2
legislation,1
violence,1
CONGENITAL DIAPHRAGMATICHERNIA,2
PATENT DUCTUSARTERIOSUS,2
FIREARMRELATED INJURIES,2
AVAILABILITY,1
LEGISLATION,1
MORTALITY,1
PREMATURE,1
HOMICIDE,1
LIGATION,1
SURVIVAL,1
Innovation,1
patent,1
copyright,1
autonomous systems,2
technological processes,2
,1
commercialization of intellectual property rights,5
innovations,1
,1
human resource,2
intellectual property,2
revenue,1
technology transfer offices,3
universityindustry technology transfer processes,4
RESOURCEBASED VIEW,2
UNIVERSITY TECHNOLOGY,2
INTELLECTUAL PROPERTY,2
PERFORMANCE,1
COMMERCIALIZATION,1
INNOVATION,1
STRATEGY,1
IMPACT,1
university technology transfer,3
equity,1
royalty,1
fixed fees,2
contract design,2
screening games,2
RESEARCHANDDEVELOPMENT,1
INTEGRATION,1
CONTRACTS,1
PATENTS,1
IMPACT,1
agriculture,1
generic drug,2
antitrust,1
pay for delay,3
cooperatives,1
CapperVolstead,1
HatchWaxman,1
,1
,1
HEALTH TECHNOLOGYASSESSMENT,2
NONINFERIORITY TRIAL,2
CROHNSDISEASE,1
COSTEFFECTIVENESS,1
INNOVATOR INFLIXIMAB,2
CLINICALOUTCOMES,1
DOUBLEBLIND,1
CTP13,1
ANTIBODIES,1
THERAPY,1
innovation,1
intermediaries,1
national innovation systems,3
regional innovation systems,3
spillover,1
universities,1
Japan,1
KNOWLEDGE PRODUCTION FUNCTION,3
TECHNOLOGYBASED FIRMS,2
MANUFACTURING EXTENSION,2
INDUSTRY COLLABORATION,2
ABSORPTIVECAPACITY,1
RESEARCH INSTITUTES,2
PUBLIC RESEARCH,2
NETWORKS,1
IMPACT,1
LINKS,1
assignment,1
inhouse exploitation,2
licensing,1
FIXED FEE,2
PATENT,1
SUPERIORITY,1
AUCTION,1
Confocal laser scanning microscopy,4
Laser micromachining,2
Pinhole exchange,2
Imaging,1
Resolution,1
,1
,1
COLORECTALCANCER,1
TRYPTOPHANASE,1
EXPRESSION,1
MICROBIOTA,1
FEXINIDAZOLE,1
FURAZOLIDONE,1
ANTIBIOTICS,1
THERAPIES,1
MECHANISM,1
IMPACT,1
firmlevel markups,2
innovation,1
quality of imported intermediates,4
INPUTTRADE LIBERALIZATION,2
PRODUCT INNOVATION,2
GROWTH,1
IMPACT,1
MODEL,1
,1
SSIMS,1
EMISSION,1
SURFACE,1
GROWTH,1
CARBON,1
OXYGEN,1
SPECTROSCOPY,1
DENSITY,1
FILMS,1
Institutional ownership,2
Firm innovation,2
Pharmaceuticalsa,1
MANAGEMENT,1
SHAREHOLDERS,1
MERGERS,1
Innovation,1
Intellectual property,2
Laboratory experiment,2
Real effort task,3
Creativity,1
PATENTS,1
COMPETITION,1
COMMUNICATION,1
PERFORMANCE,1
PROTECTION,1
TIME,1
Crop domestication,2
genetic diversity,2
breeding pipeline,2
predictive breeding,2
FROGEYE LEAFSPOT,2
SALT TOLERANCE,2
GENETIC BASE,2
RESISTANCE,1
CULTIVARS,1
YIELD,1
INHERITANCE,1
LINES,1
,1
HIGHEREDUCATION,1
DEVELOPINGCOUNTRIES,1
TECHNOLOGYTRANSFER,1
INDUSTRY LINKAGES,2
TRUST FORMATION,2
BASIC RESEARCH,2
INNOVATION,1
COLLABORATION,1
AMBIDEXTERITY,1
INSTITUTIONS,1
intellectual property rights,3
open innovation,2
organizational performance,2
MANAGEMENT,1
PATENT,1
ECONOMICS,1
INDUSTRY,1
WINE,1
mixture models,2
Additive Dose Model ADM,4
Multiplicative Survival Model MSM,4
adjuvant effect,2
HERBICIDE MIXTURES,2
JOINT ACTION,2
,1
LASER,1
POWDER,1
IPR,1
management innovation,2
RDI,1
social systems,2
State aid,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
EMPIRICALEVIDENCE,1
KNOWLEDGE,1
PATENT,1
COSTS,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT PROTECTION,2
FAIRUSE,1
INDEPENDENT INVENTION,2
PATENT,1
LAW,1
ECONOMICS,1
INNOVATION,1
DEFENSE,1
IP,1
variable load,2
sensors,1
vibration,1
gears,1
flexible torsion clutch,3
AUSTEMPERED DUCTILE IRON,3
FOURIERTRANSFORM,1
FAULTDETECTION,1
DYNAMICS,1
DECOMPOSITION,1
MISALIGNMENT,1
VIBRATIONS,1
SYSTEM,1
ROTOR,1
WEAR,1
Cranium,1
lambdoid,1
morphology,1
obliteration,1
suture,1
SKELETAL AGE,2
MORPHOLOGICALCHANGES,1
CLOSURE,1
DEATH,1
MECHANISMS,1
PATENCY,1
TBIs,1
Technology,1
Entrepreneurship,1
Startups,1
Innovation,1
India,1
,1
Case report,2
Patent foramen ovale,3
Percutaneous closure,2
Stroke,1
Paradoxical embolism,2
Syncope,1
Cerebrovascular accident,2
DIAGNOSIS,1
trademarks,1
queer,1
LGBTQ plus,2
empirical,1
queer studies,2
intellectual property,2
STEREOTYPES,1
REAPPROPRIATION,1
EPITHETS,1
STIGMA,1
SPEECH,1
LABELS,1
SLURS,1
POWER,1
LAW,1
automobiles,1
gas sensors,2
Global Positioning System,3
microcontrollers,1
humidity sensors,2
health and safety,3
microwave detectors,2
microwave measurement,2
motion measurement,2
infrared detectors,2
temperature sensors,2
temperature measurement,2
humidity measurement,2
cameras,1
microsensors,1
data acquisition,2
smart Arduinobased system,3
remote control,2
innovative complete car control system,5
children abandonment,2
unattended vehicles,2
automotive market,2
patent procedure,2
testing phase,2
microwave motion sensor,3
carbon dioxide sensor,3
vehicle Global Positioning System,4
car windows,2
health safety,2
microcamera,1
vocal detector,2
temperaturehumidity sensor,2
microcontroller board,2
alarm short message service transmission,5
HARDWARE,1
Competitive pricing strategy,3
Pharmaceutical markets,2
Directtoconsumer advertising,2
Detailing,1
Dynamic game,2
TESTS,1
INFORMATION,1
LEADERSHIP,1
CONSUMERS,1
frontal sinusotomy,2
balloon dilation,2
chronic rhinosinusitis,2
frontal sinusitis,2
functional endoscopic sinus surgery,4
CATHETER SINUSOTOMY,2
FOLLOWUP,1
OUTCOMES,1
RHINOSINUSITIS,1
SURGERY,1
SAFETY,1
OSTIA,1
Zhizhu Wan,2
Zhishi,1
Baizhu,1
functional dyspepsia,2
therapeutic mechanism,2
system pharmacology,2
KAPPAB,1
TARGET PREDICTION,2
WEB SERVER,2
PATHWAY,1
HESPERETIN,1
ASSOCIATION,1
NETWORK,1
DISEASE,1
KINASE,1
GENE,1
Youth benign paroxysmal positional vertigo,5
Right to left shunt,4
Antiplatelet treatment,2
Patent foramen ovale,3
PATENT FORAMEN OVALE,3
MIGRAINE,1
PREVALENCE,1
FEATURES,1
STROKE,1
HEART,1
Toujiequwen granules,2
COVID19,1
network pharmacology,2
target,1
molecular mechanism,2
INFECTION,1
SPIKE,1
Rising technology stars,3
Coinventor networks,2
Social potential,2
Technology performance,2
Innovation caliber,2
Tech mining,2
INNOVATION CAPABILITIES,2
RESEARCH PERFORMANCE,2
DETERMINANTS,1
INDUSTRIES,1
INDEX,1
SARSCoV2,1
3CL protease,2
traditional Chinese medicines,3
Shuanghuanglian oral liquid,3
baicalin,1
baicalein,1
SARS,1
INHIBITORS,1
DESIGN,1
OPTIMIZATION,1
REDUCTION,1
DISCOVERY,1
BAICALEIN,1
AGLYCONE,1
MODEL,1
,1
POSITIVE AIRWAY PRESSURE,3
BIRTHWEIGHT INFANTS,2
CPAP,1
INTUBATION,1
OUTCOMES,1
RATES,1
family systems,2
marital,1
coparenting,1
parentchild relationship,2
toddlers,1
MARITAL CONFLICT,2
TRANSITION,1
QUALITY,1
FOUNDATIONS,1
PERCEPTIONS,1
ATTACHMENT,1
FRAMEWORK,1
DYNAMICS,1
BEHAVIOR,1
INFANCY,1
prescription drugs,2
food and drug administration,4
regulation,1
supply,1
user fees,2
generic,1
ACT,1
Asthma,1
COPD,1
Fluticasone furoate,2
Vilanterol,1
ICSLABA combination,2
OBSTRUCTIVE PULMONARYDISEASE,2
DRY POWDER INHALER,3
ACTING BETA2ADRENOCEPTOR AGONIST,3
10025 MCG,2
VILANTEROL TRIFENATATE,2
PERSISTENT ASTHMA,2
LUNGFUNCTION,1
DOUBLEBLIND,1
MUG,1
FUROATE,1
Intellectual property rights,3
social values,2
innovation,1
comparative institutional analysis,3
crosscountry study,2
simultaneous equation model,3
FOREIGN DIRECTINVESTMENT,2
TECHNOLOGICAL CAPABILITIES,2
INSTITUTIONS,1
LAW,1
PROTECTION,1
ECONOMICS,1
PATENTS,1
FINANCE,1
POLICY,1
GROWTH,1
,1
NICKEL NANOPARTICLES,2
ORGANIC POLLUTANTS,2
GRAPHENE OXIDE,2
REDUCTION,1
4NITROPHENOL,1
DEGRADATION,1
EXTRACT,1
CITRATE,1
intellectual property,2
TRIPS,1
patent,1
copyright,1
preferential trade agreements,3
Bilateralism,1
INTELLECTUAL PROPERTYRIGHTS,2
FREETRADE AGREEMENTS,2
VETO PLAYERS,2
ACCESS,1
PROVISIONS,1
INNOVATION,1
DESIGN,1
Feminism,1
sexual violence,2
technology,1
gender,1
rape prevention,2
postfeminism,1
SELFDEFENSE,1
MOBILE PHONES,2
EMPOWERMENT,1
DISCOURSE,1
POLITICS,1
SCIENCE,1
LAW,1
APP,1
,1
,1
Epistemological pluralism,2
Ethnopharmacology,1
indigenous rights,2
intellectual property rights,3
traditional ecological knowledge,3
DRUG DISCOVERY,2
SOCIOCULTURAL PROBLEMS,2
GENETICRESOURCES,1
DEFINITION,1
MEDICINE,1
ACCESS,1
USAGE,1
LAW,1
Indicators,1
Intellectual property management,3
Performance Brazil,2
ECONOMICDEVELOPMENT,1
INCREASING RETURNS,2
RIGHTS,1
,1
COMPETITION,1
Intellectual property rights,3
Crossborder mergers and acquisitions,4
PATENT PROTECTION,2
DETERMINANTS,1
INNOVATION,1
LAWS,1
Intellectual property,2
copyright,1
patent,1
forecasting model,2
profiling model,2
property artificial intelligence,3
big data,2
open data,2
database,1
data,1
derivative work,2
,1
demandside strategy,2
diversification,1
knowledgebased services,2
outsourcing,1
relational view,2
RESOURCEBASED VIEW,2
BUYERSUPPLIER RELATIONSHIPS,2
TRANSACTIONCOST ECONOMICS,2
COMPETITIVE ADVANTAGE,2
VALUE CREATION,2
INTERORGANIZATIONAL RELATIONSHIPS,2
COLLABORATIVE RELATIONSHIPS,2
PERFORMANCE IMPLICATIONS,2
TECHNOLOGICAL RESOURCES,2
VERTICAL INTEGRATION,2
Pharmaceutical policy,2
Globalization and health,3
Health care reform,3
Drug pricing,2
Health spending,2
International trade,2
Patents,1
Data exclusivities,2
Health law,2
EXCLUSIVITY,1
DRUGS,1
TIME,1
Human rights,2
health,1
human rights impact assessment,4
intellectual property,2
international trade,2
affordable medicines,2
HEALTH,1
ACCESS,1
POLICY,1
royalties,1
tax,1
intellectual property rights,3
Palestine,1
Arab world,2
Jordan,1
Egypt,1
,1
,1
,1
Bailemian capsule,2
antiinsomnia,1
chemomics,1
network pharmacology,2
mechanism,1
,1
Economic growth,2
Convergence,1
Middleincome trap,2
ECONOMICGROWTH,1
Institutions,1
quality of government,3
innovation,1
regions,1
Europe,1
RESEARCHANDDEVELOPMENT,1
INSTITUTIONS,1
SPILLOVERS,1
GOVERNANCE,1
GROWTH,1
TECHNOLOGY,1
SYSTEMS,1
ENTREPRENEURSHIP,1
INFRASTRUCTURE,1
INDICATORS,1
,1
,1
Class actions,2
Corporate governance,2
Innovation,1
Litigation risk,2
Patents,1
SHAREHOLDER LITIGATION,2
AGENCY COSTS,2
DERIVATIVE LITIGATION,2
CASH FLOW,2
LAW,1
REFORM,1
GROWTH,1
GOVERNANCE,1
FINANCE,1
MERITS,1
Water environment,2
Technology importing,2
Competition policies,2
Green exemption,2
,1
Central environmental protection inspection,4
Green innovation,2
Legitimacy pressure,2
Corporate risk taking,3
CORPORATE ENVIRONMENTAL PERFORMANCE,3
CAMPAIGNSTYLE ENFORCEMENT,2
INNOVATION EVIDENCE,2
FIRM PERFORMANCE,2
LAWENFORCEMENT,1
CHINA,1
IMPACT,1
REGULATIONS,1
GOVERNANCE,1
COMPETITIVENESS,1
corporate environmental responsibility,3
customer concentration,2
green innovation,2
patents,1
sustainable development,2
SUPPLY CHAIN MANAGEMENT,3
PERFORMANCE EVIDENCE,2
PANELDATA,1
ENVIRONMENTAL INNOVATION,2
INSTITUTIONAL PRESSURES,2
SOCIALRESPONSIBILITY,1
FIRM PERFORMANCE,2
IMPACT,1
PROFITABILITY,1
LEGITIMACY,1
Innovation,1
Patents,1
Citations,1
Rd,1
Shorttermism,1
Auditor conservatism,2
Real effects,2
State legal liability laws,4
Financial reporting discretion,3
Goingconcern opinions,2
FINANCIALREPORTING QUALITY,2
EARNINGS MANAGEMENT,2
INSTITUTIONAL INVESTORS,2
UNITEDSTATES,1
TRADEOFF,1
INNOVATION,1
INVESTMENT,1
LIABILITY,1
FIRMS,1
MANIPULATION,1
Disruptive technological innovation,3
technology diffusion,2
complex network,2
powerlaw distribution,2
PATENT,1
IDENTIFICATION,1
EMERGENCE,1
NETWORK,1
ROLES,1
PATHS,1
fault tolerance,2
corporate innovation,2
incentive mechanism,2
stateowned enterprise reform,3
quasinatural experiment,2
BANKRUPTCY,1
LIFE,1
INCENTIVES,1
BANKS,1
LAWS,1
BAD,1
ATMD,1
Active control,2
System modeling,2
Voice coil actuator,3
Real time,2
FPGA implementation,2
Relative and absolute feedback,4
,1
data,1
human genome,2
intellectual property,2
ownership,1
privacy,1
property,1
PRIVACY,1
artist,1
invention,1
mechanics,1
nonsense,1
science,1
White Knight,2
ALICES,1
Offences Crime,2
White Color Offences,3
Socioeconomic offence,2
Fraud,1
Misrepresentation,1
Illegal economic activities,3
Commercial transactions,2
White collar crimes,3
,1
Interfirm networks,2
Trade credit,2
Default propagation,2
AGGREGATE FLUCTUATIONS,2
KNOWLEDGE SPILLOVERS,2
PATENT CITATIONS,2
PROPAGATION,1
CREDIT,1
Economic rights,2
Intellectual property,2
Formal  informal institutions,4
Legal arrangements,2
FDI,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
TRANSACTION COSTS,2
DETERMINANTS,1
IMPACT,1
TRANSITION,1
ECONOMICS,1
DISTANCE,1
SYSTEMS,1
TRADE,1
Corporate entrepreneurship,2
Innovation performance,2
Knowledge plurality,2
Internal focus,2
RD collaboration,2
RESEARCHANDDEVELOPMENT,1
CORPORATE ENTREPRENEURSHIP,2
INNOVATION PERFORMANCE,2
ABSORPTIVECAPACITY,1
KNOWLEDGEBASE,1
MODERATING ROLE,2
EXPLORATION,1
EXPLOITATION,1
SEARCH,1
ORIENTATION,1
Smart textiles,2
conductive tracks,2
cotton,1
additive,1
BYLAYER DEPOSITION,2
PET FABRICS,2
ELECTROLESS,1
FIBERS,1
NANOPARTICLES,1
PARAMETERS,1
,1
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT RIGHTS,2
INTERNATIONALTRADE,1
ECONOMICGROWTH,1
PANELDATA,1
INNOVATION,1
TRIPS,1
innovation,1
social networks,2
catalysts,1
STRONG TIES,2
POWER,1
INVOLVEMENT,1
CENTRALITY,1
BROKERAGE,1
COHESION,1
SEARCH,1
academic entrepreneurship,2
cognitive processes,2
individual motives,2
KNOWLEDGE SPILLOVER THEORY,3
BAYHDOLE ACT,2
SELFEFFICACY,1
UNIVERSITIES GENERATE,2
GROWTH INTENTIONS,2
CAREER REASONS,2
FIRM GROWTH,2
SCIENTISTS,1
IMPACT,1
TECHNOLOGY,1
imidazolines,1
indolines,1
1234tetrahydroisoquinolines,1
alphaadrenoceptors,1
imidazoline receptors,2
hypertensive effect,2
hypotensive effect,2
ALPHA1ADRENERGIC RECEPTORS,2
SELECTIVE REDUCTION,2
IMIDAZOLINE,1
ANTAGONISTS,1
LIGANDS,1
Slogan,1
Registration,1
Cosmetics,1
Lack of distinctive character,4
Failure to state reasons,4
Jurisdiction,1
Board of Appeal,3
Subjective right,2
Generic and descriptive phrase,4
,1
consumption,1
enfreakment,1
extractivism,1
hypervisibility,1
invisibility,1
irreconcilable spaces,2
performance,1
refusal,1
resistance,1
scopophilia,1
voyeurism,1
witnessing,1
,1
,1
ISOFORMSELECTIVE INHIBITORS,2
CROSSCOUPLING REACTIONS,2
ISOZYMEII,1
THERAPEUTIC APPLICATIONS,2
BENZENE SULFONAMIDES,2
IX,1
BINDING,1
POTENT,1
PATENT,1
BENZENESULFONAMIDES,1
,1
SARBANESOXLEY ACT,2
POLITICALLY CONNECTED BOARDS,3
RESEARCHANDDEVELOPMENT,1
INDEPENDENT DIRECTORS,2
FIRM PERFORMANCE,2
FINANCE,1
PRIVATIZATION,1
CORRUPTION,1
GOVERNANCE,1
GOVERNMENT,1
Complex networks,2
scalefree networks,2
accelerated growth,2
Barabasi model,2
KrapivskyRedner model,2
INTERNET,1
Olea europaea,2
phenols extraction,2
hydroxytyrosol,1
olive mill wastewaters,3
Pseudomonas savastanoi pv,3
Savastanoi,1
Agrobacterium tumefaciens,2
antimicrobial activity,2
POLYPHENOLS,1
DERIVATIVES,1
DISEASE,1
MODEL,1
,1
INTERCHANGEABILITY,1
EXTRAPOLATION,1
FDA,1
GUIDANCE,1
ONCOLOGY,1
SCIENCE,1
HURDLES,1
HeRO,1
Central vein stenosis,3
Central vein occlusion,3
Lower limb vascular access,4
HEMODIALYSIS,1
GRAFT,1
EXPERIENCE,1
PLACEMENT,1
OUTCOMES,1
International intellectual property protection,4
TRIPS flexibilities,2
Free trade agreements,3
Inter se modifications,3
Article 41 VCLT,3
Object and purpose,3
Doha Declaration,2
DOHA DECLARATION,2
PUBLICHEALTH,1
WTO,1
AGREEMENT,1
PATENTS,1
innovation intermediaries,2
knowledge spillover,2
national innovation systems,3
regional innovation systems,3
universityindustry collaborations,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGYBASED FIRMS,2
GEOGRAPHIC LOCALIZATION,2
MANUFACTURING EXTENSION,2
ACADEMIC RESEARCH,2
SCIENCE PARKS,2
NETWORKS,1
IMPACT,1
BIOTECHNOLOGY,1
PRODUCTIVITY,1
Diagnosis,1
drug delivery,2
nanosystems,1
nanotherapeutic modules,2
ophthalmics,1
SOLID LIPID NANOPARTICLES,3
DRUGDELIVERY SYSTEM,2
ENDOTHELIAL GROWTHFACTOR,2
ZINCOXIDE NANOPARTICLES,2
INVITRO EVALUATION,2
OCULAR DELIVERY,2
GOLD NANOPARTICLES,2
CYCLOSPORINEA,1
PHYSICOCHEMICAL CHARACTERIZATION,2
CHOROIDAL NEOVASCULARIZATION,2
Intangible Business Capital,3
Intellectual PropertyBased Banking Collateral and Double Cover Binding Method,9
,1
energy saving and emission reduction,5
green patents,2
heavy pollution,2
DID,1
innovation,1
ENVIRONMENTALREGULATIONS,1
PORTER HYPOTHESIS,2
PRODUCTIVITY,1
TRADE,1
FIRMS,1
TECHNOLOGY,1
MANAGEMENT,1
COST,1
,1
COMPETITION,1
Drug innovation,2
drug pricing,2
healthcare spending,2
insurance coverage,2
price elasticity,2
risk,1
,1
complementary components,2
coordination,1
disclosure,1
ecosystems,1
standard setting,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
TRANSACTION COSTS,2
INNOVATION ECOSYSTEMS,2
FIRM,1
PERFORMANCE,1
TECHNOLOGY,1
KNOWLEDGE,1
COMPETITION,1
ECONOMICS,1
ATP 2G,2
Ballast Water Treatment,3
Compliance monitoring,2
Rapid methods,2
Water exchange,2
Bacteria,1
Zooplankton,1
Phytoplankton,1
VIBRIOCHOLERAE,1
ACT Misuse,2
Malaria Case Management in Africa,5
Test Before Treatment,3
Private Medicine Vendors,3
Presumptive Malaria Treatment,3
RAPID DIAGNOSTICTESTS,2
DRUG SHOPS,2
OVERDIAGNOSIS,1
CONSUMPTION,1
REDUCTION,1
TANZANIA,1
UGANDA,1
Cournot markets,2
Optimal pricing policy,3
Patent licensing,2
Nash equilibrium,2
Dominant strategy,2
PATENTS,1
DEMAND,1
FEE,1
Intercity knowledge network,3
technology transfer,2
scientific collaboration,2
proximity and dynamic,3
The Greater Bay Area,4
RESEARCHANDDEVELOPMENT,1
RIVER DELTA,2
ABSORPTIVECAPACITY,1
SPILLOVERS,1
GEOGRAPHY,1
MARKET,1
CHINA,1
COLLABORATION,1
PATENTS,1
POLYCENTRICITY,1
,1
PRIVATESECTOR,1
HEALTH,1
URBAN,1
CARE,1
small intestinal submucosa,3
curdlan,1
dipyridamole,1
small caliber artificial vascular graft,5
SMALLINTESTINAL SUBMUCOSA,2
CONTROLLEDRELEASE,1
DIPYRIDAMOLE,1
HEPARIN,1
ENDOTHELIALIZATION,1
REGENERATION,1
Traditional Chinese medicine,3
Chinese patent drug,3
XueshuanXinmaiNing tablet,2
Coronary heart Disease,3
Network pharmacology,2
Pharmacological mechanism,2
SMOOTHMUSCLE CONTRACTION,2
CARDIOVASCULARDISEASE,1
EPIDEMIOLOGY,1
ANGIOGENESIS,1
DEPRESSION,1
innovation performance,2
national innovative capacity,3
EU investment,2
DETERMINANTS,1
,1
PEPTICULCER DISEASE,2
HELICOBACTERPYLORI,1
GASTRICCANCER,1
INFLAMMATION,1
ACTIVATION,1
COUMARINS,1
CLASSIFICATION,1
ANTIBACTERIAL,1
EXPRESSION,1
ALBIFLORIN,1
,1
IMMUNODEFICIENCYVIRUS TYPE1,2
STEADYSTATE PHARMACOKINETICS,2
PREEXPOSURE PROPHYLAXIS,2
PROTEINBINDING,1
VIRAL LOAD,2
INVIVO,1
INTRACELLULAR CONCENTRATIONS,2
HETEROSEXUAL TRANSMISSION,2
PLUS RITONAVIR,2
INFECTION,1
Zea mays L,3
exPVP,1
heterotic groups,2
SCA,1
GENETIC DIVERSITY,2
DENT CORN,2
GERMPLASM,1
TEMPERATE,1
SELECTION,1
musicians,1
church,1
brotherhoods,1
stipends,1
theatrical music,2
prohibitions,1
,1
Product innovation,2
Trademarks,1
IPO,1
MA,1
RESEARCHANDDEVELOPMENT,1
TAKEOVER DEFENSES,2
MERGERS,1
MARKET,1
GAINS,1
COMPETITION,1
OWNERSHIP,1
PATENTS,1
SEARCH,1
LAW,1
,1
VENTURE CAPITALINVESTMENT,2
PRIVATE EQUITY,2
MORAL HAZARD,2
CONSTRAINTS,1
FIRMS,1
INFORMATION,1
PATENTS,1
MODEL,1
PERFORMANCE,1
GOVERNANCE,1
scaling laws,2
statistical inference,2
allometry,1
,1
,1
,1
,1
UNCERTAINTY,1
,1
VERTICAL INTEGRATION,2
PATENT PROTECTION,2
RIGHTS,1
DETERMINANTS,1
CONTRACTS,1
biologics,1
biosimilars,1
competition,1
drug pricing,2
food and drug law,4
insulin,1
BIOSIMILARS,1
BIOLOGICS,1
KNOWLEDGE,1
PATENTS,1
IMPROVE,1
ANALOGS,1
ACCESS,1
US,1
Corruption,1
Science,1
Justice,1
Moral basis,2
Economy,1
PATENT STATISTICS,2
OCCUPATION,1
Market for trademark,3
trademark licencing,2
trademark classes,2
licensors,1
licensees,1
INTELLECTUAL PROPERTY,2
PROPENSITY SCORE,2
INDICATOR,1
BRAND,1
INNOVATION,1
SERVICES,1
PATENTS,1
LAW,1
monitoring systems,2
receiver stations,2
sturgeons,1
ultrasonic transmitters,2
BEHAVIOR,1
FISH,1
Friendly innovation environment,3
Social and political factors,4
European countries,2
Panel data analysis,3
,1
,1
PATENT HOLDUP,2
CHICAGO,1
Feng Shi Gu Tong capsule,5
Rheumatoid arthritis,2
Systemic pharmacology,2
Targets,1
TUMORNECROSISFACTOR,1
CELL LUNGCANCER,2
NETWORK PHARMACOLOGY,2
GROWTHFACTOR,1
INFLAMMATORY RESPONSE,2
NLRP3 INFLAMMASOME,2
INVITRO,1
PATHWAY,1
TARGET,1
IDENTIFICATION,1
Renouncing care,2
Health inequalities,2
Health system use,3
French Guiana,2
Health insurance coverage,3
RISKFACTORS,1
INEQUALITIES,1
DETERMINANTS,1
,1
CONDUCT,1
New RD employee,3
Dominant RD performer,3
Individualistic culture,2
Collectivistic culture,2
Leadermember relationship,2
LEADERMEMBER EXCHANGE,2
PATERNALISTIC LEADERSHIP,2
TRANSFORMATIONAL LEADERSHIP,2
NATIONAL CULTURE,2
JOBPERFORMANCE,1
SOCIAL NETWORKS,2
MEDIATING ROLE,2
WORK BEHAVIOR,2
LINKING LMX,2
CREATIVITY,1
Supraventricular tachycardia,2
SVT,1
Valsalva maneuver,2
Hiccups,1
Forced inspiratory suction and swallow tool,6
HiccAway,1
VALSALVA MANEUVER,2
catalytic combustion,2
ethylene combustion,2
kinetic modeling,2
palladium,1
postharvest storage,2
VOC,1
PLATINUM NANOPARTICLES,2
TRACE ETHYLENE,2
AUCO3O4 CATALYSTS,2
METHANE OXIDATION,2
WATER,1
SUPPORT,1
ELIMINATION,1
FRUIT,1
CO3O4,1
inverse agonists,2
ligand binding domain,3
orphan nuclear hormone receptors,4
ROR gamma t,3
Xray crystallography,2
RECEPTORGAMMA,1
NUCLEAR RECEPTORS,2
GENEEXPRESSION,1
POTENT,1
CHOLESTEROL,1
ANTAGONISTS,1
INHIBITION,1
MODULATORS,1
DISCOVERY,1
LIGAND,1
Congressional Budget Office CBO,4
Federal Trade Commission FTC,4
Generic Drug User Fee Act GDUFA,6
USFDA,1
Drug Prices,2
MEDICARE,1
Knee osteoartrhitis,2
Patented crystalline glucosamine sulfate,4
Symptomatic slowacting drugs for osteoarthritis,5
Algorithm,1
China,1
NONSTEROIDAL ANTIINFLAMMATORY DRUGS,3
QUALITYOFLIFE,1
CRYSTALLINE GLUCOSAMINE SULFATE,3
CHONDROITIN SULFATE,2
DOUBLEBLIND,1
EUROPEANSOCIETY,1
ECONOMICASPECTS,1
INSULINRESISTANCE,1
ORAL GLUCOSAMINE,2
SETTING TRIALS,2
,1
RANDOMIZED CLINICALTRIAL,2
SCHIZOAFFECTIVE DISORDER,2
ORAL ANTIPSYCHOTICS,2
RELAPSE PREVENTION,2
OPENLABEL,1
RISPERIDONE,1
2NDGENERATION,1
UNCERTAINTY,1
OLANZAPINE,1
FRAMEWORK,1
Growth,1
invasion,1
miR1013p,1
nonsmall cell lung cancer,4
SNHG6,1
COMPETING ENDOGENOUS RNA,3
PROLIFERATION,1
CARCINOMA,1
SENSITIVITY,1
METASTASIS,1
EXPRESSION,1
PATHWAY,1
EMT,1
,1
SMART HOME,2
ALIENATION,1
Access to health technologies,4
equity,1
global health,2
COVID19,1
World Health Organization,3
,1
Waste printed circuit board,4
desoldering,1
TRIZ,1
technology life cycle,3
ideal final result,3
TRIZ,1
STRATEGIES,1
RECOVERY,1
PATENTS,1
TRENDS,1
,1
LEGAL STRATEGY,2
CONFUSION,1
MARIJUANA,1
intellectual property,2
copyright,1
patent,1
plagiarism,1
creative commons,2
DISREGARD INADMISSIBLE EVIDENCE,3
CHILDRENS RESPONSE,2
PIRACY,1
LAW,1
COPYCAT,1
NORMS,1
,1
,1
construct validity,2
innovation measurement,2
multitraits multimethods,2
web content analysis,3
webmining,1
word frequency analysis,3
RESEARCHANDDEVELOPMENT,1
WORLDWIDEWEB,1
TECHNOLOGICALINNOVATION,1
ABSORPTIVECAPACITY,1
STRATEGIC ALLIANCES,2
PRODUCT DEVELOPMENT,2
CONSTRUCTVALIDITY,1
PATENT STATISTICS,2
FIRM PERFORMANCE,2
COLLABORATION,1
Pyrazoles,1
Carbonic anhydrase isoforms I II IX XII,7
Acetazolamide,1
BIOLOGICAL EVALUATION,2
PATENT,1
DISCOVERY,1
CELECOXIB,1
AGENTS,1
Palantir,1
platforms,1
archives,1
public interest,2
accountability,1
surveillance,1
JOURNALISM,1
HISTORY,1
Seigniorage revenue,2
RD,1
Augmented Solow model,3
Instrumental variables estimation,3
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
ECONOMICGROWTH,1
MONEY GROWTH,2
TECHNOLOGY,1
PATENTS,1
Angiosperm,1
Antifouling,1
Biocide,1
Insilico,1
In vitro,2
Lycopersene,1
,1
,1
PATENTS,1
SPR sensors,2
Degradation process of organic luminescent materials,6
Alq3,1
Lanthanides betadiketonate complexes,3
AFM,1
UVA dosimeters,2
BETADIKETONATE COMPLEXES,2
LIGHTEMITTINGDIODES,1
SPECTROSCOPIC ELLIPSOMETRY,2
HIGHLY LUMINESCENT,2
ORGANIC FILMS,2
STABILITY,1
PHOTOSTABILITY,1
METAL,1
Software Product Development,3
Software Startups,2
Success Factors,2
System Dynamics,2
Systems Thinking,2
SUCCESS FACTORS,2
COMPANIES,1
THINKING,1
PATENTS,1
MARKET,1
TIME,1
fragmentation,1
misappropriation,1
services,1
institutional environment,2
outsourcing,1
information and communication technologies,4
RESEARCHANDDEVELOPMENT,1
INTERNATIONAL EXPANSION,2
PROPERTYRIGHTS,1
MULTINATIONALCORPORATION,1
OFFSHORING INNOVATION,2
ORGANIZATIONAL DESIGN,2
ECONOMICGEOGRAPHY,1
TRANSACTION COSTS,2
PATENT PROTECTION,2
ENTRY STRATEGIES,2
Hibiscus mutabilis L,3
Influenza virus,2
Ribonucleoprotein,1
INFLUENZA,1
tax reform,2
corporate income taxation,3
multinational corporations,2
INVESTMENT INCENTIVES,2
POLICY,1
Technological collaboration,2
greenfield investments,2
inward and outward foreign direct investments,6
European regions,2
emerging economies,2
FOREIGN DIRECTINVESTMENT,2
INNOVATION PERFORMANCE,2
MARKET ENTERPRISES,2
FIRMS,1
INTERNATIONALIZATION,1
ACQUISITIONS,1
EXTERNALITIES,1
PRODUCTIVITY,1
ECONOMIES,1
EXPANSION,1
,1
,1
Technology transfer,2
technology acquisition,2
universityindustry,1
university climate readiness,3
firm climate readiness,3
BAYHDOLE ACT,2
KNOWLEDGE TRANSFER,2
TRIPLEHELIX,1
ABSORPTIVECAPACITY,1
RESEARCH CENTERS,2
QUADRUPLEHELIX,1
GOVERNMENT RELATIONS,2
MARKET ORIENTATION,2
INNOVATION SYSTEMS,2
COMMERCIALIZATION,1
mine shaft,2
salt rock,2
leaching,1
,1
,1
ANTIBACTERIAL PEPTIDES,2
GENERATION,1
TOOLS,1
child,1
local hyperthermia,2
periungual warts,2
refractory warts,2
CONDYLOMA ACUMINATA,2
KERATINOCYTES,1
BayhDole Act,2
Bermuda Principles,2
Big science,2
Bioinformatics,1
Biotechnology,1
C elegans,2
Celera Genomics,2
Coproduction,1
Community resource projects,3
Data hoarding,2
Data release,2
Data sharing,2
Databases,1
DNA Databank of Japan DDBJ,5
Department of Energy DOE,4
DNA sequencing,2
Ethical Legal and Social Implications ELSI,6
European Bioinformatics Institute EBI,4
GenBank,1
Gene patenting,2
Genetics,1
Genetic mapping,2
Genome commons,2
Genomics,1
Human Genome Project HGP,4
Intellectual property,2
Medical genetics,2
Model organisms,2
Molecular biology,2
Moral economy of science,4
National Center for Human Genome Research NCHGR,7
National Human Genome Research Institute NHGRI,6
National Institutes of Health NIH,5
Nematode worm,2
Open science,2
Patents,1
Physical mapping,2
Postgenomics,1
Public domain,2
Reference sequence,2
Science policy,2
Wellcome Trust,2
EXPRESSED SEQUENCE TAGS,3
BREASTCANCER SUSCEPTIBILITY,2
COMPREHENSIVE GENETICMAP,2
PROTEOMICS DATA RELEASE,3
DNASEQUENCE,1
MOLECULARBIOLOGY,1
PHYSICAL MAP,2
BIG SCIENCE,2
MENDELIANINHERITANCE,1
INTERNATIONAL SUMMIT,2
COVID19,1
Chinese patent medicines,3
active components,2
common mechanism of action,4
network pharmacology,2
ACE2,1
3CL pro,2
ACUTE LUNG INJURY,3
NETWORK PHARMACOLOGY,2
ANTIVIRAL ACTIVITY,2
OXIDATIVE STRESS,2
ACTIVE COMPOUNDS,2
CORONAVIRUS,1
FLAVONOIDS,1
QUERCETIN,1
INHIBITORS,1
PREDICTION,1
,1
PRICECOMPETITION,1
DRUGS,1
PRESCRIPTION,1
CONSUMERS,1
ENTRY,1
COST,1
ACT,1
,1
ARTICLEIII,1
SUPREMECOURT,1
FEDERALIST SOCIETY,2
POLITICALPARTIES,1
UNITEDSTATES,1
LEGAL REALISM,2
JURISDICTION,1
LAW,1
ADJUDICATION,1
SEPARATION,1
Medical device regulations,3
Hermeneutic heuristic framework,3
Lowresource settings,2
Legal transplantation,2
Frugal regulation,2
Bioethics by design,3
LEGAL,1
HEALTH,1
TECHNOLOGY,1
ETHICS,1
LAW,1
viscoelasticity,1
WPC,1
HDPE,1
composite,1
wood,1
creep,1
thermoplastic,1
flexure,1
power law,2
modeling,1
TIME,1
,1
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
LAW,1
COPYRIGHT,1
PRIVACY,1
RIGHTS,1
CYBERSPACE,1
TRAGEDY,1
PLACE,1
MONEY,1
Scarcity,1
Irresponsibility,1
Intellectual property,2
Neglected tropical diseases,3
Public domain,2
LONGER,1
PRICE,1
LAW,1
,1
REPUTATION,1
LEGAL,1
COMMUNICATION,1
DEFAMATION,1
DISCLOSURE,1
CONTRACTS,1
DISCOURSE,1
CRISIS,1
LAW,1
CRISPRCas9,1
gene editing,2
gene drive,2
EU law,2
ethics,1
risk assessment,2
proceduralism,1
CRISPR,1
TECHNOLOGIES,1
ISSUES,1
PATENTS,1
PATH,1
LAW,1
EU,1
ensemble learning,2
boosting,1
innovation activity,2
location selection,2
innovation subjects,2
influence factors,2
KNOWLEDGE SPILLOVERS,2
LOCALIZATION,1
ORGANIZATION,1
INDUSTRY,1
CITIES,1
Optical character recognition,3
Document analysis,2
Forms processing,2
Semantic web,2
,1
Degassing,1
Aluminium alloys,2
Hydrogen content,2
Electrochemical gas sensor,3
Physical pores,2
Solidification,1
,1
Green technology,2
Firm growth,2
Age,1
Quantile fixed effects,3
QUANTILE REGRESSION,2
FINANCIAL PERFORMANCE,2
EMPIRICALANALYSIS,1
PORTER HYPOTHESIS,2
CLIMATECHANGE,1
GIBRATS LAW,2
INNOVATION,1
PERSISTENCE,1
LEVEL,1
SIZE,1
intellectual property,2
preliminary injunctions,2
permanent injunctions,2
China,1
US,1
equitable approach,2
PATENT HOLDUP,2
opioids,1
race,1
pharmaceutical science,2
neuroscience,1
addiction,1
BRAIN DISEASE,2
ADDICTION,1
DRUG,1
BUPRENORPHINE,1
NEUROBIOLOGY,1
NEUROSCIENCE,1
METHADONE,1
POLITICS,1
MODEL,1
intellectual property rights,3
green technology innovation,3
open innovation,2
human capital,2
sustainable development,2
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTAL INNOVATION,2
EMPIRICALEVIDENCE,1
DEVELOPMENT COOPERATION,2
RIGHTS,1
SPILLOVERS,1
DETERMINANTS,1
ENFORCEMENT,1
STRATEGY,1
LAWS,1
innovation subject,2
topological structure,2
collaborative innovation network,3
social network analysis,3
KNOWLEDGE,1
PERFORMANCE,1
ECOSYSTEMS,1
FIRM,1
,1
TRADE SECRETS,2
PATENTS,1
RISK,1
INNOVATION,1
PRIVACY,1
HEALTH,1
LESSONS,1
QUEST,1
LAW,1
AGE,1
academic promotion,2
academic degree,2
higher education law,3
power structures,2
social order,2
MARKET,1
LAWS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FUNDAMENTAL RIGHTS,2
PATENTS,1
PROTECTION,1
INNOVATION,1
FREEDOM,1
commercialisation,1
donation,1
ethics,1
human biological material,3
law,1
COMMERCIAL USE,2
TISSUE,1
INFORMATION,1
BLOOD,1
Technological Unemployment,2
Skillbiased Technical Change,3
Labor Market Polarization,3
Robots,1
Artificial Intelligence,2
Robotics,1
Okuns Law,2
TECHNOLOGICALCHANGE,1
JOB POLARIZATION,2
EMPLOYMENT,1
INNOVATION,1
Seed commons,2
Regime complex,2
Norm interplay,2
Biodiversity governance,2
Intellectual property rights,3
Access and benefit sharing,4
GLOBAL GOVERNANCE,2
GENETICRESOURCES,1
FOOD,1
AGRICULTURE,1
ACCESS,1
FRAGMENTATION,1
ORGANIZATION,1
NETWORKS,1
PROTOCOL,1
COMPLEX,1
,1
,1
Polypharmacology,1
systems biology,2
docking,1
computer aided drug design,4
natural language processing,3
FDAAPPROVED DRUGS,2
MOLECULARDYNAMICS SIMULATIONS,2
PROTEINCOUPLED RECEPTOR,2
ELECTROSTATIC SIMILARITY,2
MULTITARGETQSAR,1
DUAL INHIBITORS,2
BINDINGSITE,1
IDENTIFICATION,1
PREDICTION,1
NETWORK,1
Family,1
Samesex,1
Social sciences,2
Profiles,1
University students,2
CONTACT HYPOTHESIS,2
OPTIMAL NUMBER,2
ATTITUDES,1
SCALE,1
PREJUDICE,1
MARRIAGE,1
LAWS,1
GAY,1
,1
INNOVATION,1
Knowledge of Malaria,3
Treatment Practices,2
Qualitative Study,2
Enugu State,2
Nigeria,1
PATENT MEDICINE VENDORS,3
RURALAREAS,1
MANAGEMENT,1
PROVIDERS,1
SERVICES,1
PATTERN,1
,1
EXPRESSION,1
acute renal failure,3
clinical pharmacology,2
clinical trials,2
neonatal intensive  critical care,5
neonatology,1
protocols  guidelines,3
RISKFACTORS,1
CLOSURE,1
IBUPROFEN,1
HEMORRHAGE,1
RESISTANT,1
Selfexpanding nitinol stent,3
Frictional behaviour law,3
Xray tomography,2
Topographical analysis,2
Perssons contact theory,3
ALLOYS,1
MODEL,1
,1
,1
Economic ideas,2
science logic,2
market logic,2
life science innovation,3
RESEARCHANDDEVELOPMENT,1
MANAGEMENT EVIDENCE,2
VALUE RELEVANCE,2
EARNINGS,1
CAPITALIZATION,1
DETERMINANTS,1
MODELS,1
CHOICE,1
IMPACT,1
SIZE,1
Digital economy,2
Innovation output,2
Regional innovation system,3
Innovation cooperation,2
R  D element flow,5
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
PATENTSTATISTICS,1
KNOWLEDGE BASES,2
GROWTH,1
INTERNATIONALIZATION,1
TRANSITIONS,1
MIGRATION,1
INTERNET,1
INDUSTRY,1
Latecomer firms,2
catchup and surpassing strategies,4
strategic paths,2
market insights,2
technology buildup,2
INNOVATION CAPABILITY,2
ORIENTATION,1
PATENTS,1
TAIWAN,1
MODEL,1
Iron overload,2
ferroportin inhibitors,2
hepcidin mimicking,2
agonists,1
polymorphs,1
hemochromatosis,1
thalassemia,1
HEPCIDIN,1
Carbonic anhydrase,2
Quinazoline,1
Sulfonamides,1
Mercaptan,1
Tumorassociated isoforms,2
LOWERING AROMATICHETEROCYCLIC SULFONAMIDES,3
ISOZYMEII,1
135TRIAZINE MOIETIES,2
PATHOGENIC BACTERIUM,2
SELECTIVE INHIBITORS,2
ZINCCOMPLEXES,1
DRUG TARGETS,2
SCHIFFBASES,1
PATENT,1
IX,1
coverage gap,2
generic entry,2
health insurance,2
Medicare Part D,3
prescription drugs,2
BEHAVIOR,1
DEMAND,1
DLEU2,1
gastric cancer,2
miR30a5p,1
proliferation,1
INHIBITS CELLPROLIFERATION,2
TUMORSUPPRESSOR,1
METASTASIS,1
INVASION,1
OR in research and development,5
Licensing,1
Information disclosure,2
Vertical separation,2
Asymmetric information,2
Real options,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PUBLICATION,2
SIGNALING GAMES,2
SPILLOVERS,1
INNOVATION,1
INCENTIVES,1
DIFFUSION,1
ROYALTIES,1
MARKET,1
citizenship,1
clothing,1
gender,1
invention,1
secret,1
sport,1
HISTORY,1
NanoCrySP,1
Nanocrystals,1
Solid dispersion,2
Bottomup technology,2
Formulation development,2
POORLY SOLUBLE DRUGS,3
SOLID DISPERSION,2
DELIVERYSYSTEM,1
FORMULATION,1
CRYSTALLIZATION,1
BIOAVAILABILITY,1
SOLUBILITY,1
ENHANCEMENT,1
DISSOLUTION,1
NUCLEATION,1
Cucurbita pepo,2
fungicides,1
resistance inducers,2
biocontrol agents,2
integrated control,2
RESISTANCE INDUCERS,2
VEGETABLE CROPS,2
PEPPER PLANTS,2
DOWNY MILDEW,2
BLIGHT,1
MANAGEMENT,1
FUNGICIDES,1
PHOSPHITE,1
DISEASES,1
Innovation,1
Coinventor cooperation,2
International collaboration,2
Developing countries,2
IPR,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
POLITICAL INSTABILITY,2
PATENT RIGHTS,2
PROTECTION,1
KNOWLEDGE,1
DETERMINANTS,1
EVOLUTION,1
NETWORKS,1
INTERNATIONALIZATION,1
Biosimilar,1
Switching,1
Interchangeable,1
Immunogenicity,1
Reference product,2
Biologics Price Competition and Innovation Act,6
DOUBLEBLIND,1
INFLIXIMAB,1
CTP13,1
Blechum pyramidatum,2
alphaGlucosidase inhibition,2
Kinetic analysis,2
Docking analysis,2
PLANTS,1
Acetylcholinesterase,1
reactivators,1
organophosphate,1
nerve agents,2
catalytic bioscavengers,2
methods of detection,3
identification,1
PHENOXYALKYL PYRIDINIUM OXIMES,3
NERVE AGENT,2
CHOLINESTERASE REACTIVATORS,2
POTENT REACTIVATOR,2
INHIBITORS,1
SITE,1
EFFICACY,1
SARIN,1
TABUN,1
BIOMARKERS,1
drones,1
unmanned,1
speculation,1
futures,1
airspace,1
GOVERNANCE,1
FUTURES,1
Imitation innovation,2
LotkaVolterra system,2
intellectual property,2
dynamic uncertainty,2
real option,2
DYNAMIC COMPETITION ANALYSIS,3
LOTKAVOLTERRA EQUATIONS,2
PATENT LIFE,2
DIFFUSION,1
MARKET,1
OPTIONS,1
POLICY,1
industrial enterprises,2
knowhow,1
acquisition and loss of knowledge,5
,1
Antioxidant,1
Bioavailability,1
Fisetin,1
Flavonoid,1
Novel drug delivery systems,4
DIETARY FLAVONOID FISETIN,3
OXIDATIVE STRESS,2
IMPROVES BIOAVAILABILITY,2
AIRWAY INFLAMMATION,2
BIOACTIVE FLAVONOL,2
POLYMERIC MICELLES,2
DELIVERYSYSTEMS,1
INVIVO,1
KAPPAB,1
NEUROINFLAMMATION,1
Biosimilari,1
costi,1
antiTNF,1
BUDGET IMPACT,2
INFLIXIMAB,1
Longterm controlled release,3
Microencapsulation,1
Polylacticcoglycolic acid microspheres,3
Peptide,1
CONTROLLEDRELEASE,1
PLGA MICROSPHERES,2
PROTEIN INSTABILITY,2
LEUPROLIDE ACETATE,2
POLYMER MICROBEADS,2
MICROCLIMATE PH,2
PEPTIDE,1
OCTREOTIDE,1
ACYLATION,1
ACID,1
,1
SUSTAINED VIROLOGICAL RESPONSE,3
GENOTYPE 1,2
RECIPIENTS,1
HCV,1
THERAPY,1
EFFICACY,1
LIVER,1
SAFETY,1
SOFOSBUVIR,1
SURVIVAL,1
Wenxin Keli,2
Systems pharmacology,2
Linoleic acid,2
Platelet activation,2
Thrombosis,1
ATRIALFIBRILLATION,1
ARTERIAL THROMBOSIS,2
CEREBRALISCHEMIA,1
VIRUSINFECTION,1
WORKING GROUP,2
METAANALYSIS,1
HEMOSTASIS,1
MECHANISMS,1
THERAPY,1
EXTRACT,1
Traderelated aspects of intellectual property rights TRIPS,7
intellectual property rights and patents,5
annual originator and generic HIV drug cost estimates,8
lowand middleincome countries,3
INTELLECTUAL PROPERTYRIGHTS,2
HIV,1
ACCESS,1
Prescription drugs,2
Generic drugs,2
Pharmaceutical economics,2
Economic competition,2
Market exclusivity,2
ACT,1
Green building technology,3
Collaborative innovation,2
Social network analysis,3
Spatialtemporal evolution,2
Construction industry,2
RESEARCHANDDEVELOPMENT,1
DECOMPOSITION ANALYSIS,2
SOCIAL NETWORKS,2
EVOLUTION,1
ENERGY,1
CENTRALITY,1
MANAGEMENT,1
TRENDS,1
POLICY,1
PERSPECTIVE,1
Psychedelics,1
policy,1
community,1
preferences,1
communitybased research,2
PSILOCYBIN,1
,1
,1
,1
NATURAL BIOACTIVE COMPOUNDS,3
AMARA L SIMAROUBACEAE,3
ANTIMALARIAL ACTIVITY,2
MULTIDISCIPLINARY APPROACH,2
FRENCHGUIANA,1
SIMALIKALACTONED,1
INDIANS,1
BOLIVIA,1
SEARCH,1
RESOURCES,1
IP strategy,2
Sustainable manufacturing,2
Business strategy,2
,1
trade secrets,2
intellectual property rights,3
unfair competition,2
misappropriation,1
disclosure,1
use,1
felony,1
Spanish legal system,3
,1
Intellectual property rights,3
Copyright,1
Digital information,2
File sharing,2
Social norms,2
Nirvana fallacy,2
LAW,1
PIRACY,1
RIGHTS,1
LABOR,1
,1
SOIL,1
Intellectual Property Rights,3
trademarks,1
reputation,1
innovation,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
SERVICE MARKS,2
BRAND,1
PERFORMANCE,1
INDICATOR,1
PATENTS,1
LAW,1
,1
,1
,1
ORGANIZATION,1
SIMILARITY,1
NAVIGATION,1
Public private partnership,3
Emerging technologies,2
Nanotechnology,1
Diseases of poverty,3
Inclusive innovation,2
PERSPECTIVES,1
HEALTH,1
,1
PATENTS,1
crowding out,2
environmental entrepreneurship,2
intergenerational fairness,2
sustainability,1
PROPERTYRIGHTS,1
CLIMATE POLICY,2
ENTREPRENEURSHIP,1
INNOVATION,1
MARKET,1
ECONOMICS,1
PATENTS,1
LAW,1
DETERMINANTS,1
CAPABILITIES,1
knowledgebased network,2
dual innovation,2
evolution,1
TECHNOLOGICAL DIVERSIFICATION,2
COLLABORATION NETWORKS,2
PERFORMANCE,1
COHERENCE,1
FIRMS,1
inventorship,1
acquire legal skills,3
acquire managerial skills,3
educate technology students,3
entrepreneurship,1
expand curriculum in Technical Universities,5
undergraduate legal and managerial course,5
,1
Legal catchphrases,2
Catchphrase extraction,2
Keyphrase extraction,2
Legal analytics,2
Sequence tagging,2
BiGRU,1
CRF,1
Doc2Vec,1
QUERY EXPANSION,2
PATENT,1
carbon intensity,2
the heavy industry,3
quantile regression analysis,3
ENVIRONMENTALREGULATION,1
EMISSIONS,1
Employment growth,2
Intellectual property rights,3
Innovative youngsters,2
Transition economies,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
FIRM GROWTH,2
GIBRATS LAW,2
SIZE,1
BEHAVIOR,1
AGE,1
,1
PROPERTYRIGHTS,1
TAKINGS,1
COMPENSATION,1
FOUNDATIONS,1
AND gate,2
double mesoscopic ring,3
transmission probability,2
IV characteristic,2
shot noise,2
magnetic flux,2
quantum interference effect,3
ELECTRONTRANSPORT,1
QUANTUMDOT,1
NOISE,1
wind turbine,2
Wall of Wind,3
wind load,2
lowrise building,2
wind energy,2
roof uplift,2
hazard mitigation,2
BUILDINGS,1
PRESSURES,1
PARAPETS,1
DAMAGE,1
academic citizenship,2
research performance,2
research excellence,2
service,1
multilevel model,2
moderation,1
RESEARCH PRODUCTIVITY,2
UNIVERSITIES EVIDENCE,2
SCIENTIFIC TEAMS,2
RESEARCH QUALITY,2
UK,1
KNOWLEDGE,1
GENDER,1
ACCOUNTABILITY,1
DETERMINANTS,1
CITIZENSHIP,1
,1
DEMONSTRATING PROMISE,2
PARTICULATE CONTROL,2
FINE,1
PERFORMANCE,1
urban and regional economic development,5
economic growth and development,4
policy and applications,3
agglomeration and externalities,3
urban and regional spatial structure,5
spatial structure,2
spatial diffusion and innovation,4
other spatial structure,3
network analysis,2
spatial analysis,2
methods,1
spatial statistics and spatial econometrics,5
EMPIRICALEVIDENCE,1
KNOWLEDGE FLOWS,2
COOPERATION,1
PROXIMITY,1
NETWORKS,1
Machine Learning,2
Social Network Analysis,3
Bibliometrics,1
Coword analysis,2
Intellectual Structure,2
,1
Innovation,1
Inventor,1
Patents,1
Supercoiled DNA,2
Gene therapy,2
Structural biology,2
Minicircle DNA,2
Minivector DNA,2
Twister Biotech Inc,3
SITESPECIFIC RECOMBINATION,2
TRANSGENE EXPRESSION,2
TOPOISOMERASEIV,1
CRYSTALSTRUCTURE,1
LINKING NUMBER,2
WRITHE,1
PURIFICATION,1
CYTOTOXICITY,1
REPLICATION,1
SEGREGATION,1
hydrophilic matrix tablets,3
tolcapone,1
sustained release,2
particle size,2
SeDeM diagram,2
direct compression,2
EXPERTSYSTEM,1
DRUG,1
PREFORMULATION,1
OPTIMIZATION,1
PARAMETERS,1
VARIABLES,1
Graph neural networks,3
citation graphs,2
graph data augmentation,3
implicit and explicit neighbors,4
,1
Patents,1
Migration,1
Technological diversification,2
Relatedness,1
Europe,1
SKILLED WORKERS,2
PATH DEPENDENCE,2
KNOWLEDGE,1
INNOVATION,1
IMMIGRATION,1
SPILLOVERS,1
RELATEDNESS,1
MIGRATION,1
NETWORKS,1
MOBILITY,1
hereditary breast cancer,3
genetic testing,2
genetic service delivery,3
BRCA,1
genetic knowledge,2
INFORMATION NONDISCRIMINATION ACT,3
RISKASSESSMENT,1
AMERICAN SOCIETY,2
EDUCATIONALNEEDS,1
OVARIANCANCER,1
PHYSICIANS,1
IMPACT,1
RECOMMENDATIONS,1
PRACTITIONERS,1
AWARENESS,1
,1
FIRM PROFITABILITY,2
PERFORMANCE,1
REFORMS,1
Farnesoid X receptor,3
enterohepatic diseases,2
metabolic diseases,2
agonists,1
antagonists,1
FARNESOIDXRECEPTOR,1
SALT EXPORT PUMP,3
AMELIORATES PORTALHYPERTENSION,2
PRIMARY BILIARY CHOLANGITIS,3
ORPHAN NUCLEAR RECEPTOR,3
HEPATIC STELLATE CELLS,3
BILEACID,1
OBETICHOLIC ACID,2
LIVER FIBROSIS,2
ACTIVATED RECEPTOR,2
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT LITIGATION,2
STRATEGIC MANAGEMENT,2
CHINA,1
INNOVATION,1
APPROPRIABILITY,1
DETERMINANTS,1
SETTLEMENT,1
DECISIONS,1
,1
,1
Industrial hydrodynamic separator,3
Multiobjective Bayesian shape optimization,4
Multisurrogate parallelization,2
Voronoi failure penalization,3
EulerianLagrangian oneway coupling,3
uRANS,1
komega SST,2
RESPONSESURFACE METHODOLOGY,2
ALGORITHM,1
Automatic assembly,2
Assembly sequence planning,3
Assembly,1
Exploded view,2
Geometrical feasibility,2
Assembly sequence generation,3
Exploded view generation,3
Assembly automation,2
ALGORITHM,1
SYSTEM,1
PARTS,1
Farmers rights,2
Intellectual property rights,3
Sui generis legislations,3
Coexistence of legal regimes,4
Legal positivism,2
Plant genetic resources,3
Cultivated diversity,2
Equity,1
PLANT BREEDERS RIGHTS,3
Technology spillovers,2
Multilevel network,2
Collaborative innovation,2
Moderating effect,2
Innovation output,2
FOREIGN DIRECTINVESTMENT,2
DEVELOPINGCOUNTRIES,1
INTERACTION TERMS,2
IMPACT,1
KNOWLEDGE,1
FDI,1
DETERMINANTS,1
LOCALIZATION,1
PRODUCTIVITY,1
CAPABILITIES,1
Commercialization of research,3
Institutional framework,2
Technology transfer offices,3
University spinoffs,2
Venure capital,2
BAYHDOLE ACT,2
TECHNOLOGYTRANSFER,1
ENTREPRENEURIAL COMPETENCES,2
ORGANIZATIONALCHANGE,1
PATENTING ACTIVITY,2
COMMERCIALIZATION,1
PERFORMANCE,1
KNOWLEDGE,1
INDUSTRY,1
CREATION,1
Intellectual property,2
Patents,1
Generic medicines,2
Compulsory licencing,2
TRIPS flexibilities,2
Trade agreements,2
TRIPSplus,1
Hepatitis C,2
Directacting antivirals,2
MEDICINES,1
ACCESS,1
HEALTH,1
Drilling Equipment,2
Circulation Sub,2
Hydraulic Modeling,2
Bypass Valve,2
Drilling Mudlosses,2
Upstream Oil and Gas,4
OIL,1
sulfamoylphenyl,1
sulfocoumarin carboxamides,2
cancer,1
carbonic anhydrase,2
inhibitors,1
glaucoma,1
RENALCELL CARCINOMA,2
CEREBRALBLOODFLOW,1
EXTRACELLULAR PH,2
CANCER CELLS,2
ISOZYMEII,1
SULFONAMIDES,1
PATENT,1
COUMARINS,1
MOIETIES,1
GROWTH,1
Periodic table,2
Werner,1
Pfeiffer,1
Mendeleev,1
3D helical periodic table,4
Elementouch,1
Janet,1
Schaltenbrand,1
Nuclear periodic table,3
Nucletouch,1
Magic number,2
Shell model,2
MADELUNG RULE,2
CONFIGURATIONS,1
,1
ACID,1
IDENTIFICATION,1
AGONIST,1
PHARMACOLOGY,1
ACTIVATION,1
POTENT,1
DISCOVERY,1
RESIDUES,1
MODEL,1
,1
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
PATENT,1
COPYRIGHT,1
RIGHTS,1
LAW,1
PRIVATE,1
EVOLUTION,1
POLICY,1
GOVERNANCE,1
Trade Mark,2
ThreeDimensional Shape,2
NonTraditional Mark,2
Distinctiveness,1
Nature of Goods,3
Technical Result,2
EU Trade Mark Directive,4
EU Trade Mark Regulation,4
The Court of Justice of the European Union Case Law,10
,1
Enolase1,1
Antibody,1
Plasmin,1
Migration,1
Fibroblasts,1
Monocytes,1
Fibrosis,1
ALPHAENOLASE,1
PLASMINOGEN,1
ACTIVATION,1
MONOCYTES,1
MACROPHAGES,1
TARGETS,1
RECRUITMENT,1
EXPRESSION,1
CYTOKINES,1
ACID,1
,1
PRESUMED PARADOXICAL EMBOLISM,3
CRYPTOGENIC STROKE PATIENTS,3
TRANSCATHETER CLOSURE,2
MEDICAL THERAPY,2
TRANSESOPHAGEAL ECHOCARDIOGRAPHY,2
TRANSCRANIAL DOPPLER,2
RESIDUAL SHUNT,2
RECURRENT,1
PREVENTION,1
EVENTS,1
cardiomegaly,1
neoplasms,1
peripheral neuropathies,2
semicarbazones,1
thiosemicarbazones,1
CHOLINERGIC SYSTEM,2
DISEASE,1
USP9X,1
compulsory licensing,2
flexibilities,1
patent,1
TRIPS,1
TRIPSplus,1
,1
eCigarette,1
Product innovation,2
Process innovation,2
AU Model,2
Inverse AU model,3
ORGANIZATIONAL INNOVATION,2
tram,1
low floor,2
independently rotating wheels,3
drive solution,2
FIELDORIENTED CONTROL,2
DC DRIVE,2
SIMULATION,1
VEHICLES,1
SAFETY,1
MODEL,1
Access to medicines,3
availability,1
affordability,1
antimalarial commodities,2
pharmaceutical policy,2
MEDICINES,1
PRICE,1
Budget impact analysis,3
Network MetaAnalysis,2
Semiannual formulation,2
Paliperidone palmitate,2
Adherence,1
ORAL ANTIPSYCHOTICS,2
METAANALYSIS,1
ADHERENCE,1
Antitrust,1
enforcement,1
competition policy,2
platforms,1
technology,1
innovation,1
nonprice competition,2
innovation competition,2
market structure,2
competitive conduct,2
horizontal mergers,2
intellectual property,2
patents,1
technology standards,2
DISCRETECHOICE MODELS,2
RESEARCHANDDEVELOPMENT,1
MARKETSTRUCTURE,1
PRODUCT DIFFERENTIATION,2
INTELLECTUAL PROPERTY,2
PRICECOMPETITION,1
REVEALED PREFERENCE,2
CONSUMER WELFARE,2
TECHNOLOGY,1
ADOPTION,1
Qifenggubiao granules,2
metabonomics,1
network pharmacology,2
cyclophosphamide,1
immunosuppression,1
POTENTIAL TRP CHANNELS,3
COUGH,1
Syndromic short stature,3
Triowholeexome sequencing,2
Wholegenome lowcoverage sequencing,3
FGFR3,1
GNAS,1
TRPS1,1
MEDICAL GENETICS,2
AMERICANCOLLEGE,1
PHENOTYPIC SPECTRUM,2
CHILDREN,1
THERAPY,1
GUIDELINES,1
STANDARDS,1
MICROARRAY,1
MUTATIONS,1
VARIANTS,1
worm gear drive,3
machining,1
undercutting,1
mathematical conditions,2
SIMULATION,1
Credibility thesis,2
property rights and institutions,4
development theory,2
endogeneity,1
institutional form and function,4
,1
Feral dogs,2
Endoparasitic fauna,2
Echinococcus granulosus sensu lato,4
Wild cycle,2
Tierra del Fuego,3
Argentina,1
CYSTIC ECHINOCOCCOSIS,2
EPIDEMIOLOGIC SURVEILLANCE,2
HYDATID CONTROL,2
SOUTHAMERICA,1
DOMESTIC DOGS,2
SHEEP STRAIN,2
WILD DOGS,2
DIAGNOSIS,1
PARASITES,1
PATENT,1
Economic growth pressure,3
Green technology innovation,3
Moderating effect,2
Government support,2
Environmental regulation,2
Financial development,2
FISCAL DECENTRALIZATION,2
PERSPECTIVE,1
EFFICIENCY,1
COMPETITIVENESS,1
SUBSIDIES,1
CHINA,1
LAW,1
Regional innovation performance,3
intellectual property protection intensity,4
RD investment,2
human resource investment,3
Panel threshold model,3
DEVELOPMENT INTENSITY,2
LEVEL,1
STRATEGIES,1
PATENTS,1
RIGHTS,1
LAW,1
generic laws,2
NPS,1
NpSG,1
structure elucidation,2
INVITRO,1
METABOLISM,1
VIVO,1
Regional development,2
capital turnover,2
employees,1
innovative startups,2
Italian macroregions,2
RESEARCHANDDEVELOPMENT,1
SMALL FIRMS,2
EMPIRICALEVIDENCE,1
JOB CREATION,2
POLICY,1
ENTREPRENEURSHIP,1
KNOWLEDGE,1
GROWTH,1
SMES,1
TECHNOLOGY,1
US Patent 9567112 B1,4
control moment gyroscope,3
actuators,1
attitude control,2
guidance,1
navigation and control,3
spacecraft dynamics,2
skewed pyramid,2
CONTROL MOMENT GYROSCOPES,3
FEEDBACKCONTROL,1
STEERING LAW,2
Trademark,1
Frims market value,3
Firsttofile,1
Intellectual property rightIPR,3
China,1
Energing economy,2
INTELLECTUAL PROPERTY,2
INNOVATION,1
LAW,1
PRODUCT,1
ISOMORPHISM,1
PERFORMANCE,1
INVESTMENT,1
PROTECTION,1
ECONOMICS,1
STRATEGY,1
Hiccups,1
Bernoullis principle,2
forced inspiratory suction and swallow tool,6
home remedies,2
HiccAway,1
Valsalva,1
Supraventricular Tachycardia,2
SUPRAVENTRICULAR TACHYCARDIA,2
HICCUPS,1
PRESSURE,1
,1
,1
air pollution emissions,3
environmental protection,2
intellectual property rights IPR,4
NorthSouth trade,2
TRIPs agreement,2
INTELLECTUAL PROPERTYRIGHTS,2
ENVIRONMENTAL KUZNETS CURVE,3
STRONGER PATENTS INDUCE,3
EMPIRICALEVIDENCE,1
PROTECTION,1
TECHNOLOGY,1
INNOVATION,1
DIFFUSION,1
TRADE,1
LAW,1
,1
,1
Pesticides,1
Coformulants,1
Policy,1
Coformulant secrecy,2
Ecotoxicology,1
,1
access and benefit sharing,4
farmers rights,2
Nigeria,1
plant breeders rights,3
plant variety protection,3
TRIPS,1
FARMERS RIGHTS,2
COMMUNITY,1
LEGAL,1
Access to medicines,3
Global health,2
Intellectual property rights,3
PUBLICHEALTH,1
PHARMACEUTICALINDUSTRY,1
TRADE AGREEMENTS,2
GLOBAL POLITICS,2
TRIPS,1
RIGHTS,1
PATENTS,1
PROTECTION,1
DIFFUSION,1
STRATEGY,1
Broadband,1
Common carrier,2
Deregulation,1
Federalism,1
Internet protocol,2
Monopoly,1
Path dependence,2
Policy experimentation,2
Public relations,2
Public utility,2
EVOLUTION,1
Rasagiline,1
In situ gel,3
Sustained release,2
Neuroprotection,1
Medication compliance,2
PARKINSONSDISEASE,1
SUSTAINEDRELEASE,1
INITIALBURST,1
IMPLANTS,1
POLYDLLACTIDE,1
NEUROPROTECTION,1
MICROSPHERES,1
DEGRADATION,1
,1
REAGENTS,1
ACTIVATION,1
ADDUCT,1
EARTHS,1
BOND,1
cervical cancer,2
nelfinavir,1
cisplatin resistance,2
autophagy,1
responsible medicine,2
HIV PROTEASE INHIBITOR,3
HUMANIMMUNODEFICIENCYVIRUS,1
ACTIVE ANTIRETROVIRAL THERAPY,3
ENDOPLASMICRETICULUM STRESS,2
PELVIC RADIATIONTHERAPY,2
PHASEI,1
INTRAEPITHELIAL NEOPLASIA,2
CONCURRENT CHEMOTHERAPY,2
CISPLATIN,1
AUTOPHAGY,1
Anthelminthics,1
drug discovery,2
drug repurposing,2
Pandemic Response Box,3
Schistosoma mansoni,2
schistosomiasis,1
SCHISTOSOMAMANSONI,1
PRAZIQUANTEL,1
SENSITIVITY,1
research and innovation,3
innovation efficiency,2
computational intelligence,2
data envelopment analysis DEA,4
European Union,2
R  I policy,4
ROAD SAFETY,2
DEA,1
DETERMINANTS,1
COUNTRIES,1
CXCR3 chemokines,2
autoimmune thyroiditis,2
graves disease and ophthalmopathy,4
inflammatory myopathies,2
rheumatoid arthritis,2
type 1 diabetes,3
MULTIPLESCLEROSIS PATIENTS,2
ACTIVE GRAVESDISEASE,2
AUTOIMMUNE THYROIDDISORDERS,2
CXCL10 SERUMLEVELS,2
NFKAPPAB,1
IFNGAMMA,1
TCELLS,1
RECEPTOR CXCR3,2
ULCERATIVECOLITIS,1
INFLAMMATORY RESPONSE,2
Cluster,1
Technology park,2
Knowledge management,2
Cooperation,1
BUSINESS,1
NETWORKS,1
BIOTECHNOLOGY,1
COLLABORATION,1
COOPERATION,1
PATENTS,1
FIRMS,1
invitro study,2
cancer cells,2
nanoemulsion,1
cisplatin,1
anticancer effects,2
TRIOXIDEMEDIATED APOPTOSIS,2
MULTIDRUGRESISTANCE,1
GLUTATHIONE METABOLISM,2
DOCOSAHEXAENOIC ACID,2
DRUGRESISTANCE,1
LUNGCANCER,1
DNAREPAIR,1
NANOPARTICLES,1
EXPRESSION,1
SURVIVAL,1
,1
,1
Mangiferin,1
Berberin HCl,2
Simultaneous equation method,3
ICH guidelines,2
Quality control,2
,1
Computeraided drug discovery,3
Inducedfit docking,2
Molecular dynamics simulation,3
Neuropathic pain,2
TRPA1 modulators,2
FLAT antagonists,2
MOLECULAR DOCKING,2
CALCIUMCHANNELS,1
RECEPTOR,1
DYNAMICS,1
INHIBITORS,1
DESIGN,1
TARGET,1
MODEL,1
RAT,1
CB2,1
academic entrepreneurship,2
conjoint analysis,2
policy makers,2
spinoff,1
technology transfer,2
BAYHDOLE ACT,2
UNIVERSITY TECHNOLOGY,2
ENTREPRENEURIAL INTENTIONS,2
PATENT QUALITY,2
COMMERCIALIZATION,1
SCIENTISTS,1
MOTIVATIONS,1
COMPANIES,1
VENTURES,1
SCIENCE,1
Cardiopulmonary nematodes,2
Felids,1
Romania,1
Troglostrongylus,1
Wildlife,1
LYNX LYNXLYNX,2
TROGLOSTRONGYLUSBREVIOR,1
AELUROSTRONGYLUSABSTRUSUS,1
STRONGYLIDA CRENOSOMATIDAE,2
ANGIOSTRONGYLUSCHABAUDI,1
SILVESTRISSILVESTRIS,1
EURASIAN LYNX,2
DIROFILARIAIMMITIS,1
LUNGWORM INFECTIONS,2
HELMINTH FAUNA,2
Bioavailability,1
biodegradable polymer,2
chitosan,1
herbal bioactives,2
nanoparticles,1
novel drug delivery system,4
DRUGDELIVERY,1
TRIPOLYPHOSPHATE NANOPARTICLES,2
ANTIOXIDANT ACTIVITY,2
ACID,1
OPTIMIZATION,1
QUERCETIN,1
NANOTECHNOLOGY,1
ENCAPSULATION,1
FORMULATION,1
PROPERTY,1
innovation,1
new product development,3
project management,2
RD,1
small business,2
EMPIRICALANALYSIS,1
TECHNOLOGICAL DIVERSIFICATION,2
PRODUCT,1
INNOVATION,1
PERFORMANCE,1
COMMERCIALIZATION,1
UNCERTAINTY,1
PORTFOLIO,1
SBIR,1
RECOMBINATION,1
Encapsulated living membrane,3
Electroencapsulated living membrane bioreactor,4
Microbial growth,2
Electrochemical process,2
Fouling mitigation,2
DENITRIFYING KLEBSIELLAPNEUMONIAE,2
ACTIVATEDSLUDGE,1
PHOSPHORUS REMOVAL,2
SPNOV,1
HETEROTROPHIC NITRIFICATION,2
SIMULTANEOUS NITROGEN,2
EMENDED DESCRIPTION,2
DIVERSITY,1
BACTERIA,1
VARIICOLA,1
buprenorphine,1
children,1
intoxication,1
METHADONE,1
Biofouling,1
Antifouling,1
Marine pollution,2
Bioaccumulation,1
Degradation,1
Coatings,1
Xanthones,1
Organic synthesis,2
PAINT BOOSTER BIOCIDES,3
SYNTHETIC ANALOGS,2
IRGAROL1051,1
Research linkages triple helix herbal medicine Taiwan,7
TRIPLEHELIX,1
INNOVATION,1
PERSPECTIVE,1
SCIENCE,1
PATENTS,1
Standards Development Organizations SDO,4
Governance,1
Committee chair selection,3
Collaborative innovation,2
Social capital,2
SETTING ORGANIZATIONS,2
EMPIRICALEVIDENCE,1
INNOVATION,1
GOVERNANCE,1
COMMITTEES,1
CONSORTIA,1
PATENTS,1
IMPACT,1
Fenugreek Trigonella foenumgraecum seeds,4
T2D,1
Clinical Investigation,2
Fasting Glucose,2
PostPrandial Glucose,2
HbA1c,1
Antihyperglycemic therapeutic,2
PATHOGENESIS,1
SAPONINS,1
Cyclodextrin,1
gold,1
immune system,2
liposomes,1
nanoparticles,1
polymer,1
SOLID LIPID NANOPARTICLES,3
EXPERIMENTAL AUTOIMMUNE UVEORETINITIS,3
ADJUVANTINDUCED ARTHRITIS,2
REPEATEDDOSE TOXICITY,2
DRUGDELIVERY,1
GOLD NANOPARTICLES,2
BETACYCLODEXTRIN,1
POLYMERIC NANOPARTICLES,2
ACID NANOPARTICLES,2
ANTIINFLAMMATORY ACTIVITY,2
,1
BAYHDOLE ACT,2
DRUG DISCOVERY,2
UNITEDSTATES,1
HEALTH,1
ACCOUNTABILITY,1
EXCLUSIVITY,1
PRICES,1
COST,1
INDUSTRY,1
BIOTECH,1
PrEP,1
modeling,1
PKPD,1
translation,1
repurposing,1
resourceconstrained,1
costefficient,1
PEP,1
NONNUCLEOSIDE REVERSETRANSCRIPTASE,2
ANTIRETROVIRAL DRUG CONCENTRATIONS,3
RESPONSE CURVE SLOPE,3
PREEXPOSURE PROPHYLAXIS,2
INVIVO,1
SECONDARY METABOLISM,2
PROTEINBINDING,1
VIRAL DYNAMICS,2
GENITALTRACT,1
600 MG,2
,1
INDUSTRIAL AGGLOMERATION,2
GEOGRAPHIC CONCENTRATION,2
SCALING LAWS,2
SIZE,1
PRODUCTIVITY,1
POPULATION,1
INNOVATION,1
ADVANTAGE,1
GROWTH,1
SHAPE,1
Patents,1
Technological innovation,2
Process control,2
Tools,1
Control systems,2
PD control,2
Tuning,1
Fractional calculus,2
fractionalorder PID control,3
industrial applications,2
frequencydomain analysis,2
optimal tuning,2
fractional control implementation,3
LIGHTING CONTROL STRATEGY,3
PID CONTROLLERS,2
ROBUST STABILITY,2
PIDMUDLAMBDA CONTROLLER,2
OPTIMIZATION ALGORITHM,2
ANALOG IMPLEMENTATION,2
CONTROL DESIGN,2
TUNING RULES,2
SYSTEMS,1
STABILIZATION,1
Technology development zones,3
Technopark,1
Universityindustry interaction,2
RD,1
Innovation,1
Triple helix,2
TECHNOLOGY PARKS,2
SCIENCE PARKS,2
INNOVATION,1
PERFORMANCE,1
FIRMS,1
VARIABLES,1
CAPACITY,1
Employee invention,2
Patent,1
Remuneration,1
Typology,1
Ideal type,2
Case study,2
O31,1
O34,1
J33,1
M52,1
COMPETITIVE ADVANTAGE,2
INCENTIVES,1
INNOVATION,1
INVENTORS,1
LAW,1
COMPENSATION,1
MANAGEMENT,1
PRODUCTIVITY,1
TECHNOLOGY,1
OWNERSHIP,1
,1
,1
,1
FINANCE THEORY,2
FRAUD,1
juju,1
oriki,1
myth,1
improvisation,1
oral chanter,2
,1
product design,2
design patents,2
innovation,1
optimal distinctiveness,2
mixed methods,2
OPTIMAL DISTINCTIVENESS,2
INNOVATION,1
UNIQUENESS,1
CULTURE,1
FORM,1
PERCEPTIONS,1
RESPONSES,1
ART,1
LAW,1
Compulsory licensing,2
access to medicines,3
universal health coverage,3
HIV,1
AIDS,1
pharmaceutical,1
realist review,2
UNIVERSAL HEALTH COVERAGE,3
AIDS TREATMENT,2
PUBLICHEALTH,1
INTELLECTUAL PROPERTY,2
LATINAMERICA,1
CIVILSOCIETY,1
ACCESS,1
MEDICINES,1
LESSONS,1
LEGISLATION,1
Intellectual property,2
Judicial protection,2
Innovationdriven,1
Business performance,2
K40,1
O31,1
O34,1
L25,1
INTELLECTUAL PROPERTYRIGHTS,2
FIRM PERFORMANCE,2
OPERATING PERFORMANCE,2
PATENT RIGHTS,2
PROTECTION,1
DYNAMICS,1
IMPACT,1
POLICY,1
GROWTH,1
ENFORCEMENT,1
absolute monarchy,2
court of high commission,4
ex officio oath,3
monopolies,1
royal prerogative,2
16thcentury constitutionalism,2
,1
Autonomy,1
Caesarean section,2
Elective caesareans,2
Pregnant women,2
Childbirth,1
Birth ethics,2
MATERNAL REQUEST,2
WOMEN,1
AUTONOMY,1
SECTION,1
DELIVERY,1
CHOICE,1
CHILDBIRTH,1
CAESAREANS,1
MORTALITY,1
ABORTION,1
Forced technology transfer policy,4
Foreigndomestic technology transfer,3
China,1
Strategy,1
Thematic analysis,2
Risk forecasting,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
EMERGING ECONOMIES,2
INNOVATION,1
INTERNATIONALIZATION,1
INDUSTRIES,1
REGIMES,1
PATENT,1
MARKET,1
ENTRY,1
,1
INTELLECTUAL PROPERTY NORMS,3
FAIRUSE,1
INNOVATION,1
PATENT,1
CONSTRAINTS,1
ECONOMICS,1
WORK,1
IMAGINATION,1
INCENTIVES,1
STATEMENTS,1
,1
INTELLECTUAL PROPERTY,2
BAYHDOLE,1
PUBLIC RESEARCH,2
MARKET POWER,2
INCENTIVES,1
PATENTS,1
PRIZES,1
RULES,1
INSTRUMENTS,1
COMPETITION,1
aAl2O3 hard layer,3
Chemical vapor deposition,3
Anisotropic stress distribution,3
Triaxial stress nature,3
Xray diffraction,2
Residual stress determination techniques,4
XRAYDIFFRACTION,1
THINFILMS,1
CONSTANTS,1
TEXTURE,1
ORIGIN,1
FIELDS,1
Modified,1
Ping Pong,2
Double guiding catheter,3
Coronary perforation,2
Rotablation,1
Anchor balloon,2
Case report,2
ARTERY PERFORATIONS,2
MANAGEMENT,1
INTERVENTION,1
ERA,1
Aroylhydrazones,1
Human prion protein,3
CopperII,1
Methionine oxidation,2
Oxidative stress,2
PRION PROTEIN,2
METHIONINE OXIDATION,2
METALIONS,1
BINDING,1
IRON,1
COORDINATION,1
PARKINSONS,1
ALZHEIMERS,1
COMPLEXES,1
HYDRAZONE,1
algorithmic curation,2
algorithms,1
content analysis,2
critical algorithm studies,3
Facebook,1
material culture analysis,3
news information,2
news values,2
MEDIA,1
COVERAGE,1
POWER,1
BIAS,1
Amyotrophic lateral sclerosis ALS,4
Electroencephalogram EEG,2
Eye blinks,2
Braincomputer interface BCI,3
Brain waves,2
COMMUNICATION,1
ARTIFACT,1
REMOVAL,1
QUALITY,1
SYSTEM,1
treatment of left atrial septal pouch,6
pfo,1
double atrial septum,3
left atrial septal pouch,4
cryptogenic stroke,2
2DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY,3
INTERATRIAL SEPTUM,2
RISKFACTOR,1
Gastric cancer,2
RBM8A,1
Protooncogene,1
Prognosis,1
,1
Biosimilars,1
Biological medicines,2
Great Britain,2
Local formularies,2
THINK,1
COVID19,1
allocation,1
vaccine,1
COVAX,1
distributional justice,2
global health ethics,3
human rights,2
,1
,1
,1
autophagy,1
CCT3,1
colorectal cancer,2
CVBD,1
senescence,1
CELLPROLIFERATION,1
CONCISE GUIDE,2
AUTOPHAGY,1
SUPPRESSION,1
CARCINOMA,1
APOPTOSIS,1
BREAST,1
invention management,2
patents,1
sociotechnical imaginaries,2
path dependency,2
technology transfer,2
Germany,1
comparison,1
UNITEDSTATES,1
SCIENCE,1
UNIVERSITIES,1
INNOVATION,1
TECHNOLOGY,1
GOVERNANCE,1
IMPACT,1
Angiogenesis,1
Wound healing,2
Traditional Chinese medicine,3
Myocardial infarction,2
Cardiovascular,1
Zebrafish,1
UPREGULATION,1
INVIVO,1
ANGIOGENESIS,1
MECHANISMS,1
Bioavailability,1
COVID19,1
idiopathic pulmonary fibrosis,3
Nintedanib,1
systemic sclerosisassociated interstitial lung disease,5
LOCALANESTHESIA PRIOR,2
FREE INJECTION SYSTEM,3
FREE JET INJECTIONS,3
CELL LUNGCANCER,2
TRANSDERMAL DELIVERY,2
INVITRO,1
MICROFABRICATED MICRONEEDLES,2
ANTIINFLAMMATORY ACTIVITY,2
DISSOLVING MICRONEEDLES,2
FORMULATION DEVELOPMENT,2
in vivo relative dosimetry,4
proton,1
radiotherapy,1
quality controls,2
beam monitoring,2
DIAMOND DETECTOR,2
SILICON DIODE,2
DOSIMETRY,1
PHOTON,1
ENERGY,1
HADRONTHERAPY,1
BEAM,1
,1
MARKET EXCLUSIVITY,2
PRESCRIPTION DRUGS,2
ORIGINS,1
ENTRY,1
ACT,1
,1
INCREASING RETURNS,2
GROWTH,1
MODELS,1
INNOVATION,1
DIVERSITY,1
GEOGRAPHY,1
Ultraperformance liquid chromatography,3
High resolution mass spectrometry,4
Glycan analysis,2
Intact mass analysis,3
Peptide mapping,2
Recombinant EPO,2
Biopharmaceutical characterization,2
NGLYCOLYLNEURAMINIC ACID,2
ELECTROPHORESISELECTROSPRAYTIME,1
GLYCOFORM CHARACTERIZATION,2
BIOLOGICALACTIVITY,1
GLYCAN ANALYSIS,2
INTACT PROTEIN,2
GLYCOSYLATION,1
CARBOHYDRATE,1
CHAINS,1
mild steel,2
acetic acid solution,3
henna leaves extract,3
corrosion inhibitor,2
WL,1
PDP,1
EIS,1
1 M HCL,3
COLDROLLED STEEL,2
ESSENTIAL OIL,2
CARBONSTEEL,1
MENTHAPULEGIUM,1
AQUEOUS EXTRACT,2
ACID,1
LEAVES,1
ANTIOXIDANT,1
DERIVATIVES,1
,1
GENETICRESOURCES,1
DENT CORN,2
GREENREVOLUTION,1
DIVERSITY,1
IMPROVEMENT,1
PROTECTION,1
INBREDS,1
Hepatitis C,2
Cirrhosis,1
Hepatocellular carcinoma,2
Direct acting antivirals,3
Distributive justice,2
Access to care,3
Prioritization,1
Ethics,1
HEPATITISC VIRUS,2
SUSTAINED VIROLOGICAL RESPONSE,3
LIVER FIBROSIS PROGRESSION,3
INFECTION,1
INTERFERON,1
THERAPY,1
IMPACT,1
BOCEPREVIR,1
CIRRHOSIS,1
RATES,1
,1
COPYRIGHT PROTECTION,2
AUTHORSHIP,1
Behavioral health care,3
Policy evaluation,2
Commercial health insurance,3
Claims data,2
Substance use disorder,3
FEDERAL PARITY,2
SERVICES,1
ABUSE,1
COMORBIDITY,1
PREVALENCE,1
ILLNESS,1
LIMITS,1
Chronic hepatitis C,3
Cirrhosis of liver,3
Sofosbuvir,1
Sustained viral response,3
ACTING ANTIVIRAL THERAPY,3
GENOTYPE 3 INFECTION,3
DECOMPENSATED CIRRHOSIS,2
PLUS RIBAVIRIN,2
REGIMENS,1
IMPACT,1
TnP,1
peptide drug,2
inflammatory diseases,2
asthma,1
lung remodeling,2
,1
Carbonic anhydrase,2
Activator,1
Inhibitor,1
Coumarin,1
Amine,1
Amino acid,2
Crystallography,1
ISOZYMEII,1
ACTIVESITE,1
CRYSTALLOGRAPHIC ANALYSIS,2
ISOFORMVII,1
GAMMACLASS,1
LHISTIDINE,1
PATENT,1
MEMORY,1
IV,1
VA,1
Food packaging,2
rice starch,2
edible film,2
nanocomposite,1
nanocellulose,1
water vapour permeability,3
tensile strength,2
film solubility,2
film colour,2
CELLULOSE NANOCRYSTALS,2
NANOCOMPOSITE FILMS,2
PHYSICOCHEMICAL PROPERTIES,2
MECHANICALPROPERTIES,1
BARRIER PROPERTIES,2
THERMOPLASTIC STARCH,2
CASSAVA STARCH,2
BANANA,1
EXTRACTION,1
BIOPOLYMER,1
functional clothing,2
herbs,1
dermatoses,1
microencapsulation,1
natural fibers,2
natural dyeing,2
FIBERS,1
Nigella sativa,2
Angelica archangelica,2
phytochemicals,1
plantbased product,2
antiinflammatory,1
cyclooxygenases,1
ANGELICAARCHANGELICA LINN,2
NIGELLASATIVA,1
THYMOQUINONE,1
CYCLOOXYGENASE2,1
MEDICINE,1
Learning organizations,2
Selfdirected learning,2
Learning culture,2
Interactional perspective,2
ORGANIZATION,1
INDIVIDUALS,1
STRATEGIES,1
Universityindustry UI,2
UI collaboration,2
innovation,1
crossborder region,2
KNOWLEDGE TRANSFER,2
ACADEMIC ENTREPRENEURSHIP,2
TECHNOLOGYTRANSFER,1
RESEARCHERS WORKING,2
QUADRUPLE HELIX,2
OPEN INNOVATION,2
SPILLOVERS,1
IMPACT,1
PATENT,1
PRODUCTIVITY,1
,1
HUMANRIGHTS,1
MACHINE,1
LIMITS,1
RULES,1
STATE,1
Drug discovery,2
Erooms law,2
Innovation systems,2
Pharmaceutical innovation,2
RD trend,2
Survey,1
RESEARCHANDDEVELOPMENT,1
INNOVATION SYSTEMS,2
FAILURE,1
RATES,1
NGA,1
Public procurement,2
EMATMEAT,1
Firstprice sealedbid auction,3
Market competition,2
Industrial policy,2
STATE AID,2
PROCUREMENT AUCTIONS,2
PUBLIC PROCUREMENT,2
POLICY,1
COMPETITION,1
DESIGN,1
CONTRACTS,1
PRICE,1
,1
JOHN,1
innovation,1
innovation city,2
Morocco,1
patent,1
public research,2
startup,1
valorization,1
,1
reciprocating compressor,2
piston pump,2
piston hybrid power machine,4
work processes,2
indicator efficiency of the compressor,5
,1
,1
SUPPLY CHAIN,2
ACCOUNTING INFORMATION,2
SMART CONTRACTS,2
AGENCY COSTS,2
TECHNOLOGY,1
OPERATIONS,1
GOVERNMENT,1
IMPACT,1
FUTURE,1
FIRM,1
Copyright,1
Trade mark,2
Patent,1
Intellectual property and constitutional rights,5
South Africa,2
,1
Analysis,1
Designer benzodiazepines,2
Metabolism,1
NPS,1
Pharmacokinetics,1
Toxicology,1
HUMAN LIVERMICROSOMES,2
RESOLUTION MASSSPECTROMETRY,2
GABAA RECEPTOR,2
VITRO PHASEI,2
LIQUIDCHROMATOGRAPHY,1
CLINICAL PHARMACOKINETICS,2
FLUBROMAZOLAM METABOLISM,2
MAJOR METABOLITES,2
URINE SAMPLES,2
HUMAN SERUM,2
cardiac surgery,2
human cadavers,2
training,1
SIMULATION,1
SKILLS,1
reasonable royalty,2
lost profits,2
price erosion,2
apportionment,1
enhanced damages,2
,1
,1
PERFORMANCE,1
DYNAMICS,1
Neonatal resuscitation,2
Neonatal transition,2
Work domain analysis,3
Ecological interface design,3
ELECTRICALIMPEDANCE TOMOGRAPHY,2
RESPIRATORYDISTRESSSYNDROME,1
ECOLOGICAL INTERFACE DESIGN,3
PATENT DUCTUSARTERIOSUS,2
SYSTEMIC BLOODFLOW,2
LUNG ULTRASOUND,2
TRANSITIONAL CIRCULATION,2
NONINVASIVE MEASUREMENTS,2
PRETERM INFANTS,2
CARBONDIOXIDE,1
generic drugs,2
leuprolide,1
Lupron Depot R,3
PLGA microspheres,2
reverse engineering,2
LEUPROLIDE ACETATE,2
INJECTABLE MICROSPHERES,2
PLGA MICROSPHERES,2
POLYLACTIC ACID,2
RELEASE,1
MICROCAPSULES,1
LEUPRORELIN,1
destructive interparental conflict,3
parentchild attachment,2
emotional insecurity,2
Chinese children,2
emotional and behavioral problems,4
RESOURCECONTROL STRATEGIES,2
ADJUSTMENT,1
QUESTIONNAIRE,1
DIFFICULTIES,1
METAANALYSIS,1
SECURITY,1
HEALTH,1
FUTURE,1
ROLES,1
Cell Proliferation,2
Esophageal Neoplasms,2
MicroRNAs,1
AUTOPHAGY,1
INHIBITION,1
PI3K,1
EXPRESSION,1
CANCER,1
University,1
higher education,2
image,1
stakeholders,1
formative measurement model,3
measurement invariance,2
HIGHEREDUCATION,1
ORGANIZATIONAL IMAGE,2
INDEX CONSTRUCTION,2
SATISFACTION,1
REPUTATION,1
LOYALTY,1
IMPACT,1
INDICATORS,1
COVARIANCE,1
PRESTIGE,1
Refractory angina,2
Coronary microvascular dysfunction,3
Hypertrophic cardiomyopathy,2
Angina pectoris,2
Myocardial ischaemia,2
Coronary sinus reducer,3
Case report,2
EFFICACY,1
INSIGHTS,1
Actinidia arguta byproducts,3
Bioactive compounds,2
Cosmetic and medical skincare application,5
Skin benefits,2
VITAMINC,1
INVITRO,1
COFFEE SILVERSKIN,2
DOUBLEBLIND,1
MATRIX METALLOPROTEINASES,2
INDUCED INFLAMMATION,2
ANTIOXIDANT ACTIVITY,2
ALPHAGLUCOSIDASE,1
CHLOROGENIC ACID,2
HARDY KIWIFRUIT,2
Kunxian Capsule,2
rheumatoid arthritis,2
pharmacological mechanism,2
side effects alleviation,3
drug matching,2
bioinformatics,1
FOLICACID,1
TRIPTOLIDE,1
EPIMEDIUM,1
PATHWAYS,1
FOLATE,1
CYCLOPHOSPHAMIDE,1
SUPPLEMENTATION,1
PROLIFERATION,1
GLUTAMINE,1
CELASTROL,1
shear stress,2
endothelial cells,2
thrombosis,1
inflammation,1
Xueshuantong capsule,2
PANAXNOTOGINSENG,1
SHEARSTRESS,1
ENDOTHELIALCELLS,1
DIFFERENT PARTS,2
ADHESION,1
EXPRESSION,1
SAPONINS,1
ACTIVATION,1
EXTRACTION,1
PATHWAY,1
drug development,2
innovation,1
pediatric,1
policy,1
MEDICINES,1
CHILDREN,1
ADOLESCENTS,1
EXPOSURE,1
PROGRAM,1
CANCER,1
ACT,1
corporate innovation,2
pressuresensitive institutional investors,3
pressureresistance institutional investors,3
RD intensity,2
institutional investors,2
China,1
RESEARCHANDDEVELOPMENT,1
FIRM INNOVATION,2
POLITICAL CONNECTIONS,2
OWNERSHIP STRUCTURE,2
PERFORMANCE,1
INVESTMENT,1
GOVERNANCE,1
MANAGEMENT,1
EFFICIENCY,1
CHINA,1
Metabolic profiling,2
Needle,1
Drought,1
Heteroblasty,1
Genotype,1
DROUGHTSTRESS,1
SECONDARY METABOLITES,2
LIPOPHILIC COMPOUNDS,2
GASCHROMATOGRAPHY,1
MASSSPECTROMETRY,1
SCOTS PINE,2
FLAVONOIDS,1
NEEDLES,1
ACCUMULATION,1
LEAVES,1
catarrhine,1
cranial synchondroses,2
craniofacial,1
hyaline cartilage,2
hypertrophic chondrocytes,2
platyrrhine,1
CRANIAL BASE,2
MIDFACIAL GROWTH,2
NASALSEPTUM,1
BASICRANIAL SYNCHONDROSES,2
MACACANEMESTRINA,1
VOMERONASAL ORGAN,2
NEWBORN PRIMATES,2
BRAIN SIZE,2
ONTOGENY,1
OSSIFICATION,1
Koolende Vries syndrome,3
Rare disease,2
tracheolaryngomalacia,1
Airway management,2
,1
Transporter,1
Shuganning injection,2
drugdrug interaction,2
Artemisia capillaris,2
Gardenia jasminoides,2
Isatis tinctoria,2
Ganoderma lucidum,2
PERFORMANCE LIQUIDCHROMATOGRAPHY,2
PGLYCOPROTEIN ACTIVITY,2
INVITRO,1
CHLOROGENIC ACID,2
HEPATICUPTAKE,1
3 SLC22A8,2
EXPRESSION,1
CELLS,1
ATORVASTATIN,1
INHIBITION,1
insecticide discovery,2
natural products,2
crop protection compounds,3
agrochemical industry,2
competitorinspired,1
firstinclass,1
NATURALPRODUCTS,1
BIOLOGICALACTIVITY,1
ACARICIDE,1
GENERATION,1
DESIGN,1
PYRETHROIDS,1
PIPELINE,1
ANALOGS,1
TRENDS,1
MIMICS,1
Corruption,1
Innovation,1
Africa,1
Asia,1
Lower and uppermiddle income,4
MEDIUMSIZED ENTERPRISES,2
DEVELOPINGCOUNTRIES,1
GROWTH EVIDENCE,2
PERFORMANCE,1
TRANSITION,1
ENTREPRENEURSHIP,1
DETERMINANTS,1
PERSISTENCE,1
BEHAVIOR,1
IMPACT,1
,1
DEMINERALIZED HUMAN DENTIN,3
CALCIUMPHOSPHATE,1
INVITRO,1
INTERFACIAL ENERGY,2
COLLAGEN FIBRILS,2
CRYSTALGROWTH,1
OSTEOPONTIN,1
HYDROXYAPATITE,1
SURFACE,1
INHIBITION,1
,1
,1
Alzheimers disease,2
Acetylcholinesterase,1
MTDLs,1
Antioxidant,1
Molecular docking,2
MONOAMINEOXIDASEB,1
ACETYLCHOLINESTERASE INHIBITORYACTIVITY,2
POTENTIAL MULTIFUNCTIONAL AGENTS,3
AMYLOIDBETA AGGREGATION,2
INVITRO ASSAY,2
BIOLOGICAL EVALUATION,2
CHOLINESTERASEINHIBITORS,1
MOLECULAR DOCKING,2
ANTICHOLINESTERASE ACTIVITY,2
DUAL INHIBITORS,2
atrial fibrillation,2
cryptogenic stroke,2
interatrial septum,2
leftsided septal pouch,3
patent foramen ovale,3
septal pouch,2
CRYPTOGENIC STROKE,2
ISCHEMICSTROKE,1
RISKFACTOR,1
THROMBUS,1
Blood brain permeability,3
Homology modeling,2
LRRK2 inhibitors,2
Leucinerich repeat kinase 2,4
Parkinson s Disease,3
Structure based virtual screening,4
REPEAT KINASE 2,3
DOPAMINERGIC NEURODEGENERATION,2
DESIGN,1
MUTATION,1
POTENT,1
MODEL,1
DEGENERATION,1
NEURONS,1
CELL,1
irrigation scheduling,2
patent,1
sensor,1
microclimate,1
GREENHOUSE,1
cyclic peptides,2
TnP,1
bioinformatics and computational tools,4
drugtarget protein interactions,3
in silico prediction,3
integrin antagonist,2
BREASTCANCER METASTASIS,2
CELLADHESION MOLECULE1,2
CRYSTALSTRUCTURE,1
INTEGRIN VLA4,2
VCAM1,1
BINDING,1
ANGIOGENESIS,1
RESPONSES,1
DOMAIN1,1
FRAGMENT,1
candidate compounds,2
FKBP52,1
screening methods,2
Tau dysfunction,2
FUNCTIONAL RECOVERY,2
NERVE REGENERATION,2
PROTEIN,1
FK506,1
PHOSPHORYLATION,1
BINDING,1
LIGANDS,1
DISEASE,1
ANALOGS,1
MODELS,1
Stem cell,2
Nanofiber,1
Coronary artery disease,3
Peripheral artery disease,3
Paracrine factor,2
CARDIOSPHEREDERIVED CELLS,2
ENDOTHELIAL PROGENITOR CELLS,3
IMPROVE MYOCARDIALFUNCTION,2
POSEIDON RANDOMIZEDTRIAL,2
BONEMARROW,1
ISCHEMIC CARDIOMYOPATHY,2
TRANSENDOCARDIAL INJECTION,2
REENDOTHELIALIZATION,1
PHASE1 TRIAL,2
REGENERATION,1
Manufacturing firms,2
Absorptive capacity,2
Open innovation,2
Organizational slack,2
Open search strategy,3
RESEARCHANDDEVELOPMENT,1
EXTERNAL KNOWLEDGE SEARCH,3
INBOUND OPEN INNOVATION,3
DEVELOPMENT EXPENDITURES,2
MODERATING ROLE,2
EXAMINER CITATIONS,2
PATENT CITATIONS,2
LOCAL SEARCH,2
HIGHTECH,1
PERFORMANCE,1
,1
CELLS,1
TRANSPORT,1
UPDATE,1
Schistosomiasis,1
Nonsteroidal antiinflammatory drugs,3
Mefenamic acid,2
Anthelmintic,1
Schistosomicidal activity,2
ANTISCHISTOSOMAL ACTIVITY,2
ANTIPARASITIC ACTIVITY,2
DISCOVERY,1
MANSONI,1
COMBINATIONS,1
DICLOFENAC,1
AGENTS,1
LEAD,1
gender violence,2
nurses,1
qualitative research,2
experiences,1
INTIMATE PARTNER VIOLENCE,3
HEALTHCARE PROFESSIONALS,2
YOUNGADULTS,1
WOMEN,1
EXPERIENCES,1
ATTITUDES,1
PROVIDERS,1
SPAIN,1
China,1
International marketing,2
Emerging market multinationals,3
Chinese multinational firms,3
Internationalization,1
Chinese firms,2
KNOWLEDGE DEVELOPMENT,2
INTERNATIONALIZATION,1
FIRMS,1
PERFORMANCE,1
INNOVATION,1
OPPORTUNITIES,1
EXPLOITATION,1
EXPLORATION,1
ENTERPRISES,1
TRANSITION,1
Loop thermosyphon,2
Cooling system,2
Variable thermal conditions,3
Fuselage,1
Air conditioning,2
Condenser,1
Avionics,1
AVIONICS,1
wildlife trade,2
pangolin,1
consumption willingness,2
species conservation,2
Guangdong province,2
SOCIALINFLUENCE,1
TRADE,1
WILDLIFE,1
BEHAVIOR,1
MEDICINE,1
MARKETS,1
SCALE,1
carotenoidbased pigmentation,2
color evolution,2
nocturnal color vision,3
skin coloration,2
tentroosting bats,2
PHYLOGENETIC SIGNAL,2
MATE CHOICE,2
VISION,1
LIGHT,1
PHYLLOSTOMIDAE,1
CHIROPTERA,1
ECOLOGY,1
Pediatric stroke,2
Pediatric arterial ischemic stroke,4
Cardiac disease,2
Stroke,1
Embolism,1
Cardiac procedure,2
CONGENITAL HEARTDISEASE,2
SCIENTIFIC STATEMENT,2
THROMBOSIS,1
RISK,1
PREVALENCE,1
INFANTS,1
Multimodal analysis,2
semiotic resources,2
British TV ads,3
stereotyped portrayals,2
gender portrayals,2
SEXROLE MESSAGES,2
TELEVISION COMMERCIALS,2
MAGAZINE ADVERTISEMENTS,2
ROLE PORTRAYALS,2
ROLES,1
IMAGES,1
REPRESENTATION,1
FEMINISM,1
VIOLENCE,1
VOICE,1
pharmaceutical marketing,2
detailing competition,2
dynamic oligopoly game,3
dynamic programming,2
detailing cost,2
restrictions on detailing,3
regulation,1
ADVERTISING STRATEGIES,2
PRESCRIBING DECISIONS,2
PRESCRIPTION DRUGS,2
PATENT EXPIRATION,2
CHOICE,1
OLIGOPOLY,1
BEHAVIOR,1
INDUSTRY,1
MARKETS,1
PROMOTION,1
,1
TUMORINITIATING CELLS,2
P75 NEUROTROPHIN RECEPTOR,3
CANCER STEMCELLS,2
ALDEHYDE DEHYDROGENASE,2
MULTIDRUGRESISTANCE,1
INVITRO,1
BRAIN,1
INHIBITION,1
LINES,1
DRUG,1
Arteriovenous fistula,2
extracellular matrix,2
haemodialysis,1
EXTRACELLULARMATRIX CORMATRIX,2
SMALLINTESTINAL SUBMUCOSA,2
PRELIMINARY EXPERIENCE,2
VALVE REPAIR,2
RISKFACTORS,1
ACCESS,1
RECONSTRUCTION,1
SCAFFOLDS,1
CONDUIT,1
SURGERY,1
,1
IFNGAMMA,1
INDOLEAMINE 23DIOXYGENASE,2
NITRICOXIDE,1
MACROPHAGE AUTOPHAGY,2
MEDIATED REGULATION,2
IMMUNERESPONSES,1
HOSTDEFENSE,1
IDO,1
INFECTION,1
TRYPTOPHAN,1
Parkinsons disease,2
Optic nerve,2
Diffusion tensor image,3
Cognition,1
MULTIPLESYSTEM ATROPHY,2
CARDIAC I123MIBG,2
DEMENTIA,1
HALLUCINATIONS,1
ASSOCIATION,1
DYSFUNCTION,1
PREVALENCE,1
ALZHEIMERS,1
PATTERNS,1
NEURITIS,1
Tetralogy of Fallot,3
Haemodynamic balance,2
Longevity,1
Natural history,2
Miracles,1
Case report,2
,1
Akt1,1
Chinese patent medicine,3
COVID19,1
Lianhua Qingwen capsule,3
molecular docking,2
network pharmacology,2
INTEGRATING INFORMATION,2
PI3KAKTMTOR PATHWAY,2
CELLDEVELOPMENT,1
LUNG INJURY,2
GENES,1
KINASE,1
CYTOSCAPE,1
Leea indica,2
anterograde amnesia,2
Alzheimers disease,2
scopolamine,1
neurodegenerative,1
memory deficits,2
,1
ecoinnovation,1
environmental patent,2
environmental regulations,2
foreign direct investment FDI,4
pollution intensity,2
FOREIGN DIRECTINVESTMENT,2
RESEARCHANDDEVELOPMENT,1
RESOURCEBASED VIEW,2
INSTITUTIONBASED VIEW,2
GREEN INNOVATION,2
KNOWLEDGE SPILLOVERS,2
MULTINATIONALENTERPRISES,1
SUSTAINABLE DEVELOPMENT,2
STAKEHOLDER PRESSURES,2
PERFORMANCE EVIDENCE,2
,1
CONFLICTOFINTEREST,1
MEDICAL DEVICE INDUSTRY,3
PHARMACEUTICAL COMPANIES,2
INTEREST DISCLOSURES,2
INTERESTPOLICIES,1
NATIONALSURVEY,1
TRANSPARENCY,1
DIFFERENCE,1
ACCURACY,1
IMPACT,1
Fufang zhenzhu tiaozhi,3
Network pharmacology,2
Type 2 diabetes mellitus,4
Nonalcoholic fatty liver disease,4
PI3KAKT signaling pathway,3
TRADITIONAL CHINESE,2
SERUM,1
NAFLD,1
,1
ASTHMA MANAGEMENT,2
Acute lung injury,3
Traditional Chinese medicine,3
Zedoary turmeric oil injection,4
Network pharmacology,2
INNATE,1
RECOGNITION,1
APOPTOSIS,1
GROWTH,1
Demand,1
MRDT,1
Health careseeking behaviour,3
Drug use,2
Fever,1
malarialike illness,2
Nigeria,1
,1
,1
ROSENMUND REDUCTION,2
ALDEHYDES,1
firm growth,2
relational embeddedness,2
demandside theory,2
relational advantage,2
client relationships,2
professional services,2
RESOURCEBASED VIEW,2
COMPETITIVE ADVANTAGE,2
FIRM GROWTH,2
VERTICAL INTEGRATION,2
ABSORPTIVECAPACITY,1
EMPLOYEE MOBILITY,2
REPEATED EXCHANGE,2
TRANSACTION COST,2
SOCIALSTRUCTURE,1
CAPTURING VALUE,2
Islamic banking,2
Murabahah,1
Ijarah,1
Musharakah mutanaqisah,2
,1
Education,1
Government,1
Services,1
Society,1
Transfer,1
UNIVERSITY,1
CONTROVERSIES,1
ACADEMICS,1
,1
,1
Awareness,1
copyright,1
faculty,1
intellectual property,2
patent,1
students,1
LAW,1
Africa,1
differentiation,1
ECOWAS,1
food security,2
intellectual property rights IPRs,4
patents,1
plant Breeders rights,3
sustainable development,2
PLANT VARIETY PROTECTION,3
SWAKOPMUND PROTOCOL,2
PROPERTY,1
BIODIVERSITY,1
FOLKLORE,1
RIGHTS,1
ARIPO,1
LEGAL,1
Dimensional analysis,2
Buckinghams pi theorem,3
Nondestructive testing  evaluation NDTE,5
Eddy current testing ECT,4
Multiparameter simultaneous estimation,3
Thickness estimation,2
Electrical conductivity estimation,3
THICKNESS MEASUREMENT,2
CONDUCTIVITY,1
Pharmaceutical companies,2
Innovation,1
India,1
Determinants of RD,3
Bivariate probit,2
Dynamic panel data,3
MARKETSTRUCTURE,1
CASH FLOW,2
FIRM SIZE,2
INNOVATION,1
DETERMINANTS,1
INVESTMENT,1
EXPORTS,1
EQUITY,1
Shunt active filters,3
Photovoltaic generators,2
Power quality,2
Harmonics maximum power point tracking algorithm,6
SimscapeElectrical matlab simulation,3
Case study,2
SYSTEM,1
MPPT,1
magnetorheological elastomer,2
control magnetic field,3
modulus of elasticity,3
loss modulus,2
wheeled vehicle,2
cushioning system,2
elastic hinges,2
suspension performance control,3
,1
Knowledge production,2
Knowledge percolation threshold,3
Combinatorial network,2
Optimization strategies,2
Knowledge transmission,2
Connectivity,1
AGENTBASED MODELS,2
COLLABORATION,1
ORGANIZATION,1
TRANSITIONS,1
HIERARCHY,1
DESIGN,1
NODES,1
methylcellulose,1
thermoresponsive,1
in situ gelling,3
3D bioprinting,2
smart surfaces,2
CELL SHEET FRAGMENTS,3
THERMOREVERSIBLE METHYLCELLULOSE,2
MOLECULARWEIGHT METHYLCELLULOSE,2
CALCIUMPHOSPHATE NANOPARTICLES,2
STIMULIRESPONSIVE POLYMERS,2
SUSTAINED DRUGDELIVERY,2
EXTRACELLULARMATRIX,1
PHYSICALPROPERTIES,1
METHYL CELLULOSE,2
STEMCELLS,1
Environmental protection tax,3
Corporate green technology innovation,4
RD investment,2
Innovative human capital,3
Financing constraints,2
,1
Nuclear forensics,2
Nuclear Forensic International Technical,4
Working Group ITWG,3
Forensic chemistry,2
Material Out of Regulatory Control MORC,6
,1
Random number generation,3
Silicon Photomultipliers,2
Cryptography,1
,1
Nuclear forensics,2
Nuclear Forensic International Technical Working Group ITWG,7
Forensic chemistry,2
Material Out of Regulatory Control MORC,6
,1
Pharmaceutical industry,2
Growth and development policies,4
Health,1
Qualitative study,2
Iran,1
TURKEY,1
AfCFTA agreement,2
IPRs,1
trade,1
Nigeria,1
access to medicines,3
,1
Ancylostoma braziliense,2
Ancylostoma caninum,2
Ancylostoma duodenale,2
dogs,1
hookworm species,2
Kenya,1
CUTANEOUS LARVA MIGRANS,3
SAOPAULO STATE,2
ANCYLOSTOMACEYLANICUM,1
ECHINOCOCCUSMULTILOCULARIS,1
GASTROINTESTINAL PARASITES,2
NECATORAMERICANUS,1
PCRRFLP,1
INFECTION,1
COMMUNITY,1
CATS,1
,1
PRODUCT INNOVATIVENESS,2
SECTORAL PATTERNS,2
GIBRATSLAW,1
TECHNOLOGY,1
SMES,1
PERFORMANCE,1
MANAGEMENT,1
IMPACT,1
FIRMS,1
INNOVATIONS,1
Intellectual property,2
Aquaculture industry,2
Intellectual capital,2
Blue sustainability,2
Market size,2
UNITROOT TESTS,2
OCCUPATIONALHEALTH,1
PANEL,1
COINTEGRATION,1
POWER,1
,1
,1
numerology,1
three,1
Visnu,1
Vamana,1
svayamatrnna,1
daena,1
Yima,1
cinuuato p partial derivative r partial derivative tu,8
vara,1
barsnumgah,1
,1
Cannabis,1
Teratology,1
Cardiovascular defects,2
Atrial septal defect,3
Gastroschisis,1
Exomphalos,1
Genotoxicity,1
ILLICIT DRUGUSE,2
BIRTHDEFECTS,1
RISKFACTORS,1
GASTROSCHISIS,1
ASSOCIATION,1
EPIGENOMICS,1
ADDICTION,1
DISEASE,1
MODELS,1
ALTERS,1
Drug Combinations,2
Drug Therapy,2
Combination,1
Medication Adherence,2
Developing Countries,2
Nigeria,1
DRUGCOMBINATIONS,1
INDIA,1
,1
,1
critical success factors,3
information management centers,3
information evaluation centers,3
speciality,1
information technology,2
stability,1
independency,1
distance from authorities,3
Iranian Research Institute for Information,5
Science and Technology IRANDOC,4
Iranian Research Organization for Science and Technology IROST,8
Regional Information Center for Science and Technology RICeST,8
INSTITUTIONAL REPOSITORIES,2
ORGANIZATIONS,1
PERSPECTIVE,1
SYSTEM,1
LIBRARIES,1
PROJECTS,1
MODEL,1
Reverse Potts shunt,3
Right ventricular dysfunction,3
Bridge to transplant,3
ATRIAL SEPTOSTOMY,2
CREATION,1
CHILDREN,1
SURVIVAL,1
ADULT,1
animal model,2
deep venous thrombosis,3
endovascular techniques,2
histology,1
in vivo study,3
porcine model,2
prosthesis,1
varicose vein,2
venous insufficiency,2
venous valve,2
BIOPROSTHETIC VALVE,2
SHORTTERM,1
INSUFFICIENCY,1
VEIN,1
RECONSTRUCTION,1
SHEEP,1
TRANSPLANTATION,1
METAANALYSIS,1
EXPERIENCE,1
REFLUX,1
Inguinal hernia repair,3
Laparoscopic,1
Fixation free hernia repair,4
ProFlor prosthesis,2
Dynamic responsivity,2
Regenerative scaffold,2
CHRONIC PAIN,2
REPAIR,1
MESH,1
METAANALYSIS,1
GUIDELINES,1
SOCIETY,1
anticoagulation,1
bleeding disorder,2
fiber blocking,2
fiber patency,2
hemodialysis,1
heparincoated,1
HEPARINBINDING,1
MEMBRANE,1
DIALYSIS,1
AN69ST,1
Atrial Function,2
Venous Baffle,2
Atrial Switch Operation,3
Transposition of the Great Arteries,5
Systemic Right Ventricle,3
PATENT FORAMEN OVALE,3
CORTRIATRIATUM DEXTER,2
EUSTACHIAN VALVE,2
INTRACARDIAC ECHOCARDIOGRAPHY,2
FOLLOWUP,1
CLOSURE,1
STROKE,1
Prescription drugs,2
generic drugs,2
pharmaceutical economics,2
economic competition,2
market exclusivity,2
,1
Traditional Chinese Medicine,3
Functional Molecule Clusters,3
Similarity Analysis,2
MultiTarget,1
Alzheimers Disease,2
Tiaoxin Recipe,2
ABETA,1
OXIDATIVE STRESS,2
ARSENIC TRIOXIDE,2
ROS,1
INFLAMMATION,1
CONTRIBUTES,1
INHIBITION,1
Gold Nanoparticles,2
AuNPs,1
Red Algae,2
Laurencia papillosa,2
ImageJ,1
TEM,1
FESEM,1
AFM,1
XRD,1
FTIR,1
XPS,1
SILVER NANOPARTICLES,2
Cement composites,2
Nanomaterials,1
Graphene oxide,2
Mechanical properties,2
MICROSTRUCTURE,1
NANOSHEETS,1
STRENGTH,1
BEHAVIOR,1
mice,1
humans,1
osteogenesis,1
osteology,1
MEDLINE,1
syndrome,1
craniosynostosis,1
skull base,2
models,1
sutures,1
craniofacial,1
plastic surgery,2
syndromic craniosynostosis,2
facial sutures,2
dysmorphologies,1
hypertelorism,1
exorbitism,1
synostosis,1
premature fusion,2
sphenooccipital synchondrosis,2
ossification,1
craniofacial malformations,2
Le Fort III,3
reconstructive surgery,2
suturectomy,1
pharmacologic FGFR inhibitors,3
SPHENOOCCIPITAL SYNCHONDROSIS,2
MOUSE MODELS,2
CRANIAL BASE,2
MIDFACE HYPOPLASIA,2
AIRWAYOBSTRUCTION,1
CROUZON SYNDROME,2
APERT,1
GROWTH,1
FUSION,1
SYNOSTOSIS,1
process and product innovation,4
recombination,1
specialization,1
TRIPS,1
Tshape,1
ORGANIZATIONAL TRANSFORMATION,2
DOMINANT LOGIC,2
KNOWLEDGE,1
SPECIALIZATION,1
INNOVATION,1
PRODUCT,1
FIRMS,1
CAPABILITIES,1
EXPLORATION,1
TECHNOLOGY,1
Ghrelin,1
Growth hormone secretagogue receptor,4
In vitro pharmacology,3
Dynamic mass redistribution,3
Calcium mobilization,2
Receptor antagonists and inverse agonists,5
ANOREXIACACHEXIA SYNDROME,2
GHRELIN RECEPTOR,2
CONSTITUTIVE ACTIVITY,2
INVERSE AGONIST,2
MESSENGERRNA,1
LUNGCANCER,1
PEPTIDE,1
RAT,1
IDENTIFICATION,1
ANTAGONIST,1
synthetic antiestrogen,2
contraceptive pill,2
breast cancer,2
chemoprevention,1
risk evaluation and management,4
adjuvant therapy,2
DANISH ADJUVANT TRIALS,3
TRANS ISOMERS,2
THERAPY,1
WOMEN,1
CIS,1
ICI,1
extracapsular extension,2
necrosis,1
head and neck cancer,4
outcomes,1
predicting ece,2
lymph node necrosis,3
LOCALLY ADVANCED HEAD,3
COMPUTEDTOMOGRAPHY,1
METASTATIC HEAD,2
SPREAD,1
CHEMOTHERAPY,1
NECROSIS,1
CANCERS,1
ACCURACY,1
TUMORS,1
biodegradable microspheres,2
controlledrelease,1
peptide delivery,2
peptidepolymer interactions,2
PLGA,1
MICROCLIMATE PH,2
DRUGRELEASE,1
DELIVERY,1
WATER,1
ACYLATION,1
MICROENCAPSULATION,1
TRANSITION,1
STABILITY,1
KINETICS,1
SYSTEMS,1
3D printing,2
additive manufacturing,2
telemedicine,1
patientcentric dosage form,3
ACCEPTABILITY,1
AGE,1
,1
BAYHDOLE ACT,2
DRUG,1
entrepreneurship,1
NASA,1
New Space,2
startups,1
technology transfer,2
,1
Caffeine,1
Attention,1
Smell,1
DISCRIMINATION,1
ADENOSINE,1
DRINKING,1
GLUCOSE,1
HEARING,1
,1
,1
development,1
production,1
insulin,1
diabetes,1
Connaught Laboratories,2
University of Toronto,3
distribution,1
biotechnology,1
,1
,1
CORRUPTION,1
INNOVATION,1
GROWTH,1
FIRMS,1
MODEL,1
INVESTMENT,1
RESOURCES,1
COUNTRIES,1
BRIBES,1
graphene,1
composite,1
microscale,1
polymer,1
COMPOSITES,1
bronchopulmonary dysplasia,2
inflammation,1
mechanical ventilation,2
BIRTHWEIGHT INFANTS,2
PATENT DUCTUSARTERIOSUS,2
FORGESTATIONALAGE,1
BRONCHOPULMONARY DYSPLASIA,2
INTRAAMNIOTIC ENDOTOXIN,2
ANTENATAL INFLAMMATION,2
LUNG INFLAMMATION,2
RISKFACTOR,1
DISEASE,1
GROWTH,1
Technological innovation,2
Project management,2
Incentive and supervision,3
Megaprojects,1
Principalagent theory,2
SUPPLY CHAIN,2
CONSTRUCTION,1
PROJECTS,1
highmolecularweight heparin,2
glutamic acid,2
mathematical simulation of chemical equilibria,5
mixed ligand complex of Ca2 with heparin and glutamate,9
MIXEDLIGAND COMPLEXATION,2
AQUEOUSSOLUTION,1
MERCURYII ETHYLENEDIAMINETETRAACETATE,2
POTENTIOMETRIC TITRATION,2
ADENOSINETRIPHOSPHATE,1
PHYSIOLOGICAL SOLUTION,2
THERMODYNAMICS,1
MAGNESIUM,1
POLARIMETRY,1
COMPOUND,1
Knowledge creation,2
Technology transfer,2
RD performance,2
Delay grey incidence analysis,4
BAYHDOLE ACT,2
EFFICIENCY ANALYSIS,2
INNOVATION,1
KNOWLEDGE,1
TRANSFORMATION,1
ENTREPRENEURSHIP,1
ENGAGEMENT,1
EUROPE,1
Trypanosoma evansi,2
acute,1
chronic,1
mice,1
PCR,1
polymerase chain reaction,3
organs,1
PCR ASSAY,2
CAMELS,1
TESTS,1
BLOOD,1
DNA,1
collective attention,2
collective memory,2
collective forgetting,2
mathematical modeling,2
computational social science,3
COLLECTIVE MEMORY,2
ATYPICAL COMBINATIONS,2
CUMULATIVE ADVANTAGE,2
PANELDATA,1
EVOLUTION,1
ATTENTION,1
MODEL,1
CITATIONS,1
DYNAMICS,1
STATES,1
Public health,2
TRIPS agreement,2
Access to medicines,3
Regional mechanism,2
TRIPS FLEXIBILITIES,2
INTERNATIONALLAW,1
sport therapy,2
box therapy,2
depression,1
antiaggression training,2
rehabilitation,1
SKELETALMUSCLE,1
EXERCISE,1
,1
ORIGINALISM,1
small values of differential pressure measurement,6
filtration,1
pressure gauges,2
,1
RD productivity,2
Pharmaceutical innovation,2
Attrition rates,2
TECHNOLOGICALCHANGE,1
INNOVATION,1
FAILURES,1
INDUSTRY,1
LESSONS,1
,1
DISCRETEEVENT SIMULATION,2
ACTING ANTIVIRAL THERAPY,3
TREATMENTNAIVE PATIENTS,2
GENOTYPE 1 INFECTION,3
CHRONIC HCV,2
UNITEDSTATES,1
FIBROSIS PROGRESSION,2
PLUS SOFOSBUVIR,2
ALCOHOLUSE,1
RIBAVIRIN,1
Dispensed medicines,2
Marketing authorisation,2
Private sector,2
Mental Health,2
Retail pharmacy,2
Multiple sourced medicines,3
Single Exit Price,3
South Africa,2
SAHPRA,1
,1
Huoxiang Zhengqi Oral Liquid HXZQOL,5
mosquito bite dermatitis,3
quercetin,1
JUN,1
IL17 signaling pathway,3
anti cellular inflammation experiment,4
INFLAMMATION,1
APIGENIN,1
ivermectin,1
ribavirin,1
acyclovir,1
ferruginol,1
directacting antivirals,2
hosttargeting antivirals,2
drug combinations,2
CHIKV,1
ZIKV,1
HHV2,1
PERFORMANCE LIQUIDCHROMATOGRAPHY,2
AROMATIC ABIETANE DITERPENOIDS,3
IMPORTIN ALPHABETA,2
REPLICATION,1
DERIVATIVES,1
FERRUGINOL,1
INHIBITOR,1
COVID19,1
PLASMA,1
REDUCE,1
CatSper,1
steroids,1
human sperm,2
highthroughput screening,2
calcium signaling,2
pharmacophore modelling,2
acrosome reaction,2
HUMAN SPERMATOZOA,2
MALEINFERTILITY,1
CA2 CHANNEL,2
PROGESTERONE,1
ACTIVATION,1
PLASMA,1
RECEPTOR,1
SERUM,1
RESPONSIVENESS,1
IDENTIFICATION,1
RNAseq,1
Transcriptome,1
Turbot,1
Enteromyxum scophthalmi,2
Myxozoa,1
Pathogenesis,1
ACUTEPHASE RESPONSE,2
INTESTINAL EPITHELIALCELLS,2
EXPERIMENTALINFECTION,1
EXTRACELLULARMATRIX,1
ENTERIC PARASITE,2
NEUROENDOCRINE SYSTEM,2
ICTALURUSPUNCTATUS,1
LEISHMANIADONOVANI,1
EXPRESSION ANALYSIS,2
CHANNEL CATFISH,2
Kangaroo,1
Liver fluke,2
Crossspecies transmission,2
Drug resistance,2
FASCIOLAHEPATICA INFECTIONS,2
TRICLABENDAZOLE RESISTANCE,2
CHALLENGE INFECTIONS,2
COPROANTIGEN ELISA,2
SHEEP,1
IMMATURE,1
EFFICACY,1
DIAGNOSIS,1
ANIMALS,1
ANTHELMINTICS,1
chemoprophylaxis vaccination with sporozoites,4
malaria,1
Plasmodium falciparum,2
primaquine,1
chloroquine,1
HUMAN MALARIA,2
HUMAN VOLUNTEERS,2
PROTECTION,1
IMMUNIZATION,1
CHALLENGE,1
BLOOD,1
CHLOROQUINE,1
PRIMAQUINE,1
MOSQUITOS,1
HUMANS,1
Auranofin,1
Thioredoxin reductase,2
Nonsmall cell lung cancer,4
Mutant p53,2
Oxidative stress,2
Cancer cell death,3
TRIETHYLPHOSPHINE GOLD AURANOFIN,3
THIOREDOXIN REDUCTASE 1,3
TUMORSUPPRESSOR,1
DRUGRESISTANCE,1
INVITRO,1
EXPRESSION,1
INHIBITOR,1
APOPTOSIS,1
GLUTATHIONE,1
PROMOTES,1
biosimilars,1
cancer drugs,2
COVID19,1
drug expenditures,2
pandemic,1
public policy,2
,1
,1
CEREBRAL INFARCTION,2
SIGNALING PATHWAY,2
EXPRESSION,1
POLYMORPHISMS,1
COAGULATION,1
DATABASE,1
RISK,1
IDENTIFICATION,1
METABOLOMICS,1
ANTIOXIDANT,1
Sanjin tablets,2
urinary tract infections,3
chemical profiling,2
LCMSn,1
network pharmacology,2
molecular docking,2
AKTPROTEIN KINASEB,2
PROTEINKINASE,1
IDENTIFICATION,1
QUERCETIN,1
CHROMATOGRAPHY,1
CONSTITUENTS,1
METABOLITES,1
FLAVONOIDS,1
ACIDS,1
Orbital floor,2
Orbital fracture,2
Bone graft,2
Iliac crest,2
Mandibular outer table,3
Silastic block,2
Titanium mesh,2
,1
Biomarker,1
Discovery,1
Stroke,1
Cerebrovascular disease,2
Ischemic stroke,2
Patent foramen ovale,3
PFO,1
Mass spectrometry,2
Proteomics,1
Albumin,1
HIGHDENSITYLIPOPROTEIN,1
HIGHTHROUGHPUT,1
OPPORTUNITIES,1
DISCOVERY,1
PEPTIDES,1
INSIGHTS,1
DISEASE,1
PLASMA,1
CELLS,1
HEART,1
Neglected diseases,2
Research and development,3
BRICS,1
Bibliometric analysis,2
TROPICAL DISEASES,2
TUBERCULOSIS,1
Knowledge management,2
Knowledge flow,2
Hightech industries,2
INNOVATION PERFORMANCE,2
PATENT CITATION,2
INFORMATION,1
MANAGEMENT,1
TECHNOLOGY,1
IMPACTS,1
SYSTEMS,1
MODEL,1
,1
,1
Genome editing,2
biotechnology entrepreneurship,2
South Korea,2
intellectual property,2
scientific virtue,2
commercialization,1
ZINCFINGER PROTEINS,2
HISTORY,1
TECHNOLOGY,1
CONSTRUCTION,1
POLITICS,1
NATIONALISM,1
SCIENCE,1
DESIGN,1
POLICY,1
CELLS,1
Convolutional neural network CNN,4
Triplet neural network,3
Trademark TM infringement,3
Trademark management,2
contentbased image retrieval CBIR,4
FEATURES,1
SCALE,1
trade and health,3
health policy,2
European Union,2
United States,2
LIBERALIZATION,1
POLICY,1
TIME,1
Micro scale extraction,3
PM25,1
Persistent organic pollutants,3
Mexico,1
POLYCYCLIC AROMATICHYDROCARBONS,2
ORGANOCHLORINE PESTICIDES,2
STOCKHOLM CONVENTION,2
ANALYTICALCHEMISTRY,1
SOLVENTEXTRACTION,1
AIRBORNE PARTICLES,2
DESIGN,1
SAMPLE,1
PBDES,1
CHINA,1
SMEs,1
financing,1
financial ecology,2
,1
,1
RETROSPECTIVE COHORT,2
COST,1
,1
POWER,1
NPY336,1
PVAX,1
hind limb ischemia,3
angiogenesis,1
functional blood flow,3
CHRONIC MYOCARDIALISCHEMIA,2
SWINE MODEL,2
THERAPEUTIC ANGIOGENESIS,2
POLYMER NANOPARTICLES,2
Y NPY,2
GROWTH,1
HYPERCHOLESTEROLEMIA,1
APOPTOSIS,1
PERFUSION,1
DELIVERY,1
Entrepreneurship,1
Firm performance,2
General selfefficacy,2
Survival,1
Job creation,2
Innovation,1
PERSONALITYTRAITS,1
FIRM PERFORMANCE,2
MEDIATING ROLE,2
SURVIVAL,1
GROWTH,1
CREATIVITY,1
MOTIVATION,1
ATTITUDES,1
SUCCESS,1
CULTURE,1
Young innovative company,3
Academic spinoff,2
New venture growth,3
Survival rate,2
Regional public policies,3
MANAGEMENT TEAM COMPOSITION,3
RESEARCHANDDEVELOPMENT,1
ENTREPRENEURIAL ORIENTATION,2
FIRM SURVIVAL,2
PERFORMANCE,1
TECHNOLOGY,1
CAPABILITIES,1
IMPACT,1
STRATEGIES,1
MORTALITY,1
,1
CHILDREN,1
hair thinning,2
telogen effluvium,2
Ganoderma lucidum,2
Linum usitatissimum L,3
Cynara scolymus L,3
Galeopsis segetum Neck,3
rutin,1
ornithine,1
ANDROGENETIC ALOPECIA,2
HAIR LOSS,2
POLYAMINES,1
NUTRITION,1
HEALTH,1
SERUM,1
IRON,1
ZINC,1
Cancer,1
Chemotherapeutic agent,2
Cytotoxicity,1
Drug delivery systems,3
Multidrug resistance,2
Nanocarriers,1
Nanotechnology,1
Nucleic acid,2
Reticuloendothelial system,2
Targeted drug delivery,3
Tumor,1
SOLID LIPID NANOPARTICLES,3
MAGNETIC NANOPARTICLES,2
POLYMERIC MICELLES,2
INVITRO,1
HYDROGEL NANOPARTICLES,2
PLGA NANOPARTICLES,2
CARBON NANOTUBES,2
CLINICALTRIALS,1
BREASTCANCER,1
QUANTUM DOTS,2
Hepatitis C,2
Access to medicine,3
Tiered pricing,2
Voluntary licensing,2
Universal access,2
Health equity,2
Africa,1
,1
diving,1
decompression sickness,2
desaturation,1
oxygen window,2
preconditioning,1
CIRCULATING VENOUS BUBBLES,3
MAXIMAL OXYGENUPTAKE,2
PATENT FORAMEN OVALE,3
LARGE BLOODVESSELS,2
NEUTROPHIL ACTIVATION,2
ENDOTHELIAL DYSFUNCTION,2
DARK CHOCOLATE,2
LUMINAL ASPECT,2
SICKNESS,1
EXERCISE,1
Cerebral revascularization,2
Bypass,1
Vertebrobasilar artery,2
Dissecting aneurysm,2
Treatment,1
Surgical algorithm,2
BYPASS,1
OCCLUSION,1
OUTCOMES,1
SERIES,1
Current density,2
Dynamic membrane formation,3
Membrane fouling,2
Membrane bioreactors,2
FORMING DYNAMIC MEMBRANE,3
FILTRATION RESISTANCE,2
ELECTROCOAGULATION,1
IMPROVEMENT,1
BEHAVIOR,1
REMOVAL,1
QUALITY,1
IMPACT,1
UNIT,1
,1
STREPTOCOCCUSPNEUMONIAE VIRULENCE,2
ACUTE LUNG INJURY,3
IMMUNOMODULATORY PROPERTIES,2
UPDATED RECOMMENDATIONS,2
ADVISORYCOMMITTEE,1
CONJUGATE VACCINE,2
CLINICALPRACTICE,1
EPITHELIALCELLS,1
PROTECTS MICE,2
ACTIVATION,1
MRDT,1
Fever,1
Malaria,1
Demand,1
Social groups,2
Providers,1
Community members,2
,1
xenogeneic epitopes,2
calcification,1
oxidative injury,2
bioprosthetic heart valves,3
IMMUNERESPONSE,1
BOVINE PERICARDIUM,2
AORTICVALVE,1
WILDTYPE,1
INVITRO,1
PORCINE,1
COLLAGEN,1
XENOTRANSPLANTATION,1
IMPLANTATION,1
LEAFLETS,1
history of France,3
Napoleonic wars,2
militaryhistorical anthropology,2
partisans,1
Soult,1
Florian,1
Bory de SaintVincent,3
,1
,1
,1
substrate,1
container,1
Darcys law,2
strain gauge,2
seedling,1
PICEAGLAUCA SEEDLINGS,2
PHYSICALPROPERTIES,1
SPHAGNUM PEAT,2
GROWTH,1
MANAGEMENT,1
PERLITE,1
AMER1 gene,2
case report,2
congenital heart disease,3
KCNE1 gene,2
wholeexome sequencing,2
,1
,1
INTELLECTUAL PROPERTY,2
ECONOMICANALYSIS,1
TITLE SYSTEMS,2
LAND,1
COPYRIGHT,1
PATENT,1
LAW,1
REGISTRATION,1
RIGHTS,1
RULES,1
,1
,1
,1
PROGRAM,1
PREP,1
RISK,1
COVID19,1
network pharmacology,2
UPLCQ,1
TOFMS,1
Yupingfeng Powder,2
TRADITIONAL CHINESE MEDICINE,3
DRUG TARGET IDENTIFICATION,3
ASTRAGALOSIDE IV,2
WEB SERVER,2
RADIX,1
EXTRACT,1
POLYSACCHARIDES,1
PROFILES,1
WOGONIN,1
GAMMA,1
Medication,1
Compound shortacting oral contraceptives,4
Obstetrics and gynecology,3
Big data,2
ESTRADIOL VALERATE,2
ETHINYL ESTRADIOL,2
Artificial intelligence,2
advance robot direct interface controller,5
interface,1
rotation per minute,3
hexadecimal,1
interfacing technique tool machining robot,5
American standard code for information interchange,6
general user interface,3
autonomous computer numeric control,4
oil country tubular goods,4
,1
Aortoiliac occlusive disease,3
iliac stent,2
internal iliac artery atherosclerosis,4
major adverse limb events,4
WALL SHEARSTRESS,2
ENDOVASCULAR TREATMENT,2
MURRAYS LAW,2
STANDARDS,1
ATHEROSCLEROSIS,1
CONSENSUS,1
SOCIETY,1
LESIONS,1
Reciprocating compressor,2
Piston pump,2
Liquid piston,2
Hybrid power machine,3
Cooling,1
Indicator efficiency,2
Flow rate,2
HEATTRANSFER,1
AIR,1
OIL,1
EFFICIENCY,1
,1
PATENT FORAMEN OVALE,3
EMBOLISM,1
SOLUBILITY,1
WATER,1
Technological innovations,2
Energy consumption,2
NARDL,1
Institutional performance,2
BRICS countries,2
FINANCIAL DEVELOPMENT,2
EMPIRICALEVIDENCE,1
CO2 EMISSIONS,2
TECHNOLOGICALINNOVATION,1
TRADE OPENNESS,2
TIMESERIES,1
IMPACT,1
INCOME,1
SUSTAINABILITY,1
GROWTH,1
robotic and autonomous systems,4
drones,1
crawlers,1
remotely operated vehicles,3
Internet of Robotic Things,4
data governance,2
user interface,2
international standards,2
DATA GOVERNANCE,2
Pregnancy,1
Unwanted,1
Unintended,1
Termination,1
Unsafe abortion,2
Womens health,2
,1
opioid,1
overdose,1
naloxone,1
emergency medical services,3
first responder,2
HOSPITAL CARDIACARREST,2
PROGRAMS PROVIDING NALOXONE,3
UNITEDSTATES,1
EXPANDED ACCESS,2
PREVENTION,1
DRUG,1
LAW,1
RESUSCITATION,1
SURVIVAL,1
STROKE,1
barometric pressure,2
climate change,2
endangered autochthonous breed,3
genetic diversity,2
gust speed,2
HispanoArabian horse breed,3
livestock,1
temperatures,1
average wind speed,3
EFFECTIVE POPULATIONSIZE,2
RANGE SHIFTS,2
PEDIGREE,1
ADAPTATION,1
TEMPERATURE,1
VARIABILITY,1
CONSERVATION,1
EVOLUTION,1
COANCESTRY,1
PLASTICITY,1
,1
FOURIERTRANSFORM RAMAN,2
SHOCKWAVES,1
VELOCITYMEASUREMENTS,1
GLOBAL VELOCIMETRY,2
ALKALI ATOMS,2
D2 LINES,2
LASER,1
INTERFEROMETER,1
SPECTROSCOPY,1
ULTRAFAST,1
Liver tissue engineering,3
Vascular reconstruction,2
Endothelialization,1
Decellularized livers,2
Transplantation,1
PRIMARY HUMAN HEPATOCYTES,3
EXTRACELLULARMATRIX,1
ENDOTHELIALCELLS,1
PORCINE KIDNEYS,2
PLASMAPROTEINS,1
HEPG2 CELLS,2
BINDING,1
DECELLULARIZATION,1
PREDICTIVITY,1
ANTITHROMBIN,1
Rheumatoid arthritis,2
Rab5a,1
Internalization of TLR4,3
Xiaowugui decoction,2
Macrophage,1
TOLLLIKE RECEPTORS,2
NFKAPPAB,1
REGULATORY FACTOR3,2
INFLAMMATION,1
ACTIVATION,1
MECHANISMS,1
INDUCTION,1
PATHWAYS,1
20R25methoxyldammarane3 beta12 beta20triol,3
Anticancer mechanisms,2
Isolation and identification,3
Metabolites,1
Panax ginseng,2
HUMAN INTESTINAL MICROFLORA,3
ANTITUMORACTIVITY,1
PANAXNOTOGINSENG,1
NATURALPRODUCT,1
GINSENG,1
20S25METHOXYLDAMMARANE3BETA,1
BIOTRANSFORMATION,1
PHARMACOKINETICS,1
PROTOPANAXADIOL,1
IDENTIFICATION,1
cell alignment,2
clinical trials,2
intestine,1
muscle,1
nerve,1
vascular tissue,2
OXYGEN GENERATING SCAFFOLDS,3
INTRACELLULAR CALCIUM,2
NEURITE ALIGNMENT,2
NETWORK FORMATION,2
ORIENTATION,1
ADHESION,1
MECHANOTRANSDUCTION,1
BIOMATERIALS,1
CURVATURE,1
HYDROGELS,1
Axillary dissection,2
breast cancer,2
methylene blue dye,3
sentinel node,2
NEOADJUVANT CHEMOTHERAPY,2
AXILLARY DISSECTION,2
SURGERY,1
VALIDATION,1
SUBAREOLAR,1
MANAGEMENT,1
INJECTION,1
Atlantic salmon,2
fish welfare,2
genetic resistance,2
policy instruments,2
regulation,1
salmon lice,2
selective breeding,2
GENETICRESOURCES,1
PROTECTION,1
ACCESS,1
EFFICIENCY,1
,1
INSECTICIDETREATED NETS,2
BED NETS,2
COUNTRIES,1
,1
,1
generic drugs,2
health expenditures,2
pharmaceutical policies,2
prices,1
BRANDNAME DRUGS,2
MEDICARE PART D,3
POTENTIAL SAVINGS,2
HEALTHCARE,1
CANCER DRUGS,2
PHARMACEUTICAL POLICY,2
PATIENTS PERCEPTIONS,2
HIGHCOST,1
MEDICINES,1
COUNTRIES,1
Network pharmacology,2
Osteoarthritis,1
Panlongqi Tablet PLQT,3
Inflammation,1
Cartilage,1
Subchondral bone,2
TOLLLIKE RECEPTORS,2
CHONDROCYTES,1
SYNOVITIS,1
PERLECAN,1
PATHWAY,1
Immune homeostasis,2
Acute lung injury,3
NLRP3 inflammasome,2
Pyroptosis,1
Th17 Treg balance,3
Zukamu granules,2
NETWORK PHARMACOLOGY,2
PREDICTION,1
eHealth,1
electronic prescription,2
process modeling,2
state diagram,2
COVID19,1
vaccination,1
vaccine,1
medical,1
communication,1
platform,1
,1
counterfeit goods,2
illicit trafficking,2
infringement of intellectual property rights,5
copyright holder,2
consumer,1
forgery,1
SHADOW ECONOMY,2
Legal form,2
Minimum capital requirements,3
Signaling,1
Access to debt,3
Financial constraints,2
CREDIT MARKETS,2
CONSTRAINTS,1
PATENTS,1
RISK,1
ENTRY,1
AVAILABILITY,1
EQUILIBRIUM,1
COMPETITION,1
VALUATION,1
FOUNDERS,1
extravascular lung water,3
fluid responsiveness,2
global enddiastolic volume,3
hemodynamic monitoring,2
preload responsiveness,2
shock,1
EXTRAVASCULAR LUNG WATER,3
ENDDIASTOLIC VOLUME,2
FLUID RESPONSIVENESS,2
CRITICALLYILL,1
PULSE PRESSURE,2
MECHANICAL VENTILATION,2
BLOODVOLUME,1
INFANTS,1
THERMODILUTION,1
MORTALITY,1
Grounded theory,2
Chaos theory,2
COVID19,1
Technological response,2
Theory of technological response and progress in chaos,8
,1
kinematics,1
joint angles,2
biofeedback,1
locomotion,1
fetlock,1
IMU,1
variability,1
range of motion,3
gait analysis,2
lameness,1
INDUCED FORELIMB LAMENESS,3
3DIMENSIONAL KINEMATICS,2
DISTAL PORTION,2
LOCOMOTION,1
SYSTEM,1
WALK,1
AGREEMENT,1
ELEVATION,1
TREADMILL,1
MOVEMENT,1
Noam Chomsky,2
intellectual engagement,2
political activism,2
pandemic,1
ethos,1
,1
infertility,1
intrauterine insemination,2
IUI,1
progesterone,1
unexplained infertility,2
ovarian stimulation,2
INVITRO FERTILIZATION,2
SERUM PROGESTERONE,2
PHYSIOLOGICAL TRIGGER,2
PLASMA PROGESTERONE,2
GONADOTROPIN,1
RISE,1
CYCLES,1
RATES,1
PROBABILITY,1
GESTATIONS,1
Mandatory vaccination,2
Fundamental rights,2
COVID19,1
Vaccine geopolitics,2
Justice,1
EXEMPTIONS,1
Nobel Prize,2
Controversy,1
Antidiabetic hormone,2
antisemitism,1
Pancreina,1
Insulin,1
ANTISEMITISM,1
Industrial Property,2
Patent,1
Trademark,1
Technology,1
Commercialization,1
,1
,1
,1
antibiotic resistance,2
pointofcare diagnosis,2
narrowspectrum drugs,2
monopoly pricing,2
ADJUVANTS,1
AngioVac R,2
thrombus,1
thrombectomy,1
cardiopulmonary bypass,2
cerebral protection,2
patent foramen,2
,1
,1
COPYRIGHT PROTECTION,2
COMPUTERPROGRAMS,1
FAIRUSE,1
ART,1
LAW,1
,1
DATA PROTECTION,2
Trademarks,1
Value indicators,2
Trademark lifecycle,2
Pharmaceutical industry,2
RESEARCHANDDEVELOPMENT,1
BRAND EXTENSION,2
MARKET VALUE,2
PRODUCT PREANNOUNCEMENT,2
INTELLECTUAL PROPERTY,2
SAMPLE SELECTION,2
INNOVATION,1
PERFORMANCE,1
PATENTS,1
SERVICES,1
Pharmaceuticals,1
Incremental innovation,2
Market exclusivity,2
Patents,1
D PRESCRIPTION BENEFIT,3
COSTEFFECTIVENESS,1
PATENT PROTECTION,2
ESCITALOPRAM,1
CITALOPRAM,1
PRICE,1
MEDICATION,1
PRODUCTS,1
INDUSTRY,1
DEMAND,1
Endogenous Growth,2
Intellectual Property Rights,3
Trade,1
Dynamic Game,2
GLOBAL PATENT PROTECTION,3
RESEARCHANDDEVELOPMENT,1
RIGHTS PROTECTION,2
INTERNATIONAL PROTECTION,2
INNOVATION,1
TECHNOLOGY,1
MODEL,1
POLITICIANS,1
IMITATION,1
Collaboration,1
Patents,1
Technological innovation,2
Power grids,2
Knowledge engineering,2
Economics,1
Social networking online,3
Evolution,1
smart grids SGs,3
network structure,2
patent collaboration network,3
social network analysis SNA,4
OPTIMAL POWERFLOW,2
MANAGEMENT RESEARCH,2
ENERGY MANAGEMENT,2
RENEWABLE ENERGY,2
OPEN INNOVATION,2
WORLD NETWORK,2
INDUSTRY,1
IMPACT,1
TECHNOLOGIES,1
CHALLENGES,1
intellectual property rights,3
patents,1
designs,1
trademarks,1
economic development,2
firm growth,2
ECONOMICGROWTH,1
INNOVATION,1
TRADEMARKS,1
INDICATOR,1
SMES,1
Differenceindifferences,1
Intellectual property rights protection,4
Manufacturing firmsindustry,2
Productivity,1
Trade liberalization,2
PATENT PROTECTION,2
FINANCIAL DEVELOPMENT,2
INTERNATIONALTRADE,1
INTERMEDIATE INPUTS,2
LEVEL PRODUCTIVITY,2
ECONOMICGROWTH,1
INNOVATION,1
QUALITY,1
FIRMS,1
INSTITUTIONS,1
network theory,2
intellectual property,2
subsidiaries,1
internal networks,2
smallworldness,1
pharmaceuticals,1
RESEARCHANDDEVELOPMENT,1
SMALLWORLD,1
COLLABORATION NETWORKS,2
MULTINATIONALENTERPRISE,1
DEVELOPMENT STRATEGIES,2
KNOWLEDGE SPILLOVERS,2
ABSORPTIVECAPACITY,1
PATENT PROTECTION,2
JOINT VENTURES,2
COUNTRY,1
CO2 Emissions,2
Green patent,2
STIRPAT Model,2
Regional effect,2
IMPACT FACTORS,2
INNOVATION,1
ENERGY,1
POPULATION,1
STIRPAT,1
CONSUMPTION,1
SPILLOVERS,1
DIFFUSION,1
US,1
Technology strategy,2
Bibliometrics,1
Animal health,2
Tech mining,2
Semantic TRIZ,2
PATENT LANDSCAPE ANALYSIS,3
TECHNOLOGY,1
INNOVATION,1
CLAIMS,1
SYNBIOTICS,1
PREBIOTICS,1
TRENDS,1
Access to medicinal products,4
Intellectual property,2
TRIPS flexibilities,2
WHO,1
African region,2
,1
Limiting effect,2
Scope of protection,3
Patent claim,2
Doctrine of Equivalents,3
Subjectmatter of a claim,4
Preamble and technical features section of a claim,8
Prior art,2
,1
Incentives,1
pharmaceutical innovation,2
Epogen,1
empirical research,2
pharmaceutical industry,2
POLICY,1
Open innovation,2
IPRs,1
Knowledge spillovers,2
RD,1
,1
Environmental protection tax,3
Corporate green technology innovation,4
RD investment,2
Innovative human capital,3
Financing constraints,2
,1
Human right,2
Intellectual Property,2
Health Right,2
Right to Life,3
Patents,1
,1
,1
,1
3D printing,2
intellectual property rights,3
blockchain,1
conceptual platform framework,3
TECHNOLOGY,1
BUSINESS,1
ARCHITECTURE,1
CHALLENGES,1
MODULARITY,1
GOVERNMENT,1
INNOVATION,1
SERVICES,1
INTERNET,1
MODELS,1
,1
LOCAL SEARCH,2
PATENT,1
LAW,1
TECHNOLOGIES,1
EXPLORATION,1
CREATIVITY,1
PSYCHOLOGY,1
KNOWLEDGE,1
TESTS,1
TOO,1
,1
PROPERTY RULES,2
LIABILITY RULES,2
LAW,1
COPYRIGHT,1
PSYCHOLOGY,1
INNOVATION,1
Intellectual property rights,3
Innovation,1
RD,1
Economic growth,2
Metaanalysis,1
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
PATENT PROTECTION,2
TECHNOLOGYTRANSFER,1
SPILLOVERS,1
INVESTMENT,1
PRODUCTIVITY,1
KNOWLEDGE,1
DEMAND,1
INDUCE,1
Intellectual property rights,3
Taxation,1
Innovation,1
Economic growth,2
E62,1
H20,1
O30,1
O31,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGYTRANSFER,1
ENDOGENOUS GROWTH,2
ECONOMICGROWTH,1
PROTECTION,1
POLICY,1
LOCATION,1
PATENTS,1
TRADE,1
Innovation,1
New products,2
Commercialization,1
Employment protection laws,3
Institutions,1
Small firms,2
INSTITUTIONBASED VIEW,2
INNOVATION PERFORMANCE,2
CORPORATE GOVERNANCE,2
KNOWLEDGE SOURCES,2
FIRM PERFORMANCE,2
LABORMARKETS,1
IMPACT,1
CAPABILITIES,1
ENGAGEMENT,1
MANAGEMENT,1
digital innovation,2
green total factor productivity,4
resource allocation efficiency,3
digital patent,2
INTELLECTUAL PROPERTY,2
TECHNOLOGY,1
PROTECTION,1
GROWTH,1
MODELS,1
FIRMS,1
shielded band sprayer,3
healthy food,2
selective plant protection,3
HERBICIDES,1
FOOD,1
access to medicine,3
ChinaUS trade disputes,3
regulatory exclusivities,2
undisclosed test data,3
TRIPS Agreement,2
,1
Human rights,2
health,1
human rights impact assessment,4
intellectual property,2
international trade,2
affordable medicines,2
HEALTH,1
ACCESS,1
POLICY,1
,1
,1
China,1
history,1
institutionbased view,2
intellectual property rights IPR,4
United States,2
INSTITUTIONBASED VIEW,2
CHINA,1
INNOVATION,1
PROTECTION,1
STRATEGIES,1
EVOLUTION,1
INVENTION,1
AMERICA,1
PATENTS,1
POLICY,1
Intellectual property rights,3
Income inequality,2
Endogenous growth,2
Nonhomothetic preferences,2
Consumption pattern,2
RESEARCHANDDEVELOPMENT,1
INEQUALITY,1
PROTECTION,1
PATENTS,1
IMPACT,1
China,1
Intellectual property,2
Legal transplanting,2
Local communities,2
Patent law,2
Traditional medical knowledge,3
INTERNATIONALLAW,1
TRIPS AGREEMENT,2
LEGAL,1
RIGHTS,1
TRADE,1
HEALTH,1
PRESERVATION,1
CONFUCIANISM,1
RENAISSANCE,1
INNOVATIONS,1
Intellectual property rights,3
patent law,2
traditional knowledge,2
WIPO,1
India,1
Traditional Knowledge Digital Library,4
REFORMULATION REGIME,2
PROPERTYRIGHTS,1
GOVERNMENT,1
PATENTS,1
IGC,1
IP,1
data exclusivity,2
clinical trial data,3
regulatory approval,2
pharmaceutical industry,2
access to medicines,3
TRIPS Plus,2
intellectual property rights,3
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PROTECTION,1
PHARMACEUTICALS,1
,1
ESSENTIAL MEDICINES,2
DEVELOPINGNATIONS,1
ACCESS,1
THAILAND,1
BRAZIL,1
INNOVATION,1
PATENTS,1
CANADA,1
vaccine hoarding,2
patent protection,2
neoliberalism,1
financialisation,1
inequalities,1
COVID19,1
,1
,1
,1
Secrecy,1
Innovation,1
Appropriability,1
Secrecy management lifecycle,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
PRODUCT DEVELOPMENT,2
EMPIRICALEVIDENCE,1
PATENTS,1
INNOVATION,1
FIRMS,1
APPROPRIABILITY,1
MECHANISMS,1
STRATEGIES,1
Anti dumping sanctions,3
USChina trade conflict,3
Innovation,1
Patents,1
Products,1
INTELLECTUAL PROPERTYRIGHTS,2
IMPACT,1
COMPETITION,1
KNOWLEDGE,1
PATENTS,1
PERFORMANCE,1
BARRIERS,1
DUTIES,1
PANEL,1
Economic growth,2
R  D,3
Firmheterogeneity,1
Innovation by incumbents,3
IPR policy,2
INTELLECTUAL PROPERTYRIGHTS,2
SCHUMPETERIAN MODEL,2
PATENT PROTECTION,2
COMPETITION,1
POLICY,1
INDUSTRY,1
PRODUCTIVITY,1
FIRMS,1
R  D internationalization,4
Intellectual property rights IPR,4
Knowledge spillovers,2
Productivity performance,2
Emerging economies,2
GEOGRAPHIC SCOPE,2
OUTWARD FDI,2
INNOVATION,1
PERFORMANCE,1
PATENTS,1
DIVERSIFICATION,1
APPROPRIABILITY,1
COLLABORATION,1
INVENTORS,1
LOCATION,1
access and benefit sharing,4
farmers rights,2
Nigeria,1
plant breeders rights,3
plant variety protection,3
TRIPS,1
FARMERS RIGHTS,2
COMMUNITY,1
LEGAL,1
Intellectual property,2
patents,1
pandemic,1
COVID19,1
right to health,3
,1
,1
,1
American Aircraft Industry,3
Boeing Corporation,2
Manufacturers Aircraft Association,3
tariff policy,2
Wright patent,2
protectionism,1
COMPETITION,1
CHINA,1
industrial application,2
lowpressure plasmas,2
medical  pharmaceutical sector,4
planetary protection,2
sterilization,1
BACILLUSSUBTILIS SPORES,2
N2O2 GASMIXTURE,2
DEINOCOCCUSRADIODURANS,1
FLOWING AFTERGLOW,2
BACTERIALSPORES,1
GASEOUS PLASMA,2
OPERATIVE TIME,2
INACTIVATION,1
DECONTAMINATION,1
COMPLICATIONS,1
Antitrust,1
Consumer protection,2
Deception,1
FTC,1
Intellectual property,2
Mergers,1
HOSPITAL MERGERS,2
COMPETITION,1
Counterfeit products,2
Indonesian trademark law,3
Intellectual property law,3
,1
,1
ENVIRONMENTALPROTECTION,1
TECHNICAL CHANGE,2
CLIMATECHANGE,1
CO2 EMISSIONS,2
POLICIES,1
COMPETITION,1
TECHNOLOGY,1
MARKET,1
LESSONS,1
Innovation,1
Disclosures,1
Search,1
Incentives,1
Policy,1
Open innovation,2
OPEN SOURCE SOFTWARE,3
KNOWLEDGE EVIDENCE,2
PATENT PROTECTION,2
LOCAL SEARCH,2
ECONOMICS,1
UNCERTAINTY,1
EXPLORATION,1
IMPACT,1
COMMUNITIES,1
PERFORMANCE,1
Urban green innovation,3
Regional difference,2
Distribution dynamic,2
Convergence,1
Green patent,2
ECOINNOVATION,1
EMPIRICALEVIDENCE,1
ENVIRONMENTALREGULATION,1
PERFORMANCE,1
IMPACT,1
DRIVERS,1
Piracy,1
Software,1
Innovation,1
Intellectual property,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
MOVIE PIRACY,2
TECHNOLOGICALINNOVATION,1
DEVELOPMENT SPILLOVERS,2
SALES DISPLACEMENT,2
PRODUCTMARKET,1
RECORDED MUSIC,2
PROTECTION,1
COPYRIGHT,1
,1
ONACHIP,1
RECENT PROGRESS,2
Weak appropriability regimes,3
Nonpatent IP protection mechanisms,4
Value appropriation,2
FIRMS,1
multinationals,1
innovation,1
IPR protection,2
institutional distance,2
patents,1
inventive capabilities,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
INTELLECTUAL PROPERTY,2
DYNAMIC CAPABILITIES,2
ABSORPTIVECAPACITY,1
KNOWLEDGE TRANSFER,2
DETERMINANTS,1
TECHNOLOGY,1
LOCATION,1
FIRM,1
Environmental protection tax,3
Environmental protection subsidy,3
Digital green innovation DGI,4
Resource base,2
Technological innovation capability,3
High pollution enterprise,3
PERFORMANCE,1
IMPACT,1
dissection with patent false lumen,5
stroke due to air embolism,5
acute type a aortic dissection,5
deep hypothermic circulatory arrestdhca,4
total arch replacement,3
MORTALITY,1
PERFUSION,1
ANEURYSM,1
SURGERY,1
REPAIR,1
MALPERFUSION,1
STROKE,1
environmental regulation,2
technological innovation,2
carbon trading rights,3
energy efficiency,2
carbon peaking,2
carbon neutrality policies,3
MULTIFACTORIAL STRESS COMBINATION,3
CARBON EMISSIONS,2
CLIMATECHANGE,1
PERFORMANCE,1
GROWTH,1
Markup,1
Inflation rate,2
Nominal interest rate,3
Economic growth rate,3
Social welfare,2
Class struggle,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPMENT SUBSIDIES,2
CASH FLOW,2
GROWTH,1
MODEL,1
INEQUALITY,1
INNOVATION,1
PROTECTION,1
INFLATION,1
,1
AORTICVALVEREPLACEMENT,1
MAMMARY ARTERY,2
BYPASS,1
THORACOTOMY,1
Technology transfer,2
Technology transfer regulation,3
Regional development,2
Brazil,1
BAYHDOLE ACT,2
INTELLECTUAL PROPERTY,2
TRANSFER OFFICES,2
ACADEMIC ENTREPRENEURSHIP,2
COMMERCIALIZATION,1
PERFORMANCE,1
KNOWLEDGE,1
IMPACT,1
INNOVATION,1
CREATION,1
China,1
Innovation,1
Complementary effect,2
Government RD subsidies,3
Intellectual property rights protection,4
Pharmaceutical manufacturing industry,3
INSTITUTIONBASED VIEW,2
TAX INCENTIVES,2
TECHNOLOGICALCHANGE,1
DEVELOPINGCOUNTRIES,1
IPR PROTECTION,2
EFFICIENCY,1
PERFORMANCE,1
OWNERSHIP,1
PATENTS,1
COMPETITION,1
KEY WORDS,2
Interfaces,1
hybrid intangible goods,3
Industrial Design,2
Patent,1
Copyright,1
work of art,3
,1
Duck hepatitis a virus,4
Metaanalysis,1
Vaccine protection rate,3
Mainland China,2
Duck,1
MOLECULAR CHARACTERIZATION,2
HETEROGENEITY,1
Patent,1
Appropriability,1
Innovation collaboration,2
Open innovation,2
Services,1
Knowledgeintensive services,2
Intellectual property rights,3
OPENNESS,1
STRATEGY,1
MODEL,1
CAPABILITIES,1
PROTECTION,1
PARADOX,1
PATENTS,1
SEARCH,1
GROWTH,1
Competitive pressure,2
Innovation,1
Merger  acquisition,3
Takeover,1
Organization,1
Hierarchy,1
Incentive,1
Patents,1
RESEARCHANDDEVELOPMENT,1
CORPORATE GOVERNANCE,2
MARKET VALUE,2
FIRMS,1
UNCERTAINTY,1
SPILLOVERS,1
MODELS,1
STOCK,1
fragmentation,1
misappropriation,1
services,1
institutional environment,2
outsourcing,1
information and communication technologies,4
RESEARCHANDDEVELOPMENT,1
INTERNATIONAL EXPANSION,2
PROPERTYRIGHTS,1
MULTINATIONALCORPORATION,1
OFFSHORING INNOVATION,2
ORGANIZATIONAL DESIGN,2
ECONOMICGEOGRAPHY,1
TRANSACTION COSTS,2
PATENT PROTECTION,2
ENTRY STRATEGIES,2
Interrupted timeseries,2
Generic drugs,2
Physicians prescribing behaviour,3
Counterfactual analysis,2
Patent expiration,2
Pharmaceutical markets,2
TIMESERIES ANALYSIS,2
BRANDNAME,1
COST,1
MARKET,1
INTERVENTIONS,1
COMPETITION,1
STATINS,1
DOCTOR,1
POLICY,1
Corporate Governance,2
equity crowdfunding,2
direct shareholder structure,3
nominee structure,2
firm performance,2
VENTURE CAPITALINVESTMENT,2
EMPIRICALEVIDENCE,1
GOVERNANCE,1
CROWD,1
INNOVATION,1
KNOWLEDGE,1
CREATION,1
SUCCESS,1
FINANCE,1
WISDOM,1
COVID19 pandemic,2
incentives,1
intellectual property rights,3
law and economics,3
patent protection,2
INNOVATION,1
ANTICOMMONS,1
PROPERTY,1
TRAGEDY,1
DISEASES,1
COMMONS,1
Intellectual property,2
Prior art search,3
University library,2
Innovation Center Technological,3
Patent,1
SERVICES,1
ENTREPRENEURSHIP,1
Standards,1
Patents,1
SEP,1
Catchup,1
Incumbent,1
ICT,1
INTELLECTUAL PROPERTYRIGHTS,2
TELECOMMUNICATION INDUSTRY,2
ESSENTIAL PATENTS,2
MARKET VALUE,2
STANDARDS,1
INNOVATION,1
DETERMINANTS,1
TECHNOLOGY,1
CITATIONS,1
DIFFUSION,1
Appropriation,1
intellectual property,2
innovation,1
performance,1
strategy,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
FIRM,1
PATENTS,1
APPROPRIABILITY,1
DETERMINANTS,1
ENTERPRISES,1
PROTECTION,1
PATTERNS,1
INDUSTRY,1
Intellectual property right,3
Design right,2
Uncertainty,1
Beliefs,1
Learning,1
EMPIRICALEVIDENCE,1
PATENT,1
INNOVATION,1
MARKET,1
FIRMS,1
INCENTIVES,1
STRATEGIES,1
INFORMATION,1
PERFORMANCE,1
LITIGATION,1
ESCA,1
plasma enhanced chemical vapor deposition,5
Raman spectroscopy,2
SEM,1
thin polycrystalline diamond film,4
Zircaloy2 pins protection against oxidation,5
DIAMOND FILMS,2
THINFILMS,1
ALLOYS,1
SPECTROSCOPY,1
CORROSION,1
FUEL,1
Competition law,2
Intellectual property rights,3
Article 101 TFEU,3
Article 102 TFEU,3
Refusal to supply,3
Reverse payment agreements,3
FRAND terms,2
,1
economic growth,2
innovation,1
Intellectual property rights,3
metaanalysis,1
technology diffusion,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
LABOR DEMAND,2
TIMESERIES,1
INNOVATION,1
GROWTH,1
POLICY,1
RIGHTS,1
METAANALYSIS,1
PRODUCTIVITY,1
Illegal imitation,2
Intellectual property rights enforcement,4
Import prohibition,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
INNOVATION,1
WELFARE,1
GROWTH,1
,1
FORCED TECHNOLOGYTRANSFER,2
WTO LAW,2
US,1
CHINA,1
ECONOMICS,1
AUTONOMY,1
POLICY,1
Privatization,1
Economic growth,2
RD,1
Intellectual property rights,3
RESEARCHANDDEVELOPMENT,1
MIXED OLIGOPOLY,2
DEVELOPMENT COMPETITION,2
PRIVATE,1
PERFORMANCE,1
PROTECTION,1
OWNERSHIP,1
DUOPOLY,1
Cancer,1
crossnational,1
Europe,1
generics,1
health policy,2
pricing,1
ENHANCE PRESCRIBING EFFICIENCY,3
ONGOING INITIATIVES,2
CANCER MEDICINES,2
CLINICAL BENEFIT,2
DRUGS,1
BIOSIMILARS,1
COUNTRIES,1
IMPLEMENTATION,1
AUTHORITIES,1
THERAPIES,1
Cooperative patent classification,3
Patentbased framework,2
Principal component analysis,3
Random forest classifier,3
Technological knowledge stock,3
PRINCIPALCOMPONENT ANALYSIS,2
PATENT QUALITY ANALYSIS,3
ENERGYSTORAGE,1
MANAGEMENTSYSTEM,1
ELECTRIC VEHICLES,2
UNITEDSTATES,1
INNOVATION,1
PERFORMANCE,1
CHALLENGES,1
SUSTAINABILITY,1
Technological cooperation,2
Technological routes,2
Emerging technology,2
Sustainable technologies,2
Solar energy,2
CITATION NETWORK,2
OPEN INNOVATION,2
TRAJECTORIES,1
DYNAMICS,1
SYSTEMS,1
INFORMATION,1
INDUSTRY,1
CHINA,1
CELLS,1
Intellectual property,2
trade,1
China,1
panel data,2
threshold effect,2
INTELLECTUAL PROPERTYRIGHTS,2
BILATERAL INTRAINDUSTRY TRADE,3
FOREIGN DIRECTINVESTMENT,2
PATENT RIGHTS,2
GRAVITY MODEL,2
INTERNATIONALTRADE,1
EMPIRICALEVIDENCE,1
US EXPORTS,2
INNOVATION,1
DETERMINANTS,1
Zea mays L,3
ExPVP inbred lines,3
Quality traits,2
NCII design,2
Combining ability analysis,3
GCA,1
SCA,1
VARIETY,1
Tabebuia alliance,2
genotypingbysequencing,1
molecular marker,2
species identification,2
cultivar variation,2
fingerprints,1
GENETIC DIVERSITY,2
MICROSATELLITE MARKERS,2
MOLECULAR MARKERS,2
PROTECTION,1
EVOLUTION,1
ORIGIN,1
PrEP,1
modeling,1
PKPD,1
translation,1
repurposing,1
resourceconstrained,1
costefficient,1
PEP,1
NONNUCLEOSIDE REVERSETRANSCRIPTASE,2
ANTIRETROVIRAL DRUG CONCENTRATIONS,3
RESPONSE CURVE SLOPE,3
PREEXPOSURE PROPHYLAXIS,2
INVIVO,1
SECONDARY METABOLISM,2
PROTEINBINDING,1
VIRAL DYNAMICS,2
GENITALTRACT,1
600 MG,2
Strategy,1
Intellectual property protection mechanism,4
Outbound open innovation,3
Innovation performance,2
Impromptu intellectual property strategy,4
Collaboration,1
APPROPRIATION MECHANISMS,2
PRODUCT INNOVATION,2
EMPIRICALEVIDENCE,1
IP STRATEGY,2
APPROPRIABILITY,1
PERFORMANCE,1
MANAGEMENT,1
PATENTS,1
FIRMS,1
COOPETITION,1
Indigenous peoples,2
Indigenous Traditional Knowledge,3
Traditional Knowledge Commons,3
Intellectual Property Rights,3
sui generis systems,3
global benefitsharing,2
PROPERTY,1
RIGHTS,1
TRAGEDY,1
,1
VERTICAL INTEGRATION,2
PATENT PROTECTION,2
RIGHTS,1
DETERMINANTS,1
CONTRACTS,1
Intellectual property IP,3
Intellectual property right IPR,4
Traditional knowledgeTK,2
,1
,1
RESEARCHANDDEVELOPMENT,1
ACCUMULATION,1
INFORMATION,1
INVESTMENT,1
Least developed countries,3
LDC transitional exemption,3
World trade organization,3
QUANTILE REGRESSION,2
PATENT PROTECTION,2
ECONOMICGROWTH,1
INNOVATION,1
RIGHTS,1
TRADE,1
DIFFERENCE,1
IMPACT,1
DETERMINANTS,1
POLICY,1
Intellectual property rights,3
Market expansion effects,3
Market power effects,3
Poisson pseudo maximum likelihood,4
Third countries,2
PATENT RIGHTS,2
INTERNATIONALTRADE,1
EXPORTS,1
GRAVITY,1
DETERMINANTS,1
TECHNOLOGY,1
MATTER,1
AGREEMENTS,1
IMITATION,1
QUALITY,1
Intellectual property rights,3
Seed trade,2
Gravity equation,2
PATENT RIGHTS,2
PROTECTION,1
INNOVATION,1
ADOPTION,1
GRAVITY,1
ACCESS,1
DETERMINANTS,1
COUNTRIES,1
,1
,1
acquisitions,1
contracts,1
technology ventures,2
innovation disclosure,2
adverse selection,2
RESEARCHANDDEVELOPMENT,1
ADVERSE CHANGE CLAUSES,3
JOINTVENTURES,1
MERGERS,1
MARKET,1
FIRMS,1
PERFORMANCE,1
SELECTION,1
EARNOUTS,1
INFORMATION,1
medical countermeasures against COVID19,4
immunization as a global public good,6
community interests under international law,5
international intellectual property rights,4
TRIPS Agreement,2
TRADE,1
Wave energy converter,3
Multipurpose shore protection,3
Wave breaking,2
Artificial reef,2
Proof of concept,3
Invention,1
TECHNOLOGIES,1
BREAKING,1
BREAKWATER,1
Decompression illness,2
Pathophysiology,1
Righttoleft shunt,2
Wetsuit,1
NEOPRENE WETSUIT,2
SHUNTS,1
Intraindustry trade,2
international trade,2
intellectual property rights,3
INTRAINDUSTRY TRADE,2
PATENT RIGHTS,2
MONOPOLISTIC COMPETITION,2
PRODUCT DIFFERENTIATION,2
INTERNATIONALTRADE,1
DETERMINANTS,1
ECONOMIES,1
SCALE,1
Dural,1
fistula,1
dural sinus,2
embolization,1
BALLOON PROTECTION,2
SIGMOID SINUS,2
ONYX,1
TRANSVERSE,1
,1
INFORMATION,1
COMPETITION,1
BIAS,1
Intellectual property rights,3
Innovation,1
Intellectual property,2
International trade,2
Technology policy,2
INCREASING RETURNS,2
PATENT PROTECTION,2
ECONOMICGROWTH,1
TRADE,1
RIGHTS,1
PRODUCT,1
INSTITUTIONS,1
SPILLOVERS,1
IMPACT,1
security,1
corporate security,2
competitiveness,1
information security,2
physical security,2
,1
IPRs,1
Segmented markets,2
Market penetration,2
Business stealing,2
Investment,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT STRENGTH,2
ENTRY,1
FIRMS,1
Trade secrets,2
Intellectual property,2
Competitive threats,2
Predation risk,2
Market dynamics,2
Product market concentration,3
RESEARCHANDDEVELOPMENT,1
PROPERTYRIGHTS,1
CORPORATE DISCLOSURE,2
ANALYST COVERAGE,2
COMPETITION,1
INNOVATION,1
INDUSTRY,1
INVESTMENTS,1
INFORMATION,1
OWNERSHIP,1
Intellectual property rights,3
International migration,2
Innovation,1
Knowledge flows,2
Brain drain,2
Diaspora,1
RESEARCHANDDEVELOPMENT,1
BRAINDRAIN,1
INTERNATIONAL MIGRATION,2
EMPIRICALEVIDENCE,1
PATENT PROTECTION,2
TRADE,1
GROWTH,1
IMPACT,1
INCOME,1
Banker directors,2
Green credit policy,3
Green innovation,2
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTALREGULATION,1
PATENT PROTECTION,2
PERFORMANCE,1
FINANCE,1
BOARDS,1
GUANXI,1
INCENTIVES,1
CHINA,1
MODEL,1
Agricultural biotechnology,2
Agricultural research output,3
Count data analysis,3
Public and private RD,4
Research and development investment,4
PRODUCTIVITY GROWTH,2
PUBLICINVESTMENT,1
INDUSTRY,1
Corporate key laboratory,3
Innovation,1
Corporate science,2
Human capital,2
R  D subsidy,4
RESEARCHANDDEVELOPMENT,1
INNOVATION EVIDENCE,2
FINANCIAL CONSTRAINTS,2
INVESTMENT,1
SCIENCE,1
PATENT,1
RIGHTS,1
EXPERIENCE,1
MANAGEMENT,1
RELIGION,1
democratization of science and technology,5
genetic diversity,2
intellectual property,2
maize germplasm,2
onfarm genetic diversity,3
Zea mays,2
HYBRID MAIZE,2
GERMPLASM,1
CORN,1
Intellectual property rights,3
Innovation,1
Imitation,1
Duopoly,1
Developing countries,2
PATENT PROTECTION,2
PARALLEL TRADE,2
INNOVATION,1
PRICE,1
PHARMACEUTICALS,1
DIFFERENTIATION,1
CHOICE,1
Licensing,1
Sequentiality,1
Oligopoly,1
Competition,1
Technology adoption,2
L13,1
L20,1
L40,1
DIVISIONALIZATION,1
MARKET,1
China,1
intellectual property protection,3
legal enforcement,2
INSTITUTIONBASED VIEW,2
PROTECTION,1
REFORM,1
Forecasting technology trend,3
Patent analysis,2
Low emission vehicle,3
OFTHEART,1
ELECTRIC VEHICLES,2
EMERGING TECHNOLOGIES,2
EMPIRICALANALYSIS,1
GOVERNMENT POLICY,2
HYBRID,1
INNOVATION,1
CLASclosure,1
ASDPDAPFO,1
CONAcongenital heart disease,3
adults,1
EMBPembolic protection devices,3
IAFimaging,1
angiographicfluoroscopic,1
TRANSESOPHAGEAL ECHOCARDIOGRAPHY,2
PARADOXICAL EMBOLISM,2
STROKE,1
THROMBUS,1
SIZE,1
RISK,1
valuation,1
licensing deal,2
drug class,2
royalty rate,2
upfront fee,2
milestones,1
deal value,2
regression,1
biotech industry,2
attrition rate,2
TECHNOLOGY,1
PROTECTION,1
MARKET,1
Appropriation mechanisms,2
Formal appropriation,2
Informal appropriation,2
External search openness,3
Incremental innovators,2
Radical innovators,2
INTELLECTUAL PROPERTY,2
CAPTURE VALUE,2
PATENTS,1
SEARCH,1
INNOVATIONS,1
PERFORMANCE,1
PROTECTION,1
APPROPRIABILITY,1
DISCLOSURE,1
STRATEGY,1
Environmental protection expenditure,3
Innovation,1
Patent,1
Longitudinal data,2
PANELDATA,1
GROWTH,1
SPILLOVERS,1
IMPACT,1
POLICY,1
WEAK,1
Industrial design,2
intellectual property,2
startups,1
innovation adoption,2
INNOVATION,1
PASSION,1
MODELS,1
,1
MACULAR HOLE SURGERY,3
INDOCYANINE GREEN,2
TRYPAN BLUE,2
TRIAMCINOLONE ACETONIDE,2
SUBRETINAL INJECTION,2
PATENT BLUE,2
RABBITS,1
VITRECTOMY,1
Local content requirements,3
Solar energy,2
Auctions,1
Green industrial policy,3
Staggered differenceindifference,2
Propensity score matching,3
RENEWABLE ELECTRICITY,2
PROTECTION,1
DEPLOYMENT,1
INDUSTRY,1
POWER,1
BIAS,1
Appropriation strategy,2
counterfeit,1
intellectual property rights,3
litigation,1
value capturing,2
RESEARCHANDDEVELOPMENT,1
STRATEGIES,1
PATENTS,1
Antelope horn,2
Cyt b,2
identification,1
melting curve analysis,3
LINKEDIMMUNOSORBENTASSAY,1
PCR,1
DIFFERENTIATION,1
PRODUCT,1
Remanufacturing,1
Patented product,2
Fixedfee licensing,2
Royalty licensing,2
Game theory,2
RESEARCHANDDEVELOPMENT,1
TAKEBACK,1
COMPETITION,1
STRATEGY,1
CONTRACTS,1
CHANNEL,1
MARKET,1
PRODUCTS,1
genetic resources,2
TRIPs Agreement,2
Convention on Biological Diversity,4
patent,1
disclosure of origin,3
,1
Intellectual property IP,3
Patents,1
Indices,1
TRIPS,1
Law on the books,4
Law in practice,3
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
RIGHTS,1
KNOWLEDGE,1
PERFORMANCE,1
STRENGTH,1
COUNTRY,1
INDEX,1
GOVERNANCE,1
biotechnology,1
developing countries,2
economic development,2
industry studies,2
DEVELOPMENT INVESTMENT,2
POLICY,1
PROTECTION,1
FOOD,1
,1
RULES,1
,1
JUSTICE,1
PRINGLE,1
COURT,1
CNO,1
CRMO,1
Treatment,1
Trial,1
Study,1
Osteomyelitis,1
Consensus,1
Outcome,1
RECURRENT MULTIFOCAL OSTEOMYELITIS,3
RHEUMATOLOGY PRELIMINARY DEFINITION,3
SAPHO SYNDROME,2
CHILDREN,1
IMPROVEMENT,1
MONOCYTES,1
ANAKINRA,1
budget impact analysis,3
drugs,1
Europe,1
nononcological diseases,2
ultraorphan,1
RARE,1
PRINCIPLES,1
RD,1
Innovation,1
IPRprotection,1
Multinational,1
Employee mobility,2
INTELLECTUAL PROPERTYRIGHTS,2
RENTSEEKING,1
TRADE,1
PATENT,1
FIRMS,1
IMITATION,1
LOCATION,1
MOBILITY,1
IMPACT,1
RACE,1
,1
,1
Financial development,2
RD activities,2
Patent protection,2
Knowledge production function,3
ARDL,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
SECTOR DEVELOPMENT,2
INNOVATION,1
LIBERALIZATION,1
DETERMINANTS,1
PERFORMANCE,1
DEPENDENCE,1
OPENNESS,1
SYSTEMS,1
DIGITAL SUSTAINABILITY,2
DATA PROTECTION,2
PRIMARY EDUCATION,2
COMPETENCYBASED TEACHING,2
PROFESSIONAL TRAINING,2
COMPETENCE,1
EDUCATION,1
Pharmaceutical market,2
COVID19,1
medications,1
patent protection,2
parallel imports,2
medical law,2
,1
Bibliometric,1
Patent,1
Groundwater contamination,2
Social network analysis,3
SOCIAL NETWORK ANALYSIS,3
AFFILIATION NETWORKS,2
SUSTAINED TREATMENT,2
PATENT ANALYSIS,2
WATERTREATMENT,1
BIODEGRADATION,1
TECHNOLOGY,1
ADSORPTION,1
SCIENCE,1
IMPACT,1
Incremental innovation,2
Transition economies,2
Financing constraints,2
IPR protection,2
Probit model,2
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT INVESTMENT,2
PATENT PROTECTION,2
CREDIT CONSTRAINTS,2
PRODUCT INNOVATION,2
EMPIRICALEVIDENCE,1
GROWTH,1
IMITATION,1
DETERMINANTS,1
TECHNOLOGY,1
,1
GENETICRESOURCES,1
DENT CORN,2
GREENREVOLUTION,1
DIVERSITY,1
IMPROVEMENT,1
PROTECTION,1
INBREDS,1
intellectual property,2
copyright,1
patent,1
plagiarism,1
creative commons,2
DISREGARD INADMISSIBLE EVIDENCE,3
CHILDRENS RESPONSE,2
PIRACY,1
LAW,1
COPYCAT,1
NORMS,1
Electrostatic discharges ESDs,3
lumpedelement model LEM,3
protection,1
spacecraft SC SpektrR,3
,1
fluidisedbed steam dryer,3
product inlet,2
distribution plate,2
plug protection system,3
rotary weir,2
,1
experience,1
innovation,1
patents,1
pharmaceuticals,1
RESEARCHANDDEVELOPMENT,1
EMPIRICALANALYSIS,1
TECHNOLOGICAL DIVERSIFICATION,2
PATENT PROTECTION,2
MARKETSTRUCTURE,1
PRODUCT,1
PERFORMANCE,1
INDICATORS,1
MANAGEMENT,1
SEARCH,1
Absorptive capacity,2
Buyerseller relationships,2
Innovation protection,2
Types of customers,3
ABSORPTIVECAPACITY,1
KNOWLEDGE,1
TIES,1
ACQUISITION,1
PERFORMANCE,1
ALLIANCES,1
NETWORK,1
TRUST,1
FIRMS,1
EMBEDDEDNESS,1
Aspiration,1
Recurrent laryngeal nerve,3
Infant,1
Esophagus,1
Deglutition,1
Deglutition disorders,2
PATENT DUCTUSARTERIOSUS,2
VOCAL FOLD IMMOBILITY,3
THYROIDSURGERY,1
EMG ACTIVITY,2
INJURY,1
PARALYSIS,1
SUCKING,1
MODEL,1
MECHANISM,1
RECOVERY,1
intellectual property pledge financing,4
enterprise innovation,2
urban sustainable development,3
digital economy,2
staggered DID,2
RESEARCHANDDEVELOPMENT,1
ORGANIZATIONAL INNOVATION,2
SHORTTERMISM,1
MARKET VALUE,2
INVESTMENT,1
PERFORMANCE,1
PATENTS,1
HORIZON,1
Intellectual property,2
Judicial protection,2
Innovationdriven,1
Business performance,2
K40,1
O31,1
O34,1
L25,1
INTELLECTUAL PROPERTYRIGHTS,2
FIRM PERFORMANCE,2
OPERATING PERFORMANCE,2
PATENT RIGHTS,2
PROTECTION,1
DYNAMICS,1
IMPACT,1
POLICY,1
GROWTH,1
ENFORCEMENT,1
alternate crystalline form,3
bioequivalency,1
neratinib,1
polymorphism,1
BREASTCANCER,1
Sectoral innovation system,3
Solar photovoltaics,2
Institutions,1
Crystallinesilicon market,2
Patent analysis,2
Environment,1
RENEWABLE ENERGY TECHNOLOGY,3
SOLAR PV,2
SECTORAL SYSTEMS,2
POWER INDUSTRY,2
POLICY MIX,2
CAPABILITIES,1
COEVOLUTION,1
NETWORKS,1
DYNAMICS,1
ECONOMY,1
Malaria,1
Human pegivirus,2
Controlled human malaria infection,4
Immune activation,2
Antibody response,2
PfSPZ vaccine,2
G VIRUS,2
PREVALENCE,1
PROTECTION,1
WOMEN,1
CONGO,1
R  D innovation,4
R  D tax credits,5
Financial markets,2
Intellectual property protection,3
Technological change,2
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPMENT TAX CREDITS,3
PATENT RIGHTS,2
FINANCIAL DEVELOPMENT,2
INNOVATION,1
GROWTH,1
CONSTRAINTS,1
INCENTIVES,1
PROTECTION,1
TECHNOLOGY,1
Law,1
conservation,1
wellbeing,1
oceans,1
human,1
health,1
biopiracy,1
bioprospecting,1
patent,1
litter,1
COASTAL PROXIMITY,2
BIODIVERSITY,1
ENVIRONMENT,1
INGESTION,1
DEBRIS,1
BEACH,1
SEA,1
intellectual property rights,3
development,1
international trade,2
threat of imitation,3
FOREIGN PATENT RIGHTS,3
INTERNATIONALTRADE,1
US EXPORTS,2
public direct RD grants,4
RD tax credit,3
intellectual property rights,3
regional innovation efficiency,3
MLP,1
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT TAX CREDITS,3
FOREIGN DIRECTINVESTMENT,2
FIRM INNOVATION,2
CATCHUP,1
DEVELOPMENT SUBSIDIES,2
CORPORATE GOVERNANCE,2
ABSORPTIVECAPACITY,1
PUBLIC SUBSIDIES,2
PATENT RIGHTS,2
,1
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONALTRADE,1
EXPORT PRICES,2
PRODUCTIVITY,1
MARKET,1
IMPACT,1
DETERMINANTS,1
INVESTMENT,1
PROTECTION,1
DYNAMICS,1
intellectual property rights,3
green technology innovation,3
open innovation,2
human capital,2
sustainable development,2
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTAL INNOVATION,2
EMPIRICALEVIDENCE,1
DEVELOPMENT COOPERATION,2
RIGHTS,1
SPILLOVERS,1
DETERMINANTS,1
ENFORCEMENT,1
STRATEGY,1
LAWS,1
Secrecy,1
Information disclosure,2
Knowledge visibility,2
Technological clusters,2
Innovation performance,2
RESEARCHANDDEVELOPMENT,1
INTERORGANIZATIONAL IMITATION,2
TECHNOLOGICALINNOVATION,1
DISCLOSURE,1
PATENTS,1
SEARCH,1
FIRMS,1
PERFORMANCE,1
STRATEGIES,1
COMPLEMENTARITY,1
ZnFe 2 O 4IP 6Au NPs,6
Synergistic effect,2
SERS,1
Onsite detection,2
Patent blue V,3
ENHANCED RAMANSCATTERING,2
RAPID DETECTION,2
PERFORMANCE,1
METAL,1
TRANSITION,1
DRINKS,1
Technology transfer,2
International business,2
Reverse technology transfer,3
INNOVATION,1
PROTECTION,1
Plasmodium,1
UIS3,1
liver stage,2
malaria,1
sterile protection,2
synergy,1
vaccines,1
HIGHEFFICIENCY TRANSFECTION,2
CD8 TCELLS,2
CIRCUMSPOROZOITE PROTEIN,2
IMMUNERESPONSES,1
LIVER,1
BERGHEI,1
IMMUNIZATION,1
PROTECTION,1
ADENOVIRUS,1
SELECTION,1
air pollution emissions,3
environmental protection,2
intellectual property rights IPR,4
NorthSouth trade,2
TRIPs agreement,2
INTELLECTUAL PROPERTYRIGHTS,2
ENVIRONMENTAL KUZNETS CURVE,3
STRONGER PATENTS INDUCE,3
EMPIRICALEVIDENCE,1
PROTECTION,1
TECHNOLOGY,1
INNOVATION,1
DIFFUSION,1
TRADE,1
LAW,1
,1
PATENT DUCTUSARTERIOSUS,2
DIFFERENTIAL EXPRESSION,2
GENEEXPRESSION,1
INDOMETHACIN,1
DRUGS,1
PERFORATION,1
Institutional investors communication,3
green innovation,2
investors green activism,3
green governance,2
JEL,1
C78,1
G23,1
G34,1
O31,1
O33,1
RESEARCHANDDEVELOPMENT,1
GOVERNANCE,1
PERFORMANCE,1
ENVIRONMENT,1
OWNERSHIP,1
Myocardial protection,2
Cardioplegia,1
Reoperation,1
Outcomes,1
Patient safety,2
AORTICVALVEREPLACEMENT,1
THORACIC ARTERY GRAFT,3
MYOCARDIAL PROTECTION,2
SURGERY,1
HEART,1
corporate transparency,2
RD,1
innovation,1
insider trading enforcement,3
European Union,2
IFRS,1
international accounting,2
security market regulation,3
disclosure,1
MANDATORY IFRS ADOPTION,3
FINANCIAL DEVELOPMENT,2
TECHNOLOGICALINNOVATION,1
ECONOMIC CONSEQUENCES,2
INFORMATION ASYMMETRY,2
INVESTMENT DECISIONS,2
PATENT PROTECTION,2
WORLD PRICE,2
DISCLOSURE,1
GROWTH,1
variable stiffness couplings,3
pneumatic torsional vibration tuners,4
design,1
patents,1
properties,1
,1
E41,1
O30,1
O40,1
economic growth,2
RD,1
inflation,1
monetary policy,2
patent policy,2
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
PATENT PROTECTION,2
ECONOMICGROWTH,1
WELFARE COST,2
INFLATION,1
MONEY,1
MODEL,1
TECHNOLOGY,1
INVESTMENT,1
,1
RISK REDUCTION,2
AGENCY COSTS,2
FIRM,1
DIVERSIFICATION,1
OWNERSHIP,1
STOCK,1
Water environment,2
Technology importing,2
Competition policies,2
Green exemption,2
,1
market integration,2
intellectual property,2
brexit,1
European economic area,3
international trade,2
EUROPEANIZATION,1
Machine learning,2
Smart grid,2
Patent law,2
Copyright law,2
AI,1
Compulsory licensing,2
,1
,1
CHANGEMITIGATION TECHNOLOGIES,2
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALEVIDENCE,1
CLIMATECHANGE,1
PATENT PROTECTION,2
INNOVATION,1
DETERMINANTS,1
CDM,1
US,1
Emissions trading,2
Technological innovation,2
Environmental regulation,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
ENVIRONMENTALREGULATION,1
EMPIRICALEVIDENCE,1
DEVELOPMENT SUBSIDIES,2
TECHNOLOGICALCHANGE,1
PORTER HYPOTHESIS,2
TECHNICAL CHANGE,2
EU ETS,2
PERFORMANCE,1
Dynamic capability DC,3
innovation appropriation,2
resourcebased view RBV,3
trade secrecy approaches,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INFORMAL APPROPRIATION MECHANISMS,3
INNOVATION PROTECTION MECHANISMS,3
DYNAMIC CAPABILITIES,2
KNOWLEDGE PROTECTION,2
EMPIRICALEVIDENCE,1
MANAGEMENT,1
PATENTS,1
APPROPRIABILITY,1
Central environmental protection inspection,4
Green innovation,2
Legitimacy pressure,2
Corporate risk taking,3
CORPORATE ENVIRONMENTAL PERFORMANCE,3
CAMPAIGNSTYLE ENFORCEMENT,2
INNOVATION EVIDENCE,2
FIRM PERFORMANCE,2
LAWENFORCEMENT,1
CHINA,1
IMPACT,1
REGULATIONS,1
GOVERNANCE,1
COMPETITIVENESS,1
bioprospecting,1
Convention on Biological Diversity,4
Indigenous,1
intellectual property,2
Maori,1
Nagoya Protocol,2
PROPERTY,1
CULTURE,1
Environmental courts,2
Local governance,2
Collusion,1
Corporate green innovation China,4
POLICY,1
ENFORCEMENT,1
China Top Brand Award,4
Intellectual property rights,3
Innovation outputs,2
RESEARCHANDDEVELOPMENT,1
PROPERTYRIGHTS PROTECTION,2
FINANCING CONSTRAINTS,2
FIRM INNOVATION,2
EMPIRICALEVIDENCE,1
STATE OWNERSHIP,2
QUALITY AWARDS,2
PRIZES,1
PERFORMANCE,1
INVESTMENT,1
vibration isolators,2
toroidal wire rope isolators,4
elastic connections,2
vibrationisolating structures,2
vibrationproof fasteners,2
vibration efficiency,2
and shockabsorption system,3
WIRE,1
STIFFNESS,1
Managerial ability,2
Intellectual property rights,3
RD,1
Investment,1
Patent,1
AsiaPacific,1
Pharmaceutical,1
DEVELOPMENT INVESTMENT EVIDENCE,3
FINANCING CONSTRAINTS,2
PATENT PROTECTION,2
UPPER ECHELONS,2
INNOVATION,1
PERFORMANCE,1
IMPACT,1
GROWTH,1
COSTS,1
DETERMINANTS,1
Competitive pricing strategy,3
Pharmaceutical markets,2
Directtoconsumer advertising,2
Detailing,1
Dynamic game,2
TESTS,1
INFORMATION,1
LEADERSHIP,1
CONSUMERS,1
,1
RESEARCHANDDEVELOPMENT,1
WORLDSFAIRS,1
SPILLOVERS,1
PATENTS,1
FIRMS,1
prosthetic valve endocarditis,3
left internal mammary artery occlusion,5
reoperations,1
myocardial protection,2
valve surgery,2
SURGERY,1
,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
COMPETITION,1
GROWTH,1
PATENTABILITY,1
SPILLOVERS,1
ECONOMICS,1
SEARCH,1
RIGHTS,1
FIRMS,1
,1
PATENT PROTECTION,2
TRADE,1
GLOBALIZATION,1
DETERMINANTS,1
INTEGRATION,1
OWNERSHIP,1
CONTRACTS,1
MARKETS,1
,1
,1
cryptogenic stroke,2
elder patients,2
patent foramen ovale,3
PFO closure,2
PFO and atrial fibrillation,4
CRYPTOGENIC STROKE,2
MEDICAL THERAPY,2
PERCUTANEOUS CLOSURE,2
UNDETERMINED SOURCE,2
LIFE,1
,1
PHENOLICCOMPOUNDS,1
SCAVENGING ACTIVITY,2
INVITRO,1
FRUITS,1
ACID,1
ANTHOCYANINS,1
HYDROXYL,1
CAPACITY,1
ATHEROSCLEROSIS,1
IDENTIFICATION,1
Meat production,2
Technological advances,2
Environment,1
Public policy,2
Dynamic panel model,3
LIFECYCLE ASSESSMENT,2
CARBON FOOTPRINT,2
ECONOMICGROWTH,1
FUTURE,1
CONSUMPTION,1
IMPACTS,1
INDUSTRY,1
CHAIN,1
INFORMATION,1
CHALLENGES,1
international trade,2
intellectual property rights,3
TECHNOLOGYTRANSFER,1
PATENT PROTECTION,2
RIGHTS,1
INNOVATION,1
ENTRY,1
INVESTMENT,1
TRADE,1
LAWS,1
innovation,1
development,1
intellectual property rights,3
economic complexity,2
RESEARCHANDDEVELOPMENT,1
PANELDATA,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
POLICY,1
TRADE,1
COMPETITION,1
INVESTMENT,1
KNOWLEDGE,1
GMM,1
Perception of competition,3
Innovation,1
Textual analysis,2
PATENT,1
GROWTH,1
POLICY,1
trademark law,2
trademarks,1
social movements,2
hashtags,1
Black Lives Matter,3
,1
,1
BAYHDOLE ACT,2
UNITEDSTATES,1
PATENT POLICY,2
DEVELOPMENT LABORATORIES,2
DEVELOPMENT AGREEMENTS,2
INTELLECTUAL PROPERTY,2
RESEARCH INSTITUTES,2
TRANSFER OFFICES,2
GOVERNANCE MODE,2
UNIVERSITY,1
,1
,1
,1
TRADE SECRETS,2
INNOVATION EVIDENCE,2
VALUE CREATION,2
SYNDICATION,1
PATENTS,1
INVESTMENT,1
PROTECTION,1
GOVERNANCE,1
MARKET,1
productivity,1
innovation,1
services,1
innovation survey,2
GROWTH,1
SECTOR,1
,1
COPYRIGHT ENFORCEMENT,2
PATENT LITIGATION,2
MUSIC INDUSTRY,2
PIRACY,1
MODEL,1
APPROPRIABILITY,1
PROTECTION,1
SETTLEMENT,1
CONTRACTS,1
ECONOMICS,1
,1
COMPARATIVE EFFICACY,2
UNITEDSTATES,1
VENOUS THROMBOEMBOLISM,2
PRICECOMPETITION,1
BRAND LOYALTY,2
HEALTH,1
INNOVATION,1
INFORMATION,1
COST,1
PROMOTION,1
,1
CIRCULAR BIOECONOMY,2
STRATEGY,1
Environmental regulation,2
Green technological innovation,3
Moderating effect,2
Transformation rate of innovation,4
achievements,1
Heterogeneity,1
RESEARCHANDDEVELOPMENT,1
PORTER HYPOTHESIS,2
NATURAL EXPERIMENT,2
EMPIRICALANALYSIS,1
ECOINNOVATION,1
CHINA,1
PROTECTION,1
VOLUNTARY,1
COMPETITIVENESS,1
PERFORMANCE,1
Opensource biotechnology,2
Intellectual property,2
Biohacking,1
DIYbio,1
Synthetic biology,2
Life patenting,2
ITYOURSELF BIOLOGY,2
SYNTHETIC BIOLOGY,2
INNOVATION,1
SCIENCE,1
KNOWLEDGE,1
EMERGENCE,1
REGIMES,1
SYSTEMS,1
SOCIETY,1
Innovation,1
Collaborative innovation,2
Regional Innovation System,3
RD,1
Patent,1
ABSORPTIVECAPACITY,1
PERFORMANCE,1
KNOWLEDGE,1
SMES,1
COLLABORATION,1
UNIVERSITIES,1
ECONOMIES,1
INDUSTRY,1
BASE,1
Intellectual property protection,3
Export product quality,3
Firm heterogeneity,2
PATENT RIGHTS,2
ECONOMICGROWTH,1
TRADE CREDIT,2
INNOVATION,1
ENFORCEMENT,1
INSTITUTIONS,1
TECHNOLOGY,1
INVESTMENT,1
COUNTRIES,1
GEOGRAPHY,1
environmental regulation,2
green technology innovation of enterprises,5
environmental protection investment,3
threshold effect,2
mediator effect,2
,1
economic development,2
growth,1
index,1
intellectual property,2
international comparison,2
PATENT PROTECTION,2
RIGHTS,1
IMPACT,1
INNOVATION,1
DETERMINANTS,1
TECHNOLOGY,1
SEARCH,1
TRADE,1
Europe,1
ICT firms,2
Mergers and acquisitions,3
Patents,1
Organizational learning,2
ABSORPTIVECAPACITY,1
TECHNOLOGICAL CAPABILITY,2
FIRM PERFORMANCE,2
MODERATING ROLE,2
ACQUISITIONS,1
INNOVATION,1
EXPLORATION,1
ADVANTAGE,1
PORTFOLIO,1
CREATION,1
Multinational firm boundaries,3
Knowledge dissipation,2
Holdup,1
Intangible assets,2
IPR protection,2
FOREIGN DIRECTINVESTMENT,2
VERTICAL INTEGRATION,2
INTERNATIONALORGANIZATION,1
INCOMPLETE CONTRACTS,2
PATENT PROTECTION,2
INTRAFIRM TRADE,2
DETERMINANTS,1
PATTERN,1
Chronic internal carotid artery occlusion,5
endovascular revascularization,2
a proximal balloon protection device,5
stroke,1
morphology,1
,1
Critical infrastructure protection,3
European Union research project,4
Hungarian scientific results,3
National security,2
Uj Szechenyi Plan,3
Obuda University,2
National University of Public Service,5
,1
TechnologyDriven Acquisition,2
Intellectual Property Rights Protection,4
Economic Distance,2
Political Distance,2
China,1
CROSSBORDER MERGERS,2
MANDA,1
FOREIGN DIRECTINVESTMENT,2
INSTITUTIONBASED VIEW,2
LOCATION CHOICE,2
PATENT RIGHTS,2
MULTINATIONALENTERPRISES,1
EMPIRICALEVIDENCE,1
STRATEGIC ASSETS,2
DEGLOBALIZATION,1
Innovation,1
Skills,1
Human capital,2
Evolutionary economics,2
Unemployment insurance,2
Active labor market policy,4
Employment protection,2
Social insurance,2
Varieties of capitalism,3
National systems of innovation,4
FLEXIBLE LABOR,2
TECHNOLOGY,1
SYSTEMS,1
EUROPE,1
SPECIALIZATION,1
FIRM,1
FLEXIBILITY,1
ECONOMIES,1
EVOLUTION,1
VARIETIES,1
Employment growth,2
Intellectual property rights,3
Innovative youngsters,2
Transition economies,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
FIRM GROWTH,2
GIBRATS LAW,2
SIZE,1
BEHAVIOR,1
AGE,1
synthetic polymer hydrogels,3
soil functioning regimes,3
water saving,2
antipathogenic protection,2
biodegradation,1
salinity protection,2
environmental monitoring,2
crop growing,2
urban landscaping,2
mathematical modeling,2
WATERRETENTION,1
SUPERABSORBENT POLYMERS,2
ENHANCE CROP,2
SANDY LOAM,2
POLYACRYLAMIDE,1
ACRYLAMIDE,1
HYDROGEL,1
RELEASE,1
DECOMPOSITION,1
PRODUCTIVITY,1
Climate impact,2
Climate change adaptation,3
Innovation,1
SUSTAINABLE ENTREPRENEURSHIP,2
EMPIRICALEVIDENCE,1
LONGITUDINAL DATA,2
ECONOMICFREEDOM,1
PATENT RIGHTS,2
AIRPOLLUTION,1
POLICY,1
INNOVATION,1
GREEN,1
BUSINESS,1
dissection,1
carotid artery,2
mesh stent,2
proximal protection system,3
distal protection system,3
ENDOVASCULAR MANAGEMENT,2
OCCLUSION,1
STROKE,1
PREVENTION,1
COMMUNITY,1
OUTCOMES,1
RISK,1
IPR protection intensity,3
Technological innovation,2
Dual mediators,2
RD investment,2
Foreign direct investment FDI,4
FOREIGN DIRECTINVESTMENT,2
TECHNOLOGICALINNOVATION,1
ECONOMICDEVELOPMENT,1
SPILLOVERS,1
TRADE,1
APPROPRIABILITY,1
PROTECTION,1
Costeffectiveness,1
Pharmaceuticals,1
Substitution,1
Stakeholder collaboration,2
Analogue medicines,2
MEDICINES,1
BELGIUM,1
PRICES,1
grantback clause,2
technology licensing,2
core technology,2
appropriability,1
RESEARCHANDDEVELOPMENT,1
INTERFIRM KNOWLEDGE TRANSFER,3
COMPLEMENTARY ASSETS,2
EMPIRICALANALYSIS,1
STRATEGIC ALLIANCES,2
FORMAL CONTRACTS,2
VALUE CREATION,2
INNOVATION,1
FIRMS,1
GOVERNANCE,1
Entomopathogenic Fungi,2
Biocontrol,1
Pesticide,1
Insect pest,2
Patents,1
Pathogenicity,1
Green pesticides,2
BIOLOGICALCONTROL AGENTS,2
BEAUVERIABASSIANA,1
METARHIZIUMANISOPLIAE,1
PAECILOMYCESFUMOSOROSEUS,1
MICROBIAL CONTROL,2
HOUSEFLY,1
GERMINATION,1
PATHOGENICITY,1
VIRULENCE,1
STRAINS,1
Blockchain,1
Decentralized ledger,2
Database,1
Hyperlink Intellectual property,3
PATENT HARMONIZATION,2
BLOCKCHAIN,1
PROTECTION,1
MARKET,1
IMPACT,1
IDEAS,1
FIELD,1
trade policy,2
uncertainty,1
innovation,1
patents,1
developing nations,2
RESEARCHANDDEVELOPMENT,1
LONGRUN,1
PRODUCTIVITY,1
INVESTMENT,1
HEALTH,1
IRREVERSIBILITY,1
COINTEGRATION,1
PROTECTION,1
DYNAMICS,1
EXPORTS,1
Pharmaceuticals,1
Environmental monitoring,2
Therapeutic hazard ratios,3
Prioritization,1
Urbanization,1
PERSONAL CARE PRODUCTS,3
WASTEWATER CONTAMINANTS,2
MIDDLEINCOME COUNTRIES,2
CHRONIC DISEASES,2
UNITEDSTATES,1
PRIORITIZING PHARMACEUTICALS,2
NATIONAL RECONNAISSANCE,2
AQUATIC ORGANISMS,2
EMERGING CONCERN,2
FATHEAD MINNOWS,2
technological proximity,2
geographical proximity,2
collaborative innovation,2
steel,1
RESEARCHANDDEVELOPMENT,1
NETWORK,1
PERFORMANCE,1
CLUSTERS,1
Nagoya Protocol,2
Pacific islands,2
Vanuatu,1
Patent landscaping,2
Custom,1
Community protocols,2
Access and benefitsharing,3
PACIFIC,1
BIODIVERSITY,1
INNOVATION,1
PROPERTY,1
PLANTS,1
PLACE,1
Probiotics,1
microrganisms,1
layerbylayer,1
mucoadhesive polymer,2
pH responsive polymer,3
PROBIOTICS,1
CELLS,1
Green innovations,2
Patent quality,2
Environmental regulation,2
Stateowned enterprises,2
Pollution,1
PRODUCTIVITY GROWTH,2
PORTER HYPOTHESIS,2
EMPIRICALEVIDENCE,1
PERFORMANCE,1
RESOURCES,1
CHINA,1
,1
INNOVATION,1
MARKET,1
Industrial Policy,2
Licensing,1
TechnoNationalism,1
Trade Policy,2
,1
Environmental sustainability,2
Asymmetric modeling,2
Environmental innovation,2
Patents on environmental technologies,4
Norway,1
UNITROOT,1
ENERGYCONSUMPTION,1
GROWTH,1
HYPOTHESIS,1
,1
KNOWLEDGE,1
POLITICS,1
COMMUNITIES,1
CONFLICT,1
REGIME,1
ACCESS,1
IDEAS,1
Zea mays L,3
exPVP,1
heterotic groups,2
SCA,1
GENETIC DIVERSITY,2
DENT CORN,2
GERMPLASM,1
TEMPERATE,1
SELECTION,1
Scale Inflexibility,2
Scale Adjustment Costs,3
Corporate Innovation,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
FLEXIBILITY,1
FIRM,1
DETERMINANTS,1
COMPETITION,1
INVESTMENT,1
LAWS,1
OWNERSHIP,1
EVMR,1
green innovation,2
environmental regulation,2
agency theory,2
G38,1
Q55,1
Q58,1
EXECUTIVECOMPENSATION,1
STATE,1
protective coatings,2
chemical corrosion,2
alkaliresistant enamel,2
frit,1
zirconium oxide,2
slip,1
firing,1
,1
drug registration,2
CRDA,1
traditional Chinese medicine,3
patent linkage,2
,1
Foreign Bank,2
State ownership,2
Corporate innovation,2
Emerging market,2
PRICE INFORMATIVENESS,2
FINANCIAL DEVELOPMENT,2
EMERGING MARKETS,2
FIRM INNOVATION,2
STOCK MARKETS,2
CREDIT,1
RISK,1
COMPETITION,1
GOVERNANCE,1
INSTITUTIONS,1
,1
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
EMPIRICALANALYSIS,1
PATENT PROTECTION,2
DIRECTINVESTMENT,1
2 FACES,2
INNOVATION,1
KNOWLEDGE,1
SPILLOVERS,1
PRODUCTIVITY,1
Dislosure of origin,3
Benefit sharing,2
Plant genetic resources,3
Agriculture,1
Biopiracy,1
Food security,2
,1
,1
FACILITY,1
HOTNES,1
monitoring systems,2
receiver stations,2
sturgeons,1
ultrasonic transmitters,2
BEHAVIOR,1
FISH,1
Trade Mark,2
ThreeDimensional Shape,2
NonTraditional Mark,2
Distinctiveness,1
Nature of Goods,3
Technical Result,2
EU Trade Mark Directive,4
EU Trade Mark Regulation,4
The Court of Justice of the European Union Case Law,10
,1
Carotid artery stenosis,3
Flow reversal,2
TransDistal radial approach,3
TransRadial approach,2
CORONARYANGIOGRAPHY,1
TRANSRADIAL ACCESS,2
FEMORAL ACCESS,2
ENDARTERECTOMY,1
METAANALYSIS,1
INTERVENTION,1
ASSOCIATION,1
EXPERIENCE,1
OUTCOMES,1
BOVINE,1
Knowledge sourcing,2
innovative performance,2
subsidiary,1
multinational enterprise,2
intellectual property rights,3
multiple embeddedness,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
EXTERNAL KNOWLEDGE,2
MULTINATIONALENTERPRISES,1
RESEARCH COLLABORATION,2
SOCIALSTRUCTURE,1
TECHNOLOGY,1
PROTECTION,1
CREATION,1
PATENT,1
Authorization,1
biosimilar medicines,2
legal perspective,2
regulatory framework,2
INTERCHANGEABILITY,1
MEDICINES,1
DRUGS,1
INDIA,1
Regional Comprehensive Economic Partnership RCEP,5
intellectual property,2
trade,1
sustainable development,2
innovation,1
PROTECTION,1
intellectual property rights,3
innovation,1
economic performance,2
semiconductor,1
pharmaceutical,1
shipbuilding,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
GROWTH,1
FIRMS,1
DETERMINANTS,1
COMPETITION,1
INDICATORS,1
IMITATION,1
RETURNS,1
MODELS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
SKILLED IMMIGRATION,2
INNOVATION,1
PRODUCT,1
QUALITY,1
VARIETY,1
REFORMS,1
TRADE,1
Institutional investor networks Innovation Mutual funds China,7
PROPERTYRIGHTS PROTECTION,2
CORPORATE GOVERNANCE,2
BOARD INTERLOCKS,2
OWNERSHIP,1
CEO,1
PERFORMANCE,1
GUANXI,1
CERTIFICATION,1
CONNECTIONS,1
EXPERIENCE,1
,1
INTELLECTUAL PROPERTY,2
FIRMS,1
INNOVATION,1
PATENTS,1
PROTECTION,1
SURVIVAL,1
INSIGHTS,1
ADOPTION,1
MODELS,1
LAW,1
Thoracoabdominal aortic aneurysm,3
Spinal cord protection,3
Open surgical repair,3
SPINALCORD PERFUSION,2
BLOODFLOW,1
REPAIR,1
PARAPLEGIA,1
PROTECTION,1
ARTERIES,1
high energy visible light,4
iron oxides,2
photoaging of the skin,4
photoprotection,1
VISIBLELIGHT,1
PIGMENTATION,1
MELASMA,1
IMPACT,1
Aspiration,1
Infant,1
Recurrent laryngeal nerve,3
Oropharyngeal pathophysiology,2
Deglutition,1
Deglutition disorders,2
PATENT DUCTUSARTERIOSUS,2
PARALYSIS,1
OROPHARYNGEAL,1
DETERMINANTS,1
ASPIRATION,1
KINEMATICS,1
ANESTHESIA,1
DYSPHAGIA,1
SUCKING,1
CLOSURE,1
organic salts,2
salicylic acid,2
plant stimulant,2
plant resistance inducer,3
sugar beet cultivation,3
Cercospora leaf spot,3
technological sugar yield,3
CERCOSPORABETICOLA,1
RESISTANCE,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT INFRINGEMENT,2
PROTECTION,1
PATENT,1
RULES,1
larynx,1
trachea,1
thyroid,1
arytenoid,1
cricoid,1
corniculate,1
cuneiform,1
epiglottic,1
cartilage,1
tissue engineering,2
proteomic,1
regenerative medicine,2
CRICOTHYROID JOINT ANATOMY,3
TISSUE,1
ULTRASTRUCTURE,1
APPROXIMATION,1
CHONDROCYTES,1
BIOMECHANICS,1
PATTERNS,1
CELLS,1
HEAD,1
Closedloop supply chain,3
strategic alliance structure,3
quality level of remanufactured products,5
patent protection,2
Stackelberg game,2
PRICECOMPETITION,1
COOPERATION,1
RISK,1
,1
IMMUNODEFICIENCYVIRUS TYPE1,2
STEADYSTATE PHARMACOKINETICS,2
PREEXPOSURE PROPHYLAXIS,2
PROTEINBINDING,1
VIRAL LOAD,2
INVIVO,1
INTRACELLULAR CONCENTRATIONS,2
HETEROSEXUAL TRANSMISSION,2
PLUS RITONAVIR,2
INFECTION,1
Innovation,1
Female owners,2
Female managers,2
Patent protection,2
RD,1
Firm size,2
Firm age,2
Sole proprietorship,2
FIRM PERFORMANCE,2
GENDER,1
ENTREPRENEURSHIP,1
WOMEN,1
Salicylamide,1
Thiazole,1
Heterocycle,1
Fungicide,1
Crop protection,2
INHIBITORS,1
DISCOVERY,1
THIAZOLE,1
POTENT,1
Highpower lightemitting diode LED lighting,5
multichannel LED driver,3
nonresonant converter,2
quadrupler rectifier,2
DESIGN,1
Firm boundaries,2
innovation,1
intellectual property,2
internalisation,1
Korean firms,2
RESEARCHANDDEVELOPMENT,1
PATENT RIGHTS,2
INTERNALIZATION THEORY,2
CUMULATIVE INNOVATION,2
EMPIRICALEVIDENCE,1
LEVEL,1
DETERMINANTS,1
ACQUISITION,1
PERFORMANCE,1
INCENTIVES,1
data breach,2
earnings management,2
mandatory disclosure,2
real activities manipulation,3
EARNINGS MANAGEMENT,2
INSTITUTIONAL INVESTORS,2
CORPORATE GOVERNANCE,2
STOCK LIQUIDITY,2
FINANCIAL FRAUD,2
CONSEQUENCES,1
EXPECTATIONS,1
INCENTIVES,1
LITIGATION,1
PRESSURE,1
,1
CARBON CAPTURE,2
FUNCTIONALAPPROACH,1
COMBINEDCYCLE,1
DESIGN,1
differenceindifference analysis,2
generic drug,2
Medicare Part D,3
medication prescription,2
FEATURES,1
,1
APPROVAL,1
COMPETITION,1
PROTECTION,1
ECONOMICS,1
PATENTS,1
GUIDE,1
LAW,1
Technology licensing,2
Intellectual property rights,3
Duration analysis,2
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGYTRANSFER,1
EMPIRICALANALYSIS,1
FIRMS,1
MARKET,1
COMPETITION,1
PROTECTION,1
INCENTIVES,1
GOVERNANCE,1
BOUNDARIES,1
Carotid endarterectomy,2
Endovascular repair,2
Highgrade carotid stenosis,3
Neurologic protection,2
Supraaortic occlusive disease,3
ENDARTERECTOMY,1
OUTCOMES,1
INTERVENTION,1
buprenorphine,1
patent,1
evergreening,1
budget impact,2
utilisation,1
CHRONIC PAIN,2
DRUGS,1
UK,1
pharmaceutical markets,2
parallel trade,2
regulation,1
welfare analysis,2
DISCRETECHOICE MODELS,2
INTELLECTUAL PROPERTY,2
PATENT EXPIRATION,2
EUROPEANUNION,1
GENERIC ENTRY,2
IMPORTS,1
INDUSTRY,1
PRODUCTS,1
DEMAND,1
PRICES,1
,1
TREERAT,1
IMMUNIZATION,1
PROTECTION,1
FALCIPARUM,1
PHYLOGENY,1
SUSCEPTIBILITY,1
SPOROZOITES,1
RADIATION,1
VIRULENCE,1
ORIGINS,1
Appropriability regime,2
profiting from innovation,3
complementary assets,2
intellectual property,2
patent protection,2
first mover advantage,3
RESEARCHANDDEVELOPMENT,1
COMPLEMENTARY ASSETS,2
TECHNOLOGICAL DISCONTINUITIES,2
INTELLECTUAL PROPERTY,2
INCUMBENTS ADVANTAGE,2
FIRM PERFORMANCE,2
COMPETITION,1
INDUSTRY,1
ALLIANCES,1
COOPERATION,1
food security,2
patent,1
management,1
Ratoons rice,2
method,1
,1
Intellectual Property,2
Customs Law,2
Copyright,1
Transboundary Movement,2
Digital Environment,2
,1
Patent genes,2
Pay to gelay,3
Pharmaceutical,1
Supreme Court,2
Actavis,1
Myriad Genetics,2
BUSINESS ETHICS,2
DECISIONMAKING,1
OFINTEREST,1
PATENTS,1
RIGHTS,1
MARKETS,1
ACCESS,1
COST,1
ORGANIZATIONS,1
COMPETITION,1
Drugs,1
Pharmaceutical industry,2
Product innovation,2
Profitability,1
Research and development,3
RESEARCHANDDEVELOPMENT,1
PRODUCT INNOVATION,2
PATENTS,1
PERFORMANCE,1
RETURNS,1
IMPACT,1
DRUGS,1
Country image,2
Trust,1
Consumer protection,2
Product quality,2
Financial brand equity,3
International marketing,2
Country of origin effect,4
CORPORATE SOCIALRESPONSIBILITY,2
BRAND TRUST,2
PURCHASE INTENTION,2
MODERATING ROLE,2
CONSUMERS,1
PERCEPTIONS,1
PERSONALITY,1
PERFORMANCE,1
IMPACT,1
CONSEQUENCES,1
COVID19,1
information ecology,2
innovation,1
intellectual property,2
knowledge commons,2
patents,1
ANTICOMMONS,1
INNOVATION,1
PROPERTY,1
Affordable medicines,2
Bangladesh,1
Bangladeshi pharmaceutical industry,3
generic drugs,2
Least Developed Countries LDCs,4
MNCs,1
TRIPS,1
WTO,1
,1
Technological innovation,2
Patents,1
Research and development,3
Stock markets,2
Investment,1
Companies,1
Manufacturing,1
Corporate activities,2
financial management,2
innovation management,2
,1
CountytoCity Upgrading,2
administrative decentralization,2
Firm Innovation,2
technological containment,2
COMPETITION,1
FEDERALISM,1
LESSONS,1
RDI subsidies,2
Innovative input,2
Innovative output,2
Firmlevel analysis,2
PUBLIC SUBSIDIES,2
PROPENSITY SCORE,2
SUPPORT,1
GOVERNMENT,1
DETERMINANTS,1
EXPENDITURES,1
PERFORMANCE,1
COMPLEMENT,1
PROGRAMS,1
MODELS,1
,1
HYALURONICACID,1
LINKING,1
Environmental tax,2
Green technology innovation,3
Green patent,2
Environmental regulation,2
REGULATION PROMOTE,2
CHINA,1
PRODUCTIVITY,1
PRESSURES,1
Service innovation,2
Service customer equity,3
Firm performance,2
Service innovation protection,3
Resourcebased view,2
RESOURCEBASED VIEW,2
COMPETITIVE ADVANTAGE,2
EMERGING MARKETS,2
FINANCIAL SERVICES,2
DOMINANT LOGIC,2
IMPACT,1
MANAGEMENT,1
SUCCESS,1
QUALITY,1
DISTINGUISHES,1
protection of information,3
electromagnetic infiltration,2
vibration infiltrations,2
3D printer,2
data acquisition,2
recreating the shape of an object,6
,1
Ecological environment,2
green intellectual property rights,4
sustainable development,2
environmental indexes,2
COORDINATED DEVELOPMENT,2
collaboration,1
copatents,1
inventors,1
RD,1
technology leakage,2
PROPERTYRIGHTS,1
EMPIRICALEVIDENCE,1
PARTNER SELECTION,2
KNOWLEDGE,1
ALLIANCES,1
BIOTECHNOLOGY,1
SCOPE,1
GOVERNANCE,1
INNOVATION,1
INTEGRATION,1
environmental disclosure quality,3
green innovation,2
financing constraints,2
cash reserves,2
highpolluting enterprises,2
CORPORATE SOCIALRESPONSIBILITY,2
FINANCIAL CONSTRAINTS,2
IMPRESSION MANAGEMENT,2
PERFORMANCE,1
LEGITIMACY,1
COMPANIES,1
CHINA,1
SUSTAINABILITY,1
GOVERNANCE,1
AfCFTA agreement,2
IPRs,1
trade,1
Nigeria,1
access to medicines,3
,1
construct validity,2
innovation measurement,2
multitraits multimethods,2
web content analysis,3
webmining,1
word frequency analysis,3
RESEARCHANDDEVELOPMENT,1
WORLDWIDEWEB,1
TECHNOLOGICALINNOVATION,1
ABSORPTIVECAPACITY,1
STRATEGIC ALLIANCES,2
PRODUCT DEVELOPMENT,2
CONSTRUCTVALIDITY,1
PATENT STATISTICS,2
FIRM PERFORMANCE,2
COLLABORATION,1
Crossregional environmental protection,3
Green total factor productivity,4
Energy saving,2
Carbon emission,2
Innovation,1
Industrial structure upgrading,3
TOTALFACTOR PRODUCTIVITY,2
REGRESSIONDISCONTINUITY,1
CO2 EMISSIONS,2
PARIS AGREEMENT,2
AIRPOLLUTION,1
REGULATIONS,1
CHINA,1
INNOVATION,1
IMPACT,1
GROWTH,1
Digital technology innovation DGTI,4
Total factor energy efficiency TFE,5
Operating costs,2
Internal control quality,3
Intellectual property protection,3
Digital industry agglomeration,3
IMPACT,1
Novel multipurpose wave energy converter,5
Submerged breakwater,2
Wave energy dissipation,3
Shore protection,2
Wave breaking,2
Wave flume,2
,1
Digital government,2
Natural resource management,3
Green technology innovation,3
Smart city pilots,3
ENVIRONMENTALREGULATION,1
PATENT EXAMINATION,2
INNOVATION,1
TRANSFORMATION,1
CHINA,1
PROTECTION,1
INVENTION,1
TRENDS,1
CITIES,1
,1
,1
innovation policy,2
public support,2
public policy,2
institutional economics,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
ENDOGENOUS INNOVATION,2
EMPLOYMENT PROTECTION,2
FINANCIAL DEVELOPMENT,2
PATENT PROTECTION,2
MARKET FAILURE,2
TECHNOLOGY,1
KNOWLEDGE,1
appropriability,1
intellectual property protection mechanisms,4
IPPMs,1
interfirm collaboration,2
paradox of openness,3
RD collaboration,2
international collaboration,2
open innovation,2
partner location,2
partner breadth,2
variety,1
partner depth,2
survey,1
RESEARCHANDDEVELOPMENT,1
PROPERTYRIGHTS,1
PERFORMANCE,1
OPENNESS,1
PATENTS,1
PROXIMITY,1
COMPLEMENTARITY,1
APPROPRIATION,1
UNIVERSITIES,1
GOVERNANCE,1
,1
,1
Exclusive rights,2
trademark registration,2
nontraditional means of individualization,4
olfactory trademark,2
patent law,2
,1
Agrochemical,1
crop protection,2
noncrop,1
RD,1
generics,1
growth,1
forecast,1
technology,1
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FUNDAMENTAL RIGHTS,2
PATENTS,1
PROTECTION,1
INNOVATION,1
FREEDOM,1
intellectual property rights,3
property rights infringements,3
global tire industry,3
China,1
Korea,1
TRIPS,1
INTELLECTUAL PROPERTYRIGHTS,2
INSTITUTIONBASED VIEW,2
CATCHUP STRATEGIES,2
PATENT PROTECTION,2
TECHNOLOGY,1
KNOWLEDGE,1
GROWTH,1
COSTS,1
FIRMS,1
COOPERATION,1
Malaria,1
Plasmodium berghei,2
Plasmodium yoelii,2
Blood tage vaccine,3
Frozenstock,1
Mixed immunization,2
Subcutaneous immunization,2
,1
Platforms,1
Google,1
Alphabet,1
surveillance,1
surveillance capitalism,2
privacy,1
human rights,2
Privacy Sandbox,2
data protection,2
GDPR,1
regulation,1
markets,1
marketing,1
advertising,1
FLoC,1
Topics,1
FLEDGE,1
DATA PROTECTION REGULATION,3
SURVEILLANCE,1
GLOBALIZATION,1
CAPITALISM,1
PRIVACY,1
BIG,1
institutionbased view,2
history,1
intellectual property rights IPR,4
United States,2
China,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
BUSINESS HISTORY,2
CATCHINGUP,1
FOREIGN,1
INNOVATION,1
STRATEGY,1
CHINA,1
APPROPRIABILITY,1
IT outsourcing,2
copyright protection,2
IT market,2
IT services,2
intellectual property,2
MAINTENANCE,1
hypothermia,1
rewarming,1
cold shock response,3
survival prediction,2
thermal protection,2
SURVIVALTIME PREDICTION,2
ACCIDENTAL HYPOTHERMIA,2
THERMAL BALANCE,2
DIVE RESPONSE,2
ALCOHOL,1
IMMERSION,1
PROTECTION,1
Enterprise investment preferences,3
Environmental legislation,2
New environmental protection law,4
RISKTAKING,1
CORPORATE,1
International intellectual property protection,4
TRIPS flexibilities,2
Free trade agreements,3
Inter se modifications,3
Article 41 VCLT,3
Object and purpose,3
Doha Declaration,2
DOHA DECLARATION,2
PUBLICHEALTH,1
WTO,1
AGREEMENT,1
PATENTS,1
sowing,1
underplanting,1
trialanderror,1
seed protector,2
afforestation,1
oak,1
OAK QUERCUS,2
FORESTS,1
SPAIN,1
L,1
,1
INNOVATION PERFORMANCE,2
KNOWLEDGE ACQUISITION,2
VALUE CREATION,2
INTEGRATION,1
CAPABILITIES,1
IMPACT,1
ENDOGENEITY,1
INVESTMENT,1
PROTECTION,1
ALLIANCES,1
,1
EMPLOYMENT PROTECTION LEGISLATION,3
WRONGFULDISCHARGE LAWS,2
MARKET,1
FLEXIBILITY,1
PROPERTY,1
COSTS,1
creative destruction,2
endogenous growth,2
monetary policy,2
RD,1
zero interest rate,3
PATENT PROTECTION,2
ECONOMICGROWTH,1
INFLATION,1
ADVANCE,1
COMPETITION,1
INNOVATION,1
Patents,1
Infringement,1
Saisiecontrefacon proceedings,2
Document disclosure,2
Placement under seal,3
Interim sequestration,2
Discretionary powers,2
,1
,1
COMPETITION,1
ECONOMICS,1
SECTOR,1
MODEL,1
,1
RESEARCHANDDEVELOPMENT,1
POLITICAL UNCERTAINTY,2
INFORMATION ASYMMETRY,2
POLICY UNCERTAINTY,2
TRADE SECRETS,2
,1
FINANCIAL CONSTRAINTS,2
FIRM PERFORMANCE,2
PRODUCT MARKET,2
ONE VOTE,2
DEPENDENCE,1
GOVERNANCE,1
OWNERSHIP,1
COSTS,1
,1
COMMERCIAL SPEECH,2
JURY,1
MARKETPLACE,1
NEUTRALITY,1
AMENDMENT,1
FREEDOM,1
COURTS,1
RIGHTS,1
LAW,1
multicopters,1
unmanned aerial vehicles,3
geophysical research,2
geophysical sounding devices,3
,1
Case Study,2
Innovation,1
Intellectual Property Rights,3
Manufacturing,1
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALEVIDENCE,1
PATENT PROTECTION,2
TECHNOLOGY,1
STRATEGIES,1
INDUSTRY,1
Australian colonization,2
Agamben Giorgio,2
postcolonial law,2
social transformation,2
discontinuity,1
postcolonial temporality,2
Indigenous sovereignty,2
,1
,1
GENERIC COMPETITION,2
MARKETS,1
Deep hypothermic circulatory arrest,4
cerebral perfusion,2
interrupted aortic arch,3
aberrant right subclavian artery,4
ventricular septal defect,3
patent ductus arteriosus,3
,1
Biodegradation,1
eye,1
lipid nanocarrier,2
ophthalmic delivery,2
patents,1
NANOPARTICLES SLN,2
OPHTHALMIC DELIVERY,2
LOW IRRITANCY,2
CARRIERS,1
SYSTEM,1
NLC,1
LIPOSOME,1
EMULSION,1
MICROEMULSIONS,1
FLURBIPROFEN,1
Companies,1
Standards organizations,2
Technological innovation,2
Collaboration,1
Complexity of standards,3
hazard model,2
multifirm settings,2
standardization,1
standardsetting organizations,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALEVIDENCE,1
DEVELOPMENT COOPERATION,2
FORMAL STANDARDIZATION,2
DEVELOPMENT CONSORTIA,2
TECHNOLOGY STANDARDS,2
ALLIANCE FORMATION,2
ESSENTIAL PATENTS,2
INNOVATION,1
Green technology acquisition,3
Cleaner production effect,3
RD innovation effect,3
Government actions,2
Nonresidential CO2 emissions,3
INNOVATIONS,1
PERFORMANCE,1
INVESTMENT,1
POLICY,1
TRADE,1
STATE,1
,1
COVID19,1
LAW,1
VACCINES,1
STATUTES,1
drug repurposing,2
drug repositioning,2
oncology,1
regulatory framework,2
policy,1
offlabel use,2
incentives,1
ORPHAN DRUGS,2
CHALLENGES,1
ONCOLOGY,1
OPPORTUNITIES,1
COMPENDIA,1
TARGETS,1
NEED,1
Firmlevel innovation,2
human capital accumulation,3
learning incentives,2
game theory,2
patent data,2
J24,1
J41,1
M51,1
M52,1
M54,1
O31,1
HUMANRESOURCE MANAGEMENT,2
LABORMARKET FLEXIBILITY,2
FIRMLEVEL,1
TECHNOLOGICALCHANGE,1
SCHUMPETERIAN PATTERNS,2
EMPLOYMENT PROTECTION,2
FLEXIBLE LABOR,2
JOB FLOWS,2
PRODUCTIVITY,1
PERFORMANCE,1
acousticmagnetic device,2
acoustic transmitter,2
geothermal water,2
heat transfer,2
simulation,1
QuickField,1
FIELD,1
Inferior vena cava,3
Venous thrombosis,2
Stents,1
Embolic protection devices,3
,1
Production restrictions,2
Air pollution,2
Economic performance,2
Industrial enterprise,2
EMISSIONS,1
CHINA,1
IMPACT,1
,1
DEEPVEINTHROMBOSIS,1
MANAGEMENT,1
DEVICE,1
internet of things,3
IoT,1
IP strategy,2
open source,2
ecosystem,1
OPEN INNOVATION,2
BUSINESS MODELS,2
MANAGEMENT,1
APPROPRIABILITY,1
COMPANIES,1
PATENTS,1
Imitation,1
topics and issues,3
innovation strategy,2
biosimilars,1
biobetters,1
,1
,1
FOREIGN DIRECTINVESTMENT,2
RESEARCHANDDEVELOPMENT,1
COMPETITION,1
RIGHTS,1
POLICY,1
MODEL,1
Environmental target constraint,3
Green innovation quality,3
Environmental accountability system,3
Environmental regulations,2
EMPIRICALEVIDENCE,1
PORTER HYPOTHESIS,2
IMPACT,1
COMPETITIVENESS,1
PERFORMANCE,1
PROTECTION,1
ENERGY,1
TARGET,1
Association,1
iCCM,1
NAPPMED,1
Regulatory agencies,2
Patent and proprietary medicine vendors,5
HEALTH,1
PROVIDERS,1
Air pollution,2
Corporate innovation,2
Regression discontinuity,2
Green innovation,2
Huai River policy,3
PRODUCTIVITY EVIDENCE,2
NATURAL EXPERIMENT,2
LIFE EXPECTANCY,2
CHINA,1
US,1
Engineering,1
information technology,2
innovation,1
inventions,1
social norms,2
OPERATIONS MANAGEMENT,2
STRATEGIC MANAGEMENT,2
KNOWLEDGE,1
RIGHTS,1
INNOVATION,1
PROTECTION,1
ECONOMY,1
PATENTS,1
BENEFIT,1
VIEW,1
Quartz fiber,2
Nonelectrode plasma synthesis,3
Al2O3 coating,2
Breaking strength,2
Mechanism,1
,1
QR code,2
Secret sharing,2
Cheater prevention,2
Sudoku,1
,1
,1
COPYRIGHT PROTECTION,2
AUTHORSHIP,1
Intellectual property regimes,3
Risk,1
Transaction costs,2
China,1
Foreignfriendliness paradoxes,2
International business,2
RESEARCHANDDEVELOPMENT,1
INSTITUTIONBASED VIEW,2
PATENT EXAMINATION,2
TRANSACTION COSTS,2
RIGHTS,1
PROTECTION,1
GOVERNANCE,1
INNOVATION,1
ENVIRONMENT,1
ECONOMICS,1
,1
HUMAN MALARIA INFECTION,3
LIVERSTAGE DEVELOPMENT,2
DIRECT VENOUS INOCULATION,3
CHLOROQUINE PROPHYLAXIS,2
ANOPHELESSTEPHENSI,1
PROTECTION,1
IMMUNIZATION,1
MOSQUITOS,1
CHALLENGE,1
DIVERSITY,1
intellectual property,2
innovation,1
integrated circuits,2
semiconductors,1
chips,1
,1
Intellectual property enforcement,3
Exports,1
Firm heterogeneity,2
TRADE LIBERALIZATION,2
TECHNOLOGYTRANSFER,1
PATENT RIGHTS,2
PERFORMANCE,1
QUALITY,1
IMPACT,1
INSTITUTIONS,1
INVESTMENT,1
PROTECTION,1
ADVANTAGE,1
China,1
Innovation,1
Patents,1
Rd,1
Research intensity,2
RESEARCHANDDEVELOPMENT,1
CORPORATE GOVERNANCE,2
MARKET VALUE,2
OWNERSHIP,1
PERFORMANCE,1
PROTECTION,1
FIRM,1
,1
LONGRUN,1
PATENT PROTECTION,2
FREE ENTRY,2
POLICY,1
TAXATION,1
INCOME,1
Stakeholder orientation,2
Marketentry,1
Incumbent response,2
Industrial organization,2
Pharmaceuticals,1
FORPROFIT,1
HEALTHCARE,1
WELFARE IMPLICATIONS,2
NONPROFIT HOSPITALS,2
PATENT PROTECTION,2
PRICECOMPETITION,1
ENTRY EVIDENCE,2
ETHICS,1
FIRMS,1
STRATEGY,1
,1
,1
aortic dissection,2
coronary artery bypass grafting,4
reoperation,1
myocardial protection,2
viable internal thoracic artery,4
SURGERY,1
Innovation,1
Coinventor cooperation,2
International collaboration,2
Developing countries,2
IPR,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
POLITICAL INSTABILITY,2
PATENT RIGHTS,2
PROTECTION,1
KNOWLEDGE,1
DETERMINANTS,1
EVOLUTION,1
NETWORKS,1
INTERNATIONALIZATION,1
Hightemperature superconductors,2
strategic planning,2
superconducting filaments and wires,4
superconducting power cable,3
,1
trade policy,2
health policy,2
progressive neoliberalism,2
investment law,2
drug policy,2
,1
complex aortic aneurysm,3
endovascular repair,2
open repair,2
aortic exclusion,2
Crawford classification,2
SPINALCORD PROTECTION,2
EDITORS CHOICE,2
THORACOABDOMINAL ANEURYSM,2
REPORTING STANDARDS,2
OPEN REPAIR,2
MANAGEMENT,1
SURGERY,1
ENDOGRAFTS,1
ISCHEMIA,1
COVERAGE,1
,1
GENETICRESOURCES,1
PROPERTY,1
AUSTRALIA,1
BIOPIRACY,1
HERITAGE,1
CULTURE,1
PLANTS,1
,1
,1
RD subsidy,2
Regulatory environment,2
WTO subsidy rules,3
Innovations,1
Patent,1
Utility model,2
DEVELOPMENT INVESTMENT,2
INNOVATION EVIDENCE,2
DEVELOPMENT POLICY,2
PROTECTION,1
LAWS,1
GOVERNMENT,1
TRADE,1
LESSONS,1
SYSTEM,1
IMPACT,1
metafrontier,1
data envelopment analysis DEA bootstrap,5
panel vector autoregression PVAR,4
spillovers,1
European regions,2
RESEARCHANDDEVELOPMENT,1
DATA ENVELOPMENT ANALYSIS,3
KNOWLEDGE FLOWS,2
DEVELOPMENT SPILLOVERS,2
MEASURING EFFICIENCY,2
ABSORPTIVECAPACITY,1
PATENT PROTECTION,2
GROWTH,1
DEA,1
HETEROGENEITY,1
,1
MARKET EXCLUSIVITY,2
PRESCRIPTION DRUGS,2
ORIGINS,1
ENTRY,1
ACT,1
Imitation innovation,2
LotkaVolterra system,2
intellectual property,2
dynamic uncertainty,2
real option,2
DYNAMIC COMPETITION ANALYSIS,3
LOTKAVOLTERRA EQUATIONS,2
PATENT LIFE,2
DIFFUSION,1
MARKET,1
OPTIONS,1
POLICY,1
,1
RESEARCHANDDEVELOPMENT,1
BRAND CHOICE,2
PRODUCTIVITY,1
INVESTMENT,1
PRICE,1
TECHNOLOGY,1
ASSETS,1
Public goods,2
Free riding,2
Innovation,1
Health,1
Pharmaceuticals,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
CROWDOUT,1
PHARMACEUTICALS,1
POLICY,1
SPILLOVERS,1
COMPLEMENT,1
CHARITY,1
Operating risk,2
Environmental regulation,2
Innovation incentive,2
Environmental management,2
GREEN INNOVATION,2
PERFORMANCE EVIDENCE,2
POLLUTION REGULATION,2
MANAGEMENT,1
IMPACT,1
POLICY,1
FIRMS,1
MIX,1
Secret hiding,2
QR code,2
exploiting modification direction,3
,1
Synthesis,1
Thiazolodiazepine analogs,2
CNS activity,2
Molecular modeling study,3
DRUGINTERACTIONS,1
PROFILE,1
Antibody therapeutics,2
next generation sequencing,3
patent,1
data mining,2
IMMUNOGLOBULIN,1
DIVERSITY,1
LIBRARY,1
,1
BIOASSAY ONTOLOGY BAO,3
DRUG DISCOVERY,2
MEDICINAL CHEMISTRY,2
SCREENING LIBRARIES,2
NEGLECTED DISEASES,2
ATTRITION RATES,2
UNITEDSTATES,1
PHASEII,1
TARGET,1
SAFETY,1
Coronary artery aneurysm,3
Coronary artery bypass grafting,4
Reoperation,1
SAPHENOUSVEIN GRAFT,2
Intellectual property rights,3
Multinational firms,2
Vertical integration,2
Outsourcing,1
International trade,2
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
KNOWLEDGE SPILLOVERS,2
TRADE,1
INCREASE,1
PRODUCTIVITY,1
DETERMINANTS,1
CONTRACTS,1
GROWTH,1
IMPACT,1
Innovation,1
productivity,1
services,1
manufacturing,1
innovation surveys,2
Latin America,2
,1
Technological preparation of production,4
Technological innovations,2
Pandemic,1
Problem companies,2
Trademarks,1
Industrial designs,2
Utility models,2
PRODUCT DESIGN,2
REFLECTIONS,1
TRADEMARK,1
COUNTRIES,1
ASIA,1
chemoprophylaxis vaccination with sporozoites,4
malaria,1
Plasmodium falciparum,2
primaquine,1
chloroquine,1
HUMAN MALARIA,2
HUMAN VOLUNTEERS,2
PROTECTION,1
IMMUNIZATION,1
CHALLENGE,1
BLOOD,1
CHLOROQUINE,1
PRIMAQUINE,1
MOSQUITOS,1
HUMANS,1
China,1
environmental centralisation,2
environmental decentralisation,2
green patent,2
total factor productivity,3
POLLUTING FIRMS,2
GROWTH,1
DECENTRALIZATION,1
FEDERALISM,1
SPILLOVERS,1
QUALITY,1
POLICY,1
COSTS,1
REGULATIONS,1
ENFORCEMENT,1
,1
POLITICS,1
PROTECTION,1
Chemically attenuated parasites,3
TafuramycinA,1
Whole parasite blood stage vaccine,5
Plasmodium falciparum FVO,3
Malaria,1
Aotus monkeys,2
MEROZOITE SURFACE PROTEIN1,3
APICAL MEMBRANE ANTIGEN1,3
INVITRO,1
PROTECTIVE IMMUNITY,2
INDUCE PROTECTION,2
MALARIA VACCINE,2
ANTIBODY TITER,2
IMMUNIZATION,1
PARASITE,1
INFECTION,1
,1
COPYRIGHT,1
LAW,1
INNOVATION,1
ECONOMICS,1
PATENT,1
PROTECTION,1
CONTRACT,1
STANDARD,1
HISTORY,1
FUTURE,1
Appraisal,1
new method,2
control,1
chicken,1
coccidiosis,1
ANTICOCCIDIAL DRUGRESISTANCE,2
FLOORPEN EXPERIMENTS,2
BROILERCHICKENS,1
EIMERIA SPP,2
INVITRO,1
DISINFECTANTS,1
EFFICACY,1
SENSITIVITY,1
TENELLA,1
SALINOMYCIN,1
sustainable business models SBMs,4
intellectual property IP,3
sustainability transition,2
business model canvas,3
IP strategy,2
RESEARCHANDDEVELOPMENT,1
OPEN INNOVATION,2
MANAGEMENT,1
STRATEGY,1
TECHNOLOGY,1
PATENTS,1
GREEN,1
PERSPECTIVE,1
PERFORMANCE,1
PROTECTION,1
Brake material,2
magnetic powder,2
friction and wear,3
properties,1
magnetism,1
preparation,1
formula optimization,2
formula design,2
TRIBOLOGICAL PERFORMANCE,2
Rapid prototyping,2
Medical,1
Tests and testing,3
Casting,1
FINITEELEMENT MODEL,2
COMPUTEDTOMOGRAPHY,1
CORTICAL BONE,2
universityindustry collaboration,2
division of labor,3
scientific productivity,2
innovation,1
interorganizational relationships,2
simultaneous discoveries,2
knowledge production,2
PUBLIC RESEARCH,2
KNOWLEDGE,1
SCIENCE,1
TECHNOLOGY,1
INNOVATION,1
LIFE,1
SCIENTISTS,1
ECONOMICS,1
NETWORKS,1
COMMERCIALIZATION,1
Zea mays L,3
ExPVP inbreds,2
Hybrids,1
Combining ability analysis,3
Gen action,2
INBRED LINES,2
HYBRIDS,1
GERMPLASM,1
hail damage,2
hail tester,2
spacer fabric,2
vehicle cover,2
vehicle protector,2
Abstandsgewebe,1
Fahrzeugabdeckung,1
Fahrzeugschutz,1
Hagelschaden,1
Hageltester,1
HAIL,1
Licenses,1
Patents,1
Companies,1
Industries,1
Silicon carbide,2
Technology transfer,2
Commercialization,1
Exploratory study,2
learning opportunities,2
licensing,1
technology management,2
technology trajectory,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGY,1
DETERMINANTS,1
IMPACT,1
MARKET,1
FIRM,1
ANTECEDENTS,1
INVENTIONS,1
PROTECTION,1
ALLIANCES,1
Renewable energy,2
Energy price,2
CO 2 emissions,3
Patent application,2
Spatial econometric model,3
Europe,1
ECONOMICGROWTH,1
CO2 EMISSIONS,2
SPATIAL ECONOMETRICS,2
CONSUMPTION,1
NEXUS,1
MODELS,1
Innovation systems,2
entrepreneurial ecosystems,2
digital technology,2
cybersecurity,1
electronic trading,2
,1
dysphagia,1
tongue kinematics,2
swallow control,2
infant,1
mammalian feeding,2
VOCAL FOLD IMMOBILITY,3
PATENT DUCTUSARTERIOSUS,2
AIRWAY PROTECTION,2
MECHANISMS,1
PARALYSIS,1
REFLEX,1
INPUT,1
DETERMINANTS,1
STIMULATION,1
INNERVATION,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONAL TECHNOLOGYTRANSFER,2
MULTINATIONAL FIRMS,2
PATENT PROTECTION,2
DIRECTINVESTMENT,1
EXPORTS,1
INNOVATION,1
EQUATIONS,1
LEVEL,1
Solar energy,2
Energy roof,2
Active thermal protection,3
Ground heat storage,3
Combined buildingenergy systems,3
Thermal barrier,2
,1
carotid artery,2
dissection,1
protection system,2
doublemesh stent,2
COMMUNITY,1
India,1
positive protection,2
traditional cultural expressions,3
traditional knowledge,2
,1
Energy conservation and environmental protection industry ECEPI,7
Collaborative innovation networks,3
Multidimensional proximity,2
Network structure,2
Network evolution,2
TECHNOLOGICAL PROXIMITY,2
RENEWABLE ENERGY,2
PERFORMANCE,1
COOPERATION,1
DYNAMICS,1
Distributed generation,2
Distribution system,2
Smart grids,2
lslanding,1
Distribution system protection,3
Antiislanding relay,2
GENERATION,1
PROTECTION,1
Green innovation efficiency,3
Ecological economics,2
Energy consumption,2
Environmental protection,2
Industrial enterprises,2
DEA MODEL,2
INVESTMENT,1
,1
AGRICULTURAL BIOTECHNOLOGY,2
INDUSTRY,1
INNOVATION,1
PATENTS,1
SCIENCE,1
ENTREPRENEURSHIP,1
CAPITALISM,1
LIFE,1
Classification of Intellectual Property Risks,5
Patent Protection,2
Exclusive Rights,2
Intellectual Property Market,3
Risk Management,2
LEGALSYSTEM,1
GLOBALIZATION,1
coronavirus,1
antiviral drugs,2
vaccines,1
SYNDROME CORONAVIRUS INFECTION,3
FDAAPPROVED DRUG,2
CONVERTINGENZYME,1
VIRALINFECTIONS,1
EBOLAVIRUS,1
INHIBITOR,1
SARS,1
MELATONIN,1
REPLICATION,1
ANTIBIOTICS,1
Farmers rights,2
Intellectual property rights,3
Sui generis legislations,3
Coexistence of legal regimes,4
Legal positivism,2
Plant genetic resources,3
Cultivated diversity,2
Equity,1
PLANT BREEDERS RIGHTS,3
Biometrics,1
iris recognition,2
statistical dependence,2
Daugman algorithm,2
template protection,2
RECOGNITION,1
corporate sustainability,2
shipping,1
technology,1
environmental protection,2
CSR,1
SOCIALRESPONSIBILITY,1
MEDIATING ROLE,2
CSR,1
INNOVATION,1
IMPACT,1
PERFORMANCE,1
GOVERNANCE,1
LOYALTY,1
IMAGE,1
Trademark,1
Frims market value,3
Firsttofile,1
Intellectual property rightIPR,3
China,1
Energing economy,2
INTELLECTUAL PROPERTY,2
INNOVATION,1
LAW,1
PRODUCT,1
ISOMORPHISM,1
PERFORMANCE,1
INVESTMENT,1
PROTECTION,1
ECONOMICS,1
STRATEGY,1
Energy management,2
Twomode network,2
Technological development,2
UIC,1
CN,1
TN,1
Energy saving industry,3
KNOWLEDGE NETWORK,2
PERFORMANCE,1
UNIVERSITY,1
IMPACT,1
COOPERATION,1
CONSUMPTION,1
PROTECTION,1
INNOVATION,1
INDUSTRY,1
PROMOTE,1
,1
,1
,1
LONGTERM OUTCOMES,2
,1
PIRACY PARADOX,2
TRADE SECRETS,2
LAW,1
INNOVATION,1
ECONOMICS,1
SEARCH,1
NORMS,1
Indian Council of Agricultural Research,5
intellectual property management system,4
intellectual property rights,3
National Institute of Veterinary Epidemiology and Disease Informatics,8
strengths,1
weaknesses,1
opportunities,1
threats analysis,2
,1
circulating fluidized bed,3
domain development trend,3
bibliometrics,1
knowledge mapping,2
COMBUSTION,1
,1
COMPETITION,1
Epistemological pluralism,2
Ethnopharmacology,1
indigenous rights,2
intellectual property rights,3
traditional ecological knowledge,3
DRUG DISCOVERY,2
SOCIOCULTURAL PROBLEMS,2
GENETICRESOURCES,1
DEFINITION,1
MEDICINE,1
ACCESS,1
USAGE,1
LAW,1
correlates of protection,3
immune response,2
malaria,1
vaccine,1
machine learning,2
FCGAMMA RECEPTORS,2
PHASE3 TRIAL,2
VACCINE,1
EFFICACY,1
SAFETY,1
EBI2,1
algorithm,1
computer program,2
patentability,1
software patent,2
intellectual property,2
G20,1
BRICS,1
,1
,1
HUMAN NPH INSULIN,3
DIABETESMELLITUS,1
COSTS,1
GLARGINE,1
THERAPY,1
ADHERENCE,1
ACCESS,1
Johann Peter Griess,3
Samuel Allsopp and Sons Brewery,5
Burton upon Trent,3
diazotization,1
azo dyes,2
Griess reaction,2
CONGORED,1
AZO DYES,2
OXIDE,1
Bacillus cereus group,3
biological control,2
cry3Aa,1
plasmid recombination,2
prophage,1
wholegenome sequencing,2
,1
,1
INNOVATION,1
KNOWLEDGE,1
RIGHTS,1
PROTECTION,1
NUTRITION,1
EVOLUTION,1
Lenalidomide,1
Thalidomide,1
FDA,1
Generic drugs,2
REMS,1
HatchWaxman Act,2
POTENT INHIBITORS,2
THALIDOMIDE,1
DRUG,1
CC5013,1
ANALOGS,1
MYELOMA,1
ACCESS,1
DEXAMETHASONE,1
BORTEZOMIB,1
STRATEGIES,1
China,1
enterprise RD investment,3
firm age,2
firm size,2
local anticorruption,2
political connections,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
MANAGERIAL TIES,2
PRODUCT,1
PERFORMANCE,1
SIZE,1
INVESTMENT,1
INDUSTRY,1
GUANXI,1
ROLES,1
RD intensity,2
sustainable development,2
impact factors,2
hightechnology exports,2
human capital,2
trade openness,2
renewable energy consumption,3
patents,1
dynamic panel data,3
systemGMM,1
INTELLECTUAL PROPERTY PROTECTION,3
PERCAPITA INCOME,2
ECONOMICGROWTH,1
DEVELOPMENT EXPENDITURES,2
DEVELOPMENT INVESTMENT,2
CARBON EMISSIONS,2
COUNTRY SIZE,2
SYSTEM GMM,2
INNOVATION,1
IMPACT,1
Intellectual property,2
copyright,1
patent,1
forecasting model,2
profiling model,2
property artificial intelligence,3
big data,2
open data,2
database,1
data,1
derivative work,2
,1
Infused,1
repellent,1
fabric,1
protective,1
garment,1
insect,1
INSECT REPELLENTS,2
ESSENTIAL OILS,2
bioequivalence,1
experts opinions,2
generic substitution,2
patent protection,2
patient copayment,2
patients rights,2
COMPETITION,1
MEDICINES,1
DRUGS,1
BEHAVIOR,1
PATENTS,1
PRICE,1
carbon peaking,2
carbon neutrality,2
green finance,2
fuzzyset qualitative comparative analysis,4
sustainable development,2
,1
digital finance,2
green technological innovation,3
spatial spillover effect,3
moderating effect,2
environmental regulation,2
INDUCE,1
Indoor thermally active panels ITAP,5
Active heatingcooling surface,3
,1
Antenatal steroids,2
Continuous positive airway pressure,4
Evidencebased practice,2
Hyaline membrane disease,3
Mechanical ventilation,2
Nutrition,1
Oxygen supplementation,2
Patent ductus arteriosus,3
Preterm infant,2
Respiratory distress syndrome,3
Surfactant therapy,2
Thermoregulation,1
POSITIVE AIRWAY PRESSURE,3
EXTREMELY PRETERM INFANTS,3
BIRTHWEIGHT INFANTS,2
HIGHFLOW THERAPY,2
OXYGENSATURATION TARGETS,2
PATENT DUCTUSARTERIOSUS,2
LARYNGEAL MASK AIRWAY,3
BRONCHOPULMONARY DYSPLASIA,2
PREMATUREINFANTS,1
RANDOMIZEDTRIAL,1
Intellectual property,2
National innovation system,3
Delphi study,2
RESEARCHANDDEVELOPMENT,1
3 FRAMES,2
DELPHI,1
TECHNOLOGY,1
PATENTS,1
POLICY,1
REFLECTIONS,1
TRAGEDIES,1
ECONOMICS,1
INVENTION,1
lotus root,2
foreign body,2
airway,1
hypersalivation,1
sore throat,2
,1
copyright,1
long tail,2
technology,1
intellectual property,2
digitization,1
WORDOFMOUTH,1
ONLINE,1
PIRACY,1
SALES,1
KNOWLEDGE,1
PATENTS,1
INFORMATION,1
COMPETITION,1
PROTECTION,1
SEARCH,1
emerging markets,2
India,1
innovation,1
RD,1
strategy,1
RESEARCHANDDEVELOPMENT,1
CATCHUP STRATEGIES,2
INDUSTRY,1
TECHNOLOGY,1
SERVICES,1
FIRMS,1
INTERNATIONALIZATION,1
BANGALORE,1
EVOLUTION,1
Economic growth,2
Workers,1
Capitalists,1
Class struggle,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
GROWTH,1
MODEL,1
POLICY,1
WELFARE,1
INCOME,1
FDI spillover,2
Innovative entrepreneurship,2
FDI innovation activities,3
FOREIGN DIRECTINVESTMENT,2
KNOWLEDGE SPILLOVERS,2
PATENT STATISTICS,2
EMERGING MARKET,2
DOMESTIC FIRMS,2
PRODUCTIVITY,1
GROWTH,1
ROLES,1
CHINA,1
Innovation,1
Intellectual property,2
Laboratory experiment,2
Real effort task,3
Creativity,1
PATENTS,1
COMPETITION,1
COMMUNICATION,1
PERFORMANCE,1
PROTECTION,1
TIME,1
Africa,1
biosimilars,1
MEA countries,2
Middle East,2
regulatory framework,2
,1
International outsourcing,2
Supplier heterogeneity,2
Competitive threat,2
Reverse engineering,2
Strategic predation,2
Technological capability,2
Learning by supplying,3
Royalty payment,2
Knowledge intensity,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
INCOMPLETE CONTRACTS,2
TECHNOLOGYTRANSFER,1
TRADE LIBERALIZATION,2
PATENT PROTECTION,2
DOMESTIC FIRMS,2
SPILLOVERS,1
FDI,1
PRODUCTIVITY,1
Advertising,1
biosimilars,1
competition,1
Italy,1
public tenders,2
scientific information,2
,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
STRATEGIC DISCLOSURE,2
UNIVERSITY INVENTIONS,2
TECHNOLOGY,1
SPILLOVERS,1
PATENTS,1
SCIENCE,1
INDUSTRY,1
SUCCESS,1
demandside policiy,2
generic medicine,2
Italy,1
market access,2
pharmaceutical,1
pricing,1
reimbursement,1
IMPACT,1
POLICY,1
capital market liberalization,3
green innovation,2
ShanghaiHong Kong Stock Connect program,5
ShenzhenHong Kong Stock Connect program,5
,1
Endogenous growth,2
RD,1
Variety innovation,2
Examination duration,2
INTELLECTUAL PROPERTYRIGHTS,2
DYNAMICANALYSIS,1
PROTECTION,1
PATENTABILITY,1
POLICY,1
Imitation,1
innovation,1
biopharmaceutical industry,2
biosimilars,1
biobetters,1
INTERORGANIZATIONAL IMITATION,2
BIOTECHNOLOGY,1
STRATEGIES,1
ECONOMICS,1
EVOLUTION,1
MODES,1
Economics of science,3
Antibiotics resistance,2
India,1
Multinationals,1
Technological abandonment,2
RESEARCHANDDEVELOPMENT,1
WELFARE IMPLICATIONS,2
PATENT PROTECTION,2
PRODUCT RECALLS,2
INNOVATION,1
INDIA,1
REPUTATION,1
SIZE,1
TECHNOLOGY,1
PHYSICIANS,1
Crop domestication,2
genetic diversity,2
breeding pipeline,2
predictive breeding,2
FROGEYE LEAFSPOT,2
SALT TOLERANCE,2
GENETIC BASE,2
RESISTANCE,1
CULTIVARS,1
YIELD,1
INHERITANCE,1
LINES,1
Design rights,2
Product design,2
Innovation,1
Research agenda,2
PRODUCT DESIGN,2
PATENT,1
TECHNOLOGY,1
OUTPUT,1
FORM,1
APPROPRIABILITY,1
INDUSTRIES,1
KNOWLEDGE,1
FASHION,1
NORMS,1
Nanobody,1
Rotavirus,1
Elisa,1
Diagnostics,1
VACCINATION,1
PROTECTION,1
DIARRHEA,1
PROTEIN,1
ELISA,1
innovation,1
investment horizon,2
managerial myopia,2
minority voting,2
FOREIGN INSTITUTIONAL INVESTORS,3
SHARE STRUCTURE REFORM,3
HEDGE FUND ACTIVISM,3
CORPORATE GOVERNANCE,2
OWNERSHIP STRUCTURE,2
FAMILY OWNERSHIP,2
SHAREHOLDER,1
ENHANCE,1
EQUITY,1
RIGHTS,1
Innovation,1
exports,1
metaanalysis,1
crosscountry,1
RESEARCHANDDEVELOPMENT,1
FIRM SIZE,2
TECHNOLOGICALINNOVATION,1
INTERNATIONALTRADE,1
PATENT RIGHTS,2
IMPACT,1
BEHAVIOR,1
SPECIALIZATION,1
INDICATORS,1
PROTECTION,1
corporate environmental responsibility,3
customer concentration,2
green innovation,2
patents,1
sustainable development,2
SUPPLY CHAIN MANAGEMENT,3
PERFORMANCE EVIDENCE,2
PANELDATA,1
ENVIRONMENTAL INNOVATION,2
INSTITUTIONAL PRESSURES,2
SOCIALRESPONSIBILITY,1
FIRM PERFORMANCE,2
IMPACT,1
PROFITABILITY,1
LEGITIMACY,1
Optimal tariffs,2
Economic growth,2
RD,1
Trade in intermediate goods,4
PATENT PROTECTION,2
TRADE LIBERALIZATION,2
ENDOGENOUS GROWTH,2
TAXREFORM,1
WELFARE,1
OPENNESS,1
PRODUCTIVITY,1
EXPENDITURE,1
COMPETITION,1
industrysponsored clinical trial,3
investigatorinitiated clinical trial,3
electronic health record,3
sharing resources,2
computational drug repositioning,3
ATRIALNATRIURETICPEPTIDE,1
GENEEXPRESSION SIGNATURES,2
LIFECYCLE MANAGEMENT,2
DRY EYE TREATMENT,3
POEMS SYNDROME,2
INSILICO,1
CONTROLLEDTRIAL,1
LUNGCANCER,1
ZONISAMIDE,1
DISEASE,1
,1
,1
Intellectual property rights,3
Foreign direct investment,3
Developing countries,2
TRIPS agreement,2
PATENT RIGHTS,2
FDI,1
DETERMINANTS,1
IQ,1
Intelligence,1
Economic complexity index,3
Innovation,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
INTELLIGENCE,1
INSTITUTIONS,1
ENVIRONMENT,1
QUALITY,1
,1
SAFETY,1
Trade secrets,2
Espionage and Foreign Interference Act,5
Economic Espionage Act,3
DTSA,1
TRIPS Agreement,2
Patents,1
ACT,1
,1
,1
Appropriability,1
Entrepreneurship,1
International entrepreneurship,2
Internationalization,1
Open innovation,2
Patents,1
Startups,1
BORNGLOBAL FIRMS,2
INNOVATIVE PERFORMANCE,2
INTELLECTUAL PROPERTY,2
ALLIANCE FORMATION,2
PARTNER DIVERSITY,2
KNOWLEDGE SOURCES,2
MARKET ENTRY,2
TECHNOLOGY,1
CAPABILITIES,1
OPPORTUNITY,1
MASP2,1
MBL,1
complement,1
genotypes,1
haplotypes,1
Schistosomiasis,1
MANNANBINDING LECTIN,2
NEGLECTED TROPICAL DISEASES,3
COMPLEMENT ACTIVATION,2
SURFACE GLYCOPROTEINS,2
GENE POLYMORPHISM,2
MANSONI,1
SUSCEPTIBILITY,1
INFECTION,1
PATHWAY,1
AGE,1
open innovation,2
intellectual property,2
lowmedium tech suppliers SMEs,4
regional clusters,2
cooperation,1
organizational matrix,2
regional specialization,2
societal path dependency,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
OPEN INNOVATION,2
EXTERNAL TECHNOLOGY,2
APPROPRIATION MECHANISMS,2
MANAGEMENTPRACTICES,1
ABSORPTIVECAPACITY,1
EMPIRICALEVIDENCE,1
UNRELATED VARIETY,2
REGIONAL GROWTH,2
WTO,1
Adjudication,1
Treaty ambiguity,2
TRIPS,1
Compulsory license,2
Public health,2
INTELLECTUAL PROPERTY,2
DISPUTE SETTLEMENT,2
DOMESTIC POLITICS,2
TRADE,1
WORLD,1
DESIGN,1
PROTECTION,1
PARTICIPATION,1
INSTITUTIONS,1
DECISIONS,1
Vertical management reform,3
Environmental decentralization,2
Environmental centralization,2
Transboundary environmental pollution,3
Green patents,2
FISCAL DECENTRALIZATION,2
POLITICAL CENTRALIZATION,2
POLLUTION REGULATION,2
GROWTH,1
PERFORMANCE,1
PRODUCTIVITY,1
ENFORCEMENT,1
INDUSTRY,1
QUALITY,1
INSTITUTIONS,1
domestic travel chemoprophylaxis,3
malaria,1
tafenoquine,1
RISKFACTOR,1
TRANSMISSION,1
REGION,1
Technological innovation,2
Government,1
Games,1
Biological system modeling,3
Green buildings,2
Instruments,1
Game theory,2
Green building technology,3
innovation cooperation network,3
evolution game,2
STRATEGIES,1
ADOPTION,1
INDUSTRY,1
DRIVERS,1
,1
ENTERIC SEPTICEMIA,2
,1
INBRED LINES,2
ASSOCIATION,1
TRAITS,1
MODEL,1
CORN,1
open innovation intellectual property risk score,6
open innovation intellectual property risk maturity,6
open innovation,2
intellectual property risks,3
IP risk management,3
analytic hierarchy process,3
conceptual model,2
PERFORMANCE,1
STRATEGIES,1
MANAGEMENT,1
CAPABILITY,1
CREATION,1
PARADOX,1
PATENTS,1
,1
LYMPHATIC FILARIASIS,2
MULTIVALENT VACCINE,2
ANTIGENB,1
RESPONSES,1
CHALLENGE,1
LARVAE,1
PARAMYOSIN,1
CANDIDATE,1
GENE,1
TROPOMYOSIN,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FREETRADE AGREEMENTS,2
PATENT PROTECTION,2
PLUS AGREEMENTS,2
ACCESS,1
DECLARATION,1
GOVERNANCE,1
POLICY,1
outward foreign direct investment OFDI,5
intellectual property rights protection IPRP,5
the Belt and Road initiative BR,6
sustainable development,2
investment risk,2
dynamic panel data,3
PATENT RIGHTS,2
LOCATION CHOICE,2
PANELDATA,1
GRAVITY,1
IMITATION,1
process and product innovation,4
recombination,1
specialization,1
TRIPS,1
Tshape,1
ORGANIZATIONAL TRANSFORMATION,2
DOMINANT LOGIC,2
KNOWLEDGE,1
SPECIALIZATION,1
INNOVATION,1
PRODUCT,1
FIRMS,1
CAPABILITIES,1
EXPLORATION,1
TECHNOLOGY,1
,1
INCENTIVES,1
PATENTS,1
COMMERCIALIZATION,1
COMPETITION,1
GROWTH,1
POLICY,1
FIRMS,1
intellectual property,2
political regimes,2
intellectual property protection,3
intellectual property rights,3
technology protection,2
RIGHTS,1
INNOVATION,1
Controlled human malaria infection,4
Malaria,1
Plasmodium falciparum,2
Cryopreserved sporozoites,2
Human challenge infection,3
INTRADERMAL INJECTION,2
CHALLENGE,1
VACCINE,1
MOSQUITOS,1
IMMUNIZATION,1
PROTECTION,1
EFFICACY,1
IMMUNITY,1
POVERTY,1
affordability,1
cost of illness,3
insulin,1
intellectual property,2
lowincome country,2
WELFARE IMPLICATIONS,2
PATENT PROTECTION,2
Drug repositioning,2
Regulatory exclusivities,2
Patents,1
Empirical study,2
Intellectual property,2
INNOVATION,1
PRICE,1
ascending aorta,2
aortic arch,2
surgery,1
circulatory arrest,2
cerebral protection,2
results,1
adolescents,1
younger adults,2
MANAGEMENT,1
3D printing,2
Additive manufacturing AM,3
Ethics of technology,3
Intellectual property,2
Safety,1
,1
Regulation and institutions,3
Industry evolution,2
Evolutionary theory,2
Pharmaceutical industry,2
Technological change,2
RESEARCHANDDEVELOPMENT,1
HISTORYFRIENDLY MODEL,2
MARKETSTRUCTURE,1
TECHNOLOGICAL REGIMES,2
VERTICAL INTEGRATION,2
PATENT PROTECTION,2
DRUG DEVELOPMENT,2
INNOVATION,1
BIOTECHNOLOGY,1
PERSPECTIVE,1
circular economy,2
design for sustainability,3
design for adaptability,3
design for disassembling,3
design for recycling,3
Quercus cerris engineered wood,4
,1
Open innovation paradox,3
Patenting,1
Licensing,1
Collaboration,1
LEVERAGING OPEN INNOVATION,3
ACADEMIC ENTREPRENEURSHIP,2
DRUG DISCOVERY,2
INDUSTRY,1
KNOWLEDGE,1
TECHNOLOGY,1
STRATEGIES,1
COLLABORATION,1
COMMUNITIES,1
EVOLUTION,1
spot inspection,2
command and control,3
innovation,1
spillover effect,2
pollution transfer,2
HAZE POLLUTION,2
REGULATIONS,1
ENFORCEMENT,1
EMPLOYMENT,1
COMMAND,1
,1
PORTABLE FTIR SPECTROMETERS,3
COLUMN MEASUREMENTS,2
EMISSIONS,1
,1
VENTURE CAPITALINVESTMENT,2
PRIVATE EQUITY,2
MORAL HAZARD,2
CONSTRAINTS,1
FIRMS,1
INFORMATION,1
PATENTS,1
MODEL,1
PERFORMANCE,1
GOVERNANCE,1
,1
,1
innovation,1
cumulative causation,2
growth gap,2
intellectual property rights,3
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
PATENT RIGHTS,2
INNOVATION,1
PROTECTION,1
INVESTMENT,1
TRANSITION,1
POLICY,1
TRADE,1
Health care markets,3
Pricing,1
Mixed oligopolies,2
ESSENTIAL MEDICINES,2
WELFARE IMPLICATIONS,2
PATENT PROTECTION,2
GENERIC ENTRY,2
LOWINCOME,1
COMPETITION,1
QUALITY,1
AVAILABILITY,1
OWNERSHIP,1
AFFORDABILITY,1
Vaccines,1
COVID19,1
Global Health,2
Delivery of Health Care,4
,1
,1
INTERCHANGEABILITY,1
EXTRAPOLATION,1
FDA,1
GUIDANCE,1
ONCOLOGY,1
SCIENCE,1
HURDLES,1
Treatment,1
Biologics,1
Target antigens,2
Biosimilars,1
Safety,1
,1
Artificial intelligence,2
law,1
ownership,1
patentability,1
liability,1
copyright,1
creativity,1
,1
profitability,1
performance,1
innovation,1
technology,1
collaboration,1
competitive advantage,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE SPILLOVERS,2
MULTINATIONALENTERPRISE,1
EXTERNAL KNOWLEDGE,2
TECHNOLOGICALINNOVATION,1
ABSORPTIVECAPACITY,1
STRATEGIC ALLIANCES,2
COORDINATION COSTS,2
PATENT PROTECTION,2
FIRM PERFORMANCE,2
Simulation,1
Intellectual Property management,3
Artifactsbased,1
Learning,1
Selfmotivation,1
,1
AIDS treatment,2
compulsory licensing,2
Doha Declaration,2
healthcare rights,2
intellectual property,2
key topics,2
TRIPS Agreement,2
,1
biologic medicinal product,3
orphan drugs,2
biologics,1
rare diseases,2
biosimilars,1
POLICY,1
Plasmodiuminfections,1
Placenta,1
Biomarkers,1
Blue Nile State,3
Sudan,1
PLASMODIUMFALCIPARUM MALARIA,2
LOWBIRTHWEIGHT,1
PREGNANTWOMEN,1
MATERNAL MALARIA,2
VIVAX MALARIA,2
INFECTION,1
AREA,1
BURDEN,1
RISK,1
IMPACT,1
craniofacial surgery,2
Crouzon syndrome,2
distraction osteogenesis,2
monobloc Le Fort III,4
ADVANCEMENT,1
OUTCOMES,1
Innovation,1
Diffusion,1
Commercialization,1
Advertising,1
Marketing,1
RD subsidies,2
RESEARCHANDDEVELOPMENT,1
SCHUMPETERIAN MODEL,2
DEVELOPMENT SUBSIDIES,2
PROTECTION,1
INFORMATION,1
SURVIVAL,1
PATENTS,1
SALES,1
,1
SULFATE,1
CHIP,1
Innovation,1
Imitation,1
Growth,1
Trade,1
Industrialization,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPMENT SPILLOVERS,2
GROWTH,1
TRADE,1
PROTECTION,1
COMPETITION,1
TECHNOLOGY,1
INVESTMENT,1
MIGRATION,1
Chemical database,2
Drug discovery,2
NGS,1
QSAR,1
Translational bioinformatics,2
CRYSTALSTRUCTURE,1
RATIONAL DESIGN,2
BINDING POCKETS,2
DATABASE,1
CLASSIFICATION,1
PREDICTION,1
MEDICINE,1
DOCKING,1
IDENTIFICATION,1
FRAMEWORK,1
Intellectual property rights,3
Emerging economies,2
Developed countries,2
Panel data,2
Machine learning,2
ClusterLasso,1
FOREIGN DIRECTINVESTMENT,2
INNOVATION PERFORMANCE,2
ECONOMICGROWTH,1
CORRUPTION,1
PATENT,1
MARKET,1
INFRASTRUCTURE,1
ENVIRONMENT,1
STRATEGIES,1
PROTECTION,1
,1
SURFACE MODIFICATION,2
PROTECTION,1
transport safety,2
human factor in transport,4
software,1
psychophysiology,1
experiment,1
WORKLOAD,1
Green Innovation,2
Environmental Performance,2
Financial Performance,2
Green Patents,2
Green Citations,2
CORPORATE SOCIALRESPONSIBILITY,2
RESOURCEBASED VIEW,2
ECOINNOVATION,1
FIRM PERFORMANCE,2
COMPETITIVE ADVANTAGE,2
BUSINESS PERFORMANCE,2
PRODUCT INNOVATION,2
EMPIRICALEVIDENCE,1
CARBON EMISSIONS,2
IMPACT,1
uniaxial graded auxetic damper,4
energy absorber,2
mechanical properties,2
finite element method,3
explicit solver,2
COMPRESSIVE PROPERTIES,2
CELLULAR STRUCTURES,2
PERFORMANCE,1
BEHAVIOR,1
PANELS,1
RATIO,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT RIGHTS,2
INTERNATIONALTRADE,1
ECONOMICGROWTH,1
PANELDATA,1
INNOVATION,1
TRIPS,1
Intellectual property rights,3
Domestic innovation,2
Foreign direct investment,3
Developing countries,2
Total Factor Productivity,3
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
TECHNOLOGYTRANSFER,1
COUNTRY,1
IMPACT,1
GROWTH,1
FDI,1
INSTITUTIONS,1
ENFORCEMENT,1
Research and development,3
Global health,2
Manufacturing,1
Secondgeneration vaccines,2
Vaccine access,2
RESEARCHANDDEVELOPMENT,1
ACCESS,1
Universities,1
Universityindustry links,2
Open innovation,2
Network centrality,2
Regions,1
I23,1
O31,1
O32,1
O33,1
O34,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGYTRANSFER OFFICES,2
REGIONAL ECONOMICDEVELOPMENT,2
KNOWLEDGE NETWORKS,2
SPINOUT,1
COLLABORATION NETWORKS,2
STRUCTURAL HOLES,2
INTERORGANIZATIONAL COLLABORATION,2
INDUSTRY COLLABORATION,2
ACADEMIC ENGAGEMENT,2
Corporate innovation,2
Stock market liberalization,3
Stock Connect scheme,3
FINANCIAL LIBERALIZATION,2
INSTITUTIONAL INVESTORS,2
ANALYST COVERAGE,2
EMERGING MARKETS,2
FOREIGN,1
PROTECTION,1
GOVERNANCE,1
Appropriability,1
innovation,1
financial performance,2
small and medium enterprises SMEs,5
RESEARCHANDDEVELOPMENT,1
PERFORMANCE,1
KNOWLEDGE,1
COOPERATION,1
COLLABORATION,1
DETERMINANTS,1
PROTECTION,1
CREATION,1
SEARCH,1
FIRMS,1
economic growth,2
quality ladder,2
RD,1
subsidies,1
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
INVESTMENT,1
PROTECTION,1
PRODUCT,1
CYCLES,1
COMPETITION,1
INNOVATION,1
FRICTIONS,1
PATENTS,1
Financial inclusion,2
RD,1
economic policy uncertainty,3
economic performance,2
IV2SLS,1
POLICY UNCERTAINTY,2
PATENT PROTECTION,2
IMPACT,1
GROWTH,1
EXPENDITURE,1
ACCESS,1
SHOCKS,1
FIRMS,1
Friendly innovation environment,3
Social and political factors,4
European countries,2
Panel data analysis,3
,1
industrial policy,2
Schumpeterian growth,2
twosectorRD,1
welfare,1
ENDOGENOUS GROWTH,2
PATENT PROTECTION,2
MODEL,1
WELFARE,1
TAXES,1
3D printing,2
Intellectual property,2
Patents,1
Trade marks,2
Designs,1
Infringement,1
,1
,1
TRADE SECRETS,2
PROTECTION,1
PATENT,1
MANAGEMENT,1
QUESTIONS,1
LAW,1
IP,1
Caffeine,1
Apnea of prematurity,3
NICU,1
Neurodevelopmental outcomes,2
Prematurity,1
VENTILATORY RESPONSE,2
DOSE CAFFEINE,2
BRAINSTEM,1
APNEA,1
THEOPHYLLINE,1
THERAPY,1
ADENOSINE,1
PREMATURITY,1
HYPOXIA,1
ASSOCIATION,1
,1
INTELLECTUAL PROPERTY,2
TRADE SECRETS,2
LAW,1
INFORMATION,1
PROTECTION,1
KNOWLEDGE,1
ECONOMICS,1
COPYRIGHT,1
CONTRACT,1
cable recycling,2
process innovation,2
dendritic copper powder,3
development research results,3
PO IR NCBiR,3
POWDER,1
Agriculture,1
Conservation,1
Cultivar,1
DNA sequence,2
In situ,2
Ex situ,2
Gene x environment interaction,4
G x E,3
Genetic diversity,2
Genome,1
Intellectual property protection,3
Molecular marker,2
Mutation,1
Plant breeder,2
Plant variety protection,3
Productivity,1
Utility patent,2
Yield,1
INSITU CONSERVATION,2
NUCLEOTIDE POLYMORPHISM,2
LINKAGE DISEQUILIBRIUM,2
UNITEDSTATES,1
MAIZE HYBRIDS,2
INBRED LINES,2
BREAD WHEAT,2
XRAYS,1
DOMESTICATION,1
LANDRACES,1
organicinorganic hybrids,2
solgel,1
lowvolatile organic content,3
hydrophobic coatings,2
anticorrosive coatings,2
epoxythiol silicates,2
RAY PHOTOELECTRONSPECTROSCOPY,2
SELFASSEMBLED MONOLAYERS,2
PERFORMANCE,1
HYDROLYSIS,1
KINETICS,1
SULFUR,1
STEEL,1
GOLD,1
agricultural biotechnology,2
European Union science policy,4
gene editing,2
governance,1
intellectual property policies,3
PUBLIC TRUST,2
INNOVATION,1
PROTECTION,1
PATENTS,1
FOOD,1
Intellectual property rights,3
China,1
Reform,1
Innovation,1
Technology transfer,2
,1
,1
,1
Aortic Aneurysm,2
Thoracic,1
Arteries,1
Cerebrospinal,1
Fluid Leak,2
Evoked Potentials,2
Motor,1
General Surgery,2
Hospitals,1
Hypothermia,1
Spinal Cord Injuries,3
Mortality,1
ADAMKIEWICZ ARTERY,2
COLLATERAL NETWORK,2
REDUCES PARAPLEGIA,2
FLUID DRAINAGE,2
REPAIR,1
BYPASS,1
PROTECTION,1
China,1
rule of law,3
governance,1
rationalized enforcement,2
accountability,1
intellectual property rights,3
environmental protection,2
DEMOCRACY,1
,1
PROPERTY,1
TRADEMARKS,1
COVID19,1
Respiratory failure,2
Bronchoscopy,1
Diagnosis,1
Treatment,1
Case report,2
,1
skyscraper,1
vertical clusters,2
modules,1
agricultural needs,2
specific activities,2
SOFT FRUITS,2
VEGETABLES,1
CULTIVATION,1
CHAMBERS,1
STORAGE,1
SYSTEM,1
,1
MALARIA TRANSMISSION,2
ANTIBODYRESPONSES,1
MEROZOITE ANTIGENS,2
CHILDREN,1
PROTECTION,1
INFECTION,1
HETEROGENEITY,1
SEROLOGY,1
ASSOCIATION,1
PREVALENCE,1
Thoracoabdominal aortic aneurysm repair,4
Aortailiac bypass,2
Mortality,1
Spinal cord injury,3
Evoked potentials,2
CEREBROSPINALFLUID DRAINAGE,2
VISCERAL PROTECTION,2
REDUCES PARAPLEGIA,2
SURGERY,1
RISK,1
PERFUSION,1
OUTCOMES,1
PARALYSIS,1
,1
FUNDAMENTAL LEGAL CONCEPTIONS,3
FAIRUSE,1
PATENT SCOPE,2
NATURAL LAW,2
COPYRIGHT,1
PREEMPTION,1
POLICY,1
INNOVATION,1
ANTITRUST,1
PROGRESS,1
Fluoroscopy,1
radiation dose,2
paediatric,1
cardiac catheterisation,2
paediatric intervention,2
IMAGE QUALITY,2
EXPOSURE,1
REDUCTION,1
ALARA,1
FLUOROSCOPY,1
PROTOCOL,1
BENCHMARKS,1
CARDIOLOGY,1
CHILDREN,1
Global green value chain,4
sustainable development,2
foreign direct investment,3
green patent application,3
green technology spillover,3
SUPPLY CHAIN,2
PERSPECTIVE,1
MANAGEMENT,1
cervical carcinoma,2
clinical trial,2
concurrent chemoradiotherapy,2
high dose rate brachytherapy,4
radiotherapy,1
RATE INTRACAVITARY IRRADIATION,3
LOCALLY ADVANCEDCARCINOMA,2
RADIATIONTHERAPY,1
RECOMMENDATIONS,1
SURVIVAL,1
TOXICITY,1
CRITERIA,1
QUALITY,1
stroke,1
pacing  electrophysiology,3
telemedicine,1
MEDICAL THERAPY,2
ANTIPLATELET THERAPY,2
OUTCOMES,1
,1
PRICECOMPETITION,1
DRUGS,1
PRESCRIPTION,1
CONSUMERS,1
ENTRY,1
COST,1
ACT,1
Steelconcrete composite beams,3
Fire resistance,2
Slimfloor beam,2
Electric furnace,2
Thermal experiments,2
Fire protection,2
Shallow floor beam,3
Integrated floor beam,3
RESISTANCE,1
BEHAVIOR,1
DESIGN,1
Agriculture,1
Chitosan,1
Chitosan nanoparticles,2
Fungi,1
Nanoformulation,1
Pesticides,1
INVITRO,1
ANTIMICROBIAL ACTIVITY,2
FUNGAL CHITOSAN,2
NANOMATERIALS,1
PROTECTION,1
DISEASE,1
DERIVATIVES,1
EFFICACY,1
SYSTEMS,1
GROWTH,1
dendrobium mixture,2
nonalcoholic fatty liver disease,4
type 2 diabetes mellitus,4
network pharmacology,2
TMTbased quantitative protomics,3
inflammation,1
PPAR gamma,2
NETWORK PHARMACOLOGY,2
DBDB MICE,2
HYPERLIPIDEMIA,1
STEATOSIS,1
NAFLD,1
,1
ANOPHELESALBIMANUS MOSQUITOS,2
INDUCED FALCIPARUMMALARIA,2
IRRADIATED SPOROZOITES,2
IMMUNERESPONSES,1
CHALLENGE MODEL,2
IMMUNIZATION,1
IMMUNOGENICITY,1
ANTIGENICITY,1
VACCINES,1
STRAIN,1
iTRAB,1
3Dadvanced culture model,3
dynamic culture conditions,3
trabecular meshwork,2
oxidative stress,2
glaucoma,1
polyphenols,1
millifluidic technology,2
EXTRACELLULARMATRIX,1
INVITRO,1
MESHWORK,1
GLAUCOMA,1
STRESS,1
MODELS,1
CELLS,1
MMPS,1
New Zealand,2
USA,1
international trade agreements and health,5
access to medicines,3
public health,2
policy analysis,2
pharmaceutical industry,2
MEDICINES,1
ACCESS,1
AUSTRALIA,1
MEDICATION,1
sustainability,1
biodegradability,1
furane,1
UV filter,2
SUSTAINABLE DEVELOPMENT,2
FILTERS,1
SUNSCREENS,1
CHEMISTRY,1
Acute stroke,2
endovascular thrombectomy,2
tandem lesion,2
INTERNAL CAROTIDARTERY,2
ACUTE ISCHEMICSTROKE,2
MECHANICAL THROMBECTOMY,2
INTRACRANIAL THROMBECTOMY,2
ENDOVASCULAR TREATMENT,2
STENT RETRIEVER,2
MANAGEMENT,1
,1
BRAND,1
GOODS,1
CONSUMERS,1
MEDICATION,1
PREFERENCE,1
ANTITRUST,1
TASTE,1
radial artery occlusion,3
transradial access,2
singleantiplatelet therapy,2
dualantiplatelet therapy,2
coronary angiography,2
CARDIACCATHETERIZATION,1
PATENT HEMOSTASIS,2
FEMORAL APPROACH,2
ACCESS SITE,2
OCCLUSION,1
INTERVENTION,1
PREVENTION,1
METAANALYSIS,1
ANGIOPLASTY,1
PREDICTORS,1
Mobile airconditioning,2
Gompertz model,2
Forecasting,1
Usage of Hydrofluorocarbons HFCs,4
Cost of Hydrofluorocarbons HFCs abatement,5
,1
combined buildingenergy systems CBES,4
renewable energy sources RES,4
energy solar roof ESR,4
ground heat storage GHS,4
peak heat source,3
panels with integrated thermal barrier,5
ground heat recovery,3
air heat exchanger,3
cooling circuits,2
GROUND HEATSTORAGE,2
SOLAR,1
SYSTEMS,1
SOUTH,1
Biosimilar,1
Biological agents,2
AUTOIMMUNEDISEASES,1
PERSPECTIVE,1
THERAPIES,1
,1
INTELLECTUAL PROPERTY,2
COMMONLAW,1
COVENANTS,1
FOUNDATIONS,1
RULES,1
Cultural preferences,2
macrobased behavioral economics,3
innovation and growth cycles,4
endogenous growth,2
underdevelopment traps,2
E71,1
O40,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
KNOWLEDGE SPILLOVERS,2
CULTURE,1
CYCLES,1
POLICY,1
MODEL,1
Intellectual property,2
Aquaculture industry,2
Intellectual capital,2
Blue sustainability,2
Market size,2
UNITROOT TESTS,2
OCCUPATIONALHEALTH,1
PANEL,1
COINTEGRATION,1
POWER,1
Green product imports,3
Green technology innovation,3
Moderating effect,2
Green patents,2
RESEARCHANDDEVELOPMENT,1
INTERNATIONALTRADE,1
CAPITAL GOODS,2
COMPETITION,1
PERFORMANCE,1
IMPACT,1
FIRMS,1
SPILLOVERS,1
PROTECTION,1
QUALITY,1
Home country bias,3
Legal system,2
Intellectual property rights,3
PATENT EXAMINATION,2
SUPREMECOURT,1
RIGHTS,1
PROTECTION,1
PROCUREMENT,1
TECHNOLOGY,1
INVESTMENT,1
DIFFUSION,1
OUTCOMES,1
SUCCESS,1
Q50,1
Q51,1
Q53,1
Q55,1
Q56,1
Q58,1
Environmental regulation,2
Patent applications,2
Technological innovation,2
Differenceindifference,1
Two Control Zones,3
TRADE LIBERALIZATION,2
PRODUCTIVITY GROWTH,2
INVESTMENTEVIDENCE,1
EXPORTS EVIDENCE,2
AIR,1
PERFORMANCE,1
POLLUTION,1
COMPETITIVENESS,1
IMPACTS,1
CENSUS,1
coatings for porous stones,4
sunlight polymerizable methacrylic protective coating,5
organicinorganic hybrids,2
MODIFIED ACRYLIC COATINGS,3
PROTECTIVECOATINGS,1
OXYGEN INHIBITION,2
STONE,1
RESTORATION,1
DURABILITY,1
POLYMERS,1
KINETICS,1
RD,1
Risktaking,1
Environment,1
Sustainability,1
MARKET VALUE,2
MANAGERIAL INCENTIVES,2
INNOVATION,1
FIRMS,1
PERFORMANCE,1
GOVERNANCE,1
COMPETITIVENESS,1
RESPONSIBILITY,1
STANDARDS,1
PATENTS,1
Intellectual property rights,3
Foreign R  D investments,5
Political capabilities,2
Intercountry perceptions,2
Innovation policy,2
POLITICAL CONNECTIONS,2
INTANGIBLE ASSETS,2
LOCATION CHOICE,2
INTERGOVERNMENTAL NETWORK,2
COMPETITIVE ADVANTAGE,2
STRATEGY RESEARCH,2
PATENT RIGHTS,2
TRADEFLOWS,1
KNOWLEDGE,1
PROTECTION,1
,1
LANGUAGE,1
MODEL,1
Staff development,2
Education,1
Biotechnology,1
Latin America,2
SCIENCE,1
ALLIANCES,1
KNOWLEDGE,1
NETWORKS,1
Media attention,2
Negative media coverage,3
Green technology innovation,3
Consumer choice pressure,3
M14,1
M21,1
O32,1
SOCIALRESPONSIBILITY,1
PERFORMANCE EVIDENCE,2
IMPACT,1
CONSTRUCTION,1
MANAGEMENT,1
EFFICIENCY,1
COVERAGE,1
SLANT,1
BAD,1
,1
SCIENCE,1
Recreational beach use,3
Count data,2
Travel cost model,3
Latent class models,3
Great Barrier Reef,3
COUNT DATA MODELS,3
TRAVEL COST METHOD,3
ENDOGENOUS STRATIFICATION,2
DEMAND,1
TRUNCATION,1
REGRESSION,1
BENEFITS,1
PATENTS,1
MARKET,1
CARE,1
Fossil fuels companies,3
Intellectual property,2
Fossil fuels expenses,3
Innovation efficiency,2
China,1
,1
Imitation,1
Innovation,1
Intellectual property,2
Inaction region,2
Optimization model,2
Numerical simulation,2
DYNAMICPROGRAMMING PROBLEMS,2
LOTKAVOLTERRA EQUATIONS,2
ONEPREDATOR SYSTEM,2
INTELLECTUAL PROPERTY,2
COMPETITION ANALYSIS,2
TECHNOLOGICALCHANGE,1
ROBUST OPTIMIZATION,2
PATENT RENEWAL,2
DIFFUSION,1
PROTECTION,1
Green technology innovation,3
Urban employment,2
Employment effect,2
Developing countries,2
Air quality,2
Industrial structure optimization,3
GROWTH,1
ENERGY,1
IMPACT,1
ENVIRONMENT,1
EFFICIENCY,1
POLLUTION,1
ECONOMY,1
Placebased policy,2
National pilot zone for ecological conservation,6
Green innovation,2
China,1
Differenceindifferences,1
EMISSION,1
Open innovation,2
intermediaries,1
benefits,1
decisionmaking,1
experience,1
risks,1
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
PRODUCT DEVELOPMENT,2
MANAGEMENTPRACTICES,1
SERVICE INNOVATION,2
PATENT PROTECTION,2
MEDIATING ROLE,2
TECHNOLOGY,1
KNOWLEDGE,1
PERFORMANCE,1
competing risks,2
Fine and Gray model,4
survival analysis,2
the duration of Plant Breeders Rights certificates,7
the length of Plant Breeders Rights examination process,8
PATENT EXAMINATION,2
CUMULATIVE INCIDENCE,2
VARIETY PROTECTION,2
DURATION ANALYSIS,2
HAZARDS MODEL,2
SUBDISTRIBUTION,1
CHINA,1
rival absorptive capacity,3
formal appropriability mechanisms,3
informal appropriability mechanisms,3
enterprises innovation performance,3
INFORMAL APPROPRIATION MECHANISMS,3
INTELLECTUAL PROPERTY,2
PROTECTION MECHANISMS,2
LOCAL SUPPLIERS,2
IMPACT,1
COOPETITION,1
PATENTS,1
SEARCH,1
COLLABORATION,1
ANTECEDENTS,1
antipsychotics,1
destigmatization,1
edutainment,1
global health,2
mental health,2
AUTISM SPECTRUM DISORDER,3
2NDGENERATION ANTIPSYCHOTICS,2
ATYPICAL ANTIPSYCHOTICS,2
CELEBRITY ENDORSEMENTS,2
PATENT PROTECTION,2
PUBLICHEALTH,1
CHILDREN,1
PRODUCT,1
DEMAND,1
MEDIA,1
,1
,1
Seed commons,2
Regime complex,2
Norm interplay,2
Biodiversity governance,2
Intellectual property rights,3
Access and benefit sharing,4
GLOBAL GOVERNANCE,2
GENETICRESOURCES,1
FOOD,1
AGRICULTURE,1
ACCESS,1
FRAGMENTATION,1
ORGANIZATION,1
NETWORKS,1
PROTOCOL,1
COMPLEX,1
International talent,2
Pollution emission intensity,3
Technological progress,2
Green patent,2
Environmental Awareness,2
PROMOTE INNOVATION,2
SELFREGULATION,1
IMMIGRATION,1
EDUCATION,1
PERFORMANCE,1
INVESTMENT,1
DIVERSITY,1
EMISSIONS,1
NETWORKS,1
SKILL,1
bioeconomy,1
bioprocesses,1
applications,1
policy,1
social welfare,2
sustainability,1
BIOBASED ECONOMY,2
PROPERTYRIGHTS,1
CELLCULTURES,1
IDENTIFICATION,1
BIODIVERSITY,1
ENVIRONMENT,1
TECHNOLOGY,1
STRATEGIES,1
INDUSTRIAL,1
BIOMASS,1
Perforated caisson breakwater,3
Physical modelling,2
Numerical modelling,2
Reflection coefficient,2
Transmission coefficient,2
RUBBLEMOUND,1
QUAYWALL,1
REFLECTION,1
GENERATION,1
EFFICIENCY,1
MODEL,1
developing countries,2
public Health,2
TRIPS,1
vaccines,1
waiver,1
PUBLICHEALTH,1
mine shaft,2
salt rock,2
leaching,1
,1
consumer surplus,2
costeffectiveness analysis,2
cures,1
dynamic efficiency,2
genericization,1
social surplus,2
valuebased pricing,2
COSTEFFECTIVENESS ANALYSIS,2
HEALTH,1
IMPACT,1
MECHANISM,1
PRICES,1
EUROPE,1
ENTRY,1
Nutrition,1
Prevention strategies,2
Public Health,2
Cohort study,2
ULTRAPROCESSED FOODS,2
GLOBALIZATION,1
PRODUCTS,1
QUALITY,1
OBESITY,1
TRENDS,1
ASIA,1
Malaria,1
Plasmodium falciparum sporozoite,3
Microbial challenge,2
Controlled human malaria infection,4
Clinical trial,2
INTRADERMAL INJECTION,2
IMMUNIZATION,1
PROTECTION,1
VACCINE,1
CHALLENGE,1
IMMUNITY,1
SAFETY,1
ADULTS,1
RISK,1
SKIN,1
Overthecounter medicine,2
Phthalate esters,2
Dinbutyl phthalate,2
Human exposure,2
Chinese population,2
PERSONAL CARE PRODUCTS,3
DI2ETHYLHEXYLPHTHALATE DEHP,2
POTENTIAL SOURCE,2
RISKASSESSMENT,1
ACID ESTERS,2
HUMAN URINE,2
MEDICATIONS,1
METABOLITES,1
POPULATION,1
WOMEN,1
Nuclear power industry,3
Collaboration networks,2
Social network analysis,3
Coevolution,1
Multidimensional collaborative innovation,3
PUBLIC ACCEPTANCE,2
ENERGY,1
KNOWLEDGE,1
COOPERATION,1
DYNAMICS,1
RISK,1
EVOLUTION,1
PATTERNS,1
SAFETY,1
Immunity,1
duration,1
severity,1
COVID19,1
antiSARSCoV2 IgG,2
antiSARSCoV2 IgTotal,2
immunogenesis,1
vaccination,1
booster,1
doses,1
comorbidity,1
age,1
relapse,1
essential oils,2
vector of infection,3
MESSENGERRNA VACCINATION,2
SARSCOV2 INFECTION,2
IMMUNOLOGICAL MEMORY,2
ANTIBODYRESPONSE,1
COVID19,1
Cancer,1
brain tumor,2
microbeam radiotherapy MRT,3
synchrotron radiation,2
women,1
XRAYENERGY,1
RADIATIONTHERAPY,1
MULTISLIT COLLIMATOR,2
MONTECARLO,1
IRRADIATION,1
BYSTANDER,1
TUMOR,1
BEAM,1
DOSIMETRY,1
OPTIMIZATION,1
entrepreneurship,1
knowledge,1
intellectual property,2
intangible,1
trademark,1
patent,1
start up valuation,3
ANOVA,1
VALUE RELEVANCE,2
MARKET VALUE,2
INTELLECTUAL PROPERTY,2
VOLUNTARY DISCLOSURE,2
EMPIRICALEVIDENCE,1
FIRM PERFORMANCE,2
INNOVATION,1
IMPACT,1
ENTREPRENEURSHIP,1
ASSETS,1
Biosimilar,1
CDSCO,1
innovator reference biological product,4
noninnovator biological product,3
RCGM,1
,1
OR in research and development,5
Licensing,1
Information disclosure,2
Vertical separation,2
Asymmetric information,2
Real options,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PUBLICATION,2
SIGNALING GAMES,2
SPILLOVERS,1
INNOVATION,1
INCENTIVES,1
DIFFUSION,1
ROYALTIES,1
MARKET,1
,1
RESEARCHANDDEVELOPMENT,1
ZIKA VIRUS,2
DNA VACCINES,2
INTELLECTUAL PROPERTY,2
MALARIA VACCINE,2
EBOLA,1
PATENTS,1
PROTECTION,1
INNOVATION,1
PHASE1,1
Asbestos,1
Asbestosfree products,2
Asbestos substitutes,2
Fibrous materials,2
DISEASE,1
,1
INTELLECTUAL PROPERTY LAW,3
COPYRIGHT,1
ECONOMICS,1
FASHION,1
DESIGN,1
,1
GEOGRAPHIC CONCENTRATION,2
,1
AESTHETIC INNOVATION,2
TRADE SECRETS,2
PATENTS,1
EXPLORATION,1
PROTECTION,1
Crop wild relatives,3
genebank,1
genetic resources,2
pomology,1
CENTERS,1
TRAITS,1
Rietveld,1
preferred orientations,2
quantitative phase analysis,3
xray data collection,3
xray sample preparation,3
ACCURACY,1
MIXTURES,1
TIO2,1
intellectual property rights,3
policy,1
renewable energy industry,3
innovation,1
China,1
TECHNOLOGICALCHANGE,1
PROTECTION,1
Absorptive capacity,2
appropriability depth,2
new product development,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
INNOVATIVE PERFORMANCE,2
TECHNOLOGICAL REGIMES,2
DEVELOPMENT SPEED,2
INHOUSE,1
PROTECTION,1
PATENTS,1
ORGANIZATION,1
PATTERNS,1
solar collector,2
flatplate vacuum collector,3
design innovation,2
bushing,1
,1
Natural dyes,2
Solgel process,2
Xenonaccelerated,1
Weathering,1
,1
China,1
Europe,1
institutions,1
intellectual property,2
OFDI,1
PATENT PROTECTION,2
INTERNATIONAL EXPANSION,2
ENTRY STRATEGIES,2
LOCATION CHOICE,2
RIGHTS,1
FIRM,1
FDI,1
TRANSITION,1
ECONOMIES,1
RESOURCES,1
,1
RAPE BRASSICANAPUS,2
BACILLUSAMYLOLIQUEFACIENS,1
TIO2 NANOPARTICLES,2
ACID,1
ADSORPTION,1
ATTACHMENT,1
DIOXIDE,1
RHIZOBACTERIA,1
NANOTIO2,1
STABILITY,1
food security and safety,4
underground heat exchanger,3
air duct,2
soil heat,2
CATTLE,1
competition,1
innovating firms,2
noninnovating firms,2
RD investments,2
welfare,1
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT INVESTMENT,2
INDUSTRIALSTRUCTURE,1
PATENT PROTECTION,2
COST REDUCTION,2
INCENTIVES,1
BERTRAND,1
COURNOT,1
PRODUCT,1
WELFARE,1
,1
CTGF,1
EXPRESSION,1
FEITAI,1
INOS,1
supply chain,2
input sourcing,2
Haiti,1
agricultural development,2
input availability,2
MARKET DEVELOPMENT,2
AFRICA,1
ORGANIZATIONS,1
ADOPTION,1
IMPACT,1
Institutional profile,2
Innovation performance,2
Global value chain,3
FOREIGN DIRECTINVESTMENT,2
INTELLECTUAL PROPERTYRIGHTS,2
TRADE FACILITATION,2
INNOVATION PERFORMANCE,2
TECHNOLOGY SPILLOVERS,2
PRODUCTION NETWORKS,2
PATENT PROTECTION,2
CHINA,1
INTERNATIONALIZATION,1
GROWTH,1
,1
ELECTRONTRANSFER DISSOCIATION,2
TANDEM MASSSPECTROMETRY,2
PERFORMANCE LIQUIDCHROMATOGRAPHY,2
ASSISTEDLASERDESORPTIONIONIZATION,1
THERAPEUTIC MONOCLONALANTIBODY,2
SIZEEXCLUSION CHROMATOGRAPHY,2
IONEXCHANGE CHROMATOGRAPHY,2
HYDROPHILIC INTERACTION CHROMATOGRAPHY,3
PROTEIN GLYCOSYLATION ANALYSIS,3
SULFATEGELELECTROPHORESIS,1
intellectual property crime,3
intellectual property rights,3
innovation,1
appropriability,1
Web of Science,3
WoS,1
bibliometric analysis,2
TECHNOLOGICALINNOVATION,1
BIBLIOMETRIC ANALYSIS,2
SOFTWARE PIRACY,2
RIGHTS,1
APPROPRIABILITY,1
MANAGEMENT,1
IMPACT,1
MODEL,1
,1
LANHAM ACT,2
Herbal raw materials,3
Mycotoxins,1
Shelflife,1
Biodeterioration,1
Essential oils,2
Nanoencapsulation,1
L ESSENTIAL OIL,3
GINGER ZINGIBEROFFICINALE,2
ROXB ESSENTIAL OIL,3
INVITRO,1
AFLATOXIN CONTAMINATION,2
LIQUIDCHROMATOGRAPHY,1
ANTIFUNGAL ACTIVITY,2
MEDICINALPLANTS,1
ANDROGRAPHISPANICULATA,1
OXIDATIVE DETERIORATION,2
,1
ANTITRUST,1
PROTECTION,1
EFFICIENCY,1
ECONOMICS,1
CONSUMER,1
COSTS,1
climate change,2
technology,1
environmental agreements,2
gravity model,2
Poisson pseudomaximum likelihood,3
CURRENCY UNIONS,2
KYOTO,1
REGULATIONS,1
GRAVITY,1
Chinas National Centralized Drug Procurement,5
policy effect assessment,3
quasinatural experiment,2
differenceindifference,1
corporate financial performance,3
DYNAMIC CAPABILITIES,2
PROGRAM,1
Environmental information disclosure EID,4
Green innovation GI,3
Digital transformation,2
Information asymmetry,2
POLITICAL CONNECTIONS,2
SOCIALRESPONSIBILITY,1
PERFORMANCE,1
COST,1
PRODUCTIVITY,1
Tax evasion,2
Innovation capacity,2
Intellectual property rights,3
RESEARCHANDDEVELOPMENT,1
INSTITUTIONAL QUALITY,2
FINANCIAL CONSTRAINTS,2
PATENT PROTECTION,2
FIRM PERFORMANCE,2
IMPACT,1
MODELS,1
INVESTMENT,1
COUNTRIES,1
CREDITS,1
Biosimilar,1
Biosimilarity index,2
Innovator biologic,2
Probabilitybased method,2
Tolerance interval,2
HIGHLY VARIABLE DRUGS,3
STATISTICAL ASSESSMENT,2
PRODUCTS,1
VARIABILITY,1
BIOEQUIVALENCE,1
PROBABILITY,1
EFFICACY,1
SAFETY,1
LIMITS,1
biomaterials,1
tissue engineering,2
polyglycerol sebecate,2
POLYGLYCEROL SEBACATE PGS,3
CARDIAC PATCH APPLICATION,3
POLY GLYCEROL SEBACATE,3
MECHANICALPROPERTIES,1
BIOMEDICAL APPLICATIONS,2
TISSUE,1
ELASTOMER,1
REGENERATION,1
EXPRESSION,1
SCAFFOLDS,1
Tsunami preparedness,2
Shelterinplace,1
Tsunami vertical evacuation,3
Tsunami horizontal evacuation,3
VERTICAL EVACUATION BUILDINGS,3
EARTHQUAKE,1
MORTALITY,1
JAPAN,1
,1
AORTICARCH,1
CEREBRAL PROTECTION,2
DISEASE,1
ENDARTERECTOMY,1
LESIONS,1
ANGIOPLASTY,1
EXPERIENCE,1
BRANCHES,1
THERAPY,1
VESSELS,1
,1
ALFAXALONE COMBINATION,2
BIOLOGICAL PARAMETERS,2
ENDOTRACHEALTUBE,1
ANESTHESIA,1
EFFICACY,1
VENTILATION,1
HYPOXEMIA,1
DELIVERY,1
CAPTURE,1
SAFETY,1
Electric vehicle,2
Technology convergence,2
Text mining,2
Link prediction,2
Network analysis,2
OPPORTUNITY DISCOVERY,2
PREDICTION,1
PATENTS,1
SYSTEM,1
HYBRID,1
MODEL,1
CLASSIFICATION,1
COLLABORATION,1
RELATEDNESS,1
DIFFUSION,1
Histamine,1
Heparin,1
Sporozoite,1
SPZ,1
Chemoprophylaxis with sporozoites,3
Wholeparasite immunization,2
Malaria vaccine,2
MALARIA,1
IMMUNIZATION,1
DIHYDROCHLORIDE,1
PROTECTION,1
INTERLEUKIN2,1
IMMUNITY,1
STAGE,1
MICE,1
Intellectual property policy,3
Innovation,1
Higher education institution,3
INTELLECTUAL PROPERTY,2
KNOWLEDGE TRANSFER,2
INNOVATION SYSTEM,2
UNIVERSITIES,1
PATENT,1
COMMERCIALIZATION,1
PROTECTION,1
receptor apparatus,2
intact teeth,2
electroodontometry,1
mastication,1
protection technique,2
lightcuring adhesive,2
antihomotoxic drug,2
,1
compulsory licensing,2
flexibilities,1
patent,1
TRIPS,1
TRIPSplus,1
,1
Catalytic capacity of technological innovation,5
Knowledge spillover,2
Patentometrics,1
Multidimensional measurement,2
RESEARCHANDDEVELOPMENT,1
PATENT CITATION,2
INTERMEDIARIES,1
INDUSTRY,1
INVENTORS,1
AUTHORS,1
COLLABORATION,1
COUNTRIES,1
TALENT,1
CHAINS,1
,1
,1
,1
,1
medical screws,2
316 LVM austenitic steel,4
metal forming,2
computer simulations,2
industrial research,2
CORROSIONRESISTANCE,1
STAINLESSSTEEL,1
MICROSTRUCTURE,1
,1
SEED STORAGE PROTEINS,3
CHITINBINDING PROTEINS,2
ANTIFUNGAL PROTEINS,2
CALLOSOBRUCHUSMACULATUS,1
3DIMENSIONAL STRUCTURE,2
DISEASE RESISTANCE,2
VICILINS,1
AGGREGATION,1
RESOLUTION,1
PHASEOLIN,1
intravascular ultrasound,2
percutaneous coronary intervention,3
PERIPROCEDURAL MYOCARDIAL INJURY,3
ROTATIONAL ATHERECTOMY,2
PROGNOSTIC VALUE,2
TERM OUTCOMES,2
INTERVENTION,1
ANGIOPLASTY,1
vaccines,1
preventatives,1
pharmaceuticals,1
innovation,1
intellectual property,2
behavioral economics,2
durable goods,2
INTELLECTUAL PROPERTY,2
UNREALISTIC OPTIMISM,2
IPPREPAREDNESS,1
ECONOMICTHEORY,1
UNITEDSTATES,1
DISEASE,1
PATENTS,1
HEALTH,1
ERADICATION,1
VACCINATION,1
ESG ratings,2
government subsidy,2
green innovation,2
sustainable development,2
CORPORATE SOCIALRESPONSIBILITY,2
FINANCIAL PERFORMANCE,2
GOVERNANCE,1
PROTECTION,1
weathering steel,2
protective ability index,3
bridge inspection,2
ATMOSPHERIC CORROSION,2
PROTECTIVE ABILITY,2
CARBONSTEEL,1
RUST,1
Heterorhabditis bacteriophora,2
mass production,2
monoxenic culture,2
optimization,1
ENTOMOPATHOGENIC NEMATODES STEINERNEMA,3
MASSPRODUCTION,1
BIOLOGICALCONTROL,1
LIFECYCLE,1
PHOTORHABDUS,1
CARPOCAPSAE,1
DESICCATION,1
SURVIVAL,1
FOOD,1
disease management,2
economics,1
enteric septicemia of catfish,4
oral vaccination platform,3
vaccine,1
CHANNEL CATFISH,2
ENTERIC SEPTICEMIA,2
PUNCTATUS RAFINESQUE,2
LIVE,1
EFFICACY,1
DISEASE,1
IMMUNE,1
FINGERLINGS,1
PERSISTENCE,1
PROTECTION,1
Innovation,1
Intellectual property,2
TRIPs compliance,2
Developing countries,2
India,1
Pharmaceutical,1
BIOTECHNOLOGY,1
KNOWLEDGE,1
PATENT,1
RIGHTS,1
MARKETS,1
GRAVITY,1
FIRMS,1
Glazing capacity,2
Blast,1
Dissipative brackets,2
Connections,1
Sustainable design,2
GLASS WINDOWS,2
MITIGATION,1
genetically modified organisms,3
intellectual property rights,3
international trade,2
PATENT RIGHTS,2
INTERNATIONALTRADE,1
GRAVITYEQUATION,1
TECHNOLOGY,1
AGREEMENTS,1
STANDARD,1
APPROVAL,1
EXPORTS,1
GROWTH,1
NORTH,1
,1
LUNGCANCER,1
INHIBITION,1
ACTIVATION,1
EXPRESSION,1
KINASE,1
RESISTANCE,1
LEUKEMIA,1
GROWTH,1
MOUSE,1
MODEL,1
economic growth,2
intellectual property rights,3
synthetic control method,3
INTELLECTUAL PROPERTYRIGHTS,2
PATENT RIGHTS,2
INTERNATIONALTRADE,1
TECHNOLOGYTRANSFER,1
FOREIGNINVESTMENT,1
EMPIRICALANALYSIS,1
PANELDATA,1
INNOVATION,1
PROTECTION,1
NORTH,1
income inequality,2
green innovation,2
environmental regulations,2
financial resources,2
executives backgrounds,2
CORPORATE SOCIALRESPONSIBILITY,2
FIRM INNOVATION,2
GOVERNANCE,1
INTENSITY,1
RESOURCE,1
BEHAVIOR,1
IMPACT,1
,1
SICKLECELL TRAIT,2
FALCIPARUMINFECTED ERYTHROCYTES,2
PLASMODIUMFALCIPARUM,1
PROTECTION,1
MOSQUITOS,1
CHILDREN,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT LITIGATION,2
STRATEGIC MANAGEMENT,2
CHINA,1
INNOVATION,1
APPROPRIABILITY,1
DETERMINANTS,1
SETTLEMENT,1
DECISIONS,1
metabolomics,1
biomarkers,1
knowledge translation,2
EXTERNAL VALIDATION,2
MASSSPECTROMETRY,1
MS,1
TRANSCRIPTOMICS,1
DIAGNOSTICS,1
PHASES,1
SERUM,1
FDI,1
Technology spillovers,2
Green innovation,2
Data Envelopment Analysis,3
FOREIGN DIRECTINVESTMENT,2
ENVIRONMENT,1
PROGRESS,1
newtype urbanization,2
green technology innovation,3
financing constraints,2
debt financing costs,3
ENVIRONMENTALREGULATION,1
ENERGY,1
POLLUTION,1
IMPACT,1
US,1
CONSUMPTION,1
PERFORMANCE,1
EFFICIENCY,1
INTENSITY,1
PRESSURE,1
Cement kiln coprocessing,3
Technological opportunity,2
Semantic similarity,2
RAKE algorithm,2
Clustering,1
LIFECYCLE ASSESSMENT,2
WASTE MANAGEMENT,2
SEWAGESLUDGE,1
RAW MEAL,2
PREDICTION,1
ASH,1
China,1
Europe,1
Outward FDI,2
Intellectual property,2
Institutional environments,2
International property rights index,4
OUTWARD DIRECTINVESTMENT,2
FDI LOCATION CHOICE,3
PATENT PROTECTION,2
EMERGING MARKETS,2
INTERNATIONALIZATION,1
DETERMINANTS,1
RIGHTS,1
MULTINATIONALS,1
ENTERPRISES,1
FIRMS,1
,1
INVESTMENT,1
MARKETS,1
CONSTRAINTS,1
COMPETITION,1
CAPACITY,1
ENTRY,1
DEBT,1
CASH,1
,1
CANDIDAALBICANS,1
THIOSEMICARBAZONES,1
DERIVATIVES,1
RESISTANCE,1
CHELATORS,1
MUTANT,1
Benzophenone,1
bisphenol A,2
endocrine disruptors,2
HPLCUV,1
thermochromic printing inks,3
TANDEM MASSSPECTROMETRY,2
LIQUIDCHROMATOGRAPHY,1
DERIVATIVES,1
WATER,1
FOOD,1
UV,1
DEGRADATION,1
EXTRACTION,1
EXPOSURE,1
SAMPLES,1
breeders rights,2
food fraud,2
protection,1
processed fruit,2
fruit,1
POLYMERASECHAINREACTION,1
DNA,1
IDENTIFICATION,1
SEQUENCE,1
FOOD,1
AUTHENTICATION,1
TRACEABILITY,1
VARIETIES,1
PRODUCTS,1
antioxidants,1
bioactive compounds,2
coffee byproducts,2
encapsulation,1
extraction,1
SPENT COFFEE GROUNDS,3
SUPERCRITICALFLUID EXTRACTION,2
GREENCOFFEE,1
ANTIOXIDANT ACTIVITY,2
CHLOROGENIC ACID,2
NATURAL ANTIOXIDANTS,2
SEED OIL,2
LIQUIDCHROMATOGRAPHY,1
PHENOLICCOMPOUNDS,1
DELIVERYSYSTEMS,1
Phosphorous recovery,2
Hydrothermal liquefaction,2
Leaching,1
Calcium phosphate precipitation,3
Product purity,2
SEWAGESLUDGE,1
STRUVITE,1
ENERGY,1
ASH,1
Automatic air quality monitoring station,5
Vertical environmental regulation,3
Enterprise green innovation,3
Staggered differenceindifferences method,3
POLICY INSTRUMENTS,2
PORTER HYPOTHESIS,2
POLLUTION,1
IMPACT,1
PERFORMANCE,1
ENFORCEMENT,1
FIRMS,1
DECENTRALIZATION,1
COMPETITIVENESS,1
OPPORTUNITIES,1
,1
FOREIGN DIRECTINVESTMENT,2
EMERGING MARKET ENTERPRISES,3
PATENT PROTECTION,2
JOINTVENTURES,1
INSTITUTIONAL DISTANCE,2
JAPANESE INVESTORS,2
CULTURAL DISTANCE,2
FIRM RESOURCES,2
CHINESE FIRMS,2
ENTRY,1
,1
,1
Digital financial inclusion,3
Green total factor productivity,4
Green innovation,2
Entrepreneurial activity,2
Heterogeneity analysis,2
EFFICIENCY,1
Intellectual property rights,3
social values,2
innovation,1
comparative institutional analysis,3
crosscountry study,2
simultaneous equation model,3
FOREIGN DIRECTINVESTMENT,2
TECHNOLOGICAL CAPABILITIES,2
INSTITUTIONS,1
LAW,1
PROTECTION,1
ECONOMICS,1
PATENTS,1
FINANCE,1
POLICY,1
GROWTH,1
Reduced levels of palmitic acid,5
Fatty acid composition of cottonseed oil,6
Chemical mutagenesis,2
FATTYACIDS,1
REGISTRATION,1
LINES,1
Intellectual property,2
Patents,1
Generic medicines,2
Compulsory licencing,2
TRIPS flexibilities,2
Trade agreements,2
TRIPSplus,1
Hepatitis C,2
Directacting antivirals,2
MEDICINES,1
ACCESS,1
HEALTH,1
Monoclonal antibodies,2
Biosimilars,1
Glycosylation,1
Analytical characterization,2
Clinical implications,2
2DIMENSIONAL LIQUIDCHROMATOGRAPHY,2
THERAPEUTIC MONOCLONALANTIBODIES,2
MOBILITYMASSSPECTROMETRY,1
HYDROPHILIC INTERACTION CHROMATOGRAPHY,3
CAPILLARYELECTROPHORESIS,1
NGLYCOSYLATION,1
HIGHTHROUGHPUT,1
STRUCTURALCHARACTERIZATION,1
MULTIATTRIBUTE METHOD,2
SAMPLE PREPARATION,2
Intellectual property right,3
Research and development,3
Economic growth,2
Trademark,1
Government effectiveness,2
PROTECTION,1
GROWTH,1
CONSEQUENCES,1
PATENTS,1
IMPACT,1
,1
MEMORY BCELLS,2
CD4 TCELLS,2
MALARIA TRANSMISSION,2
FALCIPARUM INFECTION,2
PROTECTIVE IMMUNITY,2
ERYTHROCYTIC STAGES,2
ACQUIREDIMMUNITY,1
CHABAUDIADAMI,1
HEPATITISC,1
3 SITES,2
Regional sustainable innovation efficiency,4
SBM model,2
Convergence,1
RESEARCHANDDEVELOPMENT,1
PANELDATA,1
ENVIRONMENTAL INNOVATION,2
ENERGY EFFICIENCY,2
CROSSCOUNTRY,1
PERFORMANCE,1
DYNAMICS,1
PATENTS,1
Intellectual property rights,3
mergers and acquisitions,3
gravity model,2
technological intensity,2
imitation,1
international comparison,2
FOREIGN DIRECTINVESTMENT,2
PATENT RIGHTS,2
CAPITAL FLOWS,2
TRADE,1
DETERMINANTS,1
PROTECTION,1
IMPACT,1
STRENGTH,1
EXPORTS,1
FDI,1
,1
,1
supercapacitors,1
surge protection,2
magnetic permeance,2
airgapped transformer,2
effective permeability,2
SCASA,1
,1
Phobos LIFE,2
Spaceflight experiments,2
Transpermia,1
Panspermia,1
Lithopanspermia,1
SPACE,1
SURVIVAL,1
BACTERIAL,1
ENVIRONMENT,1
EVOLUTION,1
EXPOSURE,1
SPORES,1
EARTH,1
MARS,1
Access to medicines,3
Global health,2
Intellectual property rights,3
PUBLICHEALTH,1
PHARMACEUTICALINDUSTRY,1
TRADE AGREEMENTS,2
GLOBAL POLITICS,2
TRIPS,1
RIGHTS,1
PATENTS,1
PROTECTION,1
DIFFUSION,1
STRATEGY,1
Malaria vaccine,2
adjuvants,1
TLR agonists,2
P facliparum,2
TLRs,1
pathogen associated molecular patterns PAMPs,5
pattern recognition receptors PRRs,4
POLYELECTROLYTE MULTILAYER COATINGS,3
PLASMODIUMFALCIPARUM,1
STERILE PROTECTION,2
DELIVERY VEHICLES,2
ADJUVANTS,1
IMMUNOGENICITY,1
ANTIBODY,1
RELEASE,1
PROTEIN,1
INNATE,1
Arbitration,1
Technology licensing,2
Contract design,2
Dispute,1
INTERORGANIZATIONAL RELATIONSHIPS,2
TRANSACTION COSTS,2
APPROPRIATION CONCERNS,2
COORDINATION COSTS,2
EMPIRICALEVIDENCE,1
PATENT PROTECTION,2
FORMAL CONTRACTS,2
SOCIALSTRUCTURE,1
JOINT VENTURES,2
ARBITRATION,1
,1
,1
Cryopreservation,1
Date palm,2
Germplasm,1
In situ conservation,3
Micropropagation,1
Molecular characterization,2
PHOENIXDACTYLIFERA L,2
PHENOTYPIC DIVERSITY,2
BIOCHEMICAL ATTRIBUTES,2
GENETICVARIATION,1
CULTIVARS,1
FRUIT,1
CRYOPRESERVATION,1
MICROPROPAGATION,1
BIOREACTOR,1
VARIETIES,1
Economic growth,2
Skillbiased technical change,3
Offshoring,1
PATENT PROTECTION,2
INNOVATION,1
GROWTH,1
TASKS,1
MODEL,1
Paratuberculosis,1
Vaccine,1
Nonspecific effects,2
Trained immunity,2
Cattle,1
Overall mortality,2
Killed vaccines,2
Mycobacteria,1
TRAINED IMMUNITY,2
TUBERCULIN REACTION,2
JOHNESDISEASE,1
BCG,1
MORTALITY,1
VACCINES,1
PROTECTION,1
REDUCTION,1
INFECTION,1
MEASLES,1
Extemal search,2
Openness,1
Types of partners,3
Depth of collaboration,3
Appropriability mechanisms,2
Intellectual property protection mechanisms,4
Paradox of disclosure,3
Innovation performance,2
Novelty,1
Efficiency,1
Exploration,1
Exploitation,1
Innovation phases,2
INFORMAL APPROPRIATION MECHANISMS,3
INTELLECTUAL PROPERTYRIGHTS,2
ABSORPTIVECAPACITY,1
EXTERNAL KNOWLEDGE,2
DEVELOPMENT COOPERATION,2
INTERORGANIZATIONAL COLLABORATION,2
DEVELOPMENT INVESTMENT,2
SEARCH,1
SMES,1
GOVERNANCE,1
,1
BRIDGING VEINS,2
Panax notoginseng saponins,3
endoplasmic reticulum stress,3
apoptosis,1
intracellular calcium homeostasis,3
ryanodine receptor,2
CHANNEL RYANODINE RECEPTOR,3
ER STRESS,2
OXIDATIVE STRESS,2
HEARTFAILURE,1
CELLDEATH,1
PATHWAY,1
ATHEROSCLEROSIS,1
PHOSPHORYLATION,1
THAPSIGARGIN,1
INFLAMMATION,1
Convolutional neural network CNN,4
Triplet neural network,3
Trademark TM infringement,3
Trademark management,2
contentbased image retrieval CBIR,4
FEATURES,1
SCALE,1
Atherosclerosis,1
Atherosclerotic Cardiovascular Disease,3
Traditional Chinese Medicine,3
Herbal Medicine,2
Chinese Medicine Therapeutics,3
Review,1
INDUCED APOE MICE,3
FOAM CELLFORMATION,2
OXIDATIVE STRESS,2
NITRICOXIDE,1
ATTENUATES ATHEROSCLEROSIS,2
MACROPHAGE POLARIZATION,2
BIOACTIVE COMPOUNDS,2
SIGNALING PATHWAYS,2
PATENT MEDICINE,2
APOPTOSIS,1
Economic rights,2
Intellectual property,2
Formal  informal institutions,4
Legal arrangements,2
FDI,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
TRANSACTION COSTS,2
DETERMINANTS,1
IMPACT,1
TRANSITION,1
ECONOMICS,1
DISTANCE,1
SYSTEMS,1
TRADE,1
Asthma,1
COPD,1
Fluticasone furoate,2
Vilanterol,1
ICSLABA combination,2
OBSTRUCTIVE PULMONARYDISEASE,2
DRY POWDER INHALER,3
ACTING BETA2ADRENOCEPTOR AGONIST,3
10025 MCG,2
VILANTEROL TRIFENATATE,2
PERSISTENT ASTHMA,2
LUNGFUNCTION,1
DOUBLEBLIND,1
MUG,1
FUROATE,1
,1
SCHISTOSOMIASISJAPONICA,1
VACCINATION,1
VACCINES,1
RADIATION,1
HELMINTHS,1
IMMUNITY,1
LARVAE,1
biliary atresia,2
interferonlambda,1
type III interferon,3
rhesus rotavirus,2
cholangiocytes,1
EPITHELIALCELLS,1
MOUSE STRAINS,2
INFECTION,1
OBSTRUCTION,1
innovation,1
sustainability,1
competitiveness,1
research and development,3
science and technology,3
POLICIES,1
talent policy,2
urban innovation,2
willingness of innovation,3
talent agglomeration,2
siphon effect,2
multiperiod differenceindifferences model,3
PERFORMANCE,1
POLICY,1
IMPACT,1
UNEMPLOYMENT,1
ENTERPRISES,1
STRATEGIES,1
MANAGEMENT,1
GOVERNMENT,1
MIGRATION,1
ATTITUDES,1
Fortified fresh pasta,3
Polyphenolic content,2
Antioxidant activity,2
Predicted glycaemic index,3
Pasta aroma,2
DIETARY FIBER,2
STARCH,1
POLYPHENOLS,1
COOKING,1
DURUM,1
structural health monitoring,3
vibrations,1
wavelet,1
entropy,1
hysteretic dampers,2
seismic engineering,2
WAVELET ENTROPY,2
FEATUREEXTRACTION,1
SPECTRAL ENTROPY,2
NEURALNETWORK,1
IDENTIFICATION,1
ENERGY,1
FAULT,1
PERFORMANCE,1
TRANSFORM,1
WEB,1
Cerebrospinal fluid drainage,3
Cerebrospinal fluid pressure monitoring,4
FEVAR,1
Spinal cord ischaemia,3
Ventriculoperitoneal shunt,2
,1
COVID19,1
Vaccine inequity,2
LICs,1
mRNA vaccine,2
TRIPS waiver,2
Global health,2
HISTORY,1
REALITY,1
IMPACT,1
,1
ESCHERICHIACOLI,1
INTERFERON ALPHA2A,2
EXPRESSION,1
CONTAMINATION,1
STABILITY,1
PROTEINS,1
CHILDREN,1
,1
FUEL,1
ENGINE,1
GAS,1
PERFORMANCE,1
EFFICIENCY,1
EMISSION,1
compulsory licensing,2
compulsory licensing duration,3
event history model,3
PATENTED MEDICINES,2
PUBLICHEALTH,1
ACCESS,1
CANADA,1
BRAZIL,1
,1
LAW,1
,1
LARGE UNILAMELLAR VESICLES,3
DOXORUBICIN,1
ENCAPSULATION,1
VINCRISTINE,1
GRADIENTS,1
RELEASE,1
LESSONS,1
AMINES,1
TUMOR,1
Tongmai Yangxin pills,3
Oxidative stress,2
Cisplatin,1
Cardiotoxicity,1
Network pharmacology,2
MEDIATED DNADAMAGE,2
INDUCED NEPHROTOXICITY,2
MOLECULARMECHANISMS,1
AKT PATHWAYS,2
INVITRO,1
APOPTOSIS,1
CELLS,1
INHIBITION,1
PROTECTION,1
VIEW,1
17 betaEstradiolum,2
Retina ganglion cell,3
Mitochondrial pathway,2
OXIDATIVE STRESS,2
RECEPTOR,1
ABNORMALITIES,1
APOPTOSIS,1
DYSFUNCTION,1
PROTECTION,1
PROTEINS,1
BETA,1
,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
DECISIONMAKING,1
CORPORATE REPUTATION,2
MANUFACTURING COST,2
MCDM MODEL,2
SYSTEM,1
INFORMATION,1
PERFORMANCE,1
BEHAVIOR,1
mandatory disclosure,2
corporate environmental responsibility,3
differenceindifferences DID model,3
SOCIALRESPONSIBILITY,1
CIRCULAR ECONOMY,2
PERFORMANCE,1
IMPACT,1
ENTERPRISES,1
MANAGEMENT,1
BUSINESS,1
QUALITY,1
,1
NUCLEATION,1
SOLVENT,1
SOLUBILITY,1
CHEMISTRY,1
KINETICS,1
GROWTH,1
environmental regulation,2
green technology diffusion,3
Yangtze River Delta,3
ENERGY TECHNOLOGIES,2
INNOVATION,1
INCENTIVES,1
PROTECTION,1
POLICIES,1
seed drying,2
energy demand,2
released heat,2
mathematical modelling,2
quality assessments,2
CFD SIMULATION,2
BED,1
FLOW,1
DEHYDRATION,1
Concrete,1
Durability,1
Protection,1
Waterproofing,1
Crystallization,1
Hygroscopic,1
Hydrophilic,1
Hydrophobic,1
FLYASH,1
SYSTEMS,1
DETERIORATION,1
ADSORPTION,1
TRANSPORT,1
MECHANISM,1
MOISTURE,1
Asiatic acid,2
Doxorubicininduced organ toxicity,3
Injury biomarkers,2
Nrf2 transcriptional factor,3
Nrf2 protein expression,3
Cytoprotection,1
CENTELLAASIATICA,1
FREERADICALS,1
ADRIAMYCIN,1
ANTIOXIDANT,1
SYSTEM,1
MICE,1
CARCINOGENESIS,1
HEPATOTOXICITY,1
TRITERPENOIDS,1
HEPATOCYTES,1
Author key Building dynamic identification,5
Ambient vibration test,3
Operational modal analysis,3
Reinforced concrete frame building retrofitting,5
Steel dissipative towers,3
Finiteelement model upgrading,3
SOILSTRUCTURE INTERACTION,2
SYSTEMIDENTIFICATION,1
BELLTOWER,1
VIBRATION,1
AMBIENT,1
BEHAVIOR,1
SENSOR,1
combustion strategy,2
sustainable fuels,2
vehicle,1
carbon neutrality,2
SIMULATIONMODEL,1
WAVE INFLUENCES,2
SYSTEM,1
REDUCTION,1
INLET,1
intellectual property rights IPR,4
firmspecific advantages FSAs,3
countryspecific advantages CSAs,3
multinational enterprises MNEs,3
international business,2
CONFLICTRESOLUTION,1
PATENT,1
INNOVATION,1
PROTECTION,1
PIRACY,1
CHINA,1
ENTRY,1
Tourism ecoefficiency TEE,3
Slacksbased measure SBM model,4
Social network analysis SNA,4
Tobit model,2
CARBON FOOTPRINT,2
DETERMINANTS,1
CONSUMPTION,1
CENTRALITY,1
IMPACT,1
MODEL,1
bioequivalence,1
highlyvariable drugs,2
PBPK,1
pharmacokinetics,1
tenofovir alafenamide,2
CHRONIC HEPATITISB,2
HIVINFECTED PATIENTS,2
DISOPROXIL FUMARATE,2
RENAL SAFETY,2
ANTIRETROVIRAL THERAPY,2
ENTECAVIR,1
DYSFUNCTION,1
NEPHROTOXICITY,1
REGIMENS,1
PRODRUG,1
,1
TRANSMISSION,1
chitosan,1
magnetic molecularly imprinted polymer,4
discrimination of enantiomers,3
tryptophan,1
smartphone,1
paperbased analytical device,3
GOLD NANOPARTICLES,2
CHIRAL RECOGNITION,2
POLYMERS,1
TEMPLATE,1
REMOVAL,1
DESIGN,1
DRUG,1
,1
TUMORNECROSISFACTOR,1
MODIFYING ANTIRHEUMATIC DRUGS,3
RHEUMATOIDARTHRITIS,1
FACTORALPHA,1
INFLAMMATORY DISEASES,2
DOUBLEBLIND,1
PSORIATICARTHRITIS,1
CONTROLLEDTRIAL,1
SYNOVIALFLUID,1
CROHNSDISEASE,1
hysteretic damper,2
energy dissipation,2
passive control,2
seismic,1
torsion,1
SEISMICISOLATED BRIDGES,2
GROUNDMOTION,1
PERFORMANCE,1
genetic diversity,2
genotyping,1
microsatellite markers,2
multivariate analysis,2
phenotyping,1
SWEET CHERRY CULTIVARS,3
DIVERSITY,1
GERMPLASM,1
TRAITS,1
MICROSATELLITES,1
COLLECTION,1
GENEBANK,1
SPANISH,1
active energy elements EAE,4
active thermal protection ATP,4
thermal barrier TB,3
renewable energy sources RES,4
heatcold accumulation,2
SYSTEMS,1
Entrepreneurship,1
Entrepreneurship ecosystem,2
Emerging countries,2
Egypt,1
Middle East,2
Entrepreneurship Policy,2
Economic development,2
EMERGING ECONOMIES,2
BUSINESS OWNERSHIP,2
INNOVATION,1
GROWTH,1
POLICY,1
HIV,1
antiretroviral agents,2
pharmaceutical policy,2
Mexico,1
Latin America,2
IMPROVE ACCESS,2
HIV TREATMENT,2
MEDICINES,1
PROCUREMENT,1
PRICES,1
DRUGS,1
biotechnology,1
intellectual property rights,3
EU acquis,2
Albanian legislation,2
legal approximation,2
,1
digital innovation,2
digital piracy,2
mobile applications,2
new product development,3
platforms,1
COPYRIGHT PROTECTION,2
SALES DISPLACEMENT,2
SOFTWARE PIRACY,2
ONLINE PIRACY,2
INNOVATION,1
PATENTS,1
MUSIC,1
ENTRY,1
WELFARE,1
IMPACT,1
Chaperon,1
Cyanobacteria,1
Endemism,1
Heterocyte differentiation,2
Photosystem II,2
Phylogenetic analysis,2
Polyphasic approach,2
Protease,1
CALCIUMDEPENDENT PROTEASE,2
SPNOV CYANOBACTERIA,2
GEN NOV,2
HETEROCYST DIFFERENTIATION,2
MOLECULARCLONING,1
MORPHOLOGICAL CHARACTERIZATION,2
POLYPHASIC CHARACTERIZATION,2
FORMING CYANOBACTERIA,2
SUBG DOLICHOSPERMUM,2
SUBUNIT ORGANIZATION,2
,1
,1
Sildenafil,1
Sexual intimacy,2
Suicide,1
ERECTILE DYSFUNCTION,2
SEXUALBEHAVIOR,1
LIFE,1
SATISFACTION,1
DEPRESSION,1
HAPPINESS,1
PATTERNS,1
HEALTH,1
DEATH,1
Bursting strength,2
Exhaust dyeing,2
Paramid fibres,2
UV stability,2
UVPROTECTIVE TEXTILES,2
Aroylhydrazones,1
Human prion protein,3
CopperII,1
Methionine oxidation,2
Oxidative stress,2
PRION PROTEIN,2
METHIONINE OXIDATION,2
METALIONS,1
BINDING,1
IRON,1
COORDINATION,1
PARKINSONS,1
ALZHEIMERS,1
COMPLEXES,1
HYDRAZONE,1
,1
,1
Carbon intensity,2
The heavy industry,3
Geographically weighted regression model,4
GEOGRAPHICALLY WEIGHTED REGRESSION,3
CO2 EMISSIONS,2
DIOXIDE EMISSIONS,2
CHINA,1
IMPACT,1
CONSUMPTION,1
REDUCTION,1
DECOMPOSITION,1
EFFICIENCY,1
TARGET,1
Technical frontier,2
Productivity,1
Intellectual property reform,3
PATENT PROTECTION,2
RIGHTS,1
INCREASE,1
COVID19,1
World Health Organization WHO,4
vaccine apartheid,2
indigenous peoples,2
Cuba,1
vaccine untouchables,2
vaccine genocide,2
,1
Innovation,1
digitalization,1
productivity,1
economic growth,2
convergence,1
spatial correlation,2
GROWTH,1
DETERMINANTS,1
CHINA,1
Portable personal air cleaner,4
Close proximity,2
SARSCoV2,1
Virus transmission,2
CFD analyses,2
Infectious respiratory particles,3
VENTILATION,1
PERFORMANCE,1
EXPLICIT,1
SYSTEM,1
Biosimilars,1
Biological medicines,2
Great Britain,2
Local formularies,2
THINK,1
,1
THIOLDISULPHIDE HOMEOSTASIS,2
ASTHMA,1
CHILDREN,1
AIRWAYS,1
ASSOCIATION,1
GLUTATHIONE,1
SELENIUM,1
BALANCE,1
OXIDANT,1
ADULTS,1
,1
GASTROINTESTINAL MANIFESTATIONS,2
GAUCHERDISEASE,1
1ST,1
CHILDREN,1
BIOEQUIVALENCE,1
BIOSIMILARS,1
THERAPY,1
ISSUES,1
IMPACT,1
SAFETY,1
energy consumption,2
transport,1
forklift,1
anti slip pad,3
PERFORMANCE,1
SUSTAINABILITY,1
IMPACT,1
,1
DUFFYBINDINGPROTEIN,1
APICAL MEMBRANE ANTIGEN1,3
ACQUIRED INHIBITORY ANTIBODIES,3
MALARIA VACCINE CANDIDATE,3
BRAZILIAN AMAZON,2
SEROLOGICAL MARKERS,2
PICHIAPASTORIS,1
PARASITE,1
PROTECTION,1
INTENSITY,1
mild steel,2
acetic acid solution,3
henna leaves extract,3
corrosion inhibitor,2
WL,1
PDP,1
EIS,1
1 M HCL,3
COLDROLLED STEEL,2
ESSENTIAL OIL,2
CARBONSTEEL,1
MENTHAPULEGIUM,1
AQUEOUS EXTRACT,2
ACID,1
LEAVES,1
ANTIOXIDANT,1
DERIVATIVES,1
National Science Technology and Innovation Policy,6
Vaccines,1
Immunization Programs,2
Innovation,1
Access to Essential Medicines and Health Technologies,7
,1
ICT Industry,2
Technology innovation,2
USChina Trade war,3
DifferencesinDifferences,1
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTALREGULATION,1
ANTIDUMPING PROTECTION,2
PERFORMANCE EVALUATION,2
DEVELOPMENT SUBSIDIES,2
INVESTMENT EVIDENCE,2
TRUMP,1
CONSTRAINTS,1
TECHNOLOGY,1
ENERGY,1
COVID19,1
interventional radiology,2
management protocol,2
healthcare safety,2
,1
Dengyinnaotong capsule,2
Atherosclerosis,1
Dyslipidemia,1
Fatty liver,2
Gut dysbiosis,2
Intestinal barrier,2
MONOCYTE CHEMOATTRACTANT PROTEIN1,3
CARDIOVASCULARDISEASE,1
CONTROLLEDTRIAL,1
LIVERDISEASE,1
RISK,1
HYPERCHOLESTEROLEMIA,1
DYSLIPIDEMIA,1
MACROPHAGES,1
DYSFUNCTION,1
MICROBIOME,1
Yinhuang granule,2
MAFLD,1
MCD,1
Oxidative stress,2
inflammation,1
liver fibrosis,2
CHOLINEDEFICIENT DIET,2
NONALCOHOLIC STEATOHEPATITIS,2
MOUSE MODELS,2
FIBROSIS,1
TARGETS,1
MARKERS,1
IMPACT,1
NAFLD,1
RISK,1
IP box,2
Innovation box,2
Effective tax rate,3
Gaming industry,2
FOODSUPPLY CHAINS,2
SUSTAINABLE BUSINESS MODELS,3
SMES,1
COMPETENCE,1
NETWORKS,1
ENTREPRENEURSHIP,1
INNOVATION,1
BARRIERS,1
STRATEGY,1
GROWTH,1
COVID19,1
allocation,1
vaccine,1
COVAX,1
distributional justice,2
global health ethics,3
human rights,2
,1
Biosimilar,1
biologic,1
erythropoietin analogue,2
dialysis,1
regulatory,1
therapeutic equivalency,2
reference agent,2
drug approval,2
safety,1
efficacy,1
cost,1
anemia,1
nephrology,1
endstage renal disease ESRD,4
pharmacovigilance,1
interchangeability,1
ERYTHROPOIESISSTIMULATING AGENTS,2
REDCELL APLASIA,2
DISEASE,1
LITERACY,1
EPOETIN,1
ANEMIA,1
PEGINESATIDE,1
MANAGEMENT,1
PLATELET,1
Dual layer,2
Stent,1
CASPER,1
Aneurysm,1
Visceral,1
Renal,1
Splenic,1
MICROMESH STENT,2
CURRENT MANAGEMENT,2
Foreign direct investment,3
green technology innovation,3
technology spillovers,2
granted green patents,3
ECONOMICGROWTH,1
DEVELOPINGCOUNTRIES,1
POSITIVE SPILLOVERS,2
ENERGYCONSUMPTION,1
EMPIRICALEVIDENCE,1
CARBON EMISSIONS,2
FDI,1
DETERMINANTS,1
PERFORMANCE,1
TRADE,1
Proprietary component manufacturer,3
Global supply chain,3
Tax,1
Organizational structure,2
Transfer price,2
SOURCING STRATEGIES,2
CONTROL POLICIES,2
OFFSHORE,1
DECISIONS,1
ischemic stroke,2
metformin threonate,2
microglia,1
neuroinflammation,1
functional recovery,2
ACUTE STROKE,2
NEUROGENESIS,1
MICROGLIAMACROPHAGES,1
NEUROINFLAMMATION,1
ANGIOGENESIS,1
ACTIVATION,1
AUTOPHAGY,1
SEVERITY,1
PATHWAY,1
TARGET,1
Vitis,1
genetic resources,2
exotic germplasm,2
genetic variation,2
arid region,2
molecular markers,2
multivariate analysis,2
L GERMPLASM,2
CULTIVARS,1
DIVERSITY,1
ACCESSIONS,1
GUAVA,1
IPBS,1
MAP,1
Angiostatic steroids,2
angiogenic steroids,2
angiosteroids,1
angiogenic growth factors,3
bFGF,1
Crohns disease,2
dopamine,1
gastric and duodenal ulcers,4
inflammatory bowel diseases,3
PDGF,1
pyrazole derivatives,2
ulcerative colitis,2
VEGF,1
FIBROBLASTGROWTHFACTOR,1
INFLAMMATORYBOWELDISEASE,1
PERFORATED PEPTICULCER,2
GASTRICMUCOSAL INJURY,2
DUODENALULCER,1
VASCULARPERMEABILITY,1
GASTROINTESTINAL ULCERS,2
INHIBITS ANGIOGENESIS,2
DOPAMINE,1
COLITIS,1
Circumsporozoite protein,2
Plasmodium berghei,2
Plasmodium vivax,2
PvCSP,1
Transgenic parasite,2
VK210,1
VK247,1
Vaccine,1
MALARIA VACCINE,2
TRANSMISSION,1
PROTECTION,1
CANDIDATE,1
REPEAT,1
SERA,1
Breeders rights,2
Exhaustion,1
Commercial exploitation,2
Right of ownership,3
Acts of production or reproduction,5
Variety constituents,2
Planting and harvesting,3
,1
,1
HUMAN MALARIA INFECTION,3
CD8 TCELLS,2
PFSPZ VACCINE,2
SIMIAN MALARIAS,2
PROTECTION,1
FALCIPARUM,1
SAFETY,1
IMMUNOGENICITY,1
TRANSMISSION,1
IMMUNIZATION,1
generic drugs,2
drug prices,2
drug shortages,2
drug regulation,2
PRICECOMPETITION,1
ENTRY,1
Trade secrets,2
Defend Trade Secrets Act,4
Economic Espionage Act,3
Uniform Trade Secrets Act,4
TRIPS Agreement,2
Knowhow,1
PROTECTION,1
,1
SAMPLESIZE CALCULATIONS,2
LEFT ATRIAL APPENDAGE,3
PATENT FORAMEN OVALE,3
NONINFERIORITY,1
MYOCARDIALINFARCTION,1
PERCUTANEOUS CLOSURE,2
MEDICAL THERAPY,2
FIBRILLATION,1
REPLACEMENT,1
PROTECTION,1
Deglutition,1
Respiration,1
Recurrent laryngeal nerve,3
Sensorimotor,1
Infant,1
Development,1
Animal model,2
PATENT DUCTUSARTERIOSUS,2
REFLEX PHARYNGEAL SWALLOW,3
RHYTHMIC ORAL ACTIVITY,3
PRETERM INFANTS,2
CONCURRENT MANOMETRY,2
PROCAVIASYRIACUS,1
MINIATURE PIGS,2
INSITU,1
IMPACT,1
RAT,1
drug development,2
CNS,1
translational research,2
RECEPTOR ANTAGONIST,2
STATUS EPILEPTICUS,2
ANIMALMODELS,1
TRANSLATIONAL RESEARCH,2
CNS DISORDERS,2
INVIVO,1
PROGRESS,1
DAMAGE,1
Adalimumab,1
Biosimilars,1
Biotherapeutics,1
MAM,1
Critical quality attributes,3
HRAM MS,2
AMINOACID MISINCORPORATION,2
FUNCTIONAL COMPARABILITY,2
RITUXIMAB,1
ANTIBODIES,1
Monitoring,1
Circuit faults,2
Cameras,1
Voltage,1
Temperature sensors,2
Task analysis,2
Industries,1
Artificial intelligence AI,3
drones,1
PV plant monitoring,3
sensor systems,2
FAULTDETECTION,1
PHOTOVOLTAIC MODULES,2
PVMODULES,1
DIAGNOSIS,1
CLASSIFICATION,1
IDENTIFICATION,1
INSTALLATIONS,1
FLUORESCENCE,1
CHALLENGES,1
PROTECTION,1
Ahmad Faris alShidyaq,3
Covenants of the Prophet Muhammad,5
Muawiyah,1
Ali ibn Abi Talib,4
Rashid Dahdah,2
Ibrahim Mohamed Zein,3
Ahmed ElWakil,2
Jeanne Aubert,2
William Scawen Blunt,3
Chronicle of Seert,3
Treaty of Najran,3
religious pluralism,2
John Rylands Library,3
,1
Qualitative research,2
Magnesium alloy,2
Experimental research,2
Aircraft brackets,2
Threeslide forging press,3
TECHNOLOGY,1
insecticide discovery,2
natural products,2
crop protection compounds,3
agrochemical industry,2
competitorinspired,1
firstinclass,1
NATURALPRODUCTS,1
BIOLOGICALACTIVITY,1
ACARICIDE,1
GENERATION,1
DESIGN,1
PYRETHROIDS,1
PIPELINE,1
ANALOGS,1
TRENDS,1
MIMICS,1
competitive advantage,2
global value chains,3
intangible assets,2
multinational enterprises,2
rents,1
INNOVATION,1
INVESTMENT,1
ECONOMY,1
GROWTH,1
JAPAN,1
TRADE,1
RISE,1
SIRT,1
gallbladder radiation,2
vascular anatomy,2
hepatic artery,2
cystic artery,2
extrahepatic leaking,2
RESIN MICROSPHERES,2
RADIOEMBOLIZATION,1
EMBOLIZATION,1
THERAPY,1
COILING,1
,1
ATPBINDING SITE,2
CATALYTIC SUBUNIT,2
CRYSTALSTRUCTURE,1
TYROSINE KINASE,2
STRUCTURAL BASIS,2
INVIVO,1
POTENT INHIBITOR,2
SELECTIVE INHIBITOR,2
PEPTIDE INHIBITOR,2
COMPLEX REVEALS,2
Government procurement,2
Pharmaceutical markets,2
Developing economy,2
Consumer welfare,2
Targeting,1
PATENT PROTECTION,2
FIELD EXPERIMENT,2
HEALTHSERVICES,1
MARKET,1
ENTRY,1
PHARMACEUTICALS,1
DEMAND,1
INCOME,1
COMPETITION,1
COUNTRIES,1
brain,1
caffeine,1
cytokines,1
ibuprofen,1
intermittent hypoxia,2
myelination,1
neuroinflammation,1
nonsteroidal antiinflammatory drugs,3
PATENT DUCTUSARTERIOSUS,2
WHITEMATTER,1
BRAININJURY,1
DEVELOPMENTALDISABILITY,1
KETOROLAC TROMETHAMINE,2
CEREBRALISCHEMIA,1
PREMATUREINFANTS,1
DAMAGE,1
OXYGEN,1
VULNERABILITY,1
Antiinflammatory,1
aspirin,1
drug delivery,2
gastroprotection,1
kinetics of release,3
lipids,1
micromerics,1
ulcersgugu,1
INVITRO,1
ORAL BIOAVAILABILITY,2
VIVO,1
DRUGS,1
RELEASE,1
INDOMETHACIN,1
FORMULATIONS,1
GENTAMICIN,1
PREVENTION,1
MECHANISM,1
alternative dispute resolution,3
cyberspace,1
intellectual property,2
arbitration,1
,1
Digital technology innovation,3
ESG,1
Substantive innovation,2
Symbolic innovation,2
SOCIALRESPONSIBILITY,1
INFORMATION,1
IMPACT,1
SYSTEMS,1
,1
SILVER NANOPARTICLES,2
WATERUPTAKE,1
GERMINATION,1
SULFIDATION,1
MECHANISM,1
TOXICITY,1
IMPACT,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT PROTECTION,2
FAIRUSE,1
INDEPENDENT INVENTION,2
PATENT,1
LAW,1
ECONOMICS,1
INNOVATION,1
DEFENSE,1
IP,1
aquaphotomics,1
food coatings,2
NIR spectroscopy,2
cheese ripening,2
winter melon storage,3
NEARINFRARED SPECTROSCOPY,2
WATER SPECTRAL PATTERN,3
spinal cord protection,3
aortic surgery,2
intercostal artery reconstruction,3
patency,1
AORTICSURGERY,1
BLOODFLOW,1
IMMEDIATE,1
,1
,1
Drug policy,2
developing countries,2
economic evaluation,2
effectiveness,1
essential drugs,2
evidencebased policy,2
health systems research,3
HIV,1
multivariate analysis,2
INCOME COUNTRIES,2
PROCUREMENT,1
MEDICINES,1
Market launch planning,3
New product introduction,3
Twostage stochastic programming,3
Regulatory affairs,2
DIFFUSION,1
DRUGS,1
DEMAND,1
Seed laws,2
statesociety relations,2
Venezuela,1
food sovereignty,2
bottomup policymaking,2
PERSPECTIVES,1
HISTORY,1
BRAZIL,1
Digital systems,2
Green products,2
Environmental monitoring,2
Costs,1
Electric vehicles,2
Carbon dioxide,2
Research and development,3
Digital development,2
green innovation network,3
green innovation performance,3
new energy vehicles,3
,1
Pudilan Xiaoyan Oral Liquid,4
Metabolomics,1
Network pharmacology,2
LPSinduced lung injury,3
Protective mechanism,2
LCMS,1
SYSTEMS BIOLOGY,2
AMINOACIDS,1
IL4I1,1
INFLAMMATION,1
NMR,1
,1
HEALTHCARE PROFESSIONALS,2
SPECIALISTS,1
PERCEPTION,1
KNOWLEDGE,1
ATTITUDES,1
AWARENESS,1
bioprospection,1
CaLB,1
protein,1
functional characterization,2
CANDIDAANTARCTICA,1
PICHIAPASTORIS,1
BIODIESEL PRODUCTION,2
SEQUENCE ALIGNMENT,2
EXPRESSION,1
OPTIMIZATION,1
TEMPERATURE,1
scientometric analysis,2
egg yolk immunoglobulin IgY,4
IgY technology,2
poultry,1
EGGYOLK ANTIBODIES,2
PASSIVEIMMUNIZATION,1
CHICKEN,1
HEN,1
PROTECTION,1
Trypanosomosis,1
Probiotics,1
Parasitemia,1
Immune response,2
Nitric oxide,2
Hematobiochemical,1
LACTOBACILLUSCASEI,1
OXIDATIVE STRESS,2
IMMUNERESPONSE,1
BABESIAMICROTI,1
SUPPLEMENTATION,1
INFLAMMATION,1
CHEMOTHERAPY,1
MODULATION,1
PROTECTION,1
LEADS,1
Corporate Governance,2
Cash Holding,2
Multinational Corporations,2
Foreign Subsidiary Boards,3
RESEARCHANDDEVELOPMENT,1
FIRMS HOLD,2
KNOWLEDGE FLOWS,2
AGENCY THEORY,2
GOVERNANCE,1
PERFORMANCE,1
OWNERSHIP,1
LIQUIDITY,1
POLICY,1
COSTS,1
Anemia,1
kidney disease,2
Biosimilar Pharmaceuticals,2
nephrology,1
Cost Savings,2
Drugs,1
Generic,1
EPO protein,2
human,1
erythropoietin,1
Research,1
,1
T cell,2
costimulation,1
CD8 activation,2
vein graft disease,3
vein graft failure,3
TCRT cell receptor,3
costimulatary pathway,2
SMOOTHMUSCLECELLS,1
IFNGAMMA,1
INTERFERONGAMMA,1
INVIVO,1
MEMORY,1
ATHEROSCLEROSIS,1
IMMUNITY,1
ACTIVATION,1
IL12,1
STIMULATION,1
,1
,1
Sex selection,2
Dairy goats,2
Nano monoclonal antibody,3
In vitro fertilization,3
SEXED SEMEN,2
acetylcholinesterase inhibitors,2
neuroprotection,1
organophosphate,1
oxime reactivators,2
sarin surrogate,2
,1
Replicator dynamics,2
Game theory,2
Neural dynamic,2
Load balancing,2
Datadriven control,2
Structural control,2
CONTROL STRATEGIES,2
MASS DAMPERS,2
SYSTEMS,1
PERFORMANCE,1
BUILDINGS,1
DESIGN,1
cell therapy,2
human adipose mesenchymal stem cells,5
HC016 cell conditioning treatment,4
rat preclinical contusion model,4
spinal cord injury,3
MESENCHYMAL STEMCELLS,2
HUMAN BONEMARROW,2
ADIPOSETISSUE,1
STROMAL CELLS,2
OXIDATIVE STRESS,2
GAIT ANALYSIS,2
MECHANISMS,1
CONTUSION,1
THERAPY,1
Journal evaluation,2
Scientometrics,1
Traditional knowledge,2
Impact,1
PLANTS,1
,1
PATENT,1
PERSPECTIVE,1
RIGHTS,1
LAW,1
Salmon lice,2
Genetic resistance,2
Atlantic salmon,2
Selective breeding,2
Policy instruments,2
Regulating gene editing,3
INFECTIOUS PANCREATIC NECROSIS,3
GENETICRESOURCES,1
AQUACULTURE,1
PROTECTION,1
ACCESS,1
CATTLE,1
GOALS,1
SALAR,1
LOUSE,1
SELECTION,1
wildlife trade,2
pangolin,1
consumption willingness,2
species conservation,2
Guangdong province,2
SOCIALINFLUENCE,1
TRADE,1
WILDLIFE,1
BEHAVIOR,1
MEDICINE,1
MARKETS,1
SCALE,1
,1
STRING SIGN,2
PSEUDOOCCLUSION,1
SURGERY TRIAL,2
STENOSIS,1
ENDARTERECTOMY,1
MANAGEMENT,1
BENEFITS,1
INTERVENTION,1
PROTECTION,1
DIAGNOSIS,1
Africa,1
differentiation,1
ECOWAS,1
food security,2
intellectual property rights IPRs,4
patents,1
plant Breeders rights,3
sustainable development,2
PLANT VARIETY PROTECTION,3
SWAKOPMUND PROTOCOL,2
PROPERTY,1
BIODIVERSITY,1
FOLKLORE,1
RIGHTS,1
ARIPO,1
LEGAL,1
excipients,1
filgrastim,1
formulation,1
NMR,1
structure,1
COLONYSTIMULATING FACTOR,2
PHDEPENDENCE,1
STABILITY,1
HISTIDINE,1
PROTEIN,1
VISUALIZATION,1
SPECTROSCOPY,1
SYSTEM,1
PienTzeHuang,1
Cytokines analysis,2
Untargeted metabonomics,2
Alcoholic liver injury,3
UHPLCQTOF,1
MS,1
Pathway analysis,2
FATTY LIVER,2
SILYMARIN,1
DISEASE,1
New accounting system,3
Corporate innovation,2
Accounting system reform,3
Corporate risktaking,2
Accounting standards,2
Quasinatural experiment,2
G32,1
M41,1
M48,1
O31,1
MANDATORY IFRS ADOPTION,3
PROPERTYRIGHTS PROTECTION,2
EARNINGS MANAGEMENT,2
RISKTAKING,1
STANDARDS,1
OWNERSHIP,1
PERFORMANCE,1
TECHNOLOGY,1
INCENTIVES,1
INVESTMENT,1
Biomass,1
Polyurethane dispersion,2
Solventfree,1
Environmentfriendly,1
Textile coating,2
PERFORMANCE,1
COATINGS,1
CASTOR,1
Type 2 diabetes mellitus,4
Endothelial dysfunction,2
Soluble endoglin,2
Reactive hyperemia index,3
INSULINRESISTANCE,1
CELL DYSFUNCTION,2
ADIPOSETISSUE,1
ATHEROSCLEROSIS,1
Bactrocera oleae,2
entomopathogenic fungi,2
persistence,1
soil,1
molecular detection,2
CERATITISCAPITATA DIPTERA,2
ULTRAVIOLET RADIATION,2
ENTOMOPATHOGENIC FUNGI,2
BEAUVERIABASSIANA,1
BIOCONTROL AGENT,2
ANISOPLIAE,1
CONIDIA,1
PROTECTION,1
QUANTIFICATION,1
MICROSCLEROTIA,1
Electron IORT,2
In vivo dosimetry with MOSFETs and EBT2,7
GAFCHROMIC films,2
Accelerated Partial Breast Irradiation,4
Quality Assurance,2
INTRAOPERATIVE RADIATIONTHERAPY,2
CONSENSUS STATEMENT,2
EBT2 FILM,2
RADIOTHERAPY,1
CANCER,1
DETECTORS,1
VERIFICATION,1
CALIBRATION,1
ASTRO,1
Thermal power measuring,3
Evacuated tube solar collector,4
Metal foam,2
Simultaneous operation,2
HEATPIPE,1
FLATPLATE,1
PERFORMANCE EVALUATION,2
SYSTEMS,1
EXCHANGERS,1
NANOFLUIDS,1
PREDICTION,1
PLATFORM,1
COOKER,1
DESIGN,1
Forging,1
Numerical simulations,2
Aircraft components,2
Threeslide forging press,3
Magnesium alloys Aircraft brackets with a triangular outline,8
,1
Type 2 diabetes mellitus,4
Endothelial dysfunction,2
Soluble endoglin,2
Reactive hyperemia index,3
INSULINRESISTANCE,1
CELL DYSFUNCTION,2
ADIPOSETISSUE,1
ATHEROSCLEROSIS,1
Malaria in pregnancy,3
low birth weight,3
rapid diagnostic test,3
malaria parasite detection,3
INTERMITTENT PREVENTIVE TREATMENT,3
MALARIA INFECTION,2
PREGNANTWOMEN,1
ANEMIA,1
PROTECTION,1
mass spectrometry,2
erythropoietin,1
darbepoetin alfa,2
biosimilar,1
LCMSMS,1
RECOMBINANT HUMAN ERYTHROPOIETINS,3
HAMSTER OVARY CELLS,3
HUMAN URINARY,2
STRUCTURALCHARACTERIZATION,1
DOPING ANALYSIS,2
GLYCOPEPTIDE,1
GENE,1
IDENTIFICATION,1
GLYCOSYLATION,1
PRODUCTS,1
,1
BOUNDED RATIONALITY,2
Choice,1
health management,2
mothers,1
underfive children,2
social workers,2
CARE,1
,1
,1
catheterization,1
transseptal,1
closure,1
ASD,1
PDA,1
PFO,1
embolic protection devices,3
stroke,1
imaging,1
intracardiac echocardiography,2
TRANSCATHETER CLOSURE,2
DECOMPRESSION ILLNESS,2
NEUROLOGICAL EVENTS,2
CRYPTOGENIC STROKE,2
METAANALYSIS,1
SAFETY,1
PREVENTION,1
RECURRENCE,1
MIGRAINE,1
Thoracoabdominal aortic repair,3
Artery of Adamkiewicz,3
Spinal cord injury,3
Computed tomography,2
SPINALCORD PROTECTION,2
PREOPERATIVE DEMONSTRATION,2
DEEP HYPOTHERMIA,2
SURGERY,1
IDENTIFICATION,1
ANGIOGRAPHY,1
STRATEGY,1
OUTCOMES,1
Maya area,2
bacterial diversity,2
bioconsolidation treatment,2
nutritional medium,2
carbonatogenic bacteria,2
tuff stone,2
plasters,1
CULTURALHERITAGE,1
BIODETERIORATION,1
BUILDINGS,1
PRECIPITATION,1
IMPROVEMENT,1
CATACOMBS,1
CALLIXTUS,1
BIOFILMS,1
CONCRETE,1
COPAN,1
,1
TISSUE EXPANDER,2
RADIOTHERAPY,1
INFECTION,1
IMPLANT,1
enoxaparin,1
thrombin generation,2
LMWH,1
biosimilars,1
antiXa activity,2
VENOUS THROMBOEMBOLISM,2
GENERIC VERSIONS,2
TISSUE FACTOR,2
HEPARINS,1
COAGULATION,1
antibodies,1
infectious diseases,2
malaria,1
T cells,2
NATURALLY ACQUIREDIMMUNITY,2
PLASMODIUMFALCIPARUM,1
IFNGAMMA,1
PROTECTION,1
INDUCTION,1
CYTOKINES,1
EXPOSURE,1
ANTIGEN,1
ADULTS,1
farmsaved seeds,2
intellectual property rights,3
plant breeders rights,3
royalty rates,2
INTELLECTUAL PROPERTYRIGHTS,2
PROTECTION,1
INCENTIVES,1
PATENTS,1
PIRACY,1
oxime,1
organophosphate,1
acetylcholinesterase inhibition,2
reactivation,1
neuroprotection,1
glial fibrillary acidic protein,4
CORTICOTROPINRELEASINGFACTOR,1
KAINIC ACID,2
SARIN,1
SEIZURE,1
PRALIDOXIME,1
RECEPTORS,1
NEURODEGENERATION,1
PROTECTION,1
EXPOSURE,1
BEHAVIOR,1
,1
SPINALCORD PROTECTION,2
REPAIR,1
COMPLICATIONS,1
ISCHEMIA,1
INJURY,1
Intellectual property,2
Invention,1
Patent,1
Public disclosure,2
Employees invention,2
Medical device,2
,1
Rock bolt,2
Hard rock,2
Corrosive ground condition,3
Bolt corrosion,2
,1
fire retardant coatings,3
degree of fire resistance,4
materials and structures,3
quality of fire retardant coatings,5
durability of fire retardant coatings,5
thermoelectroacoustic method,2
heat conductivity,2
thermal diffusivity,2
heat capacity,2
aging of fire retardant coatings,5
,1
digital economy,2
intellectual property,2
innovation,1
cloud computing,2
,1
digital economy,2
intellectual property,2
innovation,1
cloud computing,2
,1
,1
COSTEFFECTIVENESS,1
DEFINING ELEMENTS,2
RECOMMENDATIONS,1
,1
,1
Calcium silicate,2
Dentine,1
Hypersensitivity,1
Hydroxyapatite,1
Toothpaste,1
,1
Aneurysm,1
Dissecting,1
Coronary Artery Bypass,3
Coronary Artery Disease,3
Reoperation,1
DEL NIDO CARDIOPLEGIA,3
CARDIACSURGERY,1
Autophagy,1
Apoptosis,1
Pancreatic cancer,2
Akt,1
mTOR,1
NATURALPRODUCTS,1
SURVIVAL,1
Cerebral ischemiareperfusion,2
neuroprotection,1
signalling pathways,2
ISCHEMIAREPERFUSION INJURY,2
ACTIVATED PROTEINKINASE,2
KAPPAB ACTIVATION,2
SIGNALING PATHWAY,2
BRAININJURY,1
MOUSE MODEL,2
CELLDEATH,1
MAISAN,1
ARTERY OCCLUSION,2
GINSENOSIDE RB1,2
,1
,1
Suhuang antitussive capsule,3
Pulmonary dysfunction,2
Cough variant asthma,3
Endoplasmic reticulum stress,3
NLRP3,1
Inflammasome,1
CELLDEATH,1
PKR,1
HOMEOSTASIS,1
NECROSIS,1
FUSION,1
,1
ANTIHYPERTENSIVE MEDICATION USE,3
PLACEBOLIKE TOLERABILITY,2
BLOODPRESSURE CONTROL,2
ORAL RENIN INHIBITOR,3
CLINICALPRACTICE,1
REALLIFE,1
ALISKIREN,1
MANAGEMENT,1
ADULTS,1
EFFICACY,1
,1
CHRONIC MYELOGENOUS LEUKEMIA,3
EARLY MOLECULAR RESPONSE,3
FOLLOWUP,1
ECONOMICBENEFITS,1
PRICECOMPETITION,1
THERAPY,1
DASATINIB,1
INTERFERON,1
NILOTINIB,1
OUTCOMES,1
Fusion protein,2
Listeriolysin O,2
LLOPTS1,1
PST1,1
Pertussis,1
Vaccine,1
BORDETELLAPERTUSSIS,1
CONJUGATE VACCINES,2
HOUSEHOLD EXPOSURE,2
WHOLECELL,1
ANTIGEN,1
TOXIN,1
ANTIBODIES,1
IMMUNIZATION,1
PROTECTION,1
PROTEIN,1
shipbridge antistriking,2
water jet,2
ship yaw torque,3
tracks line,2
nozzle pressure,2
COMPOSITES,1
PROTECTION,1
India,1
Clinical trials,2
Contract Research Organisations,3
Pharmaceuticalisation,1
INNOVATION,1
INDUSTRY,1
MEDICALIZATION,1
INTERSECTIONS,1
TRENDS,1
RIGHTS,1
3D printing,2
additive manufacturing,2
telemedicine,1
patientcentric dosage form,3
ACCEPTABILITY,1
AGE,1
HuaFengDan,1
RNAseq,1
GCMS,1
bioinformatics,1
adaptation,1
GEO database,2
GENEEXPRESSION,1
REALGAR,1
MICE,1
PROTECTION,1
RESISTANCE,1
CINNABAR,1
BORNEOL,1
Artemisia annua L,3
Artemisinin,1
Bacterial challenge,2
Herbal immunostimulants,2
Stress,1
Oxidative stress,2
LEUKOCYTES RESPIRATORY BURST,3
MYRTLE MYRTUSCOMMUNIS,2
TOLLLIKE RECEPTORS,2
ASIAN SEABASS,2
DISEASE RESISTANCE,2
LABEOROHITA,1
DIETARY SUPPLEMENTATION,2
GROWTHPERFORMANCE,1
LEAF EXTRACT,2
ANTIOXIDANT CAPACITY,2
IP strategy,2
Sustainable manufacturing,2
Business strategy,2
,1
Intellectual property,2
Institution,1
Carbon emissions,2
National Intellectual Property Demonstration City,5
Difference in difference,3
Technology innovation,2
ECONOMICGROWTH EVIDENCE,2
TECHNOLOGICALINNOVATION,1
EMPIRICALEVIDENCE,1
CO2 EMISSIONS,2
PANELDATA,1
RIGHTS,1
PROTECTION,1
INVESTMENT,1
PATENTS,1
IMPACT,1
Conservation,1
Intellectual property rights,3
Traditional medical knowledge,3
Korea,1
Documentation,1
NORTH JEOLLA PROVINCE,3
MEDICINALPLANTS,1
Green innovation,2
Carbon emission performance,3
Green patent,2
Mediation effect,2
Heterogeneity,1
China,1
YANGTZERIVER DELTA,2
NATURALRESOURCE DEPENDENCE,2
ENVIRONMENTAL KUZNETS CURVE,3
NIGHTTIME LIGHT DATA,3
ECONOMICGROWTH,1
DIOXIDE EMISSIONS,2
TECHNOLOGICALINNOVATION,1
ENERGYCONSUMPTION,1
EMPIRICALEVIDENCE,1
URBAN AGGLOMERATION,2
Hong KongZhuhaiMacao Bridge project,4
Project control,2
Incentivization,1
INTERORGANIZATIONAL RELATIONSHIPS,2
INCENTIVE MECHANISMS,2
AGENCYTHEORY,1
PERFORMANCE,1
CONTRACTS,1
STRATEGIES,1
DYNAMICS,1
QUALITY,1
MODEL,1
Antenatal steroids,2
Continuous positive airway pressure,4
Evidencebased practice,2
Hyaline membrane disease,3
Mechanical ventilation,2
Nutrition,1
Oxygen supplementation,2
Patent ductus arteriosus,3
Preterm infant,2
Respiratory distress syndrome,3
Surfactant therapy,2
Thermoregulation,1
EXTREMELY PRETERM INFANTS,3
POSITIVE AIRWAY PRESSURE,3
INHALED NITRICOXIDE,2
BIRTHWEIGHT INFANTS,2
INVASIVE SURFACTANT THERAPY,3
RANDOMIZED CONTROLLEDTRIAL,2
OXYGENSATURATION TARGETS,2
PLACEBOCONTROLLED TRIAL,2
UMBILICALCORD MILKING,2
CHRONIC LUNGDISEASE,2
Waste cooking oil,3
Biojet fuel,2
Directional flow,2
Evolution game,2
Innovation support,2
SUPPLY CHAIN,2
DESIGN,1
ENERGY,1
Breast cancer,2
costeffectiveness,1
tamoxifen,1
aromatase inhibitors,2
MOLECULARWEIGHT HEPARIN,2
SEQUENTIAL TAMOXIFENEXEMESTANE,2
INITIAL ADJUVANT THERAPY,3
AROMATASE INHIBITORS,2
COSTUTILITY,1
VENOUS THROMBOEMBOLISM,2
UPFRONT ANASTROZOLE,2
ENDOMETRIAL CANCER,2
VEINTHROMBOSIS,1
LETROZOLE,1
parasite,1
nematode,1
filariasis,1
microfilaria,1
macrophage,1
lung,1
pleura,1
VACCINEINDUCED PROTECTION,2
MAJOR BASICPROTEIN,2
NITRICOXIDE,1
ONCHOCERCAVOLVULUS,1
MURINE FILARIASIS,2
BRUGIAMALAYI,1
INNATE RESISTANCE,2
INTERFERONGAMMA,1
TYPE2 IMMUNITY,2
TISSUEREPAIR,1
EAE,1
synthetic peptide,2
fish venom,2
TnP,1
preclinical,1
diseasemodifying therapies,2
MULTIPLESCLEROSIS,1
FINGOLIMOD,1
slope management,2
mineral weathering,2
greening,1
vegetation restoration,2
analytic hierarchy process,3
PLANTGROWTH PROMOTION,2
ENZYMEACTIVITY,1
NATIONALPARK,1
SOIL ENZYMES,2
BACTERIA,1
REVEGETATION,1
NITROGEN,1
RESTORATION,1
RHIZOSPHERE,1
MICROBES,1
generic substitution,2
biosimilars,1
pharmacist,1
followon biologics,2
automatic therapeutic substitution,3
,1
Data reducing,2
Optimization algorithms,2
Hysteretic dampers,2
Structural health monitoring,3
EXPERIMENTAL VALIDATION,2
STRUCTURAL DAMAGE,2
OPTIMIZATION,1
FREQUENCY,1
WEB,1
pig,1
soiltransmitted helminth,2
Ascaris suum,2
antigenspecific,1
adaptive immunity,2
infection,1
protection,1
Th1Th2,1
REGULATORY TCELLS,2
PROTECTIVE IMMUNITY,2
TRICHURISMURIS,1
PARASITIC HELMINTHS,2
TOXOPLASMAGONDII,1
TISSUE MIGRATION,2
HEPATICLESIONS,1
FATTENING PIGS,2
CYTOKINE,1
LUMBRICOIDES,1
Longterm controlled release,3
Microencapsulation,1
Polylacticcoglycolic acid microspheres,3
Peptide,1
CONTROLLEDRELEASE,1
PLGA MICROSPHERES,2
PROTEIN INSTABILITY,2
LEUPROLIDE ACETATE,2
POLYMER MICROBEADS,2
MICROCLIMATE PH,2
PEPTIDE,1
OCTREOTIDE,1
ACYLATION,1
ACID,1
biomass,1
manure,1
pocket,1
biogas yield,2
methane fermentation,2
methane production by fermentation,4
ANAEROBIC CODIGESTION,2
METHANE,1
MANURE,1
PRETREATMENT,1
WASTES,1
FUTURE,1
Antioxidant,1
Dopamine,1
MPTP,1
Parkinson disease,2
Traditional Chinese medicine,3
MPTP MOUSE MODEL,3
OXIDATIVE STRESS,2
MITOCHONDRIAL DYSFUNCTION,2
LIGUSTICUMCHUANXIONG,1
BRAIN,1
ACID,1
NEUROTOXICITY,1
PAEONIFLORIN,1
ACTIVATION,1
EXPRESSION,1
Anxiety or depression after PCI,5
Traditional Chinese medicine,3
Therapeutic drugs,2
Mechanism,1
XINKESHU,1
PHARMACOLOGICALACTIVITIES,1
SALVIANOLIC ACID,2
HEART,1
DISEASE,1
ISCHEMIA,1
STRESS,1
EXPRESSION,1
EXTRACT,1
INJURY,1
ESG,1
environment in ESG,3
fiscal and tax system,4
performancebased budgeting,2
DID,1
China,1
SOCIALRESPONSIBILITY,1
MATTER,1
Solar plant monitoring,3
Drones for power plant maintenance,5
IR and visible light cameras for solar plant,8
monitoring,1
PHOTOVOLTAIC SYSTEMS,2
FAULTDETECTION,1
PVMODULES,1
PLANTS,1
INSTALLATIONS,1
FLUORESCENCE,1
CHALLENGES,1
PROTECTION,1
RATES,1
POWER,1
,1
DEVELOPINGCOUNTRIES,1
SOPHISTICATION,1
EXPORTS,1
MEDIATION,1
SECTOR,1
IMPACT,1
,1
CARD MERCHANT RESTRAINTS,3
2SIDED MARKETS,2
COMPETITION,1
PRICELESS,1
COSTS,1
,1
INSECTICIDETREATED NETS,2
BED NETS,2
COUNTRIES,1
atherosclerosis,1
Guanxinning tablet,2
molecular docking analysis,3
network pharmacology,2
potential target,2
EPIDERMALGROWTHFACTOR,1
NFKAPPAB,1
ENDOTHELIAL DYSFUNCTION,2
OXIDIZED PHOSPHOLIPIDS,2
TRANSCRIPTION FACTOR,2
NITRICOXIDE,1
ACTIVATION,1
P53,1
INFLAMMATION,1
CYTOSCAPE,1
collateral network nearinfrared spectroscopy,4
minimally invasive segmental artery coil and plug embolization,8
spinal cord protection,3
thoracoabdominal aortic aneurysm repair,4
AORTICANEURYSM REPAIR,2
SPINALCORD ISCHEMIA,2
COIL EMBOLIZATION,2
REIMPLANTATION,1
PARAPLEGIA,1
INJURY,1
FLOW,1
Decision support,2
Laboratory information system,3
Telemedicine,1
First order predicates,3
ELECTRONIC HEALTH RECORDS,3
SUPPORTSYSTEM,1
PERSONALIZED MEDICINE,2
EMERGENCYDEPARTMENT,1
LABORATORY TESTS,2
CLINICALTRIAL,1
IMPLEMENTATION,1
INFORMATION,1
MANAGEMENT,1
KNOWLEDGE,1
schizophrenia,1
ethics,1
medical,1
mild encephalitis,2
stigmatization,1
compulsory treatment,2
autoimmune,1
encephalitis,1
MAJOR MENTALDISORDERS,2
AUTOIMMUNEDISEASES,1
RECEPTOR ANTIBODIES,2
PSYCHOTIC DISORDERS,2
BIPOLAR DISORDER,2
INFLAMMATION,1
ILLNESS,1
PREVENTION,1
IMMUNE,1
PREVALENCE,1
,1
GLOSSINAMORSITANSMORSITANS,1
PREFERRED BUFFALO,2
CATTLE,1
FLY,1
SEMIOCHEMICALS,1
TRYPANOSOMOSIS,1
INSECTICIDE,1
PALLIDIPES,1
EFFICACY,1
NUISANCE,1
HuoXiangZhengQi oral liquid,3
Characteristic chromatograms,2
Selective ion monitoring,3
Authentication,1
Quality evaluation,2
COLLISION CROSSSECTION,2
HIGHRESOLUTION,1
PATENT MEDICINES,2
MASS,1
IDENTIFICATION,1
MARKERS,1
FINGERPRINT,1
RADIX,1
Clinical trials,2
Cardiovascular,1
Drug development,2
Personalized medicine,2
New therapies,2
Health technology assessment,3
Cardiovascular disease burden,3
CORONARYHEARTDISEASE,1
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,3
SUBTILISINKEXIN TYPE 9,3
ASSOCIATION TASKFORCE,2
CREACTIVE PROTEIN,2
KEY DATA ELEMENTS,3
MONOCLONALANTIBODY,1
DOUBLEBLIND,1
ATRIALFIBRILLATION,1
HIGHRISK,1
trade and health,3
health policy,2
European Union,2
United States,2
LIBERALIZATION,1
POLICY,1
TIME,1
Fluid flow,2
Catalytic converter,2
Thermal,1
CFD,1
Experimental,1
MONOLITH CATALYSTS,2
HEATTRANSFER,1
MASS,1
SIMULATION,1
Promotion and application of green technology,6
Regional carbon reduction,3
Nonlinear regulation,2
Space overflow,2
The learning by doing effect,5
ENVIRONMENTALREGULATION,1
ENERGY,1
INNOVATION,1
DIFFUSION,1
POLICIES,1
INVESTMENT,1
Trade and investment agreements RTAs,5
Trade policy,2
Foreign investment policy,3
Diets,1
Tobacco,1
Noncommunicable diseases,2
Health outcomes,2
Systematic review,2
Cocitation analysis,2
INTERNATIONALTRADE,1
NUTRITION TRANSITION,2
PUBLICHEALTH,1
GLOBALIZATION,1
LIBERALIZATION,1
PREVENTION,1
DISEASE,1
OBESITY,1
GROWTH,1
DIET,1
Yinma Jiedu Granule,3
Lipopolysaccharide,1
Acute lung injury,3
Inflammation,1
Oxidative stress,2
JAK2STAT1 signaling pathway,3
NFKAPPAB,1
EPIDEMIOLOGY,1
LACTATE,1
Design,1
Selective laser sintering,3
Mechanical properties of materials,4
Honeycomb materials,2
Negative stiffness,2
,1
Gallic acid,2
Antioxidants,1
Gastric ulcer,2
Nrf2HO1,1
SHUANGDAN ORAL LIQUID,3
QUANTITATIVEDETERMINATION,1
ACTIVE COMPONENTS,2
INFLAMMATION,1
ANTIOXIDANT,1
PROSTAGLANDINS,1
MECHANISMS,1
PROTECTION,1
DANSHENSU,1
DISEASES,1
HCCI technology,2
Emissions NOx,2
Vehicle,1
Euro 7,2
NITROGENDIOXIDE,1
WAVE INFLUENCES,2
COMBUSTION,1
PERFORMANCE,1
DESIGN,1
INLET,1
PIPE,1
,1
SURVIVAL,1
DISEASE,1
DEATH,1
Drug repurposing,2
Clinical research,2
Research funding,2
Publicprivate partnerships,2
Crowdfunding,1
Social impact bonds,3
PUBLICPRIVATE PARTNERSHIPS,2
REPURPOSING DRUGS,2
RARE DISEASES,2
GENERIC DRUGS,2
TRIALS,1
CANCER,1
ONCOLOGY,1
CHALLENGES,1
OPPORTUNITIES,1
STRATEGIES,1
Health professional,2
Knowledge,1
Attitude,1
Confidentiality,1
Ethiopia,1
PHYSICIANS,1
PROTECTION,1
NURSES,1
Offences Crime,2
White Color Offences,3
Socioeconomic offence,2
Fraud,1
Misrepresentation,1
Illegal economic activities,3
Commercial transactions,2
White collar crimes,3
,1
antiaging,1
UV protection,2
MMP1,1
melanin pigmentation,2
wrinkle reduction,2
tyrosinase,1
elastase,1
TELOMERASE ACTIVITY,2
TYROSINASE,1
INGREDIENTS,1
FIBROBLASTS,1
ANTIOXIDANT,1
EXTRACTS,1
L,1
PFO closure,2
prior stroke,2
prior transient ischaemic attack,4
stroke,1
,1
Wastewater treatment technologies,3
Reverse osmosis,2
Membrane technologies,2
Photocatalysis,1
Pollutant removal,2
Biological water treatment,3
Environmental technology,2
Chemicals removal,2
Sustainable development,2
Environmental protection,2
PERSONAL CARE PRODUCTS,3
HEAVYMETAL REMOVAL,2
WASTEWATER,1
FATE,1
COAGULATION,1
RESISTANCE,1
acute coronary syndrome,3
clopidogrel,1
hospitalization,1
ischemic attack transient,3
propensity score,2
MYOCARDIALINFARCTION,1
ASPIRIN,1
BIOEQUIVALENCE,1
THERAPY,1
TRENDS,1
computational fluid dynamics modeling CFD,5
atrial fibrillation,2
TAVR,1
silent brain Infarcts,3
stroke,1
particle flow simulation,3
cerebroembolic protection devices,3
aortic arch,2
AORTICVALVE IMPLANTATION,2
STROKE PREVENTION,2
FIBRILLATION,1
ASSOCIATION,1
REPLACEMENT,1
WARFARIN,1
SAFETY,1
Cetylpyridinium chloride,2
Glycerin,1
Xanthan gum,2
Antiviral,1
Barrier formation,2
Prophylaxis,1
SEASONAL INFLUENZA,2
UNITEDSTATES,1
TRACT,1
VIRUS,1
ADULTS,1
SURVEILLANCE,1
FREQUENCY,1
DIAGNOSIS,1
DISEASES,1
SOCIETY,1
,1
RATIONALE,1
EUROPE,1
Coccidiosis,1
Eimeria maxima,2
Broiler,1
Genetic selection,2
Resistance,1
Tolerance,1
Growth rate,2
Bone mineralisation,2
NITRICOXIDE PRODUCTION,2
FED REPRESENTATIVE 1957,3
DIETARY VITAMINE,2
ACERVULINA INFECTION,2
IMMUNERESPONSES,1
TENELLA INFECTIONS,2
DISEASE RESISTANCE,2
COMMERCIAL BROILER,2
ANTIBODYRESPONSE,1
CROSSPROTECTION,1
global value chain,3
green innovation,2
risk identification,2
group decision characteristic root,4
index screening,2
,1
ecoinnovation,1
EcoInnovation Index,2
the European Union,3
catchingup ecoinnovators,2
ecoinnovation inputs,2
ecoinnovation activities,2
environmental protection,2
SUSTAINABLE DEVELOPMENT,2
POLAND,1
COMPETITIVENESS,1
ENTERPRISES,1
INDUSTRY,1
SYSTEM,1
FDA,1
insurers,1
health innovation,2
intellectual property,2
pharmaceuticals,1
precision medicine,2
OFFLABEL USE,2
SURROGATE ENDPOINTS,2
INFORMATIONTECHNOLOGY,1
PREEXPOSURE PROPHYLAXIS,2
PERSONALIZED MEDICINE,2
DRUG SAFETY,2
RECORDS,1
POLICY,1
RISK,1
DISCOVERY,1
body armor,2
bulletproof,1
Casimir Zeglen,2
Jan Szczepanik,2
Stephanie Louise Kwolek,3
kevlar,1
BODY ARMOR,2
invivo dosimetry,2
low instantaneous dose rate total body irradiation,7
TPS model configuration,3
INTERSTITIAL PNEUMONITIS,2
TRANSPLANTATION,1
RISK,1
UNIT,1
necrotizing enterocolitis,2
preterm Infants,2
BPD,1
ACUTE KIDNEY INJURY,3
PHAGOCYTOSIS,1
OUTCOMES,1
GROWTH,1
,1
CHIRALITY,1
Innominate artery cannulation,3
Aortic surgery,2
Axillary artery cannulation,3
HYPOTHERMIC CIRCULATORY ARREST,3
AXILLARY ARTERY,2
BRAIN PROTECTION,2
ARCH SURGERY,2
ASCENDING AORTA,2
SIDE GRAFT,2
SAFE,1
EXPERIENCE,1
SITE,1
Suxiao Jiuxin pill,3
Autophagy,1
Myocardial ischemiareperfusion injury,3
ALKBH5GSK3 betamTOR pathway,3
MESSENGERRNA,1
AUTOPHAGY,1
trait association,2
categorical data,2
cotton,1
crop germplasm,2
breeding,1
PLANT,1
GENES,1
Coronary artery bypass graft,4
Internal mammary arteries,3
Transit time flow measurement,4
,1
Entrepreneurship,1
Firm performance,2
General selfefficacy,2
Survival,1
Job creation,2
Innovation,1
PERSONALITYTRAITS,1
FIRM PERFORMANCE,2
MEDIATING ROLE,2
SURVIVAL,1
GROWTH,1
CREATIVITY,1
MOTIVATION,1
ATTITUDES,1
SUCCESS,1
CULTURE,1
,1
INTERRUPTED TIMESERIES,2
DRUG MARKETS,2
COMPETITION,1
CANADA,1
Forging,1
Numerical simulations,2
Aircraft components,2
Threeslide forging press,3
Magnesium alloys,2
Twinrib brackets,2
,1
Equity,1
Confidentiality agreements,2
Market regulation,2
MANAGED ENTRY,2
EXPERIENCES,1
PAYERS,1
robotic and autonomous systems,4
drones,1
crawlers,1
remotely operated vehicles,3
Internet of Robotic Things,4
data governance,2
user interface,2
international standards,2
DATA GOVERNANCE,2
Transcranial Doppler,2
antiphospholipid syndrome,2
cerebral blood flow,3
microembolic signals,2
righttoleft shunt,2
systemic lupus erythematosus,3
PATENT FORAMEN OVALE,3
TOLEFT SHUNT,2
SYSTEMICLUPUSERYTHEMATOSUS,1
MICROEMBOLIC SIGNALS,2
CEREBRAL MICROEMBOLI,2
ULTRASOUND,1
CLOSURE,1
STROKE,1
ANTICOAGULATION,1
MANIFESTATIONS,1
diabetes mellitus,2
diabetic complications,2
diabetic nephropathy,2
traditional Chinese medicine,3
randomized controlled trials,3
systematic review,2
evidencebased analysis,2
evidence mapping,2
CHRONIC KIDNEYDISEASE,2
QUALITYOFLIFE,1
MANAGEMENT,1
BURDEN,1
biofuel,1
biodiesel,1
second generation biofuels,3
waste animal fats,3
transesterification process,2
animal fats butyl esters,4
animal fats methyl esters,4
motor fuels testing,3
fuel parameters,2
KINEMATIC VISCOSITY,2
ANIMAL FAT,2
EMISSION CHARACTERISTICS,2
DIESEL BLENDS,2
BEEF TALLOW,2
PERFORMANCE,1
FUEL,1
OIL,1
TRANSESTERIFICATION,1
COMBUSTION,1
,1
LASER FENESTRATION,2
ARCH,1
REPLACEMENT,1
MANAGEMENT,1
COVERAGE,1
OUTCOMES,1
Broadband,1
Common carrier,2
Deregulation,1
Federalism,1
Internet protocol,2
Monopoly,1
Path dependence,2
Policy experimentation,2
Public relations,2
Public utility,2
EVOLUTION,1
,1
,1
,1
PARAAMINOBENZOIC ACID,2
CHARGETRANSFER STATE,2
EXCITEDSTATE,1
PHOTOPHYSICAL PROPERTIES,2
TRANSIENT ABSORPTION,2
INTERNALCONVERSION,1
DIPOLEMOMENTS,1
DYNAMICS,1
FLUORESCENCE,1
PHOTOPROTECTION,1
Octreotide acetate,2
somatostatin,1
acute pancreatitis,2
miR200 family,2
MICRORNA200 FAMILY,2
PREVENTION,1
INJURY,1
ROLES,1
Ground heat storage GHS,4
Renewable energy sources RES,4
Active thermal protection ATP,4
thermal barrier TB Energy solar roof ERS,7
Combined buildingenergy systems,3
Geothermic energy,2
Solar energy,2
DESIGN,1
FLUX,1
moyamoya,1
revascularization,1
stroke,1
outcomes,1
pediatric,1
cerebrovascular,1
vascular disorders,2
LONGTERM OUTCOMES,2
SURGICALTREATMENT,1
BURR HOLE,2
CHILDREN,1
SURGERY,1
REVASCULARIZATION,1
Sanqi oral solution,3
HIF1 alphaPKM2 pathway,3
Glycolysis,1
Fibroblast,1
Renoprotection,1
TUBULOINTERSTITIAL FIBROSIS,2
UPREGULATION,1
HIF1ALPHA,1
CELLS,1
RATS,1
GLYCOLYSIS,1
Fufangzhenzhutiaozhi formula,2
Diabetes mellitus,2
 cell regeneration,3
PDX1,1
MAFA,1
NGN3,1
SERUM,1
MASS,1
RAT,1
Atlantic salmon,2
fish welfare,2
genetic resistance,2
policy instruments,2
regulation,1
salmon lice,2
selective breeding,2
GENETICRESOURCES,1
PROTECTION,1
ACCESS,1
EFFICIENCY,1
Mitral surgery,2
Redo,1
Mitral repair,2
Outcomes,1
Valve disease,2
Mitral valve,2
CARDIACSURGERY,1
VALVE SURGERY,2
RISKFACTORS,1
REPLACEMENT,1
MORTALITY,1
IMPLANTATION,1
REOPERATION,1
STERNOTOMY,1
FAILURE,1
REENTRY,1
Land Law 201301,3
Land use and management,4
Benin Republic,2
,1
ESG performance,2
Green innovation,2
Government regulation,2
Sustainable development,2
MANAGEMENT,1
IMPACT,1
counterfeit goods,2
illicit trafficking,2
infringement of intellectual property rights,5
copyright holder,2
consumer,1
forgery,1
SHADOW ECONOMY,2
FEVAR,1
TEVAR,1
BEVAR,1
thoracoabdominal aortic aneurysm repair,4
endovascular aneurysm repair,3
SPINALCORD PROTECTION,2
OPEN SURGICAL REPAIR,3
STENT GRAFTS,2
OUTCOMES,1
METAANALYSIS,1
DURABILITY,1
ISCHEMIA,1
insurance marketing,2
insurance management,2
insurance technologies,2
innovations,1
the Innovations index,3
innovative development,2
Principal Component Analysis,3
Multifactor regression model,3
,1
DanDengTongNao capsules,2
HPLC fingerprint,2
UPLCQTOFMS,1
Cerebrospinal fluid pharmacology,3
OGDR,1
BMECs,1
CEREBRALISCHEMIAREPERFUSION,1
CATENIN SIGNALING PATHWAY,3
OXIDATIVE STRESS,2
STROKE,1
GSK3BETA,1
MECHANISMS,1
APOPTOSIS,1
Malaria,1
Serology,1
Surveillance,1
FALCIPARUM MEROZOITE ANTIGENS,3
PLASMODIUMFALCIPARUM,1
SURFACE PROTEIN1,2
GENETIC DIVERSITY,2
PROTECTION,1
AGE,1
ASSOCIATION,1
EXPOSURE,1
EFFICACY,1
TARGET,1
,1
MICROVASCULAR ENDOTHELIALCELLS,2
VULNERABLE PLAQUES,2
REPERFUSION INJURY,2
DOUBLEBLIND,1
NOREFLOW,1
PROTECTION,1
ELEVATION,1
ISCHEMIA,1
PATHWAY,1
ENOS,1
European asymmetries,2
TFP,1
Interest rate,2
Exchange rate,2
Labor market,2
Wage rate,2
C22,1
D21,1
D24,1
EXCHANGERATE,1
EMPLOYMENT PROTECTION,2
TECHNICAL CHANGE,2
PRODUCTIVITY,1
TECHNOLOGY,1
Securities margin trading,3
Deregulation of shortselling,3
Green innovation,2
Quasinatural experiment,2
CORPORATE CASH HOLDINGS,3
SHORTSALES CONSTRAINTS,2
ENVIRONMENTALMANAGEMENT,1
ANALYST COVERAGE,2
PRICE DISCOVERY,2
PERFORMANCE,1
GOVERNANCE,1
INVESTMENT,1
IMPACT,1
PHILANTHROPY,1
green technology,2
ingredients,1
phytobiome,1
phytofermentation,1
,1
R  D  I policies,6
Environmental Innovation,2
Technology Fund,2
Evaluation of ecoinnovation policies,4
Regional development,2
ECOINNOVATION,1
GREEN,1
PERFORMANCE,1
ECONOMICS,1
BARRIERS,1
mounting medium,2
coverslip seal,2
fixation,1
maceration,1
clearing,1
immersion oil,2
rehydration,1
permeability,1
DIMETHYL HYDANTOIN FORMALDEHYDE,3
PHASEAMPLITUDE MICROSCOPY,2
SINGLECELL RESOLUTION,2
MOUNTING MEDIUM,2
SYNTHETIC RESINS,2
GASCHROMATOGRAPHY,1
MASSSPECTROMETRY,1
PERMANENT MOUNTS,2
REFRACTIVEINDEX,1
AGING BEHAVIOR,2
Industrial Property infringements,3
patent infringements,2
patent protection in Spain,4
patent protection in Mexico,4
patent judicial protection,3
judicial process,2
administrative procedure,2
IMPI,1
,1
Patent Protection,2
Status Preference,2
Innovation,1
Social Welfare,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
ECONOMICGROWTH,1
CAPITALISM,1
SPIRIT,1
RETURNS,1
CULTURE,1
SAVINGS,1
RD,1
Patent Protection,2
Welfare Analysis,2
SemiEndogenous Growth,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
ECONOMICGROWTH,1
INNOVATION,1
POLICY,1
NORTH,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGYTRANSFER,1
IMITATION,1
PRODUCT,1
INNOVATION,1
WELFARE,1
TRADE,1
MODE,1
CAFC,1
entry,1
patent law,2
patent strategy,2
strategic patents,2
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
IMPACT,1
TECHNOLOGY,1
STRATEGIES,1
THICKETS,1
COURTS,1
ENTRY,1
FIRMS,1
Patent protection enforcement,3
RDintensity,1
Export quality,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
FINANCIAL DEPENDENCE,2
TRADE LIBERALIZATION,2
TECHNOLOGYTRANSFER,1
ECONOMICGROWTH,1
INNOVATION,1
PROTECTION,1
DETERMINANTS,1
INSTITUTIONS,1
corn,1
patent,1
plant variety protection,3
,1
Exportpatent relationship,2
foreign patenting,2
strategic patenting,2
value of patents,3
PROTECTION,1
RIGHTS,1
Innovation,1
Patent protection,2
Economic growth,2
Inequality,1
D30,1
O30,1
O40,1
STRATEGIC STABILITY,2
E44,1
O31,1
O34,1
patent protection,2
credit constraints,2
economic growth,2
convergence,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
PROTECTION,1
GROWTH,1
LENGTH,1
POLICY,1
MODEL,1
Patent policy,2
Blocking patents,2
Economic growth,2
Innovation,1
Intellectual property rights,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
SCHUMPETERIAN MODEL,2
INNOVATION,1
PATENTABILITY,1
TRADE,1
Patent,1
Computer Program,2
Indonesia,1
Comparison and Several Countries,4
,1
Patent law,2
Optimal patent design,3
Patent monopoly,2
Deadweight loss,2
INNOVATION,1
LENGTH,1
POLICY,1
pharmaceutical patent protection,3
pharmaceutical policy,2
generic drug,2
China,1
,1
Patents,1
Patent portfolio,2
Litigation,1
Collusion,1
Foreclosing,1
Entry game,2
MARKETS,1
FIRMS,1
TECHNOLOGY,1
COLLUSION,1
Copyright protection,2
software patent,2
intellectual property right,3
PATENTS,1
Patents,1
Physical Capital,2
Growth,1
OLG,1
,1
Innovation,1
Patent,1
Trade secret,2
Dynamic general equilibrium,3
INNOVATION,1
FIRMS,1
,1
FOREIGN DIRECTINVESTMENT,2
GLOBAL PATENT PROTECTION,3
ENDOGENOUS GROWTH,2
DYNAMICANALYSIS,1
MULTINATIONAL FIRMS,2
ECONOMICGROWTH,1
QUALITY LADDERS,2
RICARDIAN MODEL,2
INNOVATION,1
SOUTH,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PARALLEL IMPORTS,2
DEVELOPINGCOUNTRIES,1
PRICE CONTROLS,2
INNOVATION,1
PRODUCTS,1
WELFARE,1
TRADE,1
Patent breadth,2
inventing around,2
threat of market entry,4
market entry barriers,3
IPC codes,2
COMPETITION,1
TECHNOLOGY,1
INNOVATION,1
SCOPE,1
PERSISTENCE,1
PROTECTION,1
MONOPOLY,1
ADOPTION,1
Capital accumulation,2
Economic growth,2
Income inequality,2
Patent protection,2
R  D,3
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
ECONOMICGROWTH,1
POLICY,1
RIGHTS,1
TALE,1
Patents,1
Licensing,1
wtp,1
npe,1
Welfare,1
DEVELOPMENT SPILLOVERS,2
EMPIRICALANALYSIS,1
TECHNOLOGY,1
PERSISTENCE,1
INCENTIVES,1
MARKETS,1
TROLLS,1
Economic growth,2
Patent protection,2
R  D,3
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
INNOVATION,1
MODEL,1
STIMULATE,1
POLICY,1
RD,1
Financial development,2
Patent protection,2
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
INNOVATION,1
QUALITY,1
CONSTRAINTS,1
SIGNALS,1
Technological knowledge diffusion,3
Patent protection,2
Patent lifetime,2
Patent claim,2
INNOVATION,1
CITATION,1
INFORMATION,1
FLOWS,1
LIFE,1
,1
RESEARCHANDDEVELOPMENT,1
STRATEGIC MANAGEMENT,2
TECHNOLOGY,1
APPROPRIATION,1
PERFORMANCE,1
PROTECTION,1
FRAMEWORK,1
FIRMS,1
Innovation,1
Intellectual property rights,3
Endogenous growth,2
RESEARCHANDDEVELOPMENT,1
PROTECTION,1
INNOVATION,1
Export,1
Patents,1
Products,1
Intellectual property rights,3
Innovation,1
INNOVATION,1
FIRMS,1
RIGHTS,1
COMPETITION,1
TECHNOLOGY,1
COUNTRIES,1
PATTERNS,1
PRODUCT,1
IMPACT,1
developing economies,2
export quality,2
patent rights,2
technological stage dependence,3
INTELLECTUAL PROPERTYRIGHTS,2
TRADE LIBERALIZATION,2
IMPORT COMPETITION,2
PRODUCT,1
LEVEL,1
AGREEMENTS,1
INNOVATION,1
COUNTRIES,1
SELECTION,1
IMPACTS,1
Patents,1
Entrepreneurship,1
Venture Capital,2
Patent Examiners,2
Acquisition,1
Initial Public Offering,3
CHILD PROTECTION,2
FOSTERCARE,1
OUTCOMES,1
BIOTECHNOLOGY,1
INNOVATION,1
SIGNALS,1
IMPACT,1
FIRMS,1
UPS,1
,1
,1
Patent protection,2
Index,1
Crosscountry,1
Legislation,1
Enforcement,1
Administration,1
INTELLECTUAL PROPERTYRIGHTS,2
INSTITUTIONBASED VIEW,2
LATINAMERICA,1
REGIMES,1
TRADE,1
STRATEGY,1
IMPACT,1
BIOTECHNOLOGY,1
ENFORCEMENT,1
MANAGEMENT,1
Patent protection,2
intermediatesintensive,1
innovation,1
endogenous growth,2
INNOVATION,1
PROTECTION,1
Patents,1
Patent pools,2
Sequential innovation,2
Licensing,1
ANTICOMMONS,1
DESIGN,1
Environmental protection tax,3
Green innovation,2
Patent quantity,2
Patent quality,2
,1
Innovation,1
Patent Protection,2
Optimal Patent Licensing,3
Endogenous Market Structure,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
DYNAMICANALYSIS,1
MARKETSTRUCTURE,1
ECONOMICGROWTH,1
STIMULATE,1
POLICY,1
International patent protection,3
National treatment,2
Discrimination,1
Welfare,1
Trade barriers,2
NATIONAL TREATMENT,2
TRADE AGREEMENTS,2
Economic Growth,2
Patent Protection,2
R D,2
Capital Accumulation,2
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
POLICY,1
LENGTH,1
software innovations,2
software patents,2
patent scope,2
opensource software,2
intellectual property,2
public policy,2
Alice v CLS Bank,4
INNOVATION,1
ECONOMICS,1
FIRMS,1
APPROPRIABILITY,1
COLLABORATION,1
SURVIVAL,1
INDUSTRY,1
IMPACT,1
LAW,1
inventors,1
patents,1
mobility,1
specific human capital,3
examiner leniency,2
INNOVATION EVIDENCE,2
EMPLOYEE MOBILITY,2
LABOR MOBILITY,2
SILICON VALLEY,2
BASIC RESEARCH,2
FIRMS,1
PRODUCTIVITY,1
COVENANTS,1
SCIENCE,1
RIGHTS,1
,1
PATENT,1
PROPERTY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGICALINNOVATION,1
COMPLEMENTARY ASSETS,2
KNOWLEDGE,1
FLOW,1
,1
LINKAGE,1
International patent protection,3
Import tariffs,2
National treatment,2
RD,1
Welfare,1
NATIONAL TREATMENT,2
PATENT EXAMINATION,2
PASSTHROUGH,1
TRADE,1
,1
DATASECURITY,1
PRIVACY PRESERVATION,2
ABE,1
RD incentives,2
Cournot duopoly,2
Spillovers,1
Incomplete information,2
Patent protection,2
Tournament effect,2
D43,1
D82,1
L13,1
O31,1
,1
Blockchain technology,2
Patent registration,2
Patent trading,2
Patent protection,2
Traceability,1
Smart contract,2
TRACEABILITY,1
COPYRIGHT,1
biopharmaceutical industry,2
patent protection,2
patent infringement litigation,3
patent invalidation,2
,1
,1
,1
Patent analysis,2
Biotechnology,1
Intellectual property,2
Social network analysis,3
PATENT INDICATORS,2
Copyrights,1
trademarks,1
trade secrets,2
patents,1
entrepreneurship,1
PATENTS,1
INNOVATION,1
PROTECTION,1
COPYRIGHT,1
,1
MYRIAD,1
3dimensional printing,2
fused deposition modelling FDM,4
product design,2
,1
RD subsidies,2
Patents,1
Income inequality,2
Economic growth,2
INTELLECTUAL PROPERTYRIGHTS,2
CONSUMPTION INEQUALITY,2
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
TECHNICAL CHANGE,2
MODEL,1
POLICY,1
PROTECTION,1
LIFE,1
European Patent,2
Accession,1
Patents,1
Middle income countries,3
Regional patent system,3
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PROTECTION,1
TECHNOLOGY,1
Patent protection,2
Compulsory licensing,2
Exhaustion policies,2
Imitation,1
TRIPS,1
Quality,1
Welfare,1
WTO,1
PARALLEL IMPORTS,2
EXHAUSTION,1
INNOVATION,1
ACCESS,1
TRADE,1
Biotech patents,2
IP rights,2
Myriad Genetics,2
Patent scope,2
Purposebound compound protection,3
,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
MULTINATIONAL FIRMS,2
EMPIRICALEVIDENCE,1
ECONOMICGROWTH,1
LABOR MOBILITY,2
VALUE CHAINS,2
MIXED LOGIT,2
KNOWLEDGE,1
INNOVATION,1
RIGHTS,1
COVID19 vaccine,2
patent waiver,2
Jewish ethics,2
duty theory,2
,1
Global value chain,3
Patent protection,2
Technological innovation,2
Threshold effect,2
INTELLECTUAL PROPERTYRIGHTS,2
KNOWLEDGE SPILLOVERS,2
ECONOMICGROWTH,1
TRADE,1
Technological innovation,2
Intellectual property or patents,4
Product differentiation,2
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
MARKETSTRUCTURE,1
PROTECTION,1
COMPETITION,1
MODEL,1
PATENTABILITY,1
PERSISTENCE,1
GROWTH,1
LENGTH,1
LIFE,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
VARIETY PROTECTION,2
RIGHTS,1
FREEDOM,1
PATENTS,1
Water resources,2
waterrelated patents,2
scarcity,1
industrialization,1
,1
,1
,1
Innovation,1
Growth,1
Patent,1
RD,1
Productivity,1
Intellectual property rights,3
Stateowned enterprises,2
China,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
MARKET VALUE,2
PATENTS,1
PROTECTION,1
PRODUCTIVITY,1
OPPORTUNITY,1
COMPETITION,1
SPILLOVERS,1
OWNERSHIP,1
international economic law,3
moral rights,2
patents,1
traditional knowledge,2
TRIPS,1
INTELLECTUAL PROPERTY,2
RIGHTS,1
Regulation EC 469,3
2009,1
Supplementary protection certificate,3
CJEU Santen judgment,3
Product patent,2
Medicinal patent,2
Application patent,2
PHARMACEUTICALS,1
PATENTABILITY,1
CONVENTION,1
,1
INTELLECTUAL PROPERTY,2
GENDERDIFFERENCES,1
EX ANTE,2
COPYRIGHT,1
INFORMATION,1
MARKET,1
POST,1
ANTICOMMONS,1
INNOVATION,1
SCIENCE,1
Intellectual property rights,3
Endogenous growth,2
Blocking patent,2
Innovation,1
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
POLICY,1
PROTECTION,1
Patent protection,2
Public capital,2
Economic growth,2
Welfare,1
ENDOGENOUS GROWTH,2
MAINTENANCE,1
WELFARE,1
INFRASTRUCTURE,1
EXPENDITURE,1
INVESTMENT,1
COUNTRIES,1
TAXES,1
MODEL,1
,1
STRATEGIC EXPERIMENTATION,2
MARKETSTRUCTURE,1
COMPETITION,1
PROTECTION,1
DIRECTION,1
,1
PROTECTION,1
SYSTEMS,1
,1
RESEARCHANDDEVELOPMENT,1
PERSISTENCE,1
INNOVATION,1
disclosure,1
analyst forecast,2
patent,1
information asymmetry,2
American Inventors Protection Act,4
RESEARCHANDDEVELOPMENT,1
CORPORATE DISCLOSURE,2
INFORMATION ASYMMETRY,2
PROPERTYRIGHTS,1
MARKET,1
INNOVATION,1
IDEAS,1
PROFITABILITY,1
COVERAGE,1
RENT,1
Patent,1
utility model,2
twotiered patent system,3
intellectual property strategy,3
Germany,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
INNOVATION,1
PROTECTION,1
DISCLOSURE,1
APPROPRIATION,1
PROPENSITY,1
SECRETS,1
MOTIVES,1
SYSTEM,1
Intellectual property rights,3
Competition,1
Innovation,1
INTELLECTUAL PROPERTYRIGHTS,2
COMPETITION,1
PROTECTION,1
STIMULATE,1
INDUSTRY,1
PROGRAM,1
POLICY,1
GROWTH,1
LEVEL,1
PANEL,1
service innovation,2
video game,2
patent,1
trademark,1
innovation protection,2
MARKETING CAPABILITIES,2
CLUSTERANALYSIS,1
INFORMATION,1
DIFFUSION,1
INDICATOR,1
PATENTS,1
SECTOR,1
FIRMS,1
protection of nonpatrimonial personal rights,5
patent infringement,2
judicial and extrajudicialproceedings,3
legislation of the Russian federation,5
administrative procedures,2
,1
Digital economy,2
IRETs,1
Patent judicial protection,3
Public environmental appeal,3
INTELLECTUAL PROPERTY PROTECTION,3
CO2 EMISSIONS,2
ENVIRONMENTAL INNOVATION,2
EMPIRICALEVIDENCE,1
COAL CONSUMPTION,2
ECOINNOVATION,1
ICT,1
COSTS,1
CHINA,1
DETERMINANTS,1
drug registration,2
patent linkage system,3
pharmaceutical patent protection,3
,1
Sequential innovation,2
Complementarity,1
Patent design,2
Elasticity of the supply of inventions,6
Division of profit,3
SEQUENTIAL INNOVATION,2
DIVISION,1
PATENTABILITY,1
SEARCH,1
PROFIT,1
RIGHTS,1
MODEL,1
Intellectual Property,2
Patent,1
Innovation,1
Radiopharmaceuticals,1
Nuclear medicine,2
DRUG DEVELOPMENT,2
REGULATIONS,1
PROTECTION,1
GUIDELINE,1
,1
COPYRIGHT PROTECTION,2
COMPUTERPROGRAMS,1
PATENT,1
SOFTWARE,1
DOCTRINE,1
DESIGN,1
,1
SAMPLE SELECTION,2
PROBIT,1
PROPERTY,1
MODEL,1
Patent protection,2
RD subsidy,2
Licensing,1
Vertical separation,2
Asymmetric information,2
Real options,2
SIGNALING GAMES,2
PROPERTYRIGHTS,1
INNOVATION,1
POLICY,1
SCOPE,1
LITIGATION,1
GOVERNMENT,1
STIMULATE,1
BREADTH,1
DUOPOLY,1
Patent Litigation,2
PCT,1
National Treatment,2
Mexico,1
USMCA,1
NAFTA,1
,1
Biotechnology Inventions,2
Patents,1
Ethics,1
Morality,1
ICMR,1
Bioethics Principle,2
Patent Protection,2
Public Order,2
,1
,1
GLOBAL PRODUCTION,2
TRADE AGREEMENTS,2
PROPERTY RULES,2
ACCESS,1
PREPAREDNESS,1
VACCINATION,1
BIOSIMILARS,1
COMPETITION,1
MEDICINES,1
HEALTH,1
Dynamic,1
Human capital,2
Innovation,1
Multiregion economy,2
Patent protection,2
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
SPILLOVERS,1
Endogenous growth,2
Heterogeneousindustry model,2
Patent protection,2
RD subsidies,2
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
POLICY,1
WELFARE,1
Patent strategy,2
pregrant publication,2
patent secrecy,2
INVENTORS PROTECTION ACT,3
TECHNOLOGICALINNOVATION,1
MARKET,1
KNOWLEDGE,1
ACQUISITION,1
OPPOSITION,1
DISCLOSURE,1
FRAMEWORK,1
Trade,1
Innovation,1
Intellectual property rights,3
Patents,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
TRADE,1
INNOVATION,1
DETERMINANTS,1
INPUTS,1
LAWS,1
Trade secrets,2
Patents,1
Intellectual property,2
Stock liquidity,2
TRIPS,1
RESEARCHANDDEVELOPMENT,1
TRADE SECRETS,2
INNOVATION EVIDENCE,2
CROSSSECTION,1
RIGHTS,1
INFORMATION,1
LIQUIDITY,1
DECISIONS,1
INFERENCE,1
WINNERS,1
Intellectual property rights,3
Blocking patents,2
Endogenous growth,2
Firm survival,2
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
INNOVATION,1
PROTECTION,1
QUALITY,1
POLICY,1
patent law,2
China,1
law reform,2
,1
protection of patent rights,4
nonjurisdictional forms,2
selfdefense,1
claim,1
warning,1
mediation,1
,1
,1
,1
Licensing,1
Patent competition,2
Rent dissipation,2
Welfare,1
Overlapping research expenditure,3
Patent protection,2
RESEARCHANDDEVELOPMENT,1
PATENT,1
SEEKING,1
INNOVATION,1
MARKET,1
SECRECY,1
RACES,1
SCOPE,1
FEE,1
Patent policy,2
Income inequality,2
Innovation,1
Endogenous market structure,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
DEVELOPMENT SUBSIDIES,2
BLOCKING PATENTS,2
MARKETSTRUCTURE,1
PROTECTION,1
INCOME,1
MODEL,1
WELFARE,1
Human gene patents,3
Chinese scholars,2
Patentability,1
CONTROVERSY,1
PROTECTION,1
MYRIAD,1
,1
PROTECTION,1
Patents,1
Trade secrets,2
Intellectual property rights,3
Patentsecret combination,2
,1
Utility models,2
Performance measurement,2
Patent statistics,2
RESEARCHANDDEVELOPMENT,1
PATENT QUALITY,2
INNOVATION,1
MOTIVES,1
TECHNOLOGY,1
PROTECTION,1
Patents,1
Patent applications,2
Patent attorneys,2
Logistic regression,2
SUPREMECOURT,1
ACADEMIC RESEARCH,2
INNOVATION,1
TECHNOLOGY,1
QUALITY,1
EXPERTISE,1
CITATIONS,1
INVENTORS,1
INTERMEDIARY,1
LOCALIZATION,1
Innovation,1
Patent policy,2
Patent thickets,2
Patent puzzle,2
Trade secrets,2
Endogenous growth,2
RESEARCHANDDEVELOPMENT,1
SCHUMPETERIAN MODEL,2
TRADE SECRETS,2
INTELLECTUAL PROPERTY,2
KNOWLEDGE SPILLOVERS,2
BLOCKING PATENTS,2
BIG SECRETS,2
INNOVATION,1
PROTECTION,1
COMPETITION,1
Patents,1
trade secrets,2
single innovation,2
innovation output,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
OPENNESS,1
PERFORMANCE,1
SPILLOVERS,1
DISCLOSURE,1
STRATEGY,1
THICKET,1
SHADOW,1
LAW,1
,1
,1
patent protection,2
firm size,2
productivity,1
innovation,1
imitation,1
competition,1
INTELLECTUAL PROPERTYRIGHTS,2
MARKETSIZE,1
COMPETITION,1
ELASTICITY,1
STIMULATE,1
MODEL,1
,1
PATENTS,1
Intellectual property rights,3
firm productivity,2
conditional average treatment effect,4
F43,1
O31,1
O34,1
O43,1
P26,1
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
INNOVATION EVIDENCE,2
NATURAL EXPERIMENT,2
INSTITUTIONS,1
PROTECTION,1
OWNERSHIP,1
GROWTH,1
LEVEL,1
PERFORMANCE,1
patent strategies,2
innovation races,2
NK modeling,2
games on NK landscapes,4
strategic interaction on NK landscapes,5
RESEARCHANDDEVELOPMENT,1
CUMULATIVE INNOVATION,2
ABSORPTIVECAPACITY,1
FIRM PERFORMANCE,2
INFORMATION,1
SECRECY,1
POLICY,1
TECHNOLOGY,1
PROTECTION,1
INCENTIVES,1
closedloop supply chain,3
differential pricing,2
patent protection,2
service level,2
COMPETITION,1
MODELS,1
,1
INNOVATION,1
artificial intelligence,2
inventions,1
patent protection,2
industrial property,2
,1
Intellectual property rights,3
Endogenous takeoff,2
Innovation,1
Economic growth,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
MARKETSTRUCTURE,1
PROTECTION,1
COMPETITION,1
REVOLUTION,1
DYNAMICS,1
POLICY,1
MODEL,1
Intellectual property strategies,3
patents,1
biopharmaceutical market,2
monoclonal antibodies,2
biosimilars,1
,1
Patents,1
Software,1
Innovation,1
India,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PROTECTION,1
COUNTRIES,1
export product quality,3
international patent cooperation,3
intellectual property protection,3
patent prosecution highway,3
INNOVATION SPEED,2
TRADE LIBERALIZATION,2
MULTIPRODUCT FIRMS,2
MARKUPS EVIDENCE,2
MARKET,1
ORIENTATION,1
COMPETITION,1
PRICES,1
IMPACT,1
,1
INTELLECTUAL PROPERTY,2
FAIRUSE,1
1ST AMENDMENT,2
1STAMENDMENT,1
COPYRIGHT,1
DOCTRINE,1
LAW,1
STANDARDS,1
MATTER,1
MISUSE,1
RD,1
patents,1
technology transfer,2
knowledge production function,3
Environmental Protection Agency,3
RESEARCHANDDEVELOPMENT,1
COUNT DATA,2
MODELS,1
Intellectual property,2
Patent infringement,2
Royalty,1
International Trade Commission,3
Import injunctions,2
Administered protection,2
RIGHTS,1
Patent valuation,2
patent real option,3
binomial model,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
MARKET VALUE,2
FIRM,1
UNCERTAINTY,1
INVESTMENT,1
OPPOSITION,1
STRATEGIES,1
FAMILY,1
IMPACT,1
,1
LEGAL PROTECTION,2
ORIGINALITY,1
LAW,1
,1
,1
Patent,1
Partnership,1
Multinational enterprises MNEs,3
Management practices,2
Institutions,1
Brazil,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
SOCIALSTRUCTURE,1
TECHNOLOGICALINNOVATION,1
RELATIONAL GOVERNANCE,2
KNOWLEDGE PROTECTION,2
DEVELOPINGCOUNTRIES,1
ALLIANCE FORMATION,2
EMPIRICALEVIDENCE,1
Emerging countries,2
patent,1
regime complex,2
transnational network,2
policy diffusion,2
intellectual property,2
INTELLECTUAL PROPERTYRIGHTS,2
CHINA,1
INDIA,1
DIFFUSION,1
POLITICS,1
Blocking patents,2
Economic growth,2
Optimal patent instruments,3
Subsidies,1
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
POLICY,1
ECONOMICS,1
INNOVATION,1
SUBSIDIES,1
INFRINGEMENT,1
COMPETITION,1
LESSONS,1
LENGTH,1
,1
,1
genetic improvement,2
intellectual property,2
seed industry,2
welfare analysis,2
SEQUENTIAL INNOVATION,2
UNITEDSTATES,1
RIGHTS,1
PRODUCTIVITY,1
IMPROVEMENT,1
POLICY,1
,1
RESEARCHANDDEVELOPMENT,1
FIRMS,1
PROTECTION,1
PROPENSITY,1
INDUSTRIAL,1
COMPANIES,1
GROWTH,1
FLOWS,1
plant varieties protection,3
plant patents research exceptions,4
UPOV,1
TRIPs,1
,1
Patents,1
Neurosurgical inventions,2
Neurosurgical innovation,2
Intellectual property protection,3
Copyrights,1
Trademarks,1
Trade secrets,2
,1
Deposit Microorganism,2
Genetic Resources,2
Budapest Treaty,2
Patent Biotechnology Protection,3
Urgency,1
,1
pharmaceutical trade,2
intellectual property rights,3
patents,1
trips agreement,2
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONALTRADE,1
ESSENTIAL MEDICINES,2
AFFECT ACCESS,2
GRAVITY,1
AGREEMENTS,1
TRIPS,1
INVESTMENT,1
Environmental regulation,2
Green innovation,2
Chinas new environmental protection law,5
Patents application,2
IMPACT,1
COMPETITIVENESS,1
PERFORMANCE,1
DECENTRALIZATION,1
DETERMINANTS,1
PRODUCTIVITY,1
ISOMORPHISM,1
FEDERALISM,1
HYPOTHESIS,1
DYNAMICS,1
legal protection of computer programs,5
copyright,1
patent law,2
,1
,1
,1
Patents,1
Firm performance,2
Competition,1
Timing,1
Innovation policy,2
COMMON METHOD VARIANCE,3
STARTUPS,1
INNOVATION,1
INDUSTRY,1
FIRMS,1
foreign patenting,2
globalisation,1
harmonisation,1
intellectual property culture,3
Southern innovation,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
MULTINATIONAL ACTIVITY,2
RIGHTS,1
INNOVATION,1
TRADE,1
GRAVITY,1
MODEL,1
Patent,1
Utility model,2
Patent family,2
Priority filing,2
INTELLECTUAL PROPERTY,2
QUALITY,1
INDICATORS,1
PROTECTION,1
OFFICE,1
FAMILIES,1
BEHAVIOR,1
OUTCOMES,1
SYSTEMS,1
INDEX,1
,1
ALBUTEROL INHALERS,2
Intellectual property rights,3
Patents,1
Trade secrets,2
Foreign direct investment,3
Technology transfer,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
PROTECTION,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
ECONOMICGROWTH,1
WELFARE,1
TAXATION,1
POLICY,1
COUNTRIES,1
LABOR,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
LEGAL PROTECTION,2
TRADE SECRETS,2
SOFTWARE,1
COPYRIGHT,1
PRIVATIZATION,1
TRANSPARENCY,1
INNOVATION,1
PATENT,1
LAW,1
patent protection,2
research and development,3
economic growth,2
dynamic general equilibrium,3
L50,1
O33,1
O34,1
O41,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
PROTECTION,1
INNOVATION,1
POLICY,1
American Inventors Protection Act,4
Earnings,1
Innovation,1
Patent disclosure,2
RESEARCHANDDEVELOPMENT,1
INVENTORS PROTECTION ACT,3
VOLUNTARY DISCLOSURE,2
MARKET,1
INFORMATION,1
COST,1
PERFORMANCE,1
SPILLOVERS,1
INVESTMENT,1
CITATIONS,1
annualmaintenance fee,2
economic stimulus growth theory,4
elimination,1
legal politics,2
patent,1
,1
,1
,1
patent,1
appropriability,1
innovation,1
protection,1
competition,1
EMPIRICALEVIDENCE,1
INNOVATION,1
APPROPRIATION,1
PROPENSITY,1
SMES,1
cognitive diversity,2
top management team,3
acquisition of environmental patent,4
independent environmental innovation,3
information identification,2
FOREIGN DIRECTINVESTMENT,2
INNOVATION CAPABILITY,2
ACQUISITIONS,1
PERFORMANCE,1
FAULTLINES,1
HETEROGENEITY,1
MERGERS,1
Economic growth,2
Income inequality,2
Patent protection,2
RD subsidies,2
ACCUMULATION,1
Strategic patenting,2
Technology transfer,2
Patent analysis,2
Patent valuation,2
Patent license,2
National phases,2
INTELLECTUAL PROPERTY,2
STRATEGIES,1
TECHNOLOGY,1
COUNTRIES,1
,1
PATENT HOLDUP,2
COPYRIGHT PROTECTION,2
ROYALTY STACKING,2
LEGAL PROTECTION,2
COMPETITION,1
TECHNOLOGY,1
ANTITRUST,1
RIGHTS,1
SCOPE,1
LAW,1
Patents,1
Trade secrets,2
Licensing,1
Technology transfer,2
Imitation,1
Leakage,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
INNOVATION,1
PERSISTENCE,1
IMITATION,1
POLICY,1
FEES,1
Patentintensive industry,2
Economic contribution,2
Government strategy,2
China,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PROTECTION,1
IMPACTS,1
GROWTH,1
monopoly pricing,2
government pricing,2
optimal patent length,3
social welfare,2
social innovation,2
RESEARCHANDDEVELOPMENT,1
CROSSOWNERSHIP,1
PROTECTION,1
POLICY,1
,1
,1
Access to medicines,3
HIVAIDS,1
Patents,1
Global health,2
Trade,1
Pharmaceutical policy,2
ANTIRETROVIRAL MEDICINES,2
INTELLECTUAL PROPERTY,2
POLITICALECONOMY,1
AIDS TREATMENT,2
ACCESS,1
DRUGS,1
PRICES,1
Multiple licensing,2
Market for technology,3
Competition,1
Patent,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PATENTS,1
DETERMINANTS,1
CONTRACTS,1
IMPACT,1
RENTS,1
IDEAS,1
International patenting,2
Outwardbound international patenting,3
Intellectual property management,3
IP and trade,3
Endogenous innovation,2
Technology commercialization,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
TECHNOLOGY,1
PROTECTION,1
TRADE,1
GROWTH,1
DETERMINANTS,1
INFORMATION,1
KNOWLEDGE,1
GLOBALIZATION,1
,1
,1
Economic growth,2
Patent policy,2
Monetary policy,2
Social welfare,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
PROTECTION,1
INFLATION,1
MODEL,1
INNOVATION,1
CASH,1
,1
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
UTILITY REQUIREMENT,2
ECONOMICS,1
RETHINKING,1
SCIENCE,1
NORMS,1
LAW,1
INFRINGEMENT,1
DISCLOSURE,1
INNOVATION,1
,1
,1
genetics,1
innovation,1
intellectual property,2
patents,1
qualitative research,2
trade secrets,2
LAW,1
Innovation,1
Patent collateral,2
Pledgeability,1
Secrecy,1
Intangible assets,2
INNOVATION EVIDENCE,2
TECHNOLOGICALINNOVATION,1
INTELLECTUAL PROPERTY,2
FINANCIAL CONSTRAINTS,2
INVESTMENT,1
PROTECTION,1
DISCLOSURE,1
DEBT,1
ALLOCATION,1
CAPACITY,1
Innovation,1
patents,1
registered designs,2
copyrights,1
MEDIUMSIZED ENTERPRISES,2
MARKETSTRUCTURE,1
SMALL FIRMS,2
UK SMALL,2
INNOVATION,1
INFORMATION,1
KNOWLEDGE,1
BUSINESS,1
BARRIERS,1
OUTPUT,1
patent,1
copy,1
knock off,2
Fashion Originators Guild of America,5
design,1
trademark,1
,1
Innovation,1
Open innovation,2
Intellectual property management,3
Motives to patent,3
Patent management,2
Technology strategy,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
APPROPRIATION MECHANISMS,2
PROPENSITY,1
PROTECTION,1
MANAGEMENT,1
COLLABORATION,1
DISCLOSURE,1
INFERENCE,1
PARADOX,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
MARKET,1
INNOVATION,1
OFFICE,1
IMPACT,1
Intellectual property,2
patent,1
cybercrimes,1
business performance,2
economic growth,2
OPEN INNOVATION,2
PERFORMANCE,1
IMPACT,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
FREE ENTRY,2
STIMULATE,1
PRODUCT,1
,1
,1
pharmaceutical patent,2
public health,2
excess profit tax,3
Stackelberg game,2
,1
Patentability,1
Novelty,1
Nonobviousness,1
Semantic analysis,2
Claim features,2
Claim chart,2
ARTIFICIALINTELLIGENCE,1
NOVELTY,1
SEARCH,1
,1
INNOVATION,1
PROTECTION,1
,1
PRESCRIPTION DRUGS,2
PHARMACEUTICALS,1
APPROVAL,1
PRICES,1
,1
MARKETSIZE,1
INNOVATION,1
ACCESS,1
INVESTMENTS,1
CHALLENGES,1
ENTRY,1
US,1
patents,1
social welfare,2
innovation,1
RD incentives,2
pharmaceutical industry,2
INNOVATION,1
ECONOMICS,1
KNOWLEDGE,1
INDUSTRY,1
LIFE,1
,1
CELL,1
CARCINOMA,1
SUNITINIB,1
Information dissemination,2
American Inventors Protection Act AIPA,5
Stock price crash risk,4
Unethical behavior,2
PRODUCT MARKET COMPETITION,3
VOLUNTARY DISCLOSURE,2
EARNINGS FORECASTS,2
BADNEWS,1
CORPORATE DISCLOSURE,2
INNOVATION EVIDENCE,2
AGENCY PROBLEMS,2
SPILLOVERS,1
COMPENSATION,1
TRANSPARENCY,1
Drugs,1
Pricing,1
Patents,1
Evergreening,1
Pharmaceuticals,1
ANTITRUST ANALYSIS,2
ORPHAN,1
PATENTS,1
POLICY,1
LAW,1
INCENTIVES,1
PROPERTY,1
LIFE,1
ACT,1
US,1
Space technology transfer,3
Space applications,2
Patent,1
IP protection,2
Space heritage,2
Terrestrial applications,2
,1
Environmental quality,2
Patent policy,2
Subsidy policy,2
Two growth engines,3
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
PATENT PROTECTION,2
ECONOMICGROWTH,1
POLLUTION,1
TAXATION,1
INVESTMENT,1
TAXES,1
,1
PROTECTION,1
green principles,2
intellectual property,2
sustainable development,2
green patent,2
TRAGEDY,1
,1
PROTECTION,1
PROPERTY,1
REACH,1
Pricing,1
Remanufacturing,1
Patent protection,2
Government intervention,2
Strategic consumer behaviour,3
Consumers green preference,3
LOOP SUPPLY CHAIN,3
STRATEGIC CONSUMERS,2
COMPETITION,1
DECISION,1
RETURNS,1
,1
INTELLECTUAL PROPERTY,2
LEGAL PROTECTION,2
LIFE,1
RETURNS,1
RENEWAL,1
TROLLS,1
FEES,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
KNOWLEDGE SPILLOVERS,2
MARKET,1
ALLOCATION,1
DISCLOSURE,1
INVENTORS,1
SECRETS,1
,1
DRUG,1
Green invention,2
Decomposition analysis,2
Research and development strategy,4
Patent data,2
Log mean Divisia index,4
DECOMPOSITION ANALYSIS,2
INNOVATION,1
ENERGY,1
POLICY,1
Application filing fees,3
Patent portfolio,2
Patent renewal fees,3
Patenting,1
Renewal,1
Sequential inventions,2
FIRMS,1
COMPLEMENTARITY,1
INCENTIVES,1
PROTECTION,1
RIGHTS,1
Copyright,1
Patents,1
Digitization,1
Digital platforms,2
Mobile apps,2
Platform complementers,2
Innovation,1
PRODUCTS EVIDENCE,2
RECORDED MUSIC,2
SOFTWARE,1
PROTECTION,1
COMMERCIALIZATION,1
APPROPRIABILITY,1
INDUSTRY,1
QUALITY,1
IMPACT,1
Appropriability,1
Intangible asset,2
Obsolescence,1
Depreciation,1
Returns to RD,3
Weak patent,2
RESEARCHANDDEVELOPMENT,1
PRODUCTIVITY GROWTH,2
PATENT PROTECTION,2
IMITATION,1
KNOWLEDGE,1
POLICY,1
AMORTIZATION,1
UNCERTAINTY,1
INVESTMENT,1
REGRESSION,1
epitope mapping,2
intellectual property,2
monoclonal antibody,2
novelty nonobviousness,2
patent,1
written description,2
,1
climate variables,2
compulsory exploitation license,3
intellectual property rights,3
threestage test,2
water management,2
SCENARIOS,1
intellectual property protection,3
patent,1
innovation,1
environmental munificence,2
family firms,2
BEHAVIORAL AGENCY MODEL,3
LONGTERM ORIENTATION,2
SOCIOEMOTIONAL WEALTH,2
ENTREPRENEURIAL ORIENTATION,2
RISKTAKING,1
DEVELOPMENT INVESTMENTS,2
RESOURCE ORCHESTRATION,2
VALUE APPROPRIATION,2
FINANCIAL WEALTH,2
MODERATING ROLE,2
Assistive Technology Related to Mobility,5
Technological Prospecting for Patents,4
Physical Disability,2
,1
,1
,1
innovation disclosure,2
credit markets,2
patenting,1
private information,2
FINANCIAL INTERMEDIATION,2
PROPRIETARY INFORMATION,2
INTELLECTUAL PROPERTY,2
PATENT PUBLICATION,2
CREDIT,1
PROTECTION,1
CHOICE,1
IMPACT,1
TRADE,1
PRODUCTIVITY,1
,1
PATENTS,1
Knowledge diffusion,2
Patent citations,2
Information disclosure,2
Patent policy,2
Technology spillovers,2
AIPA,1
REGRESSION DISCONTINUITY DESIGNS,3
INVENTORS PROTECTION ACT,3
TECHNOLOGICAL OPPORTUNITIES,2
CUMULATIVE INNOVATION,2
ABSORPTIVECAPACITY,1
LOCAL SEARCH,2
SPILLOVERS,1
LOCALIZATION,1
CITATIONS,1
GEOGRAPHY,1
patent claims,2
exploitive and explorative search,4
innovation,1
ABSORPTIVECAPACITY,1
EXPLOITATION,1
PERFORMANCE,1
TECHNOLOGY,1
INNOVATION,1
CITATIONS,1
STRATEGY,1
IMPACT,1
MODEL,1
PANEL,1
Vaccines,1
patent protections,2
advance purchase agreements APA,4
COVID19,1
,1
,1
,1
Legal innovation protection method,4
nonlegal innovation protection method,4
product innovation,2
types of product innovation,4
PERFORMANCE,1
Technology transfer,2
Chile,1
european patent system,3
pharmaceuticals,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGYTRANSFER,1
EMPIRICALEVIDENCE,1
PROTECTION,1
FIRMS,1
,1
POLICY,1
SCOPE,1
,1
DESIGN,1
LAW,1
Action Research,2
Patent management,2
IPR management,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY MANAGEMENT,3
PERFORMANCE,1
Intellectual property rights,3
TRIPS,1
WTO,1
Innovation,1
Trade,1
Foreign direct investment,3
Imitation,1
Patent protection,2
Welfare,1
Exhaustion policies,2
Compulsory licensing,2
FOREIGN DIRECTINVESTMENT,2
INTERNATIONAL TECHNOLOGYTRANSFER,2
GLOBAL PATENT PROTECTION,3
RESEARCHANDDEVELOPMENT,1
PARALLEL TRADE,2
DEVELOPINGCOUNTRIES,1
MULTINATIONAL FIRMS,2
WELFARE IMPLICATIONS,2
EMPIRICALANALYSIS,1
PRICE CONTROLS,2
,1
PROTECTION,1
Biotechnology,1
Freedom to operate,3
Intellectual property,2
International patent protection,3
Neurotechnology,1
Patent costs,2
Patent prosecution,2
Patenting strategy,2
Roadmap,1
Prior art,2
,1
,1
PROCESS INNOVATION,2
COMPETITIVE PRESSURE,2
CHOICE,1
SPILLOVERS,1
KNOWLEDGE,1
RETURNS,1
developing world,2
distributive justice,2
health,1
international justice,2
medical ethics,2
pharmaceutical patents rights,3
,1
insulin,1
glucometer,1
diabetes,1
medical devices,2
patents,1
METERS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PROTECTION,1
KNOWLEDGE,1
Patent policy,2
policy combination,2
policy balance,2
patent quality,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION EVIDENCE,2
PROTECTION,1
KNOWLEDGE,1
COMMERCIALIZATION,1
PRODUCTIVITY,1
INVESTMENT,1
INDUSTRIAL,1
CITATIONS,1
Patent Protection,2
Intellectual Property Investments,3
World Court,2
Assets,1
Interpretation,1
CONTINUITY,1
LAW,1
Open Innovation,2
Startup Takeovers,2
Patent Portfolios,2
LITIGATION,1
PERFORMANCE,1
SETTLEMENT,1
MARKET,1
Canadian Firms,2
Locational Patenting Behavior,3
Patent Cooperation Treaty,3
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
PROTECTION,1
SURVIVAL,1
TRADE,1
,1
,1
Patent nonuse,2
Preemptive patents,2
Failed patents,2
US patent policy,3
Nonpracticing entities,2
TECHNOLOGY,1
MARKET,1
PROTECTION,1
INNOVATION,1
IDEAS,1
INCENTIVES,1
STRATEGIES,1
ASSETS,1
antitrust law,2
asthma,1
COPD,1
Food and Drug Administration,4
inhalers,1
patents,1
,1
,1
DILUTION ACT,2
SHAREHOLDER VALUE,2
ENTRY DETERRENCE,2
MARKET VALUE,2
INNOVATION,1
QUALITY,1
BEHAVIOR,1
RETURNS,1
PATENTS,1
LESSONS,1
research and development,3
investments,1
patents,1
cooperation,1
differentiated goods,2
RESEARCH JOINT VENTURES,3
INNOVATION ACTIVITIES,2
DEVELOPMENT POLICY,2
EMPIRICALEVIDENCE,1
FIRMS,1
PRODUCTIVITY,1
TECHNOLOGY,1
INCENTIVES,1
SUBSIDIES,1
COLLABORATION,1
,1
BIOTECHNOLOGY,1
UTILITY,1
MARKET,1
intellectual property,2
innovation,1
secrecy,1
patenting,1
INTELLECTUAL PROPERTY,2
PATENTS,1
INFORMATION,1
COMPETITION,1
LITIGATION,1
DISCLOSURE,1
OLIGOPOLY,1
Josiah Wedgwood,2
patent,1
innovation,1
Industrial Revolution,2
Richard Champion,2
,1
Dosage,1
fractionation,1
inventive step,2
patent,1
rituximab,1
trastuzumab,1
GEMTUZUMAB OZOGAMICIN,2
,1
,1
,1
RESEARCHANDDEVELOPMENT,1
INTERNAL FINANCE,2
INNOVATION,1
FIRMS,1
PROTECTION,1
COUNTRIES,1
CAPACITY,1
MATTER,1
SURGE,1
UK,1
Cerebral protection,2
Atrial thrombus,2
AngioVac system,2
Patent foramen ovale,3
COMPLICATIONS,1
,1
PROPERTYRIGHTS PROTECTION,2
DEVELOPMENT SUBSIDIES,2
ENDOGENOUS GROWTH,2
PATENT PROTECTION,2
ECONOMICGROWTH,1
WELFARE,1
COMPETITION,1
MARKET,1
DEBT,1
,1
,1
SPCs,1
patents,1
pharmaceuticals,1
medicines,1
life sciences,2
Brexit,1
,1
,1
TECHNOLOGY,1
PROTECTION,1
FIRMS,1
INTEGRATION,1
INVESTMENT,1
INNOVATION,1
SIMULATION,1
ADOPTION,1
INDUSTRY,1
RENEWAL,1
,1
INSTRUMENTAL VARIABLES,2
INTELLECTUAL PROPERTY,2
CHILD PROTECTION,2
IMPACT,1
RIGHTS,1
DISCLOSURE,1
EMPLOYMENT,1
ASSIGNMENT,1
SHOULDERS,1
SEQUENCE,1
,1
,1
,1
,1
,1
PATENTS,1
MYRIAD,1
Invention pledge,2
Lead time advantage,3
Open disclosure,2
Followon innovation,2
O36,1
O32,1
O31,1
RESEARCHANDDEVELOPMENT,1
UNITEDSTATES,1
TECHNOLOGICAL INNOVATION,2
INTELLECTUAL PROPERTY,2
STRATEGIC DISCLOSURE,2
KNOWLEDGE SPILLOVERS,2
ABSORPTIVECAPACITY,1
PATENTS,1
MARKET,1
FIRMS,1
,1
ASSERTION ENTITIES,2
patent wars,2
patent litigation,2
intellectual property IP enforcement,4
patent thicket,2
smartphone,1
platformbased markets,2
platform competition,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INSTITUTIONAL ENVIRONMENT,2
TECHNOLOGICALINNOVATION,1
SEMICONDUCTOR INDUSTRY,2
EMPIRICALANALYSIS,1
ENTRY,1
PROTECTION,1
MARKET,1
LITIGATION,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
TRAGEDY,1
COMMONS,1
TECHNOLOGY,1
PROTECTION,1
INNOVATION,1
KNOWLEDGE,1
MARKETS,1
patent rights,2
TRIPS Agreement,2
comparative analysis,2
Iranian laws,2
European Union,2
,1
Algerian law,2
American legislation,2
innovation,1
legal protectionproperty right,3
new plant variety,3
patent,1
plant,1
,1
access to medicines,3
flexibilities,1
Nigeria,1
Pharmaceutical patents,2
public health,2
TRIPS,1
womens right to health,4
INTIMATE PARTNER VIOLENCE,3
REPRODUCTIVE HEALTH,2
CARE,1
TRIPS,1
DISEASES,1
OPTIONS,1
University patents,2
Patent value,2
Patent licensing,2
TECHNOLOGICALINNOVATION,1
PROPERTY,1
MARKET,1
PROTECTION,1
CITATIONS,1
SHADOW,1
GROWTH,1
,1
INNOVATION,1
RENEWAL,1
,1
,1
Optimal patent damages,3
Patent infringement,2
Willful infringement,2
Optimal injunction scope,3
COSTLY LITIGATION,2
INNOVATION,1
,1
,1
Intellectual property protection,3
Spatial spillover effects,3
Patent output,2
National intellectual property demonstration,4
cities,1
RIGHTS,1
INNOVATION,1
Indian patent law,3
Patent infringement,2
TRIPS compliance,2
Evergreening,1
the Novartis case,3
,1
,1
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT INTENSITY,2
PATENT PROTECTION,2
FIRM PERFORMANCE,2
MARKET,1
OUTPUT,1
APPROPRIABILITY,1
STATISTICS,1
VALUATION,1
STRATEGY,1
Invention licenses,2
Patents,1
Technology transfer,2
Federal laboratories,2
Federal agencies,2
,1
intellectual property,2
international property law,3
international regulations,2
trade flows,2
multiple regression analysis,3
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONALTRADE,1
TECHNOLOGY,1
INNOVATION,1
American Inventors Protection Act AIPA,5
corporate venture capital CVC,4
disclosure,1
patent,1
startup,1
INTELLECTUAL PROPERTYRIGHTS,2
INNOVATION,1
PERFORMANCE,1
IDEAS,1
BIOTECHNOLOGY,1
INVESTORS,1
ALLIANCE,1
NETWORKS,1
SHARKS,1
MARKET,1
Patent value,2
technology,1
renewal years,2
Indian patents,2
PRIVATE VALUE,2
INFRINGEMENT,1
PROTECTION,1
QUALITY,1
MARKET,1
IMPACT,1
TRIPS compliance,2
India,1
patents,1
compulsory licensing,2
commercialisation of patents,3
,1
patent abroad,2
strategic emerging industries,3
technology innovation diffusion,3
intellectual property,2
China,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
UNITEDSTATES,1
TECHNOLOGY,1
INNOVATION,1
INTERNATIONALIZATION,1
COMPETITION,1
PROTECTION,1
DIFFUSION,1
design for remanufacturing,3
patent protection,2
closedloop supply chain,3
Stackelberg game,2
carbon emissions,2
DESIGN,1
COMPETITION,1
STRATEGY,1
COMPONENT,1
PRODUCT,1
CHOICE,1
Remanufacturing,1
Patent protection,2
Secondhand market,2
Utility function,2
Product pricing,2
LOOP SUPPLY CHAIN,3
SECONDARY MARKET,2
STRATEGY,1
PRODUCTS,1
REDUCTION,1
DESIGN,1
MODELS,1
,1
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
PERFORMANCE,1
ACQUISITION,1
,1
CARBON,1
FRACTIONATION,1
AUTHENTICITY,1
DELTAC13,1
HYDROGEN,1
ACIDS,1
economic globalization,2
intangible cultural heritage ICH,4
IPR protection,2
patent rights,2
copyrights,1
Trademark rights,2
geographical indication rights,3
,1
entomology,1
patents,1
insecticides,1
insecticide mixtures,2
insecticide formulations,2
crop protection industry,3
CROP PROTECTION RESEARCH,3
INSECTICIDES,1
DISCOVERY,1
GENERATION,1
,1
PATENT PROTECTION,2
DIFFUSION,1
ENTRY,1
DRUGS,1
,1
COPYRIGHT INFRINGEMENT,2
ECONOMICANALYSIS,1
SOCIALINFLUENCE,1
PATENT SYSTEM,2
EARLY HISTORY,2
MARKET VALUE,2
TRADE DRESS,2
LAW,1
PROTECTION,1
INNOVATION,1
Patents,1
Technological innovation,2
Indexes,1
Hazards,1
Knowledge engineering,2
Analytical models,2
Size measurement,2
Patent assignment,2
patent collateral,2
patentbased measures,2
technology market,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALANALYSIS,1
MARKET VALUE,2
KNOWLEDGE SPILLOVERS,2
TECHNOLOGY EVIDENCE,2
INNOVATION,1
FIRMS,1
DETERMINANTS,1
CITATIONS,1
Patent,1
blockchain,1
smart contract,2
Hyperledger fabric,2
,1
Intellectual property,2
protection mechanism,2
patent,1
data exclusivity,2
TRIPS agreement,2
INFORMATION,1
ACCESS,1
,1
FOREIGN DIRECTINVESTMENT,2
DEVELOPINGCOUNTRIES,1
DOMESTIC FIRMS,2
INNOVATION,1
PATENT,1
PROTECTION,1
TECHNOLOGY,1
SPILLOVERS,1
COMPLEX,1
Software patent,2
Computer program,2
Alice v CLS,3
Abstract idea,2
Innovation,1
EUROPE,1
Patenting Centers,2
intellectual property,2
public research centers,3
technology transfer,2
,1
innovation,1
intellectual property,2
natural products,2
patents,1
,1
Patents,1
RD,1
economic growth,2
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT COMPETITION,2
SEQUENTIAL INNOVATION,2
PREEMPTION GAMES,2
PROTECTION,1
MODEL,1
LAW,1
INFORMATION,1
BUYOUTS,1
RACES,1
FDI,1
Economic growth,2
TRIPS,1
Intellectual property,2
Patent enforcement,2
Patent systems,2
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
INSTRUMENTALVARIABLE ESTIMATION,2
RESEARCHANDDEVELOPMENT,1
PANELDATA,1
PROTECTION,1
US,1
PRODUCTIVITY,1
COUNTRIES,1
IMPACT,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
DEVELOPINGCOUNTRIES,1
MEDICINES,1
TRADE,1
WORLD,1
STRATEGIES,1
ACCESS,1
FFs,1
Succession,1
Intellectual property protection,3
Patents,1
Upper echelons,2
RESEARCHANDDEVELOPMENT,1
SOCIOEMOTIONAL WEALTH,2
TECHNOLOGICALINNOVATION,1
DEVELOPMENT INVESTMENTS,2
PRODUCT INNOVATION,2
UPPER ECHELONS,2
FOUNDER FIRMS,2
TRANSITION,1
ENTREPRENEURS,1
ORGANIZATION,1
Proportionality,1
Injunctive relief,2
Permanent injunctions,2
Abuse of rights,3
Equity,1
Patent assertion entities,3
Complex products,2
HOLDUP,1
Drug detection,2
patent statistics,2
patent analysis,2
development trend,2
,1
debtor protection,2
credit markets,2
innovation,1
patents,1
personal bankruptcy law,3
small businesses,2
RESEARCHANDDEVELOPMENT,1
BANKRUPTCY REFORM ACT,3
PERSONAL BANKRUPTCY,2
SMALL FIRMS,2
ENTREPRENEURSHIP,1
CONSTRAINTS,1
FINANCE,1
GROWTH,1
Commercialization lags,2
Patent term extensions,3
Pharmaceutical RD,2
Economic growth,2
Social welfare,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
GENERIC COMPETITION,2
PROTECTION,1
INNOVATION,1
MODEL,1
POLICY,1
LENGTH,1
,1
INTELLECTUAL PROPERTY,2
COPYRIGHT,1
CREATIVITY,1
LAW,1
HISTORY,1
FEIST,1
International patenting,2
Tobins q market value model,5
uncertainty,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
DEVELOPMENT INVESTMENT,2
STRATEGIES,1
IMPACT,1
FIRMS,1
IDEAS,1
phage biocontrol,2
patent landscape,2
crop production,2
RESISTANCE,1
BACTERIA,1
THREAT,1
innovation,1
intellectual property,2
natural products,2
patents,1
,1
Sequential innovation,2
Patent policy,2
Entry,1
INDUSTRY,1
RETURN,1
RISK,1
LIFE,1
,1
INTELLECTUAL PROPERTY PROTECTION,3
PATENTS,1
MECHANISMS,1
INDUSTRY,1
RIGHTS,1
Patent commercialisation channel,3
patent quality,2
selling,1
licensing,1
university patent,2
EXTERNAL TECHNOLOGY ACQUISITION,3
EMPIRICALANALYSIS,1
MARKET,1
FIRMS,1
INNOVATION,1
IDEAS,1
PERFORMANCE,1
PROTECTION,1
RENEWAL,1
IMPACT,1
COVID19 vaccines,2
COVID19 vaccines patent,3
COVID19 herd immunity,3
COVID19 conspiracy theories,3
COVID19 lowincome countries,3
COVAX AMC,2
mRNA vaccine,2
FRAMEWORK,1
Quality of patent process,4
Technological standards,2
Policy evaluation,2
Diffindiffindiff estimation,2
Patent scope,2
,1
,1
,1
,1
,1
,1
FAIRUSE,1
LIABILITY RULES,2
COPYRIGHT,1
RIGHTS,1
PROTECTION,1
LAW,1
ANTICOMMONS,1
INNOVATION,1
FAILURE,1
PATENTS,1
,1
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
CHILD PROTECTION,2
POLICY,1
MARKET,1
TECHNOLOGY,1
ASSIGNMENT,1
STRATEGIES,1
IMPACT,1
legal environment,2
technological innovation,2
sustainable economic growth,3
intellectual property protection,3
legal system,2
RESEARCHANDDEVELOPMENT,1
DIRECT FOREIGNINVESTMENT,2
PRODUCTIVITY,1
SPILLOVERS,1
FIRMS,1
SIZE,1
,1
INTELLECTUAL PROPERTY,2
DISCLOSURE,1
MARKET,1
RIGHTS,1
DELAY,1
LAW,1
innovation strategy,2
knowlege management,2
outofstate noncompetes,2
patents,1
worker mobility,2
TRADE SECRETS,2
COMPETITIVE ADVANTAGE,2
EMPLOYEE MOBILITY,2
PATENTS,1
ENTREPRENEURSHIP,1
ENFORCEABILITY,1
HETEROGENEITY,1
COMPENSATION,1
DISCLOSURE,1
AGREEMENTS,1
Pharmaceutical,1
Patent Law,2
IPR,1
Healthcare Industry,2
Legal Scenario and Policies,4
,1
intellectual property rights,3
developing countries,2
pharmaceutical sector,2
innovation,1
patents,1
TRIPS,1
RESEARCHANDDEVELOPMENT,1
SEQUENTIAL INNOVATION,2
PATENT PROTECTION,2
CUMULATIVE INNOVATION,2
TECHNOLOGICALCHANGE,1
DEVELOPINGCOUNTRIES,1
PANELDATA,1
CITATIONS,1
REGRESSION,1
INDUSTRY,1
PRs protection,2
FDI,1
INTELLECTUAL PROPERTYRIGHTS,2
DETERMINANTS,1
TRADE,1
FDI,1
EXPORTS,1
Patent litigation,2
Patent damages,2
Patent infringement awards,3
Jury system,2
Jury verdict,2
Treble damages,2
EMPIRICALANALYSIS,1
INDICATORS,1
CITATIONS,1
,1
RECORDED MUSIC,2
COPYRIGHT PROTECTION,2
DIGITAL DISTRIBUTION,2
PATENT RIGHTS,2
PIRACY,1
SALES,1
IMPACT,1
PRODUCTS,1
ARTISTS,1
Innovation,1
patents,1
secrecy,1
alienability,1
excludability,1
public goods,2
RESEARCHANDDEVELOPMENT,1
CUMULATIVE INNOVATION,2
SEQUENTIAL INNOVATION,2
INTELLECTUAL PROPERTY,2
MARKET VALUE,2
BIG SECRETS,2
OPPOSITION,1
PROTECTION,1
ECONOMICS,1
DYNAMICS,1
durable good,2
innovation,1
patents,1
plant breeders rights,3
seed saving,2
VARIETY PROTECTION,2
DURABILITY,1
copyright,1
intellectual property,2
BRICS,1
Russia,1
China,1
India,1
Brazil,1
South Africa,2
,1
,1
19THCENTURY,1
BRITAIN,1
AMERICA,1
AWARDS,1
gene patent,2
compulsory license,2
Myriad,1
research exemption,2
Taiwan Patent Act,3
patient access,2
patent eligibility,2
,1
Appropriability,1
patents,1
secret,1
imitation,1
substitution,1
SUBSTITUTION,1
STRATEGIES,1
MANAGEMENT,1
INNOVATION,1
ADC,1
antibodydrug conjugates,2
antibody,1
freedom to operate,3
immunotoxin,1
Kadcyla,1
patent,1
TUMOR,1
,1
INNOVATION,1
AMPLIFICATION,1
BIOLOGICS,1
ECONOMICS,1
INDUSTRY,1
THERAPY,1
HISTORY,1
GENOME,1
IMPACT,1
PRICE,1
European Union,2
European Patent Convention,3
European Patent Court,3
Russia,1
,1
,1
NORTHSOUTH TRADE,2
INNOVATION,1
PROTECTION,1
,1
INTELLECTUAL PROPERTY,2
SCIENTIFICRESEARCH,1
INDUSTRY,1
PROTECTION,1
COMMERCIALIZATION,1
INNOVATION,1
ECONOMICS,1
PRIZES,1
HEALTH,1
COSTS,1
cryptococcosis,1
Cryptococcus,1
cryptococcal meningitis,2
patent landscape,2
DISCOVERY,1
DISEASE,1
SURVEILLANCE,1
MENINGITIS,1
Pest management,2
Pesticide effectiveness,2
Common heritage of humankind,4
Intellectual property,2
Social justice,2
INTELLECTUAL PROPERTY,2
CROP PROTECTION,2
PRODUCTIVITY,1
RESISTANCE,1
INNOVATION,1
ISSUES,1
POLICY,1
PESTS,1
Productivity,1
Innovation,1
Development,1
Patents,1
Intellectual property rights,3
Economic complexity,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PANELDATA,1
ABSORPTIVECAPACITY,1
ECONOMICGROWTH,1
EMPIRICALEVIDENCE,1
PROTECTION,1
COUNTRIES,1
KNOWLEDGE,1
IMPACT,1
,1
,1
Patent,1
Venture capital,2
Signaling,1
Innovation,1
INTELLECTUAL PROPERTYRIGHTS,2
VENTURE CAPITALINVESTMENT,2
INNOVATION,1
MARKET,1
PERFORMANCE,1
ENFORCEMENT,1
CORPORATE,1
CHOICE,1
IMPACT,1
MATTER,1
innovation,1
interfirm mobility,2
knowledge workers,2
labor markets,2
trade secrets,2
INTELLECTUAL PROPERTY,2
LEGAL PROTECTION,2
MARKET,1
FIRMS,1
TECHNOLOGY,1
COVENANTS,1
ECONOMICS,1
MOBILITY,1
COMPETE,1
PATENTS,1
,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
INCENTIVES,1
SPILLOVERS,1
STRATEGIES,1
PROTECTION,1
RIGHTS,1
Leishmaniasis therapy,2
Intellectual property right,3
Patent,1
Claim,1
Bolar exemption,2
,1
,1
COPYRIGHT CLAUSE,2
ACCESS,1
DRUGS,1
LAW,1
Patent,1
RD,1
Infringement,1
Litigation,1
Settlement,1
Real options,2
REAL OPTIONS,2
ECONOMICANALYSIS,1
INNOVATION,1
PROTECTION,1
ALLOCATION,1
LIFE,1
SUIT,1
Essential patent,2
International patenting,2
Standard,1
INTELLECTUAL PROPERTYRIGHTS,2
CHINESE,1
Breeders rights,2
Plant Patents,2
Biotechnological inventions,2
plant varieties,2
agricultural innovation,2
,1
,1
,1
,1
DEVELOPMENT SPILLOVERS,2
TRADE,1
drug patent,2
ideas about supervision,3
patent linkage,2
priority review system,3
protection system,2
traditional Chinese medicine,3
,1
Human embryonic stem cell hESC,5
open license for patent,4
open access,2
patent,1
China,1
PATENTABILITY,1
intelligent phytoprotection,2
industrial policy,2
patent,1
DID,1
empirical view,2
,1
,1
OPTIMAL PATENT BREADTH,3
SCIENTIFICRESEARCH,1
ECONOMICANALYSIS,1
LEGAL PROTECTION,2
FAIRUSE,1
COPYRIGHT,1
INNOVATION,1
RULES,1
LAW,1
TECHNOLOGY,1
licensing,1
patent publication,2
invention disclosure,2
PROPERTYRIGHTS,1
INNOVATION,1
DISCLOSURE,1
IMPACT,1
SALE,1
US,1
Leprosy and patent,3
,1
patents,1
environmental innovations,2
sustainability,1
carbon emissions,2
Spain,1
ECONOMICGROWTH,1
ENERGYCONSUMPTION,1
CO2 EMISSIONS,2
INNOVATION,1
TRADE,1
CHALLENGES,1
MANAGEMENT,1
IMPACT,1
Video game,2
Ingame purchasing,2
Microtransaction,1
Predatory monetization,2
Consumer protection,2
Gaming disorder,2
INTERNET GAMING DISORDER,3
DECISIONMAKING,1
LOOT BOXES,2
REAL MONEY,2
MOTIVATIONS,1
PSYCHOLOGY,1
ESPORTS,1
MODEL,1
RISK,1
SELF,1
,1
LEGAL PROTECTION,2
INNOVATION,1
DESIGNS,1
TROLLS,1
START,1
AIPA,1
duplicative research,2
knowledge disclosure,2
patents,1
PRODUCT MARKET,2
PATENTS,1
SPILLOVERS,1
IDEAS,1
,1
INTELLECTUAL PROPERTY,2
LITIGATION,1
ECONOMICS,1
Pharmacy administration,2
intellectual property protection,3
drug industry,2
SQUAMOUSCELL CARCINOMA,2
human parthenotes,2
totipotency,1
commercial use,2
human embryo,2
hESC,1
European Court of Justice,4
human dignity,2
POTENTIALITY,1
Patent pledges,2
Distributive justice,2
COVID19,1
INTELLECTUAL PROPERTY,2
POOLS,1
INNOVATIONS,1
PRINCIPLES,1
THICKETS,1
BUSINESS,1
,1
,1
Innovation,1
Intellectual Property Rights Protection,4
NorthSouth Product Cycles,3
RD,1
Technology Transfer,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
PRODUCTCYCLE MODEL,2
NORTHSOUTH TRADE,2
MULTINATIONAL FIRMS,2
EMPIRICALEVIDENCE,1
GROWTH,1
IMITATION,1
DETERMINANTS,1
patent divisions,2
patent research,2
bibliometrical analysis,2
scientific research support,3
innovative activities,2
scitech libraries,2
,1
Patent survival,2
patent value,2
intellectual Property rights,3
technology,1
knowledge economy,2
INTELLECTUAL PROPERTY,2
REGRESSIONMODELS,1
SURVIVAL ANALYSIS,2
PROTECTION,1
RENEWAL,1
COMMERCIALIZATION,1
INDICATORS,1
CITATIONS,1
FAILURE,1
Property rights protection,3
Intellectual property tribunal,3
Firm innovation,2
Institutional change,2
China economy,2
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
INNOVATION EVIDENCE,2
PROTECTION,1
LAWS,1
INVESTMENT,1
OWNERSHIP,1
Artificial intelligence,2
Digitalisation,1
Patent analysis,2
International comparison,2
Specialisation,1
TECHNOLOGY,1
INNOVATION,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PROPENSITY SCORE,2
SOFTWARE PIRACY,2
SMALL FIRMS,2
PATENT,1
PROTECTION,1
INNOVATIONS,1
TECHNOLOGY,1
MANAGEMENT,1
SELECTION,1
,1
,1
patent law,2
invention,1
patentability,1
human inventor,2
artificial intelligence AI inventor,4
,1
,1
SOCIOEMOTIONAL WEALTH,2
CORPORATE DISCLOSURE,2
PERFORMANCE,1
OWNERSHIP,1
PROPRIETARY,1
AGENCY,1
PUBLICATION,1
INFORMATION,1
INNOVATION,1
SUBSIDIES,1
,1
INTELLECTUAL PROPERTY,2
UNIVERSITY TECHNOLOGY,2
COMMERCIALIZATION,1
INNOVATION,1
PROTECTION,1
SOFTWARE,1
TROLLS,1
RIGHTS,1
NORMS,1
FAITH,1
innovation,1
lefttail risk,2
patent,1
RD,1
stock market,2
GROWTH,1
RIGHTS,1
CONSTRAINTS,1
INVESTMENT,1
STABILITY,1
,1
INTELLECTUAL PROPERTY,2
FEDERAL CIRCUIT,2
PATENT SYSTEM,2
LAW,1
MYTH,1
APPROPRIABILITY,1
PROTECTION,1
INNOVATION,1
FiveYear Plan for environmental protection,5
Corporate green innovations,3
Subsidy availability,2
Financing availability,2
RESEARCHANDDEVELOPMENT,1
PRODUCTIVITY,1
COMPETITIVENESS,1
DIFFUSION,1
POLICY,1
COST,1
US,1
international technology,2
transfer,1
licensing,1
internalization,1
appropriability,1
intellectual property rights,3
technological complexity,2
and imitation risk,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INTERNATIONAL TECHNOLOGYTRANSFER,2
FOREIGN DIRECTINVESTMENT,2
LICENSING CONTRACTS,2
EXCLUSIVE RIGHTS,2
PANELDATA,1
KNOWLEDGE,1
GOVERNANCE,1
INDUSTRY,1
inhibitor,1
protease,1
HIV,1
antiviral drugs,2
patent,1
drug safety,2
pseudopolymorph,1
drug substance,2
darunavir,1
ethanolate,1
amorphous,1
xray diffraction studies,3
patent claims,2
solvation,1
crystalline form,2
ABACAVIR SULFATE,2
access to medicines,3
data exclusivity,2
patent,1
pharmaceutical monopoly extension,3
,1
Venture capital,2
innovation,1
intellectual property rights protection,4
VCFs characteristics,2
PRODUCTIVITY GROWTH,2
POLITICALECONOMY,1
PROPENSITY SCORE,2
PRIVATE FIRMS,2
GOVERNMENT,1
PERFORMANCE,1
PATENTS,1
FINANCE,1
INSTITUTIONS,1
REPUTATION,1
,1
POLITICAL PRESSURE,2
INNOVATION,1
PRICES,1
ENTRY,1
LAWS,1
PROTECTION,1
INDUSTRY,1
THREAT,1
FIRM,1
Knowledge exploration distance,3
Patent citation,2
Network embedding,2
Patent classification code,3
TECHNOLOGY,1
INNOVATION,1
IDENTIFICATION,1
EXPLOITATION,1
FIRMS,1
Quantum technologies,2
Quantum computing,2
Quantum cryptography,2
Patent landscape,2
Quantum IP,2
Quantum innovation,2
Quantum investment,2
,1
Technology transfer,2
patent transaction,2
patent assignment,2
patent,1
machine learning,2
DEEP NEURALNETWORKS,2
TECHNOLOGYTRANSFER,1
MODEL,1
IDENTIFICATION,1
INDICATORS,1
INNOVATION,1
KNOWLEDGE,1
VARIANTS,1
DYNAMICS,1
INDUSTRY,1
RD financial subsidies,3
regional RD input,3
intensity of IPP,3
sustainable patent out of SMEs,5
FIRMLEVEL EVIDENCE,2
INNOVATION EVIDENCE,2
RIGHTS,1
PRODUCTIVITY,1
MEDIATION,1
INVESTMENT,1
PERFORMANCE,1
MODERATION,1
OWNERSHIP,1
SUPPORT,1
Intellectual property,2
Standards,1
Actornetwork theory ANT,3
Patent classification,2
ACTORNETWORK THEORY,2
INTELLECTUAL PROPERTY,2
TECHNOLOGY,1
IMPLEMENTATION,1
INNOVATION,1
POLICY,1
PRINCIPLES,1
MECHANISMS,1
MARKET,1
Patentbased measures,2
Commercialization,1
Collaboration,1
Knowledge,1
Legal protection,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICAL INNOVATION,2
DRUG DEVELOPMENT,2
KNOWLEDGE,1
DYNAMICS,1
SPEED,1
BIOTECHNOLOGY,1
COLLABORATION,1
PERFORMANCE,1
STATISTICS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
BLOCKING PATENTS,2
GROWTH,1
PROTECTION,1
INNOVATION,1
POLICY,1
COMPETITION,1
WELFARE,1
ENTRY,1
MODEL,1
,1
FOREIGN DIRECTINVESTMENT,2
GLOBAL PATENT PROTECTION,3
DEVELOPINGCOUNTRIES,1
INNOVATION,1
TECHNOLOGY,1
TRADE,1
LAWS,1
PHARMACEUTICALS,1
PRODUCTIVITY,1
DIFFUSION,1
Innovation,1
Firm internationalization,2
Intellectual property rights protection,4
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
DEVELOPINGCOUNTRIES,1
MULTINATIONALCORPORATIONS,1
UNITEDSTATES,1
DEVELOPMENT OPERATIONS,2
DEVELOPMENT INVESTMENT,2
FIRM PERFORMANCE,2
ECONOMICGROWTH,1
KNOWLEDGE,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT INFRINGEMENT,2
MARKETSTRUCTURE,1
LIABILITY RULES,2
FAIRUSE,1
INDEPENDENT INVENTION,2
PROTECTION,1
COPYRIGHT,1
POLICY,1
GOODS,1
clot,1
echocardiography,1
percutaneous intervention,2
PROTECTION,1
PATIENT,1
Standardessential patents,2
FRAND principles,2
patent holdup,2
licence fee rates,3
antisuit injunction,2
,1
Crosscountry patenting,2
Technological capabilities,2
Technological gap,2
Technology index,2
RESEARCHANDDEVELOPMENT,1
RIGHTS,1
DETERMINANTS,1
INNOVATION,1
TRADE,1
CHINA,1
GLOBALIZATION,1
INDICATORS,1
STATISTICS,1
PROTECTION,1
,1
,1
Patent,1
new to the market innovation,5
new to the firm innovation,5
productprocess innovation,2
developing economies,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
MANUFACTURING FIRMS,2
TECHNOLOGYTRANSFER,1
STRATEGIES,1
PROTECTION,1
KNOWLEDGE,1
COMPETITION,1
PROPENSITY,1
GOVERNANCE,1
biotechnology,1
patents,1
PCT,1
startups,1
patenting strategy,2
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMIES,1
SCIENCE,1
FIRMS,1
Innovation,1
Intellectual property rights,3
Patent strength,2
Patent enforcement,2
TECHNOLOGICALCHANGE,1
PATENT RIGHTS,2
PROTECTION,1
Patents,1
Technological innovation,2
Economics,1
Correlation,1
Maintenance engineering,2
Market research,2
Bibliometrics,1
Backward citations,2
forward citations,2
nonprovisional application NPA,3
patent claims,2
patent renewal,2
patent value,2
provisional application PA,3
MARKET VALUE,2
CITATIONS,1
TECHNOLOGY,1
INDICATORS,1
PROTECTION,1
OPPOSITION,1
FAMILIES,1
SIZE,1
TIME,1
Patent policy,2
Patent validity,2
Patent length,2
Imitation,1
Litigation,1
Cumulative innovation,2
SEQUENTIAL INNOVATION,2
LITIGATION,1
PATENTABILITY,1
PERSISTENCE,1
SETTLEMENT,1
Value of patented inventions,4
Patents,1
Intellectual property strategy,3
China,1
Innovation policy,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
STATE,1
PERFORMANCE,1
MARKET,1
ENTERPRISES,1
PROTECTION,1
MANAGEMENT,1
KNOWLEDGE,1
genome editing,2
CRISPRCas9,1
EPO,1
opposition,1
appeal,1
RNA,1
,1
,1
Patent litigation,2
Patent systems,2
Harmonization,1
National courts,2
Unified patent court,3
LITIGATION,1
SELECTION,1
SCOPE,1
UK,1
Hydrogen,1
Hydrogen energy,2
Hydrogen power engineering,3
Fuel cells,2
Invention,1
Utility model,2
Patent,1
Patenting,1
Implementation,1
Innovation,1
Research and development,3
Commercialization of the product,4
,1
,1
,1
technological innovation,2
nontechnological innovation,2
ruralurban,1
strategic misspecification,2
exporting,1
increasing market share,3
TRADE MARKS,2
KNOWLEDGE SPILLOVERS,2
INNOVATION,1
PATENTS,1
Doctrine of equivalents,3
Garment packet,2
Patent interpretation,2
Subject matter of claim,4
Expert in the trade,4
Invalidity,1
Combination of inventions,3
Infringement by equivalence,3
,1
methods of medical treatment,4
patent history,2
parliamentary rewards,2
REWARDS,1
CREDIT,1
,1
BIG SECRETS,2
PATENTS,1
PROTECTION,1
MECHANISMS,1
INNOVATION,1
APPROPRIATION,1
STRATEGIES,1
KNOWLEDGE,1
ECONOMICS,1
VENTURES,1
trade secret,2
misappropriation,1
spinal implant,2
Defend Trade Secrets Act,4
confidentiality,1
,1
data envelopment analysis,3
industry analysis,2
market size,2
patent analysis,2
patentstrengthening strategy,2
RBD infrastructure,2
,1
Financial technology FinTech,3
FinTech index,2
patent quality,2
patent strategy,2
technology roadmap,2
FIT INDEXES,2
KNOWLEDGE,1
RENEWAL,1
CLASSIFICATION,1
INNOVATIONS,1
PERFORMANCE,1
MANAGEMENT,1
CITATIONS,1
MARKETS,1
IMPACT,1
Environmental importance,2
Green innovation,2
Environmental awareness,2
Environmental subsidies,2
PERFORMANCE,1
FEDERALISM,1
SECTOR,1
Exploitation of Patents,3
Protection and Enforcement of Intellectual Property Rights,7
Viet Nam,2
,1
Arrovian postulate,2
Appropriability tradeoff,2
Interindustry versus intraindustry spillovers,4
Userspecific patents,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE,1
PRODUCTIVITY,1
Intellectual property,2
Patent litigation,2
Patent shelter,2
Technology platforms,2
,1
,1
,1
foreign direct investment inflows,4
intellectual property reform,3
postTRIPs implementation,2
PATENT PROTECTION,2
RIGHTS,1
INNOVATION,1
Appropriability,1
Disclosure,1
Licensing,1
Market for technology,3
Patent,1
MARKET,1
SENSITIVITY,1
INNOVATION,1
ASSETS,1
IDEAS,1
BIAS,1
Patent infringement litigation,3
corporate innovation,2
executive risk preferences,3
dynamic competition,2
innovation investment,2
INTELLECTUAL PROPERTY PROTECTION,3
FIRM PERFORMANCE,2
UPPER ECHELONS,2
CONSEQUENCES,1
ORGANIZATION,1
INDUSTRY,1
RIVALRY,1
RIGHTS,1
TRADE,1
Divisional patent applications,3
Procedural rights,2
Pharmaceutical patents,2
Double patenting,2
PATENTS,1
O31,1
O34,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
PROTECTION,1
INNOVATION,1
ECONOMICS,1
LENGTH,1
POLICY,1
NORTH,1
Disclosure,1
Science,1
Firm strategy,2
Publication,1
Secrecy,1
Intellectual property IP protection,4
TECHNOLOGY,1
INNOVATION,1
SCIENCE,1
SEMICONDUCTOR,1
PERSPECTIVE,1
STRATEGIES,1
INDUSTRIAL,1
PATENTS,1
RIGHTS,1
FIRMS,1
climate disasters,2
patent examination,2
salience bias,2
UNITEDSTATES,1
TEMPERATURE,1
SENTIMENT,1
SALIENCE,1
OFFICE,1
environmental innovation,2
firm behavior,2
patent analysis,2
ECOINNOVATION,1
PANELDATA,1
DETERMINANTS,1
POLICY,1
MANAGEMENT,1
FIRMS,1
US,1
Intellectual property rights IPRs,4
Academic spinoffs ASOs,3
Science and technology ST parks and incubators,7
Startups,1
Competitiveness,1
FIRMS,1
APPROPRIABILITY,1
PROTECTION,1
MANAGEMENT,1
MECHANISMS,1
INNOVATION,1
PATENTS,1
IMPACT,1
flying geese model,3
innovation,1
intellectual property right IPR,4
national governance,2
sustainable economic development SED,4
INTELLECTUAL PROPERTY PROTECTION,3
INCREASING RETURNS,2
ENDOGENOUS GROWTH,2
RIDGEREGRESSION,1
DIFFUSION,1
RIGHTS,1
TECHNOLOGY,1
DAMAGES,1
patents,1
history,1
Switzerland,1
chemical industry,2
product patents,2
process patents,2
patent scope,2
,1
Economic policy uncertainty,3
External finance,2
Information asymmetry,2
Hightech,1
Innovation,1
Investment,1
INTELLECTUAL PROPERTYRIGHTS,2
POLITICAL UNCERTAINTY,2
FINANCIAL DEVELOPMENT,2
INVESTMENT,1
IMPACT,1
Pharmaceutical Patents,2
Product Patents,2
Grassroots Innovations,2
Indigenous medicine,2
Herb,1
Social Innovation,2
INTELLECTUAL PROPERTYRIGHTS,2
MANAGEMENT,1
SCIENCE,1
SECTOR,1
Trademarks,1
patents,1
Korea,1
tacit knowledge,2
sectoral systems of innovations,4
INTELLECTUAL PROPERTY PROTECTION,3
RESEARCHANDDEVELOPMENT,1
SECTORAL SYSTEMS,2
KNOWLEDGE BASES,2
MARKET VALUE,2
INNOVATION,1
APPROPRIABILITY,1
INDICATOR,1
PATTERNS,1
JAPANESE,1
,1
,1
Silver nanoparticles,2
patent,1
nanotechnology,1
bionanotechnology,1
nanoparticles,1
patent application,2
,1
,1
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE DIFFUSION,2
LABOR MOBILITY,2
INTERNATIONAL LABOR,2
GRAVITY MODEL,2
BRAINDRAIN,1
NETWORKS,1
TECHNOLOGY,1
INNOVATION,1
GLOBALIZATION,1
Technology mining,2
Excessive topic generation,3
Industrial immersive patenting,3
Patent data visualization,3
,1
Collaborative innovation,2
dynamic governance,2
European Union,2
governance,1
patent law,2
patent reforms,2
unitary patent,2
SYSTEM,1
Democratic Peoples Republic of Korea,5
Invention,1
Patent,1
Utility model,2
,1
,1
RESEARCHANDDEVELOPMENT,1
CHEMICALSTRUCTURE,1
PATENT LANDSCAPE,2
IDENTIFICATION,1
SOLUBILITY,1
TARGET,1
Patent strategy,2
Patent law expertise,3
Patenting performance,2
Intellectual property,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
TEAM DIVERSITY,2
INNOVATION,1
FIRM,1
STRATEGIES,1
MANAGEMENT,1
ADVANTAGE,1
SUPPLIER,1
ENTREPRENEURSHIP,1
,1
PROCESSING FLUENCY,2
VISUALLY COMPLEX,2
PRODUCT DESIGN,2
PACKAGE DESIGN,2
PRINCIPLE,1
NOVELTY,1
PERCEPTIONS,1
CHALLENGES,1
EXPERIENCE,1
PREFERENCE,1
Patent systems,2
patent quality,2
comparative analysis,2
intellectual property,2
QUALITY,1
PROTECTION,1
CITATIONS,1
ECONOMICS,1
RIGHTS,1
Political connections,2
Corporate innovation,2
R  Patents,3
Board of directors,3
RESEARCHANDDEVELOPMENT,1
POLICY UNCERTAINTY,2
FIRM PERFORMANCE,2
CONNECTED BOARDS,2
DARK SIDE,2
DIRECTORS,1
OWNERSHIP,1
MODELS,1
CHINA,1
CONSTRAINTS,1
,1
DIGITAL TRANSFORMATION,2
NETWORKS,1
TRENDS,1
Joint patenting,2
Shadow of the future,4
Performance ambiguity,2
RD alliances,2
Biotechnology firms,2
TRANSACTION COST,2
STRATEGIC ALLIANCES,2
PERFORMANCE,1
GOVERNANCE,1
MECHANISMS,1
OWNERSHIP,1
DYNAMICS,1
TRUST,1
COOPERATION,1
PROTECTION,1
,1
PATENT,1
COPYRIGHT,1
LAW,1
Patent validity,2
Patent description,2
Patent examination,2
Invalidation trials,2
Selection bias,2
GRANTS,1
Australian Register of Therapeutic Goods,5
Federal Court of Australia,4
Patent Term Extension,3
Pharmaceutical Substance,2
Therapeutic Goods Administration,3
,1
,1
EXEMPTION,1
Copyright law,2
Patent law,2
Confidential commercial information law,4
Energy efficient innovation,3
And protection of innovation,4
ECONOMICGROWTH,1
COPYRIGHT PROTECTION,2
EMISSIONS,1
CONSUMPTION,1
COUNTRIES,1
PATENTS,1
SECTOR,1
GREEN,1
LINKS,1
FDI,1
Patent transfer,2
Innovation quality,2
Substantive innovation,2
Sustainable innovation,2
Institutional threshold effect,3
Complex network analysis,3
INTELLECTUAL PROPERTYRIGHTS,2
ENVIRONMENTAL INNOVATION,2
EMPIRICALANALYSIS,1
TECHNOLOGY,1
SPILLOVERS,1
PROXIMITY,1
GEOGRAPHY,1
POLICIES,1
MARKET,1
SPACE,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGYTRANSFER,1
EMPIRICALANALYSIS,1
CURRENCY UNIONS,2
PROTECTION,1
INNOVATION,1
GRAVITY,1
EXPORTS,1
PERFORMANCE,1
INVESTMENT,1
Ethics,1
intellectual property protections,3
open science,2
policy,1
qualitative research,2
KNOWLEDGE,1
Brain patents,2
Neurolaw,1
Neuroethics,1
Human rights,2
Ordre public,2
Misuse,1
,1
,1
,1
Technological innovation,2
Patent management,2
Innovation performance,2
Fuzzy front end,3
Technological lockin,2
RESEARCHANDDEVELOPMENT,1
PREDEVELOPMENT ACTIVITIES,2
COMPLEMENTARY ASSETS,2
PRODUCT DEVELOPMENT,2
OUTPUT INDICATORS,2
FIRM,1
KNOWLEDGE,1
MARKETS,1
ACQUISITIONS,1
SPILLOVERS,1
Heterogeneous network,2
Transformation opportunity,2
Transformation condition,2
MODEL,1
FDI,1
granger causality,2
international patenting,2
network analysis,2
F10,1
F14,1
F21,1
F23,1
O33,1
O34,1
C13,1
C23,1
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
GLOBALIZATION,1
TECHNOLOGY,1
PROTECTION,1
ARCHITECTURE,1
DEPENDENCE,1
JAPANESE,1
,1
PATENTS,1
SCIENCE,1
GENES,1
DNA,1
ACT,1
,1
NEED,1
LAW,1
Intellectual property,2
developing countries,2
international trade,2
protection,1
patents,1
internal laws of states,4
,1
,1
,1
Patent,1
contract,1
infringement,1
damages,1
reasonable royalties,2
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALANALYSIS,1
TACIT KNOWLEDGE,2
LIABILITY RULES,2
LOST PROFITS,2
MARKET VALUE,2
EQUILIBRIUM,1
LITIGATION,1
PROTECTION,1
DYNAMICS,1
R D,2
Economic growth,2
Monetary policy,2
Patent breadth,2
Blocking patents,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
BLOCKING PATENTS,2
SCHUMPETERIAN MODEL,2
INFLATION,1
INEQUALITY,1
WELFARE,1
IMPACT,1
INCOME,1
game theory,2
logistic regression,2
emerging countries,2
country strategic patent policy,4
technological leapfrogging,2
liabilities of foreignness,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
HOST COUNTRY,2
INTERNATIONALTRADE,1
INNOVATION,1
PROTECTION,1
MARKET,1
US,1
IMITATION,1
PUBLICATION,1
Patent policy,2
RD,1
Licensing,1
Technology strategy,2
RESEARCHANDDEVELOPMENT,1
INNOVATION,1
DETERMINANTS,1
IMPORTS,1
CAPABILITIES,1
PROTECTION,1
RIGHTS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENTABILITY REQUIREMENT,2
INCREASING RETURNS,2
ENDOGENOUS GROWTH,2
POWER LAWS,2
PRODUCTIVITY,1
PROTECTION,1
INDUSTRY,1
IMITATION,1
Intellectual property rights,3
Debt financing,2
Legal enforcement,2
Financing constraints,2
PATENT PROTECTION,2
CAPITAL STRUCTURE,2
MARKET,1
RIGHTS,1
INNOVATION,1
CONSTRAINTS,1
COMPETITION,1
QUALITY,1
GROWTH,1
CRISES,1
,1
INNOVATION,1
PERFORMANCE,1
DYNAMICS,1
DIFFERENCE,1
VARIETY,1
MODELS,1
IMPACT,1
Main path analysis,3
Clustering,1
Research theme,2
Development trajectory,2
Citation network,2
Patenting,1
BAYHDOLE ACT,2
INTELLECTUAL PROPERTYRIGHTS,2
KNOWLEDGE FLOWS,2
EMERGING TECHNOLOGIES,2
COMMUNITY STRUCTURE,2
SCIENTIFICRESEARCH,1
NETWORKS,1
QUALITY,1
POLICY,1
UNIVERSITIES,1
supplemental experimental data,3
post filing data,3
medical innovation,2
pharmaceutical patent,2
,1
Biotechnology directive,2
Bioeconomy,1
Patent laws,2
Stem cells,2
Plant varieties,2
Animal varieties,2
European Union,2
,1
Startups,1
patents,1
location,1
collaboration,1
financing,1
DEVELOPMENT SPILLOVERS,2
INNOVATION,1
PERFORMANCE,1
KNOWLEDGE,1
DETERMINANTS,1
ALLIANCE,1
FIRMS,1
SIZE,1
RESOURCES,1
STRATEGY,1
Pharmaceutical drugs,2
Patent protection,2
Paragraph IV settlement,3
INNOVATION,1
Propatent,1
Patent litigation,2
Intellectual property IP court,4
China,1
RIGHTS,1
LITIGATION,1
ENFORCEMENT,1
ENTITIES,1
Genetic Resources,2
Traditional Medicinal Knowledge,3
National Medicine Patent Development,4
Collective Action,2
,1
,1
,1
Intellectual property rights,3
International treaties,2
Patent collaboration,2
Innovation system,2
Social network analysis,3
O35,1
,1
Clustering,1
Intellectual Property IP,3
Latent Dirichlet Allocation LDA,4
Ontology Schema,2
Patent Mining,2
CLUSTERANALYSIS,1
Intellectual property rights,3
Patents,1
Pharmaceutical industry,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
TECHNOLOGY,1
INNOVATION,1
CITATIONS,1
LESSONS,1
PERFORMANCE,1
HISTORY,1
SCIENCE,1
CRISIS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
MULTINATIONAL FIRMS,2
JAPANESE FIRMS,2
MARKET,1
INTERNATIONALIZATION,1
POLICY,1
CSR,1
Green innovation,2
Green patent,2
Chinese market,2
,1
Quality,1
EPO,1
Legal status,2
Opposition,1
Examination,1
QUALITY,1
,1
,1
Blockchain,1
Intellectual property,2
Smart contracts,2
Memory,1
Technological innovation,2
Cryptography,1
Realtime systems,2
Blockchain technology,2
original achievements protection,3
simulation,1
traceability,1
SMART CONTRACT,2
SUPPLY CHAIN,2
COPYRIGHT,1
PATENTS,1
FINANCE,1
Ethics,1
Patents,1
Biotechnology,1
Ordre public and morality,4
ISSUES,1
BIOTECHNOLOGY,1
PERSPECTIVE,1
LEGITIMACY,1
INTERESTS,1
KNOWLEDGE,1
LEGAL,1
disease diagnosis methods,3
smart healthcare,2
artificial intelligence,2
patentability,1
,1
deextinction,1
ethics,1
morality exclusions,2
OncoMouse,1
patents,1
transgenic animals,2
ETHICS,1
CONSERVATION,1
PROTECTION,1
BACK,1
intellectual property right,3
patent,1
pharmaceutical expenditure,2
highincome countries,2
PATENT PROTECTION,2
TRIPSPLUS,1
ESSENTIAL MEDICINES,2
HEALTH EXPENDITURE,2
WELFARESTATE,1
DETERMINANTS,1
ACCESS,1
IMPACT,1
INNOVATION,1
INFANT,1
Patent Licensing,2
Patent Financing,2
Trust of Patent,3
Invention Patent,2
,1
Research university,2
Patent,1
Education,1
Construction,1
INTELLECTUAL PROPERTYRIGHTS,2
Georgias and Estonias legislative frameworks in IP commercialisation,8
intellectual property,2
IP commercialisation,2
INNOVATION,1
Cyber risk,2
Hacking,1
Corporate innovation,2
Patents,1
Trade secrets,2
TRADE SECRETS,2
FINANCIAL CONSTRAINTS,2
INFORMATION,1
DISCLOSURES,1
PROTECTION,1
PATENTS,1
FIRMS,1
PRIVATIZATION,1
IMPACT,1
Intellectual property rights,3
Patents,1
Foreign direct investment,3
Multinationals,1
C23,1
F21,1
F23,1
O34,1
FOREIGN DIRECTINVESTMENT,2
PATENT PROTECTION,2
INTERNATIONAL PRODUCTION,2
IMPACT,1
DETERMINANTS,1
INNOVATION,1
COUNTRIES,1
Internationalization of technology,3
Patent analysis,2
Energy transition,2
Solar technology,2
INTELLECTUAL PROPERTY,2
KNOWLEDGE FLOWS,2
INNOVATION,1
CITATIONS,1
DETERMINANTS,1
DEPLOYMENT,1
DIFFUSION,1
COUNTRIES,1
LOCALIZATION,1
COMPETITION,1
Trade secrets,2
Noncompetition,1
Economic espionage,2
Mobility,1
Breach of confidence,3
PRINCIPLE,1
EQUALITY,1
ARMS,1
Genetically modified organisms,3
patent citation networks,3
technological trajectories,2
intellectual property,2
patent litigation,2
MAPPING TECHNOLOGICAL TRAJECTORIES,3
INNOVATION,1
CITATIONS,1
PATTERNS,1
GROWTH,1
patent quality,2
global research and development RD collaboration,6
nanotechnology,1
UNIVERSITY,1
PERSPECTIVE,1
KNOWLEDGE,1
SCIENCE,1
UK,1
International patenting,2
Social network analysis,3
Quadratic assignment procedure QAP,4
Country differences,2
Proximity,1
F14,1
F22,1
O33,1
O34,1
O38,1
R11,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGY DIFFUSION,2
INNOVATION,1
TRADE,1
CHINA,1
DETERMINANTS,1
COMPETITION,1
KNOWLEDGE,1
NETWORKS,1
Digital divide,2
Fourth Industrial Revolution,3
innovation,1
intellectual property,2
patenting,1
INTELLECTUAL PROPERTY,2
EMPIRICALEVIDENCE,1
INNOVATION,1
TECHNOLOGY,1
PROTECTION,1
PLATFORMS,1
RIGHTS,1
POLICY,1
,1
,1
appropriability,1
biotechnology,1
innovation,1
knowledge,1
market power,2
patents,1
plant breeders rights,3
plant patents,2
RD,1
trade secrets,2
RESEARCHANDDEVELOPMENT,1
SEQUENTIAL INNOVATION,2
TECHNOLOGICALCHANGE,1
UNITEDSTATES,1
WORLDSFAIRS,1
HYBRID CORN,2
PATENTS,1
PROTECTION,1
YIELD,1
ECONOMICS,1
Technological impact,2
Indicators,1
Journal technological factor,3
Journals,1
Scholarly journals,2
Patents,1
Patstat,1
Citations,1
Research performance,2
Bibliometrics,1
Nonpatent references,2
NPR,1
Nonpatent literature,2
NPL,1
IMPACT FACTOR,2
CITATION,1
SCIENCE,1
LINKAGE,1
SCOPUS,1
PUBLICATIONS,1
REFERENCES,1
Intellectual property rights,3
ICT,1
Market competition,2
SME,1
PRODUCT DIFFERENTIATION,2
INNOVATION,1
MARKET,1
STANDARDS,1
OPPORTUNITIES,1
TECHNOLOGIES,1
THICKETS,1
PARADOX,1
IMPACT,1
POLICY,1
New Environmental Protection Law,4
Ecoinnovation,1
Differenceindifference,1
Policy evaluation,2
,1
Patent,1
Cardiology,1
Innovation,1
Temporal trends,2
,1
corporate digitalization,2
financing constraints,2
green innovation,2
green patent applications and grants,5
local intellectual property protection,4
DYNAMIC CAPABILITIES,2
CONSTRAINTS,1
ROLES,1
Global diversification,2
Innovation efficiency,2
Multinational firms,2
Firm value,2
RESEARCHANDDEVELOPMENT,1
INTERNAL CAPITALMARKETS,2
CORPORATE DIVERSIFICATION,2
TECHNOLOGYTRANSFER,1
PATENT PROTECTION,2
LIABILITY RULES,2
PROPERTY RULES,2
DARK SIDE,2
PERFORMANCE,1
KNOWLEDGE,1
Intellectual property protection,3
Licensing,1
Quality of the licensed technology,5
Welfare,1
INTELLECTUAL PROPERTYRIGHTS,2
TECHNOLOGYTRANSFER,1
QUALITY,1
EXPORTS,1
Spray booth with hybrid electrical heating,6
Car body shops,3
Infringement,1
Injunction,1
Counterfeit products,2
Unfair competition,2
Invalidity,1
Lack of novelty,3
Predisclosure,1
Passing off,2
Disgorgement of profits,3
Cumulative protection,2
,1
Patents,1
data mining,2
therapeutic Antibodies,2
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
ECONOMICGROWTH,1
PROTECTION,1
LEVEL,1
Patent,1
Tax,1
Welfare,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PRIZES,1
COMPETITION,1
TECHNOLOGY,1
INCENTIVES,1
QUALITY,1
LIFE,1
,1
INTELLECTUAL PROPERTY,2
INVENTIONS,1
PATENTS,1
intellectual property,2
information demands,2
patent research,2
information resources,2
innovative activities,2
,1
Government laboratory,2
Federally funded research and development,5
centers FFRDCs,2
Scientific discovery,2
Patent protection,2
Knowledge dissemination,2
Sciencebased inventions,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGYTRANSFER,1
INTELLECTUAL PROPERTY,2
KNOWLEDGE SPILLOVERS,2
PUBLIC SCIENCE,2
INNOVATION,1
COMMERCIALIZATION,1
POLICY,1
MARKET,1
CITATIONS,1
,1
TRANSCATHETER,1
Patent infringement,2
Early warning,2
Intuitionistic fuzzy set,3
Entropy weight,2
Regionality,1
Chinese market,2
INTELLECTUAL PROPERTYRIGHTS,2
DECISIONMAKING,1
EMPIRICALANALYSIS,1
TECHNOLOGY,1
INVENTION,1
LITIGATION,1
INDICATORS,1
OWNERSHIP,1
ENTROPY,1
QUALITY,1
,1
PRODUCT INNOVATION,2
PARTNERSHIPS,1
IMITATION,1
China,1
audit input,2
patent quality,2
intellectual property market,3
information asymmetry,2
intermediary institutions,2
CORPORATE GOVERNANCE,2
NONAUDIT SERVICES,2
BEHAVIOR EVIDENCE,2
INTERNAL CONTROL,2
TIME PRESSURE,2
INNOVATION,1
FEES,1
RISK,1
EARNINGS,1
IMPACT,1
Patents,1
Filing strategy,2
Intellectual property management,3
IP intermediaries,2
Patent attorney,2
Patent strategies,2
Strategic IP management,3
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
MANAGEMENT,1
INNOVATION,1
INDUSTRY,1
MARKET,1
PERFORMANCE,1
DETERMINANTS,1
PROTECTION,1
CITATIONS,1
competitive dynamics,2
market entry,2
patent strategies,2
patent litigation,2
mobile phone industry,3
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
RESEARCHANDDEVELOPMENT,1
STRATEGIC SIMILARITY,2
MULTIMARKET CONTACT,2
MODE CHOICE,2
FIRMS,1
COMPETITION,1
SPILLOVERS,1
PROTECTION,1
Patent System,2
Intellectual Property,2
ASEAN,1
Harmonization of IP System,4
ARIPO,1
OAPI,1
,1
Design right,2
Design patent,2
Repair clause,2
Law of one price,4
Price dispersion,2
European car market,3
Automotive aftermarket,2
Spare parts,2
PRODUCT DESIGN,2
INDUSTRIALDESIGN,1
EUROPEAN DESIGN,2
LAW,1
INNOVATIONS,1
PATENTS,1
CONVERGENCE,1
COPYRIGHT,1
LESSONS,1
MARKET,1
Competition,1
Intellectual property,2
Randomcoefficient logit demand,3
Patent,1
Smartphones,1
MONOPOLY,1
EQUILIBRIUM,1
PERSISTENCE,1
INNOVATION,1
DEMAND,1
genetic resources,2
source disclosure,2
patent law,2
game theory,2
mandatory model,2
volun,1
tary model,2
patent applications,2
regulatory bodies,2
cost benefit perspective,3
INFORMATION,1
Biomaterials,1
Chitin,1
Chitosan,1
Patent,1
Patentology,1
NANOPARTICLES,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INCOMPLETE CONTRACTS,2
PROTECTION,1
INNOVATION,1
TRADE,1
QUALITY,1
LEVEL,1
WEAK,1
Innovation,1
Institutions,1
Patent enforcement,2
Unconditional quantile regression,3
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
ABSORPTIVECAPACITY,1
TECHNOLOGICALCHANGE,1
DOMESTIC INNOVATION,2
NATIONAL SYSTEMS,2
COUNTRIES,1
IMPACT,1
tacit knowledge,2
basic research,2
localization,1
knowledge diffusion,2
Singapore,1
PATENT CITATIONS,2
TRIPLEHELIX,1
SPILLOVERS,1
GEOGRAPHY,1
INNOVATION,1
FLOWS,1
US,1
,1
PROPERTYRIGHTS,1
PATENT,1
ECONOMY,1
HISTORY,1
MARKET,1
Firm innovation,2
Debt covenants,2
Covenant strictness,2
Patent filings,2
Patents,1
RESEARCHANDDEVELOPMENT,1
ABSORPTIVECAPACITY,1
PROJECT SELECTION,2
AGENCY COSTS,2
DEBT,1
CONTRACTS,1
MARKET,1
DETERMINANTS,1
PRIVATE,1
QUALITY,1
,1
INTELLECTUAL PROPERTY,2
ASSIGNMENT,1
SMEs,1
Mechanical industry,2
Patent family,2
Patent quality,2
Sales performance,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
STRATEGIC MANAGEMENT,2
INTANGIBLE ASSETS,2
MARKET VALUE,2
INNOVATION,1
IMPACT,1
PRODUCTIVITY,1
EXPLORATION,1
INDICATORS,1
product information label,3
energy efficiency labeling system,4
technological progress,2
patent data,2
INNOVATION,1
POLICIES,1
GROWTH,1
Patent,1
Examination duration,2
Grant,1
Withdrawal,1
Refusal,1
Intellectual property right IPR,4
Survival analysis,2
Competing risks,2
State intellectual property office SIPO,5
China,1
STRATEGIC MANAGEMENT,2
INNOVATION,1
PROTECTION,1
OFFICE,1
INDICATORS,1
DATABASE,1
IMPACT,1
D23,1
G24,1
L26,1
O34,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INNOVATION EVIDENCE,2
SCOPE,1
PROTECTION,1
QUALITY,1
POLICY,1
,1
DNA PATENTS,2
PROVISION,1
MYRIAD,1
International RD funding,3
Patent collateral,2
RDbased growth model,3
Optimal patent protection,3
ENDOGENOUS GROWTH,2
POLICY,1
INVESTMENT,1
SCALE,1
Financing constraints,2
Firm innovation,2
Patents,1
RD,1
PANELDATA,1
DEVELOPMENT INVESTMENTS,2
CASH FLOW,2
EQUITY,1
SENSITIVITY,1
PROTECTION,1
SIGNALS,1
IMPACT,1
patent law,2
knowledge governance,2
gender,1
women,1
STEM,1
INTELLECTUAL PROPERTY,2
SEXDIFFERENCES,1
SCIENCE,1
WOMEN,1
FEMINISM,1
LAW,1
TECHNOLOGY,1
ECONOMICS,1
INVENTION,1
EQUALITY,1
Patent indicators,2
standard essential patents SEPs,4
technological innovation,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
PATENT LITIGATION,2
KNOWLEDGE,1
MARKET,1
PERFORMANCE,1
SPEED,1
DETERMINANTS,1
DIVERSITY,1
CITATION,1
Patent disclosure,2
Innovation,1
Spillovers,1
Proprietary costs,2
Corporate disclosure,2
PUBLICATION,1
PROPRIETARY,1
INFORMATION,1
DIFFUSION,1
ECONOMICS,1
SHOULDERS,1
GIANTS,1
MARKET,1
,1
,1
Pharmaceutical patent,2
public health,2
COVID19 vaccines,2
compulsory licence,2
government use,2
Patents and Designs Act,4
,1
,1
RESEARCHANDDEVELOPMENT,1
INCENTIVES,1
PATENTS,1
,1
,1
Diffusion,1
innovation,1
military technology,2
patents,1
generalpurpose technologies,2
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
UNITEDSTATES,1
PATENT CITATIONS,2
PEACEDIVIDEND,1
INNOVATION,1
COINTEGRATION,1
Data panel model,3
Big data,2
Innovation performance,2
INVESTMENT,1
COMPLEMENTARITY,1
BEHAVIOR,1
GROWTH,1
FIRMS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
MARKETSTRUCTURE,1
INNOVATION,1
ECONOMICS,1
POOLS,1
COMPETITION,1
PHARMACEUTICALS,1
PRODUCTIVITY,1
PROTECTION,1
Patent families,2
Foreignoriented families,2
Patent family size,3
INNOVATION,1
Innovation,1
RD,1
Patents,1
Regulation,1
Standardization,1
Globalization,1
PRODUCT MARKET REGULATION,3
EMPIRICALEVIDENCE,1
ENVIRONMENTALREGULATION,1
TRADE,1
IMPACT,1
PATENTS,1
PERFORMANCE,1
COMPETITION,1
GOVERNANCE,1
MOTIVES,1
Person of ordinary skill in the art,7
Components listed in the claims,5
Equivalent infringement,2
Convenience of composition change,4
Trial for confirmation of the scope of patent right,9
Scope of protection,3
,1
Intellectual property rights,3
Patent law,2
Gravity model,2
Bilateral trade,2
F14,1
F15,1
O34,1
TECHNOLOGY,1
PROTECTION,1
VARIETY,1
GRAVITY,1
RIGHTS,1
IMPACT,1
Patents,1
Peer effects,2
Director networks,2
Innovation,1
India,1
Natural experiments,2
RESEARCHANDDEVELOPMENT,1
PATENT CITATIONS,2
FIRM INNOVATION,2
BUSINESS GROUPS,2
MARKET VALUE,2
SPILLOVERS,1
MATTER,1
Patent deployment strategies,3
Appropriability strategy,2
Biform model,2
INTELLECTUAL PROPERTY,2
MARKET,1
APPROPRIABILITY,1
MANAGEMENT,1
PROTECTION,1
INNOVATION,1
IDEAS,1
FIRM,1
DETERMINANTS,1
COMPETITION,1
,1
INTELLECTUAL PROPERTY,2
CIRCUIT,1
JUDICIARY,1
ECONOMICS,1
LAW,1
agriculture,1
biotechnology patents,2
food security,2
Iraqi Patent Law 65l1970,4
Order 812004,2
TRIPs Agreement,2
,1
Social credit,2
Patent quality,2
Knowledge breadth,2
Missionary university,2
Innovation incentive,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY PROTECTION,3
ECONOMICGROWTH,1
INNOVATION,1
TRUST,1
CONSTRAINTS,1
COMPETITION,1
PERFORMANCE,1
TOLERANCE,1
DIVERSITY,1
Environmental risk,2
Intellectual property rights,3
Nanotechnology,1
Patents,1
Regulations,1
World Intellectual Property Organization WIPO,5
Nanopesticide,1
Nanosensor,1
FOOD,1
NANOPARTICLES,1
INNOVATION,1
PATENTS,1
TRENDS,1
ISSUES,1
RISK,1
biotechnology industry,2
vertical contract,2
arbitration agreements,2
patent clearinghouse,2
L14,1
Q16,1
INTELLECTUAL PROPERTY PROTECTION,3
INCENTIVES,1
ACCESS,1
,1
,1
,1
INTELLECTUAL PROPERTY,2
ASSERTION ENTITIES,2
ROYALTY STACKING,2
INNOVATION,1
MARKET,1
WORLD,1
TECHNOLOGY,1
ADVANTAGE,1
STANDARDS,1
QUALITY,1
Digital transformation,2
Copyright,1
Patents,1
Intellectual property rights,3
,1
sustainable technology innovation,3
patent risk,2
analytic hierarchy process,3
entropy method,2
international trade,2
BUSINESS MODEL INNOVATION,3
LITIGATION,1
DECISION,1
FIRMS,1
MANAGERS,1
CONTEXT,1
AHP,1
Patent length,2
Innovation,1
Delay differential equation,3
Advance differential equation,3
Dynamics,1
Endogenous growth,2
Relaxation algorithm,2
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
BLOCKING PATENTS,2
PROTECTION,1
DYNAMICS,1
INVESTMENT,1
INNOVATION,1
ECONOMICS,1
LIFE,1
appropriability,1
entrepreneurship,1
experimentation,1
learning,1
software,1
TRADE SECRETS,2
INNOVATION EVIDENCE,2
ENTREPRENEURIAL,1
PATENTS,1
TECHNOLOGIES,1
STRATEGIES,1
BUSINESS,1
IMPACT,1
ENTRY,1
communication technology ICT,3
decomposition analysis,2
patent application,2
economic indicator,2
Logarithmic Mean Divisia Index,4
RESEARCHANDDEVELOPMENT,1
OECD COUNTRIES,2
CO2 EMISSIONS,2
ENERGY USE,2
MANUFACTURING SECTOR,2
TECHNOLOGICALCHANGE,1
INDUSTRY STRUCTURE,2
PATENT PROTECTION,2
RENEWABLE ENERGY,2
PROPERTYRIGHTS,1
France,1
Industrial property,2
PACTE law,2
More efficient procedures,3
More progressive offer,3
,1
firm performance,2
GDPR,1
innovation,1
patenting,1
privacy regulation,2
PROTECTION,1
INNOVATION,1
,1
INTELLECTUAL PROPERTY,2
TRADE SECRETS,2
HUMANGENOME,1
LAW,1
ECONOMICS,1
PROTECTION,1
SEARCH,1
SCOPE,1
ASSOCIATION,1
COMPETITION,1
Pharmaceuticals,1
Secondary patents,2
Section 3d,2
Prior Consent,2
TRIPS,1
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPINGCOUNTRIES,1
DRUG PATENTS,2
INNOVATION,1
PROTECTION,1
LAW,1
Intellectual property regimes,3
Wage inequality,2
Hightech and lowtech firms,4
Managerial compensation,2
 Snailshape Patent race,4
PRODUCT MARKET COMPETITION,3
RESEARCHANDDEVELOPMENT,1
TRADE LIBERALIZATION,2
MANAGEMENTPRACTICES,1
TECHNOLOGYTRANSFER,1
INFORMATIONTECHNOLOGY,1
ECONOMICPERFORMANCE,1
INDUSTRIALSTRUCTURE,1
PATENT PROTECTION,2
SKILL PREMIUM,2
remanufacturing,1
closedloop supply chain,3
design for remanufacturing,3
coopetition,1
COMPETITION,1
QUALITY,1
PRODUCT,1
Innovation,1
Patents,1
Geographic isolation,2
Travel time,2
Trade secrecy,2
FACETOFACE,1
HYBRID CORN,2
KNOWLEDGE SPILLOVERS,2
LOCAL SEARCH,2
TECHNOLOGY,1
FIRM,1
AGREEMENTS,1
ECONOMICS,1
MOBILITY,1
DETERMINANTS,1
Patent valuation,2
Multiple criteria decision making,4
Analytical hierarchy process,3
Fuzzy,1
Patent value measurement system,4
RESEARCHANDDEVELOPMENT,1
INDICATORS,1
STRATEGIES,1
INNOVATION,1
SYSTEM,1
AHP,1
biotechnology,1
patentability requirements,2
European patent,2
unitary patent,2
Directive 9844,2
Regulation 12572012,2
harmonization,1
,1
Patents,1
steel,1
seismic protection,2
antiseismic buildings,2
earthquakes,1
,1
Right to Health,3
Pharmaceutical Patents,2
Covid19,1
Pandemic,1
TRIPS,1
,1
Intellectual property,2
Patents,1
Appropriability,1
Entrepreneurship,1
Knowledge intensive firms,3
Gender,1
Founding teams,2
AEGIS survey,2
VENTURE PERFORMANCE,2
BIG SECRETS,2
INNOVATION,1
PATENT,1
FIRMS,1
DIVERSITY,1
GENDER,1
GROWTH,1
ENTREPRENEURSHIP,1
PROPENSITY,1
,1
RIGHTS,1
big push,2
intellectual property rights,3
technological change,2
PATENT PROTECTION,2
INDUSTRIALIZATION,1
COVID19,1
Vaccine,1
Patent waiver,2
TRIPS,1
Compulsory licensing,2
Intellectual property rights,3
EXTERNALITIES,1
JUSTIFICATION,1
EPO patents,2
export volumes,2
EU,1
GERD,1
internationalization,1
social models,2
RESEARCHANDDEVELOPMENT,1
PATENT RIGHTS,2
DEVELOPMENT INVESTMENTS,2
TRADE,1
PERFORMANCE,1
FIRMS,1
PROTECTION,1
ADVANTAGE,1
BEHAVIOR,1
GROWTH,1
Patent protection,2
Pricing decision,2
Remanufacturing degree,2
Remanufacturing management,2
LOOP SUPPLY CHAIN,3
STRATEGY,1
COORDINATION,1
MARKET,1
COMPETITION,1
DECISIONS,1
IMPACT,1
infringement disputes,2
innovation investment persistence,3
intellectual property protection,3
PATENT PROTECTION,2
RIGHTS,1
Environmental regulation,2
Ecoinnovation,1
Green patents,2
Differenceindifferences,1
TECHNOLOGY,1
INCENTIVES,1
Supply chain management,3
Remanufacturing,1
Patented product,2
Technology licensing,2
COMPETITION,1
DECISIONS,1
,1
RESEARCHANDDEVELOPMENT,1
MARKET VALUE,2
TECHNOLOGY,1
INDICATORS,1
CITATIONS,1
INDUSTRY,1
OPPOSITION,1
DYNAMICS,1
DRIVERS,1
EUROPE,1
Civil society,2
gene therapy,2
Kymriah,1
patent opposition,2
public health,2
,1
patent application,2
divisional patent application,3
division of patent application,4
Indian patent law,3
,1
marketing history,2
brand marketing,2
patent medicines,2
trademark protection,2
global marketing,2
,1
Homeopathy,1
Homeopathic medicines,2
Pharmacy,1
Property Intellectual,2
Patents,1
,1
Artificial intelligence,2
Industrial property indicators,3
Patents,1
Intellectual property,2
,1
,1
,1
National innovative capacity,3
International trade,2
Foreign direct investment,3
Intellectual property,2
Patents,1
TECHNOLOGY DIFFUSION,2
ECONOMICGROWTH,1
PRODUCTIVITY,1
ENTERPRISES,1
PROTECTION,1
COUNTRIES,1
FIRM,1
carbon neutrality,2
carbon capture,2
carbon utilization,2
carbon storage,2
CCUS,1
patent bibliometric analysis,3
CYCLIC CARBONATES,2
CO2 CAPTURE,2
EVOLUTION,1
Intellectual Property Rights,3
KORUSFTA,1
Drug approvalpatent linkage system,4
TRIPS,1
Pharmaceuticals,1
PROTECTION,1
INNOVATION,1
INDUSTRY,1
,1
,1
,1
INTERNATIONAL ECONOMICLAW,2
INTELLECTUAL PROPERTY,2
PUBLICHEALTH,1
GLOBAL GOVERNANCE,2
DOHA DECLARATION,2
FREETRADE,1
WTO,1
WORLD,1
AGREEMENT,1
DISPUTES,1
Patents,1
Litigations,1
LED,1
Lighting,1
Ecoinnovation,1
Barriers,1
PROTECTION,1
INNOVATION,1
TROLLS,1
FIRMS,1
TECHNOLOGY,1
CITATIONS,1
NETWORK,1
SCIENCE,1
MARKETS,1
FUEL,1
developing countries,2
Global South,2
patents,1
plants,1
seed,1
PATENTABILITY,1
TECHNOLOGY,1
PROTECTION,1
GENE,1
Patents,1
Intellectual property rights,3
Patent stock,2
Diversification of procedural and administrative cost,6
PATENT PROTECTION,2
MATRIX ESTIMATOR,2
GROWTH,1
PANEL,1
ENTREPRENEURSHIP,1
DETERMINANTS,1
QUALITY,1
MODELS,1
RIGHTS,1
RULES,1
,1
INTELLECTUAL PROPERTY,2
TRADE DRESS,2
COPYRIGHT,1
PATENT,1
PROTECTION,1
CREATIVITY,1
COSTS,1
INNOVATION,1
SYSTEMS,1
NORMS,1
,1
PHARMACEUTICALS,1
COMPETITION,1
EXCLUSIVITY,1
MORTALITY,1
INDUSTRY,1
DRUGS,1
employee mobility,2
innovation,1
IPR protection,2
multinational,1
R D,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
RENTSEEKING,1
HOME BIAS,2
INTEGRATION,1
COUNTRIES,1
POLICY,1
RACE,1
LAWS,1
Patentee impact,2
Heterogeneous patent innovation network,4
CWAPN,1
Chinese green patents,3
Energy field,2
INDEX,1
International patenting network IPN,4
Market covering,2
Competitive threat,2
Temporal exponential random graph model,5
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
FOREIGN FIRMS,2
TRADE,1
TECHNOLOGY,1
PROTECTION,1
CHINA,1
GLOBALIZATION,1
DETERMINANTS,1
PERFORMANCE,1
patent analysis,2
patent pattern,2
substances of medicine food homology,5
traditional Chinese medicine,3
,1
,1
PROTECTION,1
LAW,1
Knowledge transfer,2
Globalization,1
Patent management,2
General electric,2
Siemens,1
Patent management,2
KNOWLEDGE TRANSFER,2
PROTECTION,1
TECHNOLOGY,1
ASSETS,1
University patent,2
universityindustry relations,2
technology transfer,2
commercialisation,1
INSTITUTIONAL FACTORS,2
KNOWLEDGE TRANSFER,2
SCIENTISTS,1
ENTREPRENEURSHIP,1
PORTUGAL,1
SCIENCE,1
EUROPE,1
GROWTH,1
UK,1
Patent maps,2
Chinese offshore wind power,4
Key technology,2
International Patent Classification,3
ENERGY,1
INNOVATION,1
EUROPE,1
SYSTEM,1
Rare earth elements,3
Patent,1
Text mining,2
Topic detection,2
Quadratic assignment procedure QAP,4
Patent network analysis,3
Association rule,2
TECHNOLOGY,1
TRIPS,1
TRIPSPlus,1
pharmaceuticals,1
drugs,1
patents,1
prices,1
INTELLECTUAL PROPERTYRIGHTS,2
TRANSPACIFIC PARTNERSHIP,2
PUBLICHEALTH,1
AGREEMENTS,1
ACCESS,1
INNOVATION,1
COSTS,1
FLEXIBILITIES,1
EXCLUSIVITY,1
PROTECTION,1
,1
RIGHTS,1
Patent intelligence,2
Patentometrics,1
Claim analysis,2
Forward citations,2
Technological scope,2
Textmining analysis,2
VALUEAPPROPRIATION,1
EMPIRICALANALYSIS,1
TECHNOLOGY,1
CONVERGENCE,1
PERFORMANCE,1
Patents,1
Knowledge,1
Industrial property,2
Intellectual property,2
Inventors,1
INNOVATION,1
Eventstudy,1
Stock price effects,3
Patent oppositions,2
IPR,1
AIA,1
PTAB,1
,1
green innovation,2
Chinese green patents,3
heterogeneous network,2
age bias,2
JOURNAL IMPACT,2
PERFORMANCE,1
MECHANISM,1
SEARCH,1
BIAS,1
patent researches,2
scientific and technical development,4
object of economic activity,4
databases,1
medical and biological sciences,4
research institution,2
universities,1
,1
,1
RESEARCHANDDEVELOPMENT,1
TECHNOLOGY VENTURES,2
EMPIRICALEVIDENCE,1
PRODUCT,1
PERFORMANCE,1
CHINA,1
INDICATORS,1
BUSINESS,1
STRATEGY,1
ORGANIZATIONS,1
Nanobiotechnology,1
Patents,1
Zika virus,2
Technological prospection,2
Innovation,1
Emerging technologies,2
ARBOVIRUSES,1
OUTBREAK,1
,1
,1
Digital government,2
Innovation,1
Intellectual property rights protection,4
,1
Patent,1
China,1
SEP,1
Antitrust,1
Patent law,2
COUNTERFEITING TRADE AGREEMENT,3
TEXT,1
,1
,1
Technological resilience,2
technological crisis,2
patent,1
KNOWLEDGE NETWORKS,2
COLLABORATION,1
INNOVATION,1
SCIENCE,1
SYSTEMS,1
SIZE,1
PERSPECTIVE,1
PERFORMANCE,1
DIVERSITY,1
CAPACITY,1
genome editing,2
CRISPRCas9 technology,2
legal regulation,2
EU legislation,2
US legislation,2
international law,2
patents,1
FUTURE,1
CROPS,1
BIOTECHNOLOGY,1
,1
FECAL MICROBIOTA TRANSPLANTATION,3
CLOSTRIDIUMDIFFICILE INFECTION,2
INTELLECTUAL PROPERTY NORMS,3
INNOVATION,1
BURDEN,1
INCREASE,1
IMPACT,1
DRUGS,1
FIRMS,1
,1
FIXEDDOSE COMBINATIONS,2
MIDDLEINCOME,1
DISEASE,1
PREVENTION,1
MEDICINES,1
ACCESS,1
REDUCE,1
Crossborder acquisitions,2
Equity ownership,2
Preemptive power,2
International patenting,2
Signaling theory,2
INTELLECTUAL PROPERTYRIGHTS,2
JOINT VENTURES,2
REAL OPTIONS,2
OWNERSHIP STRATEGIES,2
GEOGRAPHIC DISTANCE,2
DETERMINANTS,1
KNOWLEDGE,1
MARKET,1
PERFORMANCE,1
GOVERNANCE,1
Patent,1
Index,1
Pharmaceuticals,1
Intellectual property,2
TRIPS,1
PATENTS,1
COSTS,1
TECHNOLOGY,1
PROTECTION,1
Intellectual property rights,3
Patent,1
RD,1
Sequential innovation,2
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
PROTECTION,1
INVESTMENT,1
MECHANISMS,1
TRANSITION,1
IMITATION,1
COUNTRIES,1
DIVISION,1
INCREASE,1
Patents,1
copyrights,1
trademarks,1
intellectual property,2
SBIR program,2
program evaluation,2
technology,1
,1
,1
PATENTS,1
INVENTION,1
REVOLUTION,1
Intellectual property,2
Differential pricing,2
Compulsory licensing,2
Pharmaceutical demand estimation,3
Indian pharmaceutical market,3
DISCRETECHOICE MODELS,2
EUROPEAN CAR MARKET,3
PHARMACEUTICALINDUSTRY,1
PRICE CONTROLS,2
POLITICAL PRESSURE,2
PATENT PROTECTION,2
ENTRY,1
ACCESS,1
DRUGS,1
TRIPS,1
Sustainable green technology,3
Patent data,2
Decomposition analysis,2
China,1
ENVIRONMENTAL TECHNOLOGY,2
ENERGY,1
INNOVATION,1
JAPAN,1
innovation,1
innovative organizations,2
intellectual property,2
rights,1
patents,1
,1
Drugs,1
Patent protection,2
Generics,1
Drug labels,2
,1
computerimplemented inventions,2
computer programs,2
patent,1
copyright,1
status quo,2
,1
Intellectual property rights,3
Innovation,1
Non linear relationship,3
Economic development,2
Emerging,1
Developing countries,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
INVESTMENT,1
GROWTH,1
Hops,1
Humulus lupulus,2
Cultivar,1
Plant breeders right,3
Plant variety rights,3
Plant patent,2
TRANSFORMATION,1
EXPRESSION,1
GENE,1
intellectual property,2
patent,1
trade secret,2
innovations,1
oil and gas industry,4
,1
,1
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
SUPPLIER INVOLVEMENT,2
ABSORPTIVECAPACITY,1
PRODUCT DEVELOPMENT,2
DOMESTIC FIRMS,2
MARKET,1
SPILLOVERS,1
PERFORMANCE,1
INNOVATION,1
Intellectual property rights protection,4
Panel data,2
Asian developing countries,3
Patent law,2
F42,1
K42,1
O34,1
O38,1
O57,1
INTERNATIONALTRADE,1
STRATEGIC MANAGEMENT,2
PATENT MANAGEMENT,2
ECONOMICGROWTH,1
IMPACT,1
INNOVATION,1
INVESTMENT,1
ENFORCEMENT,1
TECHNOLOGY,1
STRENGTH,1
traditional knowledge,2
intellectual property rights,3
patent,1
copyright,1
TRIPS,1
,1
Patent licensing,2
knowhow,1
trademarks,1
technology contracts,2
Brazil,1
OD32,1
D23,1
L24,1
RESEARCHANDDEVELOPMENT,1
TACIT KNOWLEDGE,2
MARKET,1
SCOPE,1
INFORMATION,1
COMPETITION,1
PROTECTION,1
ECONOMICS,1
INDUSTRY,1
TRADE,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
PARAGRAPH 6 SYSTEM,3
PUBLICHEALTH,1
TRADE,1
WTO,1
BIOSIMILARS,1
PROTECTION,1
POLITICS,1
CANADA,1
DRUGS,1
,1
PHARMACEUTICALINDUSTRY,1
INTELLECTUAL PROPERTY,2
EMPIRICALEVIDENCE,1
MARKETSIZE,1
INNOVATION,1
PROTECTION,1
RIGHTS,1
NorthSouth trade,2
imitation,1
intellectual property rights protection,4
national treatment,2
world welfare,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
NATIONAL TREATMENT,2
INNOVATION,1
PRODUCT,1
TRADE,1
IMITATION,1
GROWTH,1
standardessential patents,2
technical standards,2
good faith,2
FRAND,1
injunction,1
standardization,1
sustainability,1
technological resource,2
,1
Intellectual Property Rights,3
Multinationals,1
Knowledge spillovers,2
Competition effects,2
Pecuniary externalities,2
FDI,1
FOREIGN DIRECTINVESTMENT,2
RESEARCHANDDEVELOPMENT,1
PATENT RIGHTS,2
TECHNOLOGYTRANSFER,1
DOMESTIC FIRMS,2
LOCALPARTICIPATION,1
2 FACES,2
SPILLOVERS,1
PROTECTION,1
MULTINATIONALS,1
intellectual property rights,3
Open source software,3
firm value,2
PRIVATECOLLECTIVE INNOVATION,2
TOBINSQ,1
STRATEGIES,1
COMMUNITY,1
PATENTS,1
ORGANIZATION,1
PERFORMANCE,1
GOVERNANCE,1
COMPANIES,1
BUSINESS,1
Economic openness,2
domestic patent application,3
international technology innovation,3
AsiaPacific region,2
FOREIGN DIRECTINVESTMENT,2
INTELLECTUAL PROPERTYRIGHTS,2
PANELDATA,1
FIRMS,1
PRODUCTIVITY,1
FDI,1
PERFORMANCE,1
SPILLOVERS,1
COOPERATION,1
COMPETITION,1
Art,1
copyright,1
Ifa,1
Nigeria,1
patents,1
science,1
trade secrets,2
Yoruba philosophy,2
,1
health,1
industry,1
Intellectual Property Law,3
patents,1
,1
language translation,2
translation difficulty,2
polysemous words,2
international patenting,2
cultural context,2
INTERNATIONALBUSINESS RESEARCH,2
MACHINE TRANSLATION,2
KNOWLEDGE,1
PERSPECTIVE,1
INDICATORS,1
CAPACITY,1
Biotechnology market,2
Emerging and neglected diseases,4
Sustainable Development Goals,3
Regulation and patents,3
Vaccine innovation system,3
TECHNOLOGIES,1
ACCESS,1
BRAZIL,1
Technology transfer,2
Technology licensing,2
Patents,1
Imitation,1
Consumer surplus,2
RESEARCHANDDEVELOPMENT,1
PATENT BREADTH,2
COMPETITION,1
PROTECTION,1
INNOVATION,1
ECONOMICS,1
CONTRACT,1
POLICY,1
FEES,1
Innovation,1
Quality,1
Pharmaceuticals,1
Originality,1
Patents,1
O31,1
O30,1
L65,1
,1
Global norm,2
National treatment,2
Patent pendency,2
Patent system,2
Patent granting,2
Patent uncertainty,2
Institutions,1
INTELLECTUAL PROPERTY,2
INSTITUTIONS,1
MARKET,1
TRADE,1
MULTILATERALISM,1
PROTECTION,1
AGREEMENTS,1
INVENTION,1
PRODUCT,1
OFFICE,1
intellectual property,2
constitutions,1
constitutional protection,2
human rights,2
patents,1
access to medicines,3
Islamic law,2
Egypt,1
Tunisia,1
Arab Spring,2
globalization,1
postcolonialism,1
PATENTS,1
ACCESS,1
EGYPT,1
LAW,1
Innovation,1
patents,1
keywordbased,1
energybased,1
problemsolving,1
TECHNOLOGY,1
TRIZ,1
TRENDS,1
patent citation network,3
green industry,2
evolution characteristics,2
social network analysis,3
exponential random graph model,4
KNOWLEDGE,1
IDENTIFICATION,1
MANAGEMENT,1
INNOVATORS,1
INDUSTRIAL,1
COUNTS,1
LIGHT,1
US,1
johnson  johnson,3
mycobacterium tuberculosis mtb,3
patent,1
extensively drug resistant xdr,4
mdrtb multi drug resistant tuberculosis,5
tuberculosis,1
bedaquiline,1
,1
,1
SUPREMECOURT,1
CHEVRON,1
OFFICE,1
FOUNDATIONS,1
QUESTIONS,1
STANDARDS,1
SHADOW,1
RULES,1
PTO,1
European Union,2
market protection,2
patenting,1
pharmaceuticals,1
,1
intellectual property,2
marketing,1
ornamental plants,2
VARIETY PROTECTION,2
QUALITY,1
TESTS,1
Patent grant,2
Interpretable machine learning,3
Predictive models,2
EMERGING TECHNOLOGIES,2
KNOWLEDGE SPILLOVERS,2
MARKET,1
US,1
CLASSIFICATION,1
INNOVATION,1
ECONOMICS,1
OUTCOMES,1
OFFICE,1
SCOPE,1
Innovation,1
Research and development,3
Patent,1
Profitability,1
PANELDATA,1
PERFORMANCE,1
COMPETITION,1
SPILLOVERS,1
GROWTH,1
data,1
intellectual property protection,3
trade secrecy,2
registration,1
PATENTS,1
INNOVATION,1
RIGHTS,1
DIFFUSION,1
Manufacturing,1
Intellectual property rights,3
Innovation,1
System GMM,2
O14,1
O34,1
O31,1
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
RIGHTS,1
PROTECTION,1
INNOVATION,1
INVESTMENTS,1
SPILLOVERS,1
PATENTS,1
GMM,1
Phytochemicals,1
Pharmacology,1
Clinical application,2
Patents and products,3
Amomi fructus,2
LEAF SENESCENCE,2
VILLOSUM,1
MEDICINE,1
CELLS,1
STIMULATION,1
EXTRACTION,1
SECRETION,1
INTESTINE,1
FORMULA,1
CHINA,1
Value mapping,2
Patent documents,2
Patenting,1
Synthetic biology,2
Private value,2
Public value,2
INDICATORS,1
SCIENCE,1
CONTROVERSY,1
PROTECTION,1
CITATIONS,1
EMERGENCE,1
INSIGHTS,1
SYSTEMS,1
UK,1
futuretime reference,2
languages,1
patent citations,2
patent counts,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
MARKET VALUE,2
CORPORATE,1
COMPETITION,1
IMPACT,1
PANEL,1
CEOS,1
CONSTRAINTS,1
patent protection,2
rewardpenalty policy,2
remanufacturing,1
closedloop supply chain CLSC,4
waste collection,2
LOOP SUPPLY CHAIN,3
STRATEGY,1
Patentintensive industry,2
green innovation efficiency,3
configuration paths,2
fsQCA method,2
,1
complementarities,1
firm startups,2
intellectual property,2
outlicensing,1
performance,1
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
MANUFACTURING FIRMS,2
PRODUCT INNOVATION,2
TRADE MARKS,2
PATENTS,1
RIGHTS,1
COPYRIGHT,1
COMPLEMENTARITY,1
APPROPRIABILITY,1
Competitiveness,1
Intellectual property,2
Relative Specialization Index RSI,4
Innovation,1
Patents,1
Universities,1
RIGHTS,1
INNOVATION,1
PROTECTION,1
GROWTH,1
IMPACT,1
Intellectual property rights,3
Foods,1
Beverages,1
Patents,1
Copyright,1
Trademarks,1
Industrial designs,2
Trade secrets,2
Geographical indications,2
,1
multinational firms,2
patents,1
preferential trade agreements,3
outsourcing,1
subcontracting,1
EMPIRICALEVIDENCE,1
PATENT RIGHTS,2
PROTECTION,1
CREATION,1
FIRMS,1
LABOR,1
RD,1
information leakage,2
secrecy,1
informal IPR,2
innovationbased growth,2
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
PATENT PROTECTION,2
INNOVATION,1
IMITATION,1
Intellectual property,2
patents on agrobiotechnology,3
plant variety protection,3
seed laws,2
subSaharan Africa,2
accumulation by dispossession,3
PLANT VARIETY PROTECTION,3
INTELLECTUAL PROPERTY,2
POLITICALECONOMY,1
SECTOR DEVELOPMENT,2
FARMERS RIGHTS,2
COTTON,1
FOOD,1
BREEDERS,1
KNOWLEDGE,1
SYSTEMS,1
Intellectual property rights,3
Bank loans,2
PATENT PROTECTION,2
CREDITOR RIGHTS,2
LAWS,1
INNOVATION,1
DETERMINANTS,1
MARKET,1
LIFE,1
,1
PURE THEORY,2
PATENTS,1
INNOVATION,1
Patents,1
innovation,1
GDP per capita,3
economic growth,2
INNOVATION,1
IMPACT,1
COMPETITIVENESS,1
PROTECTION,1
,1
BACTERIOPHAGE,1
THERAPY,1
Green innovation,2
Green credit policy,3
Financial constraints,2
DID model,2
Green patents,2
,1
,1
INNOVATION,1
PROTECTION,1
OFFICE,1
SURGE,1
Bangladesh,1
mailbox patent application,3
TRIPS,1
graduating LDC,2
pharmaceuticals,1
access to medicine,3
HUMANRIGHTS,1
HEALTH,1
PROTECTION,1
FRAMEWORK,1
AGREEMENT,1
TREATIES,1
disclosure,1
knowledge spillover,2
trade secrets,2
patents,1
innovation,1
EDGAR,1
RESEARCHANDDEVELOPMENT,1
LABOR MOBILITY,2
TRADE SECRETS,2
TECHNOLOGICALINNOVATION,1
INFORMATION ASYMMETRY,2
ECONOMICIMPLICATIONS,1
CORPORATE DISCLOSURE,2
MARKET VALUE,2
PATENT,1
DETERMINANTS,1
Evergreening,1
COVID19,1
health technologies,2
SARSCoV2,1
patenting strategies,2
monopoly,1
patent examination,2
,1
,1
,1
economic development,2
economic growth,2
innovationadjusted ECI,2
INSTITUTIONS,1
INDICATORS,1
patent activity,2
objects of intellectual property rights,5
invention activity,2
innovative potential,2
information support,2
and experimental oncology,3
,1
Utility model patents,3
Utility model patent regime strength,5
Utility model patent regime strictness and appropriabilitystrength,7
China,1
East Asian latecomers,3
Catchup strategy,2
INTELLECTUAL PROPERTYRIGHTS,2
PROTECTION,1
INNOVATION,1
IMPACTS,1
INDEX,1
Industrial districts,2
Idistrict effect,2
Technological innovation,2
Patents,1
RESEARCHANDDEVELOPMENT,1
INDUSTRIAL DISTRICTS,2
Innovation,1
Debt financing source,3
Tech bubble burst,3
American Inventors Protection Act AIPA,5
G21,1
G23,1
G28,1
G32,1
INFORMATION,1
INVESTMENT,1
PRIVATE,1
Patent analysis,2
Security vulnerabilities,2
Citation networks,2
Topic modelling,2
Technological influence,2
CITATION NETWORK,2
COCITATION ANALYSIS,2
MARKET VALUE,2
IMPACT,1
INDICATORS,1
KNOWLEDGE,1
concrete structurescorrosionmaintenance,2
inspection,1
CATHODIC PROTECTION,2
patent technology,2
patent roadmap,2
scrapped cars,2
recycling,1
,1
Remanufacturing,1
Patent licensing,2
Product design,2
Price competition,2
COMPETITIVE STRATEGY,2
QUANTITY,1
NETWORK,1
IMPACT,1
hybrid electric vehicles,3
patents,1
technology lifecycle,2
technological innovation,2
technology diffusion,2
Scurve,1
ENERGY MANAGEMENT STRATEGIES,3
PLUGIN HYBRID,2
POWER MANAGEMENT,2
NETWORK ANALYSIS,2
EMISSION,1
SYSTEMS,1
FIELD,1
COMPETITION,1
DIFFUSION,1
MATURITY,1
export,1
FDI,1
GMM,1
intellectual property rights,3
F23,1
O34,1
PATENT RIGHTS,2
INTERNATIONALTRADE,1
DIRECTINVESTMENT,1
DETERMINANTS,1
RD intensity,2
patent portfolio,2
innovation performance,2
regression analysis,2
artificial intelligence enterprise,3
,1
Trade protection,2
Innovation,1
Financial constraint,2
F51,1
O31,1
FINANCIAL CONSTRAINTS,2
POLICY UNCERTAINTY,2
PRODUCTIVITY,1
IMPORTS,1
IMPACT,1
RISK,1
Granted patents,2
higher educational institutions,3
knowledge economy,2
national research laboratories,3
,1
intellectual property law,3
patents,1
claims construction,2
Coase theorem,2
,1
Video games,2
mechanics,1
patents,1
copyright,1
technical problem,2
ideaexpression,1
computerimplemented inventions,2
,1
Certificate of supplementary protection,4
Manufacturing waiver,2
Patent term extension,3
Supplementary protection certificate,3
USFDA,1
,1
,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
Expenditure rate,2
RD,1
Patent race,2
Stochastic control problem,3
HamiltonJacobiBellman equation,2
PATENT PROTECTION,2
STRATEGIES,1
FIRMS,1
MODEL,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
EMPIRICALEVIDENCE,1
EXPERIMENTAL TESTS,2
CONTROLLEDTRIALS,1
EX ANTE,2
INNOVATION,1
PROTECTION,1
POLICY,1
LAW,1
patents,1
Chile,1
nineteenth century,2
renewable energy sources,3
,1
abacavir base,2
abacavir sulfate,2
neutral and acid salts,4
sulfate,1
hemisulfate,1
protonation,1
pKa,1
patenting,1
xray diffraction analysis,3
atomic formula,2
molecular weight,2
active pharmaceutical substance APS,4
patent claim,2
Ziagen,1
registration,1
FDA USP,2
,1
Additive manufacturing,2
Strategic management,2
Service operations,2
Spare parts,2
Patent law,2
Digital businesses,2
INTELLECTUAL PROPERTY,2
OPERATIONS MANAGEMENT,2
CRITICALITY,1
distributional fairness,2
patents,1
pharmaceutical products,2
WTO,1
DEVELOPINGCOUNTRIES,1
TRADE NEGOTIATIONS,2
PROTECTION,1
INNOVATION,1
ACCESS,1
RIGHTS,1
academic patenting,2
intellectual property courses,3
technology transfer,2
university patenting,2
PATENT LIFE,2
Intellectual property,2
Digital innovation,2
Triple difference,2
China,1
RIGHTS,1
Patent,1
Policy change,2
Litigation,1
US,1
LITIGATION,1
EBAY,1
cash holdings,2
innovation,1
institutional environment,2
patent box,2
RD tax credit,3
repatriation tax,2
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
CORPORATE GOVERNANCE,2
DETERMINANTS,1
INVESTMENT,1
PROTECTION,1
VALUATION,1
LOCATION,1
TAXATION,1
FINANCE,1
Adverse selection,2
Appropriability problem,2
Blackmail,1
Patents,1
ECONOMICANALYSIS,1
PROPERTYRIGHTS,1
Technological innovation,2
Investment,1
Uncertainty,1
Patents,1
Intellectual property,2
Cultural differences,2
Globalization,1
Firm performance,2
institutionbased view,2
metaanalysis,1
national culture,2
technological innovation,2
RESEARCHANDDEVELOPMENT,1
PRODUCT DEVELOPMENT PERFORMANCE,3
INTELLECTUAL PROPERTYRIGHTS,2
ORGANIZATIONAL PERFORMANCE,2
DEVELOPMENT INVESTMENT,2
FINANCIAL PERFORMANCE,2
MANAGEMENTPRACTICES,1
MARKET PENETRATION,2
PATENT PROTECTION,2
NATIONAL CULTURE,2
Pharmaceutical innovation,2
Parallel imports,2
Price regulation,2
Research  Development,3
Patent length,2
TRADE,1
DEMAND,1
MARKET,1
DISCRIMINATION,1
COMPETITION,1
PROTECTION,1
EXHAUSTION,1
QUALITY,1
HEALTH,1
IMPACT,1
proprietary costs,2
RDactive firms,2
singlelender financing,2
American Inventors Protection Act,4
financing innovation,2
PRODUCTMARKET COMPETITION,2
CORPORATE DISCLOSURE,2
ACCOUNTING INFORMATION,2
PATENT PUBLICATION,2
EARNINGS QUALITY,2
CREDITOR RIGHTS,2
PRIVATE,1
INCENTIVES,1
INVESTMENT,1
INNOVATION,1
right of priority,3
patents,1
Paris convention,2
European Patent Convention,3
TRIPS,1
applicable law,2
,1
Transport development and innovation,4
Transport governance,2
Transport management,2
Intellectual property rights protection,4
Economic agglomeration,2
Yangtze River Delta region,4
RESEARCHANDDEVELOPMENT,1
PUBLIC TRANSPORT,2
INFRASTRUCTURE INVESTMENT,2
ECONOMICBENEFITS,1
PATENT RIGHTS,2
TRADE,1
GOVERNANCE,1
AGGLOMERATION,1
COMPETITION,1
OWNERSHIP,1
additive technologies,2
3D printing,2
patent protection,2
patent review,2
selective laser melting,3
laser cladding,2
metal powder,2
metal structure,2
mechanical properties,2
,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
SCIENTIFICRESEARCH,1
SCIENCE,1
NORMS,1
RETHINKING,1
COPYRIGHT,1
LIFE,1
LAW,1
intellectual property,2
patent,1
public health,2
,1
Tech mining,2
Topic modeling,2
Patent analysis,2
INTELLIGENCE,1
TOOL,1
developing countries,2
patent applications,2
small and medium enterprises,4
,1
Chiral drugs,2
racemates and single enantiomers,4
verapamil,1
ibuprofen,1
fluoxetine,1
Carvedilol,1
ketamine,1
regulatory aspects of drugs,4
costs of development of new drugs,6
patents and patent extensions,4
valsartan,1
generic drugs,2
generic companies,2
PHARMACOKINETICS,1
VALSARTAN,1
Biologics,1
biosimilars,1
FDA,1
law,1
patent,1
pharmaceuticals,1
,1
patent law,2
gene patents,2
purposebound,1
functionbound,1
Biotech Directive,2
EPO,1
Germany,1
Switzerland,1
,1
Patent,1
Prize,1
Intertemporal bounty,2
Taxes,1
Innovation,1
Endogenous growth,2
Transitional dynamics,2
Welfare,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
PROTECTION,1
POLICY,1
PRODUCTIVITY,1
IMITATION,1
ECONOMICS,1
LENGTH,1
RETURN,1
America Invents Act AIA,4
patents,1
product portfolio,2
systems,1
systems thinking,2
unintended consequences,2
intellectual property,2
,1
Patent rights,2
TRIPS,1
LatinAmerica,1
Developing countries,2
Multinational corporations,2
Political economy of IPR,4
INTELLECTUAL PROPERTYRIGHTS,2
DOMESTIC INNOVATION,2
PROTECTION,1
,1
PRISONERSDILEMMA GAME,2
INTELLECTUAL PROPERTY,2
PATENT,1
COOPERATION,1
BEHAVIOR,1
PARTICIPATION,1
PERFORMANCE,1
ENTERPRISES,1
PROPENSITY,1
ECOSYSTEMS,1
data exclusivities,2
drug pricing,2
healthcare reform,2
health law,2
health spending,2
health technology assessment,3
patents,1
pharmaceutical policy,2
PATENTS,1
DRUGS,1
Chinese medicinal materials,3
Cultivation,1
Bibliometrics,1
Genuine medicinal materials,3
patent analysis,2
PROTECTION,1
QUALITY,1
investment in environmental protection,4
green innovation,2
solid waste,2
Governance capacity,2
China,1
ZERO WASTE,2
DEVELOPMENT SUBSIDIES,2
POLLUTION,1
ECONOMY,1
POLICY,1
GROWTH,1
technologybased entrepreneurial firm,3
RD partner selection,3
technology complementarity,2
unintended knowledge spillover,3
STRATEGIC ALLIANCES,2
ABSORPTIVECAPACITY,1
COMPLEMENTARY TECHNOLOGIES,2
DEVELOPMENT COLLABORATION,2
OPEN INNOVATION,2
LOCAL SEARCH,2
KNOWLEDGE,1
VENTURES,1
EVOLUTION,1
PATTERNS,1
,1
RESEARCHANDDEVELOPMENT,1
OPEN INNOVATION,2
FIRMS,1
COOPERATION,1
KNOWLEDGE,1
OPENNESS,1
PATENTS,1
MANAGEMENT,1
APPROPRIABILITY,1
APPROPRIATION,1
knowledge leakage,2
trade secrets protection,3
research and development RD offshoring,5
weak intellectual property IP regimes,5
organization design,2
knowledge stickiness,2
knowledge system dependence,3
COMMON METHOD VARIANCE,3
INTELLECTUAL PROPERTY,2
INNOVATION,1
SECRETS,1
COMPLEMENTARITY,1
PATENTS,1
STRATEGIES,1
IMITATION,1
SERVICES,1
MOBILITY,1
,1
DRUG DEVELOPMENT,2
LIFE,1
COMPETITION,1
HEALTH,1
tandem helicopter,2
unmanned aircraft,2
unmanned aerial vehicles,3
unmanned helicopter,2
drones,1
,1
Reverse innovation,2
Outwardbound international patenting,3
Intellectual property management,3
Innovation policy,2
Endogenous innovation,2
Economic development,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
INDUSTRIALRESEARCH,1
EMERGING ECONOMIES,2
PROTECTION,1
TRADE,1
DETERMINANTS,1
CAPABILITIES,1
GROWTH,1
entrepreneurship,1
intellectual property rights,3
new firm formation,3
entry,1
patents,1
trademarks,1
knowledge spillovers,2
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE SPILLOVERS,2
MARKET VALUE,2
SCHUMPETERIAN COMPETITION,2
TECHNOLOGICALCHANGE,1
MANUFACTURING FIRMS,2
INNOVATION,1
ENTREPRENEURSHIP,1
GEOGRAPHY,1
LOCATION,1
Damages,1
Entry,1
Invention,1
Patents,1
Prize system,2
Royalties,1
INNOVATION,1
PROTECTION,1
PRICE,1
pharmaceutical policy,2
intellectual property rights,3
trade policy,2
NAFTA,1
free trade,2
UNIVERSAL PUBLIC COVERAGE,3
PATENTS,1
ACCESS,1
DRUGS,1
COST,1
BAD,1
PHARMACEUTICALS,1
NEOLIBERALISM,1
MEDICINES,1
BENEFITS,1
innovation quality,2
patent return,2
public enterprise,2
private enterprise,2
RD resource,2
patent value,2
PRIVATIZATION,1
INFRINGEMENT,1
PROTECTION,1
OWNERSHIP,1
RENEWAL,1
,1
INNOVATION EVIDENCE,2
PATENT POOLS,2
COMPETITION,1
GROWTH,1
ENTRY,1
copyrights,1
firmlevel data,2
information industries,2
international knowledge transfer,3
INTELLECTUAL PROPERTYRIGHTS,2
PATENT PROTECTION,2
TECHNOLOGY,1
Intellectual property rights,3
knowledge flows,2
emerging countries,2
patent citations,2
inventors collaborations,2
INTELLECTUAL PROPERTY PROTECTION,3
PATENT CITATIONS,2
GRAVITY MODEL,2
DETERMINANTS,1
TECHNOLOGY,1
DIFFUSION,1
GEOGRAPHY,1
NETWORKS,1
RIGHTS,1
Patent,1
Intellectual property,2
Industrial property,2
Prospect study,2
Innovation,1
NPD,1
,1
Employment protection,2
Inventor mobility,2
Labor Contract Law,3
China,1
EMPLOYMENT PROTECTION,2
DEVELOPMENT INTENSITY,2
CAPITAL STRUCTURE,2
PRODUCTIVITY,1
PERFORMANCE,1
INVESTMENT,1
FIRMS,1
NETWORKS,1
DATABASE,1
TAXATION,1
Trademarks,1
patents,1
Kirznerian entrepreneur,2
Schumpeterian entrepreneur,2
European Working Conditions Survey,4
Europe,1
RESEARCHANDDEVELOPMENT,1
SELFEMPLOYMENT,1
EMPIRICALEVIDENCE,1
PATENT PROTECTION,2
STARTUPS,1
INNOVATION,1
FIRMS,1
SURVIVAL,1
IMPACT,1
UNEMPLOYMENT,1
Design,1
Sustainable Design,2
Intellectual Property Rights,3
Traditional Knowledge,2
Patents,1
Industrial Design,2
,1
glassy metaphosphate composition,3
solubility,1
water treatment,2
wastefree technology,2
comprehensive protection,2
corrosion,1
salt deposition scale,3
elements of waterheating systems,4
,1
family firms,2
intellectual property protection,3
trade secret protection,3
UTSA,1
RD investments,2
socioemotional wealth,2
SOCIOEMOTIONAL WEALTH,2
CORPORATEOWNERSHIP,1
INNOVATION EVIDENCE,2
EMPIRICALANALYSIS,1
MARKETSTRUCTURE,1
NONFAMILY FIRMS,2
FOUNDER FIRMS,2
PATENT,1
PERFORMANCE,1
AGENCY,1
lowcarbon energy technology LC,4
logarithmic mean Divisia index LMDI,5
industrial sector,2
regional disparity,2
China,1
RESEARCHANDDEVELOPMENT,1
RENEWABLE ENERGY,2
DECOMPOSITION ANALYSIS,2
CO2 EMISSIONS,2
ENVIRONMENTAL TECHNOLOGY,2
GROWTH,1
POLLUTION,1
DETERMINANTS,1
INVENTIONS,1
PRIVATE,1
IP protection,2
Institutional theory,2
M  Technological intensity,4
INTELLECTUAL PROPERTYRIGHTS,2
INSTITUTIONAL DISTANCE,2
ENTRY MODE,2
KNOWLEDGE ACQUISITION,2
PATENT PROTECTION,2
TRANSACTION COSTS,2
DIRECTINVESTMENT,1
FOREIGN ENTRY,2
DETERMINANTS,1
CHOICE,1
corporate governance,2
innovation,1
patent race,2
shorttermism,1
simultaneous invention,2
CORPORATE GOVERNANCE,2
AGENCY COSTS,2
CEO DUALITY,2
FIRM,1
PERFORMANCE,1
COMPETITION,1
INVESTMENT,1
PERSISTENCE,1
INVESTORS,1
MARKET,1
Intellectual property,2
International institutions,2
World Trade Organization,3
Institutional theory,2
FOREIGN DIRECTINVESTMENT,2
HUMANRIGHTS,1
COMPETING LOGICS,2
PATENT RIGHTS,2
DIFFUSION,1
POLICY,1
SPREAD,1
WORLD,1
ORGANIZATIONS,1
GLOBALIZATION,1
,1
EMPLOYMENT PROTECTION,2
PRODUCTIVITY,1
LAWS,1
,1
FRICTION,1
PATH,1
invention,1
patent claims,2
HalfCausation,1
HalfCausation Branching,2
HalfCausation Encapsulation,2
philosophy of technological discovery,4
philosophy of inventions and patents,5
philosophy of technology,3
,1
Cancer,1
Nano therapeutics,2
Antiinflammatory nanomedicines,2
Patents,1
Clinical translation,2
MEMBRANECAMOUFLAGED NANOPARTICLES,2
REGULATORY TCELLS,2
DRUGDELIVERY,1
INVIVO,1
DENDRITIC CELLS,2
SUPPRESSORCELLS,1
LOTEPREDNOL ETABONATE,2
LIPID NANOPARTICLES,2
PHARMACOKINETICS,1
VESICLES,1
drug discovery,2
grace period,2
invention disclosure,2
novelty,1
open innovation,2
patent law harmonization,3
,1
India,1
Pharmaceutical exports,2
Empirical estimation,2
Simultaneous equation,2
Patents,1
C3,1
F14,1
L65,1
UNITROOT TESTS,2
SIMULTANEOUSEQUATIONS,1
IMPACT,1
INNOVATION,1
PROTECTION,1
Technological innovation,2
Patent analysis,2
Governmentsubsidized patent,2
Government policy,2
Governmentsubsidized innovation,2
INTERDISCIPLINARITY,1
DIVERSITY,1
DETERMINANTS,1
PORTFOLIO,1
Innovations,1
Intellectual Property Rights,3
Productivity Distribution,2
INTELLECTUAL PROPERTYRIGHTS,2
ENDOGENOUS GROWTH,2
PATENT POLICY,2
SIZE DISTRIBUTION,2
INNOVATION,1
PROTECTION,1
STIMULATE,1
KNOWLEDGE,1
IMITATION,1
MODEL,1
innovation,1
information transparency,2
corporate investment,2
information externality,2
patents,1
patent citations,2
RESEARCHANDDEVELOPMENT,1
PATENT CITATIONS,2
KNOWLEDGE SPILLOVERS,2
EARNINGS QUALITY,2
UNCERTAINTY,1
DISCLOSURE,1
FLOWS,1
PERFORMANCE,1
PROTECTION,1
OWNERSHIP,1
,1
QUERY EXPANSION,2
Renewable energy consumption,3
Intellectual property rights,3
Global financial crisis,3
Developed and developing economies,4
Generalized method of moments,4
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
PROTECTION,1
PANEL,1
DETERMINANTS,1
INNOVATION,1
CHINA,1
GMM,1
O30,1
Q54,1
Q55,1
INNOVATIVE RESPONSES,2
ABSORPTIVECAPACITY,1
PRODUCTIVITY,1
IMPACTS,1
MORTALITY,1
QUALITY,1
GROWTH,1
POOR,1
Convention on biological diversity,4
Biopiracy,1
Legal geography,2
Text mining,2
Endemic species,2
Patent analysis,2
INTELLECTUAL PROPERTYRIGHTS,2
TRADITIONAL KNOWLEDGE,2
GENUS,1
CLASSIFICATION,1
CONSERVATION,1
BIODIVERSITY,1
INNOVATION,1
PLANTS,1
Family firms,2
Propensity to patent,3
Empirical analysis,2
SOCIOEMOTIONAL WEALTH,2
TECHNOLOGICALINNOVATION,1
OWNERSHIP STRUCTURE,2
FOUNDER FIRMS,2
INTERNATIONALIZATION,1
BUSINESS,1
INVOLVEMENT,1
PERFORMANCE,1
VALIDATION,1
GOVERNANCE,1
,1
,1
Ecoinnovation,1
Appropriability,1
Green patents,2
Economic complexity,2
Judicial system,2
Property rights,2
ENVIRONMENTAL INNOVATION,2
EMPIRICALEVIDENCE,1
SUSTAINABLE INNOVATION,2
INTELLECTUAL PROPERTY,2
TECHNOLOGYPUSH,1
POLICY MIX,2
IMPACT,1
GREEN,1
DETERMINANTS,1
INSTITUTIONS,1
,1
SCIENCE,1
INNOVATION,1
DISCOVERY,1
KNOWLEDGE,1
US,1
,1
NONADHERENCE,1
DISEASE,1
TRENDS,1
Trust,1
Corporate innovation,2
Innovation output,2
Innovation input,2
SOCIETAL TRUST,2
DARK SIDE,2
CORPORATE,1
PERFORMANCE,1
COSTS,1
PROTECTION,1
KNOWLEDGE,1
ENHANCE,1
CULTURE,1
RIGHTS,1
rDNA technology,2
Genetically modified plants,3
Transformation,1
Plant variety,2
Patents,1
,1
,1
,1
Patents,1
Innovation,1
Stochastic frontier analysis,3
Knowledge,1
Corruption,1
Institutions,1
Government,1
Uncertainty,1
Efficiency,1
Regulatory quality,2
State fragility,2
RESEARCHANDDEVELOPMENT,1
DETERMINANTS,1
INEFFICIENCY,1
PRIVATE,1
PATENTS,1
SYSTEMS,1
Interest in bringing legal proceedings,5
Action for revocation,3
Filing after patent expiry,4
Infringement action,2
Main claim,2
Independent claims with same content,5
,1
,1
INTELLECTUAL PROPERTY,2
DESIGN PROTECTION,2
COPYRIGHT,1
ECONOMICS,1
INNOVATION,1
PATENTS,1
SELF,1
pharmaceutical industry,2
innovation,1
marketing,1
patent,1
health care reform,3
RESEARCHANDDEVELOPMENT,1
DRUG DISCOVERY,2
PERFORMANCE,1
STRATEGY,1
FIRMS,1
SPILLOVERS,1
PATENTS,1
MODELS,1
,1
HEALTH DIPLOMACY,2
ADHERENCE,1
FRAMEWORK,1
THERAPY,1
DRUGS,1
,1
LAW,1
transgenic maize,2
intellectual property analysis,3
carotenoids,1
insect resistance,2
humanitarian aspects,2
PROVITAMIN,1
BIOFORTIFICATION,1
TRANSFORMATION,1
PATHWAY,1
RICE,1
,1
INTELLECTUAL PROPERTY,2
ENTRY,1
EXIT,1
COORDINATION,1
TECHNOLOGY,1
INNOVATION,1
ADOPTION,1
PATENTS,1
Language,1
RD,1
Innovation,1
Economic institution,2
Futuretime reference,2
PATENT PROTECTION,2
FINANCIAL DEVELOPMENT,2
NATIONAL CULTURE,2
INNOVATION,1
STOCK,1
RISK,1
OPENNESS,1
ENHANCE,1
RIGHTS,1
Intellectual property rights,3
tariff,1
RD spillover,2
entry mode,2
DEVELOPMENT SPILLOVERS,2
PATENT PROTECTION,2
SOUTHERN INNOVATION,2
TECHNOLOGY,1
MARKET,1
COUNTRIES,1
WELFARE,1
FDI,1
Nicotiana benthamiana,2
DNA labelling,2
Patents on plant varieties,4
DNA coding,2
DNA decoding,2
REALTIME PCR,2
TRANSGENIC PLANTS,2
GENE,1
MARKERS,1
TOOL,1
,1
INTELLECTUAL PROPERTY,2
PATENTS,1
LAW,1
HISTORY,1
PROTECTION,1
DECISIONS,1
STATUTES,1
CITIZEN,1
CUSTOM,1
Indigenous knowledge,2
Aboriginal and Torres Strait Islander peoples,6
biological resources,2
patent trends,2
legal geography,2
biopiracy,1
access and benefitsharing,3
Nagoya Protocol,2
NORTHERN AUSTRALIA,2
MYOPORACEAE,1
KNOWLEDGE,1
ECOLOGY,1
LAND,1
Intellectual property rights,3
Innovation,1
Developing countries,2
Market potential,2
Trade,1
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
DOMESTIC INNOVATION,2
ECONOMICGROWTH,1
TECHNOLOGY,1
INVESTMENT,1
PHARMACEUTICALS,1
GLOBALIZATION,1
DETERMINANTS,1
DIFFUSION,1
Intellectual property rights,3
international trade,2
product categories,2
F14,1
O10,1
O34,1
PATENT RIGHTS,2
TRADE,1
PROTECTION,1
EXPORTS,1
GROWTH,1
PRICE,1
innovation,1
knowledge spillover,2
economic growth,2
generalized method of moments,4
propensity to patent,3
INTELLECTUAL PROPERTY PROTECTION,3
RESEARCHANDDEVELOPMENT,1
KNOWLEDGE SPILLOVERS,2
PATENT STATISTICS,2
PANELDATA,1
COUNTRIES,1
Technology foresight,2
Patent map,2
Technology monitoring,2
Path identification,2
Shale gas,2
ENERGY,1
CHINA,1
TRAJECTORIES,1
REVOLUTION,1
INNOVATION,1
ECONOMY,1
STORAGE,1
ASIA,1
Camelina sativa,2
Byproduct,1
Oil,1
Straw,1
Plant,1
Marginal land,2
FATTYACIDCOMPOSITION,1
SALMON SALMOSALAR,2
FISHOIL,1
DIETARY SUPPLEMENTATION,2
PROTEINSOURCE,1
OILSEED CROPS,2
SEED,1
MEAL,1
L,1
PERFORMANCE,1
University ecosystem,2
Technology transfer,2
TTO measures,2
Decision aid,2
Complex social system,3
Agentbased simulation,2
TECHNOLOGYTRANSFER OFFICES,2
INTELLECTUAL PROPERTY PROTECTION,3
WORDOFMOUTH,1
SPINOFF,1
ENTREPRENEURSHIP,1
COMMERCIALIZATION,1
SCIENTISTS,1
NETWORKS,1
FACULTY,1
MODEL,1
Chip industry,2
OLED technology,2
comparative analysis,2
PageRank algorithm,2
dominant technology,2
,1
copyright,1
intellectual property,2
patents,1
sports,1
trademark,1
,1
,1
IDENTIFICATION,1
MODEL,1
Technological Impact,2
Patents,1
Scientometric,1
PATSTAT,1
Scopus,1
SCOPUS,1
LINKAGE,1
SCIENCE,1
Human capital,2
Innovation,1
Intellectual properties,2
Knowledge production,2
MS firms,2
RESEARCHANDDEVELOPMENT,1
DEVELOPINGCOUNTRIES,1
ABSORPTIVECAPACITY,1
PERFORMANCE,1
PATENT,1
PRODUCTIVITY,1
CAPABILITIES,1
SPILLOVERS,1
trade secret,2
public policy,2
myriad genetics,2
marchin rights,2
genetic test,2
genetic variant,2
SEQUENCE VARIANTS,2
ASSOCIATION,1
GENOMICS,1
,1
INTELLECTUAL PROPERTY,2
LIABILITY RULES,2
PATENT HOLDUP,2
COVENANTS,1
KNOWLEDGE,1
DOCTRINE,1
LAW,1
Galvanisation,1
age of iron,3
French patents,2
commercial exploitation,2
corrosion protection,2
,1
access,1
Covid19,1
medicines,1
patent waiver,2
TRIPS,1
vaccines,1
,1
,1
INTELLECTUAL PROPERTY CLAUSE,3
JUDICIAL CAPACITY,2
SUPREMECOURT,1
TRADE SECRETS,2
LAW,1
PROTECTION,1
LIMITATION,1
HISTORY,1
LIMITS,1
SCOPE,1
3D electrocatalytic oxidation,3
Organic wastewater,2
Electrode material,2
Process parameters,2
Patent perspective,2
ELECTROCHEMICAL OXIDATION,2
PHOTOELECTROFENTON,1
ANODICOXIDATION,1
ACTIVATED CARBON,2
DEGRADATION,1
DYE,1
MINERALIZATION,1
PHOTOCATALYSIS,1
DECOLORIZATION,1
POLLUTANTS,1
,1
PATENT PROTECTION,2
TECHNOLOGYTRANSFER,1
IPR PROTECTION,2
RIGHTS,1
INNOVATION,1
QUALITY,1
REGIMES,1
EXPORTS,1
GROWTH,1
TRADE,1
energy industry,2
innovation,1
intellectual property rights,3
spatial transfer,2
Jiangsu,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
EMPIRICALEVIDENCE,1
PATENT RIGHTS,2
OUTWARD FDI,2
GROWTH,1
SPECIALIZATION,1
PRODUCTIVITY,1
REGRESSION,1
INTENSITY,1
,1
UNITEDSTATES,1
INHIBITORS,1
ADHERENCE,1
Intellectual property rights,3
Imports,1
Knowledge spillovers,2
Innovation,1
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
CREATIVE DESTRUCTION,2
INTERMEDIATE INPUTS,2
ECONOMICGROWTH,1
PROTECTION,1
PRODUCTIVITY,1
QUALITY,1
LIBERALIZATION,1
DYNAMICS,1
IPC,1
IPR,1
Partnerships,1
Patents,1
Technology commercialization,2
Technology protection,2
Trademarks,1
,1
intellectual property rights,3
innovation strategy,2
institutional change,2
emerging economy,2
China,1
SOCIALSTRUCTURE,1
FINANCIAL PERFORMANCE,2
CULTURAL DISTANCE,2
PATENT RIGHTS,2
TRANSITION,1
KNOWLEDGE,1
NETWORKS,1
SURVIVAL,1
EMBEDDEDNESS,1
LIABILITY,1
Incentives to patent,3
Technology transfer,2
Barriers to innovation,3
Productivity,1
GDR,1
O31,1
O34,1
O14,1
P23,1
RESEARCHANDDEVELOPMENT,1
PRODUCTIVITY GROWTH,2
KNOWLEDGE ACCUMULATION,2
INNOVATION,1
INDUSTRIAL,1
PATENTS,1
FRENCH,1
INPUTS,1
RISE,1
FAIL,1
firms imports,2
intellectual property rights,3
IPRsintensive industry,2
margins of imports,3
marketexpansion effect,2
PATENT RIGHTS,2
CAPITAL GOODS,2
TRADE,1
EXPORTS,1
INVESTMENT,1
PROTECTION,1
IMITATION,1
Carbon dioxide emissions,3
Ecopatents,1
Environmental policy,2
Environmental Taxes,2
Greenhouse gas,2
Trademark,1
RESEARCHANDDEVELOPMENT,1
ECONOMICGROWTH,1
CO2 EMISSIONS,2
ENERGYCONSUMPTION,1
DIOXIDE EMISSIONS,2
EMPIRICALEVIDENCE,1
URBANDEVELOPMENT,1
TIMESERIES,1
IMPACT,1
URBANIZATION,1
,1
INNOVATION,1
AFRICA,1
,1
INTELLECTUAL PROPERTY,2
SOUTHAFRICA,1
ACCESS,1
MEDICINES,1
HEALTH,1
POLICY,1
INNOVATION,1
PRICE,1
LAW,1
UNDP,1
patentability guidelines,2
patent examination,2
pharmaceutical patents,2
TRIPS Agreement,2
DRUGS,1
Technological trajectory,2
Knowledge spanning,2
Breakthrough invention,2
Knowledge recombination,2
Quantile regression,2
Patent data,2
GEOGRAPHIC LOCALIZATION,2
EXPLORATION,1
SEARCH,1
IMPACT,1
BREAKTHROUGHS,1
SPILLOVERS,1
CITATIONS,1
SCIENCE,1
FIRMS,1
Covid19 vaccine access,3
international intellectual property regime,4
TRIPS agreement,2
access to medicine,3
intellectual property waiver,3
compulsory licensing,2
INTELLECTUAL PROPERTY,2
Patent,1
Pharmaceutical industry,2
Generic drug,2
Compulsory license,2
Bolar exception,2
Evergreening,1
,1
Open innovation,2
Health industry,2
Intellectual property,2
Patenting activity,2
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
FIRMS MARKET VALUE,3
MANAGING KNOWLEDGE,2
PERFORMANCE,1
TECHNOLOGY,1
MANAGEMENT,1
STRATEGY,1
IMPACT,1
ORGANIZATIONS,1
Innovation,1
Patent,1
Default risk,2
Bond premium,2
Bond return,2
RESEARCHANDDEVELOPMENT,1
PERFORMANCE,1
UNCERTAINTY,1
PROTECTION,1
REVOLUTION,1
RISKINESS,1
VALUATION,1
DEBT,1
Trademark valuation,2
Maintenance and renewal decisions,4
Trademark indicators,2
RESEARCHANDDEVELOPMENT,1
PATENT PROTECTION,2
INNOVATION,1
NAME,1
IMPACT,1
MARKS,1
intellectual property protection,3
patent litigation,2
Beijing courts,2
inadequate enforcement,2
trade war,2
discrimination,1
damage,1
LAW,1
Carbon intensity of GDP,4
Environmental innovation,2
Consumptionbased CO2 emissions,3
Denmark,1
ECONOMICGROWTH,1
CARBON EMISSIONS,2
CLIMATECHANGE,1
INTERNATIONALTRADE,1
NONRENEWABLE ENERGY,2
RENEWABLE ENERGY,2
GLOBALIZATION,1
IMPACT,1
LEVEL,1
,1
COMPETITION,1
global value chain,3
innovation,1
intellectual property rights,3
ECONOMICGROWTH,1
PATENT RIGHTS,2
INNOVATION,1
TECHNOLOGY,1
COMPETITION,1
PROTECTION,1
IMITATION,1
IPRs,1
research exemption,2
farmers exemption,2
plant variety creation,3
renewals,1
PATENT RENEWALS,2
OPTIONS,1
RIGHTS,1
electronicoptic converter,2
infrared radiation,2
night surveillance devices,3
,1
aesthetics,1
copyright,1
Denmark,1
functionalism,1
patent law,2
PH lamp,2
,1
pharmaceutical regulation,2
policy analysis,2
health policy,2
pharmaceutical patents,2
,1
nonmarketbased stringency,2
marketbased subsidy,2
patent,1
municipal waste,2
recycling waste,2
domestic material consumption,3
WASTE,1
SUSTAINABILITY,1
MANAGEMENT,1
GROWTH,1
Cloud computing,2
Property,1
Intellectual property,2
Copyright,1
Trade secret,2
Patents,1
Contractual terms,2
Dispute resolution,2
Data protection,2
COPYRIGHT PROTECTION,2
SOFTWARE PATENTS,2
BIG DATA,2
LEGAL,1
FUTURE,1
ISSUES,1
FIRM,1
Dualclass,1
Innovation,1
Patents,1
Citations,1
Corporate governance,2
RESEARCHANDDEVELOPMENT,1
VOTINGRIGHTS,1
CASH FLOW,2
INVESTMENT,1
GOVERNANCE,1
INDUSTRY,1
EQUITY,1
IMPACT,1
LEVEL,1
RUN,1
Antidumping investigation,2
innovation,1
trade diversion effect,3
firm performance,2
patent filing,2
TRADE,1
COMPETITION,1
PROTECTION,1
DUTIES,1
PRODUCTIVITY,1
RESPONSES,1
GROWTH,1
activism,1
antiretrovirals,1
civil society,2
HIV,1
AIDS,1
journalism,1
patents,1
protest,1
public health,2
INTELLECTUAL PROPERTY,2
NEWS,1
AIDS,1
ACCESS,1
COVERAGE,1
TRANSFORMATION,1
HEALTH,1
POLICY,1
LIFE,1
Artistic design,2
Individuality,1
Copyright protection,2
Infringement,1
Works of applied art,4
Intellectual creations,2
Individual character,2
Unfair competition,2
Priority of use,3
,1
Strategic real investment,3
Asymmetric firms,2
Market growth,2
Patents,1
Estimation issues,2
RESEARCHANDDEVELOPMENT,1
REAL OPTIONS,2
MOVER ADVANTAGE,2
INVESTMENT,1
DYNAMICS,1
IMPACT,1
ENTRY,1
PREEMPTION,1
PROTECTION,1
FOLLOWERS,1
IPR protection,2
technological development,2
domestic innovation,2
FDI,1
FOREIGN DIRECTINVESTMENT,2
SOUTHERN INNOVATION,2
PATENT PROTECTION,2
TRADE,1
IMITATION,1
WELFARE,1
POLICY,1
MODEL,1
mandatory environmental regulations,3
environmental protection,2
green technology innovation,3
green patent,2
sustainable development,2
DIFFUSION,1
JAPAN,1
US,1
plant breeding,2
agriculture,1
crop varieties,2
prior informed consent,3
intellectual property rights,3
sui generis,2
Plant Variety Protection,3
utility patents,2
SEED EXCHANGE NETWORKS,3
VARIETY PROTECTION,2
CROP PRODUCTIVITY,2
BREEDERS RIGHTS,2
ONFARM,1
DEVELOPINGCOUNTRIES,1
ESSENTIAL DERIVATION,2
POLITICALECONOMY,1
GENETICRESOURCES,1
NORTHAMERICAN,1
Intellectual property rights,3
Cumulative innovation,2
Persistent leadership,2
Forward protection,2
Nonobviousness requirement,2
RESEARCHANDDEVELOPMENT,1
BLOCKING PATENTS,2
INNOVATION,1
GROWTH,1
COMPETITION,1
PATENTABILITY,1
INVESTMENT,1
Copyrights,1
Industrial designs,2
Patents,1
Trademarks,1
Multivariate Probit,2
INFORMAL APPROPRIATION MECHANISMS,3
EMPIRICALEVIDENCE,1
DESIGN MANAGEMENT,2
SERVICE MARKS,2
PATENTS,1
TRADEMARKS,1
FIRMS,1
PROTECTION,1
PRODUCT,1
RIGHTS,1
Intellectual property protection,3
appropriation,1
small and mediumsized enterprises,4
weak legal enforcement,3
sectoral comparison,2
RESEARCHANDDEVELOPMENT,1
TECHNOLOGICALINNOVATION,1
FIRM SIZE,2
PATENTS,1
APPROPRIABILITY,1
COLLABORATION,1
PERFORMANCE,1
MECHANISMS,1
STRATEGIES,1
SECRECY,1
Venture capital,2
Young innovative company,3
Startup,1
Patent portfolio,2
Asymmetric information,2
Signaling,1
O31,1
G24,1
L26,1
BLACKBOX,1
PERFORMANCE,1
TECHNOLOGY,1
SELECTION,1
CITATIONS,1
INVENTORS,1
MOTIVES,1
MARKETS,1
IMPACT,1
FIRMS,1
University of Brasilia,3
Patents,1
Food,1
Innovation,1
,1
Medial AI,2
Patentsharing mechanisms,2
Innovation,1
Twopronged solution,2
Knowledge sharing,2
ARTIFICIALINTELLIGENCE,1
PATENT,1
INNOVATION,1
FAIRNESS,1
LAW,1
Covenant not to sue,4
Covenant to sue last,4
Infringement,1
Litigation exhaustion,2
Consent to placing on the market,6
,1
,1
INTERNATIONAL TECHNOLOGY DIFFUSION,3
DEVELOPINGCOUNTRIES,1
SELFSELECTION,1
DRAIN,1
GROWTH,1
INNOVATION,1
TRADE,1
EARNINGS,1
ECONOMY,1
WAGES,1
trolley wire deicing,3
mechanical resonance,2
,1
agronomy,1
SciVal,1
patents,1
Europe,1
bibliometrics,1
RD,1
Scopus,1
patentometrics,1
Triple Helix,2
TRIPLEHELIX,1
ARABIDOPSISTHALIANA,1
SYSTEMS,1
INNOVATION,1
PROTECTION,1
ULTRASONICS,1
INDICATORS,1
PRESSURE,1
PARADIGM,1
INDEXES,1
intellectual property,2
innovation,1
integrated circuits,2
semiconductors,1
chips,1
,1
Reverse payment patent settlement agreements RPPSAs,6
patented drugs,2
generic drugs,2
competition law,2
,1
Intellectual property rights protection,4
Total factor productivity,3
The institutionbased view of IPR history,6
A country s development level,5
RESEARCHANDDEVELOPMENT,1
PATENT RIGHTS,2
ECONOMICGROWTH,1
INNOVATION,1
IMPACT,1
TRADE,1
INSTITUTIONS,1
TECHNOLOGY,1
COUNTRIES,1
LEVEL,1
Intellectual property protection,3
Prevention in advance,3
Punishment afterward,2
RESEARCHANDDEVELOPMENT,1
STRATEGIC BEHAVIOR,2
PATENT LIFE,2
RIGHTS,1
TECHNOLOGY,1
INNOVATION,1
IMITATION,1
EQUILIBRIUM,1
COOPERATION,1
COMPETITION,1
fruit,1
nuts,1
history,1
nurserymen,1
plant patents,2
,1
,1
ABSORPTIVECAPACITY,1
EMPIRICALEVIDENCE,1
INNOVATION,1
SCIENCE,1
NETWORKS,1
RIGHTS,1
FIRMS,1
SCIENTISTS,1
PATENTS,1
IMPACT,1
Intellectual Property Rights,3
image encryption,2
patents,1
copyrights,1
trademarks,1
integrity,1
PHASETRUNCATION,1
ALGORITHM,1
SCHEME,1
EFFICIENT,1
Patent,1
Education,1
Human capital,2
Economic growth,2
Scandinavian countries,2
Quadruple Helix model,3
CSARDL,1
QUALITY LADDERS,2
INNOVATION,1
INVESTMENT,1
SECRETS,1
HELIX,1
,1
PATENT PROTECTION,2
ECONOMICGROWTH,1
INNOVATION,1
Intellectual property,2
SME,1
innovation,1
protection strategy,2
PROPERTYRIGHTS,1
PATENT INFORMATION,2
UK SMALL,2
BUSINESS,1
TRUST,1
FIRMS,1
ENTERPRISES,1
MANAGEMENT,1
INNOVATION,1
STANDARDS,1
Patent,1
Litigation,1
Cross licensing,2
Cumulative innovation,2
RD,1
Real options,2
SEQUENTIAL INNOVATION,2
ANTITRUST,1
ECONOMICS,1
BREADTH,1
POLICY,1
POOLS,1
SCOPE,1
public policy,2
public health,2
needs assessment,2
international cooperation,2
HEALTH,1
terrorism,1
uncertainty,1
RD investment,2
real options,2
irreversibility,1
country institutions,2
PATENT PROTECTION,2
IMPACT,1
STRATEGIES,1
INNOVATION,1
ATTACKS,1
RISK,1
,1
FOREIGN DIRECTINVESTMENT,2
PRODUCTIVITY GROWTH,2
MANUFACTURING FIRMS,2
ECONOMICGROWTH,1
TRADE MARKS,2
PANELDATA,1
PATENTS,1
RIGHTS,1
INNOVATION,1
PROTECTION,1
intellectual property,2
institutional dynamics,2
patent,1
innovation,1
FOREIGN DIRECTINVESTMENT,2
PATENT RIGHTS,2
TECHNOLOGYTRANSFER,1
ECONOMICGROWTH,1
PROTECTION,1
CHINA,1
IMPACT,1
PERFORMANCE,1
DETERMINANTS,1
BUSINESSES,1
Environmental regulation,2
Carbon emissions trading,3
Green innovation,2
PRODUCTIVITY,1
TRANSITION,1
INSIGHTS,1
,1
TECHNOLOGYTRANSFER,1
PUBLIC RESEARCH,2
RIGHTS,1
INDUSTRY,1
UNIVERSITY,1
INNOVATION,1
US,1
VARIETIES,1
EXCHANGE,1
BENEFITS,1
food and drug law,4
intellectual property,2
,1
patents,1
strategic trade protection,3
INTERMEDIATE INPUTS,2
PRODUCTIVITY,1
LIBERALIZATION,1
GROWTH,1
Patent Cooperation,2
Innovation Network,2
Industrial Integration,2
ZPark,1
MANAGING INNOVATION,2
,1
LAW,1
ASEAN,1
India,1
Section 3d,2
RCEP,1
TRIPS,1
WTO,1
TRANSPACIFIC PARTNERSHIP,2
INTELLECTUAL PROPERTY PROTECTION,3
MEDICINES,1
ACCESS,1
AGREEMENT,1
POLICY,1
injunctions,1
ongoing royalties,2
patent remedies,2
profiting from innovation,3
technology licensing,2
INTELLECTUAL PROPERTYRIGHTS,2
LIABILITY RULES,2
COMPLEMENTARY ASSETS,2
PERMANENT INJUNCTIONS,2
EMPIRICALANALYSIS,1
MARKET,1
INNOVATION,1
FIRMS,1
TROLLS,1
COMPETITION,1
Intellectual property rights,3
patent,1
research  development,3
clinical trials,2
copyrights,1
generic drugs etc,3
,1
,1
INTELLECTUAL PROPERTY,2
MERGERS,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
DIRECTED TECHNICAL CHANGE,3
GLOBAL PATENT PROTECTION,3
RESEARCHANDDEVELOPMENT,1
ENDOGENOUS GROWTH,2
WELFARE ANALYSIS,2
INNOVATION,1
NORTH,1
Intellectual property rights,3
Crossborder mergers and acquisitions,4
PATENT PROTECTION,2
DETERMINANTS,1
INNOVATION,1
LAWS,1
Employment protection,2
Firing costs,2
Innovations,1
Patents,1
Productivity,1
Market imperfections,2
EQUILIBRIUM UNEMPLOYMENT,2
PRODUCTIVITY GROWTH,2
CYCLICAL BEHAVIOR,2
SEARCH,1
TURNOVER,1
DYNAMICS,1
International trade,2
Welfare gains from trade,4
Economic growth,2
Intellectual property rights,3
F10,1
F12,1
F13,1
O31,1
O41,1
ENDOGENOUS GROWTH,2
SCHUMPETERIAN MODEL,2
LIBERALIZATION,1
PRODUCTIVITY,1
INNOVATION,1
DIFFUSION,1
IMITATION,1
IMPACT,1
right to health,3
access to medicines,3
patent protection,2
compulsory licensing,2
TRIPS,1
,1
Process innovation,2
Family involvement in management,4
Technology protection,2
R D collaboration with suppliers,5
SOCIOEMOTIONAL WEALTH,2
PRODUCT INNOVATION,2
MODERATING ROLE,2
PAST RESEARCH,2
PERFORMANCE,1
TEAM,1
PATENTS,1
IMPACT,1
AMBIDEXTERITY,1
PROFITABILITY,1
,1
INTELLECTUAL PROPERTYRIGHTS,2
KNOWLEDGEBASED THEORY,2
TACIT KNOWLEDGE,2
FIRM,1
INNOVATION,1
TRADE,1
CAPABILITIES,1
ECONOMICS,1
NETWORK,1
POLICY,1
Innovation,1
Culture,1
Gravity model,2
Trust,1
Acceptance and tolerance,3
L26,1
O30,1
Z10,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INNOVATION PERFORMANCE,2
GRAVITY MODEL,2
DIVERSITY,1
RELIGION,1
TECHNOLOGY,1
LANGUAGE,1
CULTURE,1
TRUST,1
intellectual property protection,3
innovation system,2
institutional change theory,3
institutional voids,2
developing countries,2
RESEARCHANDDEVELOPMENT,1
CATCHUP STRATEGIES,2
KNOWLEDGE SPILLOVERS,2
BOUNDED RELIABILITY,2
PATENT PROTECTION,2
INNOVATION,1
INSTITUTIONS,1
FIRMS,1
MNE,1
INDUSTRY,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
PROSPECTTHEORY,1
RISK,1
INNOVATION,1
PERFORMANCE,1
SPILLOVERS,1
IMITATION,1
COLLABORATION,1
UNCERTAINTY,1
,1
INNOVATION,1
ACCESS,1
Artificial intelligence,2
Intellectual property law,3
AI,1
DABUS,1
Machine learning,2
Deep learning,2
America Invents Act,3
Text and data mining,4
Neural networks,2
Patents,1
Copyright,1
Trade secrets,2
Software protection,2
,1
Compulsory license,2
Copyright,1
Patent,1
Right to health,3
Right to information,3
,1
Technological innovation,2
Knowledge engineering,2
Patents,1
Organizations,1
Knowledge transfer,2
Weight measurement,2
Industrial communication,2
Industrial knowledge transfer network,4
knowledge transfer,2
patent transfer,2
patentintensive industry,2
network efficiency,2
TECHNOLOGYTRANSFER,1
COMPETITIVE ADVANTAGE,2
ABSORPTIVECAPACITY,1
INNOVATION NETWORK,2
SPATIALANALYSIS,1
DIFFUSION,1
PERFORMANCE,1
MANAGEMENT,1
DYNAMICS,1
CHINA,1
International law,2
access to medicines,3
right to health,3
legal hierarchy,2
treaty law,2
IP,1
patent rights,2
TRIPS,1
RIGHTS,1
DIGNITY,1
ACCESS,1
Copyright,1
DPD,1
GDPR,1
Machine learning,2
Patent,1
Patent value,2
Profiling,1
Right to explanation,3
Trade secrecy,2
,1
Energy,1
RD,1
Multinationals,1
Globalization,1
TECHNOLOGY,1
INNOVATION,1
DETERMINANTS,1
INDUSTRY,1
PANEL,1
,1
TORT LAW,2
PROPERTY,1
Green innovation,2
Environmental protection interview,3
Spatial difference in difference,4
Highly polluting enterprises,3
Spatial spillover effect,3
IMPACT,1
PERFORMANCE,1
TECHNOLOGY,1
TRADE,1
RD spending,2
RD internationalisation,2
Patent,1
Climate change mitigation technologies,4
FOREIGN DIRECTINVESTMENT,2
LOCATION CHOICE,2
INNOVATION,1
INTERNATIONALIZATION,1
STATISTICS,1
SYSTEMS,1
INDICATORS,1
PROTECTION,1
INDUSTRIAL,1
PATTERNS,1
,1
INTELLECTUAL PROPERTY,2
COMPUTERPROGRAMS,1
LAW,1
PROTECTION,1
SCOPE,1
FASHION,1
PATENTS,1
reclamation,1
bioremediation,1
potential of biological systems,4
dust suppression,2
hazard of sulfide waste from mineral processing,7
environmental safety,2
abandoned mine enterprises,3
SOIL,1
Patents,1
EPL,1
Wagesetting institutions,2
Multilevel models,2
Spatial analysis,2
RESEARCHANDDEVELOPMENT,1
FLEXIBLE LABOR,2
EMPLOYMENT PROTECTION,2
PRODUCTIVITY GROWTH,2
EMPIRICALEVIDENCE,1
MINIMUMWAGES,1
PANEL,1
UNEMPLOYMENT,1
IMPACT,1
DEREGULATION,1
Intellectual property rights,3
Foreign direct investment inflows,4
Technological exports,2
Utilitarian theory,2
Deterrence theory,2
Natural rights theory,3
F23,1
O34,1
O33,1
C23,1
PATENT RIGHTS,2
INNOVATION,1
INSTITUTIONS,1
PROTECTION,1
DETERMINANTS,1
REGRESSION,1
QUALITY,1
REGIMES,1
GROWTH,1
CHOICE,1
Trademark,1
Own brand manufacturing,3
Original equipment manufacturing,3
Innovation,1
Korea,1
Patent,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
MARKET VALUE,2
TECHNOLOGY,1
INNOVATION,1
PROTECTION,1
SMES,1
fruit protection,2
rain cover,2
plastic cover,2
orchard protection,2
hail net,2
orchard protection,2
RAIN COVER PROTECTION,3
SWEET CHERRIES,2
CRACKING,1
TUNNELS,1
FROST,1
Drug repositioning,2
Patent law,2
Regulatory protection,2
Clinical trials,2
Empirical study,2
Generic drugs,2
MEDICAL USES,2
PATENTS,1
Agaricomycetes,1
antifungal antibiotic,2
fungicide,1
higher Basidiomycetes,2
medicinal mushrooms,2
Mucidermin Spofa,2
mucidin,1
patent protection,2
strobilurin A,2
submerged cultivation,2
,1
Intellectual property rights,3
INTELLECTUAL PROPERTYRIGHTS,2
FOREIGN DIRECTINVESTMENT,2
TECHNOLOGYTRANSFER,1
PROTECTION,1
PRODUCTIVITY,1
INCREASE,1
TRADE,1
WORLD,1
SPILLOVERS,1
INNOVATION,1
culinary creations,2
copyright,1
industrial property,2
trade secrets,2
unfair competition,2
,1
Human embryonic stem cells hESCs,5
Ethics,1
Policy,1
Patentability,1
,1
Computers,1
intellectual property,2
patents,1
software,1
USA,1
LAW,1
Balance,1
innovation,1
patent law,2
patent policy,2
social costs and benefits of intellectual property,7
INNOVATION,1
ECONOMICS,1
LAW,1
Copyright,1
Copyright Act of 1976,4
Federal agencies,2
Federal laboratories,2
Federal Technology Transfer Act of 1986,6
Governmentowned contractoroperated GOCO laboratories,4
Governmentowned governmentoperated GOGO laboratories,4
Government Works software,3
Invention licenses,2
Patents,1
Software,1
Software copyrights,2
Software licenses,2
Software patents,2
Technology transfer,2
,1
access to medicines,3
COVID19,1
international patent law history,4
lowandmiddleincomecountries,1
Paris Convention,2
TRIPS Agreement,2
TRIPS flexibilities,2
INTELLECTUAL PROPERTYRIGHTS,2
PATENTS,1
POLICIES,1
TRADE,1
Photoaging,1
Photoprotection,1
Technological prospecting,2
Skin,1
ULTRAVIOLETRADIATION,1
ANTIOXIDANT,1
SKIN,1
FLAVONOIDS,1
MECHANISMS,1
SUNSCREEN,1
intellectual property rights,3
renewable energy,2
innovation,1
technology ransfer,2
climate change mitigation,3
panel regression,2
PATENT PROTECTION,2
INNOVATION,1
DETERMINANTS,1
INVESTMENT,1
Asia,1
FDI,1
formal institutions,2
India,1
intellectual property rights,3
pharmaceuticals,1
TRIPS,1
ECONOMICGROWTH,1
RIGHTS,1
PROTECTION,1
FDI,1
,1
WOMEN INVENTORS,2
PRIVACY,1
TIES,1
PROPERTY,1
STRENGTH,1
drug discovery,2
research and development RD,4
target discovery,2
academia,1
pharma,1
translation,1
translational,1
nanoscale,1
nanomedicine,1
lead discovery programs,3
hit discovery,2
lead optimization,2
US Food and Drug Administration FDA,6
World Health Organization WHO,4
nanoparticles,1
nanoscale titanium dioxide,3
silver nanoparticles,2
nanotechnology,1
nanomaterial,1
nanodrug,1
nanotherapeutic,1
nanopharmaceutical,1
nanogovernance,1
regulation,1
US Patent  Trademark Office PTO,6
patent,1
nanoproducts,1
toxicity,1
new chemical entity NCE,4
investigational new drug application INDA,5
new drug application NDA,4
new molecular entity NME,4
abbreviated new drug application ANDA,5
Academic Drug Discovery Consortium ADDC,5
intellectual property strategy,3
patent protection,2
license agreements,2
litigation,1
commercialization,1
valley of death,3
lead optimization,2
quality control,2
scaleup,1
preclinical testing,2
safety and efficacy,3
clinical trials,2
phase IV postmarket surveillance,4
basic science,2
benchtobedside,1
translational medicine,2
translational science,2
preclinical research,2
the BayhDole Act,3
the HatchWaxman Act,3
current Good Manufacturing Production cGMP,5
irreproducible preclinical research,3
scientific integrity,2
scientific misconduct,2
crowdsourced analysis,2
National Institutes of Health NIH,5
Good Institutional Practice GIP,4
Technology Transfer Offices TTOs,4
publishorperish,1
trade secrets,2
physiologicallybased pharmacokinetic PBPK modelling,4
panassay interference compounds PAINS,4
antibodies,1
FDAs Center for Drug Evaluation and Research CDER,8
Biologics License Applications BLAs,4
Center for Biologics Evaluation and Research CBER,7
Tufts Center for the Study of Drug Development of Clinical Trial,11
freedomtooperate,1
nanopatent land grabs,3
nomenclature,1
terminology,1
nanocharacter,1
emerging technologies,2
regulatory guidance,2
National Center for Advancing Translational Sciences NCATS,7
DRUG,1
PATENTS,1
FDA,1
intellectual property,2
intangible assets,2
evaluation methods,2
statistical situations,2
EPO,1
trends,1
,1
Economic growth,2
Convergence,1
Patents,1
TFP,1
Panel data,2
ECONOMICGROWTH,1
INSTITUTIONS,1
DETERMINANTS,1
ECONOMETRICS,1
PROTECTION,1
COUNTRIES,1
EMPIRICS,1
MODELS,1
RIGHTS,1
Productivity,1
innovation,1
intellectual property,2
appropriability,1
patents,1
CDM,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTY,2
FINANCIAL CONSTRAINTS,2
EMPIRICALANALYSIS,1
PATENTS,1
FIRMS,1
KNOWLEDGE,1
COUNTRIES,1
SECRECY,1
SIZE,1
TRIPS,1
intellectual property,2
hepatitis C,2
antiretroviral,1
direct acting antiviral,3
patent,1
generic,1
HIV,1
Cambodia,1
,1
WTO,1
transparency,1
coordination,1
essential goods,2
trade policy review mechanism,4
intellectual property,2
vaccines,1
waiver of patent protections,4
,1
Argentina,1
Biotechnology,1
Brazil,1
Chile,1
Commercialization,1
Cuba,1
Development,1
Latin America,2
Mexico,1
Patent cooperation treaty,3
Patents,1
PCT,1
Technology,1
INNOVATION,1
RIGHTS,1
compulsory license,2
pharmaceutical patents,2
TRIPS flexibility,2
the balance of interests,4
China,1
INTELLECTUAL PROPERTY,2
PUBLICHEALTH,1
SYSTEM,1
,1
COPYRIGHT,1
LAW,1
PERSPECTIVES,1
,1
RESEARCHANDDEVELOPMENT,1
INTELLECTUAL PROPERTYRIGHTS,2
METOO DRUGS,2
PATENTS,1
INNOVATION,1
ATORVASTATIN,1
COMPETITION,1
RETHINKING,1
PROTECTION,1
STANDARDS,1
Pollution charge system,3
Environmental protection tax system,4
Patent,1
Micro enterprise,2
Enterprise innovation,2
RESEARCHANDDEVELOPMENT,1
ENVIRONMENTALREGULATION,1
FIRM SIZE,2
COMPETITION,1
ECONOMICS,1
IMPACTS,1
ENHANCE,1
Accounting information,2
Firm ownership,2
Technological innovation,2
Agency conflict,2
Proprietary cost,2
EARNINGS MANAGEMENT,2
CORPORATE GOVERNANCE,2
INVESTOR PROTECTION,2
ANALYST COVERAGE,2
CEO TURNOVER,2
AGENCY COSTS,2
MARKETS,1
TRANSPARENCY,1
COMPETITION,1
VALUATION,1
IP protection systems,3
plant variety rights,3
patent,1
raspberry,1
ariljska malina,2
,1
Business intelligence,2
competitive intelligence,2
IP strategies,2
organizational performance,2
patents,1
TECHNOLOGY,1
DISCLOSURE,1
PATENTS,1
INDUSTRY,1
MARKET,1
Agrochemicals,1
crop protection,2
fungicide,1
MULTICOMPONENT REACTIONS,2
ORGANIC INSECTICIDES,2
ACIDAMIDES,1
NEREISTOXIN,1
ISOCYANIDES,1
HERBICIDES,1
,1
PROPERTYRIGHTS,1
PATENTS,1
INNOVATION,1
IMPACT,1
Pharmaceutical policy,2
Globalization and health,3
Health care reform,3
Drug pricing,2
Health spending,2
International trade,2
Patents,1
Data exclusivities,2
Health law,2
EXCLUSIVITY,1
DRUGS,1
TIME,1
indigenous knowledge,2
New Zealand,2
patent law,2
,1
IPRs,1
Trademarks,1
FDI inflows,2
Emerging markets,2
Vietnam,1
MNEs,1
International business,2
Business history,2
FOREIGN DIRECTINVESTMENT,2
PATENT RIGHTS,2
PROTECTION,1
INNOVATION,1
SPAIN,1
STRATEGIES,1
KNOWLEDGE,1
IMITATION,1
BUSINESS,1
MOTIVES,1
,1
,1
Initial public offering,3
Venture capital,2
Innovation,1
Startup,1
IPOS,1
RISE,1
,1
RESEARCHANDDEVELOPMENT,1
MOTIVATING INNOVATION,2
INVESTOR PROTECTION,2
PATENT STATISTICS,2
CASH FLOW,2
CONSEQUENCES,1
SHAREHOLDERS,1
PERFORMANCE,1
INDICATORS,1
KNOWLEDGE,1
closedloop supply chain,3
remanufacturing,1
fuzzy decision,2
royalty licensing,2
game theory,2
LOOP SUPPLY CHAIN,3
LICENSING CONTRACTS,2
NETWORK,1
DEMAND,1
DECISIONS,1
MODEL,1
OPTIMIZATION,1
PROTECTION,1
PRODUCTS,1
DESIGN,1
Cerebral infarction,2
tonifying qi and promoting blood circulation,6
chinese patent medicine,3
review,1
STROKE,1
METAANALYSIS,1
,1
PROTECTION,1
DISCLOSURE,1
IMPACT,1
FIRMS,1
Intellectual Property Rights,3
RD incentive of imitators,4
RESEARCHANDDEVELOPMENT,1
DEVELOPINGCOUNTRIES,1
PATENTS,1
IMITATION,1
Certificate of Supplementary Protection,4
Shingrix,1
Belsomra,1
CSP Register,2
Minister of Health Canada,4
,1
IPR protection,2
Technological frontier,2
Innovation,1
RD,1
Transition economies,2
INNOVATION,1
PROTECTION,1
DETERMINANTS,1
SPILLOVERS,1
COUNTRIES,1
PRODUCTIVITY,1
TRANSITION,1
KNOWLEDGE,1
PATENTS,1
POLICY,1
,1
PANELDATA,1
PRODUCTIVITY GROWTH,2
TECHNOLOGY FLOWS,2
PATENT RIGHTS,2
UNITROOT,1
PROTECTION,1
INNOVATION,1
TRADE,1
TESTS,1
,1
PATENT PROTECTION,2
INNOVATION,1
IMPACT,1
Corporate green innovation,3
Environmental policy uncertainty,3
Turnover of environmental protection officials EPOT,6
FIRM PERFORMANCE EVIDENCE,3
POLITICAL UNCERTAINTY,2
ECONOMICPERFORMANCE,1
INVESTMENT EVIDENCE,2
CASH HOLDINGS,2
TURNOVER,1
IRREVERSIBILITY,1
PARTICIPATION,1
LEADERS,1
GROWTH,1
Market manipulation,2
Endofday dislocation,2
Patents,1
Innovation,1
Intellectual property rights,3
Shareholder protection,2
RESEARCHANDDEVELOPMENT,1
STOCKPRICE MANIPULATION,2
INSTITUTIONAL INVESTORS,2
CORPORATE SCANDALS,2
PROPERTYRIGHTS,1
LAW,1
DETERMINANTS,1
INCENTIVES,1
EARNINGS,1
EQUITY,1
Regional innovation performance,3
intellectual property protection intensity,4
RD investment,2
human resource investment,3
Panel threshold model,3
DEVELOPMENT INTENSITY,2
LEVEL,1
STRATEGIES,1
PATENTS,1
RIGHTS,1
LAW,1
Coatings,1
UV LED,2
Photopolymers,1
Corrosion protection,2
Electrochemical impedance spectroscopy,3
ANTICORROSIVE PROPERTIES,2
PHOSPHATE PIGMENTS,2
ORGANIC COATINGS,2
OIL,1
NSS,1
intellectual property,2
economic theory,2
dynamic panel,2
FOREIGN DIRECTINVESTMENT,2
GLOBAL PATENT PROTECTION,3
GROWTH,1
RIGHTS,1
agrochemical discovery,2
crop protection compounds,3
pesticide,1
NATURALPRODUCTS,1
AGROCHEMICAL DISCOVERY,2
INSECTICIDE DISCOVERY,2
FOOD SECURITY,2
CHALLENGES,1
RESISTANCE,1
CHEMISTRY,1
MIMICS,1
MODE,1
RD outsourcing,2
IPR protection,2
Subsidiary productivity,2
TECHNOLOGYTRANSFER,1
PATENT RIGHTS,2
IMPACT,1
PRODUCTIVITY,1
FIRMS,1
INTERNATIONALIZATION,1
MULTINATIONALS,1
EXPLOITATION,1
EMBEDDEDNESS,1
CAPABILITIES,1
Export trade,2
free trade agreement,3
intellectual property protection,3
INTELLECTUAL PROPERTYRIGHTS,2
INTERNATIONALTRADE,1
PATENT RIGHTS,2
ECONOMICGROWTH,1
AGREEMENTS,1
DETERMINANTS,1
LEVEL,1
Imitation,1
IPR,1
RD,1
Skills,1
Wage Inequality,2
RESEARCHANDDEVELOPMENT,1
SCHUMPETERIAN MODEL,2
ENDOGENOUS GROWTH,2
INCOME INEQUALITY,2
WAGE INEQUALITY,2
PATENT POLICY,2
INVESTMENT,1
PROTECTION,1
GLOBALIZATION,1
POLARIZATION,1
index,1
international comparison,2
IPRs,1
trademark protection,2
TRIPs,1
INTELLECTUAL PROPERTYRIGHTS,2
RESEARCHANDDEVELOPMENT,1
INSTITUTIONBASED VIEW,2
ECONOMICGROWTH,1
INNOVATION,1
BRANDS,1
INSIGHTS,1
SYSTEMS,1
IMPACT,1
MARKET,1
C02,1
L0,1
O31,1
PRODUCT,1
LIFE,1
GROWTH,1
Technological radicalness,2
RD internationalization,2
Intellectual property protection,3
Exploration vs exploitation,3
Manufacturing companies,2
FOREIGN DIRECTINVESTMENT,2
RESOURCEBASED VIEW,2
KNOWLEDGE SPILLOVERS,2
FIRM RESOURCES,2
INNOVATION,1
GLOBALIZATION,1
US,1
COUNTRIES,1
LOCATION,1
PATENT,1
Environmental protection regulation,3
Green innovation,2
Information disclosure,2
EMPIRICALEVIDENCE,1
PORTER HYPOTHESIS,2
INVESTMENT EVIDENCE,2
RISK EVIDENCE,2
FIRM,1
PERFORMANCE,1
COMPETITIVENESS,1
DISCLOSURE,1
INCENTIVES,1
EMISSIONS,1
Central environmental protection inspection,4
CEPI,1
Green technology innovation GTI,4
Innovative targeting,2
Differenceindifference DID,2
CAMPAIGNSTYLE ENFORCEMENT,2
POLICY IMPLEMENTATION,2
CHINA,1
REGULATIONS,1
PERFORMANCE,1
IMPACT,1
Patents,1
Paris convention,2
E Merck,2
regulation,1
,1
Innovation,1
Institutional environment,2
Product Market Competition,3
China,1
PRODUCTMARKET COMPETITION,2
INTELLECTUAL PROPERTYRIGHTS,2
DEVELOPMENT INVESTMENT,2
VOLUNTARY DISCLOSURE,2
IFRS ADOPTION,2
DISCRETIONARY DISCLOSURE,2
INSTITUTIONAL CHANGE,2
FIRM PERFORMANCE,2
MODERATING ROLE,2
GOVERNANCE,1
Antibacterial,1
antiprotozoan,1
antiviral,1
cancer,1
IMPDH,1
inhibitor,1
inosine5monophosphate dehydrogenase,2
transplant rejection,2
INOSINE MONOPHOSPHATE DEHYDROGENASE,3
5MONOPHOSPHATE DEHYDROGENASE,2
POTENT,1
MECHANISM,1
DISCOVERY,1
DESIGN,1
IDENTIFICATION,1
FRAGMENTS,1
RIBAVIRIN,1
SAR,1
Outward foreign direct investment OFDI,5
Intellectual property IP protection,4
Threshold regression,2
PATENT RIGHTS,2
INNOVATION,1
,1
EMPIRICALEVIDENCE,1
FORMAL STANDARDIZATION,2
ESSENTIAL PATENTS,2
ISO 9001,2
IMPACT,1
DIFFUSION,1
MOTIVES,1
PARTICIPATION,1
SECTOR,1
new energy vehicle,3
innovative network,2
network evolution,2
technical innovation,2
RESEARCHANDDEVELOPMENT,1
STRUCTURAL HOLES,2
PERFORMANCE,1
COHESION,1
PATENTS,1
Genetic information,2
Patent law,2
Property,1
Property rights,2
Donors,1
CONSENT,1
ISSUES,1
generic drugs,2
Food and Drug Administration,4
drug access,2
regulation,1
bioequivalence,1
INVITRO,1
Innovation,1
International knowledge networks,3
Coinventor cooperation,2
Centrality,1
International collaboration,2
INTELLECTUAL PROPERTYRIGHTS,2
NETWORK CENTRALITY,2
INNOVATION PERFORMANCE,2
ABSORPTIVECAPACITY,1
SOCIALSTRUCTURE,1
PATENT RIGHTS,2
OUTWARD FDI,2
DETERMINANTS,1
CORRUPTION,1
GUANXI,1
intellectual property box regime,4
patent box regime,3
FDI,1
RD,1
design,1
testing and development activities,4
difference in differences analysis,4
MULTINATIONAL FIRMS,2
LOCATION CHOICE,2
CORPORATETAXATION,1
EMPIRICALEVIDENCE,1
EUROPEAN REGIONS,2
INVESTMENTS,1
DETERMINES,1
OWNERSHIP,1
COUNTRIES,1
PANEL,1
trade secrets,2
intellectual property rights,3
unfair competition,2
misappropriation,1
disclosure,1
use,1
felony,1
Spanish legal system,3
,1
Electric vehicles,2
Charging technology,2
Patent analysis,2
Evolutionary trajectory,2
Main path analysis,3
MAIN PATH,2
BATTERY,1
ENERGY,1
OPPORTUNITIES,1
DIRECTIONS,1
INNOVATION,1
MODELS,1
,1
KNOWLEDGE,1
APPROPRIABILITY,1
PATENTS,1
APPROPRIATION,1
COLLABORATION,1
PARADOX,1
private property protection,3
quantile regression,2
economic growth,2
Intellectual property rights,3
QUANTILE REGRESSION,2
PATENT PROTECTION,2
INTERNATIONALTRADE,1
INNOVATION,1
COUNTRIES,1
FLOWS,1
LAWS,1
FDI,1
Health innovation,2
Intellectual property,2
Patent,1
Dengue fever,2
SDGs,1
Grand challenges,2
PUBLICPRIVATE PARTNERSHIPS,2
RESEARCHANDDEVELOPMENT,1
DENGUE,1
VACCINES,1
DRUGS,1
Feedin tariffs,2
RD investment,2
Innovation,1
Wind power,2
China,1
RENEWABLE ENERGY,2
COUNT DATA,2
INDUSTRY,1
DIFFUSION,1
PATENTS,1
COST,1
PERFORMANCE,1
EMISSIONS,1
DETERMINANTS,1
ENTERPRISES,1
Secrecy,1
information security,2
organization design,2
trust,1
innovation,1
appropriability mechanisms,2
RESEARCHANDDEVELOPMENT,1
TRADE SECRETS,2
RELATIONAL CONTRACTS,2
TRUST,1
PERFORMANCE,1
COMPETITION,1
INNOVATION,1
PATENTS,1
APPROPRIABILITY,1
CONSEQUENCES,1
Labor share,2
Technological change,2
ICT capital,2
Market regulations,2
Hysteresis,1
FORCE PARTICIPATION,2
PATENT RIGHTS,2
INSTITUTIONS,1
alliance,1
learning,1
knowledge spillover,2
knowledge absorption,2
knowledge protection,2
RESEARCHANDDEVELOPMENT,1
SAMPLE SELECTION BIAS,3
STRATEGIC ALLIANCES,2
INTELLECTUAL PROPERTY,2
ABSORPTIVECAPACITY,1
PATENT CITATIONS,2
FIRM PERFORMANCE,2
LOCAL SEARCH,2
TECHNOLOGY,1
IMPACT,1
medical protection,2
antidote,1
microproduction,1
technological platform,2
medical countermeasures,2
pharmaceutical technique,2
orphan drug production,3
,1
HighTech Industry,2
Pharmaceutical Manufacturing,2
Intellectual Property Rights,3
Industrial Competitiveness,2
Technological Innovation,2
ECONOMICGROWTH,1
PATENT RIGHTS,2
TRADE,1
DETERMINANTS,1
INVESTMENT,1
INNOVATION,1
ADVANTAGE,1
COUNTRIES,1
expressions of Folklore,3
Intellectual Property,2
Naga,1
sui generis,2
GEOGRAPHICAL INDICATIONS,2
entrepreneurs,1
protection of rights,3
Intellectual Property Law,3
crimes,1
legal assets,2
,1
,1
MONOCLONALANTIBODIES,1
DOCTRINE,1
TOLERANCE,1
THERAPIES,1
HISTORY,1
POLICY,1
VIRUS,1
Food and Drug Administration FDA,5
nanoparticles,1
nanotechnology,1
nanoscale,1
nanomaterial,1
nanomedicine,1
nanobiotechnology,1
nanodrug,1
nanotherapeutic,1
nanopharmaceutical,1
bioequivalent,1
nanogovernance,1
regulation,1
bulk counterpart,2
commercialization,1
combination products,2
US Patent  Trademark Office PTO,6
patent,1
nanoproducts,1
nanoparticle toxicity,2
primary mode of action PMOA,5
International Organization for Standardization ISO,5
nanoformulations,1
new chemical entities NCEs,4
European Medicines Agency EMA,4
Environmental Protection Agency EPA,4
Centers for Disease Control and Prevention CDC,7
National Institute for Occupational Safety and Health NIOSH,8
surface plasmonresonance SPR,3
nanoshells,1
enhanced permeability and retention EPR,5
controlled manipulation,2
new drug application NDA,4
premarket approval PMA,3
surface areatovolume ratio,3
reactivity,1
multivalence,1
bioavailability,1
biodistribution,1
regulatory governance,2
Center for Drug Evaluation and Research CDER,7
Center for Biologics Evaluation and Research CBER,7
Center for Devices and Radiological Health CDRH,7
adsorption,1
distribution,1
metabolism and excretion ADME,4
physicochemical characterization PCC,3
nonbiological complex drugs NBCDs,4
COMPLEXDRUGS,1
NEXTGENERATION,1
NANOMEDICINES,1
NANOPARTICLES,1
RISK,1
wind energy,2
Ayanz Wind Turbine,3
Archimedes turbine,2
Archimedes Spiral wind blade,4
small wind turbine,3
maximum power point tracking,4
power conversion system,3
protection system,2
OFTHEART,1
Complementarities,1
matching with contracts,3
stability,1
contract design,2
COMPETITIVEEQUILIBRIUM,1
STABILITY,1
NETWORKS,1
DESIGN,1
business model,2
business model innovation,3
intellectual property,2
strategy,1
innovation,1
value capture,2
PAYPERUSE,1
VALUE CREATION,2
INNOVATION,1
PATENTS,1
FIRMS,1
APPROPRIABILITY,1
MANAGEMENT,1
PARADOX,1
SECRECY,1
intellectual property right,3
access to medicines,3
TRIPS,1
catastrophic expenditure,2
PATENT PROTECTION,2
HEALTHCARE,1
TRIPSPLUS,1
IMPACT,1
DRUGS,1
ECONOMY,1
Knowledge commons,2
Knowledge sharing,2
Hybrid governance,2
Mining industry,2
China,1
INTELLECTUAL PROPERTYRIGHTS,2
FORMAL CONTRACTS,2
TACIT KNOWLEDGE,2
MODERATING ROLE,2
INNOVATION,1
PERFORMANCE,1
NETWORK,1
GUANXI,1
MECHANISMS,1
PATENTS,1
Innovation,1
Patents,1
Research and development,3
R  D,3
Subsidies,1
Multinationals,1
Investment,1
Technology policy,2
RESEARCHANDDEVELOPMENT,1
DEVELOPMENT TAX CREDITS,3
TECHNOLOGYTRANSFER,1
PUBLIC SUBSIDIES,2
PROPENSITY SCORE,2
POLICY,1
ADDITIONALITY,1
PROTECTION,1
INTERNATIONALIZATION,1
STRATEGIES,1
knowledge transfer,2
multinational corporations MNCs and enterprises MNEs,6
intellectual property protection,3
innovation,1
patents,1
knowledge value,2
RESEARCHANDDEVELOPMENT,1
FOREIGN DIRECTINVESTMENT,2
ABSORPTIVECAPACITY,1
MULTINATIONALCORPORATIONS,1
PROPERTYRIGHTS,1
UNITEDSTATES,1
JAPANESE MULTINATIONALS,2
SUBSIDIARY PERFORMANCE,2
TECHNOLOGYTRANSFER,1
FIRM,1
Ministernotomy,1
Aortic valve,2
Reoperative,1
Patent mammary grafts,3
SHORTTERM,1
REPLACEMENT,1
OUTCOMES,1
STERNOTOMY,1
drug costs,2
branded,1
generic,1
infectious diseases,2
HIV,1
hepatitis C,2
UNITEDSTATES,1
PRICES,1
Legal system,2
Digitalization of law,3
Intellectual property,2
Electronic services,2
Scientific and technological progress,4
Patent service,2
,1
Intellectual property rights,3
Foreign direct investment,3
Informal economy,2
Institutions,1
Asia,1
FOREIGN DIRECTINVESTMENT,2
PATENT RIGHTS,2
US EXPORTS,2
TRADE,1
GROWTH,1
SALES,1
Open innovation,2
Collaborative ideation,2
Collaboration phases,2
appropriability mechanisms,2
Intellectual property,2
INTELLECTUAL PROPERTY,2
OPEN INNOVATION,2
APPROPRIATION MECHANISMS,2
OPEN STRATEGY,2
KNOWLEDGE,1
MANAGEMENT,1
OPENNESS,1
PARADOX,1
PATENTS,1
,1
PATENT PROTECTION,2
INNOVATION,1
RIGHTS,1
TECHNOLOGY,1
PERFORMANCE,1
COMPETITION,1
SPILLOVERS,1
INVESTMENT,1
IMPACT,1
MATTER,1
agrochemical discovery,2
fungicide,1
herbicide,1
insecticide,1
natural products,2
natural productbased crop protection compounds,5
innovation in agrochemical discovery,4
LEAD GENERATION,2
DISCOVERY,1
DESIGN,1
TRENDS,1
Twopart tariff contracts,3
Fee licensing,2
Royalty licensing,2
Consumers surplus,2
Welfare,1
Tariff protection,2
TECHNOLOGYTRANSFER,1
PATENT,1
POLICY,1
DUOPOLY,1
TRADE,1
PROTECTION,1
INNOVATION,1
ROYALTIES,1
MARKET,1
FEES,1
,1
ECONOMICGROWTH,1
RIGHTS,1
TECHNOLOGY,1
IMITATION,1
PERFORMANCE,1
OWNERSHIP,1
LIQUIDITY,1
CYCLE,1
